0001096906-15-000323.txt : 20150331 0001096906-15-000323.hdr.sgml : 20150331 20150330180302 ACCESSION NUMBER: 0001096906-15-000323 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 18 CONFORMED PERIOD OF REPORT: 20141231 FILED AS OF DATE: 20150331 DATE AS OF CHANGE: 20150330 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Perseon Corp CENTRAL INDEX KEY: 0000320174 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 751590407 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-32526 FILM NUMBER: 15735810 BUSINESS ADDRESS: STREET 1: 2188 W 2200 SOUTH CITY: SALT LAKE CITY STATE: UT ZIP: 84119 BUSINESS PHONE: 8019725555 MAIL ADDRESS: STREET 1: 2188 WEST STREET 2: 2200 SOUTH CITY: SALT LAKE CITY STATE: UT ZIP: 84119 FORMER COMPANY: FORMER CONFORMED NAME: BSD MEDICAL CORP DATE OF NAME CHANGE: 19920703 10-K 1 perseon.htm PERSEON CORPORATION 10K 2014-12-31 perseon.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549
  
FORM 10-K
(Mark One)
 
[   ]
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended
or

 
[X]
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
-
For the Transition Period From September 1, 2014 to December 31, 2014
 
Commission File Number:  001-32526
 
PERSEON CORPORATION
(Exact name of registrant as specified in its charter)
 
Delaware
75-1590407
(State or other jurisdiction of incorporation or organization)
 (I.R.S. Employer Identification No.)

2188 West 2200 South, Salt Lake City, Utah
84119
(Address of principal executive office)
(Zip Code)

Registrant's telephone number, including area code:  (801) 972-5555

Securities registered pursuant to Section 12(b) of the Act:
 
Title of Each Class
Name of Each Exchange on which Registered
Common Stock, Par Value $0.001
The NASDAQ Stock Market LLC

Securities registered pursuant to Section 12(g) of the Act:  None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes¨  Nox

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.  Yes ¨  No x

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes x  No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (Section 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).  Yes x  No ¨

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.  ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer ¨
Accelerated filer ¨
Non-accelerated filer ¨ (Do not check if a smaller reporting company)
Smaller reporting company x
 
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act.)  Yes ¨ No x

The aggregate market value of the common stock held by non-affiliates of the registrant as of June 30, 2014 was approximately $26,701,152.

As of March 30, 2015, the registrant had 39,689,209 shares of its common stock, par value $.001, outstanding.

 
 
 

PERSEON MEDICAL CORPORATION
FORM 10-K
For the Four Month Transition Period Ended December 31, 2014
 
TABLE OF CONTENTS

Part I
  
Item 1.
Business
2
     
  Item 1A
Risk Factors
17
     
  Item 1B
Unresolved Staff Comments
28
     
Item 2.
Properties
28
     
Item 3.
Legal Proceedings
28
     
Item 4.
Mine Safety Disclosures
29
     
Part II
  
   
Item 5.
Market for the Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
29
     
Item 7.
Management’s Discussion and Analysis of Financial Condition and Results of Operations
30
     
   Item 7A.
Quantitative and Qualitative Disclosure About Market Risk
40
     
Item 8.
Financial Statements and Supplementary Data
40
     
Item 9.
Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
40
     
   Item 9A.
Controls and Procedures
40
     
   Item 9B.
Other Information
42
     
Part III
  
   
Item 10.
Directors, Executive Officers and Corporate Governance
42
     
Item 11.
Executive Compensation
47
     
Item 12.
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
55
     
Item 13.
Certain Relationships and Related Transactions, and Director Independence
57
     
Item 14.
Principal Accountant Fees and Services
58
     
Part IV
  
Item 15.
Exhibits and Financial Statement Schedules
60
     
Signatures
63

 
1
 

PART I

ITEM 1.   BUSINESS

Forward-Looking Statements

This Transition Report on Form 10-K contains forward-looking statements that involve risks and uncertainties.  Forward-looking statements can also be identified by words such as “anticipates,” “expects,” “believes,” “plans,” “predicts,” and similar terms.  Forward-looking statements are not guarantees of future performance and our actual results may differ significantly from the results discussed in the forward-looking statements.  Factors that might cause such differences include, but are not limited to, those discussed in Item 1A, “Risk Factors,” and Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations.”  We assume no obligation to revise or update any forward-looking statements for any reason, except as required by law.

Change in Fiscal Year End

We have changed our fiscal year end for financial reporting from August 31 to December 31, effective for the four months ended December 31, 2014.  As a result of this change, this Transition Report on Form 10-K is a transition report and includes financial information for the four-month transition period from September 1, 2014 to December 31, 2014. References in this Transition Report on Form 10-K to fiscal year 2014 refer to the period of September 1, 2013 through August 31, 2014 and references to fiscal year 2013 refer to the period of September 1, 2012 through August 31, 2013. Subsequent to this Transition Report on Form 10-K, our reports on Form 10-K will cover the calendar year from January 1 to December 31, with historical periods remaining unchanged.

Overview

Perseon Corporation, formerly BSD Medical Corporation, (the “Company” or “Perseon”) was originally incorporated under the laws of the State of Utah on March 17, 1978.  On July 3, 1986 the Company was incorporated in the State of Delaware.  In February 2015, we changed the name of the Company to Perseon Corporation.  We are a life sciences company that develops, manufactures, markets and services groundbreaking medical systems to treat cancer using heat therapy.  Our MicroThermX® microwave ablation system employs precision-guided microwave energy to ablate diseased soft tissue.  We have developed extensive intellectual property and distribute our products in the United States, Europe and Asia.

We develop, manufacture, market and service systems to treat cancer and benign diseases using heat therapy delivered using focused microwave and radiofrequency (“RF”) energy.  Our business objectives are to commercialize our products for the treatment of cancer and to further expand our products to treat other diseases and medical conditions.  Our product line for cancer therapy has been created to offer hospitals and clinics a complete solution for thermal treatment of cancer using microwave/RF systems.

In spite of the advances in cancer treatment technology, the five-year survival rate for all cancers in the United States is only 68%.  Our product line includes systems that have been strategically designed to offer a range of thermal treatment systems for the treatment of cancer, including both ablation and hyperthermia treatment systems.  Studies have shown that both ablation and hyperthermia treatments kill cancer, but they have different clinical applications.

Our microwave ablation system is used to ablate (destroy) soft tissue with heat alone.  Thermal ablation usually refers to heat treatments delivered at temperatures above 55°C for short periods of time.  Thermal ablation is used to destroy local tumors using a short intense focus of heat on a specific area.

Historically, our product offerings have also included hyperthermia cancer treatment systems. Although the number of hyperthermia systems sold increased in 2014, due to negative regulatory, economic, reimbursement and other healthcare industry factors, we expect that revenue growth of this product line will be difficult in the future.  We have experienced declining hyperthermia revenues from our distributor in Europe, a related party.  Although we have entered into distribution agreements for our hyperthermia systems in China, South Korea and Taiwan and anticipate that these distribution agreements may result in hyperthermia sales in the future, certain regulatory approvals are required before we may realize such sales.

 
2
 
 
As a result, as previously announced, we intend to sell or discontinue our hyperthermia product line early in 2015.  We have an interested buyer and a non-binding term sheet for the potential sale of assets related to our hyperthermia product line has been submitted and accepted. Final terms are being negotiated and due diligence efforts are underway.  Although we expect to close the transaction on the sale of our hyperthermia assets in the spring of 2015, no assurance can be given that a sale of our hyperthermia assets will be successful.

Commercialization of our systems that are used to treat cancer is our most immediate business objective.  Current and future cancer treatment sites for our systems may include cancers of the prostate, breast, head, neck, bladder, cervix, colon/rectum, ovaries, esophagus, liver, kidney, brain, bone, stomach and lung.  In addition to these market opportunities, we believe that our technology has application for a number of other medical purposes in addition to cancer.

We have experienced recent growth in our operating revenues from our MicroThermX Microwave Ablation System (“MicroThermX”) line of products partially as a result of an exclusive, long-term, multi-million dollar distribution agreement with Terumo Europe NV (“Terumo”), a wholly owned subsidiary of Terumo Corporation, which covers 100 countries in Europe, Western Asia, and Northern Africa, along with increased MicroThermX revenue from other international distributors.  In addition, revenues from sales of disposable SynchroWave antennas and fee per use charges for MicroThermX systems have increased in the US market.

We recognize revenues from the sale of our ablation and hyperthermia cancer treatment systems and related parts and accessories (collectively, product sales), the sale of disposable devices used with certain of our systems, training, service support contracts and other miscellaneous revenues.  We also recognize revenues from equipment rental, including fee-per-use rental income from our MicroThermX.  Information regarding our revenues, assets, and results of our operations is contained in our financial statements and notes thereto and in Item 7. “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” included in this Transition Report on Form 10-K.

Our current corporate strategy includes the possibility of entering into additional collaborative arrangements with third parties to expand and improve the commercialization of all our products.  The April 2013 signing of the master distribution agreement with Terumo for our MicroThermX line of products was a result of this strategy.   There can be no assurance that the exploration of strategic alternatives will result in any agreements or transactions, or that, if completed, any agreements or transactions will be successful or on attractive terms.  In the first quarter of 2015, we engaged an investment banker to assist the Company in finding and evaluating potential strategic opportunities and possible transactions to buy assets to expand the Company, sell assets of the Company, or partner with other parties in an effort to maximize shareholder value.

Our common stock trades on the NASDAQ Capital Market (“NASDAQ”) under the symbol “PRSN.”

Our Contributions to Cancer Therapy

In the United States, the chance of developing cancer during a person’s lifetime is one in two for men and one in three for women.  Cancer is the second most common cause of death in the US, exceeded only by heart disease, accounting for nearly 1 of every 4 deaths.  Cancer develops when abnormal cells in a part of the body begin to grow out of control and spread to other parts of the body.
 
Our cancer treatment systems have been developed to both kill cancer directly with heat and to increase the effectiveness of the primary cancer treatments, which are used in conjunction with the heat therapy.  Therapies currently used to treat cancer include radiation therapy, chemotherapy, biological therapy, surgery, ablation and hyperthermia.

Because cancer remains a leading cause of death, the current primary cancer therapies are still inadequate, and there is a need for better treatments.  We have engineered systems designed to increase the effectiveness of these cancer treatments through the use of precision-focused energy to selectively heat cancer.  

 
3
 
  
Our Products and Services

We have developed technology and products for thermal ablation and hyperthermia cancer therapy through multiple techniques:

·
Thermal ablation ablates (destroys) soft tissues at high temperatures through focused microwave energy.
   
·
Superficial hyperthermia non-invasively treats cancerous tumors located within a few centimeters of the surface of the body, such as melanoma and recurrent breast cancer.
   
·
Internal or interstitial hyperthermia treats tumors in combination with internal radiation therapy by inserting tiny microwave antennas that deliver hyperthermic microwave energy to tumors through the same catheters used to deliver radioactive materials, or “seeds,” to tumors for radiation therapy.  This technique can be employed in treating prostate cancer, breast cancer, head and neck cancer as well as other cancer sites.
   
·
Deep hyperthermia non-invasively treats tumors located deep within the body.

We intend to sell or discontinue our hyperthermia product line early in 2015.  We have attracted an interested buyer, a non-binding term sheet for the potential sale of assets related to our hyperthermia product line has been submitted and accepted, final terms are being negotiated and due diligence efforts are underway.  We expect to close the transaction on the sale of our hyperthermia assets in the spring of 2015.  No assurance can be given that a sale of our hyperthermia assets will be successful.

MicroThermX® Microwave Ablation System

Our MicroThermX Microwave Ablation System (“MicroThermX”) is a compact, mobile, state-of-the-art, proprietary system that includes a microwave generator, single-patient-use disposable antennas with cooling circuit, and a thermistor-based temperature monitoring system.  The innovative design of the MicroThermX is the first of its kind that allows delivery of higher power levels using a single generator.  The MicroThermX utilizes innovative, proprietary, synchronous wave alignment technology that was developed by us to provide scalable and more uniform zones of ablation during a single procedure.

The MicroThermX introduced into our product line an innovative SynchroWave disposable antenna that is used in each ablation treatment, which we believe will provide a significant ongoing revenue stream after the sale of the system.  We expanded the MicroThermX market opportunity by introducing a new SynchroWave short tip (“ST”) antenna that can be used to deliver smaller, spherical ablation zones that more accurately target smaller tumors.  The existing SynchroWave long tip (“LT”) antenna delivers larger ablation zones, reducing the need for multiple serial ablations on larger tumors.  The multiple configurations of the SynchroWave antenna provide physicians the ability to precisely target the ablation zone to the numerous sizes and shapes of diseased tissue, significantly increasing the number of cases that can be treated with the MicroThermX. Perseon management estimates the soft tissue ablation world market potential exceeds $2.3 billion.
 
Our Table Top MicroThermX Microwave Ablation System (“T2”) is designed for our fee-per-use rental program, which is more fully described below.  Portability and ease of use are keys to successful implementation of the equipment rental program.  The T2 is a small, lightweight, tabletop configuration that has the same advanced features as the original MicroThermX configuration.

            The U.S. Food and Drug Administration (“FDA”) granted us a 510(k) clearance to market the MicroThermX for ablation of soft tissue.  Clearance from the FDA of the 510(k) Premarket Notification submission authorizes the commercial sale of the MicroThermX in the United States.  We have also received CE (Conformité Européenne) Marking for the MicroThermX, which allows us to market the MicroThermX in the thirty countries that comprise the European Union (“EU”) and the European Free Trade Association (“EFTA”).  CE Marking is also recognized in many countries outside of the EU, providing us the ability to market the MicroThermX to a number of international markets.  As further discussed below, we have established distribution in a number of countries and have accepted purchase orders for and have shipped both MicroThermX systems and SynchroWave antennas.

 
4
 
 
Clinicians have used microwave ablation systems to treat patients with cancers of the liver, lung, bone, and kidneys.

We have placed a select number of MicroThermX systems with pivotal, high-profile, interventional oncology opinion leaders in the United States and through our exclusive Eurpoean distributor, Terumo Europe, NV.  These medical facilities continue to reorder disposable SynchroWave antennas, validating the ongoing revenue stream we anticipate.  Existing users of the MicroThermX continue to report positive clinical results in the treatment of cancerous tumors.

These evaluations represent an important milestone in the MicroThermX sales cycle.  However, with hospital capital budgeting, committee review and other approvals, the sales cycle for the MicroThermX may extend to well over six months.  Political and economic uncertainty in the industry due to recent government healthcare reform and increasing regulatory requirements throughout the world are also slowing hospital acquisition of capital equipment at all levels.

In April 2013, we announced an exclusive multi-million dollar master distribution agreement with Terumo Europe NV, a wholly owned subsidiary of Terumo Corporation, for our MicroThermX line of products in 100 countries in Europe, Western Asia and Northern Africa.  Terumo Corporation is a global medical device leader with nearly $5 billion in annual sales and operations in over 160 countries.  Terumo Europe NV has established itself as a pioneer in the field of interventional oncology.   We believe this distribution agreement validates the large market opportunity for MicroThermX ablation products and is expected to drive market adoption for the MicroThermX as a leading ablation therapy system and to drive revenue growth toward profitability.

With the initial success of our relationship with Terumo Europe NV, we will continue our strategy to seek out other master distribution arrangements in other substantial geographic medical device markets.

Domestically, we restructured our sales organization and efforts in 2014 by engaging independent, specialized distributors who sell and distribute medical products to healthcare providers.  These specialized distributors typically have established relationships with interventional radiologists and other end users of cancer treatment products.  Each of these distributors are overseen, trained and serviced by sales managers who are Perseon employees.  We believe that we have now expanded our distributor network and direct sales efforts to cover all large metropolitan areas and states, with sales coverage throughout the entire United States.   

In addition to selling our MicroThermX line we also offer a MicroThermX fee-per-use equipment rental program.  The fee-per-use program allows hospitals to purchase disposable SynchroWave antennas and pay a fee-per-use equipment rental for the treatment of patients using the MicroThermX, dramatically shortening the sales cycle.  This rental program has generated a revenue stream from sales of disposable SynchroWave antennas combined with profitable equipment rental fees.  We continue to aggressively market and sell the rental program throughout the U.S. 

We are committed to “personal service” to new users of the microwave ablation technique.  We provide all of our customers with extensive hands-on training to ensure success in clinical use of the MicroThermX system.  Our representatives are experienced interventional sales representatives with seasoned contacts in the field of interventional oncology.  Our senior sales management team includes professionals with a long history in marketing medical devices and equipment worldwide.
 
Hyperthermia Systems

The Hyperthermia family of products includes the BSD-500,  the BSD-2000, the BSD-2000/3D and the BSD-2000/3D/MR.  These systems  deliver either superficial hyperthermia therapy, which is non-invasive and delivered externally using antennas placed over the tumor, or interstitial hyperthermia therapy, which is delivered using antennas that are inserted into the tumor, or both, or by applying RF energy to certain cancerous tumors, including those located deep within the body.    

Our primary FDA approval (described as a pre-market approval, or “PMA”, which is the standard FDA approval required to market Class III medical devices in the United States) for the BSD-500 is for the use of hyperthermia and radiation therapy to treat certain tumors using the BSD-500.  The BSD-500 is approved for use alone or in conjunction with radiation therapy in the palliative management of certain solid surface and subsurface malignant tumors (i.e., melanoma, squamous- or basal-cell carcinoma, adenocarcinoma, or sarcoma) that are progressive or recurrent despite conventional therapy.

 
5
 
 
On November 21, 2011 the Company obtained HDE marketing approval for the BSD-2000 from the FDA.  The BSD-2000 is approved for use in conjunction with radiation therapy for the treatment of cervical cancer patients who normally would be treated with combined chemotherapy and radiation but are ineligible for chemotherapy due to patient related factors.  The HDE approval authorizes the commercial sale of the BSD-2000.  An HDE approval is obtained after a company has demonstrated the product’s safety and probable benefit for the treatment of a disease affecting fewer than 4,000 people in the United States every year.  In addition, we cannot charge an amount for an HDE approved device that exceeds the costs of research and development, fabrication, and distribution.  A device can have both PMA and an HDE approval as long as the approvals are for different indications for use.

We previously had CE Marking for the BSD-2000 family of products, which would allow us to market the BSD-2000 systems in the thirty countries that comprise the EU and the EFTA. However, effective July 22, 2014, the EU’s Restriction of Hazardous Substances (“RoHS”) regulatory mandate prohibits us from selling our hyperthermia products in the EU under their current configuration.  Although our MicroThermX products are in compliance with RoHS requirements, in order to continue to sell  hyperthermia systems within the EU after July 22, 2014, we would need to make significant and costly changes to the  hyperthermia products to become RoHS compliant.  We made the decision that it was not economically justifiable to continue to offer hyperthermia products in the EU, given RoHS requirements.  The RoHS regulatory mandate allows us to supply replacement parts for current installations.  

CE Marking is also recognized in many countries outside of the EU, which may provide us the ability to market the BSD-2000 family of products to other international markets.   We have also obtained regulatory approval for the sale of the BSD-2000 in Taiwan and the People’s Republic of China, and are partially through the process of gaining regulatory approval for the sale of hyperthermia products in Korea.

We believe that these regulatory approvals, along with several distribution agreements signed with independent distributors discussed in the “Marketing and Distribution—Hyperthermia Systems” section below, may hold value for potential buyers interested in the hyperthermia product line.  For the immediate future, we will continue to focus our efforts on completing the negotiation and sale of the hyperthermia product line.  No assurance can be given that a sale of our hyperthermia assets will be successful or on attractive terms.

Marketing and Distribution

MicroThermX.  Our U.S. network of direct sales representatives and four domestic specialty distribution firms provide nationwide sales coverage for the MicroThermX line of products.

In addition, in April 2013 we entered into an exclusive, long-term master distribution agreement with Terumo Europe NV in 100 countries in Europe, Western Asia and Northern Africa.  We have a Director of International Sales that manages this relationship, as well as agreements with other international specialty distribution firms.  Our marketing and distribution strategy for our MicroThermX business includes seeking out and securing additional master distribution arrangements for our MicroThermX line of products in other parts of the world.

            Hyperthermia Systems.  To support our direct sales and marketing efforts for our hyperthermia systems and products in the United States, we have utilized independent sales representatives supported by our senior management.  Our recent plan has been to minimize efforts in the U.S., due to regulatory, economic and reimbursement challenges and to focus on marketing and sales efforts of hyperthermia products through distributors in Asia.

Historically we have recognized revenues derived from sales to Dr. Sennewald Medizintechnik GmbH and its affiliated entities (“Medizintechnik”) located in Munich, Germany, which is our exclusive distributor of hyperthermia systems in Germany, Austria and Switzerland, and to certain medical institutions in Belgium and the Netherlands.  This company is owned by Dr. Gerhard W. Sennewald, one of our former directors and a significant stockholder.  
 
 
6
 
 
Sales of hyperthermia products in the EU have been trending down as a percent of our total sales since fiscal 2011.  With the RoHS regulatory mandate, we are prohibited from selling our hyperthermia products in the EU in their current configuration.

Pursuant to an agreement we have with Dalian Orientech Co. LTD (“Orientech”), a privately owned company, Orientech assisted us in obtaining regulatory approval from China’s Food and Drug Administration (the “CFDA”) for the sale of the BSD-2000 in the People’s Republic of China, and acts as our distributor for the sale of the BSD-2000 in that country.  

We have an exclusive agreement with Han Beam Technology, Inc. (“Han Beam”) for the sale and distribution of our hyperthermia products in South Korea.   We are in the process of obtaining regulatory approval for the BSD-2000 in South Korea.

We have approval to market hyperthermia systems in the Russian Federation.  The Russian approval does not expire; however, any shipment into Russia also requires a GOST-R Quality Certificate.  Our GOST-R Quality Certificate expires July 26, 2015, and would have to be renewed after that date if we continue to ship products into Russia.

We have an agreement with Linden Bioscience Co., Ltd. (“Linden”), a Taiwan Corporation, for the sale and distribution of our hyperthermia products in Taiwan.  

The exclusive agreements with Orientech Hanbeam and Linden require annual minimum  purchases of BSD-2000 systems in order to maintain their exclusivity.

Third-Party Reimbursement
 
We view obtaining adequate third-party reimbursement arrangements as essential to achieving commercial acceptance of our hyperthermia and ablation therapy products.  Our products are purchased primarily by clinics, hospitals and other medical institutions that bill various third-party payers, such as Medicare, Medicaid, other government programs and private insurance plans, for the health care services provided to their patients using our products.  Additionally, managed care organizations and insurance companies directly pay for services provided to their patients.  

The Center for Medicare and Medicaid Services (“CMS”), has established billing codes that allow for third-party reimbursement and can be used for or in combination with the delivery of hyperthermia and ablation therapies, depending on the circumstances of the treatment. Appropriate codes apply to billing for certain ablation procedures.  Billing codes are available for both institutions and physicians. Even though billing codes have been established, payments must also be approved by and authorized through the various third-party payers, and third-party payers can establish varying reimbursement plans and levels that can affect hyperthermia and ablation reimbursement levels.  Obtaining reimbursement in the U.S. can be unpredictable and difficult for hyperthermia.  We believe that sales of hyperthermia products in the U.S. face significant reimbursement challenges.

Medical reimbursement rates are unpredictable, and we cannot project the extent to which our business may be affected by future legislative and regulatory developments.  There can be no assurance that future health care legislation or regulation will not have a material adverse effect on Perseon’s business, financial condition and results of operations, or that reimbursement, existing or in the future, will be adequate for all customers.

Competition

We have presented what we believe are our competitive advantages in the discussion of our products above.

Competitors in the thermal ablation market include RadioTherapeutics, a division of Boston Scientific Corporation, Covidien Ltd., Angiodynamics, Inc., NeuWave Medical, MedWaves Incorporated, and HS Hospital Service S.p.A.  Many of these companies have been in the thermal ablation business for several years, are significantly larger organizations, and have greater financial resources than us.

 
7
 
 
Competition in the medical products industry is intense.  We believe that established product lines and cancer therapies, governmental approvals, know-how and reputation in the industry are key competitive factors.  Currently, only a few companies besides Perseon have received FDA approval to manufacture and sell hyperthermia therapy systems within the United States, including U.S. Labthermics and Celsion Corporation, and only a few companies besides Perseon are marketing hyperthermia outside the U.S.  Celsion has been principally involved with clinical trials related to thermotherapy, hyperthermia and related fields; however, Celsion has announced the transformation of its company from a medical device company to a biopharmaceutical, solely focused on the development of drugs for the treatment of cancer.  Several other companies have received IDEs in the United States or other international approvals for certain hyperthermia systems designed to treat both malignant and benign diseases.  Additionally, other companies, particularly established companies that currently manufacture and sell other cancer therapy systems, could potentially become competitors (in that they are also engaged in cancer treatment businesses), and they have significantly greater resources than we do. There are other companies providing hyperthermia products in Europe and Asia.
  
Product Service

We generally provide a 12-month warranty on all our cancer treatment systems and a 90-day limited warranty on individual components.  We install and service the systems we sell to domestic customers.  In addition, we provide technical training and support to our customers.  Subsequent to the applicable warranty period, we offer our domestic customers full or limited service contracts.

Generally, our international distributors install and service our systems sold to foreign customers and are responsible for managing their own warranty programs for their customers, including labor and travel expenses.  We provide training, procedures and forms to the distributors providing these types of services.  We provide warranties for the replacement and/or repair of parts for 12 months for systems sold internationally through distributors and for 90 days for individual components.  Spare parts are generally purchased by the distributors and stored at the distributors’ maintenance facilities to allow prompt repair.

Production

We manufacture and test our systems and products at our facilities in Salt Lake City, Utah.  Our manufacturing facility is ISO 13485 certified and follows FDA quality systems regulations.  Some equipment components we purchase from suppliers are customized to our specifications.  Key factors in our manufacturing process are assembly and testing.  We purchase component parts and other materials from a variety of suppliers and believe we can acquire materials and parts from multiple sources on a timely basis.

Product Liability Exposure

The manufacturing and marketing of medical devices involves an inherent risk of product liability.  We presently carry product liability insurance with coverage limits of $5 million; however, we cannot assure that our product liability insurance will provide adequate coverage against potential claims that might be made against us.  No product liability claims are presently pending against us; however, we cannot assure that product liability claims will not be filed in the future or that such claims will not exceed our coverage limits.

Government Regulation

Domestic Regulation of Our Products and Business - Food and Drug Administration

Our research, development and clinical programs, as well as our manufacturing and marketing operations, are subject to extensive regulation in the United States and other countries. Most notably, all of our products sold in the United States are subject to the Federal Food, Drug, and Cosmetic Act (the “FDCA”), as implemented and enforced by the FDA. Certain of our products sold in the United States require FDA clearance to market under Section 510(k) of the FDCA. FDA governs the following activities that we perform or that are performed on our behalf, to ensure that medical products distributed domestically or exported internationally are safe and effective for their intended uses:
 
 
8
 
 
·
product design, development and manufacture;
   
·
product safety, testing, labeling and storage;
   
·
record keeping procedures;
   
·
product marketing, sales and distribution; and
   
·
post-marketing surveillance, complaint handling, medical device reporting, reporting of deaths, serious injuries or device malfunctions and repair or recall of products.
 
            There are numerous FDA regulatory requirements governing the approval or clearance and marketing of our products. These include:
 
·
product listing and establishment registration, which helps facilitate FDA inspections and other regulatory action;
   
·
Quality System Regulation (“QSR”) which requires manufacturers, including third-party manufacturers, to follow stringent design, testing, control, documentation and other quality assurance procedures during all aspects of the manufacturing process;
   
·
labeling regulations and FDA prohibitions against the promotion of products for uncleared, unapproved or off-label use or indication;
   
·
clearance or approval of product modifications that could significantly affect safety or efficacy or that would constitute a major change in intended use of a cleared product;
   
·
approval of product modifications that affect the safety or effectiveness of an approved product;
   
·
medical device reporting regulations, which require that manufacturers comply with FDA requirements to report if their device may have caused or contributed to a death or serious injury, or has malfunctioned in a way that would likely cause or contribute to a death or serious injury if the malfunction of the device or a similar device were to recur;
   
·
post-approval restrictions or conditions, including post-approval study commitments;
   
·
post-market surveillance regulations, which apply when necessary to protect the public health or to provide additional safety and effectiveness data for the device; and
   
·
notices of correction or removal and recall regulations.
 
We have registered our facility with the FDA as a medical device manufacturer. The FDA has broad post-market and regulatory enforcement powers. We are subject to announced and unannounced inspections by the FDA to determine our compliance with the QSR and other regulations and these inspections may include the manufacturing facilities of our suppliers.
 
FDA's premarket clearance and approval requirements. Unless an exemption applies, before we can commercially distribute medical devices in the United States, depending on the type of device, we must obtain either prior 510(k) clearance or PMA from the FDA, unless a specific exemption applies. The FDA classifies medical devices into one of three classes:
 
·
Class I devices, which are subject to only general controls (e.g., labeling, medical devices reporting, and prohibitions against adulteration and misbranding) and, in some cases, to the 510(k) premarket clearance requirements;
   
·
Class II devices, generally requiring 510(k) premarket clearance before they may be commercially marketed in the United States; and
   
·
Class III devices, consisting of devices deemed by the FDA to pose the greatest risk, such as life-sustaining, life-supporting or implantable devices, or devices deemed not substantially equivalent to a predicate device, generally requiring submission of a PMA supported by clinical trial data.
  
 
9
 
 
510(k) clearance pathway
 
When a 510(k) clearance is required, we must submit a premarket notification demonstrating that our proposed device is substantially equivalent to a previously cleared 510(k) device or a device that was in commercial distribution before May 28, 1976 for which the FDA has not yet called for the submission of PMAs. By regulation, the FDA is required to clear or deny a 510(k) premarket notification within 90 days of submission of the application. As a practical matter, clearance may take longer. The FDA may require further information, including clinical data, to make a determination regarding substantial equivalence.
 
Any modification to a 510(k)-cleared device that would constitute a major change in its intended use, or any change that could significantly affect the safety or effectiveness of the device, requires a new 510(k) clearance and may even, in some circumstances, require a PMA, if the change raises complex or novel scientific issues or the product has a new intended use. The FDA requires every manufacturer to make the determination regarding the need for a new 510(k) submission in the first instance, but the FDA may review any manufacturer's decision. We have modified our devices since they received the FDA clearance. If the FDA were to disagree with any of our determinations that changes did not require a new 510(k), it could require us to cease marketing and distribution and/or recall the modified device until 510(k) clearance or PMA approval is obtained. If the FDA requires us to seek 510(k) clearance or PMA approval for any modifications, we may be required to cease marketing and/or recall the modified device, if already in distribution, until 510(k) clearance or PMA approval is obtained and we could be subject to significant regulatory fines or penalties.
  
There is no guarantee that the FDA will grant 510(k) clearance or PMA approval of our future products and failure to obtain necessary clearances or approvals for our future products would adversely affect our ability to grow our business. Delays in receipt or failure to receive clearances or approvals, the loss of previously received clearances or approvals, or the failure to comply with existing or future regulatory requirements could reduce our sales, profitability and future growth prospects.
 
Premarket approval (PMA) pathway
 
A PMA or an HUD and HDE application must be submitted to the FDA if the device cannot be cleared through the 510(k) process. A PMA must be supported by extensive data, including but not limited to, technical, preclinical, clinical trials, manufacturing and labeling to demonstrate to the FDA's satisfaction the safety and effectiveness of the device for its intended use. During the review period, the FDA will typically request additional information or clarification of the information already provided. Also, an advisory panel of experts from outside the FDA may be convened to review and evaluate the application and provide recommendations to the FDA as to the approvability of the device. The FDA may or may not accept the panel's recommendation. In addition, the FDA will generally conduct a pre-approval inspection of the manufacturing facility or facilities to ensure compliance with the QSRs.
 
New PMAs or PMA supplements are required for modifications that affect the safety or effectiveness of the device, including, for example, certain types of modifications to the device's indication for use, manufacturing process, labeling and design. PMA supplements often require submission of the same type of information as a PMA, except that the supplement is limited to information needed to support any changes from the device covered by the original PMA and may not require as extensive clinical data or the convening of an advisory panel. There is no guarantee that the FDA will grant PMA approval of our future products and failure to obtain necessary approvals for our future products would adversely affect our ability to grow our business. Delays in receipt or failure to receive approvals, the loss of previously received approvals, or the failure to comply with existing or future regulatory requirements could reduce our sales, profitability and future growth prospects.
 
Humanitarian Device Exemption (HDE) Pathway
 
In order for a device to be eligible for an HDE, it must be intended for use in a qualifying target patient population of less than 4,000 patients per year for which there is no other comparable device available to treat the condition. This qualifying target patient population must be approved by the FDA. The FDA’s approval of an HDE to treat that qualifying patient population then requires demonstration that the device is safe for its intended application, that it is potentially effective, and that the probable benefits outweigh the associated risks, which is a lower standard than is applied to a PMA. Within the regulations for an HDE, if a device becomes available through the PMA or 510(k) pathway that addresses the same patient population as the HDE device, the HDE device may need to be withdrawn from the U.S. market. An approved HDE authorizes sales of the device to any hospital after Institutional Review Board review and approval by the hospital. New HDEs or HDE supplements are required for modifications that affect the safety or effectiveness of the device, including, for example, certain types of modifications to the device's indication for use, manufacturing process, labeling and design.
 
 
10
 
 
Clinical Trials

Clinical trials are generally required to support a PMA application and are sometimes required for 510(k) clearance and HDE approval.  Such trials generally require an investigational device exemption application (“IDE”), approved in advance by the FDA for a specified number of patients and study sites, unless the product is deemed a nonsignificant risk device eligible for more abbreviated IDE requirements. Clinical trials are subject to extensive monitoring, recordkeeping and reporting requirements. Clinical trials must be conducted under the oversight of an institutional review board (“IRB”) for the relevant clinical trial sites and must comply with FDA regulations, including but not limited to those relating to good clinical practices. To conduct a clinical trial, we also are required to obtain the patients' informed consent in form and substance that complies with both FDA requirements and state and federal privacy and human subject protection regulations. We, the FDA or the IRB could suspend a clinical trial at any time for various reasons, including a belief that the risks to study subjects outweigh the anticipated benefits. Even if a trial is completed, the results of clinical testing may not adequately demonstrate the safety and efficacy of the device or may otherwise not be sufficient to obtain FDA approval to market the product in the United States.

Pervasive and continuing regulation

After a device is placed on the market, numerous regulatory requirements apply.  These include:

·
Product listing and establishment registration, which helps facilitate FDA inspections and other regulatory action;
   
·
QSR, which requires manufacturers, including third-party manufacturers, to follow stringent design, testing, control, documentation and other quality assurance procedures during all aspects of the manufacturing process;
   
·
labeling regulations and FDA prohibitions against the promotion of products for uncleared, unapproved or off-label use or indication;
   
·
clearance of product modifications that could significantly affect safety or efficacy or that would constitute a major change in intended use of one of our cleared devices;
   
·
approval of product modifications that affect the safety or effectiveness of one of our approved devices;
   
·
medical device reporting regulations, which require that manufacturers comply with FDA requirements to report if their device may have caused or contributed to a death or serious injury, or has malfunctioned in a way that would likely cause or contribute to a death or serious injury if the malfunction of the device or a similar device were to recur;
 
 ·
post-approval restrictions or conditions, including post-approval study commitments;
   
·
post-market surveillance regulations, which apply when necessary to protect the public health or to provide additional safety and effectiveness data for the device;
   
·
the FDA's recall authority, whereby it can ask, or under certain conditions order, device manufacturers to recall from the market a product that is in violation of governing laws and regulations;
   
·
regulations pertaining to voluntary recalls; and
   
·
notices of corrections or removals.
 
 
11
 
 
Advertising and promotion of medical devices, in addition to being regulated by the FDA, are also regulated by the Federal Trade Commission and by state regulatory and enforcement authorities.  Recently, promotional activities for FDA-regulated products of other companies have been the subject of enforcement action brought under healthcare reimbursement laws and consumer protection statutes.  In addition, under the federal Lanham Act and similar state laws, competitors and others can initiate litigation relating to advertising claims.  In addition, we are required to meet regulatory requirements in countries outside the United States, which can change rapidly with relatively short notice. If the FDA determines that our promotional materials or training constitutes promotion of an unapproved use, it could request that we modify our training or promotional materials or subject us to regulatory or enforcement actions, including the issuance of an untitled letter, a warning letter, injunction, seizure, civil fine or criminal penalties.  It is also possible that other federal, state or foreign enforcement authorities might take action if they consider our promotional or training materials to constitute promotion of an unapproved use, which could result in significant fines or penalties under other statutory authorities, such as laws prohibiting false claims for reimbursement.  In that event, our reputation could be damaged and adoption of the products would be impaired.
 
Furthermore, our products could be subject to voluntary recall if we or the FDA determine, for any reason, that our products pose a risk of injury or are otherwise defective.  Moreover, the FDA can order a mandatory recall if there is a reasonable probability that our device would cause serious adverse health consequences or death.
 
The FDA has broad post-market and regulatory enforcement powers.  We are subject to unannounced inspections by the FDA to determine our compliance with the QSR and other regulations, and these inspections may include the manufacturing facilities of some of our subcontractors.  Failure by us or by our suppliers to comply with applicable regulatory requirements can result in enforcement action by the FDA or other regulatory authorities, which may result in sanctions including, but not limited to:
 
·
untitled letters, warning letters, fines, injunctions, consent decrees and civil penalties;
   
·
unanticipated expenditures to address or defend such actions
   
·
customer notifications for repair, replacement, refunds;
   
·
recall, detention or seizure of our products;
   
·
operating restrictions or partial suspension or total shutdown of production;
   
·
refusing or delaying our requests for 510(k) clearance or premarket approval of new products or modified products;
   
·
operating restrictions;
   
·
withdrawing 510(k) clearances on PMA approvals that have already been granted;
   
·
refusal to grant export approval for our products; or
   
·
criminal prosecution.
  
If the FDA determines that our promotional materials or training constitutes promotion of an unapproved use, it could request that we modify our training or promotional materials or subject us to regulatory or enforcement actions, including the issuance of an untitled letter, a warning letter, injunction, seizure, civil fine or criminal penalties. It is also possible that other federal, state or foreign enforcement authorities might take action if they consider our promotional or training materials to constitute promotion of an unapproved use, which could result in significant fines or penalties under other statutory authorities, such as laws prohibiting false claims for reimbursement. In that event, our reputation could be damaged and adoption of the products would be impaired.

 
12
 
 
The medical devices that we have developed and are developing are subject to extensive, rigorous, and unpredictable regulation by numerous governmental authorities, including the FDA and comparable foreign agencies.  

Although our MicroThermX has received FDA marketing clearance as a 510(k) submission, most of our hyperthermia treatment systems, including the BSD-500 and the BSD-2000 and related products, have required or require PMA or an HDE marketing approval from the FDA instead of the simpler 510(k) clearance.  Significant product changes for PMA or HDE approved devices must be submitted to the FDA under investigational device exemptions, or IDEs, or under PMA or HDE supplements.  As described in the above section entitled “Our Products and Services”, we have obtained a PMA for our BSD-500 system and an HDE for our BSD-2000 system.  Significant changes to the MicroThermX may require a new 510(k).

Foreign countries, in which our products are or may be sold, have regulatory requirements that can vary widely from country to country.  Sales into the EU, require compliance with the Medical Devices Directive, or MDD, and require us to obtain the necessary certifications to have a CE Mark affixed to our products.  All medical devices must be manufactured in accordance with regulations and in compliance with other applicable standards.  We have obtained necessary ISO-13485 certification of our quality, development, and manufacturing processes and we have successfully completed the CE Mark testing and Annex II audit.  

After certification and CE Marking approval, an EU approved notified body reviews quality and design records annually to maintain certification, including design and manufacturing practices, labeling, record-keeping, and required reporting of adverse experiences.  We must maintain compliance with all current and future directives and requirements to maintain ISO certification and to continue to affix the CE Mark, and there can be no assurance that we will continue to maintain compliance with regulatory requirements imposed on us.

The RoHS regulatory mandate prohibits us from selling our hyperthermia products in the EU under their current configuration.  Although our MicroThermX products are in compliance with RoHS requirements, in order to continue to sell our hyperthermia systems within the EU we would need to make significant and costly changes to component parts used in our hyperthermia products to become RoHS compliant.  We do not believe that it is economically justifiable at this time to continue to offer hyperthermia systems in the EU, given RoHS requirements.

In addition, regulations for the sale of medical devices into the EU are being revised and the revisions will impose stricter requirements on medical device companies, and there can be no assurance that we will continue to maintain compliance with future regulatory requirements.

After we receive FDA approval to market a medical device, we continue to have ongoing responsibilities under the Federal Food, Drug, and Cosmetic Act and FDA regulations.  The FDA currently mandates a post-approval study for PMA and HDE approved devices.  As a condition of our HDE approval for the BSD-2000, the FDA required Perseon to conduct a post-market registry study, “Deep Hyperthermia and Radiation in the Treatment of Cervical Cancer Patients."  Due to challenges enrolling patients and sites in a small population with this rare disease, no patients were enrolled in this initial post-approval study. Because of these challenges, Perseon initiated collaborative discussions with FDA regarding the structure of the study.   As a result, the initial post-market study structure has been revised, and we are in current discussions with our clinical sites regarding participation in the revised study. We are still experiencing challenges in enrolling patients and sites and have been unable to obtain participation in the restructured study as of the date of this filing.  The status of Perseon's post-approval study is listed as "progress inadequate" on the FDA's website.  We have initiated additional discussions with the FDA regarding how best to address these challenges, but there can be no assurance that we will be able to successfully meet our ongoing responsibilities for the post-approval study mandated by the FDA as part of our HDE approval.  We have submitted all periodic updates to the FDA as required and in a timely manner.

            The FDA also reviews design and manufacturing practices, labeling, record-keeping, and required reporting of adverse experiences.  All medical devices must be manufactured in accordance with regulations specified in the FDA Quality System Regulations, or QSR, and in compliance with other applicable standards.

 
13
 
 
In complying with the FDA, EU, and other country regulations, we must continue to expend time, money and effort in the areas of design control, production, and quality control to ensure full compliance.

The FDA’s mandatory Medical Device Reporting regulation requires us to provide information to the FDA on death or serious injuries alleged to have been associated with the use of our products, as well as information on product malfunctions that would likely cause or contribute to a death or serious injury if the malfunctions were to recur.  In Europe, the MDD vigilance system regulations require that we, through a representative in Europe, provide information to authorities on death or serious injuries alleged to have been associated with the use of our products, as well as information on product malfunctions that would likely cause or contribute to a death or serious injury if the malfunctions were to recur.   Certain regulations are subject to administrative interpretation and we cannot assure that future interpretations made by the FDA or other regulatory bodies, with possible retroactive effect, will not adversely affect us.

International sales are subject to the regulatory and safety requirements of the country into which the sale occurs.  There can be no assurance that all of the necessary approvals will be granted on a timely basis or at all.  Delays in receipt of or failure to receive such approvals would have a material adverse effect on our financial condition and results of operations.  International sales of medical devices are subject to FDA export requirements.

In addition to FDA regulations, certain U.S. health care laws apply when a claim for reimbursement for one of our medical devices is submitted to Medicare, Medicaid, or other federal health care programs.  For instance, federal law prohibits the filing of false or improper claims for federal payments.  In addition, federal law prohibits the payment of anything of value for the purpose of inducing referrals of business reimbursable under a federal health care program.  Other federal laws prohibit physicians from making referrals for certain services and items payable under certain federal programs if the physician has a financial relationship with the entity providing the service or item.

All of these laws are subject to evolving interpretations.  If the federal government were to conclude that we are not in compliance with any of these health care laws, we could be subject to substantial criminal and civil penalties, and could be excluded from participation as a supplier to beneficiaries in federal health care programs.

The Federal Communications Commission, or FCC, regulates the frequencies of microwave and radio frequency emissions from medical and other types of equipment to prevent interference with commercial and governmental communications networks. The BSD-500 fixed frequency systems and applicators and the MicroThermX ablation system and applicators emit 915 MHz, which is approved by the FCC for medical applications.  Accordingly, these systems do not require shielding to prevent interference with communications.  Our BSD-2000 deep hyperthermia variable-frequency generators and applicators require electromagnetic shielding.
  
Patents, Licenses, and Other Rights

Because of the substantial length of time and expense associated with bringing new products through development and regulatory approval to the marketplace, the medical device industry places considerable importance on obtaining patent and trade secret protection for new technologies, products and processes.  Our policy is to file patent applications to protect significant technology, inventions and product improvements.  We currently own eight non-expired patents in the United States related to certain components or technology of our ablation and hyperthermia systems.  We currently have one patent license from Duke University.  Eleven new U.S. patent applications have been published in the United States, and one foreign patent is issued and others are pending.  A total of 29 U.S. patents have been issued to Perseon.  We believe that our patents represent the early pioneering and dominant patents in this field.

In July 1979, we entered into an exclusive worldwide license for a unique temperature probe (sensor) called the Bowman Probe.  The Bowman Probe is considered to be the “gold standard” in temperature monitoring devices for hyperthermia.  The license will remain in effect as long as the technology does not become publicly known as a result of actions taken by the licensor.  We pay royalties based upon our sales of the Bowman Probe.  The license agreement was amended and renewed in August 2000 and is currently in effect.

On July 31, 2007, Perseon obtained an exclusive sub-license to a patent owned by Duke University using phased array technology for the treatment of primary breast cancer on terms that included hyperthermia equipment upgrades and payment of some prior patent costs.  
 
 
14
 
 
On July 1, 2001, we acquired the rights to all FDA approvals and the rights to manufacture all cancer products formerly owned by Clinitherm Corp.  These products are related to the hyperthermia therapy delivered by our BSD-500 systems and our enhancements to such systems involve incorporating some of the Clinitherm rights we acquired into such systems.  This involved only a one-time cash payment with no continuing costs.

We cannot assure that the patents presently issued to us will be of significant value to us in the future or will be held valid upon judicial review.  Successful litigation against these patents by a competitor would have a material adverse effect upon our business, financial condition and results of operations.  We believe that we possess significant proprietary know-how in our hardware and software capabilities.  However, we cannot assure that others will not develop, acquire or patent technologies similar to ours or that such secrecy will not be breached.

Research and Development
 
Research and development expenses for the four month transition period ended December 31, 2014 and for the fiscal years ended August 31, 2014 and 2013 were $627,769, $2,229,043 and $2,281,854, respectively.  Through the end of 2014, we have continued our efforts to enhance and improve our ablation products, sustain and fill current order requirements for our hyperthermia products, and to focus our product development, technology and engineering resources on the following:
 
·
development of SynchroWave short tip antenna used to deliver smaller, spherical ablation zones;
   
·
incorporating new requirements into the design and manufacturing processes;
   
·
designing and testing of new advanced cooled disposable microwave ablation antennas;
   
·
supporting MicroThermX regulatory requirements;
   
·
adaptation of our BSD-2000/3D/MR to both Siemens and GE MR configurations;
   
·
sustaining engineering for our BSD-500 and BSD-2000 systems where necessary to maintain ongoing manufacturability;
   
·
supporting product approvals for US and non-US governments;
   
·
research and development projects not publicly disclosed.
 
            Technological changes play an important part in the advancement of our industry.  We intend to continue to devote substantial sums to research and development.  Research and development efforts inherently involve costs, risks and uncertainties that could adversely affect our projections, outlook and operating results.
 
Seasonality

Our operations are generally not subject to seasonal fluctuations.

Segment Information and Sales Concentrations

We consider our operations to comprise one business segment.  All of our operating assets are located in the United States.

At times, in past fiscal years, we have derived a significant portion of our revenues from sales to Medizintechnik, which has been a significant distributor of our products in Europe, and which is owned by Dr. Gerhard W. Sennewald, one of our former directors and a significant shareholder.  However, with the exception of one BSD-2000 unit Medizintechnik purchased from us in 2014, we have experienced declining sales to this related party.  For the four month transition period ended December 31, 2014, we had sales to Medizintechnik of $463,423, or 42% of our total revenues.  This was comprised mostly of revenue recognized on the completion and shipment of one hyperthermia system that was ordered in early 2013.  For the year ended August 31, 2014 we had sales of $419,549, or 8% of our total sales, from the sale of hyperthermia systems and various component parts sold to Medizintechnik.   Management believes the terms of these transactions with Medizintechnik were arm’s length and fair to the Company.

 
15
 
 
A significant portion of our revenues are derived from sales to foreign customers.  During the four month transition period ended December 31, 2014, and fiscal years ended August 31, 2014 and 2013, export sales totaled $630,857, $3,381,563 and $1,470,619, or approximately 56%, 63% and 40% of total sales, respectively.  During the four month transition period ended December 31, 2014 we had sales to two foreign customers representing 42% and 11% of total revenues.  For the fiscal year ended August 31, 2014, these two customers each represented 23% of total revenues.  During the year ended August 31, 2013, we had sales to one foreign customer totaling 30% of total revenues.  

During the four month transition period ended December 31, 2014 and the fiscal years ended August 31, 2014 and 2013, domestic sales totaled $485,051, $1,946,790 and $2,202,673, or approximately 44%, 37% and 60% of total revenues, respectively.  In the four month transition period ended December 31, 2014 and the fiscal year ended August 31, 2014, no single domestic customer accounted for more than 10% of total revenues.

Backlog

As of December 31, 2014, we had a sales backlog of $347,500.

Employees

As of December 31, 2014, we had 49 employees; 47 of whom were full-time employees.  None of our employees are covered by a collective bargaining agreement.  We consider our relations with our employees to be satisfactory.  We depend upon a limited number of key management, manufacturing, and technical personnel.  Our future success will depend in part on our ability to retain these highly qualified employees.

Available Information

We file annual, quarterly and current reports, and other reports and documents with the Securities and Exchange Commission (the "SEC").  The public may read and copy any materials we file with the SEC at the SEC's Public Reference Room, 100 F Street, N.E., Washington, D.C. 20549. The public may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330.  The SEC also maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC.  The address of that website is http://www.sec.gov.

The Company's Internet address is http://www.bsdmedical.com.  We make available on or through our investor link on our website, free of charge, our Annual Reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and any amendments to those reports as soon as reasonably practicable after this material is electronically filed or furnished to the SEC.

 
16
 

ITEM 1A.  RISK FACTORS

Our future operating results are highly uncertain.  Before deciding to invest in Perseon or to maintain or increase your investment, you should carefully consider the risks described below, in addition to the other information contained in this Transition Report on Form 10-K.  If any of these risks actually occur, our business, financial condition or results of operations could be seriously harmed.  In that event, the market price for our common stock could decline and you may lose all or part of your investment.  Although we have attempted to list the factors of which we are currently aware that may have an impact on its operations, there may be other factors of which we are currently unaware or to which we do not assign sufficient significance, and the following list should not be considered comprehensive.

We have a history of significant operating losses and such losses may continue in the future.

Since our inception in 1978, our expenses have substantially exceeded our revenue, resulting in continuing losses and an accumulated deficit of $56,540,160 as of December 31, 2014.  We reported net losses of  $3,768,390 for the four month transition period ended December 31, 2014, and $7,142,832 and $8,251,691 for the fiscal years ended August 31, 2014 and 2013, respectively.

We may continue to incur operating losses in the future as we continue to incur costs to develop our products, protect our intellectual property and expand our sales and marketing activities.  To become profitable we will need to increase significantly the revenues we receive from sales of our MicroThermX line of products to improve our profitability on a quarterly or annual basis.  We have been unable to do this in the past and we may be unable to do so in the future, and therefore may never achieve profitability.

We have obtained FDA 510(k) clearance to market our MicroThermX Microwave Ablation System, and have experienced early success in sales of the MicroThermX  family of products.  You  cannot be assured that our efforts to commercialize the MicroThermX will be successful or that we will attain expected revenue levels.

In August 2010, the FDA granted us a 510(k) clearance to market our MicroThermX Microwave Ablation System for ablation of soft tissue, authorizing the commercial sale of the MicroThermX in the United States.  We have experienced growth in revenues from our MicroThermX family of products.  Our MicroThermX products represent a major part of our business plan moving forward and introduce into our product line an innovative, high-end disposable that is used in each ablation treatment and which we believe will provide a significant ongoing revenue stream.

Political and economic uncertainty in the healthcare industry due to government healthcare reform and the continuing worldwide economic turndown has made hospital acquisitions of capital equipment difficult at all levels.  With hospital capital budgeting, committee review and other approvals, the sales cycle for the MicroThermX may extend to well over six months.  To accelerate revenues from the MicroThermX line of products, we have a program that allows hospitals to purchase disposable SynchroWave antennas and pay a fee-per-use rental for the treatment of patients using the MicroThermX products.  We expanded the equipment rental program throughout the U.S., contracting with specialty medical products distributors and hiring direct sales representatives in key major metropolitan areas who provide “personal service” to new users of the microwave ablation technique.  These are experienced interventional sales representatives with established contacts and relationships in the field of interventional oncology.  We have experienced early success with these sales programs and increasing revenues; however, you cannot be assured that we will attain expected revenue levels from the MicroThermX line of products.  If these efforts are not successful, our business will be adversely affected.
 
Our profitability will be driven in large part by international sales of our MicroThermX family of products; therefore, we are dependent on our ability to successfully establish our international sales distribution channels.

With our United States direct sales network in place for our MicroThermX family of products, we are placing significant emphasis on Europe and other international markets.  International sales of our MicroThermX family of products will depend on our ability to successfully establish sales distribution channels in Europe and other international markets.  We believe that the distribution agreement with Terumo Europe NV will drive market adoption of the MicroThermX product line.  However, this agreement in in its early stages and the ultimate success of the Terumo relationship is yet to be determined.  We also expect to reach distribution agreements with additional international distribution firms.  If these efforts are not successful, our business will be adversely affected.

 
17
 
 
Our current strategy includes the possibility of entering into additional collaborative arrangements with third parties to expand and improve the commercialization of all our products; however, there can be no assurance that such strategic alternatives will result in any successful agreements or transactions.

As demonstrated by our April 2013 signing of the master distribution agreement with Terumo Europe NV for our MicroThermX line of products, our current strategy includes the possibility of entering into additional collaborative arrangements with third parties to expand and improve the commercialization of all our products.   There can be no assurance that the exploration of strategic alternatives will result in any agreements or transactions, or that, if completed, any agreements or transactions will be successful or on attractive terms.

We intend to sell or discontinue our hyperthermia product line early in 2015; there can be no assurance that a sale of our hyperthermia assets will be successful or on attractive terms.

Historically, our product offerings have included hyperthermia cancer treatment systems.  We have previously announced that we intend to sell or discontinue our hyperthermia product line early in 2015.  Our current strategy is to seek out, identify opportunities and, if possible, secure a transaction or transactions relating to our hyperthermia assets. We have attracted an interested buyer, a non-binding term sheet for the potential sale of assets related to our hyperthermia product line has been submitted and accepted, final terms are being negotiated and due diligence efforts are underway.  Although we expect to close the transaction on the sale of our hyperthermia assets in the spring of 2015, no assurance can be given that a sale of our hyperthermia assets will be successful or on attractive terms.

At times, a significant portion of our revenues have been from sales of our hyperthermia products; if we sell or discontinue our hyperthermia product line, our revenues from the sale of hyperthermia systems and related component parts and services will cease.

At times, a significant portion of our sales have been based upon a relatively small number of hyperthermia systems, the sales price of each being substantial enough to greatly impact revenue levels in the periods in which they occur.  We have experienced increasing revenues from our MicroThermX line of products, but have been unable to sustain or grow revenues from our hyperthermia systems.  We intend to sell or discontinue our hyperthermia product line early in 2015.  If we sell or discontinue our hyperthermia product line, our revenues from the sale of hyperthermia systems and related component parts and services will cease.

Adverse worldwide economic conditions have made it difficult for our customers to obtain approval for the purchase of and funding for our hyperthermia systems.

Our hyperthermia cancer treatment systems represent capital equipment purchases for our customers.  Adverse worldwide economic conditions have made it difficult for our customers to obtain approval for the purchase of and funding for our systems.  This has contributed to a lack of growth in the worldwide sales of our hyperthermia systems and to a slower than anticipated introduction into the market place of our MicroThermX line of products.  To the extent that adverse economic conditions continue, we believe our sales of cancer treatment systems will continue to be negatively impacted.
 
A significant portion of our revenues is from foreign countries.

A significant portion of our revenues are derived from sales to foreign customers.  Export sales were $630,857 for the four month transition period ended December 31, 2014, and were $3,381,563 and $1,470,619 for the fiscal years ended August 31, 2014 and 2013, respectively.  During the four month transition period ended December 31, 2014, export sales to Germany and Belgium combined were 53% of total sales. For the fiscal year ended August 31, 2014, export sales to Taiwan and Belgium combined were approximately 46% of total sales.  During the fiscal year ended August 31, 2013, export sales to Belgium and Germany were approximately 33% of total sales.

To the extent that we are unable to maintain or increase the level of our revenues derived from foreign customers, the results of our operations could be negatively impacted.

 
18
 
 
Sales of our products could be significantly reduced if government, private health insurers and other third-party payers do not provide sufficient coverage or reimbursement.

Our success in selling our products will depend in large part on the extent to which reimbursement for the costs of our products and related treatments are available from government health agencies, private health insurers and other third-party payers.  Despite the existence of general reimbursement policies, local medical review policies may differ for public and private insurance payers, which may cause payment to be refused for some hyperthermia treatments.  Private payers also may refuse to pay for hyperthermia treatments.

Medical reimbursement rates are unpredictable and we cannot predict the extent to which our business may be affected by future legislative and regulatory developments.  Future health care legislation or regulation may limit our business or impose additional delays and costs on our business and third-party reimbursement may not be adequate to cover our costs associated with producing and selling our products.

Cancer therapy is subject to rapid technological change and therapies that are more effective than ours could render our technology obsolete.

The treatment of cancer is currently subject to extensive research and development.  Many cancer therapies are being researched and our products may be rendered obsolete by existing therapies and as a result of therapy innovations by others.  If our products are rendered obsolete, our revenue will decline, we may never achieve profitability, and we may not be able to continue in business.
 
Additionally, other companies, particularly established companies that currently manufacture and sell other cancer therapy systems, could potentially become competitors (in that they are also engaged in the cancer treatment business), and they have significantly greater resources than we do.
 
We may face significant uncertainty in the industry due to government healthcare reform.
 
Political, economic and regulatory influences are subjecting the healthcare industry to fundamental changes.  We anticipate that the current and future administration, Congress and certain state legislatures will continue to review and assess alternative healthcare delivery systems and payment methods with an objective of ultimately reducing healthcare costs and expanding access.  Public debate of these issues will likely continue in the future.  The uncertainties regarding the ultimate features of reform initiatives and their enactment and implementation may have an adverse effect on our customers’ purchasing decisions regarding our products and services.  At this time, we cannot predict whether healthcare reform proposals will be successfully implemented or adopted or what impact they may have on our business.
 
We are subject to government regulations that can delay our ability to sell our products and cause us to incur substantial expenses.
 
Our research and development efforts, pre-clinical tests and clinical trials, and the manufacturing, marketing, distribution and labeling of our products are subject to extensive regulation by the FDA and comparable international agencies.  The process of obtaining FDA and other required regulatory approvals throughout the world is lengthy and expensive and our financial resources are limited.  The FDA and other comparable agencies outside the U.S. are currently implementing and considering a number of reforms in its regulatory processes, which may make the approval process longer and more cumbersome for medical devices and increase the costs required to maintain those approvals.
 
Obtaining marketing approval from the FDA and other comparable agencies outside the U.S. is necessary for us to commercially market our systems in the United States.  Obtaining and maintaining approvals is a lengthy and expensive process.  We may not be able to obtain these approvals on a timely basis, if at all, and such failure could significantly harm our business prospects.
 
            After a product is approved for commercial distribution by the FDA and other comparable agencies outside the U.S., we have ongoing responsibilities under applicable regulations, which may include regulation of our manufacturing facilities and processes, labeling and record-keeping, and reporting of adverse experiences and other information.  Failure to comply with these ongoing requirements could result in problems with our approvals outside the U.S.  In the U.S., failure to comply could result in the FDA imposing operating restrictions on us, enjoining or restraining certain violations, or imposing civil or criminal penalties on us.
 
 
19
 
 
All of these laws are subject to evolving interpretations.  If the federal government were to conclude that we are not in compliance with any of these health care laws, we could be subject to substantial criminal and civil penalties, and could be excluded from participation as a supplier to beneficiaries in federal health care programs.
 
We are also subject to ongoing compliance and review requirements with our ISO-13485 and CE Mark certifications.  The European Commission (“EC”), the executive body of the EU, drafts regulations that are then accepted or rejected by the European Council.  Once a regulation has been accepted, it becomes a directive.  We must remain current with both new directives and amendments to existing directives.  The EC has recently implemented a number of significant changes in the regulations that govern medical devices, and the European Council has approved these changes.  These changes make obtaining and maintaining required regulatory approvals more expensive and time consuming.  The EC also recommended additional significant changes in the regulations that govern medical devices, which could increase the regulatory costs and risk for marketing products in the EU.  If we fail to comply with these ongoing requirements marketing of our products could be restricted.
 
On January 2, 2013, following a protracted period of public comment, the EU issued RoHS, which restricts the use of certain hazardous substances used in electrical equipment and mandated all medical devices sold in the EU meet RoHS compliance requirements on or before July 22, 2014.  Medical devices subject to RoHS must have technical testing and accompanying documents, a declaration of conformity and CE marking affixed to the product to be deemed compliant.  Noncompliant medical devices are prohibited for sale in the EU community after July 22, 2014.

The Company’s MicroThermX products are in compliance with RoHS requirements; however the Company’s hyperthermia products contain some of the substances defined as hazardous by RoHS standards. This presents a challenge for us inasmuch as there is currently no RoHS information available from vendors of the non-compliant parts and we are not aware of  alternative replacement parts that are available or readily identifiable. In order to continue to sell the hyperthermia systems within the EU we believe we would need to make significant changes in the component parts used in the hyperthermia systems.  We currently do not intend to make the significant and costly changes to component parts used in its hyperthermia products that would be necessary to become RoHS compliant.  Because of this, our sales of new hyperthermia systems in the EU have ceased, which will impact our results of operations.
 
U.S. Regulatory – FDA
 
If we fail to maintain regulatory approvals and clearances, or are unable to obtain, or experience significant delays in obtaining, FDA clearances or approvals for our future products or product enhancements, our ability to commercially distribute and market these products could suffer.
 
Our products are subject to rigorous regulation by the FDA and numerous other federal, state and foreign governmental authorities. The process of obtaining regulatory clearances or approvals to market a medical device can be costly and time consuming, and we may not be able to obtain these clearances or approvals on a timely basis, if at all. In particular, the FDA permits commercial distribution of a new medical device only after the device has received clearance under Section 510(k) of the Federal Food, Drug and Cosmetic Act, or is the subject of an approved PMA unless the device is specifically exempt from those requirements. In addition, certain devices can be distributed under an HDE, rather than a PMA.
 
            The FDA will clear marketing of a lower risk medical device through the 510(k) process if the manufacturer demonstrates that the new product is substantially equivalent to other 510(k)-cleared products. High risk devices deemed to pose the greatest risk, such as life-sustaining, life-supporting, or implantable devices, or devices not deemed substantially equivalent to a previously cleared device, require the approval of a PMA. The PMA process is more costly, lengthy and uncertain than the 510(k) clearance process. A PMA application must be supported by extensive data, including, but not limited to, technical, preclinical, clinical trial, manufacturing and labeling data, to demonstrate to the FDA’s satisfaction the safety and efficacy of the device for its intended use.
 
 
20
 
 
In order for a device to be eligible for an HDE, it must be intended for use in a qualifying target patient population of less than 4,000 patients per year for which there is no other comparable device available to treat the condition. This qualifying target patient population must be approved by the FDA. The FDA’s approval of an HDE to treat that qualifying patient population then requires demonstration that the device is safe for its intended application, that it is potentially effective, and that the probable benefits outweigh the associated risks, which is a lower standard than is applied to a PMA. Within the regulations for an HDE, if a device becomes available through the PMA process that addresses the same patient population as the HDE device, the HDE device may need to be withdrawn from the U.S. market. An approved HDE authorizes sales of the device to any hospital after Institutional Review Board review and approval by the hospital.
 
Our currently commercialized MicroThermX Microwave Ablation System have been cleared through the 510(k) process. Our BSD-500 is the subject of an approved PMA application. Our BSD-2000 System is the subject of an approved HDE. Our HDE for the BSD-2000 could be withdrawn by FDA if the target patient population exceeds 4000 patients in a given year or if a competitive device receives PMA approval that addresses the same patient population as the BSD-2000.
 
Our failure to comply with U.S. federal, state and foreign governmental regulations could lead to the issuance of warning letters or untitled letters, the imposition of injunctions, suspensions or loss of regulatory clearance or approvals, product recalls, termination of distribution, product seizures or civil penalties. In the most extreme cases, criminal sanctions or closure of our manufacturing facility are possible.
 
Modifications to our products may require new regulatory clearances or approvals or may require us to recall or cease marketing our products until clearances or approvals are obtained.
 
Modifications to our products may require new regulatory approvals or clearances, including 510(k) clearances, premarket approvals, or HDE approvals, or require us to recall or cease marketing the modified devices until these clearances or approvals are obtained. The FDA requires device manufacturers to initially make and document a determination of whether or not a modification requires a new approval, supplement or clearance. A manufacturer may determine that a modification could not significantly affect safety or efficacy and does not represent a major change in its intended use, so that no new 510(k) clearance is necessary. However, the FDA can review a manufacturer's decision and may disagree. The FDA may also on its own initiative determine that a new clearance or approval is required. We have made modifications to our products in the past and may make additional modifications in the future that we believe do not or will not require additional clearances or approvals. If the FDA disagrees and requires new clearances or approvals for the modifications, we may be required to recall and to stop marketing our products as modified, which could require us to redesign our products and harm our operating results. In these circumstances, we may be subject to significant enforcement actions.
 
If a manufacturer determines that a modification to an FDA-cleared device could significantly affect its safety or efficacy, or would constitute a major change in its intended use, then the manufacturer must file for a new 510(k) clearance or possibly a premarket approval application. For PMA approved products, any change that affects the safety or effectiveness of the device requires the approval of PMA Supplement.  Depending on the type of change, there are different PMA Supplements ranging from 30-Day Notices to full 180-Day Supplements.  Where we determine that modifications to our products require a new 510(k) clearance, premarket approval, or HDE application, we may not be able to obtain those additional clearances or approvals for the modifications or additional indications in a timely manner, or at all. Obtaining clearances and approvals can be a time consuming process, and delays in obtaining required future clearances or approvals would adversely affect our ability to introduce new or enhanced products in a timely manner, which in turn would harm our future growth.
 
            There is no guarantee that the FDA will grant 510(k) clearance or PMA approval of our future products and failure to obtain necessary clearances or approvals for our future products would adversely affect our ability to grow our business.
 
Some of our new products may require FDA clearance of a 510(k). Other products may require the approval of a PMA. In addition some of our new products may require clinical trials to support regulatory approval and we may not successfully complete these clinical trials. The FDA may not approve or clear these products for the indications that are necessary or desirable for successful commercialization. Indeed, the FDA may refuse our requests for 510(k) clearance or premarket approval of new products. Failure to receive clearance or approval for our new products would have an adverse effect on our ability to expand our business.
 
 
21
 
 
Clinical trials necessary to support a PMA application will be expensive and will require the enrollment of large numbers of patients, and suitable patients may be difficult to identify and recruit. Delays or failures in our clinical trials will prevent us from commercializing any modified or new products and will adversely affect our business, operating results and prospects.
 
Initiating and completing clinical trials necessary to support a future PMA application or to obtain additional safety and efficacy data beyond that typically required for a 510(k) clearance will be time consuming and expensive and the outcome uncertain. Moreover, the results of early clinical trials are not necessarily predictive of future results, and any product we advance into clinical trials may not have favorable results in later clinical trials.
 
Clinical trials conducted in the United States, generally require an IDE approved in advance by the FDA for a specified number of patients and study sites, unless the product is deemed a nonsignificant risk device eligible for more abbreviated IDE requirements. Clinical trials are subject to extensive monitoring, recordkeeping and reporting requirements. Clinical trials must be conducted under the oversight of an IRB for the relevant clinical trial sites and must comply with FDA regulations, including but not limited to those relating to good clinical practices. To conduct a clinical trial, we also are required to obtain the patients’ informed consent that complies with FDA requirements, state and federal privacy regulations and human subject protection regulations. 
 
Conducting successful clinical studies will require the enrollment of large numbers of patients, and suitable patients may be difficult to identify and recruit. Patient enrollment in clinical trials and completion of patient participation and follow-up depends on many factors, including the size of the patient population, the nature of the trial protocol, the attractiveness of, or the discomforts and risks associated with, the treatments received by enrolled subjects, the availability of appropriate clinical trial investigators, support staff, and proximity of patients to clinical sites and able to comply with the eligibility and exclusion criteria for participation in the clinical trial and patient compliance. For example, patients may be discouraged from enrolling in our clinical trials if the trial protocol requires them to undergo extensive post-treatment procedures or follow-up to assess the safety and effectiveness of our products or if they determine that the treatments received under the trial protocols are not attractive or involve unacceptable risks or discomforts. Patients may also not participate in our clinical trials if they choose to participate in contemporaneous clinical trials of competitive products. In addition, patients participating in clinical trials may die before completion of the trial or suffer adverse medical events unrelated to investigational products.
 
Development of sufficient and appropriate clinical protocols to demonstrate safety and efficacy are required and we may not adequately develop such protocols to support clearance and approval. Further, the FDA may require us to submit data on a greater number of patients than we originally anticipated and/or for a longer follow-up period or change the data collection requirements or data analysis applicable to our clinical trials. Delays in patient enrollment or failure of patients to continue to participate in a clinical trial may cause an increase in costs and delays in the approval and attempted commercialization of our products or result in the failure of the clinical trial. In addition, despite considerable time and expense invested in our clinical trials, FDA may not consider our data adequate to demonstrate safety and efficacy. Such increased costs and delays or failures could adversely affect our business, operating results and prospects.
  
Perseon is currently sponsoring an IDE-approved clinical study of the BSD-2000 hyperthermia system, “Hyperthermia Combined with Radiotherapy for the Treatment of Locally Advanced, Persistent, or Recurrent Deep Tumors of the Pelvis; i.e., Cervical, Prostate, Rectal, and Bladder.”  The Phase II study is designed to enroll subjects who have advanced, persistent, or recurrent deep tumors of the pelvis and thus have already failed other standard therapy or would not be considered candidates for other standard therapy.
 
Our facility and our clinical investigational sites operate under procedures that govern the conduct and management of FDA-regulated clinical studies under 21 CFR Parts 50 and 812, and Good Clinical Practices. FDA may conduct Bioresearch Monitoring (BIMO) inspections of us and/or our clinical sites to assess compliance with 21 CFR Parts 50 and 812, our procedures, and the clinical protocol. If the FDA were to find that we or our clinical investigators are not operating in compliance with applicable regulations, we could be subject to the above FDA enforcement action as well as refusal to accept all or part of our data in support our 510(k) or PMA and/or we may need to conduct additional studies.
 
 
22
 
 
We, the FDA or the IRB could suspend a clinical trial at any time for various reasons, including a belief that the risks to study subjects outweigh the anticipated benefits. Additionally, we may decide at any time, for business or other reasons, to terminate a study. Even if a trial is completed, the results of clinical testing may not adequately demonstrate the safety and efficacy of the device or may otherwise not be sufficient to obtain FDA clearance or approval to market the product in the United States. Following completion of a study, we would need to collect, analyze and present the data in an appropriate submission to the FDA, either a 510(k) premarket notification or a PMA. Even if a study is completed and submitted to the FDA, the results of our clinical testing may not demonstrate the safety and efficacy of the device, or may be equivocal or otherwise not be sufficient to obtain approval of our product.
   
If the third parties on which we rely to conduct our clinical trials and to assist us with pre-clinical development do not perform as contractually required or expected, we may not be able to obtain regulatory approval for or commercialize our products.
 
We do not have the ability to independently conduct our pre-clinical and clinical trials for our products and we must rely on third parties, such as contract research organizations, medical institutions, clinical investigators and contract laboratories to conduct such trials. If these third parties do not successfully carry out their contractual duties or regulatory obligations or meet expected deadlines, if these third parties need to be replaced, or if the quality or accuracy of the data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for other reasons, our pre-clinical development activities or clinical trials may be extended, delayed, suspended or terminated, and we may not be able to obtain regulatory approval for, or successfully commercialize, our products on a timely basis, if at all, and our business, operating results and prospects may be adversely affected. Furthermore, our third-party clinical trial investigators may be delayed in conducting our clinical trials for reasons outside of their control.

The results of our clinical trials may not support our product candidate claims or may result in the discovery of adverse side effects.
 
Even if our clinical trials are completed as planned, we cannot be certain that their results will support our product candidate claims or that the FDA or foreign authorities will agree with our conclusions regarding them. Success in pre-clinical studies and early clinical trials does not ensure that later clinical trials will be successful, and we cannot be sure that the later trials will replicate the results of prior trials and pre-clinical studies. The clinical trial process may fail to demonstrate that our product candidates are safe and effective for the proposed indicated uses, which could cause us to abandon a product candidate and may delay development of others. Any delay or termination of our clinical trials will delay the filing of our product submissions and, ultimately, our ability to commercialize our product candidates and generate revenues. It is also possible that patients enrolled in clinical trials will experience adverse side effects that are not currently part of the product candidate’s profile.
  
With respect to our marketed products, if we or our suppliers fail to comply with ongoing FDA or other foreign regulatory authority requirements, or if we experience unanticipated problems with our products, these products could be subject to restrictions or withdrawal from the market.
 
Any product for which we obtain clearance or approval, and the manufacturing processes, reporting requirements, post-approval clinical data and promotional activities for such product, will be subject to continued regulatory review, oversight and periodic inspections by the FDA. In particular, we and our suppliers are required to comply with FDA’s Quality System Regulations or QSR for the manufacture of our products and other regulations which cover the methods and documentation of the design, testing, production, control, quality assurance, labeling, packaging, storage and shipping of any product for which we obtain clearance or approval. The FDA enforces the QSR and other regulations through periodic inspections. Our facility in Salt Lake City, Utah, is regularly inspected by the FDA. The most recent FDA inspection was conducted in December  2012. There were no deficiencies noted by the FDA as a result of this inspection and no Form 483 was issued.   
  
 
23
 
 
The failure by us or one of our suppliers to comply with applicable statutes and regulations administered by the FDA or the failure to timely and adequately respond to any adverse inspectional observations or product safety issues could result in, among other things, any of the following enforcement actions:
 
·
untitled letters, warning letters, fines, injunctions, consent decrees and civil penalties;
   
·
unanticipated expenditures to address or defend such actions
   
·
customer notifications for repair, replacement, refunds;
   
·
recall, detention or seizure of our products;
   
·
operating restrictions or partial suspension or total shutdown of production;
   
·
refusing or delaying our requests for 510(k) clearance or premarket approval of new products or modified products;
   
·
operating restrictions;
   
·
withdrawing 510(k) clearances or HDE or PMA approvals that have already been granted;
   
·
refusal to grant export approval for our products; or
   
·
criminal prosecution.
 
If any of these actions were to occur it would harm our reputation and cause our product sales and profitability to suffer and may prevent us from generating revenue. Furthermore, our key component suppliers may not currently be or may not continue to be in compliance with all applicable regulatory requirements which could result in our failure to produce our products on a timely basis and in the required quantities, if at all.
 
Even if regulatory clearance or approval of a product is granted, such clearance or approval may be subject to limitations on the intended uses for which the product may be marketed and reduce our potential to successfully commercialize the product and generate revenue from the product. If the FDA determines that our promotional materials, labeling, training or other marketing or educational activities constitute promotion of an unapproved use, it could request that we cease or modify our training or promotional materials or subject us to regulatory enforcement actions. It is also possible that other federal, state or foreign enforcement authorities might take action if they consider our training or other promotional materials to constitute promotion of an unapproved use, which could result in significant fines or penalties under other statutory authorities, such as laws prohibiting false claims for reimbursement.
 
            In addition, we may be required to conduct costly post-market testing and surveillance to monitor the safety or effectiveness of our products, and we must comply with medical device reporting requirements, including the reporting of adverse events and malfunctions related to our products. Later discovery of previously unknown problems with our products, including unanticipated adverse events or adverse events of unanticipated severity or frequency, manufacturing problems, or failure to comply with regulatory requirements such as QSR, may result in changes to labeling, restrictions on such products or manufacturing processes, withdrawal of the products from the market, voluntary or mandatory recalls, a requirement to repair, replace or refund the cost of any medical device we manufacture or distribute, fines, suspension of regulatory approvals, product seizures, injunctions or the imposition of civil or criminal penalties which would adversely affect our business, operating results and prospects.
  
For most products that receive PMA or HDE approval, the FDA imposes post-market study requirements as a condition of approval. As a condition of our HDE approval for the BSD-2000 hyperthermia system, the FDA required Perseon to conduct a post-market registry study, “Deep Hyperthermia and Radiation in the Treatment of Cervical Cancer Patients.” Due to challenges enrolling patients and sites in a small population with this rare disease, no patients were enrolled in this initial post-approval registry study. Because of these challenges, Perseon initiated collaborative discussions with FDA regarding the structure of the study.  As a result, the initial post-market study structure has been revised, and we are in current discussions with our clinical sites regarding participation in the revised study. Perseon is still experiencing challenges in enrolling patients and sites and plans to initiate additional discussions with FDA regarding how best to address these challenges.  The status of Perseon's post-approval study is listed as "progress inadequate" on the FDA's website.  We plan to initiate additional discussions with the FDA regarding how best to address these challenges, but there can be no assurance that we will be able to successfully meet our Company's ongoing responsibilities for the post-approval study mandated by the FDA as part of our HDE approval.  We have submitted all periodic updates to FDA as required and in a timely manner.
 
 
24
 
 
Our products may in the future be subject to product recalls that could harm our reputation, business and financial results.
 
The FDA and similar foreign governmental authorities have the authority to require the recall of commercialized products in the event of material deficiencies or defects in design or manufacture. In the case of the FDA, the authority to require a recall must be based on an FDA finding that there is a reasonable probability that the device would cause serious injury or death.  Manufacturers may, under their own initiative, recall a product if any material deficiency in a device is found. A government-mandated or voluntary recall by us or one of our distributors could occur as a result of component failures, manufacturing errors, design or labeling defects or other deficiencies and issues. Recalls of any of our products would divert managerial and financial resources and have an adverse effect on our financial condition and results of operations. The FDA requires that certain classifications of recalls be reported to FDA within 10 working days after the recall is initiated. Companies are required to maintain certain records of recalls, even if they are not reportable to the FDA. We may initiate voluntary recalls involving our products in the future that we determine do not require notification of the FDA. If the FDA disagrees with our determinations, they could require us to report those actions as recalls. A future recall announcement could harm our reputation with customers and negatively affect our sales. In addition, the FDA could take enforcement action for failing to report the recalls when they were conducted.
 
If our products cause or contribute to a death or a serious injury, or malfunction in certain ways, we will be subject to medical device reporting regulations, which require reports to be submitted to the FDA and can result in voluntary corrective actions or FDA enforcement actions.
 
Under the FDA medical device reporting regulations, medical device manufacturers are required to report to the FDA information that a device has or may have caused or contributed to a death or serious injury or has malfunctioned in a way that would likely cause or contribute to death or serious injury if the malfunction of the device or one of our similar devices were to recur. If we fail to report these events to the FDA within the required timeframes, or at all, FDA could take enforcement action against us. Any such adverse event involving our products also could result in future voluntary corrective actions, such as recalls or customer notifications, or agency action, such as inspection or enforcement action. Any corrective action, whether voluntary or involuntary, as well as defending ourselves in a lawsuit, will require the dedication of our time and capital, distract management from operating our business, and may harm our reputation and financial results.
  
We may be subject to fines, penalties or injunctions if we are determined to be promoting the use of our products for unapproved or "off-label" uses.
 
Our promotional materials and training methods for physicians must comply with FDA and other applicable laws and regulations. We believe that the specific surgical procedures for which our 510(k)-cleared products are marketed fall within the scope of the surgical applications that have been cleared by the FDA and that our PMA approved products are marketed in accordance with their approved labeling. However, the FDA could disagree and require us to stop promoting our products for those specific procedures until we obtain FDA clearance or approval for them. In addition, if the FDA determines that our promotional materials or training constitutes promotion of an unapproved use, it could request that we modify our training or promotional materials or subject us to regulatory or enforcement actions, including the issuance of an untitled letter, a warning letter, injunction, seizure, civil fine and criminal penalties. It is also possible that other federal, state or foreign enforcement authorities might take action if they consider our promotional or training materials to constitute promotion of an unapproved use, which could result in significant fines or penalties under other statutory authorities, such as laws prohibiting false claims for reimbursement. In that event, our reputation could be damaged and adoption of the products would be impaired.
 
 
25
 
 
Legislative or Regulatory reforms may adversely affect our ability to sell our products profitably.
 
From time to time, legislation is drafted and introduced in Congress that could significantly change the statutory provisions governing the clearance or approval, manufacture and marketing of a medical device. In addition, FDA regulations and guidance are often revised or reinterpreted by the agency in ways that may significantly affect our business and our products. It is impossible to predict whether legislative changes will be enacted or FDA regulations, guidance or interpretations changed, and what the impact of such changes, if any, may be. For example, the FDA may change its clearance and approval policies, adopt additional regulations or revise existing regulations, or take other actions that may prevent or delay approval or clearance of our products under development or impact our ability to modify our currently approved or cleared products on a timely basis. For example, in 2011, the FDA announced a Plan of Action to modernize and improve the FDA’s premarket review of medical devices, and has implemented, and continues to implement, reforms intended to streamline the premarket review process. In addition, as part of the Food and Drug Administration Safety and Innovation Act of 2012, Congress enacted several reforms entitled the Medical Device Regulatory Improvements and additional miscellaneous provisions which will further affect medical device regulation both pre- and post-approval. Any change in the laws or regulations that govern the clearance and approval processes relating to our current and future products could make it more difficult and costly to obtain clearance or approval for new products, or to produce, market and distribute existing products.

We depend on adequate protection of our patent and other intellectual property rights to stay competitive.
 
We rely on patents, trade secrets, trademarks, copyrights, know-how, license agreements and contractual provisions to establish and protect our intellectual property rights. Our success will substantially depend on our ability to protect our intellectual property rights and maintain rights granted to us through license agreements. Our intellectual property rights may only afford us limited protection and may not adequately protect our rights or remedies to gain or keep any advantages we may have over our competitors, which could reduce our ability to be competitive and generate sales and profitability.
 
In the past, we have participated in substantial litigation regarding our patent and other intellectual property rights in the medical device industry.  We have previously filed lawsuits for patent infringement against three of our competitors and subsequently settled all three of those lawsuits.  Additional litigation against other parties may be necessary in the future to enforce our intellectual property rights, to protect our patents and trade secrets, and to determine the validity and scope of our proprietary rights.  This litigation may require more financial resources than are available to us.  We cannot guarantee that we will be able to successfully protect our rights in litigation.  Failure to successfully protect our rights in litigation could reduce our ability to be competitive and generate sales and profitability.
 
            A product liability settlement could exceed our ability to pay.
 
The manufacturing and marketing of medical devices involves an inherent risk of product liability.  We presently carry product liability insurance with coverage limits of $5 million.  Our product liability insurance does not cover intended injury, injury or damage resulting from the intoxication of any person, payment of workers’ compensation benefits, injury of our own employee, injury or damage due to war, damage to property that we own, damage to our work, loss of use of property, patent infringements, pollution claims, interest payments, depreciation of property, or injury or damage resulting from asbestos inhalation.  We are responsible to pay the first $10,000 resulting from any claim up to a maximum of $50,000 in one year.  We cannot assure that our product liability insurance will provide adequate coverage against potential claims that might be made against us.  If we were to be subject to a claim in excess of our coverage or to a claim not covered by our insurance and the claim succeeded, we would be required to pay the claim from our limited resources, which would reduce our limited capital resources and liquidity and reduce capital we could otherwise use to obtain approvals for and market our products.  In addition, liability or alleged liability could harm our business by diverting the attention and resources of our management and by damaging our reputation.
 
We are dependent upon key personnel, some of whom would be difficult to replace.
 
Our success will be largely dependent upon the efforts of Clinton E. Carnell Jr, our Chief Executive Officer, William S. Barth, our Chief Financial Officer, Benjamin Beckham, our Vice President of Global Sales, Jennifer R. Hoglin, our Vice President of Global Marketing, Todd H. Turnlund, our Vice President of Research and Development, and other key employees.  We do not maintain key-person insurance on any of these employees.  Our future success also will depend in large part upon our ability to identify, attract and retain other highly qualified managerial, technical and sales and marketing personnel.  Competition for these individuals is intense.  The loss of the services of any of our key personnel, the inability to identify, attract or retain qualified personnel in the future or delays in hiring qualified personnel could make it more difficult for us to manage our business and meet key objectives such as the sale of our products and the introduction of new products.
 
 
26
 
 
The market for our stock is limited and our stock price may be volatile.
 
The market for our common stock has been limited due to low trading volume and the small number of brokerage firms acting as market makers.  Because of the limitations of our market and volatility of the market price of our stock, investors may face difficulties in selling shares at attractive prices when they want to.  The average daily trading volume for our stock has varied significantly from week to week and from month to month, and the trading volume often varies widely from day to day.  The following factors could impact the market for our stock and cause further volatility in our stock price:
 
·
announcements of new technological innovations;
   
·
FDA and other regulatory developments and changes;
   
·
changes in third-party reimbursements;
   
·
developments concerning proprietary rights;
   
·
third parties receiving FDA approval for competing products; and
   
·
market conditions generally for medical and technology stocks.
  
If the closing bid price of our stock continues to remain below $1.00 per share, our common stock may be subject to delisting from the NASDAQ Stock Market.

Shares of our common stock are listed on the NASDAQ Capital Market (“Nasdaq”) under the symbol “PRSN”. We are required to comply with Nasdaq’s listing standards in order to maintain the listing of our common stock on the exchange. Nasdaq has the authority pursuant to Nasdaq Rule 5550(a)(2) to delist our common stock if, during any period of 30 consecutive trading days, the closing bid price falls below a minimum bid price of $1.00 per share.

On August 8, 2014, we received a letter from the staff of Nasdaq notifying us that, for the previous 30 consecutive business days, the bid price for our common stock had closed below the minimum $1.00 per share requirement for continued listing on Nasdaq under Nasdaq Listing Rule 5550(a)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), we have been provided a second period of 180 calendar days, or until August 4, 2015, to regain compliance. If at any time before August 4, 2015, the bid price of our common stock closes at $1.00 per share or more for a minimum of ten consecutive business days, the Staff will provide us with written confirmation of compliance and the matter will be closed.

We are actively monitoring the bid price of our common stock and will consider any and all options available to us to achieve compliance. To the extent that we are unable to resolve the listing deficiency, there is a risk that our common stock may be delisted from Nasdaq and would likely trade only on the over-the-counter market (the “OTC”). If our common stock were to trade on the OTC, selling our common stock could be more difficult because smaller quantities of shares would likely be bought and sold, transactions could be delayed, and security analysts’ coverage may be reduced. In addition, in the event our common stock is delisted, broker-dealers transacting in our common stock would be subject to certain additional regulatory burdens, which may discourage them from effecting transactions in our common stock, thus further limiting the liquidity of our common stock and potentially resulting in lower prices and larger spreads in the bid and ask prices for our common stock.

 
27
 
 
Current and former directors and executive officers own a substantial number of shares of our capital stock, which could discourage or prevent a takeover, even if an acquisition would be beneficial to our stockholders.
 
Current and former directors and executive officers own approximately 18% of our outstanding voting power.  Accordingly, these stockholders, individually and as a group, may be able to influence the outcome of stockholder votes involving the election of directors, the adoption or amendment of provisions in our certificate of incorporation and bylaws and the approval of certain mergers or other similar transactions, such as a sale of substantially all of our assets.  Such control by existing stockholders could have the effect of delaying, deferring or preventing a change in control of our company.
 
Future sales of shares of our securities could negatively affect our stock price.
 
Future sales of shares of our securities could negatively affect the market price of our common stock. In July 2014 we completed a $5.2 million registered direct placement of our stock under our current universal shelf registration. Prior to the July 2014 offering we completed five offerings utilizing a universal shelf registration statement during calendar years 2010 and 2013.  Sales of substantial amounts of shares of our common stock or other securities could lower the market price of our common stock and impair our ability to raise capital.
 
Anti-takeover provisions in our certificate of incorporation may have a possible negative effect on our stock price.
 
Certain provisions of our certificate of incorporation and bylaws may make it more difficult for a third party to acquire, or discourage a third party from attempting to acquire, control of us.  We have in place several anti-takeover measures that could discourage or prevent a takeover, even if an acquisition would be beneficial to our stockholders.  The increased difficulties faced by a third party who wishes to acquire us could adversely affect our stock price.
 
ITEM 1B.  UNRESOLVED STAFF COMMENTS

None.

ITEM 2.  PROPERTIES

We own our office, production and research facilities located in Salt Lake City, Utah.  The complete headquarters and production facility occupies approximately 20,000 square feet.  The building is currently in good condition, is owned by us and is currently for sale. We are currently looking for a facility that will better suit our business needs.  We believe that we carry adequate insurance on the property.
 
ITEM 3.  LEGAL PROCEEDINGS
 
We are subject to various complaints, allegations and threats of lawsuit in the ordinary course of business.  We do not believe that any of the current complaints or allegations has merit, nor will have a material impact on our business or financial condition. However, complaints, allegations and threats of lawsuits are deemed serious, divert resources and could result in the payment of substantial damages. Legal counsel for Perseon  received a demand letter dated October 3, 2014 and a draft complaint from a single shareholder’s legal counsel who threatened a direct, derivative  and securities class action suit against Perseon, as well as all current and certain former  directors and  officers.  The unfiled draft complaint alleges that from November 2010 through October 2014, BSD  issued various press releases and public statements which  omitted certain material facts related to BSD’s revenue and sales, thereby misrepresenting the true financial condition of BSD.  In particular, the draft complaint alleges that BSD’s press releases “tout[ed] impressive revenue figures and purported sales” when “in reality BSD was floundering and unable to cover its operating costs, including significant executive compensation.”  The unfiled draft complaint also alleges that BSD “chose to issue additional securities at below-market prices in an effort to fund operating expenses,” rather than “raise capital through debt transactions or other methods,” and that three offerings cited in the draft complaint  resulted in “the dilution of existing shareholder positions.”     Our Board of Directors has engaged outside legal counsel specializing in securities matters and litigation to conduct an independent investigation of this draft complaint and its allegations.   Upon completion of their investigation by special legal counsel, we expect  findings and recommendations will be presented to the Board of Directors for its consideration..
 
There are no other known material legal proceedings pending against or being taken by us.
 
 
28
 
 
ITEM 4.  MINE SAFETY DISCLOSURES

This item is not applicable to the Company.

PART II
   
ITEM 5.  MARKET FOR THE REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

Our common shares trade on the NASDAQ under the symbol “PRSN”.  The following table sets forth the high and low sales prices, as provided by NASDAQ for the quarters in fiscal years ended August 31, 2013 and 2014 and the transition period ended December 31, 2014.  The amounts reflect inter-dealer prices, without retail mark-up, markdown or commission, and may not represent actual transactions.
 
Quarter Ended:
  
High
    
Low
  
November 30, 2012
  
$
2.41
    
$
1.15
  
February 28, 2013
    
2.05
      
1.32
  
May 31, 2013
    
1.87
      
0.97
  
August 31, 2013
    
1.70
      
1.20
  
November 30, 2013
    
1.78
      
1.18
  
February 28, 2014
    
1.45
      
1.03
  
May 31, 2014
    
1.66
      
.95
  
August 31, 2014
    
1.19
      
.55
  
November 30, 2014
    
.67
      
.35
  
Transition Period Ended:
                
December 31, 2014
    
.48
      
.28
  

As of December 31, 2014, there were 464 holders of record of our common stock.  We have not paid any cash dividends on our common stock since our inception, and we currently plan to retain our future earnings, if any, to fund the growth of our business.

On March 27, 2015, the last reported sales price of our common stock on NASDAQ was $0.37 per share.

Repurchases of Equity Securities

None.

Recent Sales of Unregistered Securities

None.    

 
29
 

Performance Graph

The following graph shows a comparison of the five-year cumulative total return for our common stock, the S&P 500 Index, and the S&P Health Care Equipment Index, assuming an investment of $100 on December 31, 2009.  The cumulative return of the Company was computed by dividing the difference between the price of  our common stock at the end and the beginning of the measurement period (December 31, 2009 to December 31, 2014) by the price of  our common stock at the beginning of the measurement period.

 
ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Overview

This Management’s Discussion and Analysis of Financial Condition and Results of Operations and other parts of this Transition Report on Form 10-K contain forward-looking statements that involve risks and uncertainties.  Forward-looking statements can also be identified by words such as “anticipates,” “expects,” “believes,” “plans,” “predicts,” and similar terms.  Forward-looking statements are not guarantees of future performance and our actual results may differ significantly from the results discussed in the forward-looking statements.  Factors that might cause such differences include, but are not limited to, those discussed in the subsection entitled “Forward-Looking Statements” below and the Item 1A “Risk Factors” above.  The following discussion should be read in conjunction with our financial statements and notes thereto included in Item 8 of this Form 10-K.   We assume no obligation to revise or update any forward-looking statements for any reason, except as required by law.

Perseon Corporation, formerly BSD Medical Corporation, (the “Company”) was incorporated in the State of Delaware on July 3, 1986.  In February 2015, we changed the name of the Company to Perseon Corporation.  We are a life sciences company that develops, manufactures, markets and services groundbreaking medical systems to treat cancer using heat therapy.  Our MicroThermX® microwave ablation system employs precision-guided microwave energy to ablate diseased soft tissue.  We have developed extensive intellectual property and distribute our products in the United States, Europe and Asia.  In early 2015, we are executing on our previously announced plan to either sell the assets related to hyperthermia products or discontinue manufacturing and selling hyperthermia systems.  This will allow us to more effectively follow our strategic plan of exclusively focusing on our highest return opportunity – the high-growth microwave ablation market.

In connection with our plans to either sell or divest the assets related to the hyperthermia product line, we analyzed the carrying value and estimated net realizable value of inventory and other assets related to the hyperthermia product line as of December 31, 2014.  As a result of this analysis, as of December 31, 2014, we recorded an impairment charge of $805,000 for inventory, equipment, and other assets related to the hyperthermia product line.  As of December 31, 2014, we also accrued $50,000 for legal and other costs that we estimate will be incurred in connection with the sale or divestiture.

We have changed our fiscal year end for financial reporting from August 31 to December 31, effective for the four months ended December 31, 2014.  The financial information for the four months ended December 31, 2013 provided in this report for comparative purposes is unaudited.  All adjustments (consisting only of normal recurring adjustments) necessary for the fair presentation of our results of operations and our cash flows for the four months ended December 31, 2013 have been included.  The results of operations for the four months ended December 31, 2014 may not be indicative of the results for our fiscal year ending December 31, 2015.

As of December 31, 2014, we had a sales backlog of $ 347,500.

 
30
 
 
Results of Operations

Fluctuation in Operating Results

Our results of operations have fluctuated in the past and may fluctuate in the future from year to year as well as from quarter to quarter.  Revenue may fluctuate as a result of factors relating to the demand and market acceptance for our microwave ablation systems and related component parts and services, world-wide economic conditions, availability of financing for our customers, changes in the medical capital equipment market, changes in order mix and product order configurations, competition, regulatory developments, insurance reimbursement and other matters.  In addition, our revenues in the future will not be comparable to prior periods as a result of our sale or discontinuance of the hyperthermia product line. Operating expenses may fluctuate as a result of the timing of sales and marketing activities, research and development, and general and administrative expenses associated with our potential growth.  For these and other reasons described elsewhere, our results of operations for a particular period may not be indicative of operating results for any other period.
 
Revenues

We recognize revenue from the sale of our ablation and hyperthermia cancer treatment systems and related parts and accessories (collectively, product sales), the sale of disposable devices used with certain of our systems, training, service support contracts and other miscellaneous revenues.  We also recognize revenues from equipment rental, including fee-per-use rental income from our MicroThermX.

Our revenues consisted of the following:

   
Four Months Ended
December 31,
    
Years Ended
August 31,
  
   
2014
    
2013
    
2014
    
2013
  
                         
System sales – Hyperthermia
   $ 440,000     $ 428,650     $ 2,203,650     $ 816,700  
System sales - MicroThermX
     30,875       558,250       775,875       1,118,126  
Disposable devices
     409,787       501,565       1,608,481       1,109,750  
Equipment rental
     125,900       95,200       364,600       298,600  
Service contracts and other
     109,346       100,597       375,747       330,116  
                                 
Total
   $ 1,115,908     $ 1,684,262     $ 5,328,353     $ 3,673,292  

Revenues reported in the above table for disposable devices and equipment rental is mainly MicroThermX related.

Total revenues in the four months ended December 31, 2014 decreased $568,354, or 34% compared to total revenues in the four months ended December 31, 2013.  This decrease in revenues resulted primarily from a decrease in MicroThermX systems sales.  System sales in the four months ended December 31, 2013 included significant up-front stocking orders from Terumo for MicroThermX systems as we initially engaged them as our European distributor for MicroThermX products.  Sales of MicroThermX disposable devices during the four months ended December 31, 2014 also decreased from sales of disposable devices during the four months ended December 31, 2013, again largely due to significant initial stocking orders from Terumo in the 2013 four month period.  We experienced modest increases in service call revenue and revenues from rental of MicroThermX systems on a fee per use basis.

Total revenues in the fiscal year ended August 31, 2014 increased $1,655,061, or 45%, compared to total revenues in the fiscal year ended August 31, 2013.  The growth in revenue during the fiscal year ended August 31, 2014 resulted primarily from the shipment of several BSD-2000 units that were in backlog as of August 31, 2013, along with higher revenues from disposable SynchroWave antennas and from our fee-per-use rental program for MicroThermX generators.  These higher revenues were partially offset by lower revenues from sales of MicroThermX generators.

Historically, our revenues have fluctuated significantly from period to period because our sales were based upon a relatively small number of hyperthermia systems, the sales price of each being substantial enough to greatly impact revenue levels in the periods in which they occur.  However, we have been unable to sustain an increase in the number of hyperthermia systems sold due to various factors, including: non-acceptance by cancer-treating physicians of hyperthermia therapy; inadequate reimbursement rates from third-party payers; and significant uncertainty in the U.S. healthcare industry due to recent governmental healthcare reform.  As discussed above, we are executing on our previously announced plan to either sell the assets related to hyperthermia products or discontinue manufacturing and selling hyperthermia systems.  This will allow us to more effectively follow our strategic plan of exclusively focusing on our highest return opportunity – the high-growth microwave ablation market.

At times, we have derived a significant portion of our revenues from sales to related parties.  All of our related party revenue results from the sale of hyperthermia systems and related component parts and services to Medizintechnik GmbH and its affiliated entity – BSD BioSystems Design, S.A. (“Medizintechnik”).  Dr. Sennewald, a former director and one of our significant stockholders, is a stockholder, executive officer and a director of Medizintechnik.  We derived $463,423, or approximately 42% of our total revenues in the four months ended December 31, 2014, compared to $16,686, or approximately 1% of our total revenues in the four months ended December 31, 2013 from sales to Medizintechnik.  We derived $419,549, or approximately 8% of our total revenues in the year ended August 31, 2014, compared to sales of $99,896, or 3% of our total revenues in the year ended August 31, 2013.  The increased sales to Medizintechnik in the 2014 periods resulted from revenues from the sale of one hyperthermia system that was recognized as revenue over a period of time due to the terms of the sale.  Although sales to non-related parties decreased in the four month period ended December 31, 2014 compared to the four month period ended December 31, 2013, the growth in our revenues on an annual basis has come primarily from non-related parties.

 
31
 
 
The following tables summarize the sources of our revenues:

   
Four Months Ended
December 31,
    
Years Ended
August 31,
  
Non-Related Parties
  
2014
    
2013
    
2014
    
2013
  
                         
System sales – Hyperthermia
   $ -     $ 428,650     $ 1,843,650     $ 766,700  
System sales – MicroThermX
     30,875       558,250       775,875       1,118,126  
Consumable devices
     406,555       491,515       1,572,455       1,087,100  
Equipment rental
     125,900       95,200       364,600       298,600  
Service contracts
     73,001       76,777       303,109       259,550  
Other
     16,154       17,184       49,115       43,320  
                                 
Total
   $ 652,485     $ 1,667,576     $ 4,908,804     $ 3,573,396  
 
   
Four Months Ended
December 31,
    
Years Ended
August 31,
  
Related Parties
  
2014
    
2013
    
2014
    
2013
  
                         
System sales – Hyperthermia
   $ 440,000     $ -     $ 360,000     $ 50,000  
Consumable devices
     3,232       10,050       36,026       22,650  
Other
     20,191       6,636       23,523       27,246  
                                 
Total
   $ 463,423     $ 16,686     $ 419,549     $ 99,896  
 
Gross Margin

Our gross margin and gross margin percentage has fluctuated from period to period depending on the mix of revenues reported for the period and the type and configuration of the hyperthermia systems sold during the period.  Our total gross margin was $520,399, or 47% of total sales, for the four months ended December 31, 2014 and $877,645, or 52% of total sales, for the four months ended December 31, 2013.  Our total gross margin was $2,439,488, or 46% of total sales, for the fiscal year ended August 31, 2014 and $1,411,843, or 38% of total sales, for the comparable 2013 fiscal year.  The decrease in gross margin and gross margin percentage for the four months ended December 31, 2014 compared to the four months ended December 31, 2013, resulted primarily from the lower level of sales in the 2014 period.  The increase in gross margin and gross margin percentage in the fiscal year ended August 31, 2014 compared to fiscal year ended August 31, 2013 resulted primarily from increasing sales of MicroThermX consumable devices and equipment rental, and higher sales of higher margin hyperthermia products in the 2014 period.  In addition, as sales volume increases, we believe we more fully absorb certain fixed operating costs that are included in cost of sales, thus increasing our gross profit percentage. 

 
32
 
 
Cost of Sales

Cost of sales includes raw material, labor and allocated overhead costs.  We calculate and report separately cost of sales for both non-related and related party sales, which are sales to Medizintechnik.  Cost of sales as a percentage of sales will fluctuate from period to period depending on the mix of sales for the period.  Total cost of sales for the four months ended December 31, 2014 was $595,509 compared to $806,617 for the four months ended December 31, 2013, a decrease of $211,108, or approximately 26%.  This decrease resulted from decreased sales volumes during the four months ended December 31, 2014, as further discussed above.  Total cost of sales for the fiscal year ended August 31, 2014 was $2,888,865 compared to $2,261,449 for the comparable 2013 fiscal year, an increase of $627,416, or approximately 28%.  This increase resulted from the increased sales volume of both hyperthermia and MicroThermX products in the fiscal year ended August 31, 2014 compared to the fiscal year ended August 31, 2013, as further discussed above.

Operating Costs and Expenses

Research and Development Expenses – Research and development expenses include expenditures for new product development and development of enhancements to existing products.  Our research and development expenses decreased in the four months ended December 31, 2014 compared to the four months ended December 31, 2013 and remained relatively constant in the fiscal year ended August 31, 2014 compared to the fiscal year ended August 31, 2013.  Research and development expenses were $627,769 for the four months ended December 31, 2014 compared to $701,549 for the four months ended December 31, 2013, a decrease of $73,780, or approximately 11%.  Research and development expenses were $2,229,043 for the fiscal year ended August 31, 2014 compared to $2,281,854, for the fiscal year ended August 31, 2013, a decrease of $52,811, or approximately 2%

Selling, General and Administrative Expenses – Selling, general and administrative expenses were $2,819,205 for the four months ended December 31, 2014 compared to $2,237,057 for the four months ended December 31, 2013, an increase of $582,148, or approximately 26%.  This increase resulted primarily from our accrual of severance expenses related to the departure of certain of our management.  Selling, general and administrative expenses were $7,308,643 for the fiscal year ended August 31, 2014 compared to $7,403,273 in the fiscal year ended August 31, 2013, a decrease of $94,630, or approximately 1%.  While these total expenses were relatively constant from year to year, as we continue to roll out the MicroThermX product line and the support of its global distribution network, we believe that the level of our selling, general and administrative expenses will increase over the levels reported for the four months ended December 31, 2014, if sales volumes increase in 2015.
 
Impairment of Assets –In 2014, our Board of Directors determined that it is in the best interest of Perseon shareholders to divest our assets related to the hyperthermia product line  In connection with our plans to either sell or divest the assets related to the hyperthermia product line, we analyzed the carrying value and estimated net realizable value of inventory and other assets related to the hyperthermia product line as of December 31, 2014.  As a result of this analysis, during the four months ended December 31, 2014, we recorded an impairment charge of $805,000 for inventory, equipment, and other assets related to the hyperthermia product line.  These impairment expenses are the result of our assessment of the decrease in estimated realizable value associated with assets related to the hyperthermia product line.  The inventory reserve was also increased by $50,000 in the corresponding year ended August 31, 2014, to recognize a portion of the devaluation of inventory related to the hyperthermia product line.
 
Income Tax Provision – No provision for income taxes was recorded for the four months ended December 31, 2014 and 2013. For the years ended August 31, 2014 and 2013, we recorded an income tax provision of $2,000 and $1,938, respectively.  Due to our operating losses, our income tax provision is primarily related to state income taxes and is currently immaterial to our business.

Liquidity and Capital Resources

From inception through December 31, 2014, we have generated an accumulated deficit of $56,548,160 since our operating revenues have been insufficient to cover our operating expenses.  We have financed our operations primarily through the sale of our common stock.  As of December 31, 2014, we had cash and cash equivalents of $5,594,578, comprised primarily of money market funds and savings accounts.  We will require additional capital to fund our operations.

As of December 31, 2014, we had current liabilities totaling $1,799,503, comprised of accounts payable, accrued liabilities, customer deposits and deferred revenue incurred in the normal course of our business.  As of December 31, 2014, we had no long-term liabilities.

 
33
 
 
Stock Offerings

Shelf Registration Statements

On October 1, 2009, a universal shelf registration statement was declared effective by the SEC for the issuance of common stock, preferred stock, warrants, senior debt, subordinated debt and units up to an aggregate amount of $50.0 million (the “2009 Shelf Registration Statement”).  We completed four stock offerings utilizing the 2009 Shelf Registration Statement during calendar year 2010, and we received total net proceeds of approximately $19.2 million, including proceeds from the exercise of warrants issued in the stock offerings.

On September 28, 2012, we filed a universal shelf registration statement with the SEC for the issuance of common stock, preferred stock, warrants, senior debt, subordinated debt and units up to an aggregate amount of $50.0 million (the “2012 Shelf Registration Statement”).  On October 11, 2012, the 2012 Shelf Registration Statement was declared effective by the SEC.  We have completed two stock offerings utilizing the 2012 Shelf Registration Statement, from  April 2013 through December 31, 2014, and we received total net proceeds of approximately $9 million from these offerings, as more fully described below. We may periodically offer one or more of these securities in amounts, prices and terms to be announced when and if the securities are offered.  At the time any of the securities covered by the registration statement are offered for sale, a prospectus supplement will be prepared and filed with the SEC containing specific information about the terms of any such offering.

April 2013 Offering

On April 9, 2013, we entered into a placement agency agreement (the “Agency Agreement”) with Roth Capital Partners, LLC (the “Placement Agent”), pursuant to which the Placement Agent agreed to use its reasonable efforts to arrange for the sale of up to 4,065,042 shares of our common stock and warrants to purchase up to 3,048,782 shares of our common stock in a registered direct public offering (the “April 2013 Offering”).  The Placement Agent was entitled to a cash fee of 6.5% of the gross proceeds paid to us for the securities sold in the April 2013 Offering.  We also reimbursed the Placement Agent for all reasonable and documented out-of-pocket expenses incurred by the Placement Agent in connection with the April 2013 Offering, not to exceed the lesser of (i) $35,000 or (ii) 8% of the gross proceeds of the April 2013 Offering, less the Placement Agent’s placement fee.

The Agency Agreement contains customary representations, warranties and covenants by us.  It also provides for customary indemnification by us and the Placement Agent for losses or damages arising out of or in connection with the sale of the securities being offered.  We agreed to indemnify the Placement Agent against liabilities under the Securities Act of 1933, as amended.  We also agreed to contribute to payments the Placement Agent may be required to make in respect of such liabilities.

Also on April 9, 2013, we and certain institutional investors entered into a securities purchase agreement (the “Purchase Agreement”) in connection with the April 2013 Offering, pursuant to which we agreed to sell an aggregate of 4,065,042 shares of our common stock and warrants to purchase a total of 3,048,782 shares of our common stock to such investors for aggregate gross proceeds, before deducting fees to the Placement Agent and other estimated offering expenses payable by us, of approximately $5.0 million.  The common stock and warrants were sold in fixed combinations, with each combination consisting of one share of common stock and a warrant to purchase 0.75 shares of common stock.  The purchase price was $1.23 per fixed combination.  The warrants became exercisable six months and one day following the closing date of the April 2013 Offering and will remain exercisable for five years thereafter at an exercise price of $1.65 per share.  The exercise price of the warrants is subject to adjustment in the case of stock splits, stock dividends, combinations of shares and similar recapitalization transactions.

The exercisability of the warrants may be limited if, upon exercise, the holder or any of its affiliates would beneficially own more than 4.9% of our common stock.

 
34
 
 
We agreed with each of the purchasers that, subject to certain exceptions, we will not, within the 30 trading days following the closing of the April 2013 Offering (which period may be extended in certain circumstances), enter into any agreement to issue or announce the issuance or proposed issuance of any securities.

We also agreed with each of the purchasers that while the warrants are outstanding, we will not affect or enter into an agreement to affect a “Variable Rate Transaction,” which means a transaction in which we:

•
issue or sell any convertible securities either (A) at a conversion, exercise or exchange rate or other price that is based upon and/or varies with the trading prices of, or quotations for, the shares of our common stock at any time after the initial issuance of such convertible securities, or (B) with a conversion, exercise or exchange price that is subject to being reset at some future date after the initial issuance of such convertible securities or upon the occurrence of specified or contingent events directly or indirectly related to our business or the market for our common stock, other than pursuant to a customary “weighted average” anti-dilution provision; or
   
•
enter into any agreement (including, without limitation, an equity line of credit) whereby we may sell securities at a future determined price (other than standard and customary “preemptive” or “participation” rights).

We also agreed with each of the purchasers if we issue securities within the 12 months following the closing of the April 2013 Offering, the purchasers shall have the right to purchase all of the securities on the same terms, conditions and price provided for in the proposed issuance of securities.

We also agreed to indemnify each of the purchasers against certain losses resulting from our breach of any of our representations, warranties, or covenants under agreements with each of the purchasers, as well as under certain other circumstances described in the Purchase Agreement.

We closed the April 2013 Offering on April 12, 2013 and received net proceeds of approximately $4.6 million, after deducting placement agent fees and the offering expenses borne by us.

The April 2013 Offering was completed using the 2012 Shelf Registration Statement on Form S-3, pursuant to a prospectus supplement filed with the SEC.

May 2014 Offering

On May 9, 2014, we entered into an At-the-Market Issuance Sales Agreement (the “ATM Agreement”) with MLV & Co. LLC (“MLV”).  Under this sales agreement, we could issue and sell from time to time, up to $8,000,000 of common stock.  These shares are registered under the 2012 Shelf Registration Statement filed with the SEC.  MLV would act as sales agent, using commercially reasonable efforts consistent with its normal trading and sales practices.  The Agreement provided that our common shares would be sold at market prices prevailing at the time of the sale of our common stock, at no discount to market and no warrants attached.  We were not obligated to make any sales under the sales agreement.  We paid MLV a commission rate of 3.0% of the gross proceeds from the sale of common stock sold through MLV as sales agent under the sales agreement, reimbursed MLV for certain expenses incurred in connection with entering into the sales agreement, and provided MLV with customary indemnification rights. We filed the full terms and text of the sales agreement on a Current Report on Form 8-K on May 9, 2014.  Through June 22, 2014,  we sold 46,622 shares of common stock at an average price per share of $1.074, for gross proceeds of $50,068.  The ATM Agreement was terminated on June 22, 2014.

June 2014 Offering

On June 25, 2014, we entered into a securities purchase agreement (the “June Offering”) with certain institutional investors in which we agreed to sell, pursuant to a securities purchase agreement (the “Purchase Agreement”), an aggregate of 5,500,000 shares of its common stock and warrants to purchase a total of 4,400,000 shares of our common stock to such investors for aggregate gross proceeds of approximately $5.2 million, and net proceeds of approximately $4.7 million, after deducting placement agency fees and other costs associated with the transaction.  The common stock and warrants were sold in fixed combinations, with each combination consisting of one share of common stock and a warrant to purchase 0.8 shares of common stock.  The purchase price was $0.95 per fixed combination.  The warrants will become exercisable six months and one day following the closing date of the June Offering and will remain exercisable for five years thereafter at an exercise price of $1.10 per share.  The exercise price of the warrants is subject to adjustment in the case of stock splits, stock dividends, combinations of shares and similar recapitalization transactions.  The exercisability of the warrants may be limited if, upon exercise, the holder or any of its affiliates would beneficially own more than 4.99% of our common stock.  The warrants are contingently puttable at the option of the holders upon the occurrence of a fundamental transaction (as defined in the warrant agreements).  We believe that all of the fundamental transactions are within our sole control, and that the probability of any fundamental transaction occurring and the put being exercised are both remote.

 
35
 
 
Under the Purchase Agreement, we agreed with each of the purchasers that, subject to certain exceptions we will not, within the 75 days following the closing of the June Offering enter into any agreement to issue or announce the issuance or proposed issuance of any securities.  We also agreed with each of the purchasers that for a period of four years from the date of the Purchase Agreement, we will not effect or enter into an agreement to effect a “Variable Rate Transaction,” which means a transaction in which we:

•
issue or sell any convertible securities either (A) at a conversion, exercise or exchange rate or other price that is based upon and/or varies with the trading prices of, or quotations for, the shares of our common stock at any time after the initial issuance of such convertible securities, or (B) with a conversion, exercise or exchange price that is subject to being reset at some future date after the initial issuance of such convertible securities or upon the occurrence of specified or contingent events directly or indirectly related to  our business or the market for our common stock, other than pursuant to a customary “weighted average” anti-dilution provision; or
   
•
eententer into any agreement (including, without limitation, an equity line of credit) whereby we may sell securities at a future determined price.

We also agreed to indemnify each of the purchasers against certain losses resulting from its breach of any of its representations, warranties, or covenants under agreements with each of the purchasers, as well as under certain other circumstances described in the Purchase Agreement. The transaction closed on July 1, 2014 and the net proceeds were transferred to us.

Cash Flows from Operating, Investing and Financing Activities

During the four months ended December 31, 2014, we used net cash of $2,467,242 in operating activities, primarily as a result of our net loss of $3,768,390, decreased by non-cash expenses of $1,124,951, including depreciation and amortization, stock-based compensation, loss on disposition of assets and impairment of assets.  Net cash used in operating activities also included increases in receivables of $33,334 and inventories of $46,459 and decreases in customer deposits of $114 and deferred revenue of $41,825, partially offset by a decrease in other current assets of $59,736, and increases in accounts payable of $49,569 and accrued liabilities of $188,624.

During the four months ended December 31, 2013, we used net cash of $2,006,107 in operating activities, primarily as a result of our net loss of $2,106,641, decreased by non-cash expenses of $374,531, including depreciation and amortization and stock-based compensation.  Net cash used in operating activities also included an increase in inventories of $328,517 and decreases in accounts payable of $57,272, accrued liabilities of $84,323 and deferred revenue of $46,237, partially offset by decreases in receivables of $95,124 and other current assets of $51,881, and an increase in customer deposits of $95,347.

During the year ended August 31, 2014, we used net cash of $5,916,395 in operating activities, primarily as a result of our net loss of $7,142,832, decreased by non-cash expenses of $1,200,422, including depreciation and amortization, stock-based compensation, stock issued for services and gain on disposition of property and equipment.  Net cash used in operating activities also included decreases in customer deposits of $275,699 and deferred revenue of $687,665, partially offset by decreases in receivables of $548,961, inventories of $66,581, other current assets of $53,709, and increases in accounts payable of $27,480 and accrued liabilities of $292,648.

 
36
 
 
During the year ended August 31, 2013, we used net cash of $6,200,055 in operating activities, primarily as a result of our net loss of $8,251,691, decreased by non-cash expenses of $1,446,966, including depreciation and amortization, stock-based compensation and stock issued for services.  Net cash used in operating activities also included increases in receivables of $601,326, inventories of $41,813, and other current assets of $79,959, partially offset by increases in accounts payable of $325,663, accrued liabilities of $149,182, customer deposits of $292,500, and deferred revenue of $560,423.

Net cash used in investing activities, resulting from the purchase of property and equipment, was $35,317 and $21,330 for the four months ended December 31, 2014 and 2013, respectively.  Net cash used in investing activities, resulting from the purchase of property and equipment, was $73,574 and $35,362 for the years ended August 31, 2014 and 2013, respectively.

Net cash used in financing activities comprised of payments on note payable was $33,279 for the four months ended December 31, 2014.  We had no net cash provided by or used in financing activities for the four months ended December 31, 2013.  Net cash provided by financing activities was $4,669,857 for the year ended August 31, 2014, comprised of net proceeds of $4,636,579 from the sale of common stock and $74,052 of proceeds from short term financing of an insurance policy, and payments on the short term financing of $40,774.  Net cash provided by financing activities for the year ended August 31, 2013 was $4,583,437, comprised of net proceeds from the sale of common stock.

We do not believe that our current cash and cash equivalents will be sufficient to fund our operations at their current levels for the next twelve months.  We will need to obtain additional financing.  We believe that we will be able to raise sufficient capital, to fund our operations, and on terms that are acceptable to us.  However, due to the unpredictability of global financial markets, there can be no assurance that we will be successful in raising additional funds through the sale of debt or equity securities on terms acceptable to us.  If we raise equity capital, our stockholders will be diluted.  Insufficient funds would likely require us to reduce costs, which would negatively affect our research and development programs, our efforts to expand our marketing and sales presence, the ability to hire and retain qualified personnel, as well as other operational aspects of the Company.

As of December 31, 2014, we had no significant commitments for the purchase of property and equipment.

We had no material off- balance sheet arrangements as of December 31, 2014.

Critical Accounting Policies

The following is a discussion of our critical accounting policies and estimates that management believes are material to an understanding of our results of operations and which involve the exercise of judgment or estimates by management.
 
Revenue Recognition:  Revenue from product sales is recognized when a purchase order has been received, the system has been shipped, the selling price is fixed or determinable, and collection is reasonably assured.  Most system sales are F.O.B. shipping point; therefore, shipment is deemed to have occurred when the product is delivered to the transportation carrier.  Most system sales do not include installation.  If installation is included as part of the contract, revenue is not recognized until installation has occurred, or until any remaining installation obligation is deemed to be perfunctory.  Some sales of systems may include training as part of the sale.  In such cases, the portion of the revenue related to the training, calculated based on the amount charged for training on a stand-alone basis, is deferred and recognized when the training has been provided.  The sales of our cancer treatment systems do not require specific customer acceptance provisions and do not include the right of return except in cases where the product does not function as warranted by us.  To date, returns have not been significant.

Revenue from the sale of disposable devices is recognized when a purchase order has been received, the devices have been shipped, the selling price is fixed or determinable, and collection is reasonably assured.  Currently, our customers are not required to purchase a minimum number of disposable devices in connection with the purchase of our systems.

 
37
 
 
Revenue from training services is recorded when an agreement with the customer exists for such training, the training services have been provided, and collection is reasonably assured.

Revenue from service support contracts is recognized on a straight-line basis over the term of the contract, which approximates recognizing it as it is earned.

Revenue from equipment rental under an operating lease is recognized when billed in accordance with the lease agreement.

Our revenue recognition policy is the same for sales to both related parties and non-related parties.  We provide the same products and services under the same terms for non-related parties as with related parties.
 
Sales to distributors are recognized in the same manner as sales to end-user customers.

Deferred revenue and customer deposits include amounts from service contracts as well as cash received for the sales of products, which have not been shipped.

Inventory Reserves:  We maintain a reserve for obsolete inventories to reduce excess and obsolete inventories to their estimated net realizable value.  This reserve is a significant estimate and we periodically review our inventory levels and usage, paying particular attention to slower-moving items. If projected sales do not materialize or if our systems do not receive increased market acceptance, we may be required to increase the reserve for obsolete inventories in future periods.

Product Warranty:  We provide limited product warranties on our systems.  These warranties vary from contract to contract, but generally consist of parts and labor warranties for one year from the date of installation.  To date, expenses resulting from such warranties have not been material.  We record a warranty expense at the time of each sale.  This reserve is estimated based on prior history of service expense associated with similar units sold in the past.

Allowance for Doubtful Accounts Receivable:  We maintain an allowance for doubtful accounts receivable for estimated losses resulting from the inability of our customers to make required payments.  This allowance is a significant estimate and is regularly evaluated by us for adequacy by taking into consideration factors such as past experience, credit quality of the customer base, age of the receivable balances, both individually and in the aggregate, and current economic conditions that may affect a customer’s ability to pay.  If the financial condition of our customers were to deteriorate, resulting in an impairment of their ability to make payments, additional allowances may be required.

Stock-based Compensation:  Stock-based compensation cost  of stock options and other stock-based awards to employees and directors is measured at the grant date based on the estimated value of the award granted, using the Black-Scholes option pricing model, and recognized over the period in which the award vests.  For stock awards no longer expected to vest, any previously recognized stock compensation expense is reversed in the period of termination.  The stock-based compensation expense has been allocated to the various categories of operating costs and expenses in a manner similar to the allocation of payroll expense.  The Black-Scholes valuation model utilizes inputs that are subject to change over time, including the volatility of the market price of our common stock, risk free interest rates, requisite service periods and assumptions made by us regarding the assumed life and vesting of stock options and stock-based awards.  As new options or stock-based awards are granted, additional non-cash compensation expense will be recorded by us.

Income Taxes:  We account for income taxes using the asset and liability method.  Under the asset and liability method, deferred tax assets and liabilities are recognized for the future consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases.  Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.  The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

We maintain valuation allowances where it is more likely than not that all or a portion of a deferred tax asset will not be realized.  Changes in valuation allowances are included in our income tax provision in the period of change.  In determining whether a valuation allowance is warranted, we evaluate factors such as prior earnings history, expected future earnings and our ability to carry back reversing items within two years to offset income taxes previously paid.

To the extent that we have the ability to carry back current period taxable losses to offset income taxes previously paid, we record an income tax receivable and a current income tax benefit.

 
38
 
 
Recent Accounting Pronouncements

No new accounting pronouncements were adopted during the four months ended December 31, 2014 that had a material impact on our financial statements.

In May 2014, FASB issued ASU 2014-09 Revenue from Contracts with Customers. The amendments in ASU 2014-09 affects any entity that either enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of nonfinancial assets unless those contracts are within the scope of other standards (e.g., insurance contracts or lease contracts). This ASU will supersede the revenue recognition requirements in Topic 605 Revenue Recognition and most industry-specific guidance, and creates a Topic 606 Revenue from Contracts with Customers.

The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve that core principle, an entity should apply the following steps:

Step 1: Identify the contract(s) with a customer
Step 2: Identify the performance obligations in the contract.
Step 3: Determine the transaction price.
Step 4: Allocate the transaction price to the performance obligations in the contract.
Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation.

ASU 2014-09 is effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. Early application is not permitted.  We have not yet determined how our financial statements will be affected by the adoption of ASU 2014-09.

FORWARD-LOOKING STATEMENTS

With the exception of historical facts, the statements contained in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and other parts of this Transition Report on Form 10-K are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which reflect our current expectations and beliefs regarding our future results of operations, performance and achievements.  These statements are subject to risks and uncertainties and are based upon assumptions and beliefs that may or may not materialize.  These forward-looking statements include, but are not limited to, statements concerning:

·
our belief about the market opportunities for our products;
   
·
our anticipated financial performance and business plan;
   
·
our ability to successfully execute our plan to either sell the assets related to hyperthermia products or discontinue manufacturing and selling hyperthermia systems;
   
·
our belief that the distribution agreement with Terumo Europe NV will help drive market adoption of the MicroThermX;
   
·
our expectations that the SynchroWave antennas used in conjunction with the MicroThermX will represent a significant ongoing revenue stream;
   
·
our expectations that we will reach agreements with additional international distribution firms;
   
·
our expectations that additional international shipments of the MicroThermX and supplies of SynchroWave antennas will occur in the future;
   
·
our belief that the level of our operating expenses, including selling, general and administrative expenses, will increase;
   
·
our belief that our operating results, revenue and operating expenses may fluctuate in the future from year to year as well as from quarter to quarter; and
   
·
our belief that we will be able to raise additional capital to fund our operations.
 
 
39
 
 
We wish to caution readers that the forward-looking statements and our operating results are subject to various risks and uncertainties that could cause our actual results and outcomes to differ materially from those discussed or anticipated, including the factors set forth in Item 1A – “Risk Factors” in this Transition Report and our other filings with the Securities and Exchange Commission.  We also wish to advise readers not to place any undue reliance on the forward-looking statements contained in this report, which reflect our beliefs and expectations only as of the date of this report.  We assume no obligation to update or revise these forward-looking statements to reflect new events or circumstances or any changes in our beliefs or expectations, other than as required by law.
 
ITEM 7A.  QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Our cash and cash equivalents consist primarily of money market funds and savings accounts, which are investment grade securities.  These accounts bear variable interest rates that are adjusted to market conditions and changes in financial market conditions and in market rates will affect interest income earned on these funds.  We do not believe, however, that the interest income earned on our money market funds and savings accounts is material to the results of our operations.  Further, we do not believe that we are currently exposed to changes in financial market conditions that expose our money market funds and savings accounts to material changes in the market value of their principal.

We do have significant sales to foreign customers and are therefore subject to the effects changes in foreign currency exchange rates may have on demand for our products and services. We currently do not utilize derivative instruments to offset the exposure to changes in foreign currency exchange rates.  To minimize foreign exchange risk, our export sales are transacted in United States dollars.

ITEM 8.  FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

The Financial Statements of the Company called for by this item are contained in a separate section of this report.  See “Index to Financial Statements” on Page F-1.

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

None.
  
ITEM 9A.  CONTROLS AND PROCEDURES

Disclosure Controls and Procedures
 
We maintain disclosure controls and procedures designed to provide reasonable assurance that information required to be disclosed in reports filed under the Securities Exchange Act of 1934 (the “Act”) is recorded, processed, summarized and reported within the specified time periods and accumulated and communicated to management, including our Chief Executive Officer (Principal Executive Officer) and Chief Financial Officer (Principal Accounting Officer), as appropriate, to allow timely decisions regarding required disclosure.
 
Management, under the supervision and with the participation of our Chief Executive Officer (Principal Executive Officer) and Chief Financial Officer (Principal Accounting Officer), evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) or 15d-15(e) promulgated under the Act), as of December, 2014.  Based on that evaluation, management concluded that our disclosure controls and procedures were effective as of December 31, 2014.
  
 
40
 
 
Management’s Report on Internal Control Over Financial Reporting

Management is responsible for establishing and maintaining adequate internal control over financial reporting of the Company.  Management’s intent is to design this system to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles in the United States of America (“GAAP”).

Our internal control over financial reporting includes those policies and procedures that:
 
1.
pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company;
   
2.
provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and
   
3.
provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the Company’s assets that could have a material effect on the financial statements.
 
A material weakness is a significant deficiency, or combination of significant deficiencies, in internal controls over financial reporting such that there is a reasonable possibility that a material misstatement of the annual or interim financial statements will not be prevented or detected on a timely basis.  Management performed an assessment of the effectiveness of the Company’s internal control over financial reporting as of August 31, 2014, utilizing the criteria described in the “Internal Control — Integrated Framework” issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”).  The objective of this assessment was to determine whether our internal control over financial reporting was effective as of such date.  In its assessment of the effectiveness of internal control over financial reporting as of August 31, 2014, management concluded that our internal control over financial reporting is effective.

Changes in Internal Control Over Financial Reporting

There have been no changes in our internal control over financial reporting (as such item is defined in Rule 13a-15(f) under the Act) that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Limitations on the Effectiveness of Controls

Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls or our internal controls will prevent or detect all errors and all fraud.  A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system’s objectives will be met.  Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs.  Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake.  Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls.  The design of any system of controls is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.  Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with associated policies or procedures.  Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.
  
 
41
 
 
ITEM 9B.  OTHER INFORMATION

None.
 
PART III

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

DIRECTORS
 
The names of directors, their ages and their respective business backgrounds are set forth below as of March 6, 2015.
 
 Name
Position(s) With the Company
  
Age
    
Director Since
  
Timothy C. McQuay
Independent Director and Chairman of the Board
     63       2008  
Clinton E. Carnell Jr.
President, Chief Executive Officer and Director
     45       2014  
Harold R. Wolcott
Director
     68       2009  
Michael Nobel, Ph.D.
Independent Director
     75       1998  
Steven G. Stewart
Independent Director and Financial Expert
     66       2006  
Dr. Damian E. Dupuy
Independent Director
     53       2011  
 
BUSINESS EXPERIENCE AND QUALIFICATIONS OF NOMINEES FOR ELECTION TO THE BOARD OF DIRECTORS
 
Timothy C. McQuay has served as a director of Perseon since February 2008 and currently serves as Chairman of the Board of Directors.  He is a Managing Director – Investment Banking with Noble Financial Capital Markets.  Prior to joining Noble Financial Capital Markets in November 2011, Mr. McQuay was a Managing Director – Investment Banking with B Riley & Co.  Prior to joining B Riley in September 2008, Mr. McQuay served for ten years as Managing Director – Investment Banking with A. G. Edwards & Sons, Inc., where he specialized in Healthcare, including medical technology, biotechnology and specialty pharmaceuticals.  He currently serves as a member of the Board of Directors of Superior Industries International, Inc.  Mr. McQuay holds an AB in Economics from Princeton University and an MBA from UCLA.  Mr. McQuay’s qualifications to serve on the Board include, among others, his extensive business and financial experience, his public company board and investment banking experience, his knowledge of Perseon, and his service as a director of Perseon since 2008.
 
Clinton E. Carnell Jr. was appointed a director of Perseon by unanimous written consent of our Board of Directors in November 2014.  At that time, we also named Mr. Carnell as our President and Chief Executive Officer.  Most recently, he served as an advisor to Covidien plc, a publicly traded global health care leader, in the role of 'Executive in Residence.'  From 2011 to 2014, Mr. Carnell served as Chairman, Chief Executive Officer and President of MyoScience, Inc., a commercial-stage medical device company which developed technology to target nerves for the treatment of pain, muscle disorders, aesthetic and other medical conditions.  From 2005 to 2011 Mr. Carnell was the Chief Operating Officer of Solta Medical, Inc., a publicly held medical aesthetics company where he had responsibility for the Thermage and Fraxel Brands, led the integration of three strategic acquisitions and played a key role in Solta’s IPO in 2006.  During the period from 2002 to 2005 he was Vice President of Sales for the US Surgical Division of Bausch & Lomb Prior to 2002, Mr. Carnell held management positions with healthcare companies including Gambro Healthcare, Johnson & Johnson and Charleston Renal Care, LLC.  Mr. Carnell’s qualifications to serve on the Board include, among others, his extensive business, operations and sales experience, and his management and executive experience at publicly held medical device companies.
 
 
42
 
 
            Harold R. Wolcott has served as a director of Perseon since April 2009.  Mr. Wolcott also served as President of Perseon from April 2009 until his successor was appointed in November 2014.  Mr. Wolcott has 45 years of experience managing and growing newly-formed venture capital financed corporations as well as multi-million dollar medical device businesses with international operations.  He has a wide range of experience in the areas of product research, product engineering, manufacturing and plant management, as well as expertise in all aspects of sales and marketing, acquisition/integration, and the sale of medical device businesses.  Prior to joining Perseon, Mr. Wolcott served from 2006 through 2009 as President and Chief Operating Officer, and later, as Director of Dimicron Inc., a development stage medical company utilizing synthetic diamond for orthopedic applications.  From 2001 until 2005, Mr. Wolcott served as Chief Operating Officer and Director of Rubicon Medical, Inc., a company focusing on proprietary technology in embolic protection for interventional cardiology and interventional neurology.  Mr. Wolcott’s qualifications to serve on the Board include, among others, his extensive executive and operational management experience in the medical device business, his public company board experience, his knowledge of Perseon, and his service as President and a director of Perseon from April 2009 through November 2014.
 
Michael Nobel, Ph.D., has served as a director of Perseon since January 1998.  Dr. Nobel participated in the introduction of magnetic resonance imaging as European Vice President of Fonar Corp.  He is founder and trustee of the Nobel Sustainable Trust Foundation.  From 1991 to 2007, Dr. Nobel served as the Executive Chairman of the MRAB Group, a company providing diagnostic imaging services to Sweden.    From August 2005 until June 2008, Dr. Nobel served as a director of WorldSpace Corp.  He has also been a consultant to Unesco in Paris and the United Nations Social Affairs Division in Geneva.  Today, Dr. Nobel is chairman or board member of several international companies in medical diagnostics, treatment and information systems.  He is a guest professor at the Seisa University in Japan. In December 2012 Dr. Nobel was appointed a director of CytoDyn Inc. a public company traded on the OTCQB market. Dr. Nobel’s qualifications to serve on the Board include, among others, his extensive business and financial experience, his knowledge of Perseon, and his public company experience as a director of Perseon since 1998.
 
Steven G. Stewart has served as a director of Perseon since 2006.  From July 1998 through June 2013, Mr. Stewart served in several management positions at Headwaters, Inc. (a New York Stock Exchange company), including Director of Financial Affairs, Treasurer and as the Chief Financial Officer for approximately ten years before retiring on July 1, 2013.  Prior to joining Headwaters, Mr. Stewart served as a business assurance partner for PricewaterhouseCoopers LLP (formerly Coopers & Lybrand LLP), and as an audit partner with Ernst & Young (formerly Arthur Young), including service as the Salt Lake City office Director of High Technology and Entrepreneurial Services.  Mr. Stewart’s qualifications to serve on the Board include, among others, his extensive business and financial experience, his experience as an executive finance officer of a public company, his knowledge of Perseon, and his public company experience both at Headwaters and as a director of Perseon since 2006.
 
Damian E. Dupuy, MD, was appointed a Director in April 2011.  Dr. Dupuy has been a Professor of Diagnostic Imaging at the Warren Alpert Medical School of Brown University since 2005, and has served as Director, Tumor Ablation, at Rhode Island Hospital in Providence, RI since 2001.  Dr. Dupuy, a fellow of the American College of Radiology, is a pioneer in the growing field of image guided tumor ablation, whereby various types of thermal devices destroy tumors by direct placement through the skin under image guidance.  Dr. Dupuy is internationally known for his pioneering clinical work in treating cancer patients who suffer from tumors of the lung, liver, kidney, head and neck, pelvis, adrenal and skeleton.  Dr. Dupuy has led two National Cancer Institute multi-center trials and currently is the Interventional Oncology Symposium Chair of the Radiological Society of North America.  Dr. Dupuy, who is a graduate of the University of Massachusetts, Amherst, and the University of Massachusetts Medical School, has published widely on a variety of specialized medical issues and is the recipient of numerous post-graduate honors and awards, including an American College of Radiology Imaging Network Publications Merit Award in 2010.  Dr. Dupuy’s qualifications to serve on the Board include, among others, his extensive medical and business experience, his knowledge of Perseon, and public company experience as a director of Perseon since April 2011.
 
COMPOSITION OF THE BOARD OF DIRECTORS
 
Our Board of Directors currently consists of six directors.  Directors are elected at each annual meeting of stockholders to serve until the next annual meeting of stockholders or until their successors are duly elected and qualified.  There are no family relationships among any of our directors, officers or key employees.
 
 
43
 
 
BOARD LEADERSHIP STRUCTURE
 
The Board does not have a policy regarding the separation of the roles of Chief Executive Officer and Chairman of the Board as the Board believes it is in our best interests to make that determination based upon our position and direction, and the membership of the Board.  The Board has determined at this time that our Chairman should be an Independent Director rather than the Chief Executive Officer.
 
CODE OF ETHICS
 
We have adopted a Code of Ethics that applies to all of our directors, officers and employees.  Our Code of Ethics is available on our website (www.bsdmedical.com) on our corporate governance page of the investor section of our website.  We intend to post amendments to or waivers from our Code of Ethics (to the extent applicable to our chief executive officer, principal financial officer, or principal accounting officer) on our website.
 
AFFIRMATIVE DETERMINATIONS REGARDING DIRECTOR INDEPENDENCE
 
The Board of Directors has determined each of the following directors to be an “independent director” as such term is defined in the NASDAQ Stock Market Listing Standards: Timothy C. McQuay, Michael Nobel, Steven G. Stewart, and Damian E. Dupuy.
 
In this Proxy Statement, these four directors are referred to individually as an “Independent Director” and collectively as the “Independent Directors.”
 
MEETINGS AND COMMITTEES OF THE BOARD OF DIRECTORS
 
The Board of Directors held five meetings in the four month transition period ended December 31, 2014, and met six times during fiscal year 2014.  No director attended fewer than 75% of the meetings of the Board or any of the Board committees of which a director was a member.  In addition, on one occasion during the four month transition period ended December 31, 2014, and on one occasion during fiscal year 2014, the Board of Directors took action by unanimous written consents in lieu of a board meeting.  Although we do not have a formal policy regarding attendance by directors at our annual meeting, we encourage directors to attend and all but one director attended the last annual meeting.
 
The Board of Directors has formed an audit committee, a corporate governance and nominating committee and a compensation committee.  Copies of the charters of these committees are available on the corporate governance page of the investor section of our website (www.bsdmedical.com).
 
The Audit Committee.  The Audit Committee, which held one meeting in the four month transition period ended December 31, 2014, and four meetings during the fiscal year ended August 31, 2014, is responsible for reviewing and monitoring our financial statements and internal accounting procedures, recommending the selection of independent auditors by the Board, evaluating the scope of the annual audit, reviewing audit results, consulting with management and our independent auditor prior to presentation of financial statements to stockholders and, as appropriate, initiating inquiries into aspects of our internal accounting controls and financial affairs.  The Board of Directors has adopted a written audit committee charter.
 
The members of the Audit Committee are Messrs. Stewart, Nobel and McQuay.  Mr. Stewart is currently serving as the audit committee chairman and financial expert (Audit Committee Financial Expert).  All members of the Audit Committee are Independent Directors.
 
The Corporate Governance and Nominating Committee.  The Corporate Governance and Nominating Committee, who held one meeting in the four month transition period ended December 31, 2014 and one meeting during the fiscal year ended August 31, 2014, is responsible for identifying qualified individuals to become Board members, determining the composition of the Board and its committees, monitoring and assessing Board effectiveness, and developing and implementing our corporate governance guidelines.  Additionally, the Corporate Governance and Nominating Committee recommends director nominees to our Board of Directors for the Board’s approval.  The Board of Directors has adopted a written corporate governance and nominating committee charter.
 
 
44
 
 
The members of the Corporate Governance and Nominating Committee are Messrs. Stewart, Nobel, McQuay and Dupuy.  All members of the Corporate Governance and Nominating Committee are Independent Directors.  Mr. McQuay is currently serving as the Corporate Governance and Nominating Committee chairman.
 
The Board of Directors does not have an express policy with regard to the consideration of any director candidates since the Board believes that its Corporate Governance and Nominating Committee can adequately evaluate nominees on a case-by-case basis.  The Board has not previously received any recommendations for director candidates from stockholders, and has not adopted a formal process for considering director candidates who may be recommended by stockholders.  However, the Company’s policy is to give due consideration to any and all such candidates, and in evaluating director nominees, the Corporate Governance and Nominating Committee considers the appropriate size of the Board, the needs of the Company, the skills and experience of its directors, and a candidate’s familiarity with our industry.  Although the Company does not have a formal diversity policy relating to the identification and evaluation of nominees for director, the Corporate Governance and Nominating Committee considers many criteria in identifying and selecting nominees, and in the future may establish additional minimum criteria for nominees.  A stockholder may submit a recommendation for director candidates to us at our corporate offices, to the attention of Clint Carnell.  We do not pay fees to any third parties to assist us in identifying potential nominees.
 
The Compensation Committee.  The members of the Compensation Committee are Messrs. Stewart, Nobel, and McQuay.   Mr. Boyd, who resigned as director in January 2015, was serving as the Compensation Committee chairman. A replacement has not yet been appointed.  All members of the Compensation Committee are Independent Directors.  Our Compensation Committee held one meeting in the four month transition period ended December 31, 2014, and met one time during the fiscal year ended August 31, 2014.  The Board of Directors has adopted a written compensation committee charter.  The Compensation Committee has responsibility for establishing and monitoring our executive compensation programs, and for making decisions regarding the compensation of our Named Executive Officers (as defined below).  The agenda for meetings of the Compensation Committee is determined by the Chairman of the Compensation Committee.  The Compensation Committee sets the compensation package of the Named Executive Officers and their annual bonus.  We have adopted our Third Amended and Restated 1998 Stock Incentive Plan which allows the Board of Directors to delegate to the CEO the authority to designate individuals to receive awards under the Plan and to designate the number and type of awards to be granted to the individuals so designated.  The Board did not delegate this authority to the CEO during the four month transition period ended December 31,2014.  For a further description of the Compensation Committee’s role, see “Executive Compensation” below.
 
BOARD ROLE IN RISK OVERSIGHT
 
Our Board of Directors is responsible for overseeing our management of risk.  The Board strives to effectively oversee our enterprise-wide risk management in a way that balances managing risks while enhancing the long-term value for the benefit of the stockholders.  The Board of Directors understands that its focus on effective risk oversight is critical to setting our tone and culture towards effective risk management.  To administer its oversight function, the Board seeks to understand our risk philosophy by having discussions with management to establish a mutual understanding of our overall appetite for risk.  Our Board of Directors maintains an active dialogue with management about existing risk management processes and how management identifies, assesses, and manages our most significant risk exposures.  Our Board expects frequent updates from management about our most significant risks so as to enable it to evaluate whether management is responding appropriately.
 
Our Board relies on each of its committees to help oversee the risk management responsibilities relating to the functions performed by such committees.  Our Audit Committee periodically discusses with management our major financial risk exposures and the steps management has taken to monitor and control such exposures, including our risk assessment and risk management policies.  Our Compensation Committee helps the Board to identify our exposure to any risks potentially created by our compensation programs and practices.  Our Corporate Governance and Nominating Committee oversees risks relating to our corporate compliance programs and assists the Board and management in promoting an organizational culture that encourages commitment to ethical conduct and a commitment to compliance with the law.  Each of these committees is required to make regular reports of its actions and any recommendations to the Board, including recommendations to assist the Board with its overall risk oversight function.
 
 
45
 
 
COMMUNICATIONS WITH DIRECTORS
 
We have not adopted a formal process for stockholder communications with the Board.  We believe it is appropriate to not have a formal process for stockholder communications with the Board, because historically we have received such stockholder communications very infrequently.  Nevertheless, we have tried to ensure that the views of stockholders are heard by the Board or individual directors, as applicable, and that appropriate responses are provided to stockholders in a timely manner.  We believe our responsiveness to stockholder communications to the Board has been good.  A stockholder may submit any communication with directors to us at our corporate offices, to the attention of Clinton E. Carnell Jr.
 
EXECUTIVE OFFICERS
 
The names of our executive officers, their ages, and their respective business backgrounds are set forth below as of  March 6, 2015.  For information regarding Clinton E. Carnell Jr.’s background, please see his biographical description above under “Directors”.  There are no family relationships among any of our directors, officers or key employees.
 
 Name
  
Age
  
Position
         
Clinton E. Carnell Jr.
     45  
President, Chief Executive Officer and Director
William S. Barth
     64  
Chief Financial Officer and Secretary
Benjamin Beckham
     49  
Vice President of Global Sales
Jennifer R. Hoglin
     45  
Vice President of  Global Marketing
Todd H. Turnlund
     48  
Vice President of Research & Development
 
            William S. Barth commenced his employment with us on December 10, 2012, and assumed the duties of Chief Financial Officer and Corporate Secretary effective January 1, 2013.  Mr. Barth has an extensive history as chief financial officer for both publicly and privately held companies in the medical device and biotechnology industries.  From May 2011 until December 10, 2012, he has served as an independent corporate financial and strategic planning consultant.  From June 2008 to May 2011, he served as Sr. Vice President and Chief Financial Officer for Emphusion, LLC, a private-equity-owned Contract Research Organization (CRO) providing data management and bio-statistical analysis services for new drug and medical device development.  From January 2001 through April 2008, Mr. Barth was VP of Finance and CFO for NWT Inc. /Tandem Labs (Tandem), a privately owned CRO, providing advanced bio-analytical services in support of new drug development.  Mr. Barth was instrumental in the successful merger of Tandem with Laboratory Corporation of America in February 2008.  During the 20 years prior to his experience with Tandem, he served as CFO for 6 medical device companies, two of which were publicly owned.  During this time he played critical roles in completing several equity, debt and merger transactions.  Mr. Barth began his career in finance while serving as a staff accountant with Deloitte & Touche, an international accounting and consulting firm.
 
Ben Beckham was appointed as Vice President of North American Sales for Perseon Corporation effective February 16, 2015 and was recently named Vice President of Global Sales.  Mr. Beckham is an accomplished and performance-driven life sciences executive with over 20 years of experience in medical sales management and marketing.  Prior to joining Perseon, Mr. Beckham was Vice President of Sales, Americas for Solta Medical, a medical aesthetics company acquired by Valeant Pharmaceuticals International, Inc. in 2014.  At Solta, he was responsible for all commercial activity throughout North and South America.  Prior to Solta, Mr. Beckham served as Vice President, Sales and Marketing for Lifecore Biomedical, a leader in tissue biologics, dental implants and implantable grafting products. He has also held various sales leadership positions with companies such as Interpore International and GE Medical Systems.
 
 
46
 
 
Jennifer R. Hoglin joined the Company as Vice President of Global Marketing on February 17, 2015. Ms. Hoglin is an executive marketing professional with 20 years of experience in product, brand, and business development experience in primarily life sciences as well as multiple other industries.  Ms. Hoglin’s career spans key leadership roles in go-to-market and commercialization strategy and development, most recently as Vice President of Marketing at Catheter Connections Inc., a manufacturer of infection control products. Formerly as Senior Director of Global Marketing at Edwards Lifesciences, she led integral marketing efforts involving product portfolio development and global professional education teams, programs, and tactics.  Earlier she managed strategic marketing for Myriad Genetics Laboratories’ Preventive Care Business, and she has held various positions with CR Bard and 3M.  Ms. Hoglin holds an MBA from Washington University, St. Louis, MO and a BA from The Colorado College, Colorado Springs, CO.
 
Todd H. Turnlund was appointed Vice President of Research and Development (R&D) at Perseon in January 2015 after serving as the Vice President of Engineering since January 2010.  Mr. Turnlund has over 25 years of medical device experience with both medical device startups and Fortune 500 companies.  Since 2000 prior to joining Perseon, Mr. Turnlund served in various R&D management positions including Vice President of R&D at Precision Vascular Systems, Director of R&D at Boston Scientific, an independent engineering consultant, and Director of R&D at C.R. Bard.  Mr. Turnlund has a Mechanical Engineering Degree from the University of California at Santa Barbara and an MBA from Santa Clara University.
 
ITEM 11. EXECUTIVE COMPENSATION
 
DIRECTOR COMPENSATION 2014
 
Our Fourth Amended and Restated 1998 Director Stock Plan (“Director Stock Plan”) provides an annual retainer (“Annual Retainer”) in the amount of $60,000 to each non-employee director other than the Audit Committee Financial Expert, who is to receive $65,000.  Of the Annual Retainer, $30,000 is to be paid in cash to each such director, other than the Audit Committee Financial Expert, who is to receive $35,000 in cash (the “Cash Payment”).  The Cash Payment is payable in equal installments on May 1 and November 1 of each year in which each non-employee director continues to serve as a member of the Board.  Each non-employee director is to receive the balance of the Annual Retainer in the form of shares of common stock (the “Common Stock Payment”).  The portion of the annual retainer that is paid in common stock will be determined by reference to the fair market value of our common stock on the date of issuance.  The fair market value of the common stock will be determined by reference to the closing price, as reported by the NASDAQ Stock Market, of the common stock on May 1 of each year, the payment date of the Common Stock Payment.
 
 DIRECTOR COMPENSATION TABLE
 
The table below summarizes the compensation paid by the Company to, or earned by, our non-employee directors for the four month transition period ended December 31, 2014.
 
 Name (1)
  
Fees Earned or
Paid in Cash ($)
    
Stock Awards
($)(2)
    
Option Awards
($)(3)
    
All Other
Compensation ($)
    
Total
($)
  
(a)
  
(b)
    
(c)
    
(d)
    
(g)
    
(h)
  
                               
Douglas P. Boyd
     15,000       -       -       -       60,000  
Damian E. Dupuy
     15,000       -       -       - (4)     78,360  
Timothy C. McQuay
     15,000       -       -       -       60,000  
Michael Nobel
     15,000       -       -       -       60,000  
Gerhard W. Sennewald
     15,000       -       -       -       60,000  
Steven G. Stewart
     17,500       -       -       -       65,000  

 (1)
Harold R. Wolcott served as a director in fiscal year 2014, but is omitted from the Director Compensation Table because of his status as a Named Executive Officer in the fiscal year ended August 31, 2014.  No additional remuneration was paid to Mr. Wolcott for his service as a director.
 (2)
As partial compensation for services as a director, each non-employee director is issued fully vested shares of common stock in May of each  year, and is accounted for in accordance with FASB Accounting Standards Codification (“ASC”) Topic 718.
 (3)
There were no stock options granted to the non-employee directors during the four month transition period ended December 31, 2014.  As of December 31, 2014, each non-employee director had outstanding options for the following number of shares of Common Stock: Douglas P. Boyd, 115,000 shares; Timothy C. McQuay 47,457 shares; Michael Nobel, 135,000 shares; Gerhard W. Sennewald, 90,000 shares; and Steven G. Stewart, 106,368 shares.
 (4)
Since 2007, Dr. Dupuy has served as a consultant to the Company.  During the four month transition period ended December 31, 2014, no fees were paid to Dr. Dupuy under such consulting arrangement.

 
47
 

EXECUTIVE COMPENSATION
 
COMPENSATION DISCUSSION AND ANALYSIS
 
The following discussion and analysis provides information regarding our executive compensation objectives and principles, procedures, practices and decisions, and is provided to help give perspective to the numbers and narratives that follow in the tables in this section.  This discussion will focus on our objectives, principles, practices and decisions with regards to the compensation of Clinton E. Carnell Jr., President and Chief Executive Officer, Harold R. Wolcott, former President and Chief Executive Officer, and William S. Barth, Chief Financial Officer and Secretary, our named executive officers (“Named Executive Officers”) for the four month transition period ended December 31, 2014.
 
Executive Compensation Objectives and Principles
 
The overall objective of our executive compensation program is to help create long-term value for our stockholders by attracting and retaining talented executives, rewarding superior operating and financial performance, and aligning the long-term interests of our executives with those of our stockholders.  Accordingly, our executive compensation program incorporates the following principles:
 
  ·
Compensation should be based upon individual job responsibility, demonstrated leadership ability, management experience, individual performance, and Company performance.
  ·
Compensation should reflect the fair market value of the services received.  We believe that a fair and competitive pay package is essential to attract and retain talented executives in key positions.
  ·
Compensation should reward executives for long-term strategic management and enhancement of stockholder value.
  ·
Compensation should reward performance and promote a performance oriented environment.
 
Executive Compensation Procedures
 
We believe that compensation paid to our executive officers should be closely aligned with our performance and the performance of each individual executive officer on both a short-term and a long-term basis, should be based upon the value each executive officer provides to us, and should be designed to assist us in attracting and retaining the best possible executive talent, which we believe is critical to our long-term success.  To attain our executive compensation objectives and implement the underlying compensation principles, we follow the procedures described below.
 
Role of the Compensation Committee.  The Compensation Committee has responsibility for establishing and monitoring our executive compensation programs and for making decisions regarding the compensation of our Named Executive Officers.  The agenda for meetings of the Compensation Committee is determined by the Chairman of the Compensation Committee.  The Compensation Committee sets the compensation package and annual bonus of the Named Executive Officers.   Our Chief Executive Officer recommends items to be considered by the Compensation Committee from time to time, including the compensation package for the other Named Executive Officers; and participates in meetings in which the compensation package of the other Named Executive Officers is discussed.
 
 
48
 
 
The Compensation Committee relies on its judgment in making compensation decisions after reviewing our performance and evaluating our executives’ leadership abilities and responsibilities with our Company and their current compensation arrangements.  The Compensation Committee assessment process is designed to be flexible so as to better respond to the evolving business environment and individual circumstances.
 
At our 2015 annual meeting of stockholders, over 76% of the votes cast were in favor of our executive compensation program.  When designing our executive compensation program, the Compensation Committee considered, among other things, the 2015 voting results and other feedback we received from our stockholders and determined not to make any significant changes to the design of our executive compensation program.
 
Role of Compensation Consultant.  We have not engaged a compensation consultant since 2006.
 
Elements of Compensation
 
Our executive compensation objectives and principles are implemented through the use of the following elements of compensation, each discussed more fully below:
 
·
Base Salary
·
Annual Incentive Bonuses
·
Stock-Based Compensation
·
Other Benefits
 
Base Salary.  The Compensation Committee approved the salaries of all our executive officers for the four month transition period ended December 31, 2014 and the fiscal year ended August 31, 2014.  Base salaries are offered to ensure that our executive officers receive an ongoing level of compensation.  Salary decisions concerning these officers were based upon a variety of considerations consistent with the compensation philosophy stated above.  First, salaries were competitively set relative to both other companies in the medical products industry and other comparable companies.  In determining the salaries for our executives in the fiscal year ended August 31, 2014, the Compensation Committee considered the compensation of some of the public companies in the biotechnology industry.  The Compensation Committee considered each officer’s level of responsibility and individual performance, including an assessment of the person’s overall value to the Company.  In addition, internal equity among employees was factored into the decision.  Finally, the Compensation Committee considered our financial performance and our ability to absorb any increases in salaries.
 
Annual  Incentive Bonuses.  Annual incentive bonuses are designed to reward extraordinary performance by our executives.  For four month transition period ended December 31, 2014, and for the fiscal years ended August 31, 2014 and 2013, the Compensation Committee did not precisely define the parameters of a bonus program for the Named Executive Officers, and no bonuses were awarded to the Named Executive Officers.
 
Stock-Based Compensation.  Each Named Executive Officer is eligible to participate in the Stock Incentive Plan, which provides for the granting of stock options, stock appreciation rights, performance awards, other stock-based awards, and cash-based awards to selected employees, non-employees and directors.  Stock-based compensation is designed to more closely align the interests of management with those of our stockholders.  Historically, we have issued options pursuant to this incentive plan, and typically these options vest ratably over a term of up to 5 years as determined by the Compensation Committee.  Recent stock option grants vest over 3 years.  We do not have any policies for allocating compensation between long-term and currently paid out compensation or between cash and non-cash compensation or among different forms of non-cash compensation.  Although we do not have any formal policy for determining the amount of stock options or the timing of our stock option grants, we have historically granted stock options to high-performing employees (i) in recognition of their individual achievements and contributions to our company, and (ii) in anticipation of their future service and achievements.  No stock options were granted to Mr. Wolcott or Mr. Barth during the four month transition period ended December 31, 2014, or for the year ended August 31, 2014.  In connection with his appointment as President and CEO of Perseon Corporation, we granted Mr. Carnell a non-statutory stock option to purchase 1,400,000 shares of our common stock that vests in three equal installments on the anniversary dates of his employment, has a ten year term, and an exercise price of $0.46 per share.
 
Other Benefits.  Our Named Executive Officers receive the same benefits that are available to all other full time employees, including the payment of health, dental, life and disability insurance premiums.
 
 
49
 
 
Deductibility of Executive Compensation
 
Internal Revenue Service (“IRS”) Code Section 162(m) limits the amount that we may deduct for compensation paid to our principal executive officer and to each of our three most highly compensated officers (other than our principal financial officer) to $1.0 million per person, unless certain exemption requirements are met.  Exemptions to this deductibility limit may be made for various forms of performance-based compensation.  In the past, annual salary and bonus compensation to our executive officers has not exceeded $1.0 million per person, so the compensation has been deductible.  In addition to salary and bonus compensation, upon the exercise of stock options that are not treated as incentive stock options, the excess of the current market price over the option price, or option spread, is treated as compensation and accordingly, in any year, such exercise may cause an officer’s total compensation to exceed $1.0 million.  Under certain regulations, option spread compensation from options that meet certain requirements will not be subject to the $1.0 million cap on deductibility.  While the Compensation Committee cannot predict how the deductibility limit may impact our compensation program in future years, the Compensation Committee currently anticipates that it will generally maintain an approach to executive compensation that strongly links pay to performance.
 
The Compensation Committee reviews and considers the deductibility of executive compensation under Section 162(m) of the IRS Code.  In certain situations, the Compensation Committee may approve compensation that will not meet the requirements of IRS Code Section 162(m) in order to ensure competitive levels of total compensation for its executive officers.
 
Material Issues Relating to Compensation for the Fiscal Year Ended August 31, 2014
 
On April 29, 2014, we announced that our President and Chief Executive Officer, Mr. Harold R. Wolcott, would relinquish his positions as President and Chief Executive Officer upon our hiring of a new President and Chief Executive Officer. Mr. Wolcott agreed to continue to serve on our Board of Directors and on the search committee responsible for finding our next Chief Executive Officer.
 
On April 28, 2014, we entered into a letter agreement with Mr. Wolcott, pursuant to which Mr. Wolcott would receive severance benefits that supersede the severance benefits Mr. Wolcott was previously entitled to receive under his employment agreement. Pursuant to the letter agreement, if Mr. Wolcott ceased to serve as our President and Chief Executive Officer for any reason (other than for cause), we would pay to Mr. Wolcott an amount equal to his current base salary, and the vesting of his equity awards would immediately vest and become exercisable. Notwithstanding the foregoing, if Mr. Wolcott voluntarily terminated his service with us without good reason before the first to occur of (1) the expiration of six months from the date of the letter agreement, or (2) the selection of a new Chief Executive Officer, then we would not be obligated to pay the severance benefits described in this paragraph.  A copy of the letter agreement is attached as Exhibit 10.1 to the BSD Medical Corporation Form 8-K filed April 29, 2014.
 
On November 10, 2014, we named Clinton E. Carnell Jr. as President and Chief Executive Officer.  In connection with his appointment, Mr. Carnell agreed on an annual base salary of $350,000, and an annual bonus of $150,000 for the first and second years of employment.  We also granted a non-statutory stock option to Mr. Carnell to purchase 1,400,000 shares of our common stock that vests in three equal installments on the anniversary dates of his employment, has a ten year term, and an exercise price of $0.46 per share.
 
COMPENSATION COMMITTEE REPORT
 
The Compensation Committee has reviewed the foregoing Compensation Discussion and Analysis required by Item 402(b) of Regulation S-K, and discussed the Compensation Discussion and Analysis with the Company’s management.  Based on such review and discussions with management, the Compensation Committee recommended to the Board that the foregoing Compensation Discussion and Analysis be included in this Proxy Statement.
 
 
50
 
 
COMPENSATION COMMITTEE
 
Steven G. Stewart
Michael Nobel
Timothy C. McQuay
 
Summary Compensation Table
 
 The table below summarizes the total compensation paid to or earned by each of the Named Executive Officers for services in all capacities to the Company and its affiliates for the four month transition period ended December 31, 2014, and for fiscal years ended August 31, 2014 and 2013.  References to the years in the table below represent the fiscal years ended August 31 of such year:
 
Name and
Principal Position
Year
  
Salary
    
Bonus
    
Option
Awards
    
All Other
Compensation
    
Total
  
(a)
(b)
  
(c)
    
(d)
    
(e)
    
(i)
    
(j)
  
                                 
Clinton E. Carnell Jr
President
4 months ended Dec 31, 2014
   $ 40,385     $ -     $ -     $ - (1)   $ 40,385  
                                           
Harold R. Wolcott
Former President
4 months ended Dec 31, 2014
   $ 69,279     $ -     $ -     $ 39,448 (2)   $ 108,727  
2014
     275,000       -       -       13,449 (2)     288,449  
2013
    257,019       -       99,000       13,449       369,468  
                                           
William S. Barth
Chief Financial Officer
4 months ended Dec 31, 2014
   $ 66,667     $ -     $ -     $ 12,185 (3)   $ 78,852  
2014
    200,000       -       -       12,340 (3)     212,340  
2013
    146,153       -       170,000       1,755       317,908  
 
(1)
We did not make any benefits payments to, or on behalf of Mr. Carnell in the four month transition period ended December 31, 2014.
(2)
These amounts consist of: severance payments of $31,731, consulting payments of $4,168, medical insurance reimbursement of $3,014, life insurance premiums of $42, dental insurance premiums of $121, disability insurance premiums of $372 paid by us in the four month transition period ended December 31, 2014; and medical insurance reimbursement of $9,794, life insurance premiums of $122, dental insurance premiums of $483, disability insurance premiums of $2,050, and holiday payment of $1,000 paid by us in the fiscal year ended August 31, 2014.
(3)
These amounts consist of: medical insurance reimbursement of $10,308, life insurance premiums of $55, dental insurance premiums of $161, disability insurance premiums of $661, and holiday payment of $1,000 paid by us in the four month transition period ended December 31, 2014; and medical insurance reimbursement of $8,708, life insurance premiums of $166, dental insurance premiums of $483, disability insurance premiums of $1,983, and holiday payment of $1,000 paid by us in the fiscal year ended August 31, 2014.
 
Grants of Plan-Based Awards
 
There were no plan-based awards granted to the Company's Named Executive Officers in the four month transition period ended December 31, 2014, or in the fiscal year ended August 31, 2014.
 
 
51
 
 
Employment Agreements
 
On November 10, 2014, we named Clinton E. Carnell Jr. as President and Chief Executive Officer. We also appointed Mr. Carnell to the Board of Directors . Mr. Carnell succeeds Harold (Butch) R. Wolcott, who announced in April 2014 his intent to step down as President and Chief Executive Officer upon the hiring of a successor. Effective November 10, 2014 we entered into an employment agreement with Mr. Carnell, a copy of which was filed with our Report on Form 10-Q dated January 14, 2015.
 
In connection with his appointment, we entered into an offer letter agreement with Mr. Carnell providing for at-will employment for an indefinite term, an annual base salary of $350,000, an annual bonus of $150,000 for the first year of employment, and a bonus of $150,000, or a pro rata portion thereof, for the second year of employment. If we complete and close an equity offering in fiscal 2015 that generates at least $5 million in net proceeds, then we will engage a compensation consulting firm to conduct a study of compensation of chief executive officer’s in companies comparable to us, which study shall then be used to negotiate Mr. Carnell’s overall compensation after December 31, 2015. If we do not complete and close such an equity offering during 2015, then we will engage a compensation consulting firm in 2016 to negotiate Mr. Carnell’s salary after December, 2016.  The offer letter also provides that Mr. Carnell is eligible to participate in the employee benefit programs generally available to our executives.
 
In connection with Mr. Carnell’s appointment, on November 10, 2014, we issued an inducement equity award outside our Stock Incentive Plan in accordance with the NASDAQ inducement grant exception found in NASDAQ Listing Rule 5635(c)(4).  The grant is a non-statutory stock option to purchase 1,400,000 shares of our common stock. The grant was made as a component of Mr. Carnell’s employment compensation. The inducement grant was approved by the Compensation Committee of the Board of Directors, and was made as an inducement material to Mr. Carnell's acceptance of employment.  The stock option granted to Mr. Carnell has an exercise price of $0.46 per share, equal to the closing price of our common stock on November 10, 2014. The stock option has a ten year term and vests in three equal installments beginning with the first anniversary date on November 10, 2015.
 
There are no arrangements or understandings between Mr. Carnell and any other persons pursuant to which he was selected as President and Chief Executive Officer or appointed to the Board. There are also no family relationships between Mr. Carnell and any of our directors or executive officers.
 
On April 28, 2014, we entered into a letter agreement with our President and Chief Executive Officer, Mr. Harold R. Wolcott, to relinquish his positions as President and Chief Executive Officer upon  our hiring of a new President and Chief Executive Officer. Mr. Wolcott agreed to continue to serve on our Board of Directors and on the search committee responsible for finding our next Chief Executive Officer.
 
With the hiring of a new President and Chief Executive Officer effective November 10, 2014, and under the terms of the April 28, 2014 letter agreement and the May 22, 2013 employment agreement (together, the “Wolcott Agreements”) by and between Mr. Wolcott and the Company, we now are providing severance benefits to Mr. Wolcott.   These severance benefits include payments to Mr. Wolcott, over six months, of an amount equal to one year of his base salary at the time of termination, and immediate vesting of all options and incentive awards granted to Mr. Wolcott. The employment agreement also provides that, upon Mr. Wolcott’s termination, we agree to indemnify him for expenses associated with defending certain claims made against him as a result of his positions with the Company, and directors’ and officers’ liability insurance coverage for a period of six years following his termination.  These agreements also contain a confidentiality agreement, a one-year non-competition and non-solicitation agreement and a claw back provision that enables us to claw back any incentive-based compensation or other compensation from Mr. Wolcott if required by any law, government regulation, stock exchange listing requirement, or Company policy adopted as required by such law, government regulation, or stock exchange listing requirement.
 
On November 7, 2014 we signed an agreement (“Consulting Agreement”), effective November 10, 2014, to engage Mr. Wolcott as an independent contractor to provide consulting.  These services will consist generally of transition services, development and maintenance of strategic business relationships, advice concerning product lines and personnel, and our general business efforts, as directed by our Chief Executive Officer and our Chairman of the Board of Directors. The term of the Consulting Agreement is for 24 months beginning November 10, 2014, with a provision to renew for an additional 12 month period unless either party cancels.  We will pay a retainer fee of $2,500 per month for up to 20 hours per month of time expended by Mr. Wolcott, and $125 per hour for documented hours in excess of 20 hours per month.  We will also reimburse Mr. Wolcott for actual, reasonable and documented out-of-pocket expenses incurred in connection with providing services to us.  Under this Consulting Agreement, stock options that have been granted to Mr. Wolcott will continue to vest and be exercisable, until 90 days after the expiration of the Consulting Agreement.  Mr. Wolcott will be allowed, at no cost to him, to receive benefits for the term of this Consulting Agreement, under our present employee benefit plans, to the extent permitted by the terms of such plans
 
 
52
 
 
On September 16, 2014, we entered into an employment agreement with Mr. Barth (the “Barth Agreement”).  The Barth Agreement memorializes the parties’ agreement with respect to Mr. Barth’s continued employment as our Chief Financial Officer.
 
The Barth Agreement provides that Mr. Barth’s base salary shall be $200,000, which base salary will be reviewed at least annually by the Compensation Committee of the Board of Directors, and the Board may increase (but not decrease) the base salary.  In addition to the base salary, Mr. Barth is entitled to participate in any annual incentive bonus programs and employee benefit plans adopted or maintained by the Company.  Mr. Barth is also eligible to participate in our Stock Incentive Plan.
 
We also agree to indemnify Mr. Barth for expenses associated with defending certain claims made against him as a result of his positions with the Company.  We also agreed to purchase directors’ and officers’ liability insurance providing coverage to Mr. Barth during the term of the Barth Agreement and for a period of six years following the termination of the Barth Agreement.
 
Under the Barth Agreement, if Mr. Barth is terminated by us other than for cause or if Mr. Barth resigns for good reason and if Mr. Barth complies with certain requirements, we must pay him an amount equal to his base salary for one year and he shall be entitled to receive all applicable employee benefits for one year following termination.  If the Barth Agreement is terminated for cause, Mr. Barth shall receive only the portion of his base salary that is due to him through the effective date of his termination.  If the Barth Agreement is terminated by reason of Mr. Barth’s death, his estate shall receive his salary through the end of the month in which he died plus all employee benefits due to him through the end of such month.
 
If a Change in Control (as defined in the Barth Agreement) occurs with respect to the Company, and during the six months immediately following the Change of Control, (i) we terminate Mr. Barth without cause; (ii) Mr. Barth terminates his employment with good reason; or (iii) Mr. Barth terminates but also agrees to continue serving as Chief Financial Officer for the longer of (a) six months and (b) until a new Chief Financial Officer is appointed, then in addition to the Severance Payment, all options or incentive awards granted to Mr. Barth will immediately vest and become exercisable for a period of 180 days following the termination.
 
The Barth Agreement also contains a confidentiality agreement, a one-year non-competition and non-solicitation agreement and a claw back provision that enables us to claw back any incentive-based compensation or other compensation from Mr. Barth if required by any law, government regulation, stock exchange listing requirement, or Company policy adopted as required by such law, government regulation, or stock exchange listing requirement.
 
 
53
 
 
Outstanding Equity Awards as of December 31, 2014
 
The following table provides information on the holdings of Company stock options by the Named Executive Officers at the end of the four month period ended December 31, 2014.
 
 Name
(a)
  
Number of
Securities
 Underlying
Unexercised
 Options
Exercisable (#)
(b)
    
Number of
Securities
Underlying
 Unexercised
Options
 Unexercisable (#)
(c)
    
Option
Exercise
Price ($)
(e)
  
Option
Expiration
Date
(f)
Clinton E. Carnell Jr.
     -       1,400,000 (1)     0.46  
11/10/2024
Harold R. Wolcott
     585,760       -       1.70  
04/10/2019
Harold R. Wolcott
     150,000       -       4.66  
02/02/2021
Harold R. Wolcott
     150,000       -       1.20  
05/22/2023
William S. Barth
     66,667       66,667 (1)     1.59  
12/10/2022
 
(1)
Options vest in equal annual installments (33.3% each year) on the anniversary of the grant date.
  
 
Option Exercises and Stock Vested for the Four Month Period Ended December 31, 2014
 
The Named Executive Officers did not exercise any stock options during the four month period ended December 31, 2014.
 
Payments Upon Termination
 
The information below describes and quantifies certain payments or benefits that are, or would be payable to Named Executive Officers under employment agreements and our existing plans and programs in the event that either Named Executive Officer terminates employment us.  These benefits are in addition to benefits generally available to all of our salaried employees in connection with a termination of employment such as disability and life insurance benefits, the value of employee-paid group health plan continuation coverage under COBRA, to the extent permitted by such plans, and accrued vacation pay.
 
As discussed above under “Employment Agreements,” the Wolcott Agreements define the terms of certain severance payments and benefits that are due to Mr. Wolcott upon the termination of his employment with us.  Mr. Wolcott relinquished his position of President and Chief Executive Officer effective November 10, 2014, upon the hiring of Mr. Clinton E. Carnell Jr.  Mr. Wolcott agreed to continue to serve on our Board of Directors.
 
Under the provisions of the Wolcott Agreements, Mr. Wolcott will be provided a severance payment over six months, totaling $275,000, which equates to one year of his base salary at the time of termination. Under the terms of the Wolcott Agreements, all options and incentive awards granted to Mr. Wolcott immediately vested upon his termination, and he is entitled to receive all applicable employee benefits that are allowable under the respective benefit plans.
 
Under the terms of the Consulting Agreement discussed in “Employment Agreements” above, we will pay a $2,500 per month retainer fee to Mr. Wolcott for a period of 24 months, beginning November 10, 2014, for Mr. Wolcott to provide up to 20 hours per month of consulting services.   We also pay Mr. Wolcott $125 per hour for documented hours in excess of 20 hours per month, in addition to actual, reasonable and documented out-of-pocket expenses incurred in connection with providing services to us.
 
The information below describes the compensation that would be payable under Mr. Carnell’s and Mr. Barth’s employment agreements if their employment had been terminated on December 31, 2014, given their compensation and benefit levels as of such date, and if applicable, based on our closing stock price on that date.
 
 
54
 
 
   
Carnell
Termination ($)
    
Carnell
Termination
and Change
 of Control
Stock Option
Vesting
Acceleration ($)
    
Barth
 Termination ($)
    
Barth
Termination
 and Change
 of Control
Stock Option
Vesting
Acceleration ($)
  
                         
Severance Payment (1) (2)
     350,000       350,000       200,000       200,000  
Continuance of Benefits (3)
     12,500       12,500       11,340       11,340  
Deemed Exercise and Sale of Stock Option Shares (4)
      -        -        -        -  
                                 
Total
     287,449       287,449       211,340       211,340  
 
 
(1)
Mr. Carnell’s employment agreement provides for severance pay equal to Mr. Carnell’s current annual salary.
 
(2)
Mr. Barth’s employment agreement provides for severance pay equal to Mr. Barth’s current annual salary
 
(3)
Estimated cost to Perseon of applicable employee benefits for one year following termination (including medical insurance) provided for under employment agreements.
 
(4)
The deemed value received for the exercise and sale of in-the-money stock options is $0, based on the closing stock price of our common stock of $0.36 as of December 31, 2014.
 
On September 16, 2014, we entered into an employment agreement with Mr. Barth (the “Barth Agreement”) that provides that, if Mr. Barth is terminated by us other than for cause, or if Mr. Barth resigns for good reason and if Mr. Barth complies with certain requirements, we are obligated to pay him in one lump sum payment within thirty days following the effective date of the termination an amount equal to his base salary for one year (the “Severance Payment”) and he shall be entitled to receive all applicable employee benefits for one year following termination.  If the Barth Agreement is terminated for cause, Mr. Barth shall receive only the portion of his base salary that is due to him through the effective date of his termination.  If the Barth Agreement is terminated by reason of Mr. Barth’s death, his estate shall receive his salary through the end of the month in which he died plus all employee benefits due to him through the end of such month.
 
If a Change in Control (as defined in the Barth Agreement) occurs with respect to Perseon, and during the six months immediately following the Change of Control, (i) we terminate Mr. Barth without cause; (ii) Mr. Barth terminates his employment with good reason; or (iii) Mr. Barth terminates the Barth Agreement but also agrees to continue serving as Chief Financial Officer for the longer of (a) six months and (b) until a new Chief Financial Officer is appointed, then in addition to the Severance Payment, all options or incentive awards granted to Mr. Barth will immediately vest and become exercisable for a period of 180 days following the termination.
 
The Barth Agreement also contains a confidentiality agreement, and a one-year non-competition and non-solicitation agreement.  The Barth Agreement contains a claw back provision that enables us to claw back any incentive-based compensation or other compensation from Mr. Barth if required by any law, government regulation, stock exchange listing requirement, or Company policy adopted as required by such law, government regulation, or stock exchange listing requirement.
 
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS
 
The following table sets forth information known to us with respect to beneficial ownership of our common stock as of March 6, 2015 for (i) each director, (ii) each holder of 5.0% or greater of our common stock, (iii) our Named Executive Officers, and (iv) all executive officers and directors as a group. Beneficial ownership is determined in accordance with the rules of the Commission, and generally includes voting or investment power with respect to securities.  Shares subject to options that are exercisable within 60 days following March 6, 2015 are deemed to be outstanding and beneficially owned by the optionee or group of optionees for the purpose of computing share and percentage ownership of that optionee or group of optionees, but are not deemed to be outstanding for the purpose of computing the percentage ownership of any other person.  Except as indicated by footnote, the persons named in the table have sole voting and investment power with respect to all shares of common stock shown beneficially owned by them.  The inclusion of any shares as beneficially owned does not constitute an admission of beneficial ownership of those shares.  The percentage calculation of beneficial ownership is based on 39,689,209 shares of common stock outstanding as of March 6, 2015.  Except as otherwise noted, the address of each person listed on the following table is 2188 West 2200 South, Salt Lake City, Utah 84119.
 
 
55
 
 
   
Common Stock Beneficially Owned
  
Name of Beneficial Owner
  
Shares
    
Percent
  
             
5% of Greater Stockholders
            
Dr. Gerhard W. Sennewald(1)
     6,483,226       16.3 %
Officers and Directors
                
Dr. Michael Nobel(2)
     469,545       1.2 %
Steven G. Stewart(3)
     246,368       *  
Timothy C. McQuay(4)
     180,836       *  
Damian E. Dupuy, MD
     69,330       *  
Harold R. Wolcott(5)
     898,260       2.2 %
William S. Barth(6)
     153,333       *  
Clinton E. Carnell Jr. (7)
     -       -  
                 
All Executive Officers and Directors as a Group (10 persons)(8)
     2,244,089       5.4 %
 
* Less than 1%
 
(1)
Includes 90,000 shares subject to stock options that are currently exercisable or exercisable within 60 days after March 6, 2015.  Dr. Sennewald resigned as a director on February 4, 2015
(2)
Includes 115,000 shares subject to stock options that are currently exercisable or exercisable within 60 days after March 6, 2015.
(3)
Includes 106,368 shares subject to stock options that are currently exercisable or exercisable within 60 days after March 6, 2015.
(4)
Includes 47,457 shares subject to stock options that are currently exercisable or exercisable within 60 days after March 6, 2015.
(5)
Includes 885,760 shares subject to stock options that are currently exercisable or exercisable within 60 days after March 6, 2015.  Mr. Wolcott resigned his positions as President and Chief Executive Officer effective November 10, 2014.
(6)
Includes 133,333 shares subject to stock options that are currently exercisable or exercisable within 60 days after March 6, 2015.
(7)
Mr. Carnell was appointed Chief Executive Officer and President, effective November 10, 2014.
(8)
Includes 1,509,585 shares subject to stock options that are currently exercisable or exercisable within 60 days after March 6, 2015.
 
 
56
 
 
EQUITY COMPENSATION PLAN INFORMATION
 
 
The following table summarizes our equity compensation plans as of December 31, 2014.
 
 Plan category
  
Number of
 securities to
 be issued
upon exercise
 of outstanding
 options, warrants
 and rights
    
Weighted-average
 exercise price
 of outstanding
 options, warrants
 and rights
    
Number of
securities
 remaining
available for
 future issuance
 under equity
 compensation
 plans (excluding
securities
reflected in
column (a) )
  
   
(a)
    
(b)
    
(c)
  
                   
Equity compensation plans approved by security holders (1)
     3,873,586     $ 2.92       1,969,130  
Equity compensation plans not approved by security holders (2)
     1,400,000     $ 0.46       -  
Total
     5,273,586     $ 2.23       1,969,130  
 
(1)
A total of 8,087,300 shares of common stock have been reserved for issuance under the plans. To date, a total of 2,216,561 options have been exercised under the plans.
(2)
An inducement grant was made to Clinton E. Carnell Jr. on November 10, 2014.
 
SECTION 16(A) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE
 
Section 16(a) of the Securities Exchange Act of 1934, as amended, requires our directors and officers and persons who own more than 10% of a registered class of our equity securities to file with the Commission initial reports of ownership and reports of changes in ownership of our equity securities.  Officers, directors, and greater than 10% stockholders are required to furnish us with copies of all Section 16(a) forms they file.  Based solely on review of the copies of such forms received by us, or written representations from certain reporting persons, we believe that during the four month period ended December 31, 2014 all reporting persons complied with all applicable filing requirements
 
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS, AND DIRECTOR INDEPENDENCE
 
Since September 1, 2012, there has not been, nor is there any proposed transaction in which we were or will be a party or in which we were or will be a participant, involving an amount that exceeded or will exceed $120,000 or one percent of the average of our total assets at year end for the last two completed fiscal years, and in which any director, executive officer, beneficial owner of more than 5% of any class of our voting securities, or any member of the immediate family of any of the foregoing persons had or will have a direct or indirect material interest, other than the transactions which are described below.
 
Dr. Sennewald Medizintechnik GmbH.  Perseon supplies hyperthermia therapy systems and related component parts to Dr. Sennewald Medizintechnik GmbH and its affiliate BSD BioSystems Design, S.A. (“Medizintechnik”) located in Munich, Germany, which is a significant distributor of Perseon’s products in Europe.  Medizintechnik purchases equipment, which it installs, and component parts to service the Perseon hyperthermia therapy systems that Medizintechnik sells to its customers in Europe.  For the four month transition period ended December 31, 2014 and the fiscal years ended August 31, 2014 and 2013, Perseon had revenue of  $463,423, $419,549 and $99,896, respectively, from the sale of systems and various component parts sold to Medizintechnik.  As of December 31, 2014, August 31, 2014 and 2013, accounts receivable from Medizintechnik were $13,471, $8,322 and $24,201, respectively . Perseon received $320,000 from Medizintechnik in the four month period ending December 31, 2014 for partial payment of a BSD-2000 shipped and installed.  
 
 
57
 
 
Dr. Gerhard W. Sennewald, one of Perseon’s former directors and a significant stockholders, is the President and Chief Executive Officer of Medizintechnik and its sole stockholder.  Management believes the terms of the transactions with Medizintechnik and BSD BioSystems Design, S.A. were arms-length and fair to us.
 
We do not have a formal written process for reviewing related person transactions.  We expect that the Audit Committee will review for potential conflict of interest situations, on an ongoing basis, any future proposed transaction, or series of transactions, with related persons, and either approve or disapprove each reviewed transaction or series of related transactions with related persons.
 
AFFIRMATIVE DETERMINATIONS REGARDING DIRECTOR INDEPENDENCE
 
The Board of Directors has determined each of the following directors to be an “independent director” as such term is defined in the NASDAQ Stock Market Listing Standards: Timothy C. McQuay, Michael Nobel, Steven G. Stewart, and Damian E. Dupuy.  These four directors are referred to individually as an “Independent Director” and collectively as the “Independent Directors.”
 
ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES
 
Stockholders have ratified the selection of Tanner LLC as our independent registered public accountants for 2015.  Tanner LLC audited the Company’s financial statements for the four month period ended December 31, 2014, and for the fiscal years ended August 31, 2014 and 2013.
`
The Board or Audit Committee, in their discretion, may direct the appointment of a different independent registered public accounting firm at any time during the year we determine that such change would be in our best interest and the best interest of our stockholders.
 
PRINCIPAL ACCOUNTANT FEES AND SERVICES
 
            The following table presents fees for professional services rendered by Tanner LLC for the audit of our annual financial statements for the four month period ended December 31, 2014, and for the fiscal years ended August 31, 2014 and 2013, and fees billed for other services rendered by Tanner LLC during those periods.
 
   
Four Months
 Ended
 December 31,
2014
    
Fiscal Year
Ended
August 31,
2014
    
Fiscal Year
 Ended
August 31,
2013
  
                   
Audit Fees (1)
   $ 55,000     $ 94,100     $ 83,700  
Audit Related Fees (2)
     -       16,500       10,800  
Tax Fees (3)
     14,250       13,900       14,300  
All Other Fees
     -       -       -  
Total
   $ 69,250     $ 124,500     $ 108,800  

 
(1)
Audit Fees consist of fees billed for the audit of our annual financial statements included in Form 10-K and services in connection with our various statutory and regulatory filings.  Audit fees also include fees related to the reviews of interim financial information included in Forms 10-Q.
 
(2)
Audit Related Fees consist of fees billed for consent or comfort letter procedures performed in conjunction with the filing of registration statements or completing financial transactions during the respective fiscal periods.
 
(3)
Tax Fees consist of fees for the preparation of federal and state income tax returns.
 
 
58
 
 
PRE-APPROVAL POLICIES
 
The Audit Committee pre-approved all audit, audit-related and non-audit services performed by our independent auditors and subsequently reviewed the actual fees and expenses paid to Tanner LLC.  The Audit Committee has determined that the fees paid to Tanner LLC for services are compatible with maintaining Tanner LLC’s independence as our auditors.
 
AUDIT COMMITTEE REPORT
 
The Audit Committee has reviewed and discussed our audited financial statements with our management and has discussed with Tanner LLC the matters required to be discussed by Statements of Auditing Standards No. 16, as amended (AICPA, Professional Standards, Vol. 1. AU section 380), as adopted by the Public Company Accounting Oversight Board in Rule 3200T.
 
The Audit Committee has received the written disclosures and the letter from Tanner LLC required by applicable requirements of the Public Company Accounting Oversight Board regarding the independent registered public accountant’s communications with the Audit Committee concerning independence, and has discussed with Tanner LLC its independence from us.
 
Based on its review, the Audit Committee recommended to the Board of Directors that the audited financial statements for the four month period ended December 31, 2014 be included in our Transition Report on Form 10-K for the four month period ended December 31, 2014, which was filed on March 27, 2015.
 
Submitted by:
 
Steven G. Stewart
Michael Nobel
Timothy C. McQuay

Members of the Audit Committee

 
59
 

PART IV

ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

(a)(1)       Financial Statements
 
The Index to Financial Statements on page F-1 is incorporated herein by reference as the list of financial statements required as part of this report.
 
(2)            Financial Statement Schedules
 
Financial statement schedules have been omitted because they are not required or are not applicable, or because the required information is shown in the financial statements or notes thereto.
 
(3)            Exhibits

The following exhibits are filed as part of this report or incorporated herein by reference as indicated:

Exhibit Number
Description
   
3.1
Amended and Restated Certificate of Incorporation of BSD Medical Corporation.  Incorporated by reference to Exhibit 3.1 of the BSD Medical Corporation Annual Report Form 10-KSB, filed December 1, 2003.
   
3.2
Certificate of Amendment to the Amended and Restated Certificate of Incorporation of BSD Medical Corporation.  Incorporated by reference to Exhibit 3.1 to the BSD Medical Corporation Form 8-K, filed February 7, 2011.
   
3.3
By-Laws.  Incorporated by reference to Exhibit 3.2 of the BSD Medical Corporation Registration Statement on Form S-1, filed October 16, 1986.
   
3.4
Amendment to Bylaws of BSD Medical Corporation.  Incorporated by reference to Exhibit 3.1 of Current Report on Form 8-K filed January 4, 2008.
   
4.1
Form of Common Stock Purchase Warrant.  Incorporated by reference to Exhibit 4.1 to the BSD Medical Corporation Form 8-K, filed June 26, 2014.
   
4.2
Specimen Common Stock Certificate.  Incorporated by reference to Exhibit 4 of the BSD Medical Corporation Registration Statement on Form S-1, filed October 16, 1986.
   
4.3
Form of Common Stock Purchase Warrant.  Incorporated by reference to Exhibit 4.1 to the BSD Medical Corporation Form 8-K, filed February 11, 2010.
   
4.4
Form of Common Stock Purchase Warrant.  Incorporated by reference to Exhibit 4.1 to the BSD Medical Corporation Form 8-K, filed May 3, 2010.
   
4.5
Form of Common Stock Purchase Warrant.  Incorporated by reference to Exhibit 4.1 to the BSD Medical Corporation Form 8-K, filed August 19, 2010.
   
4.6
Form of Common Stock Purchase Warrant.  Incorporated by reference to Exhibit 4.1 to the BSD Medical Corporation Form 8-K, filed November 15, 2010.
   
4.7
Form of Common Stock Purchase Warrant.  Incorporated by reference to Exhibit 4.1 to the BSD Medical Corporation Form 8-K, filed April 9, 2013.
 
 
60
 
 
10.1*
Letter Agreement, dated April 28, 2014, between the Company and Harold R. Wolcott. Incorporated by reference to Exhibit 10.1 to the BSD Medical Corporation Form 8-K, filed April 29, 2014.
   
10.2
At-the-Market Issuance Sales Agreement between BSD Medical Corporation and MLV & Co. LLC, dated May 9, 2014.  Incorporated by reference to Exhibit 10.1 to the BSD Medical Corporation Form 8-K, filed May 9, 2014.
  
10.3
Termination of At-the-Market Issuance Sales Agreement, dated June 22, 2014, by and between BSD Medical Corporation and MLV & Co. LLC.  Incorporated by reference to Exhibit 10.1 to the BSD Medical Corporation Form 8-K, filed June 23, 2014.
   
10.4
Settlement Agreement, dated as of June 20, 2014, by and between BSD Medical Corporation and Cranshire Capital Master Fund, Ltd.   Incorporated by reference to Exhibit 10.1 to the BSD Medical Corporation Form 8-K, filed June 23, 2014.
   
10.5
Securities Purchase Agreement, dated as of June 25, 2014, by and among the Company and each of the purchasers identified on the signature pages thereto.  Incorporated by reference to Exhibit 10.1 to the BSD Medical Corporation Form 8-K, filed June 26, 2014.
   
10.6*
Employment Agreement, dated September 16, 2014, between the Company and William S. Barth. Incorporated by reference to Exhibit 10.1 to the BSD Medical Corporation Form 8-K, filed September 19, 2014.
   
10.7*
Consulting  Agreement, dated November 7, 2014,  by and between BSD Medical Corporation and Harold R. Wolcott.  Incorporated by reference to Exhibit 10.7 to the BSD Medical Corporation Form 10-K, filed November 13, 2014.
   
10.8*
Stock Option Grant by Company to Clinton E. Carnell Jr., dated November 10, 2014.  Incorporated by reference to Exhibit 10.8 to the BSD Medical Corporation Form 10-K, filed November 13, 2014.
   
10.9*
BSD Medical Corporation Fourth Amended and Restated 1998 Director Stock Plan.  Incorporated by reference to Appendix A of the BSD Medical Corporation Schedule 14A, filed December 28, 2009.
   
10.10*
BSD Medical Corporation Third Amended and Restated 1998 Stock Incentive Plan.  Incorporated by reference to Appendix B of the BSD Medical Corporation Schedule 14A, filed December 28, 2009.
   
10.11*
BSD Medical Corporation Form of Employee Stock Option Grant.  Incorporated by reference to Exhibit 10.7 to BSD Medical Corporation’s Annual Report on Form 10-K filed November 14, 2008.
   
10.12*
BSD Medical Corporation Form of Director Stock Option Grant.  Incorporated by reference to Exhibit 10.8 to BSD Medical Corporation’s Annual Report on Form 10-K filed November 14, 2008.
   
10.13*
Employment Agreement dated November 2, 1988 between BSD Medical Corporation and Paul F. Turner.  Incorporated by reference to Exhibit 10.8 to BSD Medical Corporation’s Registration Statement on Form SB-2 filed January 27, 2004.
   
10.14*
Employment Agreement dated May 22, 2013 by and between BSD Medical Corporation and Harold R. Wolcott.  Incorporated by reference to Exhibit 10.1 to the BSD Medical Corporation’s Form 8-K filed May 29, 2013.
   
10.15
Exclusive Distribution Agreement by and between Sennewald/Medizintechnik GmbH dated May 13, 2009.  Incorporated by reference to Exhibit 10.1 to BSD Medical Corporation’s Quarterly Report on Form 10-Q filed on July 10, 2009.
   
10.16
Securities Purchase Agreement, dated as of April 9, 2013, by and between the Company and each of the purchasers identified on the signature pages thereto. Incorporated by reference to Exhibit 10.1 to the BSD Medical Corporation Form 8-K, filed April 9, 2013.
 
 
61
 
 
10.17*
Employment Agreement with effective date of November 10, 2014 between the Company and Clinton E. Carnell Jr.  Incorporated by reference to Exhibit 10.1 to the BSD Medical Corporation’s Form 10-Q filed January 14, 2015.
   
10.18*
Employment Agreement with effective date of February 16, 2015 between the Company and Benjamin Beckham.  
   
10.19*
Employment Agreement with effective date February 16, 2015 between the Company and Todd H. Turnlund.  
   
10.20*
Employment Agreement with effective date February 17, 2015 between the Company and Jen Hoglin.   
   
10.21
Promissory Note dated February 24, 2015
   
21.1
Subsidiaries of the Registrant
   
23.1
Consent of Independent Registered Public Accounting Firm.
   
31.1
Certification of Chief Executive Officer of Perseon pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
   
31.2
Certification of Chief Financial Officer of Perseon pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
   
32.1
Certification of  Principal Executive Officer attached pursuant to Section 906 of the Sarbanes- Oxley Act of 2002.
   
32.2
Certification of the  Principal Financial Officer of Perseon pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
   
101.INS**
XBRL Instance Document
   
101.SCH**
XBRL Taxonomy Extension Schema
   
101.CAL**
XBRL Taxonomy Extension Calculation Linkbase
   
101.DEF**
XBRL Taxonomy Extension Definition Linkbase Document
   
101.LAB**
XBRL Taxonomy Extension Label Linkbase
   
101.PRE**
XBRL Taxonomy Extension Presentation Linkbase
 
* Exhibits marked with an asterisk (*) are management contracts or compensatory plans or arrangements.

** The XBRL related information in Exhibit 101 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liability of that section and shall not be incorporated by reference into any filing or other document pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing or document.
 
 
62
 
 
SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

PERSEON CORPORATION

Date:  March 30 , 2015
By:  /s/ Clinton E. Carnell Jr.               .
 
Clinton E. Carnell Jr.
 
President, Chief Executive Officer and Member of the Board of Directors
 
(principal executive officer)
 
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

Date:  March 30 , 2015
By:  /s/ Clinton E. Carnell Jr.               .
 
Clinton E. Carnell Jr.
 
President, Chief Executive Officer and Member of the Board of Directors
 
 (principal executive officer)
   
Date:  March 30 , 2015
By /s/ William S. Barth                     .
 
William S. Barth
 
Chief Financial Officer (principal financial and accounting officer)
   
Date:  March 30 , 2015
By: /s/ Timothy C. McQuay                .
 
Timothy C. McQuay
 
Chairman of the Board of Directors
   
Date:  March 30 , 2015
By  /s/ Harold R. Wolcott                   .
 
Harold R. Wolcott
 
Member of the Board of Directors
   
Date:  March 30 , 2015
By:  /s/ Steven G. Stewart                   
 
Steven G. Stewart
 
Member of the Board of Directors
   
Date:  March 30 , 2015
By:  /s/ Michael Nobel                        .
 
Dr. Michael Nobel
 
Member of the Board of Directors
   
Date:  March 30 , 2015
By: /s/ Damian E. Dupuy                   .
 
Dr. Damian E. Dupuy
 
Member of the Board of Directors
 
 
63
 

PERSEON CORPORATION
(Formerly BSD Medical Corporation)
Index to Financial Statements

 
Page
   
Report of Independent Registered Public Accounting Firm
F-2
   
Balance Sheets
F-3
   
Statements of Comprehensive Loss
F-4
   
Statements of Stockholders’ Equity
F-5
   
Statements of Cash Flows
F-6
   
Notes to Financial Statements
F-7
 
 
F - 1
 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM



To the Board of Directors and Stockholders
  of Perseon Corporation

We have audited the accompanying balance sheets of Perseon Corporation (the Company) as of December 31, 2014, August 31, 2014 and August 31, 2013, and the related statements of comprehensive loss, stockholders’ equity and cash flows for the four month period ended December 31, 2014 and for the years ended August 31, 2014 and 2013.  These financial statements are the responsibility of the Company's management.  Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States).  Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement.  The Company is not required to have, nor were we engaged to perform, an audit of internal control over financial reporting as of December 31, 2014.  Our audit included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting.  Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements.  An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation.  We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Perseon Corporation as of December 31, 2014 and August 31, 2014 and 2013, and the results of its operations and its cash flows for the four month period ended December 31, 2014 and for the years ended August 31, 2014 and 2013, in conformity with U.S. generally accepted accounting principles.


/s/ TANNER LLC

Salt Lake City, Utah
March 30 , 2015
 
 
F - 2
 

PERSEON CORPORATION
  
(Formerly BSD Medical Corporation)
  
Balance Sheets
  
   
ASSETS
  
December 31,
2014
    
August 31,
2014
    
August 31,
2013
  
Current assets:
                  
   Cash and cash equivalents
   $ 5,594,578     $ 8,130,416     $ 9,450,528  
   Accounts receivable, net of allowance for doubtful accounts of $20,000
     275,072       366,887       899,969  
   Related party trade accounts receivable, net
     13,471       8,322       24,201  
   Inventories, net
     1,775,648       2,329,189       2,445,770  
   Other current assets
     86,583       146,319       200,028  
      Total current assets
     7,745,352       10,981,133       13,020,496  
                         
Property and equipment, net
     1,140,871       1,267,661       1,319,880  
                         
    $ 8,886,223     $ 12,248,794     $ 14,340,376  
                         
LIABILITIES AND STOCKHOLDERS’ EQUITY
                        
                         
Current liabilities:
                        
   Accounts payable
   $ 598,466     $ 548,897     $ 521,417  
   Accrued liabilities
     1,105,152       866,528       573,880  
   Note payable
     -       33,279       -  
   Customer deposits
     41,667       41,781       317,480  
   Deferred revenue – current portion
     54,218       96,043       730,593  
      Total current liabilities
     1,799,503       1,586,528       2,143,370  
                         
Deferred revenue – net of current portion
     -       -       53,115  
                         
      Total liabilities
     1,799,503       1,586,528       2,196,485  
                         
Commitments and contingencies
                        
                         
Stockholders’ equity:
                        
   Preferred stock, $.001 par value; 10,000,000 shares authorized, no shares issued and outstanding
     -       -       -  
   Common stock, $.001 par value, 80,000,000 shares authorized, 39,713,540, 39,713,540 and 34,006,202 shares issued, respectively
       39,714         39,714         34,007  
   Additional paid-in capital
     63,587,400       63,394,556       57,739,056  
   Treasury stock, 24,331 shares at cost
     (234 )     (234 )     (234 )
   Accumulated deficit
     (56,540,160 )     (52,771,770 )     (45,628,938 )
      Total stockholders’ equity
     7,086,720       10,662,266       12,143,891  
                         
    $ 8,886,223     $ 12,248,794     $ 14,340,376  
 
See accompanying notes to financial statements
 
 
F - 3
 

PERSEON CORPORATION
  
(Formerly BSD Medical Corporation)
  
Statements of Comprehensive Loss
  
   
   
Four Months Ended
December 31,
    
Years Ended
August 31,
  
   
2014
    
2013
    
2014
    
2013
  
         
(Unaudited)
              
Revenues:
                        
   Sales
   $ 526,585     $ 1,572,376     $ 4,544,204     $ 3,274,796  
   Sales to related parties
     463,423       16,686       419,549       99,896  
   Equipment rental
     125,900       95,200       364,600       298,600  
   Total revenues
     1,115,908       1,684,262       5,328,353       3,673,292  
                                 
Cost of revenues:
                                
   Cost of sales
     334,455       795,034       2,563,921       2,161,967  
   Cost of related party sales
     257,125       7,654       313,156       87,694  
   Cost of equipment rental
     3,929       3,929       11,788       11,788  
   Total cost of revenues
     595,509       806,617       2,888,865       2,261,449  
                                 
Gross margin
     520,399       877,645       2,439,488       1,411,843  
                                 
Operating costs and expenses:
                                
   Research and development
     627,769       701,549       2,229,043       2,281,854  
   Selling, general and administrative
     2,819,205       2,237,057       7,308,643       7,403,273  
   Impairment of inventory and other assets
     805,000       50,000       50,000       -  
   Total operating costs and expenses
     4,251,974       2,988,606       9,587,686       9,685,127  
                                 
Loss from operations
     (3,731,575 )     (2,110,961 )     (7,148,198 )     (8,273,284 )
                                 
Other income (expense):
                                
   Interest income
     5,672       8,167       22,491       32,225  
   Other income (expense)
     (42,487 )     (3,847 )     (15,125 )     (8,694 )
   Total other income (expense)
     (36,815 )     4,320       7,366       23,531  
                                 
Loss before income taxes
     (3,768,390 )     (2,106,641 )     (7,140,832 )     (8,249,753 )
                                 
Income tax provision
     -       -       (2,000 )     (1,938 )
                                 
Net loss and comprehensive loss
   $ (3,768,390 )   $ (2,106,641 )   $ (7,142,832 )   $ (8,251,691 )
                                 
Net loss per common share:
                                
   Basic
   $ (0.09 )   $ (0.06 )   $ (0.20 )   $ (0.26 )
   Diluted
   $ (0.09 )   $ (0.06 )   $ (0.20 )   $ (0.26 )
                                 
Weighted average number of shares outstanding:
                                
   Basic
     39,689,000       34,006,000       34,967,000       31,414,000  
   Diluted
     39,689,000       34,006,000       34,967,000       31,414,000  
   
 
See accompanying notes to financial statements
 
 
F - 4
 
 
PERSEON CORPORATION
  
(Formerly BSD Medical Corporation)
  
Statements of Stockholders’ Equity
  
Years Ended August 31, 2014 and 2013 and Four Months Ended December 31, 2014
  
   
   
 
Common Stock
    
Additional
Paid-in
Capital
    
 
Treasury Stock
    
 
Accumulated
Deficit
    
 
 
Total
  
   
Shares
    
Amount
    
Shares
    
Amount
  
                                           
Balance, September 1, 2012
     29,777,522     $ 29,778     $ 51,845,035       24,331     $ (234 )   $ (37,377,247 )   $ 14,497,332  
Common stock issued for:                                                        
Services  
     163,638       164       179,838        -        -        -       180,002  
Cash, net of offering costs of $416,565     4,065,042       4,065       4,579,372       -       -       -       4,583,437  
Stock-based compensation
     -       -       1,134,811       -       -       -       1,1,34,811  
Net loss
     -       -       -       -       -       (8,251,691 )     (8,251,691 )
Balance, August 31, 2013
     34,006,202       34,007       57,739,056       24,331       (234 )     (45,628,938 )     12,143,891  
Common stock issued for:                                                        
Services   
     160,716       161       179,839       -       -       -       180,000  
Cash, net of offering costs of $638,488     5,546,622       5,546       4,631,033       -       -       -       4,636,579  
Stock-based compensation
     -       -       844,628       -       -       -       844,628  
Net loss
     -       -       -       -       -       (7,142,832 )     (7,142,832 )
Balance, August 31, 2014
     39,713,540       39,714       63,394,556       24,331       (234 )     (52,771,770 )     10,662,266  
Stock-based compensation
     -       -       192,844       -       -       -       192,844  
Net loss
     -       -       -       -       -       (3,768,390 )     (3,768,390 )
Balance, December 31, 2014
     39,713,540     $ 39,714     $ 63,587,400       24,331     $ (234 )   $ (56,540,160 )   $ 7,086,720  
 
See accompanying notes to financial statements
 
F - 5
 
PERSEON CORPORATION
  
(Formerly BSD Medical Corporation)
  
Statements of Cash Flows
  
   
   
Four Months Ended
December 31,
    
Years Ended
August 31,
  
   
2014
    
2013
    
2014
    
2013
  
         
(Unaudited)
              
Cash flows from operating activities:
                        
   Net loss
   $ (3,768,390 )   $ (2,106,641 )   $ (7,142,832 )   $ (8,251,691 )
   Adjustments to reconcile net loss to net cash used in operating activities:
                                
      Depreciation and amortization
     43,280       40,364       125,824       132,153  
      Stock issued for services
     -       -       180,000       180,002  
      Stock-based compensation
     192,844       284,167       844,628       1,134,811  
      Loss (gain) on disposition of assets
     33,827       -       (30 )     -  
      Impairment of inventory and other assets
     805,000       50,000       50,000          
      Decrease (increase) in:
                                
         Receivables
     (33,334 )     95,124       548,961       (601,326 )
         Inventories
     (46,459 )     (328,517 )     66,581       (41,813 )
         Other current assets
     59,736       51,881       53,709       (79,959 )
      Increase (decrease) in:
                                
         Accounts payable
     49,569       (57,272 )     27,480       325,663  
         Accrued liabilities
     238,624       (84,323 )     292,648       149,182  
         Customer deposits
     (114 )     95,347       (275,699 )     292,500  
         Deferred revenue
     (41,825 )     (46,237 )     (687,665 )     560,423  
   Net cash used in operating activities
     (2,467,242 )     (2,006,107 )     (5,916,395 )     (6,200,055 )
                                 
Cash flows from investing activities:
                                
   Purchase of property and equipment
     (35,317 )     (21,330 )     (75,599 )     (35,362 )
   Proceeds from disposition of assets
     -       -       2,025       -  
   Net cash (used in) investing activities
     (35,317 )     (21,330 )     (73,574 )     (35,362 )
                                 
Cash flows from financing activities:
                                
   Net proceeds from the sale of common stock
     -       -       4,636,579       4,583,437  
   Proceeds from note payable
     -       -       74,052       -  
   Payments on note payable
     (33,279 )     -       (40,774 )     -  
   Net cash provided by financing activities
     (33,279 )     -       4,669,857       4,583,437  
                                 
Net increase (decrease) in cash and cash equivalents
     (2,535,838 )     (2,027,437 )     (1,320,112 )     (1,651,980 )
Cash and cash equivalents, beginning of period
     8,130,416       9,450,528       9,450,528       11,102,508  
                                 
Cash and cash equivalents, end of period
   $ 5,594,578     $ 7,423,091     $ 8,130,416     $ 9,450,528  
 
See accompanying notes to financial statements
 
 
F - 6
 
 
PERSEON CORPORATION
(Formerly BSD Medical Corporation)
Notes to Financial Statements


Note 1:  Organization and Significant Accounting Policies

Organization and Business – Perseon Corporation, formerly BSD Medical Corporation, (the “Company”) was incorporated in the State of Delaware on July 3, 1986.  In February 2015, we changed the name of the Company to Perseon Corporation.  We are a life sciences company that develops, manufactures, markets and services groundbreaking medical systems to treat cancer using heat therapy.  Our MicroThermX® microwave ablation system employs precision-guided microwave energy to ablate diseased soft tissue.  We have developed extensive intellectual property and distribute our products in the United States, Europe and Asia.

Financial Reporting Period – We have changed our fiscal year end for financial reporting from August 31 to December 31, effective for the four months ended December 31, 2014.  The financial information for the four months ended December 31, 2013 provided for comparative purposes is unaudited.  All adjustments (consisting only of normal recurring adjustments) necessary for the fair presentation of our results of operations and our cash flows for the four months ended December 31, 2013 have been included.  The results of operations for the four months ended December 31, 2014 may not be indicative of the results for our fiscal year ending December 31, 2015.

Cash and Cash Equivalents – Cash and cash equivalents consist of cash and investments with original maturities to the Company of three months or less.  As of December 31, 2014 and August 31, 2014, we had $25,000 in a restricted bank account.
 
Accounts Receivable – Trade accounts receivable are carried at original invoice amount less an estimate made for doubtful receivables based on a review of all outstanding amounts on a monthly basis.  Management estimates an allowance for doubtful accounts by identifying troubled accounts and by using historical experience applied to an aging of accounts.  Trade accounts receivable are written off when deemed uncollectible.  Recoveries of trade receivables previously written off are recorded when received.  Interest is not charged on trade receivables that are outstanding beyond their due date.

Inventories – Parts and supplies inventories are stated at the lower of cost or market.  Cost is determined using the average cost method.  Work-in-process and finished goods are stated at the lower of the accumulated manufacturing costs or market.  We maintain a reserve for obsolete inventories to reduce excess and obsolete inventories to their estimated net realizable value.  The reserve was $750,000 as of December 31, 2014, $150,000 as of August 31, 2014, and $100,000 as of August 31, 2013.

Property and Equipment – Property and equipment are stated at cost less accumulated depreciation.  Depreciation is determined using the straight-line method over the following estimated useful lives of the assets.

Equipment
2 – 5 years
Rental equipment
5 years
Furniture and fixtures
5 years
Building improvements
15 years
Building
40 years

Expenditures for maintenance and repairs are expensed when incurred and betterments are capitalized.  Gains and losses on sales of property and equipment are reflected in operations.

The cost and accumulated depreciation of property and equipment sold or otherwise retired are removed from the accounts and any related gain or loss on disposition is reflected in net income or loss for the period.

 
F - 7
 
 
Patents – Patent costs are expensed as incurred.

Warranty Reserve – We provide limited warranties to our customers for products sold.  Estimated future warranty obligations are accrued each period.  As of December 31, 2014, August 31, 2014 and August 31, 2013, the accrued warranty reserve was $65,102, $75,728 and $50,968, respectively.  During the four months ended December 31, 2014, total warranty expense was $13,410.  During the fiscal years ended August 31, 2014 and 2013, total warranty expense was $41,471 and $80,276, respectively.

Income Taxes – We account for income taxes using the asset and liability method.  Under the asset and liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases.  Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.  The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

Income (Loss) Per Common Share – The computation of basic income (loss) per common share is based on the weighted average number of shares outstanding during each year.

The computation of diluted earnings per common share is based on the weighted average number of shares outstanding during the year, plus the common stock equivalents that would arise from the exercise of stock options and warrants outstanding, using the treasury stock method and the average market price per share during the year.  Common stock equivalents are not included in the diluted loss per share calculation when their effect is anti-dilutive.  Options and warrants to purchase 14,989,224 shares of common stock at prices ranging from $0.44 to $7.95 were excluded from the calculation of diluted earnings per share for the four months ended December 31, 2014 because their effect was anti-dilutive.  Options and warrants to purchase 13,720,225 and 9,669,878 shares of common stock at prices ranging from $0.99 to $7.95 were excluded from the calculation of diluted earnings per share for the years ended August 31, 2014 and 2013, respectively, because their effect was anti-dilutive.

Since we had no dilutive effect of stock options and warrants for the four months ended December 31, 2014 and 2013 and the years ended August 31, 2014 and 2013, our basic weighted average number of common shares outstanding is the same as our diluted weighted average number of common shares outstanding.

Stock-Based Compensation - Stock-based compensation is measured at the grant date based on the value of the award granted using the Black-Scholes option pricing model, and recognized over the period in which the award vests.  For stock awards no longer expected to vest, any previously recognized stock compensation expense is reversed in the period of termination.  The stock-based compensation expense is allocated to the various categories of operating costs and expenses in a manner similar to the allocation of payroll expense.
 
Revenue Recognition – We recognize revenue from the sale of medical systems, disposable devices related to the systems, parts, and accessories, and equipment rental, training, and service support contracts.  Our revenues consisted of the following:

   
Four Months Ended
December 31,
    
Years Ended
August 31,
  
   
2014
    
2013
    
2014
    
2013
  
                         
Product sales
   $ 470,875     $ 986,900     $ 3,019,525     $ 1,934,826  
Disposable devices
     409,787       501,565       1,568,481       1,109,750  
Service contracts and other
     109,346       100,597       375,747       330,116  
Equipment rental
     125,900       95,200       364,600       298,600  
                                 
Total
   $ 1,115,908     $ 1,684,262     $ 5,328,353     $ 3,673,292  
 
 
F - 8
 
 
Revenue from product sales is recognized when a purchase order has been received, the cancer treatment system has been shipped, the selling price is fixed or determinable, and collection is reasonably assured.  Most system sales are F.O.B. shipping point; therefore, shipment is deemed to have occurred when the product is delivered to the transportation carrier.  Most system sales do not include installation.  If installation is included as part of the contract, revenue is not recognized until installation has occurred, or until any remaining installation obligation is deemed to be perfunctory.  Some sales of systems may include training as part of the sale.  In such cases, the portion of the revenue related to the training, calculated based on the amount charged for training on a stand-alone basis, is deferred and recognized when the training has been provided.  The sales of our cancer treatment systems do not require specific customer acceptance provisions and do not include the right of return except in cases where the product does not function as warranted by us.  To date, returns have not been significant.

Revenue from the sale of disposable devices is recognized when a purchase order has been received, the devices have been shipped, the selling price is fixed or determinable, and collection is reasonably assured.  Currently, our customers are not required to purchase a minimum number of disposable devices in connection with the purchase of our systems.

Revenue from training services is recorded when an agreement with the customer exists for such training, the training services have been provided, and collection is reasonably assured.

Revenue from service support contracts is recognized on a straight-line basis over the term of the contract, which approximates recognizing it as it is earned.

Revenue from equipment rental under an operating lease is recognized when billed in accordance with the lease agreement.

Our revenue recognition policy is the same for sales to both related parties and non-related parties.  We provide the same products and services under the same terms for non-related parties as with related parties.

Sales to distributors are recognized in the same manner as sales to end-user customers.

Deferred revenue and customer deposits include amounts from service contracts as well as cash received for the sales of products that have not been shipped.

Concentration of Credit Risk – Financial instruments that potentially subject us to concentration of credit risk consists primarily of trade receivables.  In the normal course of business, we provide credit terms to our customers.  Accordingly, we perform ongoing credit evaluations of our customers and maintain allowances for possible losses.

We have cash in the bank and short-term investments that exceed federally insured limits.  We have not experienced any losses in such accounts.

Advertising and Promotion – Advertising and promotion costs, which are principally included in sales expenses, are expensed as incurred.  Advertising and promotion expense was $56,504 for the four months ended December 31, 2014, and $206,099 and $205,442 for the years ended August 31, 2014 and 2013, respectively.

Shipping and Handling – We bill our customers for shipping and handling charges, which are included in net sales.  The cost of corresponding shipping and handling expense is reported in cost of sales.

Use of Estimates in the Preparation of Financial Statements – The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ from those estimates.

Comprehensive Loss – Comprehensive loss is the same as net loss for all years presented.

 
F - 9
 
 
Note 2:  Liquidity

As of December 31, 2014, we had cash and cash equivalents of $5,594,578, and total current assets of $7,745,352.   We do not believe these resources will be sufficient to fully execute our current strategy through at least December 31, 2015.  Our current strategy involves significant efforts to expand sales of our MicroThermX product.  To become profitable we will need to significantly increase the revenues we receive from sales of our MicroThermX products.  We do not expect that sales of the MicroThermX products will increase sufficiently to cover our total costs of operations in 2015.  We believe additional funding will be required during 2015.
 
If we are unable to raise sufficient additional funds in 2015, we will need to significantly reduce our expenses, and evaluate other business arrangements, including collaborative arrangements, partnerships, or sale of assets, to allow continued operations.  Significantly reducing our expenses would negatively affect our efforts to expand our marketing and sales presence, our research and development programs, and our ability to hire and retain qualified personnel.

Note 3:  Detail of Certain Balance Sheet Accounts

Details of certain balance sheet accounts are as follows:

   
December 31,
    
August 31,
  
   
2014
    
2014
    
2013
  
                   
Accounts receivable:
                  
                   
   Trade receivables – non-related party
   $ 293,182     $ 364,170     $ 890,985  
   Other receivables
     1,890       22,717       28,984  
   Allowance for doubtful accounts
     (20,000 )     (20,000 )     (20,000 )
                         
    $ 275,072     $ 366,887     $ 899,969  

Inventories:
                  
                   
   Parts and supplies
   $ 1,004,164     $ 1,369,960     $ 1,353,614  
   Work-in-process
     951,519       880,751       990,668  
   Finished goods
     569,965       228,478       201,488  
   Reserve for obsolete inventories
     ( 750,000 )     (150,000 )     (100,000 )
                         
    $ 1,775,648     $ 2,329,189     $ 2,445,770  

Accrued liabilities:
                  
                   
   Warranty reserve
   $ 65,102     $ 75,728     $ 50,968  
   Training and installation reserve
     2,038       4,716       5,528  
   Accrued taxes payable
     50,462       59,745       44,677  
   Payroll, commissions, legal and other
     987,550       726,339       472,707  
                         
    $ 1,105,152     $ 866,528     $ 573,880  
 
 
F - 10
 

Note 4:  Property and Equipment

Property and equipment consist of the following:

   
December 31,
    
August 31,
  
   
2014
    
2014
    
2013
  
                   
   Equipment
   $ 1,503,845     $ 1,468,528     $ 1,401,811  
   Rental equipment
     58,940       58,940       58,940  
   Furniture and fixtures
     303,226       303,226       300,061  
   Building improvements
     -       54,736       54,736  
   Building (held for sale)
     956,000       956,000       956,000  
   Land  (held for sale)
     244,000       244,000       244,000  
                         
      3,066,011       3,085,430       3,015,548  
   Less equipment impairment
     ( 85,000 )     -       -  
   Less accumulated depreciation
     (1,840,140 )     (1,817,769 )     (1,695,668 )
                         
    $ 1,140,871     $ 1,267,661     $ 1,319,880  

Depreciation expense totaled $43,280 for the four months ended December 31, 2014 and totaled $125,824 and $128,121 for the years ended August 31, 2014 and 2013, respectively.

Note 5:  Impairment
 
In 2014, our Board of Directors determined that it is in the best interest of Perseon shareholders to divest of our assets related to the hyperthermia product line    In connection with our plans to either sell or divest the assets related to the hyperthermia product line, we analyzed the carrying value and estimated net realizable value of inventory and other assets related to the hyperthermia product line as of December 31, 2014.  As a result of this analysis, during the four months ended December 31, 2014, we recorded an impairment charge of $805,000 for inventory, equipment, and other assets related to the hyperthermia product line.  These impairment expenses are the result of our assessment of the decrease in the estimated realizable value associated with assets related to the hyperthermia product line.  The inventory reserve was also increased by $50,000 in the corresponding year ended August 31, 2014, to recognize a portion of the devaluation of inventory related to the hyperthermia product line.
 
Note 6:  Patents
 
Patent costs are expense as incurred.  In prior years we had certain patents recorded net of accumulated amortization.  The patents were being amortized on a straight-line basis over their estimated legal life, up to a period of 17 years.  Amortization expense was $0 for the four months ended December 31, 2014, and was $0 and $4,032 for the years ended August 31, 2014 and 2013, respectively.

Note 7:  Stockholders’ Equity

The Company has 10,000,000 authorized shares of $.001 par value preferred stock.  As of December 31, 2014, August 31, 2014 and 2013, there were no shares of preferred stock outstanding.  The Company also has 80,000,000 authorized shares of $.001 par value common stock.

Shelf Registration Statements

On October 1, 2009, a universal shelf registration statement was declared effective by the SEC for the issuance of common stock, preferred stock, warrants, senior debt, subordinated debt and units up to an aggregate amount of $50.0 million (the “2009 Shelf Registration Statement”).  We completed four stock offerings utilizing the universal shelf registration statement during calendar year 2010, and we received total net proceeds of approximately $19.2 million, including proceeds from the exercise of warrants issued in the stock offerings.

 
F - 11
 
 
On September 28, 2012, we filed a universal shelf registration statement with the SEC for the issuance of common stock, preferred stock, warrants, senior debt, subordinated debt and units up to an aggregate amount of $50.0 million (the “2012 Shelf Registration Statement”).  On October 11, 2012, the 2012 Shelf Registration Statement was declared effective by the SEC.  We have completed two stock offerings utilizing the 2012 Shelf Registration Statement from April 2013 through December 31, 2014, and we received total net proceeds of approximately $9.0 million from these offerings, as more fully described below.  We may periodically offer one or more of these securities in amounts, prices and terms to be announced when and if the securities are offered.  At the time any of the securities covered by the registration statement are offered for sale, a prospectus supplement will be prepared and filed with the SEC containing specific information about the terms of any such offering.
 
April 2013 Offering

On April 9, 2013, we entered into a placement agency agreement (the “Agency Agreement”) with Roth Capital Partners, LLC (the “Placement Agent”), pursuant to which the Placement Agent agreed to use its reasonable efforts to arrange for the sale of up to 4,065,042 shares of our common stock and warrants to purchase up to 3,048,782 shares of our common stock in a registered direct public offering (the “April 2013 Offering”).  The Placement Agent was entitled to a cash fee of 6.5% of the gross proceeds paid to us for the securities sold in the April 2013 Offering.  We also reimbursed the Placement Agent for all reasonable and documented out-of-pocket expenses incurred by the Placement Agent in connection with the April 2013 Offering, not to exceed the lesser of (i) $35,000 or (ii) 8% of the gross proceeds of the April 2013 Offering, less the Placement Agent’s placement fee.

The Agency Agreement contains customary representations, warranties and covenants by us.  It also provides for customary indemnification by us and the Placement Agent for losses or damages arising out of or in connection with the sale of the securities being offered.  We agreed to indemnify the Placement Agent against liabilities under the Securities Act of 1933, as amended.  We also agreed to contribute to payments the Placement Agent may be required to make in respect of such liabilities.

Also on April 9, 2013, we and certain institutional investors entered into a securities purchase agreement (the “Purchase Agreement”) in connection with the April 2013 Offering, pursuant to which we agreed to sell an aggregate of 4,065,042 shares of our common stock and warrants to purchase a total of 3,048,782 shares of our common stock to such investors for aggregate gross proceeds, before deducting fees to the Placement Agent and other estimated offering expenses payable by us, of approximately $5.0 million.  The common stock and warrants were sold in fixed combinations, with each combination consisting of one share of common stock and a warrant to purchase 0.75 shares of common stock.  The purchase price was $1.23 per fixed combination.  The warrants became exercisable six months and one day following the closing date of the April 2013 Offering and will remain exercisable for five years thereafter at an exercise price of $1.65 per share.  The exercise price of the warrants is subject to adjustment in the case of stock splits, stock dividends, combinations of shares and similar recapitalization transactions.

The exercisability of the warrants may be limited if, upon exercise, the holder or any of its affiliates would beneficially own more than 4.9% of our common stock.

We agreed with each of the purchasers that, subject to certain exceptions, we will not, within the 30 trading days following the closing of the April 2013 Offering (which period may be extended in certain circumstances), enter into any agreement to issue or announce the issuance or proposed issuance of any securities.

We also agreed with each of the purchasers that while the warrants are outstanding, we will not affect or enter into an agreement to affect a “Variable Rate Transaction,” which means a transaction in which we:

•
issue or sell any convertible securities either (A) at a conversion, exercise or exchange rate or other price that is based upon and/or varies with the trading prices of, or quotations for, the shares of our common stock at any time after the initial issuance of such convertible securities, or (B) with a conversion, exercise or exchange price that is subject to being reset at some future date after the initial issuance of such convertible securities or upon the occurrence of specified or contingent events directly or indirectly related to our business or the market for our common stock, other than pursuant to a customary “weighted average” anti-dilution provision; or
   
•
enter into any agreement (including, without limitation, an equity line of credit) whereby we may sell securities at a future determined price (other than standard and customary “preemptive” or “participation” rights).
 
 
F - 12
 
 
We also agreed with each of the purchasers if we issue securities within the 12 months following the closing of the April 2013 Offering, the purchasers shall have the right to purchase all of the securities on the same terms, conditions and price provided for in the proposed issuance of securities.

We also agreed to indemnify each of the purchasers against certain losses resulting from our breach of any of our representations, warranties, or covenants under agreements with each of the purchasers, as well as under certain other circumstances described in the Purchase Agreement.

We closed the April 2013 Offering on April 12, 2013 and received net proceeds of approximately $4.6 million, after deducting placement agent fees and the offering expenses borne by us.

The April 2013 Offering was completed using the 2012 Shelf Registration Statement, pursuant to a prospectus supplement filed with the SEC.

May 2014 Offering

On May 9, 2014, the Company entered into an At-the-Market Issuance Sales Agreement (the “ATM Agreement”) with MLV & Co. LLC (“MLV”).  Under this sales agreement, we could issue and sell from time to time, up to $8,000,000 of common stock.  These shares are registered under the 2012 Shelf Registration Statement .  MLV would act as sales agent, using commercially reasonable efforts consistent with its normal trading and sales practices.  The Agreement provided that our common shares would be sold at market prices prevailing at the time of the sale of our common stock, at no discount to market and no warrants attached.  We were not obligated to make any sales under the sales agreement.  We paid MLV a commission rate of 3.0% of the gross proceeds from the sale of common stock sold through MLV as sales agent under the sales agreement, reimbursed MLV for certain expenses incurred in connection with entering into the sales agreement, and provided MLV with customary indemnification rights. The full terms and text of the sales agreement was filed by the Company on a Current Report on Form 8-K on May 9, 2014.  Through June 22, 2014, the Company sold 46,622 shares of common stock at an average price per share of $1.074, for gross proceeds of $50,068.  The ATM Agreement was terminated on June 22, 2014.

June 2014 Offering

On June 25, 2014, the Company and certain institutional investors entered into a securities purchase agreement (the “June Offering”) in which the Company agreed to sell, pursuant to a securities purchase agreement (the “Purchase Agreement”), an aggregate of 5,500,000 shares of its common stock and warrants to purchase a total of 4,400,000 shares of its common stock to such investors for aggregate gross proceeds of approximately $5.2 million, and net proceeds of approximately $4.7 million, after deducting placement agency fees and other costs associated with the transaction.  The common stock and warrants were sold in fixed combinations, with each combination consisting of one share of common stock and a warrant to purchase 0.8 shares of common stock.  The purchase price was $0.95 per fixed combination.  The warrants will become exercisable six months and one day following the closing date of the June Offering and will remain exercisable for five years thereafter at an exercise price of $1.10 per share.  The exercise price of the warrants is subject to adjustment in the case of stock splits, stock dividends, combinations of shares and similar recapitalization transactions.  The exercisability of the warrants may be limited if, upon exercise, the holder or any of its affiliates would beneficially own more than 4.99% of the Company’s common stock.  The warrants are contingently puttable at the option of the holders upon the occurrence of a fundamental transaction (as defined in the warrant agreements).  The Company considers that all of the fundamental transactions are within the Company’s sole control, and that the probability of any fundamental transaction occurring and the put being exercised are both remote.

Under the Purchase Agreement, the Company has agreed with each of the purchasers that, subject to certain exceptions, it will not, within the 75 days following the closing of the June Offering enter into any agreement to issue or announce the issuance or proposed issuance of any securities.  The Company also agreed with each of the purchasers that for a period of four years from the date of the Purchase Agreement, the Company will not affect or enter into an agreement to affect a “Variable Rate Transaction,” which means a transaction in which it:
 
 
F - 13
 

•
issues or sells any convertible securities either (A) at a conversion, exercise or exchange rate or other price that is based upon and/or varies with the trading prices of, or quotations for, the shares of common stock of the Company at any time after the initial issuance of such convertible securities, or (B) with a conversion, exercise or exchange price that is subject to being reset at some future date after the initial issuance of such convertible securities or upon the occurrence of specified or contingent events directly or indirectly related to the business of the Company or the market for the Company’s common stock, other than pursuant to a customary “weighted average” anti-dilution provision; or
   
•
enters into any agreement (including, without limitation, an equity line of credit) whereby the Company may sell securities at a future determined price.

The Company has also agreed to indemnify each of the purchasers against certain losses resulting from its breach of any of its representations, warranties, or covenants under agreements with each of the purchasers, as well as under certain other circumstances described in the Purchase Agreement. The transaction closed on July 1, 2014 and the net proceeds were transferred to the Company.

Warrants

A summary of the outstanding warrants issued in our stock offerings as of December 31, 2014 and August 31, 2014 and changes during the four months ended December 31, 2014 and the year ended August 31, 2014 is as follows:

   
Shares
    
Weighted-
Average
Exercise Price
    
Weighted-Average
Remaining
Contract Term
(Years)
  
                   
                   
Outstanding as of August 31, 2013
     5,457,305     $ 2.93       -  
Granted
     4,400,000       1.10       -  
Exercised
     -       -       -  
Forfeited or expired
     -       -       -  
                         
Outstanding as of August 31, 2014
     9,857,305     $ 2.11       4.02  
Granted
     -       -       -  
Exercised
     -       -       -  
Forfeited or expired
     -       -       -  
                         
Outstanding as of December 31, 2014
     9,857,305     $ 2.11       3.69  
                         
Exercisable as of December 31, 2014
     5,457,305     $ 2.93       2.62  

Note 8:  Deferred Revenue

We have entered into certain service contracts and other agreements for which we have received payment in advance.  We recognize these revenues over the life of the agreements.

As of December 31, 2014, August 31, 2014 and August 31, 2013, we had deferred revenue of $54,218, $96,043 and $783,708, respectively.
 
Note 9:  Major Customers and Foreign Sales

During the four months ended December 31, 2014, we had sales to two foreign customers totaling 41.53% and 11.30% of total revenues.  During the year ended August 31, 2014, we had sales to two foreign customers totaling 23.46% and 22.92% of total revenues.  During the year ended August 31, 2013, we had sales to one customer totaling 30.36% of total revenues.  

 
F - 14
 
 
Export sales were $630,857 in the four months ended December 31, 2014, and $3,381,563 and $1,470,619 in the years ended August 31 2014 and 2013, respectively.

During the four months ended December 31, 2014, export sales to Germany and Belgium combined were approximately 53%.   During fiscal year 2014, export sales to Taiwan and Belgium combined were approximately 46% of total sales.  During fiscal year 2013, export sales to Belgium and Germany combined were approximately 30%.

As of December 31, 2014, the highest account receivable due from one customer was 36% of total accounts receivable.  As of August 31, 2014, the highest account receivable due from one customer was approximately 68% of total accounts receivable.  As of August 31, 2013, the highest account receivable due from one customer was approximately 72% of total accounts receivable.

Note 10:  Related Party Transactions

We had sales of $463,423 during the four months ended December 31, 2014, and $419,549 and $99,896 during the years ended August 31, 2014 and 2013, respectively, to entities controlled by a significant stockholder and member of the Board of Directors.  These related party transactions represent approximately 42%, 8% and 3% of total sales for each respective period.

As of December 31, 2014, August 31, 2014 and August 31, 2013, receivables include $13,471, $8,322 and $24,201, respectively, from these related parties.

Note 11:  Income Taxes

The income tax provision of $2,000 and $1,938 for the years ended August 31, 2014 and 2013, respectively, is comprised of a current provision for state income taxes.

The income tax (provision) benefit differs from the amount computed at federal statutory rates as follows:   

   
Four Months Ended
December 31,
    
Years Ended
August 31,
  
   
2014
    
2014
    
2013
  
                   
Income tax benefit at federal statutory rate
   $ 1,281,000     $ 2,428,000     $ 2,805,000  
Stock-based compensation
     (66,000 )     (287,000 )     (335,000 )
State income taxes, net of federal benefit
     124,000       236,000       272,000  
Research and development credit
     33,000       99,000       106,000  
Valuation allowance
     (1,360,000 )     (2,480,000 )     (2,905,000 )
Other
     (12,000 )     2,000       55,062  
                         
    $ -     $ (2,000 )   $ (1,938 )
 
Deferred tax assets (liabilities) are comprised of the following:
 
   
December 31,
    
August 31,
  
   
2014
    
2014
    
2013
  
Current Asset:
                  
   Accruals and reserves
   $ 73,000     $ 62,000     $ 26,000  
   Deferred revenue
     18,000       33,000       266,000  
   Inventories
     298,000       90,000       68,000  
Valuation allowance
     (389,000 )     (185,000 )     (360,000 )
                         
    $ -     $ -     $ -  
Long-Term Asset (Liability):
                        
   Deferred compensation
   $ 601,000     $ 601,000     $ 601,000  
   Research and development and other tax credits
     1,929,000       1,896,000       1,804,000  
   Net operating loss carryforwards - federal
     12,951,000       13,938,000       11,380,000  
   Net operating loss carryforwards - state     2,079,000       -       -  
   Depreciation and amortization
     39,000       8,000       3,000  
Valuation allowance
     (17,599,000 )     (16,443,000 )     (13,788,000 )
                         
 
   $ -     $ -     $ -  
 
 
F - 15
 
 
The ultimate realization of the deferred tax assets is dependent, in part, upon the tax laws in effect, our future earnings, and other events.  As of December 31, 2014, we recorded a valuation allowance of $389,000 against current deferred tax assets, and a valuation allowance of $17,599,000 against net long-term deferred tax assets.  The increase in the valuation allowance for the four months ended December 31, 2014 relates primarily to our operating losses.  In recording the valuation allowance, we were unable to conclude that it is more likely than not that our deferred tax assets will be realized.

In addition to the deferred tax assets listed above, the Company has unrecorded tax benefits of approximately $2,600,000 attributable to the difference between the amount of the financial statement expense and the allowable tax deduction associated with stock-based compensation.  As a result of net operating loss carryforwards, the Company was not able to recognize the excess tax benefits of share-based compensation deductions because the deductions did not reduce income tax payable.  Although not recognized for financial reporting purposes, this unrecorded tax benefit is available to reduce future income and is incorporated into the disclosed amounts of the Company’s net operating loss carryforwards, discussed below.  If subsequently realized, the benefit will be recorded to contributed capital.

As of December 31, 2014, we had a net operating loss carryforward available to offset future taxable income of approximately $40,701,000, which will begin to expire in 2029.  If substantial changes in the Company’s ownership should occur, there would be an annual limitation of the amount of the net operating loss carryforward which could be utilized.

We perform a review of our material tax positions in accordance with recognition and measurement standards established by authoritative accounting literature, which requires a company to determine whether it is more likely than not that a tax position will be sustained upon examination based upon the technical merits of the position.  If the more-likely-than-not threshold is met, a company must measure the tax position to determine the amount to recognize in the financial statements.  Based upon our review and evaluation, during the four months ended December 31, 2014 and 2013 and the years ended August 31, 2014 and 2013, we concluded the Company had no unrecognized tax benefit that would affect its effective tax rate if recognized.

We classify any interest and penalties arising from the underpayment of income taxes in our statements of comprehensive loss in other income (expense).  As of December 31, 2014, August 31, 2014 and August 31, 2013, we had no accrued interest or penalties related to uncertain tax positions.
 
We file income tax returns in the U.S. federal jurisdiction and various state jurisdictions.  U.S. federal income tax returns from the year ended August 31, 2011 through the period ended December 31, 2014 are subject to examination.

Note 12:  Stock-Based Compensation

Our Third Amended and Restated 1998 Stock Incentive Plan (the “Plan”) authorizes the granting of incentive stock options to certain key employees and non-employees who provide services to the Company.  The Plan, as amended, provides for the granting of options for an aggregate of 6,337,300 shares.  The options vest subject to management’s discretion.

 
F - 16
 
 
Effective February 4, 2009, our Fourth Amended and Restated 1998 Directors Stock Plan (the “Director Plan”) provides an annual retainer of $60,000 to each non-employee director with the exception of the Audit Committee Chairman who is to receive $65,000.  The cash portion of the compensation of $30,000 ($35,000 for the Audit Committee Chairman) is paid 50% twice each year, with $30,000 of compensation paid in common stock of the Company once each year.  Prior to February 4, 2009, the Director Plan granted each non-employee outside director 30,000 options each year at an exercise price equal to the fair market value of the common stock at the date the option was granted.  The options vest according to a set schedule over a five-year period and expire upon the director’s termination, or after ten years from the date of grant.  The Director Plan, as amended, allows for an aggregate of 1,750,000 shares to be granted.

Stock-based compensation cost is measured at the grant date based on the estimated value of the award granted, using the Black-Scholes option pricing model, and recognized over the period in which the award vests.  For stock awards no longer expected to vest, any previously recognized stock compensation expense is reversed in the period of termination.

The stock-based compensation expense has been allocated to the various categories of operating costs and expenses in a manner similar to the allocation of payroll expense as follows:

   
Four Months
 Ended
December 31,
    
Years Ended
 August 31,
  
   
2014
    
2014
    
2013
  
                   
Cost of sales
   $ 11,776     $ 61,427     $ 67,119  
Research and development
     32,349       183,371       212,569  
Selling, general and administrative
     148,719       599,830       855,123  
                         
Total
   $ 192,844     $ 844,628     $ 1,134,811  
 
During the four months ended December 31, 2014, we granted a total of 1,450,000 stock options to employees with exercise prices ranging from $0.44 to $0.51 per share and with one third vesting each year for the next three years.  The weighted average estimated grant-date fair value per share of these stock options was $0.22, and our assumptions used in the Black-Scholes valuation model to determine this estimated fair value are shown below:

Expected volatility
62.96%
Expected dividends
0.00%
Expected term
7.24 Years
Risk-free interest rate
2.07%

The expected volatility rate was estimated based on the historical volatility of our common stock.   The expected term was estimated based on historical experience of stock option exercise and forfeitures.  The risk-free interest rate is the rate provided by the U.S. Treasury for Daily Treasury Yield Curve Rates commonly referred to as “Constant Maturity Treasury” rate in effect at the time of grant with a remaining term equal to the expected option term.
 
Unrecognized stock-based compensation expense expected to be recognized over an estimated weighted-average amortization period of 1.15 years is approximately $1,078,000 as of December 31, 2014.

A summary of the time-based stock option awards as of as of December 31, 2014 and August 31, 2014 and changes during the four months ended December 31, 2014 and the year ended August 31, 2014 is as follows:

 
F - 17
 
 
   
Shares
    
Weighted-
Average
 Exercise
Price
    
Weighted-Average
Remaining
Contract Term
(Years)
    
Aggregate
Intrinsic
Value
  
                         
Outstanding as of September 1, 2013
     4,212,573     $ 2.85              
Granted
     127,000       1.19              
Exercised
     -       -              
Forfeited or expired
     (476,653 )     2.18              
                             
Outstanding as of August 31, 2014
     3,862,920       2.88       6.32     $ -  
Granted
     1,450,000       0.46                  
Exercised
     -       -                  
Forfeited or expired
     (181,001 )     1.54                  
                                 
Outstanding as of December 31, 2014
     5,131,919     $ 2.25       7.03     $ -  
Exercisable as of December 31, 23014
     2,953,586     $ 3.30       5.31     $ -  

The aggregate intrinsic value in the preceding table represents the total pretax intrinsic value, based on the Company’s closing stock price of $0.36 as of December 31, 2014, which would have been received by the holders of in-the-money options had the option holders exercised their options as of that date.
 
Note 13:  Supplemental Cash Flow Information

We paid no amount for interest during the four months ended December 31, 2014 and the years ended August 31, 2014 and 2013.  We paid no amount for income taxes during the four months ended December 31, 2014.  During the years ended August 31, 2014 and 2013 we paid $2,000 and $1,938 for income taxes.

We had no non-cash financing and investing activities during the four months ended December 31, 2014 and the years ended August 31, 2014 and 2013.

Note 14:  Commitments and Contingencies

Employment Agreement - CEO

On January 9, 2015, we entered into an Employment Agreement (“CEO Agreement”) with Clinton E. Carnell Jr., our President and Chief Executive Officer (“CEO”).  The CEO Agreement confirms the appointment as President and CEO, and service as a member of  the Company’s Board of Directors, and sets the CEO’s annual base salary at $350,000, with a review at least annually by the Compensation Committee of the Board of Directors.  The CEO Agreement provides for an annual bonus of $150,000 for the first year of employment, and a bonus of $150,000, or a pro rata portion thereof, for the second year of employment.  If the Company completes and closes in fiscal year 2015 an equity offering that generates to the Company at least $5.0 million in net proceeds, then the Company will engage a compensation consulting firm to conduct a study of compensation of CEO’s in companies comparable to the Company, which study shall then be used to negotiate Mr. Carnell’s overall compensation after December 31, 2015.  If the Company does not complete and close such an equity offering in 2015, then the Company shall engage a compensation consulting firm in 2016 to negotiate Mr. Carnell’s salary after December 31, 2016.  The CEO Agreement also provides an award of a nonqualified stock option to purchase 1,400,000 shares of common stock at a price per share of $0.46, the closing price of the Company’s common stock on November 10, 2014, the date the option was granted.  The options will vest at one-third each year on the anniversaries of the grant.  Under the CEO Agreement the CEO is entitled to participate in all employee benefit plans, practices and programs maintained by the Company for its employees.  Additional provisions of the CEO Agreement include indemnification for expenses associated with defending certain claims made against the CEO as a result of his position with the Company, and directors’ and officers’ liability insurance providing coverage during the term of the CEO Agreement and for a period of six years following the termination of the CEO Agreement.  The CEO Agreement also provides that if he is terminated by the Company other than for cause, or if he resigns for good reason and complies with certain requirements, the Company is obligated to pay him an amount equal to his base salary (the “CEO Severance Payment”) and provide employee benefits for two years following termination.  If the CEO Agreement is terminated for cause, he shall receive only the portion of his base salary that is due to him through the effective date of his termination.  If the CEO Agreement is terminated by reason of his death, his estate shall receive his salary through the end of the month in which he died plus all employee benefits due to him through the end of such month.   If a Change in Control (as defined in the CEO Agreement) occurs with respect to the Company, and during the six months immediately following the Change of Control, (i) the Company terminates him without cause; or (ii) he terminates his employment with good reason, then in addition to the CEO Severance Payment, all options or incentive awards granted to him will immediately vest and become exercisable for a period of 180 days following the termination.  The CEO Agreement also contains a confidentiality agreement, and a one-year non-competition and non-solicitation agreement.  The CEO Agreement contains a claw back provision that enables the Company to claw back any incentive-based compensation or other compensation from him if required by any law, government regulation, stock exchange listing requirement, or Company policy adopted as required by such law, government regulation, or stock exchange listing requirement.

 
F - 18
 
 
The Company’s former President and CEO, Mr. Harold R. Wolcott, relinquished his positions as President and CEO upon the Company’s hiring of its new President and CEO.  Mr. Wolcott will continue to serve on the Company’s board of directors.  On April 28, 2014, the Company entered into a letter agreement with Mr. Wolcott, pursuant to which Mr. Wolcott will receive severance benefits that supersede the severance benefits Mr. Wolcott was previously entitled to receive under his employment agreement.  Pursuant to the letter agreement, upon Mr. Wolcott ceasing to serve as President and CEO of the Company for any reason (other than for cause), the Company will pay to Mr. Wolcott an amount equal to his current base salary, and the vesting of his equity awards will immediately vest and become exercisable.  On November 10, 2014, the Company entered into a consulting agreement with Mr. Wolcott, who resigned as President and CEO effective November 10, 2014.

Employment Agreement – CFO

On September 16, 2014, the Company entered into an employment agreement (the “CFO Agreement”) with its Chief Financial Officer (“CFO”).  The CFO Agreement provides that his base salary shall be $200,000, to be reviewed at least annually by the Compensation Committee of the Board of Directors. The CFO Agreement provides that the CFO is entitled to participate in any annual incentive bonus programs, employee benefit plans adopted or maintained by the Company, and the Company’s Stock Incentive Plan.  Additional provisions of the CFO Agreement include indemnification for expenses associated with defending certain claims made against the CFO as a result of his position with the Company, and directors’ and officers’ liability insurance providing coverage during the term of the CFO Agreement and for a period of six years following the termination of the CFO Agreement.  If the CFO is terminated by the Company other than for cause, or resigns for good reason, and complies with certain requirements, the Company is obligated to pay him an amount equal to his base salary (the “CFO Severance Payment”) and provide employee benefits for one year following termination.  If the CFO Agreement is terminated for cause, he shall receive only the portion of his base salary that is due to him through the effective date of his termination.  If the CFO Agreement is terminated by reason of his death, his estate shall receive his salary through the end of the month in which he died plus all employee benefits due to him through the end of such month.  If a Change in Control (as defined in the CFO Agreement) occurs with respect to the Company, and during the six months immediately following the Change of Control, (i) the Company terminates him without cause; (ii) he terminates his employment with good reason; or (iii) he terminates the CFO Agreement but also agrees to continue serving as CFO for the longer of (a) six months and (b) until a new CFO is appointed, then in addition to the CFO Severance Payment, all options or incentive awards granted to him will immediately vest and become exercisable for a period of 180 days following the termination.  The CFO Agreement also contains a confidentiality agreement, and a one-year non-competition and non-solicitation agreement.  The CFO Agreement contains a claw back provision that enables the Company to claw back any incentive-based compensation or other compensation from him if required by any law, government regulation, stock exchange listing requirement, or Company policy adopted as required by such law, government regulation, or stock exchange listing requirement.

Employment Agreement – CTO

On December 19, 2014, the Company terminated, without cause, the employment of its Chief Technical Officer (“CTO”).  Under the terms of an employment agreement dated November 2, 1988, the Company is obligated to provide severance pay for a one-year period, which pay includes an extension of all rights, privileges and benefits as an employee (including medical insurance).  The one-year severance pay shall be equal to the CTO’s average annual salary for the 12-month period immediately prior to the termination.  The terms of the employment agreement also require us to pay the CTO for accrued, unused vacation at the time of termination, and include a non-competition covenant prohibiting him from competing with us for one year following his termination.  We may continue the non-competition period for up to four additional years by notifying the CTO in writing and by continuing the severance payments for the additional years during which the non-competition period is extended.

 
F - 19
 

Note 15:  Recent Accounting Pronouncements

No new accounting pronouncements were adopted during the four months ended December 31, 2014 that had a material impact on our financial statements.

In May 2014, FASB issued ASU 2014-09 Revenue from Contracts with Customers. The amendments in ASU 2014-09 affects any entity that either enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of nonfinancial assets unless those contracts are within the scope of other standards (e.g., insurance contracts or lease contracts). This ASU will supersede the revenue recognition requirements in Topic 605 Revenue Recognition and most industry-specific guidance, and creates a Topic 606 Revenue from Contracts with Customers.

The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve that core principle, an entity should apply the following steps:
 
Step 1: Identify the contract(s) with a customer.
Step 2: Identify the performance obligations in the contract.
Step 3: Determine the transaction price.
Step 4: Allocate the transaction price to the performance obligations in the contract.
Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation.

ASU 2014-09 is effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. Early application is not permitted.  We have not yet determined how our financial statements will be affected by the adoption of ASU 2014-09.

Note 16:  Subsequent Events

On January 15, 2015, the Company entered into an employment agreement with its Clinton E. Carnell, Jr., to serve as President and Chief Executive Officer.
 
Effective February 16, 2015, the Company entered into an employment agreement with Benjamin Beckham to serve as Vice President of North American Sales.

Effective February 16, 2015, the Company entered into an employment agreement with Todd Turnlund to serve as Vice President of Research and Development.

Effective February 17, 2015, the Company entered into an employment agreement with Jen Hoglin to serve as Vice President of Global Marketing.

Effective February 20, 2015, Perseon Corporation amended its certificate of incorporation to change its legal corporate name to “Perseon Corporation” from “BSD Medical Corporation.”   The name change was effected pursuant to Section 242 of the Delaware General Corporation Law (the “DGCL”).  Under the DGCL, the amendment to the Company’s certificate of incorporation to effect the name change did not require stockholder approval.

On February 24, 2015, the Company executed a promissory note with an asset lender, in the amount of $750,000.   The note is secured by the Company’s headquarters and manufacturing facility.  During the one year term of the note, monthly payments of interest only at Prime Rate plus 6.0% are required, with the principal due on February 24, 2016.
 
The Company has evaluated other events occurring after the date of our accompanying balance sheets through the date of the filing of this Transition Report on Form 10-K.  No other material subsequent events requiring adjustment to our accompanying financial statements were identified.
 
 
F-20
 EX-10.18 2 perseonexh1018.htm EMPLOYMENT AGREEMENT WITH EFFECTIVE DATE OF FEBRUARY 16, 2015 BETWEEN THE COMPANY AND BENJAMIN BECKHAM. perseonexh1018.htm
Exhibit 10.18
EXECUTIVE EMPLOYMENT AGREEMENT

THIS EXECUTIVE EMPLOYMENT AGREEMENT (the “Agreement”) is made and entered into effective as of February 16, 2015 (the “Effective Date”), by and between Perseon Corporation, a Delaware corporation (“Perseon” or the “Company”) and Benjamin C. Beckham, an individual and resident of the state of Texas (the “Executive”). The Company and the Executive are referred to herein collectively as the “Parties” and may be referred to herein individually as a “Party”.
 
BACKGROUND
 
The Company made an offer of employment to the Executive pursuant to a written offer of employment dated January 21, 2015. The Executive accepted the offer of employment. The written offer of employment contemplated that the Parties would enter into an employment agreement, which employment agreement shall be subject to the approval of the Company’s Board of Directors.
 
AGREEMENT
 
NOW THEREFORE, in consideration of the premises, the agreements, and the mutual covenants contained herein and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties agree as follows:
 
1. Term. The Executive’s employment hereunder shall continue from and after the Effective Date until terminated in accordance with the applicable provisions of this Agreement (the “Term”).
 
2. Position and Responsibilities. The Company currently employs and shall continue to employ the Executive as the Vice President of North America Sales or such other position as the Parties may agree from time to time. The Executive shall report to the President and Chief Executive Office of the Company (hereinafter, the “President”) or his designee. The Executive will devote substantially all of his skill, knowledge, and working time to the conscientious performance of such duties except for reasonable vacation time, absence for sickness or similar disability, and authorized leaves of absence. To the extent that it does not significantly interfere with the performance of the Executive's duties hereunder, it shall not be a violation of this Agreement for the Executive to (i) serve on corporate, civic, or charitable boards or committees; provided, however, that the Executive shall obtain the written permission of the President prior to rendering such service, (ii) deliver lectures or fulfill speaking engagements, or (iii) manage personal investments. The Executive represents that he is entering into this Agreement voluntarily and that, to the best of his knowledge, his employment hereunder and compliance by him with the terms and conditions of this Agreement will not conflict with or result in the breach of any agreement to which he is a party or by which he may be bound. Any fees or other compensation received by the Executive for services as a director, as a trustee, or in a similar position with another entity shall be retained by the Executive.
 
3. Place of Performance. The principal place of the Executive’s employment shall be Perseon’s principal executive offices, currently located at 2188 West 2200 South, Salt Lake City, Utah. Notwithstanding the foregoing, because of the nature of his position and the extensive travel required for that position, the Company understands and agrees that the Executive will work primarily from his home office; provided, however, that the Executive understands that he reports to Perseon’s principal executive offices and will be required to travel to the executive offices at the direction of the President or as otherwise necessary to the performance of his job duties and that he may be required to spend extended periods of time at the principal executive offices as necessary to perform his job duties.
 
4. Compensation.
 
4.1 Base Salary. The Company shall pay the Executive an annual base salary at the rate of two hundred thirty one thousand and no/100 dollars ($231,000.00) (the “Base Salary”), which Base Salary shall be paid to the Executive in periodic installments in accordance with the Company’s customary payroll practices, as modified from time to time, but no less frequently than monthly. During the Term, beginning in February 16, 2016, the Company will review the Executive's Base Salary annually and, in the discretion of the President, in consultation with the Company’s Board of Directors (hereinafter, the “Board” or “Board of Directors”), may modify such Base Salary from time to time based on the performance of the Executive, the financial condition of the Company, prevailing industry salary scales, and such other factors as the Company's President shall consider relevant; provided, that the Company may not decrease Executive’s Base Salary by more than 10%, calculated based on the Base Salary in effect just prior to any such decrease, and then only by the unanimous vote of the Board after a finding by the Board that such reduction is reasonably necessary to address either a projected or actual significant financial shortfall in the Company’s financial performance or as otherwise agreed between the Company and the Executive. Any increase or decrease in the Base Salary shall not serve to limit or reduce any other obligation to the Executive under this Agreement.
 
 
 
 
 
4.2 Award of Common Stock Options or Restricted Stock Units. The Executive will be awarded an option to purchase 200,000 shares of the Company’s common stock. The exercise price per share will be equal to the fair market value per share on the date the option is granted, which date will be on or near the Effective Date. The option will be subject to the terms and conditions applicable to options granted under the Company’s long term equity-based incentive compensation plan and the applicable notice of grant of stock option or agreement thereunder. Subject to the Executive’s continued employment, the options will vest in accordance with the notice of grant of stock option or agreement.
 
If the Company awards restricted stock or restricted stock units to its executive-level employees or to employees generally, then the Executive will be eligible to participate in any such plan, subject to the terms, conditions, limitations, and eligibility requirements set forth in the applicable plan documents. Nothing in this paragraph requires the Company to adopt a plan with respect to the grant of restricted stock or restricted stock units for restricted stock units.
 
4.3 Commissions. The Company will pay the Executive commissions based on the sales revenue earned by the Company in North America in accordance with a written commission plan to be developed and/or approved by the Company’s President, in his sole discretion, after consultation with the Executive, which commission plan shall be developed and/or approved by the Company’s President no later than 60 days after the Effective Date and shall apply to all sales that occur from and after the Effective Date. The terms of any North American sales commission plan may be modified by the Company from time to time, as determined by the Company’s President, in his sole discretion; provided, however, that the Company shall provide the Executive with 30-days’ advance notice of any modification to the commission plan and any such modification to the commission plan will apply only to sales that occur after the expiration of the 30-day advance notice period.
 
4.4 Employee Benefits. During the Term, the Executive shall be entitled to participate in all employee benefit plans, practices, and programs maintained by the Company for its employees, as in effect from time to time (collectively the “Employee Benefit Plans”), subject to the terms, conditions, and limitations and eligibility requirements of any applicable plan documents. The Company reserves the right to amend or terminate any Employee Benefit Plan(s) so as to eliminate, reduce, or otherwise change any benefit payable thereunder, so long as such change complies with the terms of such Employee Benefit Plan(s), and applicable law, and so long as such change similarly affects all of the Company’s executive level employees.
 
4.5 Vacation or Other Leave of Absence. During the Term, the Executive shall be entitled to such vacation, sick leave, personal time off, or other leave policy as is available under the prevailing policies of the Company, as modified from time to time.
 
4.6 Communication Equipment. During the Term, the Company shall provide the Executive with such communication equipment as the Company deems appropriate, from time to time, for the Executive’s use in performing his duties under this Agreement and shall pay the monthly service costs associated with such communication equipment or, at the Company’s option, the Company shall reimburse the Executive for monthly service costs arising from the Executive’s use of his own personal communication equipment for the performance of his duties under this Agreement, as determined by the President.
 
4.7 Business Expenses. The Executive shall be entitled to reimbursement for all reasonable and necessary out-of-pocket business, entertainment, and travel expenses incurred by the Executive in connection with the performance of the Executive’s duties hereunder in accordance with the Company’s expense reimbursement policies and procedures in effect from time to time.
 
4.8 Indemnification. To the maximum extent permitted by law, and in the manner required by the laws of the State of Utah, the Company shall indemnify the Executive against any and all applicable claims, judgments, fines, amounts paid in settlement, and other costs actually and reasonably incurred in any Action, as defined in Section 4.8(a) below, giving rise to the Executive’s claim for indemnification; provided, however, that nothing contained herein shall require the Company to indemnify the Executive from and against Actions initiated by the Executive or the Company related to any contest or dispute between the Executive and the Company with respect to this Agreement or the Executive’s employment hereunder or arising from the Executive’s willful misconduct or gross negligence or the Executive’s violation of the Company’s policies against unlawful harassment and discrimination, as modified from time to time.
 
 
 
 
 
(a) For purposes of this Section 4, “Action” means any threatened, pending, or completed action, suit, or proceeding, whether civil, criminal, administrative, arbitrative, or investigative.
 
(b) The Company may not indemnify the Executive under this Section 4 unless a determination has been made in the specific case that indemnification of the Executive is permissible under the circumstances and under the law of the State of Utah. Such determination shall be made (a) by the President, (b) by the majority vote of the Board, or
(c) by special legal counsel selected by the President.
 
(c) Expenses, including attorney’s fees, or some part of such expenses, incurred by the Executive in defending any Action shall be paid by the Company in advance of the final disposition of such Action upon the receipt of written undertaking by or on behalf of the Executive to repay the amount advanced if it ultimately is determined that the Executive is not entitled to be indemnified by the Company as authorized under applicable law or the provisions of this Section 4.
 
(d) By action of the President or by majority vote of the Board, notwithstanding any interest of the Company or any individual member of the Board in such Action, the Company may purchase and maintain insurance in such amounts as the President or the majority vote of the Board may deem appropriate on behalf of the Executive against any liability asserted against the Executive and incurred by the Executive, whether or not the Company would have the power to indemnify the Executive against such liability under applicable provisions of law.
 
(e) The Company shall have the right to impose, as conditions to any indemnification provided by the Company, such reasonable requirements and conditions as may appear appropriate to the President of the Company in each specific case and circumstance, including but not limited to any one or more of the following: (a) that any counsel representing the Executive in connection with the defense or settlement of any Action shall be counsel mutually agreeable to the Executive and the Company, (b) that the Company shall have the right, at the Company’s option, to assume and control the defense or settlement of any Action made, initiated, or threatened against the Executive, and (c) that the Company shall be subrogated, to the extent of any payments made by way of indemnification, to all of the Executive’s right of recovery and that the Executive shall execute all writings and do everything necessary to assure such rights of subrogation to the Company.
 
4.9 Claw Back Provisions. Notwithstanding any other provision in this Agreement to the contrary, any incentive-based compensation, or any other compensation other than the Base Salary, paid to the Executive pursuant to this Agreement or any other Agreement or arrangement with the Company which is subject to recovery under any law, government regulation, or stock exchange listing requirement will be subject to such deductions and claw back as may be required to be made pursuant to such law, government regulation, or stock exchange listing requirement (or any policy adopted by the Company as required pursuant to such law, government regulation, or stock exchange listing requirement).
 
5. Termination and Termination Payments and Rights.
 
5.1 Termination Upon Death. If the Executive dies during the Term of his employment with the Company, this Agreement shall terminate as of the date of his death. On termination upon the Executive’s death, the Executive’s estate shall be entitled to be paid that portion of the Executive’s Base Salary that would otherwise have been payable to the Executive through and including the final day of the month in which the Executive’s death occurs, together with all benefits due to the Executive under the Employee Benefit Plans through and including such date to the extent allowed by law and the terms, conditions, and limitations of the applicable plan documents.
 
5.2 Termination By the Company for Cause. The Company may, at any time, by written notice to the Executive terminate the Executive’s employment under this Agreement immediately for Cause, as defined below, and the Executive shall have no right to receive any compensation or benefit hereunder on or after the date of such notice.
 
For purposes of this Agreement, "Cause" means (i) a violation of the Employer’s illegal drug policy and/or a material violation of the Employer’s alcohol abuse policy; (ii) a material violation of the Employer’s policy against unlawful harassment or discrimination; (iii) the Executive’s material breach of this Agreement, including without limitation a material failure to perform or an habitual neglect of his job duties, as set forth in this Agreement, to the satisfaction of the Company or a material failure to follow the Company’s material policies and procedures; (iv) insubordination or other willful refusal to comply with any lawful request of the Company, including without limitation failure to cooperate in any investigation conducted and/or undertaken by the Company that has reasonable and legitimate objectives; (v) violation of any confidentiality, non-competition, non-solicitation, employee invention, or similar agreement that the Company may require the Executive to sign as a condition of his employment or continued employment with the Company except as required in performing the Executive’s job duties and responsibilities; (vi) material breach of fiduciary duty; (vii) conduct that reasonably could discredit the goodwill, good name, or reputation of the Employer; (viii) fraud, misappropriation of any money, assets, or other property of the Employer, or other act of material dishonesty; (ix) material misfeasance, malfeasance, or nonfeasance in the performance of the Executive’s duties for the Employer; or (x) the Executive is convicted of a felony or other serious crime or is convicted of a misdemeanor involving moral turpitude or a crime of dishonesty by any governmental authority or the Executive is charged with a felony and pleads guilty or nolo contendre to a reduced charge.
 
 
 
 
 
Prior to the Company’s termination of the Executive’s employment pursuant to any of the provisions of Section 5.2(i) (as it relates to alcohol only), (iii), (iv), (vii), or (ix) (hereinafter, the “Prior Notice Cause/s”), the Company shall give the Executive written notice of the “Cause” event and shall give the Executive thirty (30) days, or such greater period of time as determined reasonable by the Company, in its sole business judgment, in which to cure the breach or event giving the Company the right to terminate this Agreement or to provide information and documentation, in writing, which, in the reasonable business judgment of the Company, demonstrates that the Executive has not engaged in conduct that constitutes Cause under the Prior Notice Cause/s (the “Cure Period”). If the Executive shall correct or cure the event giving rise to the Company’s right to terminate for Cause under the provisions of the Prior Notice Cause/s within such Cure Period, then this Agreement shall not be terminated as a result of such event. The Company shall only be obligated to give the Executive one right to cure period for any similar type or kind of conduct that gives rise to a right to cure under any of the Prior Notice Cause/s during the Term of this Agreement. If a second event of a similar type or kind of conduct shall occur during the Term that gives the Company a right to terminate for cause under any Prior Notice Cause/s, the Company may immediately terminate the Executive without any additional notice or right to cure. The Company is not obligated to give any advance notice or right to cure period for any termination under the provisions of Section 5.2(i) (as it relates to violation of the Employer’s illegal drug policy), (ii), (v), (vi), (viii), or (x).
 
5.3 Termination Without Cause.
 
(a) The Company may terminate the Executive’s employment under this Agreement without Cause by giving thirty (30) days written notice to the Executive. In such event, and subject to the Executive’s signing, without revocation, of a separation agreement and release of all claims in a form acceptable to the Company (the “Release”), the Executive shall have the right to receive an amount equal to his Base Salary for a period of six (6) months (such amount, the “Separation Payment”), payable in accordance with the terms of the Release, in addition to all portions of the Executive’s Base Salary due as of the effective date of such termination of employment.
 
(b) If the Executive properly elects continuation coverage under the Company’s group medical insurance plan pursuant to Sections 601 through 607 of the Employee Retirement Income Security Act of 1974, as amended (“COBRA”), the Company will pay that portion of the premium which the Company paid on behalf of the Executive and his enrolled family members immediately prior to the termination of Executive’s employment through the earlier of (a) six (6) months from the Executive’s termination date; (b) the date Executive first becomes eligible for coverage under any group health plan maintained by another employer of Executive or his spouse, if any; or (c) the date such COBRA continuation coverage otherwise terminates as to Executive under the provisions of the Company’s group medical insurance plan (the “COBRA Period”); provided that such Company-subsidized COBRA continuation coverage does not violate federal non-discrimination laws or rules applicable to the Company’s group health plans in a manner that adversely affects the Company. Nothing herein shall be deemed to extend the otherwise applicable maximum period in which COBRA continuation coverage is provided or supersede the plan provisions relating to early termination of such COBRA continuation coverage. The Executive agrees that he is responsible to pay that portion of the premium for such coverage as the Executive would be required to pay had he remained an active employee of the Company during such COBRA Period.
 
5.4 Termination by the Executive With Good Reason.
 
(a) The Executive may at any time and upon thirty (30) days written notice to the Company with Good Reason terminate his employment under this Agreement, in which case the Executive will have the right to receive the Separation Payment, subject to his execution and delivery to the Company of the Release and payable in accordance with the terms of the Release; provided, however, that such notice must be given within ninety (90) days of the date of the occurrence of an event or circumstance giving rise to Good Reason.
 
 
 
 
 
(b) For purposes of this Agreement “Good Reason” shall mean one of the reasons set forth below which remains uncured for a period of fifteen (15) days following receipt of notice thereof from the Executive to the Company:
 
(i) A demotion by the Company or its successor from the Executive’s position as VP of North America Sales or a material diminution in the Executive’s job duties and responsibilities;
 
(ii) A reduction by the Company or its successor of the Executive’s Base Salary except as allowed under Section 4.1 of this Agreement;
 
(iii) The Company’s requirement, without his consent, that the Employee primarily perform the duties of his employment at the Company’s principal executive offices, which currently are located at 2188 West 2200 South, Salt Lake City, Utah.
 
5.5 Termination by the Employee Without Good Reason. The Executive may terminate his employment under this Agreement without Good Reason upon thirty (30) days prior written notice to the Company, and upon the effective date of such termination the Executive will be entitled to receive only that portion of his Base Salary which is due and owing upon such effective date of termination.
 
5.6 Termination by the Executive Following a Change of Control.
 
(a) If a "Change Control" (as herein defined) occurs during the Term, and if during the six (6) month period immediately following the effective date of such Change in Control (i) the Company terminates the employment of the Executive hereunder without Cause or (ii) the Executive terminates his employment hereunder with Good Reason, then, in addition to the Separation Payment, all options or other equity-based incentive awards granted to the Executive by the Company shall immediately vest and become fully exercisable on the effective date of such termination, notwithstanding any provision of this Agreement or of any Employee Benefit Plans pursuant to which such options or awards were granted.
 
(b) For purposes of this Agreement, the term "Change in Control" shall mean the occurrence of any of the following:
 
(i) One person (or more than one person acting as a group) acquires ownership of stock of the Company that, together with the stock held by such person or group prior to such acquisition, constitutes more than fifty-percent (50%) of the total voting power of all of the issued and outstanding stock of the Company; or
 
(ii) A majority of the members of the Board are replaced during any twelve-month period by directors whose appointment or election is not endorsed by 2/3 of the members of the Board as constituted before the date of such appointment or election; or
 
(iii) The sale of all or substantially of the Company's assets.
 
5.7 Mitigation. In no event shall the Executive be obligated to seek other employment or take any other action by way of mitigation of the amounts payable to the Executive under any of the provisions of this Agreement and any amounts payable to the Executive pursuant to this Section 5 shall not be reduced by any compensation earned by the Executive on account of employment with another employer following the termination of his employment hereunder.
 
6. Section 280G.
 
(a) If any of the payments or benefits received or to be received by the Executive (including, without limitation, any payment or benefits received in connection with a Change in Control or the termination of the Executive’s employment, whether pursuant to the terms of this Agreement or any other plan, arrangement, or agreement or otherwise) (all such payments collectively referred to herein as the "280G Payments") constitute "excess parachute payments" within the meaning of Section 280G of the Internal Revenue Code of 1986, as amended (the "Code") and will be non-deductible under Section 280G of the Code, the amounts otherwise payable to the Executive in connection with the termination of his employment shall be reduced to the maximum amount of such payments that can be made without resulting in any “excess parachute payments” under Code Section 280G.
 
 
 
 
 
(b) All calculations and determinations under this Section 6 shall be made by an independent accounting firm or independent tax counsel appointed by the Company (the "Tax Counsel") whose determination shall be conclusive and binding on the Company and the Executive for all purposes. For purposes of making the calculations and determinations required by this Section 6(b), the Tax Counsel may rely on reasonable, good faith assumptions and approximations concerning the applicability of Section 280G of the Code. The Company and the Executive shall furnish the Tax Counsel with such information and documents as the Tax Counsel may reasonably request in order to make its determinations under this Section 6(b). The Company shall bear all costs of the Tax Counsel reasonably incurred in connection with the performance of its duties under this Section 6(b).
 
7. No Deferrals; Code Section 409A.
 
(a) It is intended that the provisions of the Agreement comply with Section 409A of the Code and the regulations promulgated thereunder (“Section 409A”), and all provisions of this Agreement shall be construed and interpreted in a manner consistent with the requirements for avoiding taxes or penalties under Section 409A.
 
(b) Neither Executive nor any of his creditors or beneficiaries shall have the right to subject any deferred compensation (within the meaning of Section 409A) payable under this Agreement or under any other plan, policy, arrangement, or agreement of or with the Company or any of its affiliates (the Agreement and such other plans, policies, arrangements, and agreements, the “Company Plans”) to any anticipation, alienation, sale, transfer, assignment, pledge, encumbrance, attachment, or garnishment. Except as permitted under Section 409A, any deferred compensation (within the meaning of Section 409A) payable to Executive or for Executive’s benefit under any Company Plan may not be reduced by, or offset against, any amount owing by Executive to the Company or any of its affiliates.
 
(c) If, at the time of Executive’s separation from service (within the meaning of Section 409A), (i) Executive is a “specified employee” (within the meaning of Section 409A and using the identification methodology selected by the Company from time to time) and (ii) the Company shall make a good faith determination that an amount payable under the Company Plans constitutes deferred compensation (within the meaning of Section 409A) the payment of which is required to be delayed pursuant to the six-month delay rule set forth in Section 409A in order to avoid taxes or penalties under Section 409A, then the Company shall not pay such amount on the otherwise scheduled payment date, but shall instead accumulate such amount and pay it, without interest, on the first business day after such six-month period. To the extent required by Section 409A, any payment or benefit that would be considered deferred compensation subject to, and not exempt from, Section 409A, payable or provided upon a termination of Executive’s employment, shall only be paid or provided to Executive upon his separation from service (within the meaning of Section 409A).
 
(d) For purposes of Section 409A, each payment under the Agreement will be deemed to be a separate payment as permitted under Treasury Regulation Section 1.409A-2(b)(2)(iii).
 
(e) Except as specifically permitted by Section 409A or as otherwise specifically set forth in the Agreement, the benefits and reimbursements provided to Executive under the Agreement and any Company Plan during any calendar year shall not affect the benefits and reimbursements to be provided to Executive under the relevant section of the Agreement or any Company Plan in any other calendar year, and the right to such benefits and reimbursements cannot be liquidated or exchanged for any other benefit and shall be provided in accordance with Treas. Reg. Section 1.409A-3(i)(1)(iv) or any successor thereto. Further, in the case of reimbursement payments, reimbursement payments shall be made to Executive as soon as practicable following the date that the applicable expense is incurred, but in no event later than the last day of the calendar year following the calendar year in which the underlying expense is incurred.
 
(f) The Company makes no representations concerning the tax consequences of Executive’s participation in this Agreement under Section 409A of the Code or any other federal, state or local tax law. Executive’s tax consequences shall depend, in part, upon the application of relevant tax law, including Section 409A, to the relevant facts and circumstances.
 
(g) Notwithstanding any provision in this Agreement to the contrary, if the 28-day or 52-day period for making and not revoking the Release described in Sections 5.3 and 5.4 of this Agreement ends in a calendar year commencing after the Executive’s effective date of termination, no separation benefit payable under Section 5.3 or 5.4 shall be payable earlier than the first day of the calendar year following such effective date of termination.
 
8. Taxation of Payments. All payments to be made to the Executive hereunder will be subject to all applicable required withholding of federal, state, local, and foreign taxes, including income and employment taxes. Notwithstanding any provision of this Agreement to the contrary, in no event shall the Company nor its directors, officers, agents, or employees be liable to the Executive or to any taxing authority or agency on account of the Company’s failure to withhold any tax of any kind that may be owed to any federal, state, or local government agency arising from or relating to any compensation paid by the Company to the Executive under this Agreement; provided, however, that the Company shall be liable for the employer’s portion of any payroll withholding taxes related to any compensation paid by the Company to the Executive under this Agreement.
 
 
 
 
 
9. Conflict of Interest. The Executive will not become involved in a situation which reasonably might create or appear to create a conflict of interest, including but not limited to being connected directly or indirectly with any business (as owner, officer, director, manager, participant, licensee, consultant, shareholder, or the recipient of wages) which is involved with any aspect of Executive’s duties hereunder or which is in direct or indirect competition with the Company. The Executive will report immediately any circumstances or situations arising in the future that might involve the Executive or appear to involve the Executive in a conflict of interest, including without limitation the reporting of gifts, entertainment, or any other personal favors given to or received from anyone with whom the Company has or is likely to have any business dealings which go beyond common courtesies usually associated with accepted business practices. The Executive shall fully comply with any code of conduct and/or code of ethics that the Company may adopt from time to time.
 
10. Additional Agreements. As a condition of his employment or continued employment with the Company, the Executive will sign such confidentiality, non-competition, non-solicitation, employee invention, or similar agreement that the Company may, from time to time, require be signed by its executive-level employees generally.
 
11. Miscellaneous.
 
(a) Company Policies. Executive shall comply with the Company’s lawful policies and rules as they may be in effect from time to time.
 
(b) Notices. Any notice or other communication required or which may be given hereunder shall be in writing and shall be delivered personally, or sent by certified, registered, or express mail, postage prepaid, to the Parties at the following addresses, or at such other addresses as shall be specified by the Parties by like notice, and shall be deemed given when so delivered personally or, if mailed, two days after the date of mailing, as follows:
 
If to Company to:
 
Perseon Corporation
2188 West 2200 South
Salt Lake City, Utah 84119
Attn: President and CEO
 
If to the Executive:
 
(c) Entire Agreement. This Agreement contains the entire agreement between the Parties with respect to the subject matter hereof and supersedes all prior contracts and other agreements, written or oral, with respect thereto.
 
(d) Waivers and Amendments. This Agreement may be amended, modified, superseded, cancelled, renewed or extended, and the terms and conditions hereof may be waived, only by a written instrument signed by the Parties or, in the case of a waiver, by the Party waiving compliance.
 
(e) Governing Law. This Agreement shall be governed by, and construed in accordance with and subject to, the laws of the State of Utah without regard to its conflicts of laws principles.
 
(f) Consent to Jurisdiction. The Parties irrevocably submit to the exclusive jurisdiction of any state or federal court in Salt Lake City, Utah, in any action, suit, or proceeding brought by or against such Party in connection with, arising from, or relating to this Agreement, and each Party hereby waives and further agrees not to assert as a defense in any such suit, action, or proceeding any claim that such Party is not personally subject to the jurisdiction of any such courts, that the venue of the suit, action or proceeding is brought in an inconvenient forum, or that this Agreement or the subject matter hereof may not be enforced in or by such courts.
 
 
 
 
 
(g) Assignment. This Agreement, and the Executive’s rights and obligations hereunder, may not be assigned by the Executive. The Company may assign this Agreement and its rights, together with its obligations, hereunder only in connection with any sale, transfer, or other disposition of all or substantially all of its assets or business, whether by merger, consolidation or otherwise. This Agreement will be binding upon the Company’s successors and assigns which shall be required to perform this Agreement in the same manner and to the same extent that Company would be required to perform if no sale, transfer, or other disposition of all or substantially all of its assets or business, whether by merger, consolidation or otherwise, had occurred. This Agreement shall inure to the benefit of and be binding upon the Parties hereto and any successors and permitted assigns.
 
(h) Counterparts; Execution. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original but all of which together shall constitute one and the same instrument. Execution and delivery of this Agreement by facsimile or e-mail is legal, valid, and binding execution and delivery for all purposes.
(i) Headings. The headings in this Agreement are for reference purposes only and shall in no way affect the meaning or interpretation of this Agreement.
 
(j) Survival. Sections 4.8, 4.9, 5, 6, 7, 8, 11, and any other provision of this Agreement which by its terms is intended to survive the termination of this Agreement, and Executive’s rights to the Separation Payment hereunder, shall survive termination of this Agreement.
 
(k) Severability. To the extent any provision of this Agreement shall be invalid or unenforceable, it shall be considered deleted herefrom and the remainder of such provision and of this Agreement shall be unaffected and shall continue in full force and effect.
 
(l) Delays or Omissions. No delay or omission to exercise any right, power, or remedy accruing to either Party upon any breach or default of the other party hereto shall impair any such right, power, or remedy of such non-defaulting party, nor shall it be construed to be a waiver of any such breach or default or an acquiescence therein, or of or in any similar breach or default thereafter occurring; nor shall any waiver of a breach or default be deemed to be a waiver of any other breach or default.
 
(m) Expenses Incurred in Enforcing Rights. If any action at law or in equity or any arbitration proceeding is brought to enforce or interpret the terms of this Agreement, each Party shall bear its own attorney’s fees and costs, including expert fees, incurred therein, whether incurred before or after judgment or arbitration award.
 
IN WITNESS WHEREOF, the Parties have executed this Employment Agreement as of the Effective Date, as herein first written.
 
The Company:
 
PERSEON CORPORATION

By: /s/ Clinton E. Carnell, Jr.
Its: Chief Executive Officer


The Executive:

/s/ Benjamin C. Beckham
Benjamin C. Beckham
 
 
 
 
 EX-10.19 3 perseonexh1019.htm EMPLOYMENT AGREEMENT WITH EFFECTIVE DATE FEBRUARY 16, 2015 BETWEEN THE COMPANY AND TODD H. TURNLUND. perseonexh1019.htm
Exhibit 10.19
EXECUTIVE EMPLOYMENT AGREEMENT
 
THIS EXECUTIVE EMPLOYMENT AGREEMENT (the “Agreement”) is made and entered into effective as of February 17, 2015 (the “Effective Date”), by and between Perseon Corporation, a Delaware corporation (“the “Company”) and Jen Hoglin, an individual (the “Executive”). The Company and the Executive are referred to herein collectively as the “Parties” and may be referred to herein individually as a “Party”.
 
BACKGROUND
 
The Company made an offer of employment to the Executive pursuant to a written offer of employment. The Executive accepted the offer of employment. The written offer of employment contemplated that the Parties would enter into an employment agreement, which employment agreement shall be subject to the approval of the Company’s Board of Directors.
 
AGREEMENT
 
NOW THEREFORE, in consideration of the premises, the agreements, and the mutual covenants contained herein and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties agree as follows:
 
12. Term. The Executive’s employment hereunder shall continue from and after the Effective Date until terminated in accordance with the applicable provisions of this Agreement (the “Term”).
 
13. Position and Responsibilities. The Company currently employs and shall continue to employ the Executive as the Vice President of Marketing or such other position as the Parties may agree from time to time. The Executive shall report to the President and Chief Executive Office of the Company (hereinafter, the “President”) or his designee. The Executive will devote substantially all of her skill, knowledge, and working time to the conscientious performance of such duties except for reasonable vacation time, absence for sickness or similar disability, and authorized leaves of absence. To the extent that it does not significantly interfere with the performance of the Executive's duties hereunder, it shall not be a violation of this Agreement for the Executive to (i) serve on corporate, civic, or charitable boards or committees; provided, however, that the Executive shall obtain the written permission of the President prior to rendering such service, (ii) deliver lectures or fulfill speaking engagements, or (iii) manage personal investments. The Executive represents that she is entering into this Agreement voluntarily and that, to the best of her knowledge, her employment hereunder and compliance by her with the terms and conditions of this Agreement will not conflict with or result in the breach of any agreement to which she is a party or by which she may be bound. Any fees or other compensation received by the Executive for services as a director, as a trustee, or in a similar position with another entity shall be retained by the Executive.
 
14. Place of Performance. The principal place of the Executive’s employment shall be the Company’s principal executive offices, currently located at 2188 West 2200 South, Salt Lake City, Utah; provided that the Executive may be required to travel on Company business from time to time during the Term, to fulfill her role as Vice President of Marketing or such other position as she may hold with the Company from time to time.
 
15. Compensation.
 
15.1 Base Salary. The Company shall pay the Executive an annual base salary at the rate of two hundred twenty thousand and no/100 dollars ($220,000.00) (the “Base Salary”), which Base Salary shall be paid to the Executive in periodic installments in accordance with the Company’s customary payroll practices, as modified from time to time, but no less frequently than monthly. During the Term, beginning in February 16, 2016, the Company will review the Executive's Base Salary annually and, in the discretion of the President, in consultation with the Company’s Board of Directors (hereinafter, the “Board” or “Board of Directors”), may modify such Base Salary from time to time based on the performance of the Executive, the financial condition of the Company, prevailing industry salary scales, and such other factors as the Company's President shall consider relevant; provided, that the Company may not decrease Executive’s Base Salary by more than 10%, calculated based on the Base Salary in effect just prior to any such decrease, and then only by the unanimous vote of the Board after a finding by the Board that such reduction is reasonably necessary to address either a projected or actual significant financial shortfall in the Company’s financial performance or as otherwise agreed between the Company and the Executive. Any increase or decrease in the Base Salary shall not serve to limit or reduce any other obligation to the Executive under this Agreement.
 
15.2 Award of Common Stock Options or Restricted Stock Units. Executive acknowledges that, on February 17, 2015, the Company awarded her an option to purchase 200,000 shares of the Company’s common stock at an exercise price per share equal to the fair market value per share on the date the option was granted. The option is subject to the terms and conditions applicable to options granted under the Company’s long term equity-based incentive compensation plan and the applicable notice of grant of stock option or agreement thereunder. Subject to the Executive’s continued employment, the options will vest in accordance with the notice of grant of stock option or agreement.
 
If the Company awards restricted stock or restricted stock units to its executive-level employees or to employees generally, then the Executive will be eligible to participate in any such plan, subject to the terms, conditions, limitations, and eligibility requirements set forth in the applicable plan documents. Nothing in this paragraph requires the Company to adopt a plan with respect to the grant of restricted stock or restricted stock units for restricted stock units.
 
15.3 Individual Performance Bonus. The Executive shall be eligible for an annual individual performance bonus, as determined by the President, in his sole discretion, of up to $50,000. In determining the amount of the individual performance bonus, if any, the President shall take into consideration the Executive’s performance, the financial condition of the Company, and such other factors as the President, in his sole discretion, shall deem appropriate. Said individual performance bonus shall be paid to the Executive on or before March 31 of the calendar year immediately following the calendar year to which the individual bonus, if any, relates.
 
15.4 Employee Benefits. During the Term, the Executive shall be entitled to participate in all employee benefit plans, practices, and programs maintained by the Company for its employees, as in effect from time to time (collectively the “Employee Benefit Plans”), subject to the terms, conditions, and limitations and eligibility requirements of any applicable plan documents. The Company reserves the right to amend or terminate any Employee Benefit Plan(s) so as to eliminate, reduce, or otherwise change any benefit payable thereunder, so long as such change complies with the terms of such Employee Benefit Plan(s), and applicable law, and so long as such change similarly affects all of the Company’s executive level employees.
 
15.5 Vacation or Other Leave of Absence. During the Term, the Executive shall be entitled to such vacation, sick leave, personal time off, or other leave policy as is available under the prevailing policies of the Company, as modified from time to time.
 
15.6 Communication Equipment. During the Term, the Company shall provide the Executive with such communication equipment as the Company deems appropriate, from time to time, for the Executive’s use in performing her duties under this Agreement and shall pay the monthly service costs associated with such communication equipment or, at the Company’s option, the Company shall reimburse the Executive for monthly service costs arising from the Executive’s use of her own personal communication equipment for the performance of her duties under this Agreement, as determined by the President.
 
15.7 Business Expenses. The Executive shall be entitled to reimbursement for all reasonable and necessary out-of-pocket business, entertainment, and travel expenses incurred by the Executive in connection with the performance of the Executive’s duties hereunder in accordance with the Company’s expense reimbursement policies and procedures in effect from time to time.
 
15.8 Indemnification. To the maximum extent permitted by law, and in the manner required by the laws of the State of Utah, the Company shall indemnify the Executive against any and all applicable claims, judgments, fines, amounts paid in settlement, and other costs actually and reasonably incurred in any Action, as defined in Section 4.8(a) below, giving rise to the Executive’s claim for indemnification; provided, however, that nothing contained herein shall require the Company to indemnify the Executive from and against Actions initiated by the Executive or the Company related to any contest or dispute between the Executive and the Company with respect to this Agreement or the Executive’s employment hereunder or arising from the Executive’s willful misconduct or gross negligence or the Executive’s violation of the Company’s policies against unlawful harassment and discrimination, as modified from time to time.
 
(a) For purposes of this Section 4, “Action” means any threatened, pending, or completed action, suit, or proceeding, whether civil, criminal, administrative, arbitrative, or investigative.
 
(b) The Company may not indemnify the Executive under this Section 4 unless a determination has been made in the specific case that indemnification of the Executive is permissible under the circumstances and under the law of the State of Utah. Such determination shall be made (a) by the President, (b) by the majority vote of the Board, or (c) by special legal counsel selected by the President.
 
(c) Expenses, including attorney’s fees, or some part of such expenses, incurred by the Executive in defending any Action shall be paid by the Company in advance of the final disposition of such Action upon the receipt of written undertaking by or on behalf of the Executive to repay the amount advanced if it ultimately is determined that the Executive is not entitled to be indemnified by the Company as authorized under applicable law or the provisions of this Section 4.
 
(d) By action of the President or by majority vote of the Board, notwithstanding any interest of the Company or any individual member of the Board in such Action, the Company may purchase and maintain insurance in such amounts as the President or the majority vote of the Board may deem appropriate on behalf of the Executive against any liability asserted against the Executive and incurred by the Executive, whether or not the Company would have the power to indemnify the Executive against such liability under applicable provisions of law.
 
(e) The Company shall have the right to impose, as conditions to any indemnification provided by the Company, such reasonable requirements and conditions as may appear appropriate to the President of the Company in each specific case and circumstance, including but not limited to any one or more of the following: (a) that any counsel representing the Executive in connection with the defense or settlement of any Action shall be counsel mutually agreeable to the Executive and the Company, (b) that the Company shall have the right, at the Company’s option, to assume and control the defense or settlement of any Action made, initiated, or threatened against the Executive, and (c) that the Company shall be subrogated, to the extent of any payments made by way of indemnification, to all of the Executive’s right of recovery and that the Executive shall execute all writings and do everything necessary to assure such rights of subrogation to the Company.
 
15.9 Claw Back Provisions. Notwithstanding any other provision in this Agreement to the contrary, any incentive-based compensation, or any other compensation other than the Base Salary, paid to the Executive pursuant to this Agreement or any other Agreement or arrangement with the Company which is subject to recovery under any law, government regulation, or stock exchange listing requirement will be subject to such deductions and claw back as may be required to be made pursuant to such law, government regulation, or stock exchange listing requirement (or any policy adopted by the Company as required pursuant to such law, government regulation, or stock exchange listing requirement).
 
16. Termination and Termination Payments and Rights.
 
16.1 Termination Upon Death. If the Executive dies during the Term of her employment with the Company, this Agreement shall terminate as of the date of her death. On termination upon the Executive’s death, the Executive’s estate shall be entitled to be paid that portion of the Executive’s Base Salary that would otherwise have been payable to the Executive through and including the final day of the month in which the Executive’s death occurs, together with all benefits due to the Executive under the Employee Benefit Plans through and including such date to the extent allowed by law and the terms, conditions, and limitations of the applicable plan documents.
 
16.2 Termination By the Company for Cause. The Company may, at any time, by written notice to the Executive terminate the Executive’s employment under this Agreement immediately for Cause, as defined below, and the Executive shall have no right to receive any compensation or benefit hereunder on or after the date of such notice.
 
For purposes of this Agreement, "Cause" means (i) a violation of the Employer’s illegal drug policy and/or a material violation of the Employer’s alcohol abuse policy; (ii) a material violation of the Employer’s policy against unlawful harassment or discrimination; (iii) the Executive’s material breach of this Agreement, including without limitation a material failure to perform or an habitual neglect of her job duties, as set forth in this Agreement, to the satisfaction of the Company or a material failure to follow the Company’s material policies and procedures; (iv) insubordination or other willful refusal to comply with any lawful request of the Company, including without limitation failure to cooperate in any investigation conducted and/or undertaken by the Company that has reasonable and legitimate objectives; (v) violation of any confidentiality, non-competition, non-solicitation, employee invention, or similar agreement that the Company may require the Executive to sign as a condition of her employment or continued employment with the Company except as required in performing the Executive’s job duties and responsibilities; (vi) material breach of fiduciary duty; (vii) conduct that reasonably could discredit the goodwill, good name, or reputation of the Employer; (viii) fraud, misappropriation of any money, assets, or other property of the Employer, or other act of material dishonesty; (ix) material misfeasance, malfeasance, or nonfeasance in the performance of the Executive’s duties for the Employer; or (x) the Executive is convicted of a felony or other serious crime or is convicted of a misdemeanor involving moral turpitude or a crime of dishonesty by any governmental authority or the Executive is charged with a felony and pleads guilty or nolo contendre to a reduced charge.
 
Prior to the Company’s termination of the Executive’s employment pursuant to any of the provisions of Section 5.2(i) (as it relates to alcohol only), (iii), (iv), (vii), or (ix) (hereinafter, the “Prior Notice Cause/s”), the Company shall give the Executive written notice of the “Cause” event and shall give the Executive thirty (30) days, or such greater period of time as determined reasonable by the Company, in its sole business judgment, in which to cure the breach or event giving the Company the right to terminate this Agreement or to provide information and documentation, in writing, which, in the reasonable business judgment of the Company, demonstrates that the Executive has not engaged in conduct that constitutes Cause under the Prior Notice Cause/s (the “Cure Period”). If the Executive shall correct or cure the event giving rise to the Company’s right to terminate for Cause under the provisions of the Prior Notice Cause/s within such Cure Period, then this Agreement shall not be terminated as a result of such event. The Company shall only be obligated to give the Executive one right to cure period for any similar type or kind of conduct that gives rise to a right to cure under any of the Prior Notice Cause/s during the Term of this Agreement. If a second event of a similar type or kind of conduct shall occur during the Term that gives the Company a right to terminate for cause under any Prior Notice Cause/s, the Company may immediately terminate the Executive without any additional notice or right to cure. The Company is not obligated to give any advance notice or right to cure period for any termination under the provisions of Section 5.2(i) (as it relates to violation of the Employer’s illegal drug policy), (ii), (v), (vi), (viii), or (x).
 
16.3 Termination Without Cause.
 
(a) The Company may terminate the Executive’s employment under this Agreement without Cause by giving thirty (30) days written notice to the Executive. In such event, and subject to the Executive’s signing, without revocation, of a separation agreement and release of all claims in a form acceptable to the Company (the “Release”), the Executive shall have the right to receive an amount equal to her Base Salary for a period of six (6) months (such amount, the “Separation Payment”), payable in accordance with the terms of the Release, in addition to all portions of the Executive’s Base Salary due as of the effective date of such termination of employment.
 
(b) If the Executive properly elects continuation coverage under the Company’s group medical insurance plan pursuant to Sections 601 through 607 of the Employee Retirement Income Security Act of 1974, as amended (“COBRA”), the Company will pay that portion of the premium which the Company paid on behalf of the Executive and her enrolled family members immediately prior to the termination of Executive’s employment through the earlier of (a) six (6) months from the Executive’s termination date; (b) the date Executive first becomes eligible for coverage under any group health plan maintained by another employer of Executive or her spouse, if any; or (c) the date such COBRA continuation coverage otherwise terminates as to Executive under the provisions of the Company’s group medical insurance plan (the “COBRA Period”); provided that such Company-subsidized COBRA continuation coverage does not violate federal non-discrimination laws or rules applicable to the Company’s group health plans in a manner that adversely affects the Company. Nothing herein shall be deemed to extend the otherwise applicable maximum period in which COBRA continuation coverage is provided or supersede the plan provisions relating to early termination of such COBRA continuation coverage. The Executive agrees that she is responsible to pay that portion of the premium for such coverage as the Executive would be required to pay had she remained an active employee of the Company during such COBRA Period.

16.4 Termination by the Executive With Good Reason.
 
(a) The Executive may at any time and upon thirty (30) days written notice to the Company with Good Reason terminate her employment under this Agreement, in which case the Executive will have the right to receive the Separation Payment, subject to her execution and delivery to the Company of the Release and payable in accordance with the terms of the Release; provided, however, that such notice must be given within ninety (90) days of the date of the occurrence of an event or circumstance giving rise to Good Reason.
 
(b) For purposes of this Agreement “Good Reason” shall mean one of the reasons set forth below which remains uncured for a period of fifteen (15) days following receipt of notice thereof from the Executive to the Company:
 
(i) A demotion by the Company or its successor from the Executive’s position as VP of Marketing or a material diminution in the Executive’s job duties and responsibilities;
 
(ii) A reduction by the Company or its successor of the Executive’s Base Salary except as allowed under Section 4.1 of this Agreement;
 
(iii) The Company’s requirement that the Employee perform the duties of her employment at a principal location that is more than fifty (50) miles from the Company’s present principal executive offices, which are located at 2188 West 2200 South, Salt Lake City, Utah.
 
16.5 Termination by the Employee Without Good Reason. The Executive may terminate her employment under this Agreement without Good Reason upon thirty (30) days prior written notice to the Company, and upon the effective date of such termination the Executive will be entitled to receive only that portion of her Base Salary which is due and owing upon such effective date of termination.
 
16.6 Termination by the Executive Following a Change of Control.
 
(a) If a "Change Control" (as herein defined) occurs during the Term, and if during the six (6) month period immediately following the effective date of such Change in Control (i) the Company terminates the employment of the Executive hereunder without Cause or (ii) the Executive terminates her employment hereunder with Good Reason, then, in addition to the Separation Payment, all options or other equity-based incentive awards granted to the Executive by the Company shall immediately vest and become fully exercisable on the effective date of such termination, notwithstanding any provision of this Agreement or of any Employee Benefit Plans pursuant to which such options or awards were granted.
 
(b) For purposes of this Agreement, the term "Change in Control" shall mean the occurrence of any of the following:
 
(i) One person (or more than one person acting as a group) acquires ownership of stock of the Company that, together with the stock held by such person or group prior to such acquisition, constitutes more than fifty-percent (50%) of the total voting power of all of the issued and outstanding stock of the Company; or
 
(ii) A majority of the members of the Board are replaced during any twelve-month period by directors whose appointment or election is not endorsed by 2/3 of the members of the Board as constituted before the date of such appointment or election; or
 
(iii) The sale of all or substantially of the Company's assets.
 
16.7 Mitigation. In no event shall the Executive be obligated to seek other employment or take any other action by way of mitigation of the amounts payable to the Executive under any of the provisions of this Agreement and any amounts payable to the Executive pursuant to this Section 5 shall not be reduced by any compensation earned by the Executive on account of employment with another employer following the termination of her employment hereunder.
 
17. Section 280G.
 
(a) If any of the payments or benefits received or to be received by the Executive (including, without limitation, any payment or benefits received in connection with a Change in Control or the termination of the Executive’s employment, whether pursuant to the terms of this Agreement or any other plan, arrangement, or agreement or otherwise) (all such payments collectively referred to herein as the "280G Payments") constitute "excess parachute payments" within the meaning of Section 280G of the Internal Revenue Code of 1986, as amended (the "Code") and will be non-deductible under Section 280G of the Code, the amounts otherwise payable to the Executive in connection with the termination of her employment shall be reduced to the maximum amount of such payments that can be made without resulting in any “excess parachute payments” under Code Section 280G.
 
(b) All calculations and determinations under this Section 6 shall be made by an independent accounting firm or independent tax counsel appointed by the Company (the "Tax Counsel") whose determination shall be conclusive and binding on the Company and the Executive for all purposes. For purposes of making the calculations and determinations required by this Section 6(b), the Tax Counsel may rely on reasonable, good faith assumptions and approximations concerning the applicability of Section 280G of the Code. The Company and the Executive shall furnish the Tax Counsel with such information and documents as the Tax Counsel may reasonably request in order to make its determinations under this Section 6(b). The Company shall bear all costs of the Tax Counsel reasonably incurred in connection with the performance of its duties under this Section 6(b).
 
18. No Deferrals; Code Section 409A.
 
(a) It is intended that the provisions of the Agreement comply with Section 409A of the Code and the regulations promulgated thereunder (“Section 409A”), and all provisions of this Agreement shall be construed and interpreted in a manner consistent with the requirements for avoiding taxes or penalties under Section 409A.
 
(h) Neither Executive nor any of her creditors or beneficiaries shall have the right to subject any deferred compensation (within the meaning of Section 409A) payable under this Agreement or under any other plan, policy, arrangement, or agreement of or with the Company or any of its affiliates (the Agreement and such other plans, policies, arrangements, and agreements, the “Company Plans”) to any anticipation, alienation, sale, transfer, assignment, pledge, encumbrance, attachment, or garnishment. Except as permitted under Section 409A, any deferred compensation (within the meaning of Section 409A) payable to Executive or for Executive’s benefit under any Company Plan may not be reduced by, or offset against, any amount owing by Executive to the Company or any of its affiliates.
 
(i) If, at the time of Executive’s separation from service (within the meaning of Section 409A), (i) Executive is a “specified employee” (within the meaning of Section 409A and using the identification methodology selected by the Company from time to time) and (ii) the Company shall make a good faith determination that an amount payable under the Company Plans constitutes deferred compensation (within the meaning of Section 409A) the payment of which is required to be delayed pursuant to the six-month delay rule set forth in Section 409A in order to avoid taxes or penalties under Section 409A, then the Company shall not pay such amount on the otherwise scheduled payment date, but shall instead accumulate such amount and pay it, without interest, on the first business day after such six-month period. To the extent required by Section 409A, any payment or benefit that would be considered deferred compensation subject to, and not exempt from, Section 409A, payable or provided upon a termination of Executive’s employment, shall only be paid or provided to Executive upon her separation from service (within the meaning of Section 409A).
 
(j) For purposes of Section 409A, each payment under the Agreement will be deemed to be a separate payment as permitted under Treasury Regulation Section 1.409A-2(b)(2)(iii).
 
(k) Except as specifically permitted by Section 409A or as otherwise specifically set forth in the Agreement, the benefits and reimbursements provided to Executive under the Agreement and any Company Plan during any calendar year shall not affect the benefits and reimbursements to be provided to Executive under the relevant section of the Agreement or any Company Plan in any other calendar year, and the right to such benefits and reimbursements cannot be liquidated or exchanged for any other benefit and shall be provided in accordance with Treas. Reg. Section 1.409A-3(i)(1)(iv) or any successor thereto. Further, in the case of reimbursement payments, reimbursement payments shall be made to Executive as soon as practicable following the date that the applicable expense is incurred, but in no event later than the last day of the calendar year following the calendar year in which the underlying expense is incurred.
 
(l) The Company makes no representations concerning the tax consequences of Executive’s participation in this Agreement under Section 409A of the Code or any other federal, state or local tax law. Executive’s tax consequences shall depend, in part, upon the application of relevant tax law, including Section 409A, to the relevant facts and circumstances.
 
(m) Notwithstanding any provision in this Agreement to the contrary, if the 28-day or 52-day period for making and not revoking the Release described in Sections 5.3 and 5.4 of this Agreement ends in a calendar year commencing after the Executive’s effective date of termination, no separation benefit payable under Section 5.3 or 5.4 shall be payable earlier than the first day of the calendar year following such effective date of termination.
 
19. Taxation of Payments. All payments to be made to the Executive hereunder will be subject to all applicable required withholding of federal, state, local, and foreign taxes, including income and employment taxes. Notwithstanding any provision of this Agreement to the contrary, in no event shall the Company nor its directors, officers, agents, or employees be liable to the Executive or to any taxing authority or agency on account of the Company’s failure to withhold any tax of any kind that may be owed to any federal, state, or local government agency arising from or relating to any compensation paid by the Company to the Executive under this Agreement; provided, however, that the Company shall be liable for the employer’s portion of any payroll withholding taxes related to any compensation paid by the Company to the Executive under this Agreement.
 
20. Conflict of Interest. The Executive will not become involved in a situation which reasonably might create or appear to create a conflict of interest, including but not limited to being connected directly or indirectly with any business (as owner, officer, director, manager, participant, licensee, consultant, shareholder, or the recipient of wages) which is involved with any aspect of Executive’s duties hereunder or which is in direct or indirect competition with the Company. The Executive will report immediately any circumstances or situations arising in the future that might involve the Executive or appear to involve the Executive in a conflict of interest, including without limitation the reporting of gifts, entertainment, or any other personal favors given to or received from anyone with whom the Company has or is likely to have any business dealings which go beyond common courtesies usually associated with accepted business practices. The Executive shall fully comply with any code of conduct and/or code of ethics that the Company may adopt from time to time.
 
21. Additional Agreements. As a condition of her employment or continued employment with the Company, the Executive will sign such confidentiality, non-competition, non-solicitation, employee invention, or similar agreement that the Company may, from time to time, require be signed by its executive-level employees generally.
 
22. Miscellaneous.
 
(a) Company Policies. Executive shall comply with the Company’s lawful policies and rules as they may be in effect from time to time.
 
(b) Notices. Any notice or other communication required or which may be given hereunder shall be in writing and shall be delivered personally, or sent by certified, registered, or express mail, postage prepaid, to the Parties at the following addresses, or at such other addresses as shall be specified by the Parties by like notice, and shall be deemed given when so delivered personally or, if mailed, two days after the date of mailing, as follows:
 
If to Company to:
 
Perseon Corporation
2188 West 2200 South
Salt Lake City, Utah 84119
Attn: President and CEO
 
If to the Executive:
 
 
(c) Entire Agreement. This Agreement contains the entire agreement between the Parties with respect to the subject matter hereof and supersedes all prior contracts and other agreements, written or oral, with respect thereto.
 
(d) Waivers and Amendments. This Agreement may be amended, modified, superseded, cancelled, renewed or extended, and the terms and conditions hereof may be waived, only by a written instrument signed by the Parties or, in the case of a waiver, by the Party waiving compliance.
 
(e) Governing Law. This Agreement shall be governed by, and construed in accordance with and subject to, the laws of the State of Utah without regard to its conflicts of laws principles.
 
(f) Consent to Jurisdiction. The Parties irrevocably submit to the exclusive jurisdiction of any state or federal court in Salt Lake City, Utah, in any action, suit, or proceeding brought by or against such Party in connection with, arising from, or relating to this Agreement, and each Party hereby waives and further agrees not to assert as a defense in any such suit, action, or proceeding any claim that such Party is not personally subject to the jurisdiction of any such courts, that the venue of the suit, action or proceeding is brought in an inconvenient forum, or that this Agreement or the subject matter hereof may not be enforced in or by such courts.
 
(g) Assignment. This Agreement, and the Executive’s rights and obligations hereunder, may not be assigned by the Executive. The Company may assign this Agreement and its rights, together with its obligations, hereunder only in connection with any sale, transfer, or other disposition of all or substantially all of its assets or business, whether by merger, consolidation or otherwise. This Agreement will be binding upon the Company’s successors and assigns which shall be required to perform this Agreement in the same manner and to the same extent that Company would be required to perform if no sale, transfer, or other disposition of all or substantially all of its assets or business, whether by merger, consolidation or otherwise, had occurred. This Agreement shall inure to the benefit of and be binding upon the Parties hereto and any successors and permitted assigns.
 
(h) Counterparts; Execution. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original but all of which together shall constitute one and the same instrument. Execution and delivery of this Agreement by facsimile or e-mail is legal, valid, and binding execution and delivery for all purposes.
 
(i) Headings. The headings in this Agreement are for reference purposes only and shall in no way affect the meaning or interpretation of this Agreement.
 
(j) Survival. Sections 4.8, 4.9, 5, 6, 7, 8, 11, and any other provision of this Agreement which by its terms is intended to survive the termination of this Agreement, and Executive’s rights to the Separation Payment hereunder, shall survive termination of this Agreement.
 
(k) Severability. To the extent any provision of this Agreement shall be invalid or unenforceable, it shall be considered deleted herefrom and the remainder of such provision and of this Agreement shall be unaffected and shall continue in full force and effect.
 
(l) Delays or Omissions. No delay or omission to exercise any right, power, or remedy accruing to either Party upon any breach or default of the other party hereto shall impair any such right, power, or remedy of such non-defaulting party, nor shall it be construed to be a waiver of any such breach or default or an acquiescence therein, or of or in any similar breach or default thereafter occurring; nor shall any waiver of a breach or default be deemed to be a waiver of any other breach or default.
 
(m) Expenses Incurred in Enforcing Rights. If any action at law or in equity or any arbitration proceeding is brought to enforce or interpret the terms of this Agreement, each Party shall bear its own attorney’s fees and costs, including expert fees, incurred therein, whether incurred before or after judgment or arbitration award.
 
IN WITNESS WHEREOF, the Parties have executed this Employment Agreement as of the Effective Date, as herein first written.
 
The Company:
 
PERSEON CORPORATION

By: /s/ Clinton E. Carnell, Jr
Its: Chief Executive Officer

The Executive:
/s/ Jen Hoglin
Jen Hoglin
 
 

  EX-10.20 4 perseonexh1020.htm EMPLOYMENT AGREEMENT WITH EFFECTIVE DATE FEBRUARY 17, 2015 BETWEEN THE COMPANY AND JEN HOGLIN. perseonexh1020.htm
Exhibit 10.20
EXECUTIVE EMPLOYMENT AGREEMENT

THIS EXECUTIVE EMPLOYMENT AGREEMENT (the “Agreement”) is made and entered into effective as of February 16, 2015 (the “Effective Date”), by and between Perseon Corporation, a Delaware corporation (“the “Company”) and Todd Turnlund, an individual (the “Executive”). The Company and the Executive are referred to herein collectively as the “Parties” and may be referred to herein individually as a “Party”.
 
BACKGROUND
 
The Company has employed the Executive since January 2010. The Company has offered the Executive the position of Vice President of Research & Development, and the Executive has accepted the offer. The Parties agree to the following terms and conditions of employment, subject to the approval of the Company’s Board of Directors.
 
AGREEMENT
 
NOW THEREFORE, in consideration of the premises, the agreements, and the mutual covenants contained herein and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties agree as follows:
 
23. Term. The Executive’s employment hereunder shall continue from and after the Effective Date until terminated in accordance with the applicable provisions of this Agreement (the “Term”).
 
24. Position and Responsibilities. The Company currently employs and shall continue to employ the Executive as the Vice President of Research & Development or such other position as the Parties may agree from time to time. The Executive shall report to the President and Chief Executive Office of the Company (hereinafter, the “President”) or his designee. The Executive will devote substantially all of his skill, knowledge, and working time to the conscientious performance of such duties except for reasonable vacation time, absence for sickness or similar disability, and authorized leaves of absence. To the extent that it does not significantly interfere with the performance of the Executive's duties hereunder, it shall not be a violation of this Agreement for the Executive to (i) serve on corporate, civic, or charitable boards or committees; provided, however, that the Executive shall obtain the written permission of the President prior to rendering such service, (ii) deliver lectures or fulfill speaking engagements, or (iii) manage personal investments. The Executive represents that he is entering into this Agreement voluntarily and that, to the best of his knowledge, his employment hereunder and compliance by him with the terms and conditions of this Agreement will not conflict with or result in the breach of any agreement to which he is a party or by which he may be bound. Any fees or other compensation received by the Executive for services as a director, as a trustee, or in a similar position with another entity shall be retained by the Executive.
 
25. Place of Performance. The principal place of the Executive’s employment shall be the Company’s principal executive offices, currently located at 2188 West 2200 South, Salt Lake City, Utah; provided that the Executive may be required to travel on Company business from time to time during the Term to fulfill his role as Vice President of Research & Development or such other position as he may hold with the Company from time to time.
 
26. Compensation.
 
26.1 Base Salary. The Company shall pay the Executive an annual base salary at the rate of one hundred ninety four thousand seven hundred forty and 26/100 Dollars ($194,740.26) (the “Base Salary”), which Base Salary shall be paid to the Executive in periodic installments in accordance with the Company’s customary payroll practices, as modified from time to time, but no less frequently than monthly. During the Term, beginning in February 16, 2016, the Company will review the Executive's Base Salary annually and, in the discretion of the President, in consultation with the Company’s Board of Directors (hereinafter, the “Board” or “Board of Directors”), may modify such Base Salary from time to time based on the performance of the Executive, the financial condition of the Company, prevailing industry salary scales, and such other factors as the Company's President shall consider relevant; provided, that the Company may not decrease Executive’s Base Salary by more than 10%, calculated based on the Base Salary in effect just prior to any such decrease, and then only by the unanimous vote of the Board after a finding by the Board that such reduction is reasonably necessary to address either a projected or actual significant financial shortfall in the Company’s financial performance or as otherwise agreed between the Company and the Executive. Any increase or decrease in the Base Salary shall not serve to limit or reduce any other obligation to the Executive under this Agreement.
 
 
 
 
 
26.2 Award of Restricted Stock Units. If the Company awards restricted stock or restricted stock units to its executive-level employees or to employees generally, then the Executive will be eligible to participate in any such plan, subject to the terms, conditions, limitations, and eligibility requirements set forth in the applicable plan documents. Nothing in this paragraph requires the Company to adopt a plan with respect to the grant of restricted stock or restricted stock units for restricted stock units.
 
26.3 Individual Performance Bonus. The Executive shall be eligible for an annual individual performance bonus, as determined by the President, in his sole discretion, of up to $50,000. In determining the amount of the individual performance bonus, if any, the President shall take into consideration the Executive’s performance, the financial condition of the Company, and such other factors as the President, in his sole discretion, shall deem appropriate. Said individual performance bonus shall be paid to the Executive on or before March 31 of the calendar year immediately following the calendar year to which the individual bonus, if any, relates.
 
26.4 Employee Benefits. During the Term, the Executive shall be entitled to participate in all employee benefit plans, practices, and programs maintained by the Company for its employees, as in effect from time to time (collectively the “Employee Benefit Plans”), subject to the terms, conditions, and limitations and eligibility requirements of any applicable plan documents. The Company reserves the right to amend or terminate any Employee Benefit Plan(s) so as to eliminate, reduce, or otherwise change any benefit payable thereunder, so long as such change complies with the terms of such Employee Benefit Plan(s), and applicable law, and so long as such change similarly affects all of the Company’s executive level employees.
 
26.5 Vacation or Other Leave of Absence. During the Term, the Executive shall be entitled to such vacation, sick leave, personal time off, or other leave policy as is available under the prevailing policies of the Company, as modified from time to time.
 
26.6 Communication Equipment. During the Term, the Company shall provide the Executive with such communication equipment as the Company deems appropriate, from time to time, for the Executive’s use in performing his duties under this Agreement and shall pay the monthly service costs associated with such communication equipment or, at the Company’s option, the Company shall reimburse the Executive for monthly service costs arising from the Executive’s use of his own personal communication equipment for the performance of his duties under this Agreement, as determined by the President.
 
26.7 Business Expenses. The Executive shall be entitled to reimbursement for all reasonable and necessary out-of-pocket business, entertainment, and travel expenses incurred by the Executive in connection with the performance of the Executive’s duties hereunder in accordance with the Company’s expense reimbursement policies and procedures in effect from time to time.
 
26.8 Indemnification. To the maximum extent permitted by law, and in the manner required by the laws of the State of Utah, the Company shall indemnify the Executive against any and all applicable claims, judgments, fines, amounts paid in settlement, and other costs actually and reasonably incurred in any Action, as defined in Section 4.8(a) below, giving rise to the Executive’s claim for indemnification; provided, however, that nothing contained herein shall require the Company to indemnify the Executive from and against Actions initiated by the Executive or the Company related to any contest or dispute between the Executive and the Company with respect to this Agreement or the Executive’s employment hereunder or arising from the Executive’s willful misconduct or gross negligence or the Executive’s violation of the Company’s policies against unlawful harassment and discrimination, as modified from time to time.
 
(a) For purposes of this Section 4, “Action” means any threatened, pending, or completed action, suit, or proceeding, whether civil, criminal, administrative, arbitrative, or investigative.
 
(b) The Company may not indemnify the Executive under this Section 4 unless a determination has been made in the specific case that indemnification of the Executive is permissible under the circumstances and under the law of the State of Utah. Such determination shall be made (a) by the President, (b) by the majority vote of the Board, or
 
 
 
 
 
(c) by special legal counsel selected by the President.
 
(c) Expenses, including attorney’s fees, or some part of such expenses, incurred by the Executive in defending any Action shall be paid by the Company in advance of the final disposition of such Action upon the receipt of written undertaking by or on behalf of the Executive to repay the amount advanced if it ultimately is determined that the Executive is not entitled to be indemnified by the Company as authorized under applicable law or the provisions of this Section 4.
 
(d) By action of the President or by majority vote of the Board, notwithstanding any interest of the Company or any individual member of the Board in such Action, the Company may purchase and maintain insurance in such amounts as the President or the majority vote of the Board may deem appropriate on behalf of the Executive against any liability asserted against the Executive and incurred by the Executive, whether or not the Company would have the power to indemnify the Executive against such liability under applicable provisions of law.
 
(e) The Company shall have the right to impose, as conditions to any indemnification provided by the Company, such reasonable requirements and conditions as may appear appropriate to the President of the Company in each specific case and circumstance, including but not limited to any one or more of the following: (a) that any counsel representing the Executive in connection with the defense or settlement of any Action shall be counsel mutually agreeable to the Executive and the Company, (b) that the Company shall have the right, at the Company’s option, to assume and control the defense or settlement of any Action made, initiated, or threatened against the Executive, and (c) that the Company shall be subrogated, to the extent of any payments made by way of indemnification, to all of the Executive’s right of recovery and that the Executive shall execute all writings and do everything necessary to assure such rights of subrogation to the Company.
 
26.9 Claw Back Provisions. Notwithstanding any other provision in this Agreement to the contrary, any incentive-based compensation, or any other compensation other than the Base Salary, paid to the Executive pursuant to this Agreement or any other Agreement or arrangement with the Company which is subject to recovery under any law, government regulation, or stock exchange listing requirement will be subject to such deductions and claw back as may be required to be made pursuant to such law, government regulation, or stock exchange listing requirement (or any policy adopted by the Company as required pursuant to such law, government regulation, or stock exchange listing requirement).
 
27. Termination and Termination Payments and Rights.
 
27.1 Termination Upon Death. If the Executive dies during the Term of his employment with the Company, this Agreement shall terminate as of the date of his death. On termination upon the Executive’s death, the Executive’s estate shall be entitled to be paid that portion of the Executive’s Base Salary that would otherwise have been payable to the Executive through and including the final day of the month in which the Executive’s death occurs, together with all benefits due to the Executive under the Employee Benefit Plans through and including such date to the extent allowed by law and the terms, conditions, and limitations of the applicable plan documents.
 
27.2 Termination By the Company for Cause. The Company may, at any time, by written notice to the Executive terminate the Executive’s employment under this Agreement immediately for Cause, as defined below, and the Executive shall have no right to receive any compensation or benefit hereunder on or after the date of such notice.
 
For purposes of this Agreement, "Cause" means (i) a violation of the Employer’s illegal drug policy and/or a material violation of the Employer’s alcohol abuse policy; (ii) a material violation of the Employer’s policy against unlawful harassment or discrimination; (iii) the Executive’s material breach of this Agreement, including without limitation a material failure to perform or an habitual neglect of his job duties, as set forth in this Agreement, to the satisfaction of the Company or a material failure to follow the Company’s material policies and procedures; (iv) insubordination or other willful refusal to comply with any lawful request of the Company, including without limitation failure to cooperate in any investigation conducted and/or undertaken by the Company that has reasonable and legitimate objectives; (v) violation of any confidentiality, non-competition, non-solicitation, employee invention, or similar agreement that the Company may require the Executive to sign as a condition of his employment or continued employment with the Company except as required in performing the Executive’s job duties and responsibilities; (vi) material breach of fiduciary duty; (vii) conduct that reasonably could discredit the goodwill, good name, or reputation of the Employer; (viii) fraud, misappropriation of any money, assets, or other property of the Employer, or other act of material dishonesty; (ix) material misfeasance, malfeasance, or nonfeasance in the performance of the Executive’s duties for the Employer; or (x) the Executive is convicted of a felony or other serious crime or is convicted of a misdemeanor involving moral turpitude or a crime of dishonesty by any governmental authority or the Executive is charged with a felony and pleads guilty or nolo contendre to a reduced charge.
 
 
 
 
 
Prior to the Company’s termination of the Executive’s employment pursuant to any of the provisions of Section 5.2(i) (as it relates to alcohol only), (iii), (iv), (vii), or (ix) (hereinafter, the “Prior Notice Cause/s”), the Company shall give the Executive written notice of the “Cause” event and shall give the Executive thirty (30) days, or such greater period of time as determined reasonable by the Company, in its sole business judgment, in which to cure the breach or event giving the Company the right to terminate this Agreement or to provide information and documentation, in writing, which, in the reasonable business judgment of the Company, demonstrates that the Executive has not engaged in conduct that constitutes Cause under the Prior Notice Cause/s (the “Cure Period”). If the Executive shall correct or cure the event giving rise to the Company’s right to terminate for Cause under the provisions of the Prior Notice Cause/s within such Cure Period, then this Agreement shall not be terminated as a result of such event. The Company shall only be obligated to give the Executive one right to cure period for any similar type or kind of conduct that gives rise to a right to cure under any of the Prior Notice Cause/s during the Term of this Agreement. If a second event of a similar type or kind of conduct shall occur during the Term that gives the Company a right to terminate for cause under any Prior Notice Cause/s, the Company may immediately terminate the Executive without any additional notice or right to cure. The Company is not obligated to give any advance notice or right to cure period for any termination under the provisions of Section 5.2(i) (as it relates to violation of the Employer’s illegal drug policy), (ii), (v), (vi), (viii), or (x).
 
27.3 Termination Without Cause.
 
(a) The Company may terminate the Executive’s employment under this Agreement without Cause by giving thirty (30) days written notice to the Executive. In such event, and subject to the Executive’s signing, without revocation, of a separation agreement and release of all claims in a form acceptable to the Company (the “Release”), the Executive shall have the right to receive an amount equal to his Base Salary for a period of six (6) months (such amount, the “Separation Payment”), payable in accordance with the terms of the Release, in addition to all portions of the Executive’s Base Salary due as of the effective date of such termination of employment.
 
(b) If the Executive properly elects continuation coverage under the Company’s group medical insurance plan pursuant to Sections 601 through 607 of the Employee Retirement Income Security Act of 1974, as amended (“COBRA”), the Company will pay that portion of the premium which the Company paid on behalf of the Executive and his enrolled family members immediately prior to the termination of Executive’s employment through the earlier of (a) six (6) months from the Executive’s termination date; (b) the date Executive first becomes eligible for coverage under any group health plan maintained by another employer of Executive or his spouse, if any; or (c) the date such COBRA continuation coverage otherwise terminates as to Executive under the provisions of the Company’s group medical insurance plan (the “COBRA Period”); provided that such Company-subsidized COBRA continuation coverage does not violate federal non-discrimination laws or rules applicable to the Company’s group health plans in a manner that adversely affects the Company. Nothing herein shall be deemed to extend the otherwise applicable maximum period in which COBRA continuation coverage is provided or supersede the plan provisions relating to early termination of such COBRA continuation coverage. The Executive agrees that he is responsible to pay that portion of the premium for such coverage as the Executive would be required to pay had he remained an active employee of the Company during such COBRA Period.
 
27.4 Termination by the Executive With Good Reason.
 
(a) The Executive may at any time and upon thirty (30) days written notice to the Company with Good Reason terminate his employment under this Agreement, in which case the Executive will have the right to receive the Separation Payment, subject to his execution and delivery to the Company of the Release and payable in accordance with the terms of the Release; provided, however, that such notice must be given within ninety (90) days of the date of the occurrence of an event or circumstance giving rise to Good Reason.
 
(b) For purposes of this Agreement “Good Reason” shall mean one of the reasons set forth below which remains uncured for a period of fifteen (15) days following receipt of notice thereof from the Executive to the Company:
 
(i) A demotion by the Company or its successor from the Executive’s position as Vice President of Research & Development or a material diminution in the Executive’s job duties and responsibilities;
 
(ii) A reduction by the Company or its successor of the Executive’s Base Salary except as allowed under Section 4.1 of this Agreement;
 
(iii) The Company’s requirement that the Employee perform the duties of his employment at a principal location that is more than fifty (50) miles from the Company’s present principal executive offices, which are located at 2188 West 2200 South, Salt Lake City, Utah.
 
 
 
 
 
27.5 Termination by the Employee Without Good Reason. The Executive may terminate his employment under this Agreement without Good Reason upon thirty (30) days prior written notice to the Company, and upon the effective date of such termination the Executive will be entitled to receive only that portion of his Base Salary which is due and owing upon such effective date of termination.
 
27.6 Termination by the Executive Following a Change of Control.
 
(a) If a "Change Control" (as herein defined) occurs during the Term, and if during the six (6) month period immediately following the effective date of such Change in Control (i) the Company terminates the employment of the Executive hereunder without Cause or (ii) the Executive terminates his employment hereunder with Good Reason, then, in addition to the Separation Payment, all options or other equity-based incentive awards granted to the Executive by the Company shall immediately vest and become fully exercisable on the effective date of such termination, notwithstanding any provision of this Agreement or of any Employee Benefit Plans pursuant to which such options or awards were granted.
 
(b) For purposes of this Agreement, the term "Change in Control" shall mean the occurrence of any of the following:
 
(i) One person (or more than one person acting as a group) acquires ownership of stock of the Company that, together with the stock held by such person or group prior to such acquisition, constitutes more than fifty-percent (50%) of the total voting power of all of the issued and outstanding stock of the Company; or
 
(ii) A majority of the members of the Board are replaced during any twelve-month period by directors whose appointment or election is not endorsed by 2/3 of the members of the Board as constituted before the date of such appointment or election; or
 
(iii) The sale of all or substantially of the Company's assets.
 
27.7 Mitigation. In no event shall the Executive be obligated to seek other employment or take any other action by way of mitigation of the amounts payable to the Executive under any of the provisions of this Agreement and any amounts payable to the Executive pursuant to this Section 5 shall not be reduced by any compensation earned by the Executive on account of employment with another employer following the termination of his employment hereunder.
 
28. Section 280G.
 
(a) If any of the payments or benefits received or to be received by the Executive (including, without limitation, any payment or benefits received in connection with a Change in Control or the termination of the Executive’s employment, whether pursuant to the terms of this Agreement or any other plan, arrangement, or agreement or otherwise) (all such payments collectively referred to herein as the "280G Payments") constitute "excess parachute payments" within the meaning of Section 280G of the Internal Revenue Code of 1986, as amended (the "Code") and will be non-deductible under Section 280G of the Code, the amounts otherwise payable to the Executive in connection with the termination of his employment shall be reduced to the maximum amount of such payments that can be made without resulting in any “excess parachute payments” under Code Section 280G.
 
(b) All calculations and determinations under this Section 6 shall be made by an independent accounting firm or independent tax counsel appointed by the Company (the "Tax Counsel") whose determination shall be conclusive and binding on the Company and the Executive for all purposes. For purposes of making the calculations and determinations required by this Section 6(b), the Tax Counsel may rely on reasonable, good faith assumptions and approximations concerning the applicability of Section 280G of the Code. The Company and the Executive shall furnish the Tax Counsel with such information and documents as the Tax Counsel may reasonably request in order to make its determinations under this Section 6(b). The Company shall bear all costs of the Tax Counsel reasonably incurred in connection with the performance of its duties under this Section 6(b).
 
29. No Deferrals; Code Section 409A.
 
(a) It is intended that the provisions of the Agreement comply with Section 409A of the Code and the regulations promulgated thereunder (“Section 409A”), and all provisions of this Agreement shall be construed and interpreted in a manner consistent with the requirements for avoiding taxes or penalties under Section 409A.
 
 
 
 
 
(n) Neither Executive nor any of his creditors or beneficiaries shall have the right to subject any deferred compensation (within the meaning of Section 409A) payable under this Agreement or under any other plan, policy, arrangement, or agreement of or with the Company or any of its affiliates (the Agreement and such other plans, policies, arrangements, and agreements, the “Company Plans”) to any anticipation, alienation, sale, transfer, assignment, pledge, encumbrance, attachment, or garnishment. Except as permitted under Section 409A, any deferred compensation (within the meaning of Section 409A) payable to Executive or for Executive’s benefit under any Company Plan may not be reduced by, or offset against, any amount owing by Executive to the Company or any of its affiliates.
 
(o) If, at the time of Executive’s separation from service (within the meaning of Section 409A), (i) Executive is a “specified employee” (within the meaning of Section 409A and using the identification methodology selected by the Company from time to time) and (ii) the Company shall make a good faith determination that an amount payable under the Company Plans constitutes deferred compensation (within the meaning of Section 409A) the payment of which is required to be delayed pursuant to the six-month delay rule set forth in Section 409A in order to avoid taxes or penalties under Section 409A, then the Company shall not pay such amount on the otherwise scheduled payment date, but shall instead accumulate such amount and pay it, without interest, on the first business day after such six-month period. To the extent required by Section 409A, any payment or benefit that would be considered deferred compensation subject to, and not exempt from, Section 409A, payable or provided upon a termination of Executive’s employment, shall only be paid or provided to Executive upon his separation from service (within the meaning of Section 409A).
 
(p) For purposes of Section 409A, each payment under the Agreement will be deemed to be a separate payment as permitted under Treasury Regulation Section 1.409A-2(b)(2)(iii).
 
(q) Except as specifically permitted by Section 409A or as otherwise specifically set forth in the Agreement, the benefits and reimbursements provided to Executive under the Agreement and any Company Plan during any calendar year shall not affect the benefits and reimbursements to be provided to Executive under the relevant section of the Agreement or any Company Plan in any other calendar year, and the right to such benefits and reimbursements cannot be liquidated or exchanged for any other benefit and shall be provided in accordance with Treas. Reg. Section 1.409A-3(i)(1)(iv) or any successor thereto. Further, in the case of reimbursement payments, reimbursement payments shall be made to Executive as soon as practicable following the date that the applicable expense is incurred, but in no event later than the last day of the calendar year following the calendar year in which the underlying expense is incurred.
 
(r) The Company makes no representations concerning the tax consequences of Executive’s participation in this Agreement under Section 409A of the Code or any other federal, state or local tax law. Executive’s tax consequences shall depend, in part, upon the application of relevant tax law, including Section 409A, to the relevant facts and circumstances.
 
(s) Notwithstanding any provision in this Agreement to the contrary, if the 28-day or 52-day period for making and not revoking the Release described in Sections 5.3 and 5.4 of this Agreement ends in a calendar year commencing after the Executive’s effective date of termination, no separation benefit payable under Section 5.3 or 5.4 shall be payable earlier than the first day of the calendar year following such effective date of termination.
 
30. Taxation of Payments. All payments to be made to the Executive hereunder will be subject to all applicable required withholding of federal, state, local, and foreign taxes, including income and employment taxes. Notwithstanding any provision of this Agreement to the contrary, in no event shall the Company nor its directors, officers, agents, or employees be liable to the Executive or to any taxing authority or agency on account of the Company’s failure to withhold any tax of any kind that may be owed to any federal, state, or local government agency arising from or relating to any compensation paid by the Company to the Executive under this Agreement; provided, however, that the Company shall be liable for the employer’s portion of any payroll withholding taxes related to any compensation paid by the Company to the Executive under this Agreement.
 
31. Conflict of Interest. The Executive will not become involved in a situation which reasonably might create or appear to create a conflict of interest, including but not limited to being connected directly or indirectly with any business (as owner, officer, director, manager, participant, licensee, consultant, shareholder, or the recipient of wages) which is involved with any aspect of Executive’s duties hereunder or which is in direct or indirect competition with the Company. The Executive will report immediately any circumstances or situations arising in the future that might involve the Executive or appear to involve the Executive in a conflict of interest, including without limitation the reporting of gifts, entertainment, or any other personal favors given to or received from anyone with whom the Company has or is likely to have any business dealings which go beyond common courtesies usually associated with accepted business practices. The Executive shall fully comply with any code of conduct and/or code of ethics that the Company may adopt from time to time.
 
 
 
 
 
32. Additional Agreements. As a condition of his employment or continued employment with the Company, the Executive will sign such confidentiality, non-competition, non-solicitation, employee invention, or similar agreement that the Company may, from time to time, require be signed by its executive-level employees generally.
 
33. Miscellaneous.
 
(a) Company Policies. Executive shall comply with the Company’s lawful policies and rules as they may be in effect from time to time.
 
(b) Notices. Any notice or other communication required or which may be given hereunder shall be in writing and shall be delivered personally, or sent by certified, registered, or express mail, postage prepaid, to the Parties at the following addresses, or at such other addresses as shall be specified by the Parties by like notice, and shall be deemed given when so delivered personally or, if mailed, two days after the date of mailing, as follows:
 
 
 
 
 
If to Company to:            
 
Perseon Corporation
2188 West 2200 South
Salt Lake City, Utah 84119
Attn: President and CEO
 
If to the Executive:
 
(c) Entire Agreement. This Agreement contains the entire agreement between the Parties with respect to the subject matter hereof and supersedes all prior contracts and other agreements, written or oral, with respect thereto.
 
(d) Waivers and Amendments. This Agreement may be amended, modified, superseded, cancelled, renewed or extended, and the terms and conditions hereof may be waived, only by a written instrument signed by the Parties or, in the case of a waiver, by the Party waiving compliance.
 
(e) Governing Law. This Agreement shall be governed by, and construed in accordance with and subject to, the laws of the State of Utah without regard to its conflicts of laws principles.
 
(f) Consent to Jurisdiction. The Parties irrevocably submit to the exclusive jurisdiction of any state or federal court in Salt Lake City, Utah, in any action, suit, or proceeding brought by or against such Party in connection with, arising from, or relating to this Agreement, and each Party hereby waives and further agrees not to assert as a defense in any such suit, action, or proceeding any claim that such Party is not personally subject to the jurisdiction of any such courts, that the venue of the suit, action or proceeding is brought in an inconvenient forum, or that this Agreement or the subject matter hereof may not be enforced in or by such courts.
 
(g) Assignment. This Agreement, and the Executive’s rights and obligations hereunder, may not be assigned by the Executive. The Company may assign this Agreement and its rights, together with its obligations, hereunder only in connection with any sale, transfer, or other disposition of all or substantially all of its assets or business, whether by merger, consolidation or otherwise. This Agreement will be binding upon the Company’s successors and assigns which shall be required to perform this Agreement in the same manner and to the same extent that Company would be required to perform if no sale, transfer, or other disposition of all or substantially all of its assets or business, whether by merger, consolidation or otherwise, had occurred. This Agreement shall inure to the benefit of and be binding upon the Parties hereto and any successors and permitted assigns.
 
(h) Counterparts; Execution. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original but all of which together shall constitute one and the same instrument. Execution and delivery of this Agreement by facsimile or e-mail is legal, valid, and binding execution and delivery for all purposes.
 
(i) Headings. The headings in this Agreement are for reference purposes only and shall in no way affect the meaning or interpretation of this Agreement.
 
(j) Survival. Sections 4.8, 4.9, 5, 6, 7, 8, 11, and any other provision of this Agreement which by its terms is intended to survive the termination of this Agreement, and Executive’s rights to the Separation Payment hereunder, shall survive termination of this Agreement.
 
(k) Severability. To the extent any provision of this Agreement shall be invalid or unenforceable, it shall be considered deleted herefrom and the remainder of such provision and of this Agreement shall be unaffected and shall continue in full force and effect.
 
(l) Delays or Omissions. No delay or omission to exercise any right, power, or remedy accruing to either Party upon any breach or default of the other party hereto shall impair any such right, power, or remedy of such non-defaulting party, nor shall it be construed to be a waiver of any such breach or default or an acquiescence therein, or of or in any similar breach or default thereafter occurring; nor shall any waiver of a breach or default be deemed to be a waiver of any other breach or default.
 
(m) Expenses Incurred in Enforcing Rights. If any action at law or in equity or any arbitration proceeding is brought to enforce or interpret the terms of this Agreement, each Party shall bear its own attorney’s fees and costs, including expert fees, incurred therein, whether incurred before or after judgment or arbitration award.
 
IN WITNESS WHEREOF, the Parties have executed this Employment Agreement as of the Effective Date, as herein first written.
 
 
The Company:
 
PERSEON CORPORATION

By: /s/ Clinton E. Carnell, Jr.
Its: Chief Executive Officer


The Executive:

/s/ Todd Turnlund
Todd Turnlund



 
 
 EX-10.21 5 perseonexh1021.htm PROMISSORY NOTE DATED FEBRUARY 24, 2015 perseonexh1021.htm
Exhibit 10.21
PROMISSORY NOTE


$750,000.00
Loan No. BSDM01


February 24, 2015 Bellevue, Washington


FOR VALUE RECEIVED, PERSEON CORPORATION, a Delaware corporation f/k/a BSD Medical corporation ( "Borrower"), promises to pay, in lawful money of the United States of America, to the order of ACCESS BUSINESS FINANCE, LLC, a Washington limited liability company, ( "Lender") at 14205 S.
E. 36th Street, Suite 350, Bellevue, WA 98006, or such other place either within or without the State of Washington as Lender may designate in writing from time to time, the principal sum of SEVEN HUNDRED FIFTY THOUSAND and no/100 DOLLARS ($750,000.00), with interest as provided below.

 
1.
I nterest. The principal balance of the loan (the "Loan") evidenced by this Note shall bear interest at a variable rate per annum equal to SIX PERCENT (6.0%) plus the Prime Rate; provided that the interest rate on this Note shall not be less than NINE AND ONE-QUARTER PERCENT (9.25%). As used herein, "Prime Rate" means the "Prime Rate" as published in The Wall Street Journal. If the Prime Rate is no longer published or available, it shall be replaced by a comparable interest rate index selected by Lender in its sole discretion. The interest rate shall be adjusted simultaneously with each adjustment in the Prime Rate. Borrower acknowledges that the Prime Rate may not be the lowest rate of interest charged by Lender. Interest shall be calculated based on the actual number of days elapsed of a 360 day year.

 
2.
Payments. Borrower shall make monthly installment payments of interest only beginning on April 1, 2015, and continuing the same day of each succeeding month through the Maturity Date, at which time the entire balance of all principal and all accrued but unpaid interest shall become immediately due and payable.

 
3.
Maturity. The entire principal balance and all accrued interest shall become immediately due and payable on February 24, 2016 ( "Maturity Date").

 
4.
Prepayment. "Prepayment" means any (a) partial or full payment of the Principal Balance before the originally scheduled Maturity Date for any reason, whether voluntarily, involuntarily, by operation of law, acceleration or otherwise, or (b) an acceleration of the Loan by Lender upon an Event of Default by Borrower, including without limitation a violation of the restrictions on Transfer in the Deed of Trust. Borrower may make a Prepayment in whole or part upon no less than seven (7) days prior written notice to Lender; PROVIDED that if Lender receives any Prepayment before August 24, 2015, Borrower shall pay Lender a prepayment premium equal to TWO PERCENT (2.0%) of the Prepayment amount. No prepayment premium will be charged on any partial or full principal Prepayment on or after August 24, 2015.

 
5.
Loan Fees.

 
(a)
Borrower has paid Lender a Loan application fee of FOUR THOUSAND and no/100 DOLLARS ($4,000.00), which fee has been fully earned, is non-refundable, and shall be applied as provided in the terms letter dated JANUARY 6, 2015, from Lender to Borrower.

 
(b)
At closing of the Loan, Borrower shall pay to Lender a non-refundable Loan commitment fee of EIGHTEEN THOUSAND SEVEN HUNDRED FIFTY HUNDRED and no/100 DOLLARS ($18,750.00), which fee may be paid from Loan proceeds and which shall be deemed to be fully earned upon execution of this Note.

 
6.
Late Charges. If any monthly payment is not made within five (5) days of the date it is due, Lender may assess a late charge equal to ten percent (10%) of the payment due. If this Note is not fully paid within five (5) days from the Maturity Date, Lender may assess a late charge equal to fourpercent (4%) of the payment amount that was not made. The late charge is due and payable immediately upon Lender's demand and may be assessed only once on each overdue payment. The late charge shall not be construed in any way to (a) excuse Borrower from its obligation to make each payment under this Note promptly when due or (b) preclude Lender from exercising any rights or remedies available under the Loan Documents upon an Event of Default. Borrower shall pay a fee of $25 for each returned check. Payment of the late charge and returned check charges shall be a condition to curing any default or satisfaction of this Note.
 
Page 1 of 5
 
 
 
 
 
7.
Security; Loan Documents. This Note is secured by a Deed of Trust, Assignment of Rents and Leases, Fixture Filing and Security Agreement ( "Deed of Trust") encumbering real and personal property ("Property") located at 2188 West 2200 South in the City of West Valley City, Salt Lake County, Utah. The Deed of Trust prohibits a transfer or encumbrance of the Property, and the transfer of ownership interests in the owner of the Property and certain entities holding ownership interests in the owner of the Property. Borrower is also executing a Hazardous Substance Indemnity ("Indemnity Agreement") for the benefit of Lender in connection with the Property. This Note, the Deed of Trust, and all related documents and instruments (except the Indemnity Agreement) are collectively referred to as the "Loan Documents".

 
8.
Financial Reports. Borrower shall deliver to Lender: (a) annual income tax returns, complete with all schedules, for Borrower promptly upon filing of such returns with the IRS, and in any event within 10 days of the date of filing; (b) monthly income statements and balance sheets for Borrower, within 30 days of the end of each calendar month; (c) annual financial statements for Borrower, which shall be provided after the end of each fiscal year or annual period (as applicable) but in any event no later than 60 days thereafter; and (d) such other data and information regarding Borrower or the Property as from time to time may be requested by Lender. Borrower will maintain a standard system of accounting, established and administered in accordance with generally accepted accounting principles consistently followed throughout the periods involved, and will set aside on its books for each fiscal year the proper amounts for depreciation, obsolescence, amortization, bad debts, current and deferred taxes, and other purposes as shall be required by generally accepted accounting principles.

 
9.
Default. Any one or more of the following is an "Event of Default" under this Note: (a) Borrower fails to make any payment when due under this Note, the Deed of Trust, or any of the other Loan Documents. (b) There is any other Event of Default under the Deed of Trust or other Loan Documents or under the Indemnity Agreement. (c) A default occurs under any other indebtedness now or hereafter owing to Lender on which Borrower or any guarantor of this Note is a maker or a guarantor and such default is not cured within the applicable cure period, if any, under the instrument(s) evidencing such indebtedness.

 
10.
Remedies; Default I nterest. If there is an Event of Default, then in addition to any other rights and remedies available to Lender, Lender may declare the principal balance and accrued but unpaid interest immediately due and payable. Whether or not Lender exercises this right to accelerate, the entire principal balance of this Note, all accrued interest, and all other amounts payable hereunder or otherwise due in connection with the Loan, shall bear interest from the date of such Event of Default at ten percent (10%) per annum over the interest rate that would otherwise be in effect under this Note. Such interest shall be payable on demand, and payment of such default interest shall be a condition to curing any Event of Default or satisfaction of this Note. Lender's failure to exercise any right or remedy shall not be a waiver of the right to exercise the same upon any subsequent Event of Default.

 
11.
Waiver of Jury Trial. Borrower (by executing this Note) and Lender (by accepting this Note) each hereby waives any right to a trial by jury In any action or proceeding to enforce or defend any rights under this Note and the other Loan Documents or relating thereto or arising from the lending relationship which is the subject of this Note, and Borrower and Lender agree that any such action or proceeding shall be tried before a court and not before a jury. Borrower and Lender also hereby waive any right to consolidate any such action in which a jury trial has been waived with any other action In which a jury trial cannot be or has not been waived. Either Borrower or Lender may file an original counterpart or a copy of this section with any court as written evidence of Borrower's and Lender's waiver of its right to trial by jury.

 
12.
General Provisions.

 
(a)
Collection Expenses. Borrower agrees to reimburse Lender on demand for all reasonable legal fees and other costs and expenses incurred in collecting or enforcing this Note and protecting or realizing on any collateral, together with interest at the default rate specified above. Without limitation such shall include fees, costs and expenses incurred with or without suit and in any appeal, any proceedings under any present or future federal bankruptcy act or state receivership and any post-judgment collection proceeding. Payment of such fees, costs, expenses and interest shall be a condition precedent to the curing of any Event of Default or the satisfaction of this Note.

 
(b)
Borrower's Waivers. Except as otherwise provided in this Note and the other Loan Documents, Borrower waives all notices required by law; including without limitation presentment and demand for payment, protest, and notice of demand, protest, dishonor and nonpayment.

 
(c)
No Offset. This Note shall not be subject to offset of any kind.

 
(d)
Joint and Several Liability. The liability of each person or entity included within the term "Borrower", and each general partner or joint venturer of Borrower if Borrower is a partnership or joint venture, is joint and several with respect to all obligations hereunder.

 
(e)
Governing Law. Jurisdiction and Venue. This Note and the other Loan Documents shall be construed, enforced and otherwise governed exclusively by the laws of the State of Washington, except that matters relating to the validity and enforcement of the Deed of Trust (which encumbers Property located in the State of Utah), shall be subject to and governed by the laws of the State of Utah. Borrower agrees that to the fullest extent permitted by law, Washington law shall apply to all actions, defenses and remedies, including without limitation, the existence and calculation of any deficiency judgment upon foreclosure of the Deed of Trust, and Borrower agrees that the courts of the States of Washington and Utah, at Lender's sole and exclusive election, shall have exclusive jurisdiction of all actions, proceedings, defenses or remedies arising out of the execution or enforcement of this Note or any of the other Loan Documents. Borrower consents to personal jurisdiction in the courts of Washington and Utah, as provided herein, and specifically waives any objection to such jurisdiction based upon a forum non conveniens.

 
(f)
Amendment and Waiver. Only a writing signed by Borrower and Lender may amend this Note. No failure or delay in exercising any right hereunder shall impair any such right that Lender may have, nor shall any waiver by Lender hereunder be deemed a waiver of any default or breach subsequently occurring. Lender's rights and remedies herein are cumulative and not exclusive of each other or of any rights or remedies that Lender would otherwise have.

 
(g)
Definitions. The term "Lender" shall include any subsequent holder of the Note, or in whole or in part. Lender may assign the Loan Documents in whole or in part. Lender may make available to any proposed assignee or participant all credit and financial data with respect to Borrower, the Property, and any Guarantor of the Loan as may be in the possession of Lender. Borrower agrees to provide any additional information that any proposed assignee or participant may reasonably request.

 
(h)
Notices. All notices required or permitted hereunder shall be in writing and shall be given to Lender at Access Business Finance, L.L.C., 14205 S.E. 36th Street, Suite 350, Bellevue, WA 98006, Attn: Sam West, Fax No. (425) 747-1404, and to Borrower to the address indicated below its signature of this Note. The above addresses may be changed by written notice to the other party; provided that no notice of a change of address shall be effective until actual receipt of such notice. All notices required to be given to any party other than Lender shall be deemed given upon the first to occur of (i) three (3) days after deposit thereof in a receptacle under the control of the United States Postal Service, (ii) transmittal by electronic means to a facsimile machine or other receiver under the control of such party; or (iii) actual receipt by such party or an employee or agent of such party. All notices to Lender shall be deemed given upon actual receipt by a responsible officer of Lender.
 
(i) Application of Payments. Except as applicable law may otherwise require, all payments received by Lender under this Note shall be applied by Lender in the following order of priority: Lender's (and the Trustee's under the Deed of Trust) expenses incurred in any efforts to enforce any terms of this Note; interest payable on advances made to protect the security of the Deed of Trust; principal of such advances; amounts payable to Lender by Borrower under the Deed if Trust for reserves; interest and late charges payable on this Note; principal of this Note; and any other obligations of Borrower in such order as Lender, at its option, may determine; provided, however that Lender may, at its option, apply any such payments received to interest on or principal of this Note prior to applying such payments to interest on and principal of advances made to protect the security of the Deed of Trust.
 
 
Page 2 of 5
 
 
 
 
 
(j)
Damages from Late Payments. The parties intend the late charge, default interest and prepayment premium described in this Note to defray the overhead expenses of Lender incident to a delay in payment, including Lender's expenses incurred in handling and processing such delinquent payment(s) and to compensate Lender for the loss of the use of such funds. Borrower acknowledges that it would be extremely difficult or impracticable to determine Lender's actual damages resulting from a late payment, an Event of Default, or a prepayment, and the late charges, default interest and prepayment premium are reasonable estimates of those damages and do not constitute a penalty.

 
(k)
Limitation on Interest and Charges. Notwithstanding any other provision in this Note or the other Loan Documents, the total liability for payments in the nature of interest shall not exceed the highest lawful rate permitted by applicable state or federal interest rate law (the "Maximum Rate''). If any payment in the nature of interest, additional interest, or other charges made under this Note or the other Loan Documents are held to be in excess of the Maximum Rate, then in compliance with the desires of Lender and Borrower, it is agreed that the amount held to be in excess shall be considered a payment of principal, and the indebtedness evidenced by this Note or the other Loan Documents shall be reduced by such amount in the inverse order of maturity so that the total liability for payments in the nature of interest, additional interest and other charges shall not exceed the Maximum Rate. No prepayment premium shall be assessed on prepayments under this Section.

 
(I)
Partial Invalidity. If any term or provision of this Note is illegal or invalid for any reason, such illegality or invalidity shall not affect the enforceability of the remaining provisions of this Note and the other Loan Documents.

 
(m)
Business Purpose. Borrower warrants and represents that all funds advanced under this Note shall be applied to and are intended solely for business, commercial, or investment purposes.

 
(n)
Replacement Note. If this Note is lost, stolen, destroyed or mutilated, Borrower shall execute a replacement note upon the written request of Lender.

 
(o)
Time. Time is of the essence for purposes of this Note and the other Loan Documents.

EXCEPT AS OTHERWISE PROVIDED IN THIS NOTE OR THE OTHER LOAN DOCUMENTS, BORROWER ACKNOWLEDGES LIABILITY FOR PAYMENT OF ALL AMOUNTS OWING UNDER THIS NOTE AND THE OTHER LOAN DOCUMENTS AND AGREES THAT LENDER DOES NOT HAVE

Page 3 of 5

 
 
 

 
TO FORECLOSE ITS DEED OF TRUST OR ANY OTHER COLLATERAL BEFORE DEMANDING FULL PAYMENT FROM BORROWER.

ORAL AGREEMENTS OR ORAL COMMITMENTS TO LOAN MONEY, EXTEND CREDIT, OR FORBEAR FROM ENFORCING REPAYMENT OF A DEBT ARE NOT ENFORCEABLE UNDER WASHINGTON LAW.
 

"Borrower"

PERSEON CORPORATION, a Delaware corporation f/k/a BSD Medical corporation


By: /s/ William S. Barth
Name: William S. Barth
Title: Chief Financial Officer

Borrower's Address:
2188 West 2200 South
West Valley City, Utah 84119 Fax No.: (801) 972-5930


Page 4 of 5

 
 EX-21.1 6 perseonexh21.htm SUBSIDIARIES OF THE REGISTRANT perseonexh21.htm
Exhibit 21.1
SUBSIDIARIES OF THE REGISTRANT


None.
 
 
 

 
 
 
 
 
 
 
 EX-23.1 7 perseonexh231.htm CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM. perseonexh231.htm
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM


The Board of Directors and Stockholders
Perseon Corporation


We consent to the incorporation by reference in Registration Statement No. 333-184164 on Form S-3 and Registration Statements No. 333-157025, No. 333-142973, No. 333-50588, and No. 333-165885 on Form S-8 of Perseon Corporation of our reports dated March 30, 2015 with respect to the financial statements of Perseon Corporation contained in this Transition Report on Form 10-K for the four month period ended December 31, 2014.

/s/ Tanner LLC
Salt Lake City, Utah
March 30, 2015
 
 
 
 
 EX-31.1 8 perseonexh311.htm CERTIFICATION OF CHIEF EXECUTIVE OFFICER OF PERSEON PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002. perseonexh311.htm
Exhibit 31.1
Perseon Corporation
Certification Pursuant to Section 302
of the Sarbanes – Oxley Act of 2002

I, Clinton E. Carnell Jr., certify that:

 
1.
I have reviewed this Transition Report on Form 10-K of Perseon Corporation;
 
 
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
 
 
4.
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 
a.
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 
 
b.
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 
c.
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 
 
d.
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 
5.
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
 
 
a.
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
 
b.
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date:
March 30, 2015
   
By:
/s/ Clinton E. Carnell Jr.
 
Clinton E. Carnell Jr.
 
Chief Executive Officer
 
 
 
 
 EX-31.2 9 perseonexh312.htm CERTIFICATION OF CHIEF FINANCIAL OFFICER OF PERSEON PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002. perseonexh312.htm
Exhibit 31.2
Perseon Corporation
Certification Pursuant to Section 302
of the Sarbanes – Oxley Act of 2002

I, William S. Barth, certify that:

 
1.
I have reviewed this Transition Report on Form 10-K of Perseon Corporation;
 
 
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
 
 
4.
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 
a.
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 
 
b.
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 
c.
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and 
     
 
d.
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 
5.
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): 
     
 
a.
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
 
b.
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date:
March 30, 2015
   
By:
/s/ William S. Barth
 
William S. Barth
 
Chief Financial Officer



 
EX-32.1 10 perseonexh321.htm CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER ATTACHED PURSUANT TO SECTION 906 OF THE SARBANES- OXLEY ACT OF 2002. perseonexh321.htm
Exhibit 32.1
 
Certification Pursuant to 18 U.S.C. Section 1350 as
Adopted Pursuant to Section 906 of the Sarbanes – Oxley Act of 2002


In connection with the Transition Report on Form 10-K of Perseon Corporation (the “Company”) for the four month period ended December 31, 2014, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Clinton E. Carnell Jr., Chief Executive Officer (Principal Executive Officer) of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes – Oxley Act of 2002, that:

1.
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.



Date:
March 30, 2015
   
By:
/s/ Clinton E. Carnell Jr.
 
Clinton E. Carnell Jr.
 
Chief Executive Officer
 
(Principal Executive Officer)
 
 
 
 
 
 
 

 
 EX-32.2 11 perseonexh322.htm CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER OF PERSEON PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002. perseonexh322.htm
Exhibit 32.2
Certification Pursuant to 18 U.S.C. Section 1350 as
Adopted Pursuant to Section 906 of the Sarbanes – Oxley Act of 2002


In connection with the Transition Report on Form 10-K of Perseon Corporation (the “Company”) for the four month period ended December 31, 2014, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, William S. Barth, Chief Financial Officer (Principal Financial and Accounting Officer) of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes – Oxley Act of 2002, that:

1.
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 

Date:
March 30, 2015
   
By:
/s/ William S. Barth
 
William S. Barth
 
Chief Financial Officer
 
(Principal Financial and Accounting Officer)
 
 
 
 
 
 
 
 
 
 
 
 EX-101.INS 12 bsdm-20141231.xml XBRL INSTANCE DOCUMENT 20000 20000 20000 0.001 0.001 10000000 10000000 0.001 0.001 80000000 80000000 39713540 39713540 34006202 24331 24331 24331 526585 1572376 4544204 3274796 463423 16686 334455 795034 2563921 2161967 257125 7654 313156 87694 3929 3929 11788 11788 595509 806617 2888865 2261449 520399 877645 2439488 1411843 627769 701549 2229043 2281854 2819205 2237057 7308643 7403273 4251974 2988606 9587686 9685127 -3731575 -2110961 -7148198 -8273284 5672 8167 22491 32225 -42487 -3847 -15125 -8694 -36815 4320 7366 23531 -3768390 -2106641 -7140832 -8249753 -0.09 -0.06 -0.20 -0.26 -0.09 -0.06 -0.20 -0.26 39689000 34006000 34967000 31414000 39689000 34006000 34967000 31414000 29778 51845035 -234 -37377247 14497332 29777522 24331 164 179838 163638 4065 4579372 4583437 4065042 1134811 -8251691 34007 57739056 -234 -45628938 34006202 24331 161 179839 160716 5546 4631033 4636579 5546622 844628 -7142832 39714 63394556 -234 -52771770 39713540 24331 192844 -3768390 39714 63587400 -234 -56540160 39713540 24331 -3768390 -2106641 -7142832 -8251691 -43280 -40364 -125824 -132153 180000 180002 284167 33827 -30 805000 50000 50000 -33334 95124 548961 -601326 -46459 -328517 66581 -41813 59736 51881 53709 -79959 -49569 57272 -27480 -325663 -238624 84323 -292648 -149182 114 -95347 275699 -292500 41825 46237 687665 -560423 -2467242 -2006107 -5916395 -6200055 35317 21330 75599 35362 2025 -35317 -21330 -73574 -35362 4636579 4583437 74052 -33279 -40774 -33279 4669857 4583437 -2535838 -2027437 -1320112 -1651980 11102508 7423091 8130416 9450528 275072 366887 899969 86583 146319 200028 10981133 13020496 8886223 12248794 14340376 598466 548897 521417 33279 41667 41781 317480 54218 96043 730593 1799503 1586528 2143370 53115 1799503 1586528 2196485 39714 39714 34007 63587400 63394556 57739056 234 234 234 -56540160 -52771770 -45628938 7086720 10662266 12143891 8886223 12248794 14340376 10-K 2014-12-31 false Perseon Corp 0000320174 --12-31 39689209 26701152 Smaller Reporting Company Yes No No 2014 FY <!--egx--><p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'><b>Note 1:&nbsp;&nbsp;Organization and Significant Accounting Policies</b></p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'><b>Organization and Business</b> &#150; Perseon Corporation, formerly BSD Medical Corporation, (the &#147;Company&#148;) was incorporated in the State of Delaware on July 3, 1986.&nbsp;&nbsp;In February 2015, we changed the name of the Company to Perseon Corporation.&#160; We are a life sciences company that develops, manufactures, markets and services groundbreaking medical systems to treat cancer using heat therapy.&nbsp;&nbsp;Our MicroThermX<sup>&#174; </sup>microwave ablation system employs precision-guided microwave energy to ablate diseased soft tissue.&#160; We have developed extensive intellectual property and distribute our products in the United States, Europe and Asia.</p> <p style='margin-right:0in;margin-left:0in;margin-top:0in;margin-right:.1pt;margin-bottom:0in;margin-left:.1pt;margin-bottom:.0001pt;text-indent:.5in'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'><b>Financial Reporting Period &#150; </b>We have changed our fiscal year end for financial reporting from August 31 to December 31, effective for the four months ended December 31, 2014.&#160; The financial information for the four months ended December 31, 2013 provided for comparative purposes is unaudited. &#160;All adjustments (consisting only of normal recurring adjustments) necessary for the fair presentation of our results of operations and our cash flows for the four months ended December 31, 2013 have been included.&#160; The results of operations for the four months ended December 31, 2014 may not be indicative of the results for our fiscal year ending December 31, 2015.</p> <p style='margin-right:0in;margin-left:0in;margin-top:0in;margin-right:.1pt;margin-bottom:0in;margin-left:.1pt;margin-bottom:.0001pt'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'><b>Cash and Cash Equivalents</b> &#150; Cash and cash equivalents consist of cash and investments with original maturities to the Company of three months or less.&nbsp;&nbsp;As of December 31, 2014 and August 31, 2014, we had $25,000 in a restricted bank account.</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'><b>Accounts Receivable</b> &#150; Trade accounts receivable are carried at original invoice amount less an estimate made for doubtful receivables based on a review of all outstanding amounts on a monthly basis.&nbsp;&nbsp;Management estimates an allowance for doubtful accounts by identifying troubled accounts and by using historical experience applied to an aging of accounts.&nbsp;&nbsp;Trade accounts receivable are written off when deemed uncollectible.&nbsp;&nbsp;Recoveries of trade receivables previously written off are recorded when received.&nbsp;&nbsp;Interest is not charged on trade receivables that are outstanding beyond their due date.</p> <p style='margin-right:0in;margin-left:0in;margin-top:0in;margin-right:.1pt;margin-bottom:0in;margin-left:.1pt;margin-bottom:.0001pt'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'><b>Inventories &#150; </b>Parts and supplies inventories are stated at the lower of cost or market.&nbsp;&nbsp;Cost is determined using the average cost method.&nbsp;&nbsp;Work-in-process and finished goods are stated at the lower of the accumulated manufacturing costs or market.&nbsp;&nbsp;We maintain a reserve for obsolete inventories to reduce excess and obsolete inventories to their estimated net realizable value.&nbsp;&nbsp;The reserve was $750,000 as of December 31, 2014, $150,000 as of August 31, 2014, and $100,000 as of August 31, 2013.</p> <p style='margin-right:0in;margin-left:0in;margin-top:0in;margin-right:.1pt;margin-bottom:0in;margin-left:.1pt;margin-bottom:.0001pt'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'><b>Property and Equipment</b> &#150; Property and equipment are stated at cost less accumulated depreciation.&nbsp;&nbsp;Depreciation is determined using the straight-line method over the following estimated useful lives of the assets.</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <table border="0" cellspacing="0" cellpadding="0" style='margin-left:86.3pt;border-collapse:collapse'> <tr align="left"> <td width="168" valign="top" style='width:126.1pt;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>Equipment</p> </td> <td width="60" valign="top" style='width:45.0pt;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="168" valign="top" style='width:1.75in;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>2 &#150; 5 years</p> </td> </tr> <tr align="left"> <td width="168" valign="top" style='width:126.1pt;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>Rental equipment</p> </td> <td width="60" valign="top" style='width:45.0pt;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="168" valign="top" style='width:1.75in;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>5 years</p> </td> </tr> <tr align="left"> <td width="168" valign="top" style='width:126.1pt;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>Furniture and fixtures</p> </td> <td width="60" valign="top" style='width:45.0pt;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="168" valign="top" style='width:1.75in;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>5 years</p> </td> </tr> <tr align="left"> <td width="168" valign="top" style='width:126.1pt;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>Building improvements</p> </td> <td width="60" valign="top" style='width:45.0pt;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="168" valign="top" style='width:1.75in;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>15 years</p> </td> </tr> <tr align="left"> <td width="168" valign="top" style='width:126.1pt;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>Building</p> </td> <td width="60" valign="top" style='width:45.0pt;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="168" valign="top" style='width:1.75in;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>40 years</p> </td> </tr> </table> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>Expenditures for maintenance and repairs are expensed when incurred and betterments are capitalized.&nbsp;&nbsp;Gains and losses on sales of property and equipment are reflected in operations.</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>The cost and accumulated depreciation of property and equipment sold or otherwise retired are removed from the accounts and any related gain or loss on disposition is reflected in net income or loss for the period.</p> <p style='margin-right:0in;margin-left:0in;margin-top:0in;margin-right:.1pt;margin-bottom:0in;margin-left:.1pt;margin-bottom:.0001pt'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'><b>Patents</b> &#150; Patent costs are expensed as incurred.</p> <p style='margin-right:0in;margin-left:0in;margin-top:0in;margin-right:.1pt;margin-bottom:0in;margin-left:.1pt;margin-bottom:.0001pt'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'><b>Warranty Reserve</b> &#150; We provide limited warranties to our customers for products sold.&nbsp;&nbsp;Estimated future warranty obligations are accrued each period.&nbsp;&nbsp;As of December 31, 2014, August 31, 2014 and August 31, 2013, the accrued warranty reserve was $65,102, $75,728 and $50,968, respectively.&nbsp;&nbsp;During the four months ended December 31, 2014, total warranty expense was $13,410.&#160; During the fiscal years ended August 31, 2014 and 2013, total warranty expense was $41,471 and $80,276, respectively.</p> <p style='margin-right:0in;margin-left:0in;margin-top:0in;margin-right:.1pt;margin-bottom:0in;margin-left:.1pt;margin-bottom:.0001pt;text-indent:.5in'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'><b>Income Taxes</b> &#150; We account for income taxes using the asset and liability method.&nbsp;&nbsp;Under the asset and liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases.&nbsp;&nbsp;Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.&nbsp;&nbsp;The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.</p> <p style='margin-right:0in;margin-left:0in;margin-top:0in;margin-right:.1pt;margin-bottom:0in;margin-left:.1pt;margin-bottom:.0001pt;text-indent:.5in'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'><b>Income (Loss) Per Common Share</b> &#150; The computation of basic income (loss) per common share is based on the weighted average number of shares outstanding during each year.</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>The computation of diluted earnings per common share is based on the weighted average number of shares outstanding during the year, plus the common stock equivalents that would arise from the exercise of stock options and warrants outstanding, using the treasury stock method and the average market price per share during the year.&nbsp;&nbsp;Common stock equivalents are not included in the diluted loss per share calculation when their effect is anti-dilutive.&nbsp;&nbsp;Options and warrants to purchase 14,989,224 shares of common stock at prices ranging from $0.44 to $7.95 were excluded from the calculation of diluted earnings per share for the four months ended December 31, 2014 because their effect was anti-dilutive.&#160; Options and warrants to purchase 13,720,225 and 9,669,878 shares of common stock at prices ranging from $0.99 to $7.95 were excluded from the calculation of diluted earnings per share for the years ended August 31, 2014 and 2013, respectively, because their effect was anti-dilutive.</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>Since we had no dilutive effect of stock options and warrants for the four months ended December 31, 2014 and 2013 and the years ended August 31, 2014 and 2013, our basic weighted average number of common shares outstanding is the same as our diluted weighted average number of common shares outstanding.</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'><b>Stock-Based Compensation - </b>Stock-based compensation is measured at the grant date based on the value of the award granted using the Black-Scholes option pricing model, and recognized over the period in which the award vests.&nbsp;&nbsp;For stock awards no longer expected to vest, any previously recognized stock compensation expense is reversed in the period of termination.&nbsp;&nbsp;The stock-based compensation expense is allocated to the various categories of operating costs and expenses in a manner similar to the allocation of payroll expense.&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin-top:0in;margin-right:.1pt;margin-bottom:0in;margin-left:.1pt;margin-bottom:.0001pt;text-indent:.5in'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'><b>Revenue Recognition</b> &#150; We recognize revenue from the sale of medical systems, disposable devices related to the systems,&nbsp;parts, and accessories, and equipment rental, training, and service support contracts.&nbsp;&nbsp;Our revenues consisted of the following:</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>&nbsp;</p> <table border="1" cellspacing="0" cellpadding="0" style='margin-left:19.6pt;border-collapse:collapse;border:none'> <tr align="left"> <td width="208" valign="top" style='width:155.9pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="180" colspan="2" valign="top" style='width:134.9pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'><b>Four Months Ended December 31,</b></p> </td> <td width="177" colspan="2" valign="top" style='width:132.4pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'><b>Years Ended August 31, </b></p> </td> </tr> <tr align="left"> <td width="208" valign="top" style='width:155.9pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="92" valign="top" style='width:68.7pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'><b>2014</b></p> </td> <td width="88" valign="top" style='width:66.2pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'><b>&#160;&#160;&#160;&#160;&#160;&#160;&#160; 2013</b></p> </td> <td width="88" valign="top" style='width:66.2pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'><b>&#160;&#160;&#160;&#160;&#160;&#160;&#160; 2014</b></p> </td> <td width="88" valign="top" style='width:66.2pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'><b>&#160;&#160;&#160;&#160;&#160;&#160;&#160; </b><b>2013</b></p> </td> </tr> <tr align="left"> <td width="208" valign="top" style='width:155.9pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="92" valign="top" style='width:68.7pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="88" valign="top" style='width:66.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="88" valign="top" style='width:66.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="88" valign="top" style='width:66.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> </tr> <tr align="left"> <td width="208" valign="top" style='width:155.9pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>Product sales</p> </td> <td width="92" valign="top" style='width:68.7pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>$&#160; &#160;&#160;&#160;&#160;&#160;&#160;470,875</p> </td> <td width="88" valign="top" style='width:66.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;986,900</p> </td> <td width="88" valign="top" style='width:66.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>$&#160;&#160;&#160; 3,019,525</p> </td> <td width="88" valign="top" style='width:66.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>$&#160;&#160;&#160; 1,934,826</p> </td> </tr> <tr align="left"> <td width="208" valign="top" style='width:155.9pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>Disposable devices</p> </td> <td width="92" valign="top" style='width:68.7pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>409,787</p> </td> <td width="88" valign="top" style='width:66.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>501,565</p> </td> <td width="88" valign="top" style='width:66.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>1,568,481</p> </td> <td width="88" valign="top" style='width:66.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>1,109,750</p> </td> </tr> <tr align="left"> <td width="208" valign="top" style='width:155.9pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>Service contracts and other</p> </td> <td width="92" valign="top" style='width:68.7pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>109,346</p> </td> <td width="88" valign="top" style='width:66.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>100,597</p> </td> <td width="88" valign="top" style='width:66.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>375,747</p> </td> <td width="88" valign="top" style='width:66.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>330,116</p> </td> </tr> <tr align="left"> <td width="208" valign="top" style='width:155.9pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>Equipment rental</p> </td> <td width="92" valign="top" style='width:68.7pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>125,900</p> </td> <td width="88" valign="top" style='width:66.2pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>95,200</p> </td> <td width="88" valign="top" style='width:66.2pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>364,600</p> </td> <td width="88" valign="top" style='width:66.2pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>298,600</p> </td> </tr> <tr align="left"> <td width="208" valign="top" style='width:155.9pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="92" valign="top" style='width:68.7pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="88" valign="top" style='width:66.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="88" valign="top" style='width:66.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="88" valign="top" style='width:66.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> </tr> <tr align="left"> <td width="208" valign="top" style='width:155.9pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>Total</p> </td> <td width="92" valign="top" style='width:68.7pt;border:none;border-bottom:double windowtext 1.5pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>$&#160;&#160; &#160;&#160;1,115,908</p> </td> <td width="88" valign="top" style='width:66.2pt;border:none;border-bottom:double windowtext 1.5pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>$&#160;&#160;&#160; 1,684,262</p> </td> <td width="88" valign="top" style='width:66.2pt;border:none;border-bottom:double windowtext 1.5pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>$&#160;&#160;&#160; 5,328,353</p> </td> <td width="88" valign="top" style='width:66.2pt;border:none;border-bottom:double windowtext 1.5pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>$&#160;&#160;&#160; 3,673,292</p> </td> </tr> </table> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>Revenue from product sales is recognized when a purchase order has been received, the cancer treatment system has been shipped, the selling price is fixed or determinable, and collection is reasonably assured.&nbsp;&nbsp;Most system sales are F.O.B. shipping point; therefore, shipment is deemed to have occurred when the product is delivered to the transportation carrier.&nbsp;&nbsp;Most system sales do not include installation.&nbsp;&nbsp;If installation is included as part of the contract, revenue is not recognized until installation has occurred, or until any remaining installation obligation is deemed to be perfunctory.&nbsp;&nbsp;Some sales of systems may include training as part of the sale.&nbsp;&nbsp;In such cases, the portion of the revenue related to the training, calculated based on the amount charged for training on a stand-alone basis, is deferred and recognized when the training has been provided.&nbsp;&nbsp;The sales of our cancer treatment systems do not require specific customer acceptance provisions and do not include the right of return except in cases where the product does not function as warranted by us.&nbsp;&nbsp;To date, returns have not been significant.</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>Revenue from the sale of disposable devices is recognized when a purchase order has been received, the devices have been shipped, the selling price is fixed or determinable, and collection is reasonably assured.&nbsp;&nbsp;Currently, our customers are not required to purchase a minimum number of disposable devices in connection with the purchase of our systems.</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>Revenue from training services is recorded when an agreement with the customer exists for such training, the training services have been provided, and collection is reasonably assured.</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>Revenue from service support contracts is recognized on a straight-line basis over the term of the contract, which approximates recognizing it as it is earned.</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>Revenue from equipment rental under an operating lease is recognized when billed in accordance with the lease agreement.</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>Our revenue recognition policy is the same for sales to both related parties and non-related parties.&nbsp;&nbsp;We provide the same products and services under the same terms for non-related parties as with related parties.</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>Sales to distributors are recognized in the same manner as sales to end-user customers.</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>Deferred revenue and customer deposits include amounts from service contracts as well as cash received for the sales of products that have not been shipped.</p> <p style='margin-right:0in;margin-left:0in;margin-top:0in;margin-right:.1pt;margin-bottom:0in;margin-left:.1pt;margin-bottom:.0001pt'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'><b>Concentration of Credit Risk</b> &#150; Financial instruments that potentially subject us to concentration of credit risk consists primarily of trade receivables.&nbsp;&nbsp;In the normal course of business, we provide credit terms to our customers.&nbsp;&nbsp;Accordingly, we perform ongoing credit evaluations of our customers and maintain allowances for possible losses.</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>We have cash in the bank and short-term investments that exceed federally insured limits.&nbsp;&nbsp;We have not experienced any losses in such accounts.</p> <p style='margin-right:0in;margin-left:0in;margin-top:0in;margin-right:.1pt;margin-bottom:0in;margin-left:.1pt;margin-bottom:.0001pt'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'><b>Advertising and Promotion &#150; </b>Advertising and promotion costs, which are principally included in sales expenses, are expensed as incurred.&nbsp;&nbsp;Advertising and promotion expense was $56,504 for the four months ended December 31, 2014, and $206,099 and $205,442 for the years ended August 31, 2014 and 2013, respectively.</p> <p style='margin-right:0in;margin-left:0in;margin-top:0in;margin-right:.1pt;margin-bottom:0in;margin-left:.1pt;margin-bottom:.0001pt'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'><b>Shipping and Handling</b> &#150; We bill our customers for shipping and handling charges, which are included in net sales.&#160; The cost of corresponding shipping and handling expense is reported in cost of sales.</p> <p style='margin-right:0in;margin-left:0in;margin-top:0in;margin-right:.1pt;margin-bottom:0in;margin-left:.1pt;margin-bottom:.0001pt;text-indent:.5in'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'><b>Use of Estimates in the Preparation of Financial Statements</b> &#150; The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.&nbsp;&nbsp;Actual results could differ from those estimates.</p> <p style='margin-right:0in;margin-left:0in;margin-top:0in;margin-right:.1pt;margin-bottom:0in;margin-left:.1pt;margin-bottom:.0001pt'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'><b>Comprehensive Loss</b> &#150; Comprehensive loss is the same as net loss for all years presented.</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-align:justify'>&nbsp;</p> <!--egx--><p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'><b>Note 2:&nbsp;&nbsp;Liquidity</b></p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; As of December 31, 2014, we had cash and cash equivalents of $5,594,578, and total current assets of $7,745,352.&#160; We do not believe these resources will be sufficient to fully execute our current strategy through at least December 31, 2015.&#160; Our current strategy involves significant efforts to expand sales of our MicroThermX product.&#160; To become profitable we will need to significantly increase the revenues we receive from sales of our MicroThermX products.&#160; We do not expect that sales of the MicroThermX products will increase sufficiently to cover our total costs of operations in 2015.&#160; We believe additional funding will be required during 2015.</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>If we are unable to raise sufficient additional funds in 2015, we will need to significantly reduce our expenses, and evaluate other business arrangements, including collaborative arrangements, partnerships, or sale of assets, to allow continued operations.&#160; Significantly reducing our expenses would negatively affect our efforts to expand our marketing and sales presence, our research and development programs, and our ability to hire and retain qualified personnel.</p> <!--egx--><p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'><b>Note 3:&nbsp;&nbsp;Detail of Certain Balance Sheet Accounts</b></p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-align:justify;text-indent:.5in'>Details of certain balance sheet accounts are as follows:</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-align:justify;text-indent:.5in'>&nbsp;</p> <table border="0" cellspacing="0" cellpadding="0" width="491" style='margin-left:.5in;border-collapse:collapse'> <tr align="left"> <td width="236" valign="top" style='width:176.65pt;padding:0'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="85" valign="top" style='width:63.8pt;padding:0'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'><b>December 31,</b></p> </td> <td width="170" colspan="2" valign="top" style='width:127.55pt;padding:0'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'><b>August 31,</b></p> </td> </tr> <tr align="left"> <td width="236" valign="top" style='width:176.65pt;padding:0'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="85" valign="top" style='width:63.8pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'><b>2014</b></p> </td> <td width="85" valign="top" style='width:63.75pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'><b>2014</b></p> </td> <td width="85" valign="top" style='width:63.8pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'><b>2013</b></p> </td> </tr> <tr align="left"> <td width="236" valign="top" style='width:176.65pt;padding:0'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="85" valign="top" style='width:63.8pt;border:none;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="85" valign="top" style='width:63.75pt;border:none;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="85" valign="top" style='width:63.8pt;border:none;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> </tr> <tr align="left"> <td width="236" valign="top" style='width:176.65pt;padding:0'> <p style='margin-right:0in;margin-left:0in'>Accounts receivable:</p> </td> <td width="85" valign="top" style='width:63.8pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="85" valign="top" style='width:63.75pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="85" valign="top" style='width:63.8pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> </tr> <tr align="left"> <td width="236" valign="top" style='width:176.65pt;padding:0'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="85" valign="top" style='width:63.8pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="85" valign="top" style='width:63.75pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="85" valign="top" style='width:63.8pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> </tr> <tr align="left"> <td width="236" valign="top" style='width:176.65pt;padding:0'> <p style='margin-right:0in;margin-left:0in'>&#160;&#160; Trade receivables &#150; non-related party</p> </td> <td width="85" valign="top" style='width:63.8pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>$&#160;&#160;&#160;&#160;&#160;&#160; 293,182</p> </td> <td width="85" valign="top" style='width:63.75pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>$&#160;&#160;&#160;&#160;&#160;&#160; 364,170</p> </td> <td width="85" valign="top" style='width:63.8pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>$&#160;&#160;&#160;&#160;&#160;&#160; 890,985</p> </td> </tr> <tr align="left"> <td width="236" valign="top" style='width:176.65pt;padding:0'> <p style='margin-right:0in;margin-left:0in'>&#160;&#160; Other receivables</p> </td> <td width="85" valign="top" style='width:63.8pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>1,890</p> </td> <td width="85" valign="top" style='width:63.75pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>22,717</p> </td> <td width="85" valign="top" style='width:63.8pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>28,984</p> </td> </tr> <tr align="left"> <td width="236" valign="top" style='width:176.65pt;padding:0'> <p style='margin-right:0in;margin-left:0in'>&#160;&#160; Allowance for doubtful accounts</p> </td> <td width="85" valign="top" style='width:63.8pt;border:none;border-bottom:solid black 1.0pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>(20,000)</p> </td> <td width="85" valign="top" style='width:63.75pt;border:none;border-bottom:solid black 1.0pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>(20,000)</p> </td> <td width="85" valign="top" style='width:63.8pt;border:none;border-bottom:solid black 1.0pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>(20,000)</p> </td> </tr> <tr align="left"> <td width="236" valign="top" style='width:176.65pt;padding:0'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="85" valign="top" style='width:63.8pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="85" valign="top" style='width:63.75pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="85" valign="top" style='width:63.8pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> </tr> <tr style='height:13.3pt'> <td width="236" valign="top" style='width:176.65pt;padding:0;height:13.3pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="85" valign="top" style='width:63.8pt;border:none;border-bottom:double windowtext 1.5pt;padding:0;height:13.3pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 275,072</p> </td> <td width="85" valign="top" style='width:63.75pt;border:none;border-bottom:double windowtext 1.5pt;padding:0;height:13.3pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>$&#160;&#160;&#160;&#160;&#160;&#160; 366,887</p> </td> <td width="85" valign="top" style='width:63.8pt;border:none;border-bottom:double windowtext 1.5pt;padding:0;height:13.3pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>$&#160;&#160;&#160;&#160;&#160;&#160; 899,969</p> </td> </tr> </table> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-align:justify;text-indent:.5in'>&nbsp;</p> <table border="0" cellspacing="0" cellpadding="0" width="491" style='margin-left:.5in;border-collapse:collapse'> <tr align="left"> <td width="236" valign="top" style='width:176.65pt;padding:0'> <p style='margin-right:0in;margin-left:0in'>Inventories:</p> </td> <td width="85" valign="top" style='width:63.8pt;padding:0'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'>&nbsp;</p> </td> <td width="85" valign="top" style='width:63.75pt;padding:0'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'>&nbsp;</p> </td> <td width="85" valign="top" style='width:63.8pt;padding:0'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'>&nbsp;</p> </td> </tr> <tr align="left"> <td width="236" valign="top" style='width:176.65pt;padding:0'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="85" valign="top" style='width:63.8pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="85" valign="top" style='width:63.75pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="85" valign="top" style='width:63.8pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> </tr> <tr align="left"> <td width="236" valign="top" style='width:176.65pt;padding:0'> <p style='margin-right:0in;margin-left:0in'>&#160;&#160; Parts and supplies</p> </td> <td width="85" valign="top" style='width:63.8pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>$&#160;&#160;&#160; 1,004,164</p> </td> <td width="85" valign="top" style='width:63.75pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>$ &#160;&#160;&#160;1,369,960</p> </td> <td width="85" valign="top" style='width:63.8pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>$&#160;&#160;&#160; 1,353,614</p> </td> </tr> <tr align="left"> <td width="236" valign="top" style='width:176.65pt;padding:0'> <p style='margin-right:0in;margin-left:0in'>&#160;&#160; Work-in-process</p> </td> <td width="85" valign="top" style='width:63.8pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>951,519</p> </td> <td width="85" valign="top" style='width:63.75pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>880,751</p> </td> <td width="85" valign="top" style='width:63.8pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>990,668</p> </td> </tr> <tr align="left"> <td width="236" valign="top" style='width:176.65pt;padding:0'> <p style='margin-right:0in;margin-left:0in'>&#160;&#160; Finished goods</p> </td> <td width="85" valign="top" style='width:63.8pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>569,965</p> </td> <td width="85" valign="top" style='width:63.75pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>228,478</p> </td> <td width="85" valign="top" style='width:63.8pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>201,488</p> </td> </tr> <tr align="left"> <td width="236" valign="top" style='width:176.65pt;padding:0'> <p style='margin-right:0in;margin-left:0in'>&#160;&#160; Reserve for obsolete inventories</p> </td> <td width="85" valign="top" style='width:63.8pt;border:none;border-bottom:solid black 1.0pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>(&#160; 750,000)</p> </td> <td width="85" valign="top" style='width:63.75pt;border:none;border-bottom:solid black 1.0pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>(150,000)</p> </td> <td width="85" valign="top" style='width:63.8pt;border:none;border-bottom:solid black 1.0pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>(100,000)</p> </td> </tr> <tr align="left"> <td width="236" valign="top" style='width:176.65pt;padding:0'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="85" valign="top" style='width:63.8pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="85" valign="top" style='width:63.75pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="85" valign="top" style='width:63.8pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> </tr> <tr style='height:13.3pt'> <td width="236" valign="top" style='width:176.65pt;padding:0;height:13.3pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="85" valign="top" style='width:63.8pt;border:none;border-bottom:double windowtext 1.5pt;padding:0;height:13.3pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>$&#160;&#160;&#160; 1,775,648</p> </td> <td width="85" valign="top" style='width:63.75pt;border:none;border-bottom:double windowtext 1.5pt;padding:0;height:13.3pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>$&#160;&#160;&#160; 2,329,189</p> </td> <td width="85" valign="top" style='width:63.8pt;border:none;border-bottom:double windowtext 1.5pt;padding:0;height:13.3pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>$&#160;&#160;&#160; 2,445,770</p> </td> </tr> </table> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-align:justify;text-indent:.5in'>&nbsp;</p> <table border="0" cellspacing="0" cellpadding="0" width="491" style='margin-left:.5in;border-collapse:collapse'> <tr align="left"> <td width="236" valign="top" style='width:176.65pt;padding:0'> <p style='margin-right:0in;margin-left:0in'>Accrued liabilities:</p> </td> <td width="85" valign="top" style='width:63.8pt;padding:0'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'>&nbsp;</p> </td> <td width="85" valign="top" style='width:63.75pt;padding:0'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'>&nbsp;</p> </td> <td width="85" valign="top" style='width:63.8pt;padding:0'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'><b> </b></p> </td> </tr> <tr align="left"> <td width="236" valign="top" style='width:176.65pt;padding:0'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="85" valign="top" style='width:63.8pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="85" valign="top" style='width:63.75pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="85" valign="top" style='width:63.8pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> </tr> <tr align="left"> <td width="236" valign="top" style='width:176.65pt;padding:0'> <p style='margin-right:0in;margin-left:0in'>&#160;&#160; Warranty reserve</p> </td> <td width="85" valign="top" style='width:63.8pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>$&#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;65,102</p> </td> <td width="85" valign="top" style='width:63.75pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>$&#160;&#160;&#160;&#160;&#160;&#160;&#160; 75,728</p> </td> <td width="85" valign="top" style='width:63.8pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>$&#160;&#160;&#160;&#160;&#160;&#160;&#160; 50,968</p> </td> </tr> <tr align="left"> <td width="236" valign="top" style='width:176.65pt;padding:0'> <p style='margin-right:0in;margin-left:0in'>&#160;&#160; Training and installation reserve</p> </td> <td width="85" valign="top" style='width:63.8pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>2,038</p> </td> <td width="85" valign="top" style='width:63.75pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>4,716</p> </td> <td width="85" valign="top" style='width:63.8pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>5,528</p> </td> </tr> <tr align="left"> <td width="236" valign="top" style='width:176.65pt;padding:0'> <p style='margin-right:0in;margin-left:0in'>&#160;&#160; Accrued taxes payable</p> </td> <td width="85" valign="top" style='width:63.8pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>50,462</p> </td> <td width="85" valign="top" style='width:63.75pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>59,745</p> </td> <td width="85" valign="top" style='width:63.8pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>44,677</p> </td> </tr> <tr align="left"> <td width="236" valign="top" style='width:176.65pt;padding:0'> <p style='margin-right:0in;margin-left:0in'>&#160;&#160; Payroll, commissions, legal and other</p> </td> <td width="85" valign="top" style='width:63.8pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>987,550</p> </td> <td width="85" valign="top" style='width:63.75pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>726,339</p> </td> <td width="85" valign="top" style='width:63.8pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>472,707</p> </td> </tr> <tr align="left"> <td width="236" valign="top" style='width:176.65pt;padding:0'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="85" valign="top" style='width:63.8pt;border:none;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="85" valign="top" style='width:63.75pt;border:none;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="85" valign="top" style='width:63.8pt;border:none;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> </tr> <tr style='height:13.3pt'> <td width="236" valign="top" style='width:176.65pt;padding:0;height:13.3pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="85" valign="top" style='width:63.8pt;border:none;border-bottom:double windowtext 1.5pt;padding:0;height:13.3pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>$&#160;&#160;&#160; 1,105,152</p> </td> <td width="85" valign="top" style='width:63.75pt;border:none;border-bottom:double windowtext 1.5pt;padding:0;height:13.3pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>$&#160;&#160;&#160;&#160;&#160; 866,528</p> </td> <td width="85" valign="top" style='width:63.8pt;border:none;border-bottom:double windowtext 1.5pt;padding:0;height:13.3pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>$&#160;&#160;&#160;&#160;&#160; 573,880</p> </td> </tr> </table> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <!--egx--><p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'><b>Note 4:&nbsp;&nbsp;Property and Equipment</b></p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>Property and equipment consist of the following:</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>&nbsp;</p> <table border="0" cellspacing="0" cellpadding="0" width="491" style='margin-left:.5in;border-collapse:collapse'> <tr align="left"> <td width="236" valign="top" style='width:176.65pt;padding:0'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="85" valign="top" style='width:63.8pt;padding:0'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'><b>December 31,</b></p> </td> <td width="170" colspan="2" valign="top" style='width:127.55pt;padding:0'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'><b>August 31,</b></p> </td> </tr> <tr align="left"> <td width="236" valign="top" style='width:176.65pt;padding:0'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="85" valign="top" style='width:63.8pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'><b>2014</b></p> </td> <td width="85" valign="top" style='width:63.75pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'><b>2014</b></p> </td> <td width="85" valign="top" style='width:63.8pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'><b>2013</b></p> </td> </tr> <tr align="left"> <td width="236" valign="top" style='width:176.65pt;padding:0'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="85" valign="top" style='width:63.8pt;border:none;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="85" valign="top" style='width:63.75pt;border:none;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="85" valign="top" style='width:63.8pt;border:none;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> </tr> <tr align="left"> <td width="236" valign="top" style='width:176.65pt;padding:0'> <p style='margin-right:0in;margin-left:0in'>&#160;&#160; Equipment</p> </td> <td width="85" valign="bottom" style='width:63.8pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:3.7pt;text-align:right'>$&#160;&#160;&#160; 1,503,845</p> </td> <td width="85" valign="bottom" style='width:63.75pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:3.7pt;text-align:right'>$&#160;&#160;&#160; 1,468,528</p> </td> <td width="85" valign="bottom" style='width:63.8pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:3.7pt;text-align:right'>$&#160;&#160;&#160; 1,401,811</p> </td> </tr> <tr align="left"> <td width="236" valign="top" style='width:176.65pt;padding:0'> <p style='margin-right:0in;margin-left:0in'>&#160;&#160; Rental equipment</p> </td> <td width="85" valign="bottom" style='width:63.8pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:3.7pt;text-align:right'>58,940</p> </td> <td width="85" valign="bottom" style='width:63.75pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:3.7pt;text-align:right'>58,940</p> </td> <td width="85" valign="bottom" style='width:63.8pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:3.7pt;text-align:right'>58,940</p> </td> </tr> <tr align="left"> <td width="236" valign="top" style='width:176.65pt;padding:0'> <p style='margin-right:0in;margin-left:0in'>&#160;&#160; Furniture and fixtures</p> </td> <td width="85" valign="bottom" style='width:63.8pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:3.7pt;text-align:right'>303,226</p> </td> <td width="85" valign="bottom" style='width:63.75pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:3.7pt;text-align:right'>303,226</p> </td> <td width="85" valign="bottom" style='width:63.8pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:3.7pt;text-align:right'>300,061</p> </td> </tr> <tr align="left"> <td width="236" valign="top" style='width:176.65pt;padding:0'> <p style='margin-right:0in;margin-left:0in'>&#160;&#160; Building improvements</p> </td> <td width="85" valign="bottom" style='width:63.8pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:3.7pt;text-align:right'>-</p> </td> <td width="85" valign="bottom" style='width:63.75pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:3.7pt;text-align:right'>54,736</p> </td> <td width="85" valign="bottom" style='width:63.8pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:3.7pt;text-align:right'>54,736</p> </td> </tr> <tr align="left"> <td width="236" valign="top" style='width:176.65pt;padding:0'> <p style='margin-right:0in;margin-left:0in'>&#160;&#160; Building (held for sale)</p> </td> <td width="85" valign="bottom" style='width:63.8pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:3.7pt;text-align:right'>956,000</p> </td> <td width="85" valign="bottom" style='width:63.75pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:3.7pt;text-align:right'>956,000</p> </td> <td width="85" valign="bottom" style='width:63.8pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:3.7pt;text-align:right'>956,000</p> </td> </tr> <tr align="left"> <td width="236" valign="top" style='width:176.65pt;padding:0'> <p style='margin-right:0in;margin-left:0in'>&#160;&#160; Land&#160; (held for sale)</p> </td> <td width="85" valign="bottom" style='width:63.8pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:3.7pt;text-align:right'>244,000</p> </td> <td width="85" valign="bottom" style='width:63.75pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:3.7pt;text-align:right'>244,000</p> </td> <td width="85" valign="bottom" style='width:63.8pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:3.7pt;text-align:right'>244,000</p> </td> </tr> <tr align="left"> <td width="236" valign="top" style='width:176.65pt;padding:0'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="85" valign="bottom" style='width:63.8pt;border:none;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:3.7pt;text-align:right'>&nbsp;</p> </td> <td width="85" valign="bottom" style='width:63.75pt;border:none;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:3.7pt;text-align:right'>&nbsp;</p> </td> <td width="85" valign="bottom" style='width:63.8pt;border:none;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:3.7pt;text-align:right'>&nbsp;</p> </td> </tr> <tr align="left"> <td width="236" valign="top" style='width:176.65pt;padding:0'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="85" valign="bottom" style='width:63.8pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:3.7pt;text-align:right'>3,066,011</p> </td> <td width="85" valign="bottom" style='width:63.75pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:3.7pt;text-align:right'>3,085,430</p> </td> <td width="85" valign="bottom" style='width:63.8pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:3.7pt;text-align:right'>3,015,548</p> </td> </tr> <tr align="left"> <td width="236" valign="top" style='width:176.65pt;padding:0'> <p style='margin-right:0in;margin-left:0in'>&#160;&#160; Less equipment impairment</p> </td> <td width="85" valign="bottom" style='width:63.8pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&#160;(&#160;&#160;&#160;&#160; 85,000)</p> </td> <td width="85" valign="bottom" style='width:63.75pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>-</p> </td> <td width="85" valign="bottom" style='width:63.8pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>-</p> </td> </tr> <tr align="left"> <td width="236" valign="top" style='width:176.65pt;padding:0'> <p style='margin-right:0in;margin-left:0in'>&#160;&#160; Less accumulated depreciation</p> </td> <td width="85" valign="bottom" style='width:63.8pt;border:none;border-bottom:solid black 1.0pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>(1,840,140)</p> </td> <td width="85" valign="bottom" style='width:63.75pt;border:none;border-bottom:solid black 1.0pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>(1,817,769)</p> </td> <td width="85" valign="bottom" style='width:63.8pt;border:none;border-bottom:solid black 1.0pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>(1,695,668)</p> </td> </tr> <tr align="left"> <td width="236" valign="top" style='width:176.65pt;padding:0'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="85" valign="bottom" style='width:63.8pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="85" valign="bottom" style='width:63.75pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="85" valign="bottom" style='width:63.8pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> </tr> <tr style='height:13.3pt'> <td width="236" valign="top" style='width:176.65pt;padding:0;height:13.3pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="85" valign="bottom" style='width:63.8pt;border:none;border-bottom:double windowtext 1.5pt;padding:0;height:13.3pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>$&#160;&#160;&#160; 1,140,871</p> </td> <td width="85" valign="bottom" style='width:63.75pt;border:none;border-bottom:double windowtext 1.5pt;padding:0;height:13.3pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>$&#160;&#160;&#160; 1,267,661</p> </td> <td width="85" valign="bottom" style='width:63.8pt;border:none;border-bottom:double windowtext 1.5pt;padding:0;height:13.3pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>$&#160;&#160;&#160; 1,319,880</p> </td> </tr> </table> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-align:justify;text-indent:.5in'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>Depreciation expense totaled $43,280 for the four months ended December 31, 2014 and totaled $125,824 and $128,121 for the years ended August 31, 2014 and 2013, respectively.</p> <!--egx--><p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'><b>Note 5:&#160; Impairment&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </b></p> <p style='margin-right:0in;margin-left:0in;text-indent:.5in;background:white'>In 2014, our Board of Directors determined that it is in the best interest of Perseon shareholders to divest of our assets related to the hyperthermia product line &#160;&#160;&#160;In connection with our plans to either sell or divest the assets related to the hyperthermia product line, we analyzed the carrying value and estimated net realizable value of inventory and other assets related to the hyperthermia product line as of December 31, 2014.&#160; As a result of this analysis, during the four months ended December 31, 2014, we recorded an impairment charge of $805,000 for inventory, equipment, and other assets related to the hyperthermia product line.&#160; These impairment expenses are the result of our assessment of the decrease in the estimated realizable value associated with assets related to the hyperthermia product line.&#160; The inventory reserve was also increased by $50,000 in the corresponding year ended August 31, 2014, to recognize a portion of the devaluation of inventory related to the hyperthermia product line.</p> <!--egx--><p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'><b>Note 6:&nbsp;&nbsp;Patents</b></p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>Patent costs are expense as incurred.&nbsp;&nbsp;In prior years we had certain patents recorded net of accumulated amortization.&nbsp;&nbsp;The patents were being amortized on a straight-line basis over their estimated legal life, up to a period of 17 years.&#160; Amortization expense was $0 for the four months ended December 31, 2014, and was $0 and $4,032 for the years ended August 31, 2014 and 2013, respectively.</p> <!--egx--><p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'><b>Note 7:&nbsp;&nbsp;Stockholders&#146; Equity</b></p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>The Company has 10,000,000 authorized shares of $.001 par value preferred stock.&nbsp;&nbsp;As of December 31, 2014, August 31, 2014 and 2013, there were no shares of preferred stock outstanding.&nbsp;&nbsp;The Company also has 80,000,000 authorized shares of $.001 par value common stock.</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'><b><i>Shelf Registration Statements</i></b></p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>On October 1, 2009, a universal shelf registration statement was declared effective by the SEC for the issuance of common stock, preferred stock, warrants, senior debt, subordinated debt and units up to an aggregate amount of $50.0 million (the &#147;2009 Shelf Registration Statement&#148;).&nbsp;&nbsp;We completed four stock offerings utilizing the universal shelf registration statement during calendar year 2010, and we received total net proceeds of approximately $19.2 million, including proceeds from the exercise of warrants issued in the stock offerings.</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>On September 28, 2012, we filed a universal shelf registration statement with the SEC for the issuance of common stock, preferred stock, warrants, senior debt, subordinated debt and units up to an aggregate amount of $50.0 million (the &#147;2012 Shelf Registration Statement&#148;).&nbsp;&nbsp;On October 11, 2012, the 2012 Shelf Registration Statement was declared effective by the SEC.&nbsp;&nbsp;We have completed two stock offerings utilizing the 2012 Shelf Registration Statement from April 2013 through December 31, 2014, and we received total net proceeds of approximately $9.0 million from these offerings, as more fully described below.&#160; We may periodically offer one or more of these securities in amounts, prices and terms to be announced when and if the securities are offered.&nbsp;&nbsp;At the time any of the securities covered by the registration statement are offered for sale, a prospectus supplement will be prepared and filed with the SEC containing specific information about the terms of any such offering.</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'><b><i>April 2013 Offering</i></b></p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>On April 9, 2013, we entered into a placement agency agreement (the &#147;Agency Agreement&#148;) with Roth Capital Partners, LLC (the &#147;Placement Agent&#148;), pursuant to which the Placement Agent agreed to use its reasonable efforts to arrange for the sale of up to 4,065,042 shares of our common stock and warrants to purchase up to 3,048,782 shares of our common stock in a registered direct public offering (the &#147;April 2013 Offering&#148;).&nbsp;&nbsp;The Placement Agent was entitled to a cash fee of 6.5% of the gross proceeds paid to us for the securities sold in the April 2013 Offering.&nbsp;&nbsp;We also reimbursed the Placement Agent for all reasonable and documented out-of-pocket expenses incurred by the Placement Agent in connection with the April 2013 Offering, not to exceed the lesser of (i) $35,000 or (ii) 8% of the gross proceeds of the April 2013 Offering, less the Placement Agent&#146;s placement fee.</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>The Agency Agreement contains customary representations, warranties and covenants by us.&nbsp;&nbsp;It also provides for customary indemnification by us and the Placement Agent for losses or damages arising out of or in connection with the sale of the securities being offered.&nbsp;&nbsp;We agreed to indemnify the Placement Agent against liabilities under the Securities Act of 1933, as amended.&nbsp;&nbsp;We also agreed to contribute to payments the Placement Agent may be required to make in respect of such liabilities.</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>Also on April 9, 2013, we and certain institutional investors entered into a securities purchase agreement (the &#147;Purchase Agreement&#148;) in connection with the April 2013 Offering, pursuant to which we agreed to sell an aggregate of 4,065,042 shares of our common stock and warrants to purchase a total of 3,048,782 shares of our common stock to such investors for aggregate gross proceeds, before deducting fees to the Placement Agent and other estimated offering expenses payable by us, of approximately $5.0 million.&nbsp;&nbsp;The common stock and warrants were sold in fixed combinations, with each combination consisting of one share of common stock and a warrant to purchase 0.75 shares of common stock.&nbsp;&nbsp;The purchase price was $1.23 per fixed combination.&nbsp;&nbsp;The warrants became exercisable six months and one day following the closing date of the April 2013 Offering and will remain exercisable for five years thereafter at an exercise price of $1.65 per share.&nbsp;&nbsp;The exercise price of the warrants is subject to adjustment in the case of stock splits, stock dividends, combinations of shares and similar recapitalization transactions.</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>The exercisability of the warrants may be limited if, upon exercise, the holder or any of its affiliates would beneficially own more than 4.9% of our common stock.</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>We agreed with each of the purchasers that, subject to certain exceptions, we will not, within the 30 trading days following the closing of the April 2013 Offering (which period may be extended in certain circumstances), enter into any agreement to issue or announce the issuance or proposed issuance of any securities.</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>We also agreed with each of the purchasers that while the warrants are outstanding, we will not affect or enter into an agreement to affect a &#147;Variable Rate Transaction,&#148; which means a transaction in which we:</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <table border="0" cellspacing="0" cellpadding="0" width="98%" style='width:98.16%;margin-left:8.9pt'> <tr align="left"> <td width="5%" valign="top" style='width:5.7%;padding:0'> <p align="center" style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-align:center'>&#149;</p> </td> <td width="94%" valign="top" style='width:94.3%;padding:0'> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>issue or sell any convertible securities either (A) at a conversion, exercise or exchange rate or other price that is based upon and/or varies with the trading prices of, or quotations for, the shares of our common stock at any time after the initial issuance of such convertible securities, or (B) with a conversion, exercise or exchange price that is subject to being reset at some future date after the initial issuance of such convertible securities or upon the occurrence of specified or contingent events directly or indirectly related to our business or the market for our common stock, other than pursuant to a customary &#147;weighted average&#148; anti-dilution provision; or</p> </td> </tr> <tr align="left"> <td width="5%" valign="top" style='width:5.7%;padding:0'> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>&nbsp; </p> </td> <td width="94%" valign="top" style='width:94.3%;padding:0'> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>&nbsp; </p> </td> </tr> <tr align="left"> <td width="5%" valign="top" style='width:5.7%;padding:0'> <p align="center" style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-align:center'>&#149;</p> </td> <td width="94%" valign="top" style='width:94.3%;padding:0'> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>enter into any agreement (including, without limitation, an equity line of credit) whereby we may sell securities at a future determined price (other than standard and customary &#147;preemptive&#148; or &#147;participation&#148; rights).</p> </td> </tr> </table> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>We also agreed with each of the purchasers if we issue securities within the 12 months following the closing of the April 2013 Offering, the purchasers shall have the right to purchase all of the securities on the same terms, conditions and price provided for in the proposed issuance of securities.</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>We also agreed to indemnify each of the purchasers against certain losses resulting from our breach of any of our representations, warranties, or covenants under agreements with each of the purchasers, as well as under certain other circumstances described in the Purchase Agreement.</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>We closed the April 2013 Offering on April 12, 2013 and received net proceeds of approximately $4.6 million, after deducting placement agent fees and the offering expenses borne by us.</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>The April 2013 Offering was completed using the 2012 Shelf Registration Statement, pursuant to a prospectus supplement filed with the SEC.</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'><b><i>May 2014 Offering</i></b></p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>On May 9, 2014, the Company entered into an At-the-Market Issuance Sales Agreement (the &#147;ATM Agreement&#148;) with MLV &amp; Co. LLC (&#147;MLV&#148;).&nbsp;&nbsp;Under this sales agreement, we could issue and sell from time to time, up to $8,000,000 of common stock.&nbsp;&nbsp;These shares are registered under the 2012 Shelf Registration Statement .&nbsp;&nbsp;MLV would act as sales agent, using commercially reasonable efforts consistent with its normal trading and sales practices.&nbsp;&nbsp;The Agreement provided that our common shares would be sold at market prices prevailing at the time of the sale of our common stock, at no discount to market and no warrants attached.&nbsp;&nbsp;We were not obligated to make any sales under the sales agreement.&nbsp;&nbsp;We paid MLV a commission rate of 3.0% of the gross proceeds from the sale of common stock sold through MLV as sales agent under the sales agreement, reimbursed MLV for certain expenses incurred in connection with entering into the sales agreement, and provided MLV with customary indemnification rights. The full terms and text of the sales agreement was filed by the Company on a Current Report on Form 8-K on May 9, 2014.&nbsp;&nbsp;Through June 22, 2014, the Company sold 46,622 shares of common stock at an average price per share of $1.074, for gross proceeds of $50,068.&nbsp;&nbsp;The ATM Agreement was terminated on June 22, 2014.</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'><b><i>June 2014 Offering</i></b></p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>On June 25, 2014, the Company and certain institutional investors entered into a securities purchase agreement (the &#147;June Offering&#148;) in which the Company agreed to sell, pursuant to a securities purchase agreement (the &#147;Purchase Agreement&#148;), an aggregate of 5,500,000 shares of its common stock and warrants to purchase a total of 4,400,000 shares of its common stock to such investors for aggregate gross proceeds of approximately $5.2 million, and net proceeds of approximately $4.7 million, after deducting placement agency fees and other costs associated with the transaction.&nbsp;&nbsp;The common stock and warrants were sold in fixed combinations, with each combination consisting of one share of common stock and a warrant to purchase 0.8 shares of common stock.&nbsp;&nbsp;The purchase price was $0.95 per fixed combination.&nbsp;&nbsp;The warrants will become exercisable six months and one day following the closing date of the June Offering and will remain exercisable for five years thereafter at an exercise price of $1.10 per share.&nbsp;&nbsp;The exercise price of the warrants is subject to adjustment in the case of stock splits, stock dividends, combinations of shares and similar recapitalization transactions.&nbsp;&nbsp;The exercisability of the warrants may be limited if, upon exercise, the holder or any of its affiliates would beneficially own more than 4.99% of the Company&#146;s common stock.&nbsp;&nbsp;The warrants are contingently puttable at the option of the holders upon the occurrence of a fundamental transaction (as defined in the warrant agreements).&nbsp;&nbsp;The Company considers that all of the fundamental transactions are within the Company&#146;s sole control, and that the probability of any fundamental transaction occurring and the put being exercised are both remote.</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>Under the Purchase Agreement, the Company has agreed with each of the purchasers that, subject to certain exceptions, it will not, within the 75 days following the closing of the June Offering enter into any agreement to issue or announce the issuance or proposed issuance of any securities.&nbsp;&nbsp;The Company also agreed with each of the purchasers that for a period of four years from the date of the Purchase Agreement, the Company will not affect or enter into an agreement to affect a &#147;Variable Rate Transaction,&#148; which means a transaction in which it:</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>&nbsp;</p> <table border="0" cellspacing="0" cellpadding="0" width="97%" style='width:97.22%;margin-left:13.4pt'> <tr align="left"> <td width="4%" valign="top" style='width:4.8%;padding:0'> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>&#160;&#160;&#160; &#149;</p> </td> <td width="95%" style='width:95.2%;padding:0'> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>issues or sells any convertible securities either (A) at a conversion, exercise or exchange rate or other price that is based upon and/or varies with the trading prices of, or quotations for, the shares of common stock of the Company at any time after the initial issuance of such convertible securities, or (B) with a conversion, exercise or exchange price that is subject to being reset at some future date after the initial issuance of such convertible securities or upon the occurrence of specified or contingent events directly or indirectly related to the business of the Company or the market for the Company&#146;s common stock, other than pursuant to a customary &#147;weighted average&#148; anti-dilution provision; or</p> </td> </tr> <tr align="left"> <td width="4%" valign="top" style='width:4.8%;padding:0'> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td width="95%" style='width:95.2%;padding:0'> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>&nbsp; </p> </td> </tr> <tr align="left"> <td width="4%" valign="top" style='width:4.8%;padding:0'> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>&#149;</p> </td> <td width="95%" style='width:95.2%;padding:0'> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>enters into any agreement (including, without limitation, an equity line of credit) whereby the Company may sell securities at a future determined price.</p> </td> </tr> </table> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>The Company has also agreed to indemnify each of the purchasers against certain losses resulting from its breach of any of its representations, warranties, or covenants under agreements with each of the purchasers, as well as under certain other circumstances described in the Purchase Agreement. The transaction closed on July 1, 2014 and the net proceeds were transferred to the Company.</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'><b><i>Warrants</i></b></p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-align:justify'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-align:justify;text-indent:.5in'>A summary of the outstanding warrants issued in our stock offerings as of December 31, 2014 and August 31, 2014 and changes during the four months ended December 31, 2014 and the year ended August 31, 2014 is as follows:</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-align:justify;text-indent:.5in'>&nbsp;</p> <table border="1" cellspacing="0" cellpadding="0" width="100%" style='width:100.0%;border-collapse:collapse;border:none'> <tr style='height:42.7pt'> <td width="41%" valign="top" style='width:41.92%;border:none;padding:0;height:42.7pt'> <p style='margin-right:0in;margin-left:0in;margin-left:8.8pt;text-indent:-8.8pt'>&nbsp;</p> </td> <td width="19%" valign="bottom" style='width:19.36%;border:none;border-bottom:solid windowtext 1.0pt;padding:0;height:42.7pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'><b>Shares</b></p> </td> <td width="2%" valign="bottom" style='width:2.18%;border:none;border-bottom:solid windowtext 1.0pt;padding:0;height:42.7pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="16%" valign="bottom" style='width:16.12%;border:none;border-bottom:solid windowtext 1.0pt;padding:0;height:42.7pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'><b>Weighted- Average Exercise Price</b></p> </td> <td width="20%" valign="bottom" style='width:20.42%;border:none;border-bottom:solid windowtext 1.0pt;padding:0;height:42.7pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'><b>Weighted-Average Remaining Contract Term (Years)</b></p> </td> </tr> <tr style='height:12.9pt'> <td width="41%" valign="top" style='width:41.92%;border:none;padding:0;height:12.9pt'> <p style='margin-right:0in;margin-left:0in;margin-left:8.8pt;text-indent:-8.8pt'>&nbsp;</p> </td> <td width="19%" valign="bottom" style='width:19.36%;border:none;padding:0;height:12.9pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'>&nbsp;</p> </td> <td width="2%" valign="bottom" style='width:2.18%;border:none;border-bottom:solid windowtext 1.0pt;padding:0;height:12.9pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="16%" valign="bottom" style='width:16.12%;border:none;padding:0;height:12.9pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'>&nbsp;</p> </td> <td width="20%" valign="bottom" style='width:20.42%;border:none;padding:0;height:12.9pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'>&nbsp;</p> </td> </tr> <tr style='height:12.9pt'> <td width="41%" valign="top" style='width:41.92%;border:none;padding:0;height:12.9pt'> <p style='margin-right:0in;margin-left:0in;margin-left:8.8pt;text-indent:-8.8pt'>&nbsp;</p> </td> <td width="19%" valign="bottom" style='width:19.36%;border:none;border-top:solid windowtext 1.0pt;padding:0;height:12.9pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'>&nbsp;</p> </td> <td width="2%" valign="bottom" style='width:2.18%;border:none;padding:0;height:12.9pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="16%" valign="bottom" style='width:16.12%;border:none;border-top:solid windowtext 1.0pt;padding:0;height:12.9pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'>&nbsp;</p> </td> <td width="20%" valign="bottom" style='width:20.42%;border:none;border-top:solid windowtext 1.0pt;padding:0;height:12.9pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'>&nbsp;</p> </td> </tr> <tr style='height:12.9pt'> <td width="41%" valign="bottom" style='width:41.92%;border:none;padding:0;height:12.9pt'> <p style='margin-right:0in;margin-left:0in;margin-left:8.8pt;text-indent:-8.8pt'>Outstanding as of August 31, 2013</p> </td> <td width="19%" valign="bottom" style='width:19.36%;border:none;padding:0;height:12.9pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.2in;text-align:right'>5,457,305</p> </td> <td width="2%" valign="bottom" style='width:2.18%;border:none;padding:0;height:12.9pt'> <p style='margin-right:0in;margin-left:0in'>$</p> </td> <td width="16%" valign="bottom" style='width:16.12%;border:none;padding:0;height:12.9pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'>2.93</p> </td> <td width="20%" valign="bottom" style='width:20.42%;border:none;padding:0;height:12.9pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'>-</p> </td> </tr> <tr style='height:12.6pt'> <td width="41%" valign="bottom" style='width:41.92%;border:none;padding:0;height:12.6pt'> <p style='margin-right:0in;margin-left:0in;margin-left:8.8pt;text-indent:-8.8pt'>Granted</p> </td> <td width="19%" valign="bottom" style='width:19.36%;border:none;padding:0;height:12.6pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.2in;text-align:right'>4,400,000</p> </td> <td width="2%" valign="bottom" style='width:2.18%;border:none;padding:0;height:12.6pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="16%" valign="bottom" style='width:16.12%;border:none;padding:0;height:12.6pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'>1.10</p> </td> <td width="20%" valign="bottom" style='width:20.42%;border:none;padding:0;height:12.6pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'>-</p> </td> </tr> <tr style='height:13.5pt'> <td width="41%" valign="bottom" style='width:41.92%;border:none;padding:0;height:13.5pt'> <p style='margin-right:0in;margin-left:0in;margin-left:8.8pt;text-indent:-8.8pt'>Exercised</p> </td> <td width="19%" valign="bottom" style='width:19.36%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.2in;text-align:right'>-</p> </td> <td width="2%" valign="bottom" style='width:2.18%;border:none;padding:0;height:13.5pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="16%" valign="bottom" style='width:16.12%;border:none;padding:0;height:13.5pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'>-</p> </td> <td width="20%" valign="bottom" style='width:20.42%;border:none;padding:0;height:13.5pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'>-</p> </td> </tr> <tr style='height:13.5pt'> <td width="41%" valign="bottom" style='width:41.92%;border:none;padding:0;height:13.5pt'> <p style='margin-right:0in;margin-left:0in;margin-left:8.8pt;text-indent:-8.8pt'>Forfeited or expired</p> </td> <td width="19%" valign="bottom" style='width:19.36%;border:none;border-bottom:solid windowtext 1.0pt;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.2in;text-align:right'>-</p> </td> <td width="2%" valign="bottom" style='width:2.18%;border:none;border-bottom:solid windowtext 1.0pt;padding:0;height:13.5pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="16%" valign="bottom" style='width:16.12%;border:none;border-bottom:solid windowtext 1.0pt;padding:0;height:13.5pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'>-</p> </td> <td width="20%" valign="bottom" style='width:20.42%;border:none;border-bottom:solid windowtext 1.0pt;padding:0;height:13.5pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'>-</p> </td> </tr> <tr style='height:13.5pt'> <td width="41%" valign="bottom" style='width:41.92%;border:none;padding:0;height:13.5pt'> <p style='margin-right:0in;margin-left:0in;margin-left:8.8pt;text-indent:-8.8pt'>&nbsp;</p> </td> <td width="19%" valign="bottom" style='width:19.36%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.2in;text-align:right'>&nbsp;</p> </td> <td width="2%" valign="bottom" style='width:2.18%;border:none;padding:0;height:13.5pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="16%" valign="bottom" style='width:16.12%;border:none;padding:0;height:13.5pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'>&nbsp;</p> </td> <td width="20%" valign="bottom" style='width:20.42%;border:none;padding:0;height:13.5pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'>&nbsp;</p> </td> </tr> <tr style='height:13.5pt'> <td width="41%" valign="bottom" style='width:41.92%;border:none;padding:0;height:13.5pt'> <p style='margin-right:0in;margin-left:0in;margin-left:8.8pt;text-indent:-8.8pt'>Outstanding as of August 31, 2014</p> </td> <td width="19%" valign="bottom" style='width:19.36%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.2in;text-align:right'>9,857,305</p> </td> <td width="2%" valign="bottom" style='width:2.18%;border:none;padding:0;height:13.5pt'> <p style='margin-right:0in;margin-left:0in'>$</p> </td> <td width="16%" valign="bottom" style='width:16.12%;border:none;padding:0;height:13.5pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'>2.11</p> </td> <td width="20%" valign="bottom" style='width:20.42%;border:none;padding:0;height:13.5pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'>4.02</p> </td> </tr> <tr style='height:13.5pt'> <td width="41%" valign="bottom" style='width:41.92%;border:none;padding:0;height:13.5pt'> <p style='margin-right:0in;margin-left:0in;margin-left:8.8pt;text-indent:-8.8pt'>Granted</p> </td> <td width="19%" valign="bottom" style='width:19.36%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.2in;text-align:right'>-</p> </td> <td width="2%" valign="bottom" style='width:2.18%;border:none;padding:0;height:13.5pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="16%" valign="bottom" style='width:16.12%;border:none;padding:0;height:13.5pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'>-</p> </td> <td width="20%" valign="bottom" style='width:20.42%;border:none;padding:0;height:13.5pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'>-</p> </td> </tr> <tr style='height:13.5pt'> <td width="41%" valign="bottom" style='width:41.92%;border:none;padding:0;height:13.5pt'> <p style='margin-right:0in;margin-left:0in;margin-left:8.8pt;text-indent:-8.8pt'>Exercised</p> </td> <td width="19%" valign="bottom" style='width:19.36%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.2in;text-align:right'>-</p> </td> <td width="2%" valign="bottom" style='width:2.18%;border:none;padding:0;height:13.5pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="16%" valign="bottom" style='width:16.12%;border:none;padding:0;height:13.5pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'>-</p> </td> <td width="20%" valign="bottom" style='width:20.42%;border:none;padding:0;height:13.5pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'>-</p> </td> </tr> <tr style='height:13.5pt'> <td width="41%" valign="bottom" style='width:41.92%;border:none;padding:0;height:13.5pt'> <p style='margin-right:0in;margin-left:0in;margin-left:8.8pt;text-indent:-8.8pt'>Forfeited or expired</p> </td> <td width="19%" valign="bottom" style='width:19.36%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.2in;text-align:right'>-</p> </td> <td width="2%" valign="bottom" style='width:2.18%;border:none;padding:0;height:13.5pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="16%" valign="bottom" style='width:16.12%;border:none;padding:0;height:13.5pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'>-</p> </td> <td width="20%" valign="bottom" style='width:20.42%;border:none;padding:0;height:13.5pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'>-</p> </td> </tr> <tr style='height:13.5pt'> <td width="41%" valign="bottom" style='width:41.92%;border:none;padding:0;height:13.5pt'> <p style='margin-right:0in;margin-left:0in;margin-left:8.8pt;text-indent:-8.8pt'>&nbsp;</p> </td> <td width="19%" valign="bottom" style='width:19.36%;border:none;border-top:solid windowtext 1.0pt;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.2in;text-align:right'>&nbsp;</p> </td> <td width="2%" valign="bottom" style='width:2.18%;border:none;border-top:solid windowtext 1.0pt;padding:0;height:13.5pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="16%" valign="bottom" style='width:16.12%;border:none;border-top:solid windowtext 1.0pt;padding:0;height:13.5pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'>&nbsp;</p> </td> <td width="20%" valign="bottom" style='width:20.42%;border:none;border-top:solid windowtext 1.0pt;padding:0;height:13.5pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'>&nbsp;</p> </td> </tr> <tr style='height:12.6pt'> <td width="41%" valign="bottom" style='width:41.92%;border:none;padding:0;height:12.6pt'> <p style='margin-right:0in;margin-left:0in;margin-left:8.8pt;text-indent:-8.8pt'>Outstanding as of December 31, 2014</p> </td> <td width="19%" valign="bottom" style='width:19.36%;border:none;border-bottom:double windowtext 1.5pt;padding:0;height:12.6pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.2in;text-align:right'>9,857,305</p> </td> <td width="2%" valign="bottom" style='width:2.18%;border:none;border-bottom:double windowtext 1.5pt;padding:0;height:12.6pt'> <p style='margin-right:0in;margin-left:0in'>$</p> </td> <td width="16%" valign="bottom" style='width:16.12%;border:none;border-bottom:double windowtext 1.5pt;padding:0;height:12.6pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'>2.11</p> </td> <td width="20%" valign="bottom" style='width:20.42%;border:none;border-bottom:double windowtext 1.5pt;padding:0;height:12.6pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'>3.69</p> </td> </tr> <tr style='height:12.15pt'> <td width="41%" valign="bottom" style='width:41.92%;border:none;padding:0;height:12.15pt'> <p style='margin-right:0in;margin-left:0in;margin-left:8.8pt;text-indent:-8.8pt'>&nbsp;</p> </td> <td width="19%" valign="bottom" style='width:19.36%;border:none;padding:0;height:12.15pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'>&nbsp;</p> </td> <td width="2%" valign="bottom" style='width:2.18%;border:none;padding:0;height:12.15pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="16%" valign="bottom" style='width:16.12%;border:none;padding:0;height:12.15pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'>&nbsp;</p> </td> <td width="20%" valign="bottom" style='width:20.42%;border:none;padding:0;height:12.15pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'>&nbsp;</p> </td> </tr> <tr style='height:14.85pt'> <td width="41%" valign="bottom" style='width:41.92%;border:none;padding:0;height:14.85pt'> <p style='margin-right:0in;margin-left:0in;margin-left:8.8pt;text-indent:-8.8pt'>Exercisable as of December 31, 2014</p> </td> <td width="19%" valign="bottom" style='width:19.36%;border:none;border-bottom:double windowtext 1.5pt;padding:0;height:14.85pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.2in;text-align:right'>5,457,305</p> </td> <td width="2%" valign="bottom" style='width:2.18%;border:none;border-bottom:double windowtext 1.5pt;padding:0;height:14.85pt'> <p style='margin-right:0in;margin-left:0in'>$</p> </td> <td width="16%" valign="bottom" style='width:16.12%;border:none;border-bottom:double windowtext 1.5pt;padding:0;height:14.85pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'>2.93</p> </td> <td width="20%" valign="bottom" style='width:20.42%;border:none;border-bottom:double windowtext 1.5pt;padding:0;height:14.85pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'>2.62</p> </td> </tr> </table> <!--egx--><p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'><b>Note 8:&nbsp;&nbsp;Deferred Revenue</b></p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>We have entered into certain service contracts and other agreements for which we have received payment in advance.&nbsp;&nbsp;We recognize these revenues over the life of the agreements.</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>As of December 31, 2014, August 31, 2014 and August 31, 2013, we had deferred revenue of $54,218, $96,043 and $783,708, respectively.</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>&nbsp;</p> <!--egx--><p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'><b>Note 9:&nbsp;&nbsp;Major Customers and Foreign Sales</b></p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>During the four months ended December 31, 2014, we had sales to two foreign customers totaling 41.53% and 11.30% of total revenues.&#160; During the year ended August 31, 2014, we had sales to two foreign customers totaling 23.46% and 22.92% of total revenues.&nbsp;&nbsp;During the year ended August 31, 2013, we had sales to one customer totaling 30.36% of total revenues.&nbsp;&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>Export sales were $630,857 in the four months ended December 31, 2014, and $3,381,563 and $1,470,619 in the years ended August 31 2014 and 2013, respectively.</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; During the four months ended December 31, 2014, export sales to Germany and Belgium combined were approximately 53%.&#160;&#160; During fiscal year 2014, export sales to Taiwan and Belgium combined were approximately 46% of total sales.&nbsp;&nbsp;During fiscal year 2013, export sales to Belgium and Germany combined were approximately 30%.</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-align:justify;text-indent:.5in'>As of December 31, 2014, the highest account receivable due from one customer was 36% of total accounts receivable. &#160;As of August 31, 2014, the highest account receivable due from one customer was approximately 68% of total accounts receivable.&nbsp;&nbsp;As of August 31, 2013, the highest account receivable due from one customer was approximately 72% of total accounts receivable.</p> <!--egx--><p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'><b>Note 10:&nbsp;&nbsp;Related Party Transactions</b></p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>We had sales of $463,423 during the four months ended December 31, 2014, and $419,549 and $99,896 during the years ended August 31, 2014 and 2013, respectively, to entities controlled by a significant stockholder and member of the Board of Directors.&nbsp;&nbsp;These related party transactions represent approximately 42%, 8% and 3% of total sales for each respective period.</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>As of December 31, 2014, August 31, 2014 and August 31, 2013, receivables include $13,471, $8,322 and $24,201, respectively, from these related parties.</p> <!--egx--><p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'><b>Note 11:&nbsp;&nbsp;Income Taxes</b></p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-align:justify'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>The income tax provision of $2,000 and $1,938 for the years ended August 31, 2014 and 2013, respectively, is comprised of a current provision for state income taxes.&#160; </p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>The income tax (provision) benefit differs from the amount computed at federal statutory rates as follows:&nbsp;&nbsp;&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>&nbsp;</p> <table border="0" cellspacing="0" cellpadding="0" width="567" style='border-collapse:collapse'> <tr align="left"> <td width="252" valign="top" style='width:188.9pt;padding:0'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="126" valign="top" style='width:94.6pt;padding:0'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'><b>Four Months Ended December 31, </b></p> </td> <td width="189" colspan="2" valign="top" style='width:141.75pt;padding:0'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'><b>Years Ended August 31,</b></p> </td> </tr> <tr align="left"> <td width="252" valign="top" style='width:188.9pt;padding:0'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="126" valign="top" style='width:94.6pt;border:none;border-bottom:solid black 1.0pt;padding:0'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'><b>2014</b></p> </td> <td width="95" valign="top" style='width:70.9pt;border:none;border-bottom:solid black 1.0pt;padding:0'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'><b>2014</b></p> </td> <td width="94" valign="top" style='width:70.85pt;border:none;border-bottom:solid black 1.0pt;padding:0'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'><b>2013</b></p> </td> </tr> <tr align="left"> <td width="252" valign="top" style='width:188.9pt;padding:0'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="126" valign="top" style='width:94.6pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.1in;text-align:right'>&nbsp;</p> </td> <td width="95" valign="top" style='width:70.9pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.1in;text-align:right'>&nbsp;</p> </td> <td width="94" valign="top" style='width:70.85pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.1in;text-align:right'>&nbsp;</p> </td> </tr> <tr align="left"> <td width="252" valign="top" style='width:188.9pt;padding:0'> <p style='margin-right:0in;margin-left:0in'>Income tax benefit at federal statutory rate</p> </td> <td width="126" valign="top" style='width:94.6pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.1in;text-align:right'>$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 1,281,000</p> </td> <td width="95" valign="top" style='width:70.9pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:3.7pt;text-align:right'>$&#160;&#160;&#160;&#160; 2,428,000</p> </td> <td width="94" valign="top" style='width:70.85pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:3.7pt;text-align:right'>$&#160;&#160;&#160;&#160; 2,805,000</p> </td> </tr> <tr align="left"> <td width="252" valign="top" style='width:188.9pt;padding:0'> <p style='margin-right:0in;margin-left:0in'>Stock-based compensation</p> </td> <td width="126" valign="top" style='width:94.6pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>(66,000)</p> </td> <td width="95" valign="top" style='width:70.9pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>(287,000)</p> </td> <td width="94" valign="top" style='width:70.85pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>(335,000)</p> </td> </tr> <tr align="left"> <td width="252" valign="top" style='width:188.9pt;padding:0'> <p style='margin-right:0in;margin-left:0in'>State income taxes, net of federal benefit</p> </td> <td width="126" valign="top" style='width:94.6pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.1in;text-align:right'>124,000</p> </td> <td width="95" valign="top" style='width:70.9pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:3.7pt;text-align:right'>236,000</p> </td> <td width="94" valign="top" style='width:70.85pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:3.7pt;text-align:right'>272,000</p> </td> </tr> <tr align="left"> <td width="252" valign="top" style='width:188.9pt;padding:0'> <p style='margin-right:0in;margin-left:0in'>Research and development credit</p> </td> <td width="126" valign="top" style='width:94.6pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.1in;text-align:right'>33,000</p> </td> <td width="95" valign="top" style='width:70.9pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:3.7pt;text-align:right'>99,000</p> </td> <td width="94" valign="top" style='width:70.85pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:3.7pt;text-align:right'>106,000</p> </td> </tr> <tr align="left"> <td width="252" valign="top" style='width:188.9pt;padding:0'> <p style='margin-right:0in;margin-left:0in'>Valuation allowance</p> </td> <td width="126" valign="top" style='width:94.6pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>(1,360,000)</p> </td> <td width="95" valign="top" style='width:70.9pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>(2,480,000)</p> </td> <td width="94" valign="top" style='width:70.85pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>(2,905,000)</p> </td> </tr> <tr align="left"> <td width="252" valign="top" style='width:188.9pt;padding:0'> <p style='margin-right:0in;margin-left:0in'>Other</p> </td> <td width="126" valign="top" style='width:94.6pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>(12,000)</p> </td> <td width="95" valign="top" style='width:70.9pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:3.7pt;text-align:right'>2,000</p> </td> <td width="94" valign="top" style='width:70.85pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:3.7pt;text-align:right'>55,062</p> </td> </tr> <tr style='height:14.35pt'> <td width="252" valign="top" style='width:188.9pt;padding:0;height:14.35pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="126" valign="top" style='width:94.6pt;border:none;padding:0;height:14.35pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="95" valign="top" style='width:70.9pt;border:none;padding:0;height:14.35pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:3.7pt;text-align:right'>&nbsp;</p> </td> <td width="94" valign="top" style='width:70.85pt;border:none;padding:0;height:14.35pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:3.7pt;text-align:right'>&nbsp;</p> </td> </tr> <tr style='height:12.6pt'> <td width="252" valign="top" style='width:188.9pt;padding:0;height:12.6pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="126" valign="top" style='width:94.6pt;border:none;border-bottom:double windowtext 1.5pt;padding:0;height:12.6pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:5.65pt;text-align:right'>&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</p> </td> <td width="95" valign="top" style='width:70.9pt;border:none;border-bottom:double windowtext 1.5pt;padding:0;height:12.6pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (2,000)</p> </td> <td width="94" valign="top" style='width:70.85pt;border:none;border-bottom:double windowtext 1.5pt;padding:0;height:12.6pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (1,938)</p> </td> </tr> </table> <p style='margin-right:0in;margin-left:0in;text-indent:.5in'>Deferred tax assets (liabilities) are comprised of the following:</p> <table border="0" cellspacing="0" cellpadding="0" style='margin-left:5.4pt;border-collapse:collapse'> <tr align="left"> <td width="293" valign="top" style='width:219.75pt;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="102" valign="top" style='width:76.35pt;padding:0in 5.4pt 0in 5.4pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'><b>December 31,</b></p> </td> <td width="188" colspan="2" valign="top" style='width:141.3pt;padding:0in 5.4pt 0in 5.4pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'><b>August 31,</b></p> </td> </tr> <tr align="left"> <td width="293" valign="top" style='width:219.75pt;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="102" valign="top" style='width:76.35pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'><b>2014</b></p> </td> <td width="94" valign="top" style='width:70.65pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'><b>2014</b></p> </td> <td width="94" valign="top" style='width:70.65pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'><b>2013</b></p> </td> </tr> <tr align="left"> <td width="293" valign="top" style='width:219.75pt;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>Current Asset:</p> </td> <td width="102" valign="top" style='width:76.35pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="94" valign="top" style='width:70.65pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="94" valign="top" style='width:70.65pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> </tr> <tr align="left"> <td width="293" valign="top" style='width:219.75pt;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>&#160;&#160; Accruals and reserves</p> </td> <td width="102" valign="top" style='width:76.35pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>$&#160;&#160;&#160;&#160;&#160;&#160;&#160; 73,000</p> </td> <td width="94" valign="top" style='width:70.65pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 62,000</p> </td> <td width="94" valign="top" style='width:70.65pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 26,000</p> </td> </tr> <tr align="left"> <td width="293" valign="top" style='width:219.75pt;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>&#160;&#160; Deferred revenue</p> </td> <td width="102" valign="top" style='width:76.35pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>18,000</p> </td> <td width="94" valign="top" style='width:70.65pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>33,000</p> </td> <td width="94" valign="top" style='width:70.65pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>266,000</p> </td> </tr> <tr align="left"> <td width="293" valign="top" style='width:219.75pt;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>&#160;&#160; Inventories</p> </td> <td width="102" valign="top" style='width:76.35pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>298,000</p> </td> <td width="94" valign="top" style='width:70.65pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>90,000</p> </td> <td width="94" valign="top" style='width:70.65pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>68,000</p> </td> </tr> <tr align="left"> <td width="293" valign="top" style='width:219.75pt;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>Valuation allowance</p> </td> <td width="102" valign="top" style='width:76.35pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>(389,000)</p> </td> <td width="94" valign="top" style='width:70.65pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>(185,000)</p> </td> <td width="94" valign="top" style='width:70.65pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>(360,000)</p> </td> </tr> <tr align="left"> <td width="293" valign="top" style='width:219.75pt;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="102" valign="top" style='width:76.35pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>&nbsp;</p> </td> <td width="94" valign="top" style='width:70.65pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>&nbsp;</p> </td> <td width="94" valign="top" style='width:70.65pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>&nbsp;</p> </td> </tr> <tr align="left"> <td width="293" valign="top" style='width:219.75pt;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="102" valign="top" style='width:76.35pt;border:none;border-bottom:double windowtext 1.5pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; -</p> </td> <td width="94" valign="top" style='width:70.65pt;border:none;border-bottom:double windowtext 1.5pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; -</p> </td> <td width="94" valign="top" style='width:70.65pt;border:none;border-bottom:double windowtext 1.5pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; -</p> </td> </tr> <tr align="left"> <td width="293" valign="top" style='width:219.75pt;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>Long-Term Asset (Liability):</p> </td> <td width="102" valign="top" style='width:76.35pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>&nbsp;</p> </td> <td width="94" valign="top" style='width:70.65pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>&nbsp;</p> </td> <td width="94" valign="top" style='width:70.65pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>&nbsp;</p> </td> </tr> <tr align="left"> <td width="293" valign="top" style='width:219.75pt;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>&#160;&#160; Deferred compensation</p> </td> <td width="102" valign="bottom" style='width:76.35pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>$&#160;&#160;&#160;&#160;&#160;&#160; 601,000</p> </td> <td width="94" valign="bottom" style='width:70.65pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>$&#160;&#160;&#160;&#160;&#160;&#160; 601,000</p> </td> <td width="94" valign="bottom" style='width:70.65pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:3.7pt;text-align:right'>$&#160;&#160;&#160;&#160;&#160;&#160; 601,000</p> </td> </tr> <tr align="left"> <td width="293" valign="top" style='width:219.75pt;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>&#160;&#160; Research and development and other tax credits</p> </td> <td width="102" valign="bottom" style='width:76.35pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>1,929,000</p> </td> <td width="94" valign="bottom" style='width:70.65pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>1,896,000</p> </td> <td width="94" valign="bottom" style='width:70.65pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:3.7pt;text-align:right'>1,804,000</p> </td> </tr> <tr align="left"> <td width="293" valign="top" style='width:219.75pt;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>&#160; Net operating loss carryforwards - federal</p> </td> <td width="102" valign="bottom" style='width:76.35pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>12,951,000</p> </td> <td width="94" valign="bottom" style='width:70.65pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>13,938,000</p> </td> <td width="94" valign="bottom" style='width:70.65pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:3.7pt;text-align:right'>11,380,000</p> </td> </tr> <tr align="left"> <td width="293" valign="top" style='width:219.75pt;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>&#160; Net operating loss carryforwards - state</p> </td> <td width="102" valign="bottom" style='width:76.35pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>2,079,000</p> </td> <td width="94" valign="bottom" style='width:70.65pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>-</p> </td> <td width="94" valign="bottom" style='width:70.65pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:3.7pt;text-align:right'>-</p> </td> </tr> <tr align="left"> <td width="293" valign="top" style='width:219.75pt;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>&#160;&#160; Depreciation and amortization</p> </td> <td width="102" valign="bottom" style='width:76.35pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>39,000</p> </td> <td width="94" valign="bottom" style='width:70.65pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>8,000</p> </td> <td width="94" valign="bottom" style='width:70.65pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:3.7pt;text-align:right'>3,000</p> </td> </tr> <tr align="left"> <td width="293" valign="top" style='width:219.75pt;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>Valuation allowance</p> </td> <td width="102" valign="bottom" style='width:76.35pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>(17,599,000)</p> </td> <td width="94" valign="bottom" style='width:70.65pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>(16,443,000)</p> </td> <td width="94" valign="bottom" style='width:70.65pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>(13,788,000)</p> </td> </tr> <tr align="left"> <td width="293" valign="top" style='width:219.75pt;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="102" valign="bottom" style='width:76.35pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>&nbsp;</p> </td> <td width="94" valign="bottom" style='width:70.65pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>&nbsp;</p> </td> <td width="94" valign="bottom" style='width:70.65pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:3.7pt;text-align:right'>&nbsp;</p> </td> </tr> <tr align="left"> <td width="293" valign="top" style='width:219.75pt;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>&#160;&#160; </p> </td> <td width="102" valign="bottom" style='width:76.35pt;border:none;border-bottom:double windowtext 1.5pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; -</p> </td> <td width="94" valign="bottom" style='width:70.65pt;border:none;border-bottom:double windowtext 1.5pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; -</p> </td> <td width="94" valign="bottom" style='width:70.65pt;border:none;border-bottom:double windowtext 1.5pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:3.7pt;text-align:right'>$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160;&#160;&#160;-</p> </td> </tr> </table> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>The ultimate realization of the deferred tax assets is dependent, in part, upon the tax laws in effect, our future earnings, and other events.&nbsp;&nbsp;As of December 31, 2014, we recorded a valuation allowance of $389,000 against current deferred tax assets, and a valuation allowance of $17,599,000 against net long-term deferred tax assets.&nbsp;&nbsp;The increase in the valuation allowance for the four months ended December 31, 2014 relates primarily to our operating losses.&nbsp;&nbsp;In recording the valuation allowance, we were unable to conclude that it is more likely than not that our deferred tax assets will be realized.</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>In addition to the deferred tax assets listed above, the Company has unrecorded tax benefits of approximately $2,600,000 attributable to the difference between the amount of the financial statement expense and the allowable tax deduction associated with stock-based compensation.&nbsp;&nbsp;As a result of net operating loss carryforwards, the Company was not able to recognize the excess tax benefits of share-based compensation deductions because the deductions did not reduce income tax payable.&nbsp;&nbsp;Although not recognized for financial reporting purposes, this unrecorded tax benefit is available to reduce future income and is incorporated into the disclosed amounts of the Company&#146;s net operating loss carryforwards, discussed below.&nbsp;&nbsp;If subsequently realized, the benefit will be recorded to contributed capital.</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>As of December 31, 2014, we had a net operating loss carryforward available to offset future taxable income of approximately $40,701,000, which will begin to expire in 2029.&nbsp;&nbsp;If substantial changes in the Company&#146;s ownership should occur, there would be an annual limitation of the amount of the net operating loss carryforward which could be utilized.</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>We perform a review of our material tax positions in accordance with recognition and measurement standards established by authoritative accounting literature, which requires a company to determine whether it is more likely than not that a tax position will be sustained upon examination based upon the technical merits of the position.&nbsp;&nbsp;If the more-likely-than-not threshold is met, a company must measure the tax position to determine the amount to recognize in the financial statements.&nbsp;&nbsp;Based upon our review and evaluation, during the four months ended December 31, 2014 and 2013 and the years ended August 31, 2014 and 2013, we concluded the Company had no unrecognized tax benefit that would affect its effective tax rate if recognized.</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>We classify any interest and penalties arising from the underpayment of income taxes in our statements of comprehensive loss in other income (expense).&nbsp;&nbsp;As of December 31, 2014, August 31, 2014 and August 31, 2013, we had no accrued interest or penalties related to uncertain tax positions.</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>We file income tax returns in the U.S. federal jurisdiction and various state jurisdictions.&nbsp;&nbsp;U.S. federal income tax returns from the year ended August 31, 2011 through the period ended December 31, 2014 are subject to examination.</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <!--egx--><p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'><b>Note 12:&nbsp;&nbsp;Stock-Based Compensation</b></p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>Our Third Amended and Restated 1998 Stock Incentive Plan (the &#147;Plan&#148;) authorizes the granting of incentive stock options to certain key employees and non-employees who provide services to the Company.&nbsp;&nbsp;The Plan, as amended, provides for the granting of options for an aggregate of 6,337,300 shares.&nbsp;&nbsp;The options vest subject to management&#146;s discretion.</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>Effective February 4, 2009, our Fourth Amended and Restated 1998 Directors Stock Plan&nbsp;(the &#147;Director Plan&#148;) provides an annual retainer of $60,000 to each non-employee director with the exception of the Audit Committee Chairman who is to receive $65,000.&nbsp;&nbsp;The cash portion of the compensation of $30,000 ($35,000 for the Audit Committee Chairman) is paid 50% twice each year, with $30,000 of compensation paid in common stock of the Company once each year.&nbsp;&nbsp;Prior to February 4, 2009, the Director Plan granted each non-employee outside director 30,000 options each year at an exercise price equal to the fair market value of the common stock at the date the option was granted.&nbsp;&nbsp;The options vest according to a set schedule over a five-year period and expire upon the director&#146;s termination, or after ten years from the date of grant.&nbsp;&nbsp;The Director Plan, as amended, allows for an aggregate of 1,750,000 shares to be granted.</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>Stock-based compensation cost is measured at the grant date based on the estimated value of the award granted, using the Black-Scholes option pricing model, and recognized over the period in which the award vests.&nbsp;&nbsp;For stock awards no longer expected to vest, any previously recognized stock compensation expense is reversed in the period of termination.</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>The stock-based compensation expense has been allocated to the various categories of operating costs and expenses in a manner similar to the allocation of payroll expense as follows:</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>&nbsp;</p> <table border="0" cellspacing="0" cellpadding="0" width="510" style='margin-left:5.4pt;border-collapse:collapse'> <tr style='height:8.1pt'> <td width="227" valign="top" style='width:170.05pt;padding:0in 5.4pt 0in 5.4pt;height:8.1pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="95" valign="top" style='width:70.9pt;padding:0in 5.4pt 0in 5.4pt;height:8.1pt'> <p align="center" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:center'><b>Four Months Ended December 31,</b></p> </td> <td width="189" colspan="2" valign="bottom" style='width:141.75pt;padding:0in 5.4pt 0in 5.4pt;height:8.1pt'> <p align="center" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:center'><b>Years Ended &#160;August 31,</b></p> </td> </tr> <tr style='height:8.1pt'> <td width="227" valign="top" style='width:170.05pt;padding:0in 5.4pt 0in 5.4pt;height:8.1pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="95" valign="bottom" style='width:70.9pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:8.1pt'> <p align="center" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:center'><b>2014</b></p> </td> <td width="95" valign="bottom" style='width:70.9pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:8.1pt'> <p align="center" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:center'><b>2014</b></p> </td> <td width="94" valign="top" style='width:70.85pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:8.1pt'> <p align="center" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:center'><b>2013</b></p> </td> </tr> <tr style='height:8.1pt'> <td width="227" valign="top" style='width:170.05pt;padding:0in 5.4pt 0in 5.4pt;height:8.1pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="95" valign="bottom" style='width:70.9pt;border:none;padding:0in 5.4pt 0in 5.4pt;height:8.1pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>&nbsp;</p> </td> <td width="95" valign="top" style='width:70.9pt;border:none;padding:0in 5.4pt 0in 5.4pt;height:8.1pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>&nbsp;</p> </td> <td width="94" valign="top" style='width:70.85pt;border:none;padding:0in 5.4pt 0in 5.4pt;height:8.1pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>&nbsp;</p> </td> </tr> <tr style='height:8.1pt'> <td width="227" valign="bottom" style='width:170.05pt;padding:0in 5.4pt 0in 5.4pt;height:8.1pt'> <p style='margin-right:0in;margin-left:0in'>Cost of sales</p> </td> <td width="95" valign="bottom" style='width:70.9pt;padding:0in 5.4pt 0in 5.4pt;height:8.1pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>$&#160;&#160;&#160;&#160;&#160;&#160; 11,776</p> </td> <td width="95" valign="bottom" style='width:70.9pt;padding:0in 5.4pt 0in 5.4pt;height:8.1pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>$&#160;&#160;&#160;&#160;&#160;&#160; 61,427</p> </td> <td width="94" valign="bottom" style='width:70.85pt;padding:0in 5.4pt 0in 5.4pt;height:8.1pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>$&#160;&#160;&#160;&#160;&#160;&#160; 67,119</p> </td> </tr> <tr align="left"> <td width="227" valign="bottom" style='width:170.05pt;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>Research and development</p> </td> <td width="95" valign="bottom" style='width:70.9pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>32,349</p> </td> <td width="95" valign="bottom" style='width:70.9pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>183,371</p> </td> <td width="94" valign="bottom" style='width:70.85pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>212,569</p> </td> </tr> <tr align="left"> <td width="227" valign="bottom" style='width:170.05pt;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>Selling, general and administrative</p> </td> <td width="95" valign="bottom" style='width:70.9pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>148,719</p> </td> <td width="95" valign="bottom" style='width:70.9pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>599,830</p> </td> <td width="94" valign="bottom" style='width:70.85pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>855,123</p> </td> </tr> <tr align="left"> <td width="227" valign="bottom" style='width:170.05pt;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="95" valign="bottom" style='width:70.9pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>&nbsp;</p> </td> <td width="95" valign="bottom" style='width:70.9pt;border:none;border-top:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>&nbsp;</p> </td> <td width="94" valign="bottom" style='width:70.85pt;border:none;border-top:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>&nbsp;</p> </td> </tr> <tr align="left"> <td width="227" valign="bottom" style='width:170.05pt;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>Total</p> </td> <td width="95" valign="bottom" style='width:70.9pt;border:none;border-bottom:double windowtext 1.5pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>$&#160;&#160;&#160; 192,844</p> </td> <td width="95" valign="bottom" style='width:70.9pt;border:none;border-bottom:double windowtext 1.5pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>$&#160; &#160;&#160;&#160;844,628</p> </td> <td width="94" valign="bottom" style='width:70.85pt;border:none;border-bottom:double windowtext 1.5pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>$&#160; 1,134,811</p> </td> </tr> </table> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>During the four months ended December 31, 2014, we granted a total of 1,450,000&nbsp;stock options to employees with exercise prices ranging from $0.44 to $0.51&nbsp;per share and with one third vesting each year for the next three years.&nbsp;&nbsp;The weighted average estimated grant-date fair value per share of these stock options was $0.22, and our assumptions used in the Black-Scholes valuation model to determine this estimated fair value are shown below:</p> <div align="center"> <table border="0" cellspacing="0" cellpadding="0" style='border-collapse:collapse'> <tr style='height:.05pt'> <td width="349" style='width:261.45pt;padding:0;height:.05pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="121" style='width:90.45pt;padding:0;height:.05pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> </tr> <tr style='height:13.5pt'> <td width="349" valign="top" style='width:261.45pt;padding:0;height:13.5pt'> <p style='margin-right:0in;margin-left:0in;margin-left:8.8pt;text-indent:-8.8pt'>Expected volatility</p> </td> <td width="121" valign="bottom" style='width:90.45pt;padding:0;height:13.5pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'>62.96%</p> </td> </tr> <tr style='height:13.5pt'> <td width="349" valign="top" style='width:261.45pt;padding:0;height:13.5pt'> <p style='margin-right:0in;margin-left:0in;margin-left:8.8pt;text-indent:-8.8pt'>Expected dividends</p> </td> <td width="121" valign="bottom" style='width:90.45pt;padding:0;height:13.5pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'>0.00%</p> </td> </tr> <tr style='height:13.5pt'> <td width="349" valign="top" style='width:261.45pt;padding:0;height:13.5pt'> <p style='margin-right:0in;margin-left:0in;margin-left:8.8pt;text-indent:-8.8pt'>Expected term</p> </td> <td width="121" valign="bottom" style='width:90.45pt;padding:0;height:13.5pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'>7.24 Years</p> </td> </tr> <tr style='height:13.5pt'> <td width="349" valign="top" style='width:261.45pt;padding:0;height:13.5pt'> <p style='margin-right:0in;margin-left:0in;margin-left:8.8pt;text-indent:-8.8pt'>Risk-free interest rate</p> </td> <td width="121" valign="bottom" style='width:90.45pt;padding:0;height:13.5pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'>2.07%</p> </td> </tr> </table> </div> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>The expected volatility rate was estimated based on the historical volatility of our common stock.&nbsp;&nbsp;&nbsp;The expected term was estimated based on historical experience of stock option exercise and forfeitures.&nbsp;&nbsp;The risk-free interest rate is the rate provided by the U.S. Treasury for Daily Treasury Yield Curve Rates commonly referred to as &#147;Constant Maturity Treasury&#148; rate in effect at the time of grant with a remaining term equal to the expected option term.</p> <p align="right" style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-align:right'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>Unrecognized stock-based compensation expense expected to be recognized over an estimated weighted-average amortization period of&nbsp;1.15 years is approximately $1,078,000 as of December 31, 2014.</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>A summary of the time-based stock option awards as of as of December 31, 2014 and August 31, 2014 and changes during the four months ended December 31, 2014 and the year ended August 31, 2014 is as follows:</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>&nbsp;</p> <table border="1" cellspacing="0" cellpadding="0" width="100%" style='width:100.0%;border-collapse:collapse;border:none'> <tr style='height:41.85pt'> <td width="36%" valign="bottom" style='width:36.2%;border:none;padding:0;height:41.85pt'> <p style='margin-right:0in;margin-left:0in;margin-right:.2in'>&nbsp;</p> </td> <td width="16%" valign="bottom" style='width:16.68%;border:none;border-bottom:solid windowtext 1.0pt;padding:0;height:41.85pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'><b>Shares</b></p> </td> <td width="15%" colspan="2" valign="bottom" style='width:15.7%;border:none;border-bottom:solid windowtext 1.0pt;padding:0;height:41.85pt'> <p style='margin-right:0in;margin-left:0in'><b>Weighted- Average &#160;Exercise Price</b></p> </td> <td width="18%" valign="bottom" style='width:18.64%;border:none;border-bottom:solid windowtext 1.0pt;padding:0;height:41.85pt'> <p style='margin-right:0in;margin-left:0in'><b>Weighted-Average Remaining Contract Term (Years)</b></p> </td> <td width="12%" colspan="2" valign="bottom" style='width:12.78%;border:none;border-bottom:solid windowtext 1.0pt;padding:0;height:41.85pt'> <p style='margin-right:0in;margin-left:0in'><b>Aggregate Intrinsic Value</b></p> </td> </tr> <tr style='height:12.9pt'> <td width="36%" valign="top" style='width:36.2%;border:none;padding:0;height:12.9pt'> <p style='margin-right:0in;margin-left:0in;margin-left:8.8pt;text-indent:-8.8pt'>&nbsp;</p> </td> <td width="16%" valign="bottom" style='width:16.68%;border:none;padding:0;height:12.9pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'>&nbsp;</p> </td> <td width="1%" valign="bottom" style='width:1.96%;border:none;padding:0;height:12.9pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="13%" valign="bottom" style='width:13.74%;border:none;padding:0;height:12.9pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'>&nbsp;</p> </td> <td width="18%" valign="bottom" style='width:18.64%;border:none;padding:0;height:12.9pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'>&nbsp;</p> </td> <td width="1%" valign="bottom" style='width:1.0%;border:none;padding:0;height:12.9pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="11%" valign="bottom" style='width:11.78%;border:none;padding:0;height:12.9pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> </tr> <tr style='height:12.9pt'> <td width="36%" valign="bottom" style='width:36.2%;border:none;padding:0;height:12.9pt'> <p style='margin-right:0in;margin-left:0in;margin-left:8.8pt;text-indent:-8.8pt'>Outstanding as of September 1, 2013</p> </td> <td width="16%" valign="bottom" style='width:16.68%;border:none;padding:0;height:12.9pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.2in;text-align:right'>4,212,573</p> </td> <td width="1%" valign="bottom" style='width:1.96%;border:none;padding:0;height:12.9pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>$</p> </td> <td width="13%" valign="bottom" style='width:13.74%;border:none;padding:0;height:12.9pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>2.85</p> </td> <td width="18%" valign="bottom" style='width:18.64%;border:none;padding:0;height:12.9pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="1%" valign="bottom" style='width:1.0%;border:none;padding:0;height:12.9pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="11%" valign="bottom" style='width:11.78%;border:none;padding:0;height:12.9pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> </tr> <tr style='height:13.5pt'> <td width="36%" valign="bottom" style='width:36.2%;border:none;padding:0;height:13.5pt'> <p style='margin-right:0in;margin-left:0in;margin-left:8.8pt;text-indent:-8.8pt'>Granted</p> </td> <td width="16%" valign="bottom" style='width:16.68%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.2in;text-align:right'>127,000</p> </td> <td width="1%" valign="bottom" style='width:1.96%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="13%" valign="bottom" style='width:13.74%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>1.19</p> </td> <td width="18%" valign="bottom" style='width:18.64%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="1%" valign="bottom" style='width:1.0%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="11%" valign="bottom" style='width:11.78%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> </tr> <tr style='height:13.5pt'> <td width="36%" valign="bottom" style='width:36.2%;border:none;padding:0;height:13.5pt'> <p style='margin-right:0in;margin-left:0in;margin-left:8.8pt;text-indent:-8.8pt'>Exercised</p> </td> <td width="16%" valign="bottom" style='width:16.68%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.2in;text-align:right'>-</p> </td> <td width="1%" valign="bottom" style='width:1.96%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="13%" valign="bottom" style='width:13.74%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&#160;&#160;&#160;&#160;&#160; -</p> </td> <td width="18%" valign="bottom" style='width:18.64%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="1%" valign="bottom" style='width:1.0%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="11%" valign="bottom" style='width:11.78%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.1in;text-align:right'>&nbsp;</p> </td> </tr> <tr style='height:13.5pt'> <td width="36%" valign="bottom" style='width:36.2%;border:none;padding:0;height:13.5pt'> <p style='margin-right:0in;margin-left:0in;margin-left:8.8pt;text-indent:-8.8pt'>Forfeited or expired</p> </td> <td width="16%" valign="bottom" style='width:16.68%;border:none;border-bottom:solid windowtext 1.0pt;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:11.35pt;text-align:right'>(476,653)</p> </td> <td width="1%" valign="bottom" style='width:1.96%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="13%" valign="bottom" style='width:13.74%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>2.18</p> </td> <td width="18%" valign="bottom" style='width:18.64%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="1%" valign="bottom" style='width:1.0%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="11%" valign="bottom" style='width:11.78%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> </tr> <tr style='height:13.5pt'> <td width="36%" valign="bottom" style='width:36.2%;border:none;padding:0;height:13.5pt'> <p style='margin-right:0in;margin-left:0in;margin-left:8.8pt;text-indent:-8.8pt'>&nbsp;</p> </td> <td width="16%" valign="bottom" style='width:16.68%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.2in;text-align:right'>&nbsp;</p> </td> <td width="1%" valign="bottom" style='width:1.96%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="13%" valign="bottom" style='width:13.74%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="18%" valign="bottom" style='width:18.64%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="1%" valign="bottom" style='width:1.0%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="11%" valign="bottom" style='width:11.78%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> </tr> <tr style='height:13.5pt'> <td width="36%" valign="bottom" style='width:36.2%;border:none;padding:0;height:13.5pt'> <p style='margin-right:0in;margin-left:0in;margin-left:8.8pt;text-indent:-8.8pt'>Outstanding as of August 31, 2014</p> </td> <td width="16%" valign="bottom" style='width:16.68%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.2in;text-align:right'>3,862,920</p> </td> <td width="1%" valign="bottom" style='width:1.96%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="13%" valign="bottom" style='width:13.74%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>2.88</p> </td> <td width="18%" valign="bottom" style='width:18.64%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>6.32</p> </td> <td width="1%" valign="bottom" style='width:1.0%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>$</p> </td> <td width="11%" valign="bottom" style='width:11.78%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.1in;text-align:right'>-</p> </td> </tr> <tr style='height:13.5pt'> <td width="36%" valign="bottom" style='width:36.2%;border:none;padding:0;height:13.5pt'> <p style='margin-right:0in;margin-left:0in;margin-left:8.8pt;text-indent:-8.8pt'>Granted</p> </td> <td width="16%" valign="bottom" style='width:16.68%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.2in;text-align:right'>1,450,000</p> </td> <td width="1%" valign="bottom" style='width:1.96%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="13%" valign="bottom" style='width:13.74%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>0.46</p> </td> <td width="18%" valign="bottom" style='width:18.64%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="1%" valign="bottom" style='width:1.0%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="11%" valign="bottom" style='width:11.78%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.1in;text-align:right'>&nbsp;</p> </td> </tr> <tr style='height:13.5pt'> <td width="36%" valign="bottom" style='width:36.2%;border:none;padding:0;height:13.5pt'> <p style='margin-right:0in;margin-left:0in;margin-left:8.8pt;text-indent:-8.8pt'>Exercised</p> </td> <td width="16%" valign="bottom" style='width:16.68%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.2in;text-align:right'>-</p> </td> <td width="1%" valign="bottom" style='width:1.96%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="13%" valign="bottom" style='width:13.74%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&#160;&#160;&#160;&#160;&#160; -</p> </td> <td width="18%" valign="bottom" style='width:18.64%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="1%" valign="bottom" style='width:1.0%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="11%" valign="bottom" style='width:11.78%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.1in;text-align:right'>&nbsp;</p> </td> </tr> <tr style='height:13.5pt'> <td width="36%" valign="bottom" style='width:36.2%;border:none;padding:0;height:13.5pt'> <p style='margin-right:0in;margin-left:0in;margin-left:8.8pt;text-indent:-8.8pt'>Forfeited or expired</p> </td> <td width="16%" valign="bottom" style='width:16.68%;border:none;border-bottom:solid windowtext 1.0pt;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:14.2pt;text-align:right'>(181,001)</p> </td> <td width="1%" valign="bottom" style='width:1.96%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="13%" valign="bottom" style='width:13.74%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>1.54</p> </td> <td width="18%" valign="bottom" style='width:18.64%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="1%" valign="bottom" style='width:1.0%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="11%" valign="bottom" style='width:11.78%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.1in;text-align:right'>&nbsp;</p> </td> </tr> <tr style='height:13.5pt'> <td width="36%" valign="bottom" style='width:36.2%;border:none;padding:0;height:13.5pt'> <p style='margin-right:0in;margin-left:0in;margin-left:8.8pt;text-indent:-8.8pt'>&nbsp;</p> </td> <td width="16%" valign="bottom" style='width:16.68%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:14.2pt;text-align:right'>&nbsp;</p> </td> <td width="1%" valign="bottom" style='width:1.96%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="13%" valign="bottom" style='width:13.74%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="18%" valign="bottom" style='width:18.64%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="1%" valign="bottom" style='width:1.0%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="11%" valign="bottom" style='width:11.78%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.1in;text-align:right'>&nbsp;</p> </td> </tr> <tr style='height:13.5pt'> <td width="36%" valign="bottom" style='width:36.2%;border:none;padding:0;height:13.5pt'> <p style='margin-right:0in;margin-left:0in;margin-left:8.8pt;text-indent:-8.8pt'>Outstanding as of December 31, 2014</p> </td> <td width="16%" valign="bottom" style='width:16.68%;border:none;border-bottom:double windowtext 1.5pt;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:14.2pt;text-align:right'>5,131,919</p> </td> <td width="1%" valign="bottom" style='width:1.96%;border:none;border-bottom:double windowtext 1.5pt;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>$</p> </td> <td width="13%" valign="bottom" style='width:13.74%;border:none;border-bottom:double windowtext 1.5pt;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>2.25</p> </td> <td width="18%" valign="bottom" style='width:18.64%;border:none;border-bottom:double windowtext 1.5pt;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>7.03</p> </td> <td width="1%" valign="bottom" style='width:1.0%;border:none;border-bottom:double windowtext 1.5pt;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>$</p> </td> <td width="11%" valign="bottom" style='width:11.78%;border:none;border-bottom:double windowtext 1.5pt;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.1in;text-align:right'>-</p> </td> </tr> <tr style='height:13.5pt'> <td width="36%" valign="bottom" style='width:36.2%;border:none;padding:0;height:13.5pt'> <p style='margin-right:0in;margin-left:0in;margin-left:8.8pt;text-indent:-8.8pt'>Exercisable as of December 31, 23014</p> </td> <td width="16%" valign="bottom" style='width:16.68%;border:none;border-bottom:double windowtext 1.5pt;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.2in;text-align:right'>2,953,586</p> </td> <td width="1%" valign="bottom" style='width:1.96%;border:none;border-bottom:double windowtext 1.5pt;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>$</p> </td> <td width="13%" valign="bottom" style='width:13.74%;border:none;border-bottom:double windowtext 1.5pt;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>3.30</p> </td> <td width="18%" valign="bottom" style='width:18.64%;border:none;border-bottom:double windowtext 1.5pt;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>5.31</p> </td> <td width="1%" valign="bottom" style='width:1.0%;border:none;border-bottom:double windowtext 1.5pt;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>$</p> </td> <td width="11%" valign="bottom" style='width:11.78%;border:none;border-bottom:double windowtext 1.5pt;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.1in;text-align:right'>-</p> </td> </tr> </table> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>The aggregate intrinsic value in the preceding table represents the total pretax intrinsic value, based on the Company&#146;s closing stock price of $0.36 as of December 31, 2014, which would have been received by the holders of in-the-money options had the option holders exercised their options as of that date.</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <!--egx--><p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'><b>Note 13:&nbsp;&nbsp;Supplemental Cash Flow Information</b></p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>We paid no amount for interest during the four months ended December 31, 2014 and the years ended August 31, 2014 and 2013.&nbsp;&nbsp;We paid no amount for income taxes during the four months ended December 31, 2014.&#160; During the years ended August 31, 2014 and 2013 we paid $2,000 and $1,938 for income taxes.&#160; </p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>We had no non-cash financing and investing activities during the four months ended December 31, 2014 and the years ended August 31, 2014 and 2013.</p> <!--egx--><p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'><b>Note 14:&nbsp;&nbsp;Commitments and Contingencies</b></p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'><b><i>Employment Agreement - CEO</i></b></p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>On January 9, 2015, we entered into an Employment Agreement (&#147;CEO Agreement&#148;) with Clinton E. Carnell Jr., our President and Chief Executive Officer (&#147;CEO&#148;).&nbsp;&nbsp;The CEO Agreement confirms the appointment as President and CEO, and service as a member of&nbsp;&nbsp;the Company&#146;s Board of Directors, and sets the CEO&#146;s annual base salary at $350,000, with a review at least annually by the Compensation Committee of the Board of Directors.&nbsp;&nbsp;The CEO Agreement provides for an annual bonus of $150,000 for the first year of employment, and a bonus of $150,000, or a pro rata portion thereof, for the second year of employment.&nbsp;&nbsp;If the Company completes and closes in fiscal year 2015 an equity offering that generates to the Company at least $5.0 million in net proceeds, then the Company will engage a compensation consulting firm to conduct a study of compensation of CEO&#146;s in companies comparable to the Company, which study shall then be used to negotiate Mr. Carnell&#146;s overall compensation after December 31, 2015.&nbsp;&nbsp;If the Company does not complete and close such an equity offering in 2015, then the Company shall engage a compensation consulting firm in 2016 to negotiate Mr. Carnell&#146;s salary after December 31, 2016.&nbsp;&nbsp;The CEO Agreement also provides an award of a nonqualified stock option to purchase 1,400,000 shares of common stock at a price per share of $0.46, the closing price of the Company&#146;s common stock on November 10, 2014, the date the option was granted.&nbsp;&nbsp;The options will vest at one-third each year on the anniversaries of the grant.&nbsp;&nbsp;Under the CEO Agreement the CEO is entitled to participate in all employee benefit plans, practices and programs maintained by the Company for its employees.&nbsp;&nbsp;Additional provisions of the CEO Agreement include indemnification for expenses associated with defending certain claims made against the CEO as a result of his position with the Company, and directors&#146; and officers&#146; liability insurance providing coverage during the term of the CEO Agreement and for a period of six years following the termination of the CEO Agreement.&nbsp;&nbsp;The CEO Agreement also provides that if he is terminated by the Company other than for cause, or if he resigns for good reason and complies with certain requirements, the Company is obligated to pay him an amount equal to his base salary (the &#147;CEO Severance Payment&#148;) and provide employee benefits for two years following termination.&nbsp;&nbsp;If the CEO Agreement is terminated for cause, he shall receive only the portion of his base salary that is due to him through the effective date of his termination.&nbsp;&nbsp;If the CEO Agreement is terminated by reason of his death, his estate shall receive his salary through the end of the month in which he died plus all employee benefits due to him through the end of such month.&nbsp;&nbsp;&nbsp;If a Change in Control (as defined in the CEO Agreement) occurs with respect to the Company, and during the six months immediately following the Change of Control, (i) the Company terminates him without cause; or (ii) he terminates his employment with good reason, then in addition to the CEO Severance Payment, all options or incentive awards granted to him will immediately vest and become exercisable for a period of 180 days following the termination.&nbsp;&nbsp;The CEO Agreement also contains a confidentiality agreement, and a one-year non-competition and non-solicitation agreement.&nbsp;&nbsp;The CEO Agreement contains a claw back provision that enables the Company to claw back any incentive-based compensation or other compensation from him if required by any law, government regulation, stock exchange listing requirement, or Company policy adopted as required by such law, government regulation, or stock exchange listing requirement.</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>The Company&#146;s former President and CEO, Mr. Harold R. Wolcott, relinquished his positions as President and CEO upon the Company&#146;s hiring of its new President and CEO.&nbsp;&nbsp;Mr. Wolcott will continue to serve on the Company&#146;s board of directors.&nbsp;&nbsp;On April 28, 2014, the Company entered into a letter agreement with Mr. Wolcott, pursuant to which Mr. Wolcott will receive severance benefits that supersede the severance benefits Mr. Wolcott was previously entitled to receive under his employment agreement.&nbsp;&nbsp;Pursuant to the letter agreement, upon Mr. Wolcott ceasing to serve as President and CEO of the Company for any reason (other than for cause), the Company will pay to Mr. Wolcott an amount equal to his current base salary, and the vesting of his equity awards will immediately vest and become exercisable.&nbsp;&nbsp;On November 10, 2014, the Company entered into a consulting agreement with Mr. Wolcott, who resigned as President and CEO effective November 10, 2014.</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'><b><i>Employment Agreement &#150; CFO</i></b></p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>On September 16, 2014, the Company entered into an employment agreement (the &#147;CFO Agreement&#148;) with its Chief Financial Officer (&#147;CFO&#148;).&nbsp;&nbsp;The CFO Agreement provides that his base salary shall be $200,000, to be reviewed at least annually by the Compensation Committee of the Board of Directors. The CFO Agreement provides that the CFO is entitled to participate in any annual incentive bonus programs, employee benefit plans adopted or maintained by the Company, and the Company&#146;s Stock Incentive Plan.&nbsp;&nbsp;Additional provisions of the CFO Agreement include indemnification for expenses associated with defending certain claims made against the CFO as a result of his position with the Company, and directors&#146; and officers&#146; liability insurance providing coverage during the term of the CFO Agreement and for a period of six years following the termination of the CFO Agreement.&nbsp;&nbsp;If the CFO is terminated by the Company other than for cause, or resigns for good reason, and complies with certain requirements, the Company is obligated to pay him an amount equal to his base salary (the &#147;CFO Severance Payment&#148;) and provide employee benefits for one year following termination.&nbsp;&nbsp;If the CFO Agreement is terminated for cause, he shall receive only the portion of his base salary that is due to him through the effective date of his termination.&nbsp;&nbsp;If the CFO Agreement is terminated by reason of his death, his estate shall receive his salary through the end of the month in which he died plus all employee benefits due to him through the end of such month.&nbsp;&nbsp;If a Change in Control (as defined in the CFO Agreement) occurs with respect to the Company, and during the six months immediately following the Change of Control, (i) the Company terminates him without cause; (ii) he terminates his employment with good reason; or (iii) he terminates the CFO Agreement but also agrees to continue serving as CFO for the longer of (a) six months and (b) until a new CFO is appointed, then in addition to the CFO Severance Payment, all options or incentive awards granted to him will immediately vest and become exercisable for a period of 180 days following the termination.&nbsp;&nbsp;The CFO Agreement also contains a confidentiality agreement, and a one-year non-competition and non-solicitation agreement.&nbsp;&nbsp;The CFO Agreement contains a claw back provision that enables the Company to claw back any incentive-based compensation or other compensation from him if required by any law, government regulation, stock exchange listing requirement, or Company policy adopted as required by such law, government regulation, or stock exchange listing requirement.</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'><b><i>Employment Agreement &#150; CTO</i></b></p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>On December 19, 2014, the Company terminated, without cause, the employment of its Chief Technical Officer (&#147;CTO&#148;).&nbsp;&nbsp;Under the terms of an employment agreement dated November 2, 1988, the Company is obligated to&nbsp;provide severance pay for a one-year period, which pay includes an extension of all rights, privileges and benefits as an employee (including medical insurance).&nbsp;&nbsp;The one-year severance pay shall be equal to the CTO&#146;s average annual salary for the 12-month period immediately prior to the termination.&nbsp;&nbsp;The terms of the employment agreement also require us to pay the CTO for accrued, unused vacation at the time of termination, and include a non-competition covenant prohibiting him from competing with us for one year following his termination.&nbsp;&nbsp;We may continue the non-competition period for up to four additional years by notifying the CTO in writing and by continuing the severance payments for the additional years during which the non-competition period is extended.&nbsp;</p> <!--egx--><p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'><b>Note 15:&nbsp;&nbsp;Recent Accounting Pronouncements</b></p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; No new accounting pronouncements were adopted during the four months ended December 31, 2014 that had a material impact on our financial statements.</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>In May 2014, FASB issued ASU 2014-09 <i>Revenue from Contracts with Customers</i>. The amendments in ASU 2014-09 affects any entity that either enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of nonfinancial assets unless those contracts are within the scope of other standards (e.g., insurance contracts or lease contracts). This ASU will supersede the revenue recognition requirements in Topic 605 Revenue Recognition and most industry-specific guidance, and creates a Topic 606 <i>Revenue from Contracts with Customers</i>.</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve that core principle, an entity should apply the following steps:</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:35.9pt;margin-bottom:.0001pt'>Step 1: Identify the contract(s) with a customer.</p> <p style='margin-right:0in;margin-left:0in;margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:35.9pt;margin-bottom:.0001pt'>Step 2: Identify the performance obligations in the contract.</p> <p style='margin-right:0in;margin-left:0in;margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:35.9pt;margin-bottom:.0001pt'>Step 3: Determine the transaction price.</p> <p style='margin-right:0in;margin-left:0in;margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:35.9pt;margin-bottom:.0001pt'>Step 4: Allocate the transaction price to the performance obligations in the contract.</p> <p style='margin-right:0in;margin-left:0in;margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:35.9pt;margin-bottom:.0001pt'>Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation.</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>ASU 2014-09 is effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. Early application is not permitted.&nbsp;&nbsp;We have not yet determined how our financial statements will be affected by the adoption of ASU 2014-09.</p> <!--egx--><p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'><b>Note 16:&nbsp;&nbsp;Subsequent Events</b></p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>On January 15, 2015, the Company entered into an employment agreement with its Clinton E. Carnell, Jr., to serve as President and Chief Executive Officer.</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>Effective February 16, 2015, the Company entered into an employment agreement with Benjamin Beckham to serve as Vice President of North American Sales. </p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>Effective February 16, 2015, the Company entered into an employment agreement with Todd Turnlund to serve as Vice President of Research and Development. </p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>Effective February 17, 2015, the Company entered into an employment agreement with Jen Hoglin to serve as Vice President of Global Marketing. </p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>Effective February 20, 2015, Perseon Corporation amended its certificate of incorporation to change its legal corporate name to &#147;Perseon Corporation&#148;&nbsp;from &#147;BSD Medical Corporation.&#148; &#160;&#160;The name change was effected pursuant to Section 242 of the Delaware General Corporation Law (the &#147;DGCL&#148;).&nbsp;&nbsp;Under the DGCL, the amendment to the Company&#146;s certificate of incorporation to effect the name change did not require stockholder approval.</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>On February 24, 2015, the Company executed a promissory note with an asset lender, in the amount of $750,000.&#160;&#160; The note is secured by the Company&#146;s headquarters and manufacturing facility.&#160; During the one year term of the note, monthly payments of interest only at Prime Rate plus 6.0% are required, with the principal due on February 24, 2016.</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>The Company has evaluated other events occurring after the date of our accompanying balance sheets through&nbsp;the date of the filing of this Transition Report on Form 10-K.&nbsp;&nbsp;No other material subsequent events requiring adjustment to our accompanying financial statements were identified.</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <!--egx--><p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'><b>Organization and Business</b> &#150; Perseon Corporation, formerly BSD Medical Corporation, (the &#147;Company&#148;) was incorporated in the State of Delaware on July 3, 1986.&nbsp;&nbsp;In February 2015, we changed the name of the Company to Perseon Corporation.&#160; We are a life sciences company that develops, manufactures, markets and services groundbreaking medical systems to treat cancer using heat therapy.&nbsp;&nbsp;Our MicroThermX<sup>&#174; </sup>microwave ablation system employs precision-guided microwave energy to ablate diseased soft tissue.&#160; We have developed extensive intellectual property and distribute our products in the United States, Europe and Asia.</p> <!--egx--><p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'><b>Financial Reporting Period &#150; </b>We have changed our fiscal year end for financial reporting from August 31 to December 31, effective for the four months ended December 31, 2014.&#160; The financial information for the four months ended December 31, 2013 provided for comparative purposes is unaudited. &#160;All adjustments (consisting only of normal recurring adjustments) necessary for the fair presentation of our results of operations and our cash flows for the four months ended December 31, 2013 have been included.&#160; The results of operations for the four months ended December 31, 2014 may not be indicative of the results for our fiscal year ending December 31, 2015.</p> <!--egx--><p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'><b>Cash and Cash Equivalents</b> &#150; Cash and cash equivalents consist of cash and investments with original maturities to the Company of three months or less.&nbsp;&nbsp;As of December 31, 2014 and August 31, 2014, we had $25,000 in a restricted bank account.</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <!--egx--><p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'><b>Accounts Receivable</b> &#150; Trade accounts receivable are carried at original invoice amount less an estimate made for doubtful receivables based on a review of all outstanding amounts on a monthly basis.&nbsp;&nbsp;Management estimates an allowance for doubtful accounts by identifying troubled accounts and by using historical experience applied to an aging of accounts.&nbsp;&nbsp;Trade accounts receivable are written off when deemed uncollectible.&nbsp;&nbsp;Recoveries of trade receivables previously written off are recorded when received.&nbsp;&nbsp;Interest is not charged on trade receivables that are outstanding beyond their due date.</p> <!--egx--><p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'><b>Inventories &#150; </b>Parts and supplies inventories are stated at the lower of cost or market.&nbsp;&nbsp;Cost is determined using the average cost method.&nbsp;&nbsp;Work-in-process and finished goods are stated at the lower of the accumulated manufacturing costs or market.&nbsp;&nbsp;We maintain a reserve for obsolete inventories to reduce excess and obsolete inventories to their estimated net realizable value.&nbsp;&nbsp;The reserve was $750,000 as of December 31, 2014, $150,000 as of August 31, 2014, and $100,000 as of August 31, 2013.</p> <!--egx--><p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'><b>Property and Equipment</b> &#150; Property and equipment are stated at cost less accumulated depreciation.&nbsp;&nbsp;Depreciation is determined using the straight-line method over the following estimated useful lives of the assets.</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <table border="0" cellspacing="0" cellpadding="0" style='margin-left:86.3pt;border-collapse:collapse'> <tr align="left"> <td width="168" valign="top" style='width:126.1pt;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>Equipment</p> </td> <td width="60" valign="top" style='width:45.0pt;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="168" valign="top" style='width:1.75in;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>2 &#150; 5 years</p> </td> </tr> <tr align="left"> <td width="168" valign="top" style='width:126.1pt;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>Rental equipment</p> </td> <td width="60" valign="top" style='width:45.0pt;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="168" valign="top" style='width:1.75in;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>5 years</p> </td> </tr> <tr align="left"> <td width="168" valign="top" style='width:126.1pt;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>Furniture and fixtures</p> </td> <td width="60" valign="top" style='width:45.0pt;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="168" valign="top" style='width:1.75in;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>5 years</p> </td> </tr> <tr align="left"> <td width="168" valign="top" style='width:126.1pt;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>Building improvements</p> </td> <td width="60" valign="top" style='width:45.0pt;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="168" valign="top" style='width:1.75in;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>15 years</p> </td> </tr> <tr align="left"> <td width="168" valign="top" style='width:126.1pt;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>Building</p> </td> <td width="60" valign="top" style='width:45.0pt;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="168" valign="top" style='width:1.75in;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>40 years</p> </td> </tr> </table> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>Expenditures for maintenance and repairs are expensed when incurred and betterments are capitalized.&nbsp;&nbsp;Gains and losses on sales of property and equipment are reflected in operations.</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>The cost and accumulated depreciation of property and equipment sold or otherwise retired are removed from the accounts and any related gain or loss on disposition is reflected in net income or loss for the period.</p> <!--egx--><p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'><b>Patents</b> &#150; Patent costs are expensed as incurred.</p> <!--egx--><p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'><b>Warranty Reserve</b> &#150; We provide limited warranties to our customers for products sold.&nbsp;&nbsp;Estimated future warranty obligations are accrued each period.&nbsp;&nbsp;As of December 31, 2014, August 31, 2014 and August 31, 2013, the accrued warranty reserve was $65,102, $75,728 and $50,968, respectively.&nbsp;&nbsp;During the four months ended December 31, 2014, total warranty expense was $13,410.&#160; During the fiscal years ended August 31, 2014 and 2013, total warranty expense was $41,471 and $80,276, respectively.</p> <!--egx--><p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'><b>Income Taxes</b> &#150; We account for income taxes using the asset and liability method.&nbsp;&nbsp;Under the asset and liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases.&nbsp;&nbsp;Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.&nbsp;&nbsp;The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.</p> <!--egx--><p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'><b>Income (Loss) Per Common Share</b> &#150; The computation of basic income (loss) per common share is based on the weighted average number of shares outstanding during each year.</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>The computation of diluted earnings per common share is based on the weighted average number of shares outstanding during the year, plus the common stock equivalents that would arise from the exercise of stock options and warrants outstanding, using the treasury stock method and the average market price per share during the year.&nbsp;&nbsp;Common stock equivalents are not included in the diluted loss per share calculation when their effect is anti-dilutive.&nbsp;&nbsp;Options and warrants to purchase 14,989,224 shares of common stock at prices ranging from $0.44 to $7.95 were excluded from the calculation of diluted earnings per share for the four months ended December 31, 2014 because their effect was anti-dilutive.&#160; Options and warrants to purchase 13,720,225 and 9,669,878 shares of common stock at prices ranging from $0.99 to $7.95 were excluded from the calculation of diluted earnings per share for the years ended August 31, 2014 and 2013, respectively, because their effect was anti-dilutive.</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>Since we had no dilutive effect of stock options and warrants for the four months ended December 31, 2014 and 2013 and the years ended August 31, 2014 and 2013, our basic weighted average number of common shares outstanding is the same as our diluted weighted average number of common shares outstanding.</p> <!--egx--><p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'><b>Stock-Based Compensation - </b>Stock-based compensation is measured at the grant date based on the value of the award granted using the Black-Scholes option pricing model, and recognized over the period in which the award vests.&nbsp;&nbsp;For stock awards no longer expected to vest, any previously recognized stock compensation expense is reversed in the period of termination.&nbsp;&nbsp;The stock-based compensation expense is allocated to the various categories of operating costs and expenses in a manner similar to the allocation of payroll expense.&nbsp;</p> <!--egx--><p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'><b>Revenue Recognition</b> &#150; We recognize revenue from the sale of medical systems, disposable devices related to the systems,&nbsp;parts, and accessories, and equipment rental, training, and service support contracts.&nbsp;&nbsp;Our revenues consisted of the following:</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>&nbsp;</p> <table border="1" cellspacing="0" cellpadding="0" style='margin-left:19.6pt;border-collapse:collapse;border:none'> <tr align="left"> <td width="208" valign="top" style='width:155.9pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="180" colspan="2" valign="top" style='width:134.9pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'><b>Four Months Ended December 31,</b></p> </td> <td width="177" colspan="2" valign="top" style='width:132.4pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'><b>Years Ended August 31, </b></p> </td> </tr> <tr align="left"> <td width="208" valign="top" style='width:155.9pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="92" valign="top" style='width:68.7pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'><b>2014</b></p> </td> <td width="88" valign="top" style='width:66.2pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'><b>&#160;&#160;&#160;&#160;&#160;&#160;&#160; 2013</b></p> </td> <td width="88" valign="top" style='width:66.2pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'><b>&#160;&#160;&#160;&#160;&#160;&#160;&#160; 2014</b></p> </td> <td width="88" valign="top" style='width:66.2pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'><b>&#160;&#160;&#160;&#160;&#160;&#160;&#160; </b><b>2013</b></p> </td> </tr> <tr align="left"> <td width="208" valign="top" style='width:155.9pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="92" valign="top" style='width:68.7pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="88" valign="top" style='width:66.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="88" valign="top" style='width:66.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="88" valign="top" style='width:66.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> </tr> <tr align="left"> <td width="208" valign="top" style='width:155.9pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>Product sales</p> </td> <td width="92" valign="top" style='width:68.7pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>$&#160; &#160;&#160;&#160;&#160;&#160;&#160;470,875</p> </td> <td width="88" valign="top" style='width:66.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;986,900</p> </td> <td width="88" valign="top" style='width:66.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>$&#160;&#160;&#160; 3,019,525</p> </td> <td width="88" valign="top" style='width:66.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>$&#160;&#160;&#160; 1,934,826</p> </td> </tr> <tr align="left"> <td width="208" valign="top" style='width:155.9pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>Disposable devices</p> </td> <td width="92" valign="top" style='width:68.7pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>409,787</p> </td> <td width="88" valign="top" style='width:66.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>501,565</p> </td> <td width="88" valign="top" style='width:66.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>1,568,481</p> </td> <td width="88" valign="top" style='width:66.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>1,109,750</p> </td> </tr> <tr align="left"> <td width="208" valign="top" style='width:155.9pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>Service contracts and other</p> </td> <td width="92" valign="top" style='width:68.7pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>109,346</p> </td> <td width="88" valign="top" style='width:66.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>100,597</p> </td> <td width="88" valign="top" style='width:66.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>375,747</p> </td> <td width="88" valign="top" style='width:66.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>330,116</p> </td> </tr> <tr align="left"> <td width="208" valign="top" style='width:155.9pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>Equipment rental</p> </td> <td width="92" valign="top" style='width:68.7pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>125,900</p> </td> <td width="88" valign="top" style='width:66.2pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>95,200</p> </td> <td width="88" valign="top" style='width:66.2pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>364,600</p> </td> <td width="88" valign="top" style='width:66.2pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>298,600</p> </td> </tr> <tr align="left"> <td width="208" valign="top" style='width:155.9pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="92" valign="top" style='width:68.7pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="88" valign="top" style='width:66.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="88" valign="top" style='width:66.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="88" valign="top" style='width:66.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> </tr> <tr align="left"> <td width="208" valign="top" style='width:155.9pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>Total</p> </td> <td width="92" valign="top" style='width:68.7pt;border:none;border-bottom:double windowtext 1.5pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>$&#160;&#160; &#160;&#160;1,115,908</p> </td> <td width="88" valign="top" style='width:66.2pt;border:none;border-bottom:double windowtext 1.5pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>$&#160;&#160;&#160; 1,684,262</p> </td> <td width="88" valign="top" style='width:66.2pt;border:none;border-bottom:double windowtext 1.5pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>$&#160;&#160;&#160; 5,328,353</p> </td> <td width="88" valign="top" style='width:66.2pt;border:none;border-bottom:double windowtext 1.5pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>$&#160;&#160;&#160; 3,673,292</p> </td> </tr> </table> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>Revenue from product sales is recognized when a purchase order has been received, the cancer treatment system has been shipped, the selling price is fixed or determinable, and collection is reasonably assured.&nbsp;&nbsp;Most system sales are F.O.B. shipping point; therefore, shipment is deemed to have occurred when the product is delivered to the transportation carrier.&nbsp;&nbsp;Most system sales do not include installation.&nbsp;&nbsp;If installation is included as part of the contract, revenue is not recognized until installation has occurred, or until any remaining installation obligation is deemed to be perfunctory.&nbsp;&nbsp;Some sales of systems may include training as part of the sale.&nbsp;&nbsp;In such cases, the portion of the revenue related to the training, calculated based on the amount charged for training on a stand-alone basis, is deferred and recognized when the training has been provided.&nbsp;&nbsp;The sales of our cancer treatment systems do not require specific customer acceptance provisions and do not include the right of return except in cases where the product does not function as warranted by us.&nbsp;&nbsp;To date, returns have not been significant.</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>Revenue from the sale of disposable devices is recognized when a purchase order has been received, the devices have been shipped, the selling price is fixed or determinable, and collection is reasonably assured.&nbsp;&nbsp;Currently, our customers are not required to purchase a minimum number of disposable devices in connection with the purchase of our systems.</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>Revenue from training services is recorded when an agreement with the customer exists for such training, the training services have been provided, and collection is reasonably assured.</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>Revenue from service support contracts is recognized on a straight-line basis over the term of the contract, which approximates recognizing it as it is earned.</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>Revenue from equipment rental under an operating lease is recognized when billed in accordance with the lease agreement.</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>Our revenue recognition policy is the same for sales to both related parties and non-related parties.&nbsp;&nbsp;We provide the same products and services under the same terms for non-related parties as with related parties.</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>Sales to distributors are recognized in the same manner as sales to end-user customers.</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>Deferred revenue and customer deposits include amounts from service contracts as well as cash received for the sales of products that have not been shipped.</p> <!--egx--><p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'><b>Concentration of Credit Risk</b> &#150; Financial instruments that potentially subject us to concentration of credit risk consists primarily of trade receivables.&nbsp;&nbsp;In the normal course of business, we provide credit terms to our customers.&nbsp;&nbsp;Accordingly, we perform ongoing credit evaluations of our customers and maintain allowances for possible losses.</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>We have cash in the bank and short-term investments that exceed federally insured limits.&nbsp;&nbsp;We have not experienced any losses in such accounts.</p> <!--egx--><p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'><b>Advertising and Promotion &#150; </b>Advertising and promotion costs, which are principally included in sales expenses, are expensed as incurred.&nbsp;&nbsp;Advertising and promotion expense was $56,504 for the four months ended December 31, 2014, and $206,099 and $205,442 for the years ended August 31, 2014 and 2013, respectively.</p> <!--egx--><p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'><b>Shipping and Handling</b> &#150; We bill our customers for shipping and handling charges, which are included in net sales.&#160; The cost of corresponding shipping and handling expense is reported in cost of sales.</p> <!--egx--><p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'><b>Use of Estimates in the Preparation of Financial Statements</b> &#150; The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.&nbsp;&nbsp;Actual results could differ from those estimates.</p> <!--egx--><p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'><b>Comprehensive Loss</b> &#150; Comprehensive loss is the same as net loss for all years presented.</p> <!--egx--><p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <table border="0" cellspacing="0" cellpadding="0" style='margin-left:86.3pt;border-collapse:collapse'> <tr align="left"> <td width="168" valign="top" style='width:126.1pt;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>Equipment</p> </td> <td width="60" valign="top" style='width:45.0pt;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="168" valign="top" style='width:1.75in;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>2 &#150; 5 years</p> </td> </tr> <tr align="left"> <td width="168" valign="top" style='width:126.1pt;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>Rental equipment</p> </td> <td width="60" valign="top" style='width:45.0pt;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="168" valign="top" style='width:1.75in;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>5 years</p> </td> </tr> <tr align="left"> <td width="168" valign="top" style='width:126.1pt;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>Furniture and fixtures</p> </td> <td width="60" valign="top" style='width:45.0pt;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="168" valign="top" style='width:1.75in;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>5 years</p> </td> </tr> <tr align="left"> <td width="168" valign="top" style='width:126.1pt;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>Building improvements</p> </td> <td width="60" valign="top" style='width:45.0pt;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="168" valign="top" style='width:1.75in;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>15 years</p> </td> </tr> <tr align="left"> <td width="168" valign="top" style='width:126.1pt;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>Building</p> </td> <td width="60" valign="top" style='width:45.0pt;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="168" valign="top" style='width:1.75in;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>40 years</p> </td> </tr> </table> <!--egx--> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>&nbsp;</p> <table border="1" cellspacing="0" cellpadding="0" style='margin-left:19.6pt;border-collapse:collapse;border:none'> <tr align="left"> <td width="208" valign="top" style='width:155.9pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="180" colspan="2" valign="top" style='width:134.9pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'><b>Four Months Ended December 31,</b></p> </td> <td width="177" colspan="2" valign="top" style='width:132.4pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'><b>Years Ended August 31, </b></p> </td> </tr> <tr align="left"> <td width="208" valign="top" style='width:155.9pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="92" valign="top" style='width:68.7pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'><b>2014</b></p> </td> <td width="88" valign="top" style='width:66.2pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'><b>&#160;&#160;&#160;&#160;&#160;&#160;&#160; 2013</b></p> </td> <td width="88" valign="top" style='width:66.2pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'><b>&#160;&#160;&#160;&#160;&#160;&#160;&#160; 2014</b></p> </td> <td width="88" valign="top" style='width:66.2pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'><b>&#160;&#160;&#160;&#160;&#160;&#160;&#160; </b><b>2013</b></p> </td> </tr> <tr align="left"> <td width="208" valign="top" style='width:155.9pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="92" valign="top" style='width:68.7pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="88" valign="top" style='width:66.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="88" valign="top" style='width:66.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="88" valign="top" style='width:66.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> </tr> <tr align="left"> <td width="208" valign="top" style='width:155.9pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>Product sales</p> </td> <td width="92" valign="top" style='width:68.7pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>$&#160; &#160;&#160;&#160;&#160;&#160;&#160;470,875</p> </td> <td width="88" valign="top" style='width:66.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;986,900</p> </td> <td width="88" valign="top" style='width:66.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>$&#160;&#160;&#160; 3,019,525</p> </td> <td width="88" valign="top" style='width:66.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>$&#160;&#160;&#160; 1,934,826</p> </td> </tr> <tr align="left"> <td width="208" valign="top" style='width:155.9pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>Disposable devices</p> </td> <td width="92" valign="top" style='width:68.7pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>409,787</p> </td> <td width="88" valign="top" style='width:66.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>501,565</p> </td> <td width="88" valign="top" style='width:66.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>1,568,481</p> </td> <td width="88" valign="top" style='width:66.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>1,109,750</p> </td> </tr> <tr align="left"> <td width="208" valign="top" style='width:155.9pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>Service contracts and other</p> </td> <td width="92" valign="top" style='width:68.7pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>109,346</p> </td> <td width="88" valign="top" style='width:66.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>100,597</p> </td> <td width="88" valign="top" style='width:66.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>375,747</p> </td> <td width="88" valign="top" style='width:66.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>330,116</p> </td> </tr> <tr align="left"> <td width="208" valign="top" style='width:155.9pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>Equipment rental</p> </td> <td width="92" valign="top" style='width:68.7pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>125,900</p> </td> <td width="88" valign="top" style='width:66.2pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>95,200</p> </td> <td width="88" valign="top" style='width:66.2pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>364,600</p> </td> <td width="88" valign="top" style='width:66.2pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>298,600</p> </td> </tr> <tr align="left"> <td width="208" valign="top" style='width:155.9pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="92" valign="top" style='width:68.7pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="88" valign="top" style='width:66.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="88" valign="top" style='width:66.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="88" valign="top" style='width:66.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> </tr> <tr align="left"> <td width="208" valign="top" style='width:155.9pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>Total</p> </td> <td width="92" valign="top" style='width:68.7pt;border:none;border-bottom:double windowtext 1.5pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>$&#160;&#160; &#160;&#160;1,115,908</p> </td> <td width="88" valign="top" style='width:66.2pt;border:none;border-bottom:double windowtext 1.5pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>$&#160;&#160;&#160; 1,684,262</p> </td> <td width="88" valign="top" style='width:66.2pt;border:none;border-bottom:double windowtext 1.5pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>$&#160;&#160;&#160; 5,328,353</p> </td> <td width="88" valign="top" style='width:66.2pt;border:none;border-bottom:double windowtext 1.5pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>$&#160;&#160;&#160; 3,673,292</p> </td> </tr> </table> <!--egx--> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-align:justify;text-indent:.5in'>&nbsp;</p> <table border="0" cellspacing="0" cellpadding="0" width="491" style='margin-left:.5in;border-collapse:collapse'> <tr align="left"> <td width="236" valign="top" style='width:176.65pt;padding:0'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="85" valign="top" style='width:63.8pt;padding:0'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'><b>December 31,</b></p> </td> <td width="170" colspan="2" valign="top" style='width:127.55pt;padding:0'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'><b>August 31,</b></p> </td> </tr> <tr align="left"> <td width="236" valign="top" style='width:176.65pt;padding:0'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="85" valign="top" style='width:63.8pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'><b>2014</b></p> </td> <td width="85" valign="top" style='width:63.75pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'><b>2014</b></p> </td> <td width="85" valign="top" style='width:63.8pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'><b>2013</b></p> </td> </tr> <tr align="left"> <td width="236" valign="top" style='width:176.65pt;padding:0'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="85" valign="top" style='width:63.8pt;border:none;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="85" valign="top" style='width:63.75pt;border:none;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="85" valign="top" style='width:63.8pt;border:none;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> </tr> <tr align="left"> <td width="236" valign="top" style='width:176.65pt;padding:0'> <p style='margin-right:0in;margin-left:0in'>Accounts receivable:</p> </td> <td width="85" valign="top" style='width:63.8pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="85" valign="top" style='width:63.75pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="85" valign="top" style='width:63.8pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> </tr> <tr align="left"> <td width="236" valign="top" style='width:176.65pt;padding:0'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="85" valign="top" style='width:63.8pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="85" valign="top" style='width:63.75pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="85" valign="top" style='width:63.8pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> </tr> <tr align="left"> <td width="236" valign="top" style='width:176.65pt;padding:0'> <p style='margin-right:0in;margin-left:0in'>&#160;&#160; Trade receivables &#150; non-related party</p> </td> <td width="85" valign="top" style='width:63.8pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>$&#160;&#160;&#160;&#160;&#160;&#160; 293,182</p> </td> <td width="85" valign="top" style='width:63.75pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>$&#160;&#160;&#160;&#160;&#160;&#160; 364,170</p> </td> <td width="85" valign="top" style='width:63.8pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>$&#160;&#160;&#160;&#160;&#160;&#160; 890,985</p> </td> </tr> <tr align="left"> <td width="236" valign="top" style='width:176.65pt;padding:0'> <p style='margin-right:0in;margin-left:0in'>&#160;&#160; Other receivables</p> </td> <td width="85" valign="top" style='width:63.8pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>1,890</p> </td> <td width="85" valign="top" style='width:63.75pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>22,717</p> </td> <td width="85" valign="top" style='width:63.8pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>28,984</p> </td> </tr> <tr align="left"> <td width="236" valign="top" style='width:176.65pt;padding:0'> <p style='margin-right:0in;margin-left:0in'>&#160;&#160; Allowance for doubtful accounts</p> </td> <td width="85" valign="top" style='width:63.8pt;border:none;border-bottom:solid black 1.0pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>(20,000)</p> </td> <td width="85" valign="top" style='width:63.75pt;border:none;border-bottom:solid black 1.0pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>(20,000)</p> </td> <td width="85" valign="top" style='width:63.8pt;border:none;border-bottom:solid black 1.0pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>(20,000)</p> </td> </tr> <tr align="left"> <td width="236" valign="top" style='width:176.65pt;padding:0'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="85" valign="top" style='width:63.8pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="85" valign="top" style='width:63.75pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="85" valign="top" style='width:63.8pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> </tr> <tr style='height:13.3pt'> <td width="236" valign="top" style='width:176.65pt;padding:0;height:13.3pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="85" valign="top" style='width:63.8pt;border:none;border-bottom:double windowtext 1.5pt;padding:0;height:13.3pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 275,072</p> </td> <td width="85" valign="top" style='width:63.75pt;border:none;border-bottom:double windowtext 1.5pt;padding:0;height:13.3pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>$&#160;&#160;&#160;&#160;&#160;&#160; 366,887</p> </td> <td width="85" valign="top" style='width:63.8pt;border:none;border-bottom:double windowtext 1.5pt;padding:0;height:13.3pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>$&#160;&#160;&#160;&#160;&#160;&#160; 899,969</p> </td> </tr> </table> <!--egx--><p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-align:justify;text-indent:.5in'>&nbsp;</p> <table border="0" cellspacing="0" cellpadding="0" width="491" style='margin-left:.5in;border-collapse:collapse'> <tr align="left"> <td width="236" valign="top" style='width:176.65pt;padding:0'> <p style='margin-right:0in;margin-left:0in'>Inventories:</p> </td> <td width="85" valign="top" style='width:63.8pt;padding:0'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'>&nbsp;</p> </td> <td width="85" valign="top" style='width:63.75pt;padding:0'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'>&nbsp;</p> </td> <td width="85" valign="top" style='width:63.8pt;padding:0'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'>&nbsp;</p> </td> </tr> <tr align="left"> <td width="236" valign="top" style='width:176.65pt;padding:0'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="85" valign="top" style='width:63.8pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="85" valign="top" style='width:63.75pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="85" valign="top" style='width:63.8pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> </tr> <tr align="left"> <td width="236" valign="top" style='width:176.65pt;padding:0'> <p style='margin-right:0in;margin-left:0in'>&#160;&#160; Parts and supplies</p> </td> <td width="85" valign="top" style='width:63.8pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>$&#160;&#160;&#160; 1,004,164</p> </td> <td width="85" valign="top" style='width:63.75pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>$ &#160;&#160;&#160;1,369,960</p> </td> <td width="85" valign="top" style='width:63.8pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>$&#160;&#160;&#160; 1,353,614</p> </td> </tr> <tr align="left"> <td width="236" valign="top" style='width:176.65pt;padding:0'> <p style='margin-right:0in;margin-left:0in'>&#160;&#160; Work-in-process</p> </td> <td width="85" valign="top" style='width:63.8pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>951,519</p> </td> <td width="85" valign="top" style='width:63.75pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>880,751</p> </td> <td width="85" valign="top" style='width:63.8pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>990,668</p> </td> </tr> <tr align="left"> <td width="236" valign="top" style='width:176.65pt;padding:0'> <p style='margin-right:0in;margin-left:0in'>&#160;&#160; Finished goods</p> </td> <td width="85" valign="top" style='width:63.8pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>569,965</p> </td> <td width="85" valign="top" style='width:63.75pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>228,478</p> </td> <td width="85" valign="top" style='width:63.8pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>201,488</p> </td> </tr> <tr align="left"> <td width="236" valign="top" style='width:176.65pt;padding:0'> <p style='margin-right:0in;margin-left:0in'>&#160;&#160; Reserve for obsolete inventories</p> </td> <td width="85" valign="top" style='width:63.8pt;border:none;border-bottom:solid black 1.0pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>(&#160; 750,000)</p> </td> <td width="85" valign="top" style='width:63.75pt;border:none;border-bottom:solid black 1.0pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>(150,000)</p> </td> <td width="85" valign="top" style='width:63.8pt;border:none;border-bottom:solid black 1.0pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>(100,000)</p> </td> </tr> <tr align="left"> <td width="236" valign="top" style='width:176.65pt;padding:0'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="85" valign="top" style='width:63.8pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="85" valign="top" style='width:63.75pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="85" valign="top" style='width:63.8pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> </tr> <tr style='height:13.3pt'> <td width="236" valign="top" style='width:176.65pt;padding:0;height:13.3pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="85" valign="top" style='width:63.8pt;border:none;border-bottom:double windowtext 1.5pt;padding:0;height:13.3pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>$&#160;&#160;&#160; 1,775,648</p> </td> <td width="85" valign="top" style='width:63.75pt;border:none;border-bottom:double windowtext 1.5pt;padding:0;height:13.3pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>$&#160;&#160;&#160; 2,329,189</p> </td> <td width="85" valign="top" style='width:63.8pt;border:none;border-bottom:double windowtext 1.5pt;padding:0;height:13.3pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>$&#160;&#160;&#160; 2,445,770</p> </td> </tr> </table> <!--egx--><p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-align:justify;text-indent:.5in'>&nbsp;</p> <table border="0" cellspacing="0" cellpadding="0" width="491" style='margin-left:.5in;border-collapse:collapse'> <tr align="left"> <td width="236" valign="top" style='width:176.65pt;padding:0'> <p style='margin-right:0in;margin-left:0in'>Accrued liabilities:</p> </td> <td width="85" valign="top" style='width:63.8pt;padding:0'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'>&nbsp;</p> </td> <td width="85" valign="top" style='width:63.75pt;padding:0'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'>&nbsp;</p> </td> <td width="85" valign="top" style='width:63.8pt;padding:0'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'><b> </b></p> </td> </tr> <tr align="left"> <td width="236" valign="top" style='width:176.65pt;padding:0'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="85" valign="top" style='width:63.8pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="85" valign="top" style='width:63.75pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="85" valign="top" style='width:63.8pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> </tr> <tr align="left"> <td width="236" valign="top" style='width:176.65pt;padding:0'> <p style='margin-right:0in;margin-left:0in'>&#160;&#160; Warranty reserve</p> </td> <td width="85" valign="top" style='width:63.8pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>$&#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;65,102</p> </td> <td width="85" valign="top" style='width:63.75pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>$&#160;&#160;&#160;&#160;&#160;&#160;&#160; 75,728</p> </td> <td width="85" valign="top" style='width:63.8pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>$&#160;&#160;&#160;&#160;&#160;&#160;&#160; 50,968</p> </td> </tr> <tr align="left"> <td width="236" valign="top" style='width:176.65pt;padding:0'> <p style='margin-right:0in;margin-left:0in'>&#160;&#160; Training and installation reserve</p> </td> <td width="85" valign="top" style='width:63.8pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>2,038</p> </td> <td width="85" valign="top" style='width:63.75pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>4,716</p> </td> <td width="85" valign="top" style='width:63.8pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>5,528</p> </td> </tr> <tr align="left"> <td width="236" valign="top" style='width:176.65pt;padding:0'> <p style='margin-right:0in;margin-left:0in'>&#160;&#160; Accrued taxes payable</p> </td> <td width="85" valign="top" style='width:63.8pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>50,462</p> </td> <td width="85" valign="top" style='width:63.75pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>59,745</p> </td> <td width="85" valign="top" style='width:63.8pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>44,677</p> </td> </tr> <tr align="left"> <td width="236" valign="top" style='width:176.65pt;padding:0'> <p style='margin-right:0in;margin-left:0in'>&#160;&#160; Payroll, commissions, legal and other</p> </td> <td width="85" valign="top" style='width:63.8pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>987,550</p> </td> <td width="85" valign="top" style='width:63.75pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>726,339</p> </td> <td width="85" valign="top" style='width:63.8pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>472,707</p> </td> </tr> <tr align="left"> <td width="236" valign="top" style='width:176.65pt;padding:0'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="85" valign="top" style='width:63.8pt;border:none;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="85" valign="top" style='width:63.75pt;border:none;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="85" valign="top" style='width:63.8pt;border:none;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> </tr> <tr style='height:13.3pt'> <td width="236" valign="top" style='width:176.65pt;padding:0;height:13.3pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="85" valign="top" style='width:63.8pt;border:none;border-bottom:double windowtext 1.5pt;padding:0;height:13.3pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>$&#160;&#160;&#160; 1,105,152</p> </td> <td width="85" valign="top" style='width:63.75pt;border:none;border-bottom:double windowtext 1.5pt;padding:0;height:13.3pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>$&#160;&#160;&#160;&#160;&#160; 866,528</p> </td> <td width="85" valign="top" style='width:63.8pt;border:none;border-bottom:double windowtext 1.5pt;padding:0;height:13.3pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>$&#160;&#160;&#160;&#160;&#160; 573,880</p> </td> </tr> </table> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <!--egx--> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>&nbsp;</p> <table border="0" cellspacing="0" cellpadding="0" width="491" style='margin-left:.5in;border-collapse:collapse'> <tr align="left"> <td width="236" valign="top" style='width:176.65pt;padding:0'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="85" valign="top" style='width:63.8pt;padding:0'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'><b>December 31,</b></p> </td> <td width="170" colspan="2" valign="top" style='width:127.55pt;padding:0'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'><b>August 31,</b></p> </td> </tr> <tr align="left"> <td width="236" valign="top" style='width:176.65pt;padding:0'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="85" valign="top" style='width:63.8pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'><b>2014</b></p> </td> <td width="85" valign="top" style='width:63.75pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'><b>2014</b></p> </td> <td width="85" valign="top" style='width:63.8pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'><b>2013</b></p> </td> </tr> <tr align="left"> <td width="236" valign="top" style='width:176.65pt;padding:0'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="85" valign="top" style='width:63.8pt;border:none;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="85" valign="top" style='width:63.75pt;border:none;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="85" valign="top" style='width:63.8pt;border:none;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> </tr> <tr align="left"> <td width="236" valign="top" style='width:176.65pt;padding:0'> <p style='margin-right:0in;margin-left:0in'>&#160;&#160; Equipment</p> </td> <td width="85" valign="bottom" style='width:63.8pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:3.7pt;text-align:right'>$&#160;&#160;&#160; 1,503,845</p> </td> <td width="85" valign="bottom" style='width:63.75pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:3.7pt;text-align:right'>$&#160;&#160;&#160; 1,468,528</p> </td> <td width="85" valign="bottom" style='width:63.8pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:3.7pt;text-align:right'>$&#160;&#160;&#160; 1,401,811</p> </td> </tr> <tr align="left"> <td width="236" valign="top" style='width:176.65pt;padding:0'> <p style='margin-right:0in;margin-left:0in'>&#160;&#160; Rental equipment</p> </td> <td width="85" valign="bottom" style='width:63.8pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:3.7pt;text-align:right'>58,940</p> </td> <td width="85" valign="bottom" style='width:63.75pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:3.7pt;text-align:right'>58,940</p> </td> <td width="85" valign="bottom" style='width:63.8pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:3.7pt;text-align:right'>58,940</p> </td> </tr> <tr align="left"> <td width="236" valign="top" style='width:176.65pt;padding:0'> <p style='margin-right:0in;margin-left:0in'>&#160;&#160; Furniture and fixtures</p> </td> <td width="85" valign="bottom" style='width:63.8pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:3.7pt;text-align:right'>303,226</p> </td> <td width="85" valign="bottom" style='width:63.75pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:3.7pt;text-align:right'>303,226</p> </td> <td width="85" valign="bottom" style='width:63.8pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:3.7pt;text-align:right'>300,061</p> </td> </tr> <tr align="left"> <td width="236" valign="top" style='width:176.65pt;padding:0'> <p style='margin-right:0in;margin-left:0in'>&#160;&#160; Building improvements</p> </td> <td width="85" valign="bottom" style='width:63.8pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:3.7pt;text-align:right'>-</p> </td> <td width="85" valign="bottom" style='width:63.75pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:3.7pt;text-align:right'>54,736</p> </td> <td width="85" valign="bottom" style='width:63.8pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:3.7pt;text-align:right'>54,736</p> </td> </tr> <tr align="left"> <td width="236" valign="top" style='width:176.65pt;padding:0'> <p style='margin-right:0in;margin-left:0in'>&#160;&#160; Building (held for sale)</p> </td> <td width="85" valign="bottom" style='width:63.8pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:3.7pt;text-align:right'>956,000</p> </td> <td width="85" valign="bottom" style='width:63.75pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:3.7pt;text-align:right'>956,000</p> </td> <td width="85" valign="bottom" style='width:63.8pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:3.7pt;text-align:right'>956,000</p> </td> </tr> <tr align="left"> <td width="236" valign="top" style='width:176.65pt;padding:0'> <p style='margin-right:0in;margin-left:0in'>&#160;&#160; Land&#160; (held for sale)</p> </td> <td width="85" valign="bottom" style='width:63.8pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:3.7pt;text-align:right'>244,000</p> </td> <td width="85" valign="bottom" style='width:63.75pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:3.7pt;text-align:right'>244,000</p> </td> <td width="85" valign="bottom" style='width:63.8pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:3.7pt;text-align:right'>244,000</p> </td> </tr> <tr align="left"> <td width="236" valign="top" style='width:176.65pt;padding:0'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="85" valign="bottom" style='width:63.8pt;border:none;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:3.7pt;text-align:right'>&nbsp;</p> </td> <td width="85" valign="bottom" style='width:63.75pt;border:none;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:3.7pt;text-align:right'>&nbsp;</p> </td> <td width="85" valign="bottom" style='width:63.8pt;border:none;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:3.7pt;text-align:right'>&nbsp;</p> </td> </tr> <tr align="left"> <td width="236" valign="top" style='width:176.65pt;padding:0'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="85" valign="bottom" style='width:63.8pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:3.7pt;text-align:right'>3,066,011</p> </td> <td width="85" valign="bottom" style='width:63.75pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:3.7pt;text-align:right'>3,085,430</p> </td> <td width="85" valign="bottom" style='width:63.8pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:3.7pt;text-align:right'>3,015,548</p> </td> </tr> <tr align="left"> <td width="236" valign="top" style='width:176.65pt;padding:0'> <p style='margin-right:0in;margin-left:0in'>&#160;&#160; Less equipment impairment</p> </td> <td width="85" valign="bottom" style='width:63.8pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&#160;(&#160;&#160;&#160;&#160; 85,000)</p> </td> <td width="85" valign="bottom" style='width:63.75pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>-</p> </td> <td width="85" valign="bottom" style='width:63.8pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>-</p> </td> </tr> <tr align="left"> <td width="236" valign="top" style='width:176.65pt;padding:0'> <p style='margin-right:0in;margin-left:0in'>&#160;&#160; Less accumulated depreciation</p> </td> <td width="85" valign="bottom" style='width:63.8pt;border:none;border-bottom:solid black 1.0pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>(1,840,140)</p> </td> <td width="85" valign="bottom" style='width:63.75pt;border:none;border-bottom:solid black 1.0pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>(1,817,769)</p> </td> <td width="85" valign="bottom" style='width:63.8pt;border:none;border-bottom:solid black 1.0pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>(1,695,668)</p> </td> </tr> <tr align="left"> <td width="236" valign="top" style='width:176.65pt;padding:0'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="85" valign="bottom" style='width:63.8pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="85" valign="bottom" style='width:63.75pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="85" valign="bottom" style='width:63.8pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> </tr> <tr style='height:13.3pt'> <td width="236" valign="top" style='width:176.65pt;padding:0;height:13.3pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="85" valign="bottom" style='width:63.8pt;border:none;border-bottom:double windowtext 1.5pt;padding:0;height:13.3pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>$&#160;&#160;&#160; 1,140,871</p> </td> <td width="85" valign="bottom" style='width:63.75pt;border:none;border-bottom:double windowtext 1.5pt;padding:0;height:13.3pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>$&#160;&#160;&#160; 1,267,661</p> </td> <td width="85" valign="bottom" style='width:63.8pt;border:none;border-bottom:double windowtext 1.5pt;padding:0;height:13.3pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>$&#160;&#160;&#160; 1,319,880</p> </td> </tr> </table> <!--egx--><p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-align:justify;text-indent:.5in'>&nbsp;</p> <table border="1" cellspacing="0" cellpadding="0" width="100%" style='width:100.0%;border-collapse:collapse;border:none'> <tr style='height:42.7pt'> <td width="41%" valign="top" style='width:41.92%;border:none;padding:0;height:42.7pt'> <p style='margin-right:0in;margin-left:0in;margin-left:8.8pt;text-indent:-8.8pt'>&nbsp;</p> </td> <td width="19%" valign="bottom" style='width:19.36%;border:none;border-bottom:solid windowtext 1.0pt;padding:0;height:42.7pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'><b>Shares</b></p> </td> <td width="2%" valign="bottom" style='width:2.18%;border:none;border-bottom:solid windowtext 1.0pt;padding:0;height:42.7pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="16%" valign="bottom" style='width:16.12%;border:none;border-bottom:solid windowtext 1.0pt;padding:0;height:42.7pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'><b>Weighted- Average Exercise Price</b></p> </td> <td width="20%" valign="bottom" style='width:20.42%;border:none;border-bottom:solid windowtext 1.0pt;padding:0;height:42.7pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'><b>Weighted-Average Remaining Contract Term (Years)</b></p> </td> </tr> <tr style='height:12.9pt'> <td width="41%" valign="top" style='width:41.92%;border:none;padding:0;height:12.9pt'> <p style='margin-right:0in;margin-left:0in;margin-left:8.8pt;text-indent:-8.8pt'>&nbsp;</p> </td> <td width="19%" valign="bottom" style='width:19.36%;border:none;padding:0;height:12.9pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'>&nbsp;</p> </td> <td width="2%" valign="bottom" style='width:2.18%;border:none;border-bottom:solid windowtext 1.0pt;padding:0;height:12.9pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="16%" valign="bottom" style='width:16.12%;border:none;padding:0;height:12.9pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'>&nbsp;</p> </td> <td width="20%" valign="bottom" style='width:20.42%;border:none;padding:0;height:12.9pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'>&nbsp;</p> </td> </tr> <tr style='height:12.9pt'> <td width="41%" valign="top" style='width:41.92%;border:none;padding:0;height:12.9pt'> <p style='margin-right:0in;margin-left:0in;margin-left:8.8pt;text-indent:-8.8pt'>&nbsp;</p> </td> <td width="19%" valign="bottom" style='width:19.36%;border:none;border-top:solid windowtext 1.0pt;padding:0;height:12.9pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'>&nbsp;</p> </td> <td width="2%" valign="bottom" style='width:2.18%;border:none;padding:0;height:12.9pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="16%" valign="bottom" style='width:16.12%;border:none;border-top:solid windowtext 1.0pt;padding:0;height:12.9pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'>&nbsp;</p> </td> <td width="20%" valign="bottom" style='width:20.42%;border:none;border-top:solid windowtext 1.0pt;padding:0;height:12.9pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'>&nbsp;</p> </td> </tr> <tr style='height:12.9pt'> <td width="41%" valign="bottom" style='width:41.92%;border:none;padding:0;height:12.9pt'> <p style='margin-right:0in;margin-left:0in;margin-left:8.8pt;text-indent:-8.8pt'>Outstanding as of August 31, 2013</p> </td> <td width="19%" valign="bottom" style='width:19.36%;border:none;padding:0;height:12.9pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.2in;text-align:right'>5,457,305</p> </td> <td width="2%" valign="bottom" style='width:2.18%;border:none;padding:0;height:12.9pt'> <p style='margin-right:0in;margin-left:0in'>$</p> </td> <td width="16%" valign="bottom" style='width:16.12%;border:none;padding:0;height:12.9pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'>2.93</p> </td> <td width="20%" valign="bottom" style='width:20.42%;border:none;padding:0;height:12.9pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'>-</p> </td> </tr> <tr style='height:12.6pt'> <td width="41%" valign="bottom" style='width:41.92%;border:none;padding:0;height:12.6pt'> <p style='margin-right:0in;margin-left:0in;margin-left:8.8pt;text-indent:-8.8pt'>Granted</p> </td> <td width="19%" valign="bottom" style='width:19.36%;border:none;padding:0;height:12.6pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.2in;text-align:right'>4,400,000</p> </td> <td width="2%" valign="bottom" style='width:2.18%;border:none;padding:0;height:12.6pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="16%" valign="bottom" style='width:16.12%;border:none;padding:0;height:12.6pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'>1.10</p> </td> <td width="20%" valign="bottom" style='width:20.42%;border:none;padding:0;height:12.6pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'>-</p> </td> </tr> <tr style='height:13.5pt'> <td width="41%" valign="bottom" style='width:41.92%;border:none;padding:0;height:13.5pt'> <p style='margin-right:0in;margin-left:0in;margin-left:8.8pt;text-indent:-8.8pt'>Exercised</p> </td> <td width="19%" valign="bottom" style='width:19.36%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.2in;text-align:right'>-</p> </td> <td width="2%" valign="bottom" style='width:2.18%;border:none;padding:0;height:13.5pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="16%" valign="bottom" style='width:16.12%;border:none;padding:0;height:13.5pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'>-</p> </td> <td width="20%" valign="bottom" style='width:20.42%;border:none;padding:0;height:13.5pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'>-</p> </td> </tr> <tr style='height:13.5pt'> <td width="41%" valign="bottom" style='width:41.92%;border:none;padding:0;height:13.5pt'> <p style='margin-right:0in;margin-left:0in;margin-left:8.8pt;text-indent:-8.8pt'>Forfeited or expired</p> </td> <td width="19%" valign="bottom" style='width:19.36%;border:none;border-bottom:solid windowtext 1.0pt;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.2in;text-align:right'>-</p> </td> <td width="2%" valign="bottom" style='width:2.18%;border:none;border-bottom:solid windowtext 1.0pt;padding:0;height:13.5pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="16%" valign="bottom" style='width:16.12%;border:none;border-bottom:solid windowtext 1.0pt;padding:0;height:13.5pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'>-</p> </td> <td width="20%" valign="bottom" style='width:20.42%;border:none;border-bottom:solid windowtext 1.0pt;padding:0;height:13.5pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'>-</p> </td> </tr> <tr style='height:13.5pt'> <td width="41%" valign="bottom" style='width:41.92%;border:none;padding:0;height:13.5pt'> <p style='margin-right:0in;margin-left:0in;margin-left:8.8pt;text-indent:-8.8pt'>&nbsp;</p> </td> <td width="19%" valign="bottom" style='width:19.36%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.2in;text-align:right'>&nbsp;</p> </td> <td width="2%" valign="bottom" style='width:2.18%;border:none;padding:0;height:13.5pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="16%" valign="bottom" style='width:16.12%;border:none;padding:0;height:13.5pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'>&nbsp;</p> </td> <td width="20%" valign="bottom" style='width:20.42%;border:none;padding:0;height:13.5pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'>&nbsp;</p> </td> </tr> <tr style='height:13.5pt'> <td width="41%" valign="bottom" style='width:41.92%;border:none;padding:0;height:13.5pt'> <p style='margin-right:0in;margin-left:0in;margin-left:8.8pt;text-indent:-8.8pt'>Outstanding as of August 31, 2014</p> </td> <td width="19%" valign="bottom" style='width:19.36%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.2in;text-align:right'>9,857,305</p> </td> <td width="2%" valign="bottom" style='width:2.18%;border:none;padding:0;height:13.5pt'> <p style='margin-right:0in;margin-left:0in'>$</p> </td> <td width="16%" valign="bottom" style='width:16.12%;border:none;padding:0;height:13.5pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'>2.11</p> </td> <td width="20%" valign="bottom" style='width:20.42%;border:none;padding:0;height:13.5pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'>4.02</p> </td> </tr> <tr style='height:13.5pt'> <td width="41%" valign="bottom" style='width:41.92%;border:none;padding:0;height:13.5pt'> <p style='margin-right:0in;margin-left:0in;margin-left:8.8pt;text-indent:-8.8pt'>Granted</p> </td> <td width="19%" valign="bottom" style='width:19.36%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.2in;text-align:right'>-</p> </td> <td width="2%" valign="bottom" style='width:2.18%;border:none;padding:0;height:13.5pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="16%" valign="bottom" style='width:16.12%;border:none;padding:0;height:13.5pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'>-</p> </td> <td width="20%" valign="bottom" style='width:20.42%;border:none;padding:0;height:13.5pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'>-</p> </td> </tr> <tr style='height:13.5pt'> <td width="41%" valign="bottom" style='width:41.92%;border:none;padding:0;height:13.5pt'> <p style='margin-right:0in;margin-left:0in;margin-left:8.8pt;text-indent:-8.8pt'>Exercised</p> </td> <td width="19%" valign="bottom" style='width:19.36%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.2in;text-align:right'>-</p> </td> <td width="2%" valign="bottom" style='width:2.18%;border:none;padding:0;height:13.5pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="16%" valign="bottom" style='width:16.12%;border:none;padding:0;height:13.5pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'>-</p> </td> <td width="20%" valign="bottom" style='width:20.42%;border:none;padding:0;height:13.5pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'>-</p> </td> </tr> <tr style='height:13.5pt'> <td width="41%" valign="bottom" style='width:41.92%;border:none;padding:0;height:13.5pt'> <p style='margin-right:0in;margin-left:0in;margin-left:8.8pt;text-indent:-8.8pt'>Forfeited or expired</p> </td> <td width="19%" valign="bottom" style='width:19.36%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.2in;text-align:right'>-</p> </td> <td width="2%" valign="bottom" style='width:2.18%;border:none;padding:0;height:13.5pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="16%" valign="bottom" style='width:16.12%;border:none;padding:0;height:13.5pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'>-</p> </td> <td width="20%" valign="bottom" style='width:20.42%;border:none;padding:0;height:13.5pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'>-</p> </td> </tr> <tr style='height:13.5pt'> <td width="41%" valign="bottom" style='width:41.92%;border:none;padding:0;height:13.5pt'> <p style='margin-right:0in;margin-left:0in;margin-left:8.8pt;text-indent:-8.8pt'>&nbsp;</p> </td> <td width="19%" valign="bottom" style='width:19.36%;border:none;border-top:solid windowtext 1.0pt;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.2in;text-align:right'>&nbsp;</p> </td> <td width="2%" valign="bottom" style='width:2.18%;border:none;border-top:solid windowtext 1.0pt;padding:0;height:13.5pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="16%" valign="bottom" style='width:16.12%;border:none;border-top:solid windowtext 1.0pt;padding:0;height:13.5pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'>&nbsp;</p> </td> <td width="20%" valign="bottom" style='width:20.42%;border:none;border-top:solid windowtext 1.0pt;padding:0;height:13.5pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'>&nbsp;</p> </td> </tr> <tr style='height:12.6pt'> <td width="41%" valign="bottom" style='width:41.92%;border:none;padding:0;height:12.6pt'> <p style='margin-right:0in;margin-left:0in;margin-left:8.8pt;text-indent:-8.8pt'>Outstanding as of December 31, 2014</p> </td> <td width="19%" valign="bottom" style='width:19.36%;border:none;border-bottom:double windowtext 1.5pt;padding:0;height:12.6pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.2in;text-align:right'>9,857,305</p> </td> <td width="2%" valign="bottom" style='width:2.18%;border:none;border-bottom:double windowtext 1.5pt;padding:0;height:12.6pt'> <p style='margin-right:0in;margin-left:0in'>$</p> </td> <td width="16%" valign="bottom" style='width:16.12%;border:none;border-bottom:double windowtext 1.5pt;padding:0;height:12.6pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'>2.11</p> </td> <td width="20%" valign="bottom" style='width:20.42%;border:none;border-bottom:double windowtext 1.5pt;padding:0;height:12.6pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'>3.69</p> </td> </tr> <tr style='height:12.15pt'> <td width="41%" valign="bottom" style='width:41.92%;border:none;padding:0;height:12.15pt'> <p style='margin-right:0in;margin-left:0in;margin-left:8.8pt;text-indent:-8.8pt'>&nbsp;</p> </td> <td width="19%" valign="bottom" style='width:19.36%;border:none;padding:0;height:12.15pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'>&nbsp;</p> </td> <td width="2%" valign="bottom" style='width:2.18%;border:none;padding:0;height:12.15pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="16%" valign="bottom" style='width:16.12%;border:none;padding:0;height:12.15pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'>&nbsp;</p> </td> <td width="20%" valign="bottom" style='width:20.42%;border:none;padding:0;height:12.15pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'>&nbsp;</p> </td> </tr> <tr style='height:14.85pt'> <td width="41%" valign="bottom" style='width:41.92%;border:none;padding:0;height:14.85pt'> <p style='margin-right:0in;margin-left:0in;margin-left:8.8pt;text-indent:-8.8pt'>Exercisable as of December 31, 2014</p> </td> <td width="19%" valign="bottom" style='width:19.36%;border:none;border-bottom:double windowtext 1.5pt;padding:0;height:14.85pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.2in;text-align:right'>5,457,305</p> </td> <td width="2%" valign="bottom" style='width:2.18%;border:none;border-bottom:double windowtext 1.5pt;padding:0;height:14.85pt'> <p style='margin-right:0in;margin-left:0in'>$</p> </td> <td width="16%" valign="bottom" style='width:16.12%;border:none;border-bottom:double windowtext 1.5pt;padding:0;height:14.85pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'>2.93</p> </td> <td width="20%" valign="bottom" style='width:20.42%;border:none;border-bottom:double windowtext 1.5pt;padding:0;height:14.85pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'>2.62</p> </td> </tr> </table> <!--egx--> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>&nbsp;</p> <table border="0" cellspacing="0" cellpadding="0" width="567" style='border-collapse:collapse'> <tr align="left"> <td width="252" valign="top" style='width:188.9pt;padding:0'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="126" valign="top" style='width:94.6pt;padding:0'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'><b>Four Months Ended December 31, </b></p> </td> <td width="189" colspan="2" valign="top" style='width:141.75pt;padding:0'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'><b>Years Ended August 31,</b></p> </td> </tr> <tr align="left"> <td width="252" valign="top" style='width:188.9pt;padding:0'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="126" valign="top" style='width:94.6pt;border:none;border-bottom:solid black 1.0pt;padding:0'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'><b>2014</b></p> </td> <td width="95" valign="top" style='width:70.9pt;border:none;border-bottom:solid black 1.0pt;padding:0'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'><b>2014</b></p> </td> <td width="94" valign="top" style='width:70.85pt;border:none;border-bottom:solid black 1.0pt;padding:0'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'><b>2013</b></p> </td> </tr> <tr align="left"> <td width="252" valign="top" style='width:188.9pt;padding:0'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="126" valign="top" style='width:94.6pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.1in;text-align:right'>&nbsp;</p> </td> <td width="95" valign="top" style='width:70.9pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.1in;text-align:right'>&nbsp;</p> </td> <td width="94" valign="top" style='width:70.85pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.1in;text-align:right'>&nbsp;</p> </td> </tr> <tr align="left"> <td width="252" valign="top" style='width:188.9pt;padding:0'> <p style='margin-right:0in;margin-left:0in'>Income tax benefit at federal statutory rate</p> </td> <td width="126" valign="top" style='width:94.6pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.1in;text-align:right'>$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 1,281,000</p> </td> <td width="95" valign="top" style='width:70.9pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:3.7pt;text-align:right'>$&#160;&#160;&#160;&#160; 2,428,000</p> </td> <td width="94" valign="top" style='width:70.85pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:3.7pt;text-align:right'>$&#160;&#160;&#160;&#160; 2,805,000</p> </td> </tr> <tr align="left"> <td width="252" valign="top" style='width:188.9pt;padding:0'> <p style='margin-right:0in;margin-left:0in'>Stock-based compensation</p> </td> <td width="126" valign="top" style='width:94.6pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>(66,000)</p> </td> <td width="95" valign="top" style='width:70.9pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>(287,000)</p> </td> <td width="94" valign="top" style='width:70.85pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>(335,000)</p> </td> </tr> <tr align="left"> <td width="252" valign="top" style='width:188.9pt;padding:0'> <p style='margin-right:0in;margin-left:0in'>State income taxes, net of federal benefit</p> </td> <td width="126" valign="top" style='width:94.6pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.1in;text-align:right'>124,000</p> </td> <td width="95" valign="top" style='width:70.9pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:3.7pt;text-align:right'>236,000</p> </td> <td width="94" valign="top" style='width:70.85pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:3.7pt;text-align:right'>272,000</p> </td> </tr> <tr align="left"> <td width="252" valign="top" style='width:188.9pt;padding:0'> <p style='margin-right:0in;margin-left:0in'>Research and development credit</p> </td> <td width="126" valign="top" style='width:94.6pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.1in;text-align:right'>33,000</p> </td> <td width="95" valign="top" style='width:70.9pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:3.7pt;text-align:right'>99,000</p> </td> <td width="94" valign="top" style='width:70.85pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:3.7pt;text-align:right'>106,000</p> </td> </tr> <tr align="left"> <td width="252" valign="top" style='width:188.9pt;padding:0'> <p style='margin-right:0in;margin-left:0in'>Valuation allowance</p> </td> <td width="126" valign="top" style='width:94.6pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>(1,360,000)</p> </td> <td width="95" valign="top" style='width:70.9pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>(2,480,000)</p> </td> <td width="94" valign="top" style='width:70.85pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>(2,905,000)</p> </td> </tr> <tr align="left"> <td width="252" valign="top" style='width:188.9pt;padding:0'> <p style='margin-right:0in;margin-left:0in'>Other</p> </td> <td width="126" valign="top" style='width:94.6pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>(12,000)</p> </td> <td width="95" valign="top" style='width:70.9pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:3.7pt;text-align:right'>2,000</p> </td> <td width="94" valign="top" style='width:70.85pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:3.7pt;text-align:right'>55,062</p> </td> </tr> <tr style='height:14.35pt'> <td width="252" valign="top" style='width:188.9pt;padding:0;height:14.35pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="126" valign="top" style='width:94.6pt;border:none;padding:0;height:14.35pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="95" valign="top" style='width:70.9pt;border:none;padding:0;height:14.35pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:3.7pt;text-align:right'>&nbsp;</p> </td> <td width="94" valign="top" style='width:70.85pt;border:none;padding:0;height:14.35pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:3.7pt;text-align:right'>&nbsp;</p> </td> </tr> <tr style='height:12.6pt'> <td width="252" valign="top" style='width:188.9pt;padding:0;height:12.6pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="126" valign="top" style='width:94.6pt;border:none;border-bottom:double windowtext 1.5pt;padding:0;height:12.6pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:5.65pt;text-align:right'>&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</p> </td> <td width="95" valign="top" style='width:70.9pt;border:none;border-bottom:double windowtext 1.5pt;padding:0;height:12.6pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (2,000)</p> </td> <td width="94" valign="top" style='width:70.85pt;border:none;border-bottom:double windowtext 1.5pt;padding:0;height:12.6pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (1,938)</p> </td> </tr> </table> <!--egx--> <table border="0" cellspacing="0" cellpadding="0" style='margin-left:5.4pt;border-collapse:collapse'> <tr align="left"> <td width="293" valign="top" style='width:219.75pt;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="102" valign="top" style='width:76.35pt;padding:0in 5.4pt 0in 5.4pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'><b>December 31,</b></p> </td> <td width="188" colspan="2" valign="top" style='width:141.3pt;padding:0in 5.4pt 0in 5.4pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'><b>August 31,</b></p> </td> </tr> <tr align="left"> <td width="293" valign="top" style='width:219.75pt;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="102" valign="top" style='width:76.35pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'><b>2014</b></p> </td> <td width="94" valign="top" style='width:70.65pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'><b>2014</b></p> </td> <td width="94" valign="top" style='width:70.65pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'><b>2013</b></p> </td> </tr> <tr align="left"> <td width="293" valign="top" style='width:219.75pt;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>Current Asset:</p> </td> <td width="102" valign="top" style='width:76.35pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="94" valign="top" style='width:70.65pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="94" valign="top" style='width:70.65pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> </tr> <tr align="left"> <td width="293" valign="top" style='width:219.75pt;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>&#160;&#160; Accruals and reserves</p> </td> <td width="102" valign="top" style='width:76.35pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>$&#160;&#160;&#160;&#160;&#160;&#160;&#160; 73,000</p> </td> <td width="94" valign="top" style='width:70.65pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 62,000</p> </td> <td width="94" valign="top" style='width:70.65pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 26,000</p> </td> </tr> <tr align="left"> <td width="293" valign="top" style='width:219.75pt;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>&#160;&#160; Deferred revenue</p> </td> <td width="102" valign="top" style='width:76.35pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>18,000</p> </td> <td width="94" valign="top" style='width:70.65pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>33,000</p> </td> <td width="94" valign="top" style='width:70.65pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>266,000</p> </td> </tr> <tr align="left"> <td width="293" valign="top" style='width:219.75pt;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>&#160;&#160; Inventories</p> </td> <td width="102" valign="top" style='width:76.35pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>298,000</p> </td> <td width="94" valign="top" style='width:70.65pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>90,000</p> </td> <td width="94" valign="top" style='width:70.65pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>68,000</p> </td> </tr> <tr align="left"> <td width="293" valign="top" style='width:219.75pt;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>Valuation allowance</p> </td> <td width="102" valign="top" style='width:76.35pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>(389,000)</p> </td> <td width="94" valign="top" style='width:70.65pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>(185,000)</p> </td> <td width="94" valign="top" style='width:70.65pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>(360,000)</p> </td> </tr> <tr align="left"> <td width="293" valign="top" style='width:219.75pt;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="102" valign="top" style='width:76.35pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>&nbsp;</p> </td> <td width="94" valign="top" style='width:70.65pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>&nbsp;</p> </td> <td width="94" valign="top" style='width:70.65pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>&nbsp;</p> </td> </tr> <tr align="left"> <td width="293" valign="top" style='width:219.75pt;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="102" valign="top" style='width:76.35pt;border:none;border-bottom:double windowtext 1.5pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; -</p> </td> <td width="94" valign="top" style='width:70.65pt;border:none;border-bottom:double windowtext 1.5pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; -</p> </td> <td width="94" valign="top" style='width:70.65pt;border:none;border-bottom:double windowtext 1.5pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; -</p> </td> </tr> <tr align="left"> <td width="293" valign="top" style='width:219.75pt;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>Long-Term Asset (Liability):</p> </td> <td width="102" valign="top" style='width:76.35pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>&nbsp;</p> </td> <td width="94" valign="top" style='width:70.65pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>&nbsp;</p> </td> <td width="94" valign="top" style='width:70.65pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>&nbsp;</p> </td> </tr> <tr align="left"> <td width="293" valign="top" style='width:219.75pt;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>&#160;&#160; Deferred compensation</p> </td> <td width="102" valign="bottom" style='width:76.35pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>$&#160;&#160;&#160;&#160;&#160;&#160; 601,000</p> </td> <td width="94" valign="bottom" style='width:70.65pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>$&#160;&#160;&#160;&#160;&#160;&#160; 601,000</p> </td> <td width="94" valign="bottom" style='width:70.65pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:3.7pt;text-align:right'>$&#160;&#160;&#160;&#160;&#160;&#160; 601,000</p> </td> </tr> <tr align="left"> <td width="293" valign="top" style='width:219.75pt;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>&#160;&#160; Research and development and other tax credits</p> </td> <td width="102" valign="bottom" style='width:76.35pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>1,929,000</p> </td> <td width="94" valign="bottom" style='width:70.65pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>1,896,000</p> </td> <td width="94" valign="bottom" style='width:70.65pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:3.7pt;text-align:right'>1,804,000</p> </td> </tr> <tr align="left"> <td width="293" valign="top" style='width:219.75pt;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>&#160; Net operating loss carryforwards - federal</p> </td> <td width="102" valign="bottom" style='width:76.35pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>12,951,000</p> </td> <td width="94" valign="bottom" style='width:70.65pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>13,938,000</p> </td> <td width="94" valign="bottom" style='width:70.65pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:3.7pt;text-align:right'>11,380,000</p> </td> </tr> <tr align="left"> <td width="293" valign="top" style='width:219.75pt;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>&#160; Net operating loss carryforwards - state</p> </td> <td width="102" valign="bottom" style='width:76.35pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>2,079,000</p> </td> <td width="94" valign="bottom" style='width:70.65pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>-</p> </td> <td width="94" valign="bottom" style='width:70.65pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:3.7pt;text-align:right'>-</p> </td> </tr> <tr align="left"> <td width="293" valign="top" style='width:219.75pt;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>&#160;&#160; Depreciation and amortization</p> </td> <td width="102" valign="bottom" style='width:76.35pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>39,000</p> </td> <td width="94" valign="bottom" style='width:70.65pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>8,000</p> </td> <td width="94" valign="bottom" style='width:70.65pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:3.7pt;text-align:right'>3,000</p> </td> </tr> <tr align="left"> <td width="293" valign="top" style='width:219.75pt;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>Valuation allowance</p> </td> <td width="102" valign="bottom" style='width:76.35pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>(17,599,000)</p> </td> <td width="94" valign="bottom" style='width:70.65pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>(16,443,000)</p> </td> <td width="94" valign="bottom" style='width:70.65pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>(13,788,000)</p> </td> </tr> <tr align="left"> <td width="293" valign="top" style='width:219.75pt;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="102" valign="bottom" style='width:76.35pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>&nbsp;</p> </td> <td width="94" valign="bottom" style='width:70.65pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>&nbsp;</p> </td> <td width="94" valign="bottom" style='width:70.65pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:3.7pt;text-align:right'>&nbsp;</p> </td> </tr> <tr align="left"> <td width="293" valign="top" style='width:219.75pt;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>&#160;&#160; </p> </td> <td width="102" valign="bottom" style='width:76.35pt;border:none;border-bottom:double windowtext 1.5pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; -</p> </td> <td width="94" valign="bottom" style='width:70.65pt;border:none;border-bottom:double windowtext 1.5pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; -</p> </td> <td width="94" valign="bottom" style='width:70.65pt;border:none;border-bottom:double windowtext 1.5pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:3.7pt;text-align:right'>$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160;&#160;&#160;-</p> </td> </tr> </table> <!--egx--> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>&nbsp;</p> <table border="0" cellspacing="0" cellpadding="0" width="510" style='margin-left:5.4pt;border-collapse:collapse'> <tr style='height:8.1pt'> <td width="227" valign="top" style='width:170.05pt;padding:0in 5.4pt 0in 5.4pt;height:8.1pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="95" valign="top" style='width:70.9pt;padding:0in 5.4pt 0in 5.4pt;height:8.1pt'> <p align="center" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:center'><b>Four Months Ended December 31,</b></p> </td> <td width="189" colspan="2" valign="bottom" style='width:141.75pt;padding:0in 5.4pt 0in 5.4pt;height:8.1pt'> <p align="center" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:center'><b>Years Ended &#160;August 31,</b></p> </td> </tr> <tr style='height:8.1pt'> <td width="227" valign="top" style='width:170.05pt;padding:0in 5.4pt 0in 5.4pt;height:8.1pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="95" valign="bottom" style='width:70.9pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:8.1pt'> <p align="center" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:center'><b>2014</b></p> </td> <td width="95" valign="bottom" style='width:70.9pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:8.1pt'> <p align="center" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:center'><b>2014</b></p> </td> <td width="94" valign="top" style='width:70.85pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:8.1pt'> <p align="center" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:center'><b>2013</b></p> </td> </tr> <tr style='height:8.1pt'> <td width="227" valign="top" style='width:170.05pt;padding:0in 5.4pt 0in 5.4pt;height:8.1pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="95" valign="bottom" style='width:70.9pt;border:none;padding:0in 5.4pt 0in 5.4pt;height:8.1pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>&nbsp;</p> </td> <td width="95" valign="top" style='width:70.9pt;border:none;padding:0in 5.4pt 0in 5.4pt;height:8.1pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>&nbsp;</p> </td> <td width="94" valign="top" style='width:70.85pt;border:none;padding:0in 5.4pt 0in 5.4pt;height:8.1pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>&nbsp;</p> </td> </tr> <tr style='height:8.1pt'> <td width="227" valign="bottom" style='width:170.05pt;padding:0in 5.4pt 0in 5.4pt;height:8.1pt'> <p style='margin-right:0in;margin-left:0in'>Cost of sales</p> </td> <td width="95" valign="bottom" style='width:70.9pt;padding:0in 5.4pt 0in 5.4pt;height:8.1pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>$&#160;&#160;&#160;&#160;&#160;&#160; 11,776</p> </td> <td width="95" valign="bottom" style='width:70.9pt;padding:0in 5.4pt 0in 5.4pt;height:8.1pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>$&#160;&#160;&#160;&#160;&#160;&#160; 61,427</p> </td> <td width="94" valign="bottom" style='width:70.85pt;padding:0in 5.4pt 0in 5.4pt;height:8.1pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>$&#160;&#160;&#160;&#160;&#160;&#160; 67,119</p> </td> </tr> <tr align="left"> <td width="227" valign="bottom" style='width:170.05pt;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>Research and development</p> </td> <td width="95" valign="bottom" style='width:70.9pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>32,349</p> </td> <td width="95" valign="bottom" style='width:70.9pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>183,371</p> </td> <td width="94" valign="bottom" style='width:70.85pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>212,569</p> </td> </tr> <tr align="left"> <td width="227" valign="bottom" style='width:170.05pt;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>Selling, general and administrative</p> </td> <td width="95" valign="bottom" style='width:70.9pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>148,719</p> </td> <td width="95" valign="bottom" style='width:70.9pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>599,830</p> </td> <td width="94" valign="bottom" style='width:70.85pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>855,123</p> </td> </tr> <tr align="left"> <td width="227" valign="bottom" style='width:170.05pt;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="95" valign="bottom" style='width:70.9pt;border:none;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>&nbsp;</p> </td> <td width="95" valign="bottom" style='width:70.9pt;border:none;border-top:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>&nbsp;</p> </td> <td width="94" valign="bottom" style='width:70.85pt;border:none;border-top:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>&nbsp;</p> </td> </tr> <tr align="left"> <td width="227" valign="bottom" style='width:170.05pt;padding:0in 5.4pt 0in 5.4pt'> <p style='margin-right:0in;margin-left:0in'>Total</p> </td> <td width="95" valign="bottom" style='width:70.9pt;border:none;border-bottom:double windowtext 1.5pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>$&#160;&#160;&#160; 192,844</p> </td> <td width="95" valign="bottom" style='width:70.9pt;border:none;border-bottom:double windowtext 1.5pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>$&#160; &#160;&#160;&#160;844,628</p> </td> <td width="94" valign="bottom" style='width:70.85pt;border:none;border-bottom:double windowtext 1.5pt;padding:0in 5.4pt 0in 5.4pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.05in;text-align:right'>$&#160; 1,134,811</p> </td> </tr> </table> <p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>&nbsp;</p> <!--egx--><div align="center"> <table border="0" cellspacing="0" cellpadding="0" style='border-collapse:collapse'> <tr style='height:.05pt'> <td width="349" style='width:261.45pt;padding:0;height:.05pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="121" style='width:90.45pt;padding:0;height:.05pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> </tr> <tr style='height:13.5pt'> <td width="349" valign="top" style='width:261.45pt;padding:0;height:13.5pt'> <p style='margin-right:0in;margin-left:0in;margin-left:8.8pt;text-indent:-8.8pt'>Expected volatility</p> </td> <td width="121" valign="bottom" style='width:90.45pt;padding:0;height:13.5pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'>62.96%</p> </td> </tr> <tr style='height:13.5pt'> <td width="349" valign="top" style='width:261.45pt;padding:0;height:13.5pt'> <p style='margin-right:0in;margin-left:0in;margin-left:8.8pt;text-indent:-8.8pt'>Expected dividends</p> </td> <td width="121" valign="bottom" style='width:90.45pt;padding:0;height:13.5pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'>0.00%</p> </td> </tr> <tr style='height:13.5pt'> <td width="349" valign="top" style='width:261.45pt;padding:0;height:13.5pt'> <p style='margin-right:0in;margin-left:0in;margin-left:8.8pt;text-indent:-8.8pt'>Expected term</p> </td> <td width="121" valign="bottom" style='width:90.45pt;padding:0;height:13.5pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'>7.24 Years</p> </td> </tr> <tr style='height:13.5pt'> <td width="349" valign="top" style='width:261.45pt;padding:0;height:13.5pt'> <p style='margin-right:0in;margin-left:0in;margin-left:8.8pt;text-indent:-8.8pt'>Risk-free interest rate</p> </td> <td width="121" valign="bottom" style='width:90.45pt;padding:0;height:13.5pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'>2.07%</p> </td> </tr> </table> </div> <!--egx--><p style='margin-right:0in;margin-left:0in;margin:0in;margin-bottom:.0001pt;text-indent:.5in'>&nbsp;</p> <table border="1" cellspacing="0" cellpadding="0" width="100%" style='width:100.0%;border-collapse:collapse;border:none'> <tr style='height:41.85pt'> <td width="36%" valign="bottom" style='width:36.2%;border:none;padding:0;height:41.85pt'> <p style='margin-right:0in;margin-left:0in;margin-right:.2in'>&nbsp;</p> </td> <td width="16%" valign="bottom" style='width:16.68%;border:none;border-bottom:solid windowtext 1.0pt;padding:0;height:41.85pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'><b>Shares</b></p> </td> <td width="15%" colspan="2" valign="bottom" style='width:15.7%;border:none;border-bottom:solid windowtext 1.0pt;padding:0;height:41.85pt'> <p style='margin-right:0in;margin-left:0in'><b>Weighted- Average &#160;Exercise Price</b></p> </td> <td width="18%" valign="bottom" style='width:18.64%;border:none;border-bottom:solid windowtext 1.0pt;padding:0;height:41.85pt'> <p style='margin-right:0in;margin-left:0in'><b>Weighted-Average Remaining Contract Term (Years)</b></p> </td> <td width="12%" colspan="2" valign="bottom" style='width:12.78%;border:none;border-bottom:solid windowtext 1.0pt;padding:0;height:41.85pt'> <p style='margin-right:0in;margin-left:0in'><b>Aggregate Intrinsic Value</b></p> </td> </tr> <tr style='height:12.9pt'> <td width="36%" valign="top" style='width:36.2%;border:none;padding:0;height:12.9pt'> <p style='margin-right:0in;margin-left:0in;margin-left:8.8pt;text-indent:-8.8pt'>&nbsp;</p> </td> <td width="16%" valign="bottom" style='width:16.68%;border:none;padding:0;height:12.9pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'>&nbsp;</p> </td> <td width="1%" valign="bottom" style='width:1.96%;border:none;padding:0;height:12.9pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="13%" valign="bottom" style='width:13.74%;border:none;padding:0;height:12.9pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'>&nbsp;</p> </td> <td width="18%" valign="bottom" style='width:18.64%;border:none;padding:0;height:12.9pt'> <p align="center" style='margin-right:0in;margin-left:0in;text-align:center'>&nbsp;</p> </td> <td width="1%" valign="bottom" style='width:1.0%;border:none;padding:0;height:12.9pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> <td width="11%" valign="bottom" style='width:11.78%;border:none;padding:0;height:12.9pt'> <p style='margin-right:0in;margin-left:0in'>&nbsp;</p> </td> </tr> <tr style='height:12.9pt'> <td width="36%" valign="bottom" style='width:36.2%;border:none;padding:0;height:12.9pt'> <p style='margin-right:0in;margin-left:0in;margin-left:8.8pt;text-indent:-8.8pt'>Outstanding as of September 1, 2013</p> </td> <td width="16%" valign="bottom" style='width:16.68%;border:none;padding:0;height:12.9pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.2in;text-align:right'>4,212,573</p> </td> <td width="1%" valign="bottom" style='width:1.96%;border:none;padding:0;height:12.9pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>$</p> </td> <td width="13%" valign="bottom" style='width:13.74%;border:none;padding:0;height:12.9pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>2.85</p> </td> <td width="18%" valign="bottom" style='width:18.64%;border:none;padding:0;height:12.9pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="1%" valign="bottom" style='width:1.0%;border:none;padding:0;height:12.9pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="11%" valign="bottom" style='width:11.78%;border:none;padding:0;height:12.9pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> </tr> <tr style='height:13.5pt'> <td width="36%" valign="bottom" style='width:36.2%;border:none;padding:0;height:13.5pt'> <p style='margin-right:0in;margin-left:0in;margin-left:8.8pt;text-indent:-8.8pt'>Granted</p> </td> <td width="16%" valign="bottom" style='width:16.68%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.2in;text-align:right'>127,000</p> </td> <td width="1%" valign="bottom" style='width:1.96%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="13%" valign="bottom" style='width:13.74%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>1.19</p> </td> <td width="18%" valign="bottom" style='width:18.64%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="1%" valign="bottom" style='width:1.0%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="11%" valign="bottom" style='width:11.78%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> </tr> <tr style='height:13.5pt'> <td width="36%" valign="bottom" style='width:36.2%;border:none;padding:0;height:13.5pt'> <p style='margin-right:0in;margin-left:0in;margin-left:8.8pt;text-indent:-8.8pt'>Exercised</p> </td> <td width="16%" valign="bottom" style='width:16.68%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.2in;text-align:right'>-</p> </td> <td width="1%" valign="bottom" style='width:1.96%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="13%" valign="bottom" style='width:13.74%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&#160;&#160;&#160;&#160;&#160; -</p> </td> <td width="18%" valign="bottom" style='width:18.64%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="1%" valign="bottom" style='width:1.0%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="11%" valign="bottom" style='width:11.78%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.1in;text-align:right'>&nbsp;</p> </td> </tr> <tr style='height:13.5pt'> <td width="36%" valign="bottom" style='width:36.2%;border:none;padding:0;height:13.5pt'> <p style='margin-right:0in;margin-left:0in;margin-left:8.8pt;text-indent:-8.8pt'>Forfeited or expired</p> </td> <td width="16%" valign="bottom" style='width:16.68%;border:none;border-bottom:solid windowtext 1.0pt;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:11.35pt;text-align:right'>(476,653)</p> </td> <td width="1%" valign="bottom" style='width:1.96%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="13%" valign="bottom" style='width:13.74%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>2.18</p> </td> <td width="18%" valign="bottom" style='width:18.64%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="1%" valign="bottom" style='width:1.0%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="11%" valign="bottom" style='width:11.78%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> </tr> <tr style='height:13.5pt'> <td width="36%" valign="bottom" style='width:36.2%;border:none;padding:0;height:13.5pt'> <p style='margin-right:0in;margin-left:0in;margin-left:8.8pt;text-indent:-8.8pt'>&nbsp;</p> </td> <td width="16%" valign="bottom" style='width:16.68%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.2in;text-align:right'>&nbsp;</p> </td> <td width="1%" valign="bottom" style='width:1.96%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="13%" valign="bottom" style='width:13.74%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="18%" valign="bottom" style='width:18.64%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="1%" valign="bottom" style='width:1.0%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="11%" valign="bottom" style='width:11.78%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> </tr> <tr style='height:13.5pt'> <td width="36%" valign="bottom" style='width:36.2%;border:none;padding:0;height:13.5pt'> <p style='margin-right:0in;margin-left:0in;margin-left:8.8pt;text-indent:-8.8pt'>Outstanding as of August 31, 2014</p> </td> <td width="16%" valign="bottom" style='width:16.68%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.2in;text-align:right'>3,862,920</p> </td> <td width="1%" valign="bottom" style='width:1.96%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="13%" valign="bottom" style='width:13.74%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>2.88</p> </td> <td width="18%" valign="bottom" style='width:18.64%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>6.32</p> </td> <td width="1%" valign="bottom" style='width:1.0%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>$</p> </td> <td width="11%" valign="bottom" style='width:11.78%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.1in;text-align:right'>-</p> </td> </tr> <tr style='height:13.5pt'> <td width="36%" valign="bottom" style='width:36.2%;border:none;padding:0;height:13.5pt'> <p style='margin-right:0in;margin-left:0in;margin-left:8.8pt;text-indent:-8.8pt'>Granted</p> </td> <td width="16%" valign="bottom" style='width:16.68%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.2in;text-align:right'>1,450,000</p> </td> <td width="1%" valign="bottom" style='width:1.96%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="13%" valign="bottom" style='width:13.74%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>0.46</p> </td> <td width="18%" valign="bottom" style='width:18.64%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="1%" valign="bottom" style='width:1.0%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="11%" valign="bottom" style='width:11.78%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.1in;text-align:right'>&nbsp;</p> </td> </tr> <tr style='height:13.5pt'> <td width="36%" valign="bottom" style='width:36.2%;border:none;padding:0;height:13.5pt'> <p style='margin-right:0in;margin-left:0in;margin-left:8.8pt;text-indent:-8.8pt'>Exercised</p> </td> <td width="16%" valign="bottom" style='width:16.68%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.2in;text-align:right'>-</p> </td> <td width="1%" valign="bottom" style='width:1.96%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="13%" valign="bottom" style='width:13.74%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&#160;&#160;&#160;&#160;&#160; -</p> </td> <td width="18%" valign="bottom" style='width:18.64%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="1%" valign="bottom" style='width:1.0%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="11%" valign="bottom" style='width:11.78%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.1in;text-align:right'>&nbsp;</p> </td> </tr> <tr style='height:13.5pt'> <td width="36%" valign="bottom" style='width:36.2%;border:none;padding:0;height:13.5pt'> <p style='margin-right:0in;margin-left:0in;margin-left:8.8pt;text-indent:-8.8pt'>Forfeited or expired</p> </td> <td width="16%" valign="bottom" style='width:16.68%;border:none;border-bottom:solid windowtext 1.0pt;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:14.2pt;text-align:right'>(181,001)</p> </td> <td width="1%" valign="bottom" style='width:1.96%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="13%" valign="bottom" style='width:13.74%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>1.54</p> </td> <td width="18%" valign="bottom" style='width:18.64%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="1%" valign="bottom" style='width:1.0%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="11%" valign="bottom" style='width:11.78%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.1in;text-align:right'>&nbsp;</p> </td> </tr> <tr style='height:13.5pt'> <td width="36%" valign="bottom" style='width:36.2%;border:none;padding:0;height:13.5pt'> <p style='margin-right:0in;margin-left:0in;margin-left:8.8pt;text-indent:-8.8pt'>&nbsp;</p> </td> <td width="16%" valign="bottom" style='width:16.68%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:14.2pt;text-align:right'>&nbsp;</p> </td> <td width="1%" valign="bottom" style='width:1.96%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="13%" valign="bottom" style='width:13.74%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="18%" valign="bottom" style='width:18.64%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="1%" valign="bottom" style='width:1.0%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>&nbsp;</p> </td> <td width="11%" valign="bottom" style='width:11.78%;border:none;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.1in;text-align:right'>&nbsp;</p> </td> </tr> <tr style='height:13.5pt'> <td width="36%" valign="bottom" style='width:36.2%;border:none;padding:0;height:13.5pt'> <p style='margin-right:0in;margin-left:0in;margin-left:8.8pt;text-indent:-8.8pt'>Outstanding as of December 31, 2014</p> </td> <td width="16%" valign="bottom" style='width:16.68%;border:none;border-bottom:double windowtext 1.5pt;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:14.2pt;text-align:right'>5,131,919</p> </td> <td width="1%" valign="bottom" style='width:1.96%;border:none;border-bottom:double windowtext 1.5pt;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>$</p> </td> <td width="13%" valign="bottom" style='width:13.74%;border:none;border-bottom:double windowtext 1.5pt;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>2.25</p> </td> <td width="18%" valign="bottom" style='width:18.64%;border:none;border-bottom:double windowtext 1.5pt;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>7.03</p> </td> <td width="1%" valign="bottom" style='width:1.0%;border:none;border-bottom:double windowtext 1.5pt;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>$</p> </td> <td width="11%" valign="bottom" style='width:11.78%;border:none;border-bottom:double windowtext 1.5pt;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.1in;text-align:right'>-</p> </td> </tr> <tr style='height:13.5pt'> <td width="36%" valign="bottom" style='width:36.2%;border:none;padding:0;height:13.5pt'> <p style='margin-right:0in;margin-left:0in;margin-left:8.8pt;text-indent:-8.8pt'>Exercisable as of December 31, 23014</p> </td> <td width="16%" valign="bottom" style='width:16.68%;border:none;border-bottom:double windowtext 1.5pt;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.2in;text-align:right'>2,953,586</p> </td> <td width="1%" valign="bottom" style='width:1.96%;border:none;border-bottom:double windowtext 1.5pt;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>$</p> </td> <td width="13%" valign="bottom" style='width:13.74%;border:none;border-bottom:double windowtext 1.5pt;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>3.30</p> </td> <td width="18%" valign="bottom" style='width:18.64%;border:none;border-bottom:double windowtext 1.5pt;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>5.31</p> </td> <td width="1%" valign="bottom" style='width:1.0%;border:none;border-bottom:double windowtext 1.5pt;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;text-align:right'>$</p> </td> <td width="11%" valign="bottom" style='width:11.78%;border:none;border-bottom:double windowtext 1.5pt;padding:0;height:13.5pt'> <p align="right" style='margin-right:0in;margin-left:0in;margin-right:.1in;text-align:right'>-</p> </td> </tr> </table> Delaware 1986-07-03 P2Y P5Y P5Y P5Y P15Y P40Y 13410 41471 80276 14989224 0.44 7.95 13720225 0.99 7.95 470875 986900 3019525 1934826 409787 501565 1568481 1109750 109346 100597 375747 330116 125900 95200 364600 298600 1115908 1684262 5328353 3673292 56504 206099 205442 5594578 7745352 293182 364170 890985 1890 22717 28984 -20000 -20000 -20000 275072 366887 899969 1004164 1369960 1353614 951519 880751 990668 569965 228478 201488 750000 150000 100000 1775648 2329189 2445770 65102 75728 50968 2038 4716 5528 50462 59745 44677 987550 726339 472707 1105152 866528 573880 1503845 1468528 1401811 58940 58940 58940 303226 303226 300061 54736 54736 956000 956000 956000 244000 244000 244000 3066011 3085430 3015548 -85000 -1840140 -1817769 -1695668 1140871 1267661 1319880 43280 125824 128121 805000 0 0 4032 10000000 0.001 80000000 0.001 4065042 3048782 1.23 1.65 5457305 2.93 4400000 1.10 9857305 2.11 4.02 9857305 2.11 3.69 5457305 2.93 2.62 54218 96043 783708 0.4153 0.1130 0.2346 0.2292 0.3036 630857 3381563 1470619 0.5300 0.4600 0.3000 0.3600 0.6800 0.7200 419549 99896 13471 8322 24201 1281000 2428000 2805000 -66000 -287000 -335000 124000 236000 272000 33000 99000 106000 -1360000 -2480000 -2905000 -12000 2000 55062 73000 62000 26000 18000 33000 266000 298000 90000 68000 -185000 -360000 601000 601000 601000 1929000 1896000 1804000 12951000 13938000 11380000 2079000 39000 8000 3000 -16443000 -13788000 -389000 -17599000 -40701000 6337300 60000 65000 30000 35000 30000 30000 1750000 11776 61427 67119 32349 183371 212569 148719 599830 855123 192844 844628 1134811 0.44 0.51 0.22 0.6296 P7Y2M26D 0.0207 P1Y1M24D 1078000 4212573 2.85 127000 1.19 -476653 2.18 3862920 2.88 P6Y3M25D 1450000 0.46 -181001 1.54 5131919 2.25 P7Y11D 2953586 3.30 P5Y3M22D 0.36 -2000 -1938 350000 200000 0000320174 2014-09-01 2014-12-31 0000320174 2014-12-31 0000320174 2014-01-01 2014-12-31 0000320174 2014-08-31 0000320174 2013-08-31 0000320174 2013-09-01 2013-12-31 0000320174 2013-09-01 2014-08-31 0000320174 2012-09-01 2013-08-31 0000320174 us-gaap:CommonStockMember 2012-09-01 2013-08-31 0000320174 us-gaap:AdditionalPaidInCapitalMember 2012-09-01 2013-08-31 0000320174 us-gaap:RetainedEarningsMember 2012-09-01 2013-08-31 0000320174 us-gaap:CommonStockMember 2012-08-31 0000320174 us-gaap:AdditionalPaidInCapitalMember 2012-08-31 0000320174 us-gaap:TreasuryStockMember 2012-08-31 0000320174 us-gaap:RetainedEarningsMember 2012-08-31 0000320174 2012-08-31 0000320174 us-gaap:CommonStockMember 2013-08-31 0000320174 us-gaap:AdditionalPaidInCapitalMember 2013-08-31 0000320174 us-gaap:TreasuryStockMember 2013-08-31 0000320174 us-gaap:RetainedEarningsMember 2013-08-31 0000320174 us-gaap:CommonStockMember 2013-09-01 2014-08-31 0000320174 us-gaap:AdditionalPaidInCapitalMember 2013-09-01 2014-08-31 0000320174 us-gaap:RetainedEarningsMember 2013-09-01 2014-08-31 0000320174 us-gaap:CommonStockMember 2014-08-31 0000320174 us-gaap:AdditionalPaidInCapitalMember 2014-08-31 0000320174 us-gaap:TreasuryStockMember 2014-08-31 0000320174 us-gaap:RetainedEarningsMember 2014-08-31 0000320174 us-gaap:AdditionalPaidInCapitalMember 2014-09-01 2014-12-31 0000320174 us-gaap:RetainedEarningsMember 2014-09-01 2014-12-31 0000320174 us-gaap:CommonStockMember 2014-12-31 0000320174 us-gaap:AdditionalPaidInCapitalMember 2014-12-31 0000320174 us-gaap:TreasuryStockMember 2014-12-31 0000320174 us-gaap:RetainedEarningsMember 2014-12-31 0000320174 2013-12-31 0000320174 2014-06-30 0000320174 us-gaap:MinimumMember 2014-09-01 2014-12-31 0000320174 us-gaap:MaximumMember 2014-09-01 2014-12-31 0000320174 us-gaap:MinimumMember 2013-09-01 2014-08-31 0000320174 us-gaap:MaximumMember 2013-09-01 2014-08-31 0000320174 us-gaap:EquipmentMember 2014-12-31 0000320174 us-gaap:EquipmentMember 2014-08-31 0000320174 us-gaap:EquipmentMember 2013-08-31 0000320174 us-gaap:EquipmentLeasedToOtherPartyMember 2014-12-31 0000320174 us-gaap:EquipmentLeasedToOtherPartyMember 2014-08-31 0000320174 us-gaap:EquipmentLeasedToOtherPartyMember 2013-08-31 0000320174 us-gaap:FurnitureAndFixturesMember 2014-12-31 0000320174 us-gaap:FurnitureAndFixturesMember 2014-08-31 0000320174 us-gaap:FurnitureAndFixturesMember 2013-08-31 0000320174 us-gaap:BuildingImprovementsMember 2014-08-31 0000320174 us-gaap:BuildingImprovementsMember 2013-08-31 0000320174 us-gaap:BuildingMember 2014-12-31 0000320174 us-gaap:BuildingMember 2014-08-31 0000320174 us-gaap:BuildingMember 2013-08-31 0000320174 us-gaap:LandMember 2014-12-31 0000320174 us-gaap:LandMember 2014-08-31 0000320174 us-gaap:LandMember 2013-08-31 0000320174 2013-04-09 0000320174 us-gaap:CostOfSalesMember 2014-09-01 2014-12-31 0000320174 us-gaap:CostOfSalesMember 2013-09-01 2014-08-31 0000320174 us-gaap:CostOfSalesMember 2012-09-01 2013-08-31 0000320174 us-gaap:ResearchAndDevelopmentExpenseMember 2014-09-01 2014-12-31 0000320174 us-gaap:ResearchAndDevelopmentExpenseMember 2013-09-01 2014-08-31 0000320174 us-gaap:ResearchAndDevelopmentExpenseMember 2012-09-01 2013-08-31 0000320174 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2014-09-01 2014-12-31 0000320174 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2013-09-01 2014-08-31 0000320174 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2012-09-01 2013-08-31 0000320174 us-gaap:EquipmentMemberus-gaap:MinimumMember 2014-01-01 2014-12-31 0000320174 us-gaap:EquipmentMemberus-gaap:MaximumMember 2014-01-01 2014-12-31 0000320174 us-gaap:EquipmentLeasedToOtherPartyMember 2014-01-01 2014-12-31 0000320174 us-gaap:FurnitureAndFixturesMember 2014-01-01 2014-12-31 0000320174 us-gaap:BuildingImprovementsMember 2014-01-01 2014-12-31 0000320174 us-gaap:BuildingMember 2014-01-01 2014-12-31 0000320174 2015-03-30 iso4217:USD shares iso4217:USD shares pure EX-101.SCH 13 bsdm-20141231.xsd XBRL TAXONOMY EXTENSION SCHEMA 000050 - Statement - Statements of Stockholders' Equity link:presentationLink link:definitionLink link:calculationLink 000510 - Disclosure - Note 12: Stock-based Compensation: Stock Option Rollforward (Tables) link:presentationLink link:definitionLink link:calculationLink 000210 - Disclosure - Note 15: Recent Accounting Pronouncements link:presentationLink link:definitionLink link:calculationLink 000470 - Disclosure - Note 11: Income Taxes: Schedule of Income Tax (Provision) Benefit Computed at Federal Rates (Tables) link:presentationLink link:definitionLink link:calculationLink 000660 - Disclosure - Note 6: Patents (Details) link:presentationLink link:definitionLink link:calculationLink 000530 - Disclosure - Note 1: Organization and Significant Accounting Policies: Inventories (Details) link:presentationLink link:definitionLink link:calculationLink 000810 - Disclosure - Note 12: Stock-based Compensation: Stock Option Rollforward (Details) link:presentationLink link:definitionLink link:calculationLink 000260 - Disclosure - Note 1: Organization and Significant Accounting Policies: Accounts Receivable (Policies) link:presentationLink link:definitionLink link:calculationLink 000790 - Disclosure - Note 12: Stock-based Compensation (Details) link:presentationLink link:definitionLink link:calculationLink 000300 - Disclosure - Note 1: Organization and Significant Accounting Policies: Warranty Reserve (Policies) link:presentationLink link:definitionLink link:calculationLink 000160 - Disclosure - Note 10: Related Party Transactions link:presentationLink link:definitionLink link:calculationLink 000460 - Disclosure - Note 7: Stockholders' Equity: Schedule of Stockholders' Equity Note, Warrants or Rights (Tables) link:presentationLink link:definitionLink link:calculationLink 000720 - Disclosure - Note 9: Major Customers and Foreign Sales (Details) link:presentationLink link:definitionLink link:calculationLink 000600 - Disclosure - Note 3: Detail of Certain Balance Sheet Accounts: Detail of Accounts Receivable (Details) link:presentationLink link:definitionLink link:calculationLink 000080 - Disclosure - Note 2: Liquidity link:presentationLink link:definitionLink link:calculationLink 000340 - Disclosure - Note 1: Organization and Significant Accounting Policies: Revenue Recognition (Policies) link:presentationLink link:definitionLink link:calculationLink 000020 - Statement - Balance Sheets link:presentationLink link:definitionLink link:calculationLink 000710 - Disclosure - Note 8: Deferred Revenue (Details) link:presentationLink link:definitionLink link:calculationLink 000180 - Disclosure - Note 12: Stock-based Compensation link:presentationLink link:definitionLink link:calculationLink 000750 - Disclosure - Note 11: Income Taxes: Schedule of Income Tax (Provision) Benefit Computed at Federal Rates (Details) link:presentationLink link:definitionLink link:calculationLink 000490 - Disclosure - Note 12: Stock-based Compensation: Schedule of Stock Based Compensation (Tables) link:presentationLink link:definitionLink link:calculationLink 000250 - Disclosure - Note 1: Organization and Significant Accounting Policies: Cash and Cash Equivalents (Policies) link:presentationLink link:definitionLink link:calculationLink 000740 - Disclosure - Note 11: Income Taxes (Details) link:presentationLink link:definitionLink link:calculationLink 000440 - Disclosure - Note 3: Detail of Certain Balance Sheet Accounts: Detail of Accrued Liabilities (Tables) link:presentationLink link:definitionLink link:calculationLink 000650 - Disclosure - Note 5: Impairment (Details) link:presentationLink link:definitionLink link:calculationLink 000320 - Disclosure - Note 1: Organization and Significant Accounting Policies: Income (loss) Per Common Share (Policies) link:presentationLink link:definitionLink link:calculationLink 000100 - Disclosure - Note 4: Property and Equipment link:presentationLink link:definitionLink link:calculationLink 000680 - Disclosure - Note 7: Stockholders' Equity: Universal Shelf Registration Statement (Details) link:presentationLink link:definitionLink link:calculationLink 000550 - Disclosure - Note 1: Organization and Significant Accounting Policies: Warranty Reserve (Details) link:presentationLink link:definitionLink link:calculationLink 000070 - Disclosure - Note 1: Organization and Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 000620 - Disclosure - Note 3: Detail of Certain Balance Sheet Accounts: Detail of Accrued Liabilities (Details) link:presentationLink link:definitionLink link:calculationLink 000570 - Disclosure - Note 1: Organization and Significant Accounting Policies: Revenue Recognition: Schedule of Revenue Recognition (Details) link:presentationLink link:definitionLink link:calculationLink 000190 - Disclosure - Note 13: Supplemental Cash Flow Information link:presentationLink link:definitionLink link:calculationLink 000630 - Disclosure - Note 4: Property and Equipment: Schedule of Property and Equipment (Details) link:presentationLink link:definitionLink link:calculationLink 000090 - Disclosure - Note 3: Detail of Certain Balance Sheet Accounts link:presentationLink link:definitionLink link:calculationLink 000580 - Disclosure - Note 1: Organization and Significant Accounting Policies: Advertising and Promotion (Details) link:presentationLink link:definitionLink link:calculationLink 000390 - Disclosure - Note 1: Organization and Significant Accounting Policies: Comprehensive Loss (Policies) link:presentationLink link:definitionLink link:calculationLink 000350 - Disclosure - Note 1: Organization and Significant Accounting Policies: Concentration of Credit Risk (Policies) link:presentationLink link:definitionLink link:calculationLink 000500 - Disclosure - Note 12: Stock-based Compensation: Schedule of Assumptions Used (Tables) link:presentationLink link:definitionLink link:calculationLink 000410 - Disclosure - Note 1: Organization and Significant Accounting Policies: Revenue Recognition: Schedule of Revenue Recognition (Tables) link:presentationLink link:definitionLink link:calculationLink 000820 - Disclosure - Note 13: Supplemental Cash Flow Information (Details) link:presentationLink link:definitionLink link:calculationLink 000290 - Disclosure - Note 1: Organization and Significant Accounting Policies: Patents (Policies) link:presentationLink link:definitionLink link:calculationLink 000060 - Statement - Statements of Cash Flows link:presentationLink link:definitionLink link:calculationLink 000360 - Disclosure - Note 1: Organization and Significant Accounting Policies: Advertising and Promotion (Policies) link:presentationLink link:definitionLink link:calculationLink 000690 - Disclosure - Note 7: Stockholders' Equity: April 2013 Offering (Details) link:presentationLink link:definitionLink link:calculationLink 000270 - Disclosure - Note 1: Organization and Significant Accounting Policies: Inventories (Policies) link:presentationLink link:definitionLink link:calculationLink 000200 - Disclosure - Note 14: Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 000560 - Disclosure - Note 1: Organization and Significant Accounting Policies: Income (loss) Per Common Share (Details) link:presentationLink link:definitionLink link:calculationLink 000450 - Disclosure - Note 4: Property and Equipment: Schedule of Property and Equipment (Tables) link:presentationLink link:definitionLink link:calculationLink 000760 - Disclosure - Note 11: Income Taxes: Schedule of Deferred Tax Assets (Liabilities) (Details) link:presentationLink link:definitionLink link:calculationLink 000230 - Disclosure - Note 1: Organization and Significant Accounting Policies: Organization and Business (Policies) link:presentationLink link:definitionLink link:calculationLink 000520 - Disclosure - Note 1: Organization and Significant Accounting Policies: Organization and Business (Details) link:presentationLink link:definitionLink link:calculationLink 000010 - Document - Document and Entity Information link:presentationLink link:definitionLink link:calculationLink 000370 - Disclosure - Note 1: Organization and Significant Accounting Policies: Shipping and Handling (Policies) link:presentationLink link:definitionLink link:calculationLink 000170 - Disclosure - Note 11: Income Taxes link:presentationLink link:definitionLink link:calculationLink 000110 - Disclosure - Note 5: Impairment link:presentationLink link:definitionLink link:calculationLink 000480 - Disclosure - Note 11: Income Taxes: Schedule of Deferred Tax Assets (Liabilities) (Tables) link:presentationLink link:definitionLink link:calculationLink 000590 - Disclosure - Note 2: Liquidity (Details) link:presentationLink link:definitionLink link:calculationLink 000240 - Disclosure - Note 1: Organization and Significant Accounting Policies: Financial Reporting Period (Policies) link:presentationLink link:definitionLink link:calculationLink 000610 - Disclosure - Note 3: Detail of Certain Balance Sheet Accounts: Detail of Inventories (Details) link:presentationLink link:definitionLink link:calculationLink 000310 - Disclosure - Note 1: Organization and Significant Accounting Policies: Income Taxes (Policies) link:presentationLink link:definitionLink link:calculationLink 000540 - Disclosure - Note 1: Organization and Significant Accounting Policies: Property and Equipment: Schedule of Property Plant and Equipment Useful Life (Details) link:presentationLink link:definitionLink link:calculationLink 000330 - Disclosure - Note 1: Organization and Significant Accounting Policies: Stock-based Compensation (Policies) link:presentationLink link:definitionLink link:calculationLink 000770 - Disclosure - Note 12: Stock-based Compensation: Stock Incentive Plan (Details) link:presentationLink link:definitionLink link:calculationLink 000120 - Disclosure - Note 6: Patents link:presentationLink link:definitionLink link:calculationLink 000670 - Disclosure - Note 7: Stockholders' Equity (Details) link:presentationLink link:definitionLink link:calculationLink 000030 - Statement - Balance Sheets Parenthetical link:presentationLink link:definitionLink link:calculationLink 000640 - Disclosure - Note 4: Property and Equipment (Details) link:presentationLink link:definitionLink link:calculationLink 000420 - Disclosure - Note 3: Detail of Certain Balance Sheet Accounts: Detail of Accounts Receivable (Tables) link:presentationLink link:definitionLink link:calculationLink 000430 - Disclosure - Note 3: Detail of Certain Balance Sheet Accounts: Detail of Inventories (Tables) link:presentationLink link:definitionLink link:calculationLink 000830 - Disclosure - Note 14: Commitments and Contingencies (Details) link:presentationLink link:definitionLink link:calculationLink 000130 - Disclosure - Note 7: Stockholders' Equity link:presentationLink link:definitionLink link:calculationLink 000040 - Statement - Statements of Comprehensive Loss link:presentationLink link:definitionLink link:calculationLink 000700 - Disclosure - Note 7: Stockholders' Equity: Schedule of Stockholders' Equity Note, Warrants or Rights (Details) link:presentationLink link:definitionLink link:calculationLink 000220 - Disclosure - Note 16: Subsequent Events link:presentationLink link:definitionLink link:calculationLink 000150 - Disclosure - Note 9: Major Customers and Foreign Sales link:presentationLink link:definitionLink link:calculationLink 000280 - Disclosure - Note 1: Organization and Significant Accounting Policies: Property and Equipment (Policies) link:presentationLink link:definitionLink link:calculationLink 000140 - Disclosure - Note 8: Deferred Revenue link:presentationLink link:definitionLink link:calculationLink 000800 - Disclosure - Note 12: Stock-based Compensation: Schedule of Assumptions Used (Details) link:presentationLink link:definitionLink link:calculationLink 000780 - Disclosure - Note 12: Stock-based Compensation: Schedule of Stock Based Compensation (Details) link:presentationLink link:definitionLink link:calculationLink 000730 - Disclosure - Note 10: Related Party Transactions (Details) link:presentationLink link:definitionLink link:calculationLink 000400 - Disclosure - Note 1: Organization and Significant Accounting Policies: Property and Equipment: Schedule of Property Plant and Equipment Useful Life (Tables) link:presentationLink link:definitionLink link:calculationLink 000380 - Disclosure - Note 1: Organization and Significant Accounting Policies: Use of Estimates in The Preparation of Financial Statements (Policies) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 14 bsdm-20141231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 15 bsdm-20141231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 16 bsdm-20141231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cost of Sales Accruals and reserves Customer Two Deferred Revenue Outstanding Warrants Aggregate issuance amount Warranty Expense Property, Plant and Equipment, Useful Life Range Net cash provided by financing activities Net cash provided by financing activities Purchase of property and equipment Purchase of property and equipment Increase (decrease) in accounts payable Increase (decrease) in accounts payable Cash flows from operating activities: Common Stock Issued For Services Stock issued for services Statement Other income (expense) Treasury stock shares Total liabilities and stockholders' equity Total liabilities and stockholders' equity LIABILITIES AND STOCKHOLDERS' EQUITY Other current assets Related party trade accounts receivable, net Exercisable options, weighted average exercise price Exercisable Forfeited or expired Selling, General and Administrative Expenses Building Equipment Stock Option Rollforward Tables/Schedules Accounts Receivable Note 14: Commitments and Contingencies Note 13: Supplemental Cash Flow Information Decrease (increase) in: Net loss Net loss and comprehensive loss Interest income Operating costs and expenses: Entity Registrant Name Annual base salary - CFO Outstanding, Intrinsic Value Annual retainer, audit committee chair Effective Income Tax Rate Reconciliation, Deduction, Other, Amount Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount Operating Loss Carryforward Operating Loss Carryforward Parts and supplies Comprehensive Loss Note 12: Stock-based Compensation Cash flows from financing activities: Loss (gain) on disposition of assets Revenues: Accumulated deficit Amendment Description Current Fiscal Year End Date Exercise price, upper limit Shares available for grant, Director Plan Current Inventories Property, Plant and Equipment, Gross Detail of Accrued Liabilities Detail of Inventories Revenue Recognition Income (loss) Per Common Share Note 10: Related Party Transactions Note 2: Liquidity Weighted average number of shares outstanding: Diluted Research and development Cost of revenues: Total revenues Total revenues Sales to related parties Sales Preferred stock par value Accounts receivable, net of allowance for doubtful accounts of $20,000 Entity Current Reporting Status Document and Entity Information Outstanding, weighted average remaining contract term Outstanding beginning of period, weighted average exercise price Weighted Average Exercise Price of Warrants Exercisable Payroll, commissions and other Concentration of Credit Risk Warranty Reserve Payments on note payable Stock-based compensation Common Stock Issued For Cash, net of offering costs of $638,488 Additional paid-in capital Stockholders' equity: Total liabilities Total liabilities Risk-free interest rate Unrecognized stock-based compensation expense Export Sales Weighted Average Exercise Price of Warrants Outstanding Sale of Common Stock and Warrants Land {1} Land Warranty Reserve {1} Warranty Reserve Range {1} Range Schedule of Stockholders' Equity Note, Warrants or Rights Property and Equipment Decrease (increase) in receivables Statement {1} Statement Common stock par value Commitments and contingencies Deferred revenue - net of current portion Property and equipment, net Income Statement Location {1} Income Statement Location Long Term Depreciation and Amortization Equipment Impairment Minimum Schedule of Income Tax (Provision) Benefit Computed at Federal Rates Increase (decrease) in: Adjustments to reconcile net loss to net cash used in operating activities: Statements of Cash Flows Income tax provision Income tax provision Total cost of revenues Total cost of revenues Common stock shares issued Deferred revenue - current portion Accrued liabilities Total assets Total assets Entity Central Index Key Document Period End Date Document Type Research and Development Expense {1} Research and Development Expense Annual retainer, cash portion Deferred Compensation Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount Weighted Average Remaining Contractual Term of Warrants Exercisable Accounts Receivable, Net, Noncurrent Allowance for Doubtful Accounts Receivable Trade Receivables - Non-Related Party Disposable devices Note 16: Subsequent Events Note 9: Major Customers and Foreign Sales Note 8: Deferred Revenue Increase (decrease) in deferred revenue Increase (decrease) in deferred revenue Common Stock Issued For Cash, net of offering costs of $638,488 - Shares Balance - Shares Balance - Shares Balance - Shares Impairment of inventory and other assets Cost of related party sales Total current assets Total current assets Inventories, net ASSETS Amendment Flag Expected term, years Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition Grant date fair value per share Percentage of Accounts Receivable Due From One Customer Warrants Granted April 2013 Offering Purchase Price Per Fixed Combination Maximum Building Improvements Furniture and Fixtures Details Schedule of Property and Equipment Schedule of Property Plant and Equipment Useful Life Common Stock Statements of Comprehensive Loss Preferred stock shares authorized Balance Sheets Parenthetical Entity Filer Category Closing stock price Granted Valuation Allowance Valuation Allowance Net Proceeds from Stock Offering Work-in-process Property, Plant and Equipment, Type {1} Property, Plant and Equipment, Type Detail of Accounts Receivable Financial Reporting Period Proceeds from note payable Document Fiscal Year Focus Entity Common Stock, Shares Outstanding Annual Retainer, Paid in Common Stock Net Operating Loss Carryforwards Research and development and other tax credits Export Sales to Certain Countries as a Percentage of Total Sales April 2013 Offering to purchase common stock shares Finished goods Cash and Cash Equivalents Note 6: Patents Note 5: Impairment Decrease (increase) in other current assets Decrease (increase) in inventories Treasury Stock Weighted average number of shares outstanding: Basic Net loss per common share: Basic Loss from operations Loss from operations Gross margin Gross margin Cost of equipment rental Preferred stock shares outstanding Customer deposits Note payable Entity Incorporation, Date of Incorporation Entity Well-known Seasoned Issuer Exercisable options, weighted average remaining contract term Liability Valuation Allowance Liability Valuation Allowance Weighted Average Remaining Contractual Term of Warrants Outstanding April 2013 Offering Warrant Exercise Price (per share) Other Receivables Reserve for obsolete inventories Reserve for obsolete inventories Use of Estimates in The Preparation of Financial Statements Income Taxes Note 11: Income Taxes Note 4: Property and Equipment Net cash used in operating activities Net cash used in operating activities Equity Components Net loss per common share: Diluted Total operating costs and expenses Total operating costs and expenses Equipment rental Preferred stock shares issued Granted, weighted average exercise price Expected volatility Annual retainer, audit committee chair cash portion Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Compensation Cost, Amount Customer One Depreciation Expense Accumulated depreciation Training and Installation Reserve Service contracts and other Antidilutive Securities Excluded from Computation of Net Income, Per Outstanding Unit, Amount Schedule of Stock Based Compensation Patents Net cash (used in) investing activities Net cash (used in) investing activities Accumulated Deficit Other income (expense): Cash and cash equivalents Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period Forfeited or expired, weighted average exercise price Weighted Average Exercise Price of Warrants Granted Advertising and Promotion Expense Product Sales Equipment Leased to Other Party Property, Plant and Equipment, Type Schedule of Assumptions Used Shipping and Handling Note 7: Stockholders' Equity Net proceeds from the sale of common stock Proceeds from disposition of assets Increase (decrease) in customer deposits Increase (decrease) in customer deposits Common Stock Issued For Cash, net of offering costs of $416,565 Common stock, $.001 par value, 80,000,000 shares authorized, 39,713,540, 39,713,540 and 34,006,202 shares issued, respectively Entity Public Float Annual base salary - CEO Exercise price, lower limit Income Statement Location Annual retainer, non-employee directors Shares available for grant Deferred Tax Assets, Operating Loss Carryforwards, State and Local Amortization expense Accrued taxes payable Advertising and Promotion Stock-based Compensation Inventories Policies Note 15: Recent Accounting Pronouncements Notes Cash flows from investing activities: Increase (decrease) in accrued liabilities Increase (decrease) in accrued liabilities Total other income (expense) Total other income (expense) Treasury stock, 24,331 shares at cost Treasury stock, 24,331 shares at cost Current assets: Document Fiscal Period Focus Exercisable aggregate intrinsic value Outstanding, End of Period Annual Retainer, Options Granted Current Deferred Revenue Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Schedule of Revenue Recognition Organization and Business Note 3: Detail of Certain Balance Sheet Accounts Additional Paid In Capital Statements of Stockholders' Equity Loss before income taxes Loss before income taxes Common stock shares authorized Total current liabilities Total current liabilities Entity Incorporation, State Country Name Entity Voluntary Filers Outstanding, weighted average exercise price Options Outstanding, beginning of period Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount Exercisable Warrants Schedule of Deferred Tax Assets (Liabilities) Note 1: Organization and Significant Accounting Policies Net increase (decrease) in cash and cash equivalents Net increase (decrease) in cash and cash equivalents Depreciation and amortization Depreciation and amortization Common Stock Issued For Cash, net of offering costs of $416,565 - Shares Common Stock Issued For Services - Shares Equity Component Selling, general and administrative Cost of sales Allowance for doubtful accounts Total stockholders' equity Total stockholders' equity Balance Balance Preferred stock, $.001 par value; 10,000,000 shares authorized, no shares issued and outstanding Accounts payable Current liabilities: Balance Sheets EX-101.PRE 17 bsdm-20141231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 18 chart.jpg begin 644 chart.jpg M_]C_X``02D9)1@`!`0$`8`!@``#_X0!F17AI9@``34T`*@````@`!`$:``4` M```!````/@$;``4````!````1@$H``,````!``(```$Q``(````0````3@`` M``````!@`````0```&`````!4&%I;G0N3D54('8U+C`P`/_;`$,``0$!`0$! M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$! M`0$!`0$!`0$!`0$!`?_;`$,!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$! M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`?_``!$(`?4" M]@,!(@`"$0$#$0'_Q``?```!!0$!`0$!`0```````````0(#!`4&!P@)"@O_ MQ`"U$``"`0,#`@0#!04$!````7T!`@,`!!$%$B$Q008346$'(G$4,H&1H0@C M0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-CH.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJ MLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X M^?K_Q``?`0`#`0$!`0$!`0$!`````````0(#!`4&!P@)"@O_Q`"U$0`"`0($ M!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B M7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>X MN;K"P\3%QL?(RKR\_3U]O?X^?K_V@`,`P$` M`A$#$0`_`/[D****^@/'"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB M@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****` M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`* M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB M@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****` M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`* M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`K8 MT_1+O4H6G@DMT1)6B(E>16W*B.2`D4@VXD&#D'(/'0G'KT'PG_R#IO\`K]D_ M]$6U88BI*G3FFUC%_X1/4?^>UE_W\G_`/D:C_A$ M]1_Y[67_`'\G_P#D:O0:*X/KE;O'_P`!.OZM2[2^_P#K^GZ6\^_X1/4?^>UE M_P!_)_\`Y&H_X1/4?^>UE_W\G_\`D:O0:*/KE;O'_P`!#ZM2[2^_^OZ?I;S[ M_A$]1_Y[67_?R?\`^1J/^$3U'_GM9?\`?R?_`.1J]!HH^N5N\?\`P$/JU+M+ M[_Z_I^EO/O\`A$]1_P">UE_W\G_^1J/^$3U'_GM9?]_)_P#Y&KT&BCZY6[Q_ M\!#ZM2[2^_\`K^GZ6\^_X1/4?^>UE_W\G_\`D:C_`(1/4?\`GM9?]_)__D:O M0:*/KE;O'_P$/JU+M+[_`.OZ?I;S[_A$]1_Y[67_`'\G_P#D:C_A$]1_Y[67 M_?R?_P"1J]!HH^N5N\?_``$/JU+M+[_Z_I^EO/O^$3U'_GM9?]_)_P#Y&H_X M1/4?^>UE_P!_)_\`Y&KT&BCZY6[Q_P#`0^K4NTOO_K^GZ6\^_P"$3U'_`)[6 M7_?R?_Y&H_X1/4?^>UE_W\G_`/D:O0:*/KE;O'_P$/JU+M+[_P"OZ?I;S[_A M$]1_Y[67_?R?_P"1J/\`A$]1_P">UE_W\G_^1J]!HH^N5N\?_`0^K4NTOO\` MZ_I^EO/O^$3U'_GM9?\`?R?_`.1J/^$3U'_GM9?]_)__`)&KT&BCZY6[Q_\` M`0^K4NTOO_K^GZ6\^_X1/4?^>UE_W\G_`/D:C_A$]1_Y[67_`'\G_P#D:O0: M*/KE;O'_`,!#ZM2[2^_^OZ?I;S[_`(1/4?\`GM9?]_)__D:C_A$]1_Y[67_? MR?\`^1J]!HH^N5N\?_`0^K4NTOO_`*_I^EO/O^$3U'_GM9?]_)__`)&H_P"$ M3U'_`)[67_?R?_Y&KT&BCZY6[Q_\!#ZM2[2^_P#K^GZ6\^_X1/4?^>UE_P!_ M)_\`Y&H_X1/4?^>UE_W\G_\`D:O0:*/KE;O'_P`!#ZM2[2^_^OZ?I;S[_A$] M1_Y[67_?R?\`^1J/^$3U'_GM9?\`?R?_`.1J]!HH^N5N\?\`P$/JU+M+[_Z_ MI^EO/O\`A$]1_P">UE_W\G_^1J/^$3U'_GM9?]_)_P#Y&KT&BCZY6[Q_\!#Z MM2[2^_\`K^GZ6\^_X1/4?^>UE_W\G_\`D:C_`(1/4?\`GM9?]_)__D:O0:*/ MKE;O'_P$/JU+M+[_`.OZ?I;S[_A$]1_Y[67_`'\G_P#D:C_A$]1_Y[67_?R? M_P"1J]!HH^N5N\?_``$/JU+M+[_Z_I^EO/O^$3U'_GM9?]_)_P#Y&H_X1/4? M^>UE_P!_)_\`Y&KT&BCZY6[Q_P#`0^K4NTOO_K^GZ6\^_P"$3U'_`)[67_?R M?_Y&H_X1/4?^>UE_W\G_`/D:O0:*/KE;O'_P$/JU+M+[_P"OZ?I;S[_A$]1_ MY[67_?R?_P"1J/\`A$]1_P">UE_W\G_^1J]!HH^N5N\?_`0^K4NTOO\`Z_I^ MEO/O^$3U'_GM9?\`?R?_`.1J/^$3U'_GM9?]_)__`)&KT&BCZY6[Q_\``0^K M4NTOO_K^GZ6\^_X1/4?^>UE_W\G_`/D:C_A$]1_Y[67_`'\G_P#D:O0:*/KE M;O'_`,!#ZM2[2^_^OZ?I;S[_`(1/4?\`GM9?]_)__D:C_A$]1_Y[67_?R?\` M^1J]!HH^N5N\?_`0^K4NTOO_`*_I^EO/O^$3U'_GM9?]_)__`)&H_P"$3U'_ M`)[67_?R?_Y&KT&BCZY6[Q_\!#ZM2[2^_P#K^GZ6\^_X1/4?^>UE_P!_)_\` MY&H_X1/4?^>UE_W\G_\`D:O0:*/KE;O'_P`!#ZM2[2^_^OZ?I;S[_A$]1_Y[ M67_?R?\`^1J/^$3U'_GM9?\`?R?_`.1J]!HH^N5N\?\`P$/JU+M+[_Z_I^EO M/O\`A$]1_P">UE_W\G_^1J/^$3U'_GM9?]_)_P#Y&KT&BCZY6[Q_\!#ZM2[2 M^_\`K^GZ6\^_X1/4?^>UE_W\G_\`D:C_`(1/4?\`GM9?]_)__D:O0:*/KE;O M'_P$/JU+M+[_`.OZ?I;S[_A$]1_Y[67_`'\G_P#D:C_A$]1_Y[67_?R?_P"1 MJ]!HH^N5N\?_``$/JU+M+[_Z_I^EO/O^$3U'_GM9?]_)_P#Y&H_X1/4?^>UE M_P!_)_\`Y&KT&BCZY6[Q_P#`0^K4NTOO_K^GZ6\^_P"$3U'_`)[67_?R?_Y& MH_X1/4?^>UE_W\G_`/D:O0:*/KE;O'_P$/JU+M+[_P"OZ?I;S[_A$]1_Y[67 M_?R?_P"1J/\`A$]1_P">UE_W\G_^1J]!HH^N5N\?_`0^K4NTOO\`Z_I^EO/O M^$3U'_GM9?\`?R?_`.1J/^$3U'_GM9?]_)__`)&KT&BCZY6[Q_\``0^K4NTO MO_K^GZ6\^_X1/4?^>UE_W\G_`/D:C_A$]1_Y[67_`'\G_P#D:O0:*/KE;O'_ M`,!#ZM2[2^_^OZ?I;S[_`(1/4?\`GM9?]_)__D:C_A$]1_Y[67_?R?\`^1J] M!HH^N5N\?_`0^K4NTOO_`*_I^EO/O^$3U'_GM9?]_)__`)&H_P"$3U'_`)[6 M7_?R?_Y&KT&BCZY6[Q_\!#ZM2[2^_P#K^GZ6\^_X1/4?^>UE_P!_)_\`Y&H_ MX1/4?^>UE_W\G_\`D:O0:*/KE;O'_P`!#ZM2[2^_^OZ?I;S[_A$]1_Y[67_? MR?\`^1J/^$3U'_GM9?\`?R?_`.1J]!HH^N5N\?\`P$/JU+M+[_Z_I^EO/O\` MA$]1_P">UE_W\G_^1J/^$3U'_GM9?]_)_P#Y&KT&BCZY6[Q_\!#ZM2[2^_\` MK^GZ6\^_X1/4?^>UE_W\G_\`D:C_`(1/4?\`GM9?]_)__D:O0:*/KE;O'_P$ M/JU+M+[_`.OZ?I;S[_A$]1_Y[67_`'\G_P#D:C_A$]1_Y[67_?R?_P"1J]!H MH^N5N\?_``$/JU+M+[_Z_I^EO')XFMYIH'*EX99(F*Y*EHW*,5)"DJ2IP2`< M=0.E15=U+_D(W_\`U^W7_H^2J5>K%MQBWU2?WH\][OU84444Q!1110`4444` M%%%%`!7H/A/_`)!TW_7[)_Z(MJ\^KT'PG_R#IO\`K]D_]$6U2>@%%%%`!1110`4444`%%%%`!1110`4444`%)G^F?8$__ M`*_R-+7Y]_\`!2_]O#2_^">/[-$GQN7X;:O\:/B+XL^(OP_^"'P*^"^@ZO:^ M']5^*_QL^*VL'1O!?@V#7[RQU.+1()5@U+5M1U$:;J4T>F:5>QVFGWM[);6[ M@'Z`F10,G/(R!@@GH,`'!SDA<'G<0IP64%=PQG.1DC(Y&0VTC/3.[Y<9SG@C M@X_!#X!_M&_\%Z/A[^TW^SO\./VZOV/?V.OBG\#/VA[77M-\1?%']@K7_B[I M^H_LHZ[HFAP^(UUCX]/\>/$>H>&=9T&ZC^U:%'I?@W55&I7\5^_@[Q;XH\2V MGAKX?^.O(+3_`(*,_P#!6#]O/XS_`+4=C_P20^"W["VF?LO_`+)OQ5US]GC4 M?C=^W5KWQRFU+]H7XR>#;2"X^(%M\'?#WP0N]-_X1GPYX/O+BSTJWG\:2SZ? MXETW7?#/BBS\4:?=ZEXA\(>#`#^DTN!QCL3U7MG/5AT.`3T!8`GK@WC.,')W M=NZ\8YQU/0GY>G(WIN_DX_:&_P"#@7]I/1_^"95S^T;\$_V;?A_X+_;N^%O[ M>&C?\$__`-HS]EOXS1>)?B/X6\&?&CR/%,>IV'A35?`GC7X::EXC@UV;3?#D MWAK5EU^72[*YN_$7AJ:7Q,FD6WBN_P"*_;@_X.,OCA\'?^"5'_!.']LO]FKX M:?`[QG^T-^V=IGB[7?'/@KQOX?\`'_BGX:^&O#_P"\(:UI_[45]X7T3PM\2/ M!OBNRM/!OQ=30=-TV\UKQEK5KH7AQ[S3-;35=5O+#5;4`_K]+`8]R0!ZD9)` M]2`"2!EL`\<&ER./.H[XYK^5VU_X*:?\%A_VFOVNO"?[+G[#_A/ M_@FGI=ZO_!/+]EW]M+QSK7[5>@?M26-K_:WQM\.>&+CQ3H'A/4?A'X^UVX;2 M[+Q#XCMSH&F:QX=^U6^C6TYU+Q1JNH+`+B3PA_P7H^.OAW_@F3_P43^//[0' MPL^!5C^VQ^P1^T5XJ_9%M]$^$-_XS\8_LW_'+XU:KXHTCPY\)[_P#8MXEF\> MW6CG4/$#6WC'P7#XYNO$%YI'A"^\5+K7@U_%C>#O`P!_4Z'!('S#.,95EZ@$ M?>`YYP?0X5L,0"T2*>F>GH1@]`#G&TDY4`X^967[RD5^)O\`P3'_`."CWQ^_ M:I_9G_;(D_:C^'GPR^&'[:_[#'QE^./P4^-WP[^'NF^*+?X:/K7P_P!&G\1^ M!O%GARTU_P`8^*->O_!OBBT^U:;;:B/&,O\`PDLOAK5O$>BG3]#UG0V'Y)?# M/_@JS_P7_P#'G_!-E/\`@K`O@3_@CI-^S#IG@/QS\6-;^']RG[8GA/XZW_@O MX8^-_$7@WQ;HNCQ:GXYUOX9V?B_5[KPEJZ^$XKGQAJ\5VUUI*16-_K%]#X8D M`/[(#(H(!/)&['0A1U9@<$*.['@'Y<[B%)O7&?\%9-0\`>&=9T3P/KW[1_AOX7>$);KPE'\.-3\6ZG=WNCB[\"3/87N@^) MOA_J5S>/X5U;XDQ`'],]CD[3@D+]XC/`P.<@C(()02+M#9X.#G((Y& M[J"5P%^8D$C:-V=N"?P8_:P_X**?MO\`CK]NSQ%_P3<_X)5?"+]FWQ;\;O@; M\//"GQ?_`&J/CE^V-JWQ-L_@!\(]#\>:,VI^`_A;:>'_`(0/8_$'5?B1XST[ M6?"GBFRU>TNM0TRRT6YN;!_#%\DFN:_X.\,TW_@L7^U]\+?@W_P4N^"W[77P M+^!_PX_X*3?\$]_V8_&?[47AY?AYJ/C?Q;^R=^TM\+3_`&]<^!OB=\/=)U7Q M+I?Q2T;PEI5XWA;PIXU\,>(/&D/B"YU*^CU*VO/">J7NL?#_`,"`']+6]>V2 M<9QM;/OD$`Y`P2,9Y7C+*">8O&,G/((!.1QRN,EEPP^8949`)!(%?R(Q_P#! MQW\3?&__``0G^(O_``43^&W@;X)V'[:/P%\<_"GX;_&_X*>+]`^(=_\`"[0] M8^)/Q$\.Z7X>\7Z-X>A\?>&_B`W@GXD_"WQ)9^-/`NH3^.+FUL]<&N>%WUWQ M6WA2\O-3_I^_:2_:`^'7[*OP"^+W[2/Q;OM0L?AO\$_`'B7XB>,9M%M8]2UF M;2O#6FSWSZ;H>FSW%K;ZAKNL2I%I.AV$]Y9PW>K7MC;7%Y:PO)=P@'N.]00# MD$].#@D`'`.,$X.>#T#'HC8`P/?J<#/?DCC\N#W[9K^5*V_X*6_\%[U_96@_ MX*?WO[$O[`Y_8CF\$R_M"77[*]G\3?CDW[=EI^S.;"7Q`GBH_$:Y@A^!%SJD M?@!8OBEYZ^#H]_P`>OVSOV1_V;_\` M@D]IG[#NK^!OVJ_^">OA_P#;MT+QE^V[X?\`C]9W-MI6J>.?%'AVZT*6\^!_ MC6672M2M-,LO#L4GAZZ\(ZG+8Z]%XCM[GQ1)$EC:VP!_39N&<<\`$\8ZG`Y; M`YY_+UQD#J<=><8X.>3CD=1@\'(&#P><@?&G[%(_X*!_\*X\2'_@HN?V-Q\7 MQXVO#X/_`.&*%^-1^'`^&[Z'X?-D/$@^.F/%7_"(M%T/QIJ6N6WPRB`/ZF]XR!T).`IP">YQDX.!\Q`)(7MGB MC>,@<\]\<<].>ASZ@D9(!()4'\%_^"[W_!8B_P#^"3O[,?A/Q+\+_!GASQ[^ MU-\8-4\OX8?#GQYINJ^(/"GAOP;X6N=&O/BE\1?BAIW@;Q-H.J3>&/#5IKFC M^$K;^QO&>EK>>._&7AVXM[^_T+3=>23]=Q\1]<_X9P/Q@%II*^)&^"9^)/V' M[-=G0_[>/@4^*?LK6@U!+\Z4-18P_9O[42[^SED-^;@_:P`>WB5#CD\@G!4@ M\8!&",D@D*P`)5B$;#$`NWCW'3@@J3]WD`X.!N7<>BDX.&!`_D'_`.":G_!Q ME\<_VE/V#?\`@H_^TG^U7\,?@EX$^+G[&_P4M?CU\*]"^'&B>.O#7@/XH^#_ M`!?X=\?:/\/[:^T[Q?\`$KQQKMY-/\8_`%QX0UO4-+\4Z7"8/$>D6=II]G?V M[7=WG_LH?\''?[1WB7_@G#\4OVEOVD_V'KK2]1U?QB/$.K&\M--WZ1 MX?\`""6>DZUK<6JL`?V$;@!D\^*OC\0-X`U3XW:!\;-3UF#Q3X)U^\CU31-1O_`(=/ M)I/AH:-K.K7_`(ON-5;X?^"?B4?LC?\`!=#Q)\3/^"RW[7O_``2\_:*\+?#/ MP/X;\)^._%W@K]CWXB^%=,\5Z'?^.O$WPQC75_&WP[^(FI^(O%OB;0M>\<:U MX1UC3/%'AJ;PQIG@FQL?^$:U?2+W3M5U;Q9X7A@`/Z3]PYZ\=>/UYQQ[]#@@ M$D&@L`<=^O;U`'&<\YX[9X)!P#^`'['/[6EQ8E+BUU.S\.2W"7!ETK3XXXK8_FA\)?\`@KA_P7C^(7[,_P"WM^UQ?>"? M^"1MM\)/^">_Q$_:H^"OQ>T2U\-?MCP_$;Q/\3?V;OAQ8^)[J_\`AQILWQ)O M?#&M>!M5\0>*/"D,%WXH\2>"M>U'1X?$"/H_A^\ATZ:X`/[+0X.1SD9XXSP< M#'/<\#W^4X<%0I<`@'.3G&`2>#@G`R<#(R<8&1D@D9_!_P#:Z_X*??'KX!_\ M$"_"?_!4_P`'>$?A!J?[06N_LQ?L0_&N[\&^)=`\8WGP@Z3:_%+Q#)X1MIOB%<:E87%EHS:QJVNPVM_!J'Z?\`C_\` M:;\'_!']C[Q#^UW\99+C3O!GPZ^`+_'/X@Q^%K(75X-/TKP-'XLU?2_"NE:E MJ"+>:CJ$HFTWP[I]_K*BZO[BPM;O5D21KR,`^H2X'7\!W/0_+_>X/\.>X&3Q M2"12%(.0P)7DF",X)`/\`+WX0_P""@W_!P7XA^%7P5_;GL_\` M@GG^R!XZ_9/^-WB/P!J^D_L=_"[QY\9M8_X*$>&?A!\8-7C\/?#SQEKGCG67 MTOX`3Q0Q:OX4^(/B/5AX5MD\-^`-::\^(OAGX66FA_$#7?AS^COP$_;L^+_Q M3_X*Q_MK_L)>(?"?@#1?A+^S=\!?V=/BIX)U2STK7$^*5UXB^+VBZ;JOB?2O M&^L?\)QK7@W5+'2[NZEATD>'?#&F2VI'F76M:O&&><`_6G>);Z>QU/PMJ?@C0TOH+:>7P_K^&O'NL_#;P-XO^"4_Q M8UWXUZR_AO1/B1IGCJTT70?AE\+1XG:.?XAW4OA^3Q'8'4+[4[*SD\\`_KB# MJ<<]^.Q^OY'TK^<;]A;_@KQ^TC^T]^ MUE_P3W^!'CWP3\#]*\'?M8_\$JK;]N?XC:GX1\,^/K#Q%HOQ(_!A\.^ M"[W6/B/KNE:=\.TL='M98]*UW2?$?B-;_P`R=?&,EN8HJTOV@/\`@K;^T=\* M?C[_`,%P/A9X?\$_!6\\/?\`!-/]CKX3_M"_`N]UKPUXZNM8\5>,_'GP<7XB MZMI?Q:N+/XD:?9Z]X:MM786](!_10#G_`#_G M_`]1Q32P7KQ[X.!U/)Z#H>3@9P.I`/R]^Q'\;?%'[2/[%O[(G[1GCNPT#2_& MWQ]_9@^`?QK\8:7X4M=0L?#&G>*?BG\*O"7CCQ!8>&[/5]4UK5;/0;/5]>NK M;2;;5-:U>_MM/2WBOM5OITENY?P3_P""G7_!=7X_?L7?MZ7?PC^$?PJ^#GCS M]CW]EK1?V5-:_P""B_Q-\5:?XXU#XG?"0?M0_%*;P[HVD^!W\.^--(\/:9?V MGPWO/"_C+3I/$7A3Q/'JEWX@2UD2UA2Q74P#^HSS%&#_P#@F/??"S_@IA^UO^PI\(?`MG\!=`_:HN?B#X4^$W[4.GWWB7QO M>^*[?XB_$"P\/:#\1]%\/:IX0B\(W>D:GX\\-:=K2>)4U?3/$%@-+F8`_K%W M@C/X8XZ_W>N`V>,,1SQ2!P>@;DD#@]02&]P%(.2P&>BY)&?PR_87_P""J?CO MQ_X<_P""J>C_`+<.F?"KX=_$W_@EI\;?B?HWQ+G^%VC^,?"OA'7OV=-'\+ZY MXN^%OQ9&D>.O%WCS6K&Y^(6C>!_'&HV2)KLT-UIUII3VNEV,]X8%_+_P9_P6 M0_X+(_&[2/\`@DGX(^$WPG_X)Y^!_C]_P5(\,?M@?%'1M(^.W@_]I&Q^&7@3 MX:_`BSN/&?PSGN=7\!?%_P`1^*3J/CSX7:%K'BR75(M$U>WUBX\3^#+:/1/! MD$>LW)`/[#0ZGH1U`Y(')`8#!.0<,."`>1Q@YI2X7DY`ZDG@`=R2!O'O/MWVWR(%@!^9_^"P?[1O\`P5._8_\` MA5XZ_:?_`&+=*_X)_P"M?LY?`KX)Z_\`$7XS:-^T_8?M$ZC\:M1\0^']2U*Y MO;7X7Z?\)];\+^!KG1IO#0T@6D7BGQ%H]ZVM-J@GO$L39R*`?M<7`_\`UKU/ M09)`RQP%&/KC/3&`,8.`<'K@*Q'\GS_\`!7#_`(*V_!;] MG?\`9Q\9?'7X*_L"?&W]HC_@IOH_PFTO_@F9\%?V7M0_:%\)/:^)?B1X%7QS MXF\=?M9WOQDUF]TBR^'GPGTCQA\,[KQ%HGPZ\8V-SJ5W?ZOIESX_\,^'#+X_ M\/?4G@W_`(*$?\%._P!D#]JK]FWX"_\`!6WX1?L6W'PJ_;4\>:3\$O@)^T;^ MPGKOQIA\*>!?C_J2ZN/#WPM^,'ACXZR3^*-3O/BC.-%LO".M>%[+1-,T.Z^T MSSR^)H;C5XO!@!_0YO&,X(YPA.<9&/^"A/[='_``7<_9#_`&G_`('?##P3X=_X))ZY\+OVS_VL=4_9 MY_91N_$^C?MCZC\0-#TK4[RXO?!.J_M"W.C^+?#7AW2M0C\.?V:GBV\^&^G> M+K<:S]L72-#DL$B#^7_\%#?^"Q7_``5:_8(TGX+?!Z;X0_L&_'#]L/P;^SQ\ M;_VR?VZ-&^%-O\?[_P"#W@;]F;P5\7-$\#?#K5OA3_PDGC'PGX]TC6]8T6^U M,^,M4\:Q>(K&QUC0[Z^T?0I-(2!IP#^M?%_&'A-]*\=II6B>'Y-#O]8N/ M$GA^S2YO4U+PUJ[O#+!^T^"!CC.21][&3N.,$D@#MST&`%&!0`I8#UX]`2?I M@9)/LH)'?C%&\$D9R0<''/09/3.,=\X()']Y<_SP?MG?MW_\%3/^'KNE_P#! M-O\`X)Y>'/V!,+^Q+HW[7&M>+/VS=)_:&('_`!=_Q%\,->T32]<^!_BQ2`^/ M"=UI.E7?@=V=O^$CN;OQ0L9T_3(OFF7_`(+6?M[_``<^"?\`P6(\!_M+?"K] MCZ?]MK_@E_X-^#/Q%TCQ/\`IOBSXG_95^('A[XUV6A7>DZ#K?A_Q9XNTGXHZ M?XA\+1W%U-J?G>+_``U=ZPVL+8Q>'=!'A&ZU;Q>`?U:!USCH(+N]\"P_% M*V\$:AJ$7A^VUO4+WPG!XM6SMM4O+K1UEE?P3_@J?^WA_P`%N?V%_C+\)S\, MO#G_``2N\0_L\_M5?MB?##]D?]F;_A.M'_:WU7XS:-XA^+EM?CPSK?QT/A_Q M=X1\#:;HMC>:+K!UW4?`2>);^UMI-,^P>&=4F>Z,(!_3F'4@'(P<8R1SDX&. M>@_#GUQGMD5_/Q^R/^WA_P4I7_@J;I_\`P3=_;P\. M_L-_VE_PP1KW[7.K>*_V1='^/9L_^$C7X_CX7^&-&L-=^,OC![C^Q?\`A$%: M\U_3[SP$VHGQ%METSQ&VFAK(>/\`[1W_``68_:>^#WC+_@O9X>\,>`_@+>6/ M_!+/X??LD>*_V?YM;\+?$&>Y\7ZC\>_!UMK_`(MM_C(]G\4--BUZQL;V9E\, MP^"8?AW<:?#&(M7N->W`XZ\^I`.,X)&<`@G^2_XI_\`!4+_`(+>?L6?!3]G+]MS]LSX=?\`!*CQ MY^R'\6_&_P`#-#\3>#/V8[_]K#0?VEX/#GQWTU=0T.Z\*6_Q8UB]\#WGB'P] M;W$%_K7A_2HO&E[?FQN;&TMX=(74?%F@^_6__!='Q'X#_P""^'Q@_P""47QV M\+?##PO^SZ5^#/@+X"_&33=/\6:?XS;X\?%CX&?"_P"*WAKP#\4-?U3Q=JW@ MW4T^(VM>)?%_@WX(;F_U+4(`#^E/..H(_#WP/SSG MV'WL4`Y_`X_SC/48([X(SBOYK_`W_!6/]O\`^*OPS_X*62_`[]ESX1_&[XW_ M`+,W_!3GX^_L!_LX>!?"^D?''2;'4]&\)VFK6'PM\?\`Q=;1+'XF:!.\?BQ- M%F^*WBKQS\1OV1/@AIOA675]3O?BSX%UN/PYH7BC]VOV:OBIXM^-?P;\,?$S MQK\.=6^$^N>)+SQ0/^$"\1:9\0]#\3Z'I>C^*]:T'13XJ\/_`!0^''PN\5>' MO$VHZ3I=GJFMZ+%X>UGPG87][-'X`^(_Q;\"'PY\4/%P![O1110`4444`%%% M%`!1110`4444`>2:E_R$;_\`Z_;K_P!'R52J[J7_`"$;_P#Z_;K_`-'R52KW MH?!'_#'\D>0]WZO\PHHHJA!1110`4444`%%%%`!7H/A/_D'3?]?LG_HBVKSZ MO0?"?_(.F_Z_9/\`T1;5RXS^"_\`%$Z,-_$_[=?Z'3T445Y)Z`4444`%%%%` M!1110`4444`%%%%`!1110`5^,'_!-V0"`0,\T`? M@=\!/^"K?[:W[6_[3'[.?PK^#?\`P22_;%^`/P;E&N:]^V7\7/V]_AQJ?[-^ MF_#KPT/#KP:'9?`*^N+W65^*OB;_`(3:ZM#]AE\.)KNN:39I8W'A+P;I&MZ_ M\3OAQ\,_LO\`Q7_:L_X(;^-_VROV7OB?_P`$Y_VXOVS?@?\`%;]J3XN?M2_L MI_M`?L*_""U^/UKXC\/?%Z#0;[6O`?QC\-6'B+1-1^%>M^"]3L-.TN34]:6X MU'Q)J\_BJ;P_X)?$G]:I0\88`]\*-I;.20ISMW'(;!R59@26VNB M"/&`.@.03@D$%L'[N&P"%^;)(PQ.]=S@'\+_`,5O^">W[=+?L*7_`,=_BS^S MSXT3]J#]N7_@N/\``K]M[XA?LX?"+P]K?Q9UC]GCX.)K/B.STG2_&,O@BQUR M,+X(9UBL=%TW6O#^G>*(](\36VK:99_(_Q2_P""7?[;%CXG_P"" MUOP_F^`GQP\6_`S]F+X/_M!^$O\`@G1X8T#X.^/M2L_'C?ML_M2^#?C=JR_! M233=!N5^*6L^$O`.C:KX5\YMX-9M=*D,%N?\`19VMS\W)QZ_B M>#N[MA2S*ORXQ@@FUL\8QEBP)+9&?E`.!C/!.=P09C12"&4`_BG^#7_!'?X< M_MJ_\%'?"L'_``4%_8X^,'B_X%>!?^".O[#FB>&/$/C"U_:`^#GA#3?CYX1\ M,^`/#_BWP9/X[\#:]\/(-0^(OAO3)M=LO$'@+5=?NK[1WCO;O5=`@FTY9X?< M?^"A_P#P3%\5:K\3?^"8O_!*3_@F1\+O$/[&/[+/@/XI^._VY/B]^TOHOP#\ M8?&WX/>`?BO\,M+G;X%7/Q$\3^.[^3PO\9_B3K'B/1M>TZ[\%?%KXBZOJ6H: M1/\`#3^U89_!VE:)I;?USA#QENF#\N5Z'=C@C*YX'0X&'+@ME!'TR?Y<]FW' M'S[QC=G^ZIY(W$`_D)^"/[(G_!1#]@S_`(*G_'^;XQ_$[XF?M^?#O_@IG^Q% MXV@^+/[2WPV_8V;X.^$/"O[2'P%\*^(-+^$>B_$[0/@M<>*?AKX1N[GX&_"/BO4=2T74/B%XG^(T^C-HR:QITVL:S^2_A'_`(-Y=6L_^"/O['W[=OPD M_9`\16O_``4L_9R\4^*/C?\`M!?LH_'[P)\1O$L/[6?@CP'\;_%JZ5_HO>4! MD]2SAV.%R6!!4GY>2H`123N5`N&RJD*4;:5!'S==V6"@XW`!=A(;GJPVD\94 M!*`/YI/`UA\5OC[_`,%I_P#@G!^V%HW[*W[0OP5^#%[_`,$JOB)X<\66'Q)^ M"'Q`\`Z=\"?B%J7C[7W7X&?$&YUGPIHFA^#_`!EH91K#2-&N!I@\0Z5%IWB+ MPO!JOAG4--O+C\2/^"A'P'_:(^/GQ.^-%KK'_!&W]J7X;?\`!:;0/VF/"^A? MLL_\%%_^"??A'XF?#?\`8M\;>`;#XBZ#J'@#XX_$_P"+<_Q=\1>!/"GC/5/! M>N:S<>-/&7B73[OQGH-SIGA/2?'GQ#^%EQX>UKPGX'_T$E3:H`Z@`'G@X7'8 M*!SW"<*,*J@*%38=H`/.26;).2<]FW9!X3!R0G`;*@T`?RT_$#2OVQ/^"5?_ M``5"^.G[?&J_LF_'[]OC]GG]O_X)_LT^`?CE>_L4>`K7XF_''X/?M&?L^?") M/`EE>V'P2CNO#^KZW\*O&]KX+OM4N/%D]WX>\.>'[WQ9:V-[K%EKEGX7\+>- MOESXD_L__MD?MWV/_!9#_@J!XR_9#^-W[/ME\8_^"8_Q)_8-_8B_9:\>^"=4 M/[6OQ%\&6&NW?BSQ)XP^)/P6T)M;\2>#O%GB;Q_X-M;7P3X+DL[O5-7T?64. MA)KOAJ'PYXV^(/\`9R8P>,*1DGD9P2&&0#D?Q-G&"P8AB?FW+L^[SG&!V!&- MO0@``9125"J">>F!0!_G0_\`!53_`(),_ME>'O\`@G9^Q+\;OV0O@5\9_$?B MO]I#_@G[^P3^RU_P44_98\$_"CQ]XD^)L?Q`_9]^&7PH\9_"CXN:[\+=$T:\ M\4:9XW\$77P^G^#7Q#U/5=&M+GP186.DZ*^EVEWXS\87D7]R7_!0S]F#5?VT M/V'OVH?V5M`\2Z=X1\1?'#X-^+?`WAGQ-K4=R^C:1XHO+(7'AF[U_P"S0WNH M?V`-=MK"/7I+&SO=2ATJ6]FL;:XOXX+>7[,*-@;<#!!`)<#@@A1M(PI&1R&` M^7*,JA*38VX'(P`00"5SD*,X'&0%QD[F/\+QKN5P#^/=?VZO^"CLO_!.&W_X M):#_`((W?MW6G[>+_LVV_P"Q,_Q$NOA]X:N/V%(!_P`*ZA^$UQ\7Y/VK[;Q; M)X!:T3P*'\9MID$5QX+C\K^*K;5KGPSJFG3WVB3%+68_VI[#T#8!)+<2I8(8RQ^;=P58`^8_P!D;]C? M]F[]A'X-:=^S[^RI\.C\+/A#I&NZ]XGL/"7_``EWCSQP+;7/$]TM[KE]_;WQ M'\3^,/$\OVZ[43&TGUR2VM2H2SMK>(E:_B'_`."@G_!./XG>%OBA_P`%;?V= M;3_@EA\9OVIOVD/^"AO[4OPW^/W[!G[>'PR^$^B^,?A?\&]"^(GQ6TKQ-XU\ M+_$G]H"ZNM-O_P!EJX\!WZ>,K'74FN8K3QU:7L-U\01HOPSD\.>,]9_N,_:J M_:2\'_LD?`[QC\=_''AWQUXVTGPD_A^RL_`OPLT.P\2_$OQOXA\5^(])\*>' M?"?@CP_J>L^';#5-;UC5]6M`#?ZYH^F:=96]_K6L:E8Z/I]]<6^;XX_;._9" M^%O@_P`">._BG^U'^SY\)_!WQ-\&0_$/X>>(OBM\7O`'PSTWQ?X#N'\+PQ>+ M/#\GCO7M!-_H:3>.?!EC/J$"&SL+_P`6^'+&\\B]UO3;.Y`/XZ?^"PW_``3# M_P""S>N^#OV]/CL+#]E;]KWPC\7/@-^S#^SMX)M3\)_L_>!O"_P[LO`\5W\0?C38W'Q?^-,VN2^,[_5-&L=3UBUU30QI ML>EK_5M\!=!_::/_``3C\/\`A?\`:>T?X:']I1OV=O%>A>+/#WP&T_QX?!'V MX>'=?T[P/HGAS2_B!`OCJ3Q(WA!?"UIXKL=1@+MX\;7X-%B_L\Z5^UA M^RUKEK\9[W1/VE/@#K5C^S:;W_AHJ]TGXQ?#J_M/@(U@FNS:D?C1/:>(9H?A M9_9\7AOQ'-=?\)W)H?DPZ#KDDW.E7S0\QJ7[=/[$>C?"SPU\<]8_;&_96TKX M)^-;[5M-\'_&+4OVA?A'8_"SQ9J&@:HVAZ[9>&OB!=^,$\):]=Z-KH.CZK:: M7JUS/IFJYT^\2"[!BH`_@0^&O_!*W]N'4_A=_P`$6?AW:_L[?'[PE\/OVM/A MS>?LK?\`!27PEX@^#_Q%T/\`X5E\(O@;_P`%)]0_:>TC7_C1INH>'[&?X<7O MB+P7KDD7@S4/'Z:;I_BO0-&DT?3"8]46Z/VKX"_X)M_MV^+OV<_VJ_BI\*_@ M#XYT[]HC]E#_`(.//&W_``4:^!/P6^,/A_5?A!%^T[\-?`Q\)M;+X`UOXAV6 M@:9-(+J]\,ZW:>&M?T'2I-4U>_L#:_V7>-/VROV0?AMHOPH\ M2_$/]JK]G#X?^&OCOHC^)?@=K_C;XW_#3PIH/QF\.+IF@ZP_B'X4:IKOB?3M M/^(V@KH_BKPOK#ZOX.GUK3/[-\1Z#?FZ2UUG3[B[J?M'_M0^'?V=/AQX'^(= MO\/OB-\='^)OQ'^'7PN^'7@SX)7'PJG\1^,/%/Q3N39>$GTK6OBM\2OA-\-; M?1KO'VN;6M8\?Z98+;RJT$MRLL,)`/YO?VLOC-^U;_P7/M_V7/V*OAM_P35_ M;C_8[^$T/QX^%_QU_;1^/'[<_P`&S\"?"_@7X<_"75-+U\>"O@0FH:U=ZA\8 M/%GB[7KB^TNQDM;/P[J^EG2O#TVL>$[?PSXD\5>+?AGY!K__``2Q_:!_:A\3 M?\%Q=?\`#O@CXD_`K]I/P1_P43^'O[8W_!.'XX^)_!_B;P3;:]\4OA-X2UZZ MTC4?AYXFUC3].T_Q=X+\9VLMUX+O]4TR?7/"^F^(-6\->+M6L]4OO">F62_T MM_#[]OKX4:M%\=(/C]X8\7_L0Z[^SCI'PW\8?%K1?VM?%_[/?AG3_#GPX^,5 M[XJTCX8_$J?XE_"?XW_&'X)CPAXP\4>`O'O@JS2[^)MIXHTWQ-X-U6PU[P_I M45_X;OM>]=O/VN/V4K'3_A/JM]^T[^SU9:5\>_[-D^!NIWOQG^&]OIWQICU? M6-!\/Z2WPFO)_$:V_P`18]3U[Q1X9T73G\'OJXO]6\0:!IMJYN=8TR*<`_&_ M_@V6^'GQ[^&G_!-_7+3]I;X,?$?X#?%;QC^U7\?_`(B:O\/OB=\.O&GPO\06 ML'C74=!U:+4+/PMX_L=/\1Q>'[NY^VIHUU<"[62TM]IOKHV\]P?A3]G3]F;] MI#1/^"/G_!Q5\,M:_9^^-VC_`!(^-W[;O_!33Q7\&/A]JGPI\=:?XV^+WA;Q MY\+?A;I_@?Q)\,/"UWH,.N>/M`\::AIU_I_A+6/"=CJ^G^)KZRN[70[F^GMI MHQ_3MX+_`&POV1_B+X-^)GQ%^'G[4G[.GCSX??!2"^N/C)XY\&_&WX9^)O!O MPDM=,T^[U;5;CXF>)M#\37VC>`HM-TW3=1U*]?Q3>:2+.RL;VZG,5K:S2Q-O M/VQ?V1M.^"6E_M,:A^U+^SE8_LY:Y?R:5HO[0%U\;OAE!\$M8U.+7M0\*S:9 MI?Q6E\3)X&U"_3Q+H^J^'I[2U\03S0Z[I&HZ5*JWMA-?$7P M"MOVC+6Z_9UNO&VMZ38Z_9Z-KOQ.?Q;X4_X5C;P^`;:#6;RUT;PX?#<<^F_U M@?M1_LH>(/VO?^"7OQ'_`&0[?6H_A[XS^+G[*-C\-M+U7Q-9WEO9^%_&[>!] M(_L0>*[%+2;6+33[/Q#96EIXDAM["35;73FU$VUB^H1V\1][\?\`[:_[&WPI M/@O_`(6C^UM^S+\-O^%D:%X<\4?#K_A/OCW\*_!P\?>'/&!O#X0U_P`&-XB\ M5:;_`,)1HGBPZ=J0\-:IHAOM.UQ=.OO[+EN/LEQY7TV<`H`0."%&TDD`XX'# M_(&QG=M3>VX=T`/Y3O@7_P`%-?\`@IO\*OV9_P!E[]AKP-_P1>_;#G_;S^%& MD_"']GWQYXN^*O@VTT/_`()\KX:^%%O8>'O&'Q%TS]K?POXFN_#>H_\`"6?# M+PG#J.BM:VH\*>&?'7BM]-TG7_BL/">C:#\3>M^.OB']HS_@FW_P62^._P"W M%J7["W[6?[8'[.7[;'[*WP>^'[ZC^PQ\-W_:$\??"KXN_!+^R])O?#?BSP`; MGP??Z?X9U/2+7^UM.\6ZM=:3IVI+?:?%HB:EJMEXJT3PY^C_`,-_^"V?_!.G MXDR^&+R/]H3X=>!?`WBE?VKXX?BY\1/BO\"_#/PBT75?V2?CM\+/@3XFT'7_ M`![_`,+7OM'L/$/Q5D^-'PZ^,'P-TB*26?QU\"_%&D>/]37PX=/?C>8_^%+^"?%7Q3\">'O%GQ>^TS6,,(^& M/AO5M=L]7\?F:;4]-AA_X16QU=I'O[2-!,;I!*`?Q3_'O]CC]MCXJ_\`!&C_ M`(+1_&?4_P!D3XZ>%/BS_P`%%?V^?A[^TA\$_P!E.T\#:[XQ_:+TWX0VOQR^ M%&I:+>^,_A5X+T_7_$^@>*TT:+7M0\4^&KZS_M31K30-0UO4K+3]-EMII>0^ M-'_!,O\`;!G_`&[/^"IO@^Q^!_QGUC]DCP!^QU_P4N_;4_9?DT;X:^.]1\'? M%']L?]O7]B'P'\%/%GPZ\%W-EI-QHWCOXFQZ_?\`BV'PKX!T6WO]?\/:KH>L MW.G6T=YXCMTO/[:/VB_VC]#_`&>M-^'L+>`OB/\`&+XC?&'QX/AK\(O@U\)$ M\!+\0OB-XJM/!_BOXC^([;2M1^*WCWX7?"WPYI7A?X(?'OQ'\ M&Z!%8:"-#TO4[_QKXB\(^'/$?B+_`/!0GX:I\&-<^)5S\+?C/:?$7PS\>]!_ M98\0_LO7L/PATWX]:7^T;XMO/";>&?A-<:C=_&&#]G^/6?$/A?QUX.^(N@^* MXOCU)\.]4\`^)M&UJQ\;7-S?V]DP!_,1\&/A9^US_P`$^O$G_!%3_@H/J7[# M/[5_[0O@'P+_`,$PI/V&/VD_@I\`?A=JWB?]JCX'^,WU;Q#\2/"VN:G\`-8C M\,^)[NRU;4M2;0=2NKJZTK2/#*Z3J+^*M7T+6+WP%I7CWMI/@E^UG^UEX)_X M.+_V^[W]CC]H_P"!.@?MN_LA^#_@=^RE^SU\7?A[?:1^U3XYE^#/P1USX?\` MB&\UKX%Z"VO>*-&U+Q'XDTO1Y/"VE1Q7,NLQZP\>@-KVG6J:]J/]&/B3_@HI MX#M?A'^R5\5/AW\#OCY\<-4_;.\7WG@/X1?"3X>0_`W0_B/8^*]#^$OQ2^-' MC+2_&-]\:/CG\)/A3HZ^"?#'P6^(5EK5_IWQ1US2=3UW1;6W\%W_`(HT_5-* MU*\]S_9T_::TC]H:7XHZ'_V_\`!WXB_%WX4>*=&\3^!O&6@ZQINJ>"/B5XEBLIY]1\.:\N MC>*]%UK0]-`/PH_X)S_\%7O$?PF_9J_8/_8]^(7_``26_P""UOA?Q=\,O@;^ MS!^S;XW^)NH?L`Z]#\'?#WB3P7X!\#_"_P`3^/;WQ%+XZ7Q1#\,-(U2PO=?N M]>?P4NNQ^%X'O6\+O?;](7\U/@+_`,$B_P#@J/\`\%$/@9_P4%_:,\>?M;>) MOV#[?_@IS\8/B?KGQ)_8H^.W[!G@WQ3X_P!;^'OPYU_6]!^`/ASQKXY^*GB' MPO\`$_X36OAW2;>'1_!7_",:0U[H'AS3="\>Z5K/B*^U5+D?U">#?^"B6A^) M_A!\1OVB]<_9D_::^'O[.7@;X8>+?BUX8^-_BR3]FC6?#GQGT'PU??9](T_X M5>"_A=^TK\0OC-+XA^(-NS:EX'T[X@?#'X>6^KVAALM5NM!U:^L-'O*/_#R/ MP_::?XWT+Q-^RQ^U#X._:"\(^/\`X0_#[2/V3=;G_98O_C?\2+WXX6/B'6/A MYXB\!>(/"?[3WB7]G63PG>Z)X`^+>N:CJ_B[X^>#IM&L_@[\1$O[*#4;/P_8 M^(`#\IO#\W[6W[1W_!L!\3_AE\6OV?/VA-%_:]T']CKXB_L\:S\(/%_P?^(F MD_&+QOXF^&5O/X)\'ZMH/@K4]!C\6^-KOQ[X.TOPUKL6KZ-I=_'K^NW^K0V4 MMY<6T['C/VM_V=_V@/$W[)'_``;">&_#GP,^,>O^(?@!^V-_P2N\4?'?0M#^ M&7C35-;^"WAGX=_#/PQ8>/?$7Q8TJQT2YU#X>:%X'OH9K7Q?J_BZUTC3?#%U M;SVVO7>G7">77]!'PO\`VL_!/Q/^`GC_`./9\$_$?P'%\)M0^,6@?%/X6>-[ M/P8OQ1\!^,O@7JFO:3X]\':LG@[QMXP^'NJZLDGAU[WP[JOA;XB>(?"'B71] M5T'6]'\3SZ7J,-Y'D:=^WK^QPR_!72O%W[27P0^%GC[]H#PS\//%'PQ^#WQ8 M^,/PP\"?&+Q$OQ2T_1+[P9H>G_#W5O&)US5_$FJS>(M*T>'2]`CUK^T-9NX] M.T^YU*:XMQ<@'\J?_!)[7]B;X3_$OQ'\(O^"QOP%^#G[+ M/[7'Q"^''PY\9^)-`^"/B'X9_'_X5IJ7QC^(_B;P]87'A[PAI]_\%+&S\!F7 MQGK&@Z)J/@_4/BI<7!EO--M[_3?1O^"Z_P"QG\/#^U=_P1XT3QG_`,$^?VP_ MVW?V`_V:_@K^T=\,_BM\(_V.OA3\5?B)XOTCP]9_#7P5X.^!&BOK7PP\2_#R M?P_-IGC+2?"6N)#=_$/PC+J^B>%-?C@BURVBN/#]Y_31\1OVZOV8OAQ\;_`' M[-=U\5?!OBKX_P#CGXC>&?AQ2X\ M!>+M?^(-I=>!M&\/>*(]+U75_&MM=^&+&SEUJ"2RC`/QJ_X(?>&/V%/A=XQ_ M:#\'_L5?\$F_^"D7_!.+_A-_#?P_\1_$SQ3^VU\*_B_X-\'_`!/_`.$%U3Q3 MIG@W0/!>L?%;X^?&9Y/$?A[_`(6#XLU*[T[0+308[G2]0DNM5N]0-CI,4'WM M_P`%CO`OCCXH_P#!+']O'X>_#7P;XJ^(?C[QA^S?\1M"\(^"/`WA[5_%OB[Q M3K5YIA2QT?PYX;\/V>HZSK>JWK`):Z?IEG=7=Q*1'#"TA"5^@NC^,?!_B'5_ M%?A[0O%?AS7=?\!:OINA>-]#TC6M*U#5_!>N:QH&D>*-+TGQ5I5I<2WOAS4] M7\,>(-#\2Z;I^L16UWJ'A_7=)UJRBFTW4[&YFZ4#?R01@@N_%OX]?\`!+'X4_"3Q5\4 M?V1-8:;P#\3/'/@'Q-^S1\-?"GQI\+>';;7+"35;7XN^#T\$_P!E:7X%;0[[ MQ-=ZGJ6IVVF>&O$OBK2-.\$Z_#\6_&O[2?\`P6X_:S_8#\&^%OV`?VSOV,OV M4/V(OVI?AS^VK\>?B[^WA\'$^`/C'Q?XS^&+:[+\,_A/\'?!,OB3Q'=>.-,\ M131ZK9>-]>T35ISX?@U?3K[6(_#8L?#Y\9_U7"/!7#'C<#TYW'.26#L2,+T8 M;R"9"Y-!B&"%^7..1\O``'\`4Y(``/#)DE&&!0!^#'_!8CX/_%OXG?M3?\$3 MO$7PT^&'Q&^(6@?"O_@HKX7\;_%'6_`_@?Q/XNT;X;^#(=&AAF\9^/\`4_#^ MG7UGX/\`"UK*K12:]K]QIND[RZF\W`@_F%X3_P"">W_!2K_@HM^VO_P5-_:] MTC]J#QY_P3?^'GQ-\7Z_^P5X0\`_'+]@7PM\7-:^.G[(_@#PIH^D7.JZ#HWQ M_P!2\%7GACX4_$>2_N/$$&N^%K*]B\7Z[K'B:"?6+6X\,M:0_P!DGEXQT)'` M.%4X)7/S*G'RJJX4#[HYR%*KLR#@X)#8."#@A0<'&0&?>`?P$^,_ MAC^WAX!_X)/?L2_LT?$7]D7]LGXR?$7_`()6?\%U_AM8O:_#7]F;XI^)O%'Q MD_91^"%G^T!XF\._&+X/::FC):>-/AM)#K(\!>$/%5GJT?@Z&-/!&G7?B:"U MUS2=2OOZI?V//^"IR_M?_%X?"/\`X=S?\%4OV7/^*7UOQ0/B=^V'^R&/@G\( MF_L66PA_X1U?&?\`PL+Q,Q\4ZM_:'FZ+I']F?Z=#8W[&XA,,:S?JB4RV[OZ< M`'IP2`&88&/F)7H2A*C"*C*`#AB.`C0_%/P1X`\+?M# M:;^T+XDAT&RTGXL^$I=)\(WWQ)T'PCXMUO7;#X>^)=2U_3KJRN4U76_!NK65 MO%L_/3X>_L=_M2?LE?\`!+7_`(+)_P#!(34OV)OB+XM^(7@[P_<^.?V-OCK\/+?Q'&;3P#+XFU MGQ5H'@V\UGPCHFEOI/PH\0>(;[^\S;[GC&.3U`(R2"&;C&=S-G`/!YI@C89R MV<[@.J[0>0`WS-R0"Y/WV+.?EVQ*`?PM?\$^/@S_`,$N/@M\6?V0/%>B_P#! MO#_P6W^&W[4_A'7O@]83_M!^+?V>?VG+3X3^$/B]=1Z)X=\2?%7Q,WBG]JZ[ M\)Z;\/-+\17VI^)-8N]4^'HTG2O#2W-V?"T*VT>GP_M?_P`%X_@W\7OC$?\` M@DO_`,*F^%7Q'^*(^'/_``6`_9!^)OQ$/P[\#>*/&;>`OAOX;?QJWB/Q_P", MCX;TW4QX5\%Z`+NV_MOQ5KHLM!TG[1;B_P!1MVN(!)^^_E]<8YY`'R+D'=_# MR0QSNW%P>>,,RD\O``'.`1SCN#@_=QGL>/F!.[=@`@'\T/[?%E^T%^Q+_P`% MGO@M_P`%1/#/[(/[27[8_P"S?X[_`&%M=_8E^)GAW]C[P,?C)\=_AGX\M/BC MXG^,NA>*#\)[>[T:\U7P9KT5GX?\.GQ!)K&FZ#HLG]OOK.K6>O2>"?#WC/\` M-[QK^SA^U_\`M-?LN?\`!QO^W%=_L;?M'_"2Y_X**Z!^SGX2_99_9E\?_#O5 M8_VJO$/AK]FR*X\`ZUKOBWX'^'H==\6^&=7\3B+3=8T7P_Y5Q$Y/#/B77?[@=OL.2G_#_ M`$CX-:/^V_\`L2/X`\9?'[XE6&O>+?"UI?ZK^TK\)O`?Q!D\7^/=#^+7PT\9 M7GVHZ'X=>V'@/QGH/@37=-T?POX:L/B7JME]3?$W_@F%XS_X*!?\%!/^"^&D M^*_`?Q2^$/AKXW>`?^";OQ+_`&*?VG/&7PX^)7P\\/Z1^T!\'?V:M*&@>-O` M/BO5-$T*^N-6\`>*)+OP;\2]/\.O+XM\(V>M>)O#VH6.C^("UNG]@GEXZ'&! MA1@849R<<;^3@GY\DC(*TH0COCJ>&.&;G5_#.H_9772=6O8;(RG^G MB,87')Y/4$=R``#T```&`JG[RJH.`Q8BI)+;L@CG(QGOM!V$_*O)7(^8*53; M&LH__5WX_G^>?K0`M%%%`!1110`4444`%%%%`!1110!Y)J7_`"$;_P#Z_;K_ M`-'R52J[J7_(1O\`_K]NO_1\E4J]Z'P1_P`,?R1Y#W?J_P`PHHHJA!1110`4 M444`%%%%`!7H/A/_`)!TW_7[)_Z(MJ\^KT'PG_R#IO\`K]D_]$6U2>@%%%%`!1110`4444`%%%%`!1110`4444`%%%%`! M1110`4444`%%%%`!1110`4444`%%%%`!29YQ_GGI^?M2U&^>HY(4G&-VUOX& MVCYCT8<9)[>H`%,BKC<0">0"0#@%03R1PI903TR0!EF4%2X&>N0,XQVSCGL, M]1N(&,GHK8_)K]KW_@I?J?[(?Q[\"_#7QE\/O@%%X!\<_$'X%_#OPZ/&7[9W M@;P)^U9\4I?C3\1/"GPVU'QW^SM^R-'\/O%6H_%3X=_"[Q!XUT^V\;:MXI^+ MGPB\6B7PM\2[C1/`FI>'O#/ACQ-XZ\ST'_@K7XOTR\T[Q]\$?B]X>_:#NOB%\2KG7OV`M/_:?\4>-_%/B/X+'X&>#=*\,>"O& M/@7]DSXKWVC7D'Q@UOQ)IGBNRT[PW=^%KCP]JNG^-K\`^K_VJ/V=_C#^TQ\= M?@-I_A_XN_%C]F[X6?`2R\6?&2/XJ?"6/X"ZUXH\7_'7Q!IU_P#"_P`$>%+; MPW\!/ASKWQ5\0>)9O%'PCEBN/$7C3X8ZOX!\46OB+P9X@_LW M\U_@7_P3^_:2^&GQ2\+?"?QS\/3\3_@?^RC^QK_P4E_94_9R^./B[5?@8]_X MY\$_M"^-/V+/&_[-?A^X\&^%9_"Y\'^(O"?PSTOXS_LXZ[=V/PI^'7@R#3/A M%>3006GA7XA>%I?$OVC^SA^T_P#M? M!7@SPE\3=.^,=EJFJZW\5_#FB6$GC+Q5J7P?^$?BWPC\6O">@:@^D>/OAQHJ M>-?A1IPUSP_?>$_B?X\U236H_#?Q;>?MO_\`!1JV_:@O_AUH7A/X0>+-/E_X M*Z_$W]E;X??#QOBW9:#I/C+X,Z-_P2]^('[1EEX/^(/CN;]E.?7OAMH'@[Q? M8>!/CSJ'C+PII7Q8^)VJ:[>^-_@S:VVL>$_".A77Q0`*.H?L"?M)Z)X-^`$W MA_X&:3J]I\"OV&O^"4GAWQ#\';;Q9\*-'T[XG?$?]B7]IJ\^-?Q*^`&FO>ZT M?"D'B;3M%$NK_#+Q#XCN-%^$>J_$MO#VG7OQ)\):/>:[XN\/>R_"/]E/X[>, M/VU?`O[77CW]G:;X0>#_`!!^UA\=OCA)\*O&?BCX/>)?'?P2MK[]A_X9_LM> M&OB!XQ7X<_$3X@^`6^)GQ?\`%?@+Q#JSI\'?%'C@Z-X.\0:%+XP\3KK]]XJL M=/YGQM_P70\'^#?"GP^37/!G[-7PR^+-]X2_:!\4_%/P+^TG^W/X'_9V\'Z5 M<_LW_M&?$K]ESQE\/_@%\3/&/PJU&7]H;XD>,/BE\'OB)+\.M(OO!'PC\+3^ M$=$L]<^)GC3X77WB7PYHVJ?='[2W[0/Q>\9_L&^'OVD_V*O"WQ*\;WOQ+\)_ M!#XK:;8_#CPQ\.-:_:#M/V=OB%?>#_%7Q)\1?!?X>_&+5[#X7>(?V@='^#&K M:]J7PU\'^/9/$'AN[\>V^FV]YX-^)4L,7P\\6`'\]?QZ:3]@SX._&GX)?&OP M#\*_'_Q4_:V_X)I^,_V9?AA^SQ+^T!^R3I'Q/^&.K>&/VA_VX_$/@Y-)^#/C MKXHZ1\4/BUX#^/6D_M%>`;7P/X?_`&5/`OQ_^)>L?$#X!_\`"NV^&<_B&/X> M:/:?O9^U1^RWXV^.W[-G['7P@@TCQ=+_`,(-\=?V4/$OQ4D\!_%/Q'\&?&'A MGP1\/5C3QUKOASXC>#/&?P^\?Z!J&CI\T+^`?$=CXOEC!BT:)9"ZI\;7?[_LM:[^R/^SAX9\>:_XVU#2WG_8I\3Z+\`-1\(_%GX@2>)OAUX\L MM>LOACXIUK5N+N_V^?B[JO\`P2\\+_%S2_VF?'EA\5/$'[5?[,'A6\\8>&OA M[\!OB?\`MN^!OV5?V@O^"@^A?`;1KOXJ?LV_#'X1_$[X9:;^U)J7PLLOB/X* M?P!X0_9\U:6'XH>$M9\%:7\/KWXI^$O$7AVT`/HG]KW_`()QWOAWX'M4\.^*]6\#2^!?BGXMMO& M:>;?LE_L*?&3P9^T)\./BU\0OA3\0+WPMK'P)_X*?W?C(_M'?$W]F?6OB'IG MQ=_:V_:$_8W\7Z#I_C>R_92^'7@'X4?#WQ#\8/#7PU^,WC#QI#\`_"'Q*\)> M$-1U?Q0^M?%#QCXH\7I'KGU;^PE\0?CIXQ^+?QETS4?B;^UI\=?V:-)^'/PL MU#P;\4OVUOV5+7]D;XQ6_P`>-2\2_%.U^)GP^\*>$(/V7/V--0\7_#/1O`6F M_"GQ`/$VI?`VYL=.\6>)=2T[1_BGXPNSKOA3X9_"?Q6_X*M^,_`'[&/_``40 MO6UC]H\_M*?!?XT_M^^!?@Y\2_#?[!G[0OC7X.>$-+^%7QV^)_A3X,PZC\:/ M#/[-FO\`[*\UCX,\*:'H&E>)==\<^-+JVL+C3+V3XE7ZZY%K+4`>-Q_L$?MR M>(_@QXN\$>&_!7[0_@/PI\)O#/[#8^&W@GX^^*?^";OQ'_:)U!/V1/VC)OBV M?@?^S)^T'X$\&>*/"GQ'^#7@WPHD]_\`!)_^"E>B:KJ>K?&G2?A]JGB33_A; MIGB/XI^,-.]_^#G[,/[4/P?^(_A;]L75/@!^U-\<->3]H[XV?$/Q?\$_B_\` M%K_@GC)^U'J$_P`3/V:?A3\`=#^.^B^%_@CHW[.7[#G@'QCI'_"L+_PCJ_A3 MP[\>M<\1:Y\)_'>N?$37/B-J/Q`\0:Y\$]/]S\2?\%FO@WX>_:[E_9QNYO@! M'X>T_P#:G\$?L:WUE??M9^"K/]L+4?C)\0-2\(^$]"\5^$?V*AX-O?$7B+X! M6?Q,\<^'_`^L_$BZ^+/AWQOIRZ?XO\?V_P`([[X7^'K#QEXB^;?VM_\`@L/\ M5O`_A']M+X1:)X<_9]^$W[0/P\_8P_;?^.OPIG^%7[6_PK_:?^/'P$\5?LX^ M&-!UCP;:_M>_LXCX56?@WX,^+_%NE>,-(\4Z'X?T+XA?M'>!QK7ASQ%X7U76 M]6L+2RU[5P!?A]_P3H^/^B?#']H_3/$_P6\(R:_\5O\`@E;^T5\`O`WABS\1 M_#_5K'P3XZ_:,_:+_:T^.$7[)6CZQJ>KVT5OX6^'OA?XK?"7X;WNL-#I?P@U MM?".AG3-432?#]G%8_M3^SIXYEUC0M6^%6I^'_$.D^+/V?=.^%GPU\=ZAJMU MX7U+2=9\7:A\%OAQX_OQH6H>'O%'B&[9M%T_QIIUAK%KXJLO#>NO?A=8L-*U M'P=K/A/Q3XC_`!?U/]N#_@HW:?M@>,/A;X<\*_"+Q=X>M/\`@KQXL_97^&/@ M&X^+-CX;TWQ;\%K+_@D?K_[4$/@WXB^-9_V4+S7OACX;\->,A\._VB=4\;>% M+?XM?$N[\5>(?B)\!+*+7?`'P\\':Y\7?T+C_;WU&X_X)O?&G]N6Z^%=OX?\ M9?!;P5^U&[V^\(W-MKU]X8TFZFFTBW`/BK]E+]C;X^^'/VCO"VK_%OX`3 M:1X+^$OAK_@N#X1TKQQXF\2?!CQ/H7BO4_VV_P#@H=\(/VD_@+XF\!Z1X?\` MB!XG\:V.F>._@;JGQ$\/:R?&7A/P-XA\-:EX9\<^%_%NC:7H?B'P?J'C7X>T M[_@F9^W!I7P4\'?![Q1X>_:JN;3X_?\`!/C_`()S_LT_%+0OV>OBQ_P3D\*^ M$_AG\0/V=_@Y!\-OB%X<_:0^+'[2GP@^.7QU\*>&/A=XTUC4_BC\-?BE^P__ M`,+IUNWUO7?B1K_A#X;:7X\TGPUXB^)'[O?#_P"$/[;WPK\6?#SQKXF_:RU# M]J#0]9LM9B_:-^$GCSX??!+X9>&O#=U+X)U76=.US]CBZ^&'PF\(>-=*2Q^* MEGI'@[3_`(>?M/\`Q=^*L-Q\*/$UYJ>O?&E?'?@7^U/B%\%/_P`%J]=T?5_C MGX$UWX'?L\>,_BW\(_`_P[\9)\,OV;_V]/!7[0&M^'-=\4_M+_#_`/9I\7_! M?]HN]M/@WX1TOX`?';P#XH^)GAN\D\)V,_Q7\$:W=:?XMTF#XF:9:^'H=>U0 M`^Y_^"A_P?U3XQ_#WX8Z7=?LLZ+^U_\`#OPK\6-'\<>./AGH/C#3?A=^TMX3 MU+1M)UFW^'OQH_9"^,'B#XL?!+PS\-/C7\-?&6H6-]>:Y<_%GX5:_+\-M5\> M?\(5X_L_%,=CX/\`&WY>_$[]B[]J/XQ?LUZO\)/CA\$?VK/C5^QCX^_:D\3> M+-5_8=\8?M=_#GQA^W3X6^`FF_"#1/\`A5MIXA_:9\=_M!W'@[QL_A/]M+PY M??M!:-X%U/\`;8\1ZCX>^&=[\-;74/BAXP/A?7OV9T]V^*__``6K\-?`3XT> M(O@G\:]"_92\'^+O@SX@^!O@7]I'P5'^W-HUM\;;3QM\=--\#>*+/_ADKX'^ M.?@7\//&'[57@'P)X$^)_@/QAXU\8ZG=?`C7;R!O&WACX9^!OB1X\\#2^&-: M]R_X*3_'/Q]\+?B1^QGX)\._'+]IGX%>"OBUXT^,^G_$37_V2/V:M$_:C^,V MKQ>#/A7<^)/"FFZ3\/-0_99_:]U.WTA->1)M>UK0OA86L]/$IU/6]+LT,B@' MPS\'OV+?V\/BSX)_8/\`A%^VEX*\8:'X<_9C_:[OO$9\3?`;XT^"/V<&\`_L MH6O_``3*^,/P8^$6D^$O$G[(GQ`^$_Q2\(^/-"^+WB#PMX.^/_A[P!JMWX=N M?B=XR^(]O\(-:UO]CA_#>C>$_P!S?@W^SI\+_P!G;PGXL\._"'1_$9N_&6M7 M?C+Q=XC^(7Q9^+'Q7^(_Q!\82>'-&\)V&M^/_C7\6_%OQ*^+OB>]T_PKX6\* M^#-#U7Q%XF\0W7A3P5X;T#POX8AM="T#2-)MOA#PK^U)\4O!VC?`_P"$GP&' MQZ_;?^-OQU7X]?%'2-0_;]\,_P##O;7_``G\&_@#-\,O#?Q*U3Q%I?AS]@CX M7:YI[VGCSXN?"?PQ\,]%O?V9+>X\>W?Q'U;Q!J/Q,M?"/AQ+ZSY#0/\`@K=) MKOP%_:*^-LG[.>I:%-\`/^"8/A;_`(*/S>!]8^)]F^K:Y+XEOOVQ=/;X&ZE? MZ9X(U#3O#6H:/+^R9LU#X@V"^+-/^T^.I+2T\+-'X82^\3`'R$__``3W\'?%?P#\EI!8_P#!0G5]6\,>%/''QZT+ M5-;E^"VI/+;Z!>:YX9^W^J6W_!1/X]7WQQF^`?P9_9\LOC7X]\?_`+1/[1W@ M#0KKXQ_M#Z-\)/AE\+O#7P$^!_[-7Q2U&\U/Q'\./V5O&OB^/P3K;_&2X\/: M#:3>"/BYX\L_'\UA'JWBZZ\`^)I-3^%?!>,O^"R_Q"T_0/&'COP'^QI!XM\` M_!#]D/X7?M=_M)S^(?VD-&\'^-_A[I7B'XX_M*?`GXK?"KX>^%]+^%7C;PS\ M5OB3\-O$?[,7C74O#$^I?$/X;^`?B)91:A%J'CCX>S6NA+XJ`/JOX'_!?XOO M^RA^V;+XM^&6K_#GXH_M4_$7]K#XH:#\&?$WBCX=ZWXF\(V_Q$T>Z\#_``T\ M+>+O$W@7Q3XG^%Z>)];\.^&O#6N:]%H/COQ5X7\,:EXAN-`7QAJL>C3:I)\, MZW^P/^T+>_`/]LW0$^#>FS_$SXH?\$^O^">WP-^&TTGB/X;OJ^L?$GX`>&?B M$_C;PG#K\GB=ET9/!'B[6-$OK'5M4U;3/#5]JDL.K>%]4NY+2ZO8_:/BK_P5 MRUGX`6GC;P3^T1\*/V=O@E^T#H_[0_P]^!W@^Q^(?[:-OX/_`&5I]'^(?P+D M_:'M?'_Q5_:M\:_L^>&+OX4'3?!'AOQ_X9O?"&D_!/XF:GJOQ+TWP-X5\'ZI MXBT7QW=>+_"'->&O^"P7Q*^-^@^"[C]D[]E_X._''Q`_P7_:8^+?Q2O-0_;. ML_#7P@\-2?LK?$^S^$'C;1?A#\7_`(?_`+/GQEM_CEI'Q#\1:II6M_!/QW8^ M%O`VB>(_`FJVNL?$:W^%/B.&^\':>`<;>_LL_M3K\2_A;\%V_9JU;7=$^'7_ M``4^_:._;)E_;JN/B%\%4T"'X6?M!1_M$^)O#C>&?"TGQ1L?CV/BK\-;7XX^ M%?@3X@\//\-?"?@\>#_A=;ZUX$\2ZSIG_"/Z;9>"_LY?L+?M=_"OP1X2\'_$ M;]G[X]?M`Z[^S]^Q/\5?V(=,\)?'CXG_`/!-+P_^R'\4[3XOZI\'?AQK&G_# MC0?V?/@WX._:-^)7[*OBB'P1/\:/B@W[7?C+X??&?PS\/_#.E0>'_@_^T!\? M/%VJ:5H7Z<_L1_M8?'#]IG]I3]I5M:T7PCIW[,MO\'?V0/BK\`8X?_P`0 M=)L/CS\+;KX@3VWB;P[#\(O#L%K=ZY;S?:M;\SXK^,[3PQ?:-IFF^'(;VQUK M4+[2?&O!O[>/[5;^/+'X*>!/A!X$_:,^)?Q/_:V_X*,^`?"NL?$OXR1?LV^` M?A7\*?V2/B1HFF^'+'Q)K'@/X!?&?Q%X@@FT+Q5IWAG1[K2_`VN>*YM?BTF; MQ)O\`P)^((UGQCJ7@OQ[XJUNW_:/U M[7+?6==_::7XA:I>>-9OB3XUCU/Q=XM\;Z;\3=%DU;_A`/',7B:XAT*_G\,: M=JGPX&D^`KW0_`O@G[<#XP-AZ#!4`+G:I"\L""Q)"[@H7`#%=T>_^?;X]?\` M!5S]H#XD_L0?''XO?L9_`73]-\>_#[_@FQ>?M;_%'Q1XY^+6AZ7XC_9N\9_$ M[X<_%ZZ^&&B_#'PC"=&]%E_X+5?";2?VE-/^`-[<_L\R6$?[1/PZ_9`U&TU;]K3 MP5HG[7VL?''XC-X0\,:)XM\+_L4VW@*\\1:M\`%^*?CS0?`>O?$N;XEZ%XTT MZ&P\;_$;3_@S?_"WP]I_B_Q"`?N*9%!YR!\V21M"A#G/7CU!'8'C\_SR.HKX4_9C_:]\5?M#?$7QI\,KWX*O\/\`7?@/HDWAC]I^ M[NO&EUKND?#/]H^YU+1[KPW\&/AU>MX$T!/B[X;USX:W$GQHE^)LS^`+C3/A M[XT^!+R^`I_$'Q*\5Z'\*/NF/H>_S$9&.3_%D+P_@`/F#'`SB@!]%%%`! M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`>2 M:E_R$;__`*_;K_T?)5*KNI?\A&__`.OVZ_\`1\E4J]Z'P1_PQ_)'D/=^K_,* M***H04444`%%%%`!1110`5Z#X3_Y!TW_`%^R?^B+:O/J]!\)_P#(.F_Z_9/_ M`$1;5RXS^"_\43HPW\3_`+=?Z'3T445Y)Z`4444`%%%%`!1110`4444`%%%% M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%-9(M5O-8D[N/_@F_P#L_2^$_A+X%UJ[\<^)_"'P MB_:#_:]_:+L/#WB'5/#MUIOB_P`2?ML:?^U=I'QB\&>-XK/PI8/J'P[M]+_; M$^*ECX2TC19-`U^QM]-\%)K_`(H\2_V7KK>)OOZB@#X)_9P_8&\._L[?%.W^ M+\W[0_[2_P`<_%.D?`S3/V:_"%M\=/%'PSUG1O!'P6T#Q%8>)_#?A31;7X>? M";X9W>M:SHVIV3I=?$WQ]?>,OBQXWLKOR/B5XY\:2Z-X4N/#K]/_`."??PTT M_P#:3G_:47XE_&2ZU)?VF!^UIHWPNN=0^&I^&'AOXQW_`.Q]XO\`V)_&&I:4 M\/POA^)]UHGCSX5>*K37?$&@:]\3-8L=,\>^#_#6I>"%\(>'+KQEX5\6_>=% M`'YG)_P3$\!^&[:&Y^#?[1G[4'[/7C:?4?VCO^$F^)OPEU[X*R^-?&O@_P#: M;_:-^(?[4WC'X=^(8OB;\"OB/X-M=#\&_%?XG^*KGX2^+_"WA#PW\8?AYHMY M>:=I/Q-:;Q#XLO-?^H_C-^S#X%^-7PC\.?"75O$/Q'\+#P%JO@CQ5\+_`(F^ M%_&^I7OQ?^&WQ!^&LMO<>!?B/HWCGQ['XXF\5>+M(N+'OC?\.4_9[U7QCKGP>\.^!/#GPV^`_@3]G"W\)>$M M7^)OQ:O=2\->)O@%XHTSXAQ_%;QOI?Q0B\9Z/&?"VN>.]3\,>#/AU\3/#OPPT+P%\/M7^'?@W1)?#G@WPK\2;KQ' M\1M>_5>B@"/R^F><#')8X(*X.&+!V&T$2/EU89R0Q`^+M:_83^$NN_LS_M'_ M`+*UYXC^(T?P^_:B\6_M&^,?B#K%MJWA=/&.D:G^T]X\\6_$3Q]#X/U"7P=- MHEC9Z1KGC'4K;P>FM>'=>N=/TNVT^#5[K79X9[FZ^U:*`/B*V_8?T32/C7JG MQ5\'_M!?M*_#WP/XI^+4'QX\??LT^!/&G@GP_P#`_P`?_&"+1M-TJ?Q?K^JQ M_#>;]H+2])UF\\/^&/$WC'X4^"/COX0^!_Q#\3:)>7OQ"^&/BFR\>?%+3?'? MQPO_``1`^`DOPS@^#6K_`+1?[6NN_"OP_P#L[_'[]E7X:>!;KQ%\`=*T+X4? M!']H[PO'X9\?>'_"L/A;]G3P_+XF\3H;+1=>LOBE\7I?B=\5M4\1:'::AXS\ M;>*[;4?$FGZ[^TE%`'P7:?\`!/CX8V7[3UQ^U!#\2?C$=8D_:3@_:RM/A=)J M'PU?X6Z9\:I?V,/$/["/B+7K,CX7K\4)-,\7_!'6='N=:\/:C\3[_2++QQX' M\+Z_X6MO#MA>>,]#\6^O?#/]E'X4?#7X$^.?V<6M-3\>_"OXD^+?VF/%7C;0 M_B#+INK#Q!%^U?\`%_XI?&;XJ>%;X:3I6A6DOA,Z[\7?%/AW0[![1[^#PC%I MMGK&J:WK,=]KU_\`2U%`'YO:/_P32\!75QX0M/C-^T+^U%^TWX&^%7ASQ5X: M^!GPT^./C'X:R^&O@Q%XM^'6O?!R\\1Z'XC^%WPD^&/Q4^)GQ$TSX1>*/$GP M\T#XI?M#_$3XT?$C2=.\1^)?$#O"O@7X M,_LT_"KP#HS^%/%?P-TK1CXEMO"Z^+_%'@SQ;XA\.^-]?\30^&/@[-\+/UZH MH`^)?&/[$.@^(OC1XJ^+_A+X]_M&_!6S^*6O?#SQ7\=_A;\&/%O@/PCX%^._ MBKX8:;H/ASPOXB\:>([WX9ZY\;_!^JS>"?"7@OX>^*+GX'?&'X2'QIX"\&>' M/"WBU=:TZUN4O.F_:3_91_X:&\2_!CQUHWQ[^-O[/'Q"^!.L^-=8\$^./@E: M_`O5-5F'Q!\*R>#_`!-I6MZ1^T%\$/CUX-O-.NM'E=+9[?PO::G8RNTEKJ$> M%`^M**`/SY\3?L%ZUXPTGP/J7B/]MG]KN\^.WPTU#XB6_@']JJRLOV0/#WQN M\-?#SXLZ1X0TSXB_!R'1_#'[).B_`+5?AWXFOO`/@[Q3-+XB^!^M>/K#Q=X< MT/7-*\=V$NB:-%I_R5X)_P""-VD:M^RSX`^!OQ0_:!^-?PXUV\_8O'[$7[1U MI^SKXU\&7O@[XZ?!^WN_B'=Z)HFNZY\I6OB;2/BGX0\1W^DZEKD/B3PO=-XCM/#^I^#_3[G_@E=^S@_@#X MR?#6QU[XMZ9X<^.?[(7P_P#V,?<?B[1]7UQ?A_\/\`QM^T#\1%\>66N>*? M"GB'4KWXO^,O%_[2OQ%UOQSXK\37/B#1]9OUT6[M?"^FSQ:N^L_I710!\'?% M/_@G[\-?B3X_\;_&'2OB5\8_A5\:_$WQ%^&?Q5\(?%WX?"GQ-XP\$?$3PQ\5O!OQ/\-Z[I_BO4=4T M[2]#\2:9X6UKP]J^$OV%O`_AW78?%_B'XN?'[XI^.)O@9\9?@1XA\:_%/QSH M7B;7O%6B_'?XAZ-\3O'?B>]CM?!NDZ)X9UJ'Q'HMM9^#/"7PZT;P5\&OA[X5 M,?@[P3\*]#\,Z;HNF:7]N44`?&O[/'[%/@?]F;QG/XK^'GQ%^*U[I=]\!/@5 M\!=5\!^*KOX>:IX3U:U_9Y\.OX0\`_$J[O;#X<:/X]A^)#>%I9]$UU=,\<:= M\-]1CN9-3A^'-EKJ0ZJD/@#]AGX3_#GXK^&_C%HGB#X@W/B?PM\0OVL/B3IU MCJ>I^%IM"?7?VQ/%7A?Q=\3;2XMK3P;9:@=)T;4O"6G1>";>WU2VO--L[G4$ M\0ZAXJNIH+NV^T**`/R)\9_\$>+_`((>,4L_$G@"7XG?$)/#_B7X9P?# MS4-=TGQ;JOA;XCMXZ\&_8O#EG]#:=^P;HGAKXI7_`([\`?M'?M0_#/P'K_Q% MM/C)XR_9Y\!>-/AYHOP>\:?%^S\,:7X>'CO6M5F^%5]\==.L]4O/#GA3Q7XN M^$_A#XU^%_@-\0_%&AWMW\1/A5XKTSQ[\5=(\??>%%`'R3\#_P!CCX>?`#7? M#?B?P+XJ^(,GB*#P)J_A#XJZUK5_X5N[_P#:-U_6/&-_\0Y/BQ\;9;/P?IPO M_B?8^//%'Q.\4:7J/P^7X>>%["?XM^-]$C\)OX4M_!>@>$/K5=P`#')XR?P] M@`3ZD!0>R@[]7^844450@HHHH`****`"BBB@`KT'PG_R#IO^OV3_`-$6 MU>?5Z#X3_P"0=-_U^R?^B+:N7&?P7_BB=&&_B?\`;K_0Z>BBBO)/0"BBB@`H MHJGJ&HV&DV-YJFJ7EKIVFZ=:7%_J&H7T\5K8V%C9POW4[QP6MI:V\G:YH>HV.M:+K%A::IH^KZ3>6VI:7JNF M:A;K=V&HZ=J%G+-:7EA?6LD5S:7L$SVMS!+%+#*Z.&J^9`,GDXW'@9)"G#D* M/F.T]0!D_P`(8D9`'T4PR*O4]\<8))XZ`')/(X'S'@`$LH8\Q<9SV8\\?=(5 MLDD!2"0"K$,#D$`@@`#Z*`<]B.3U]CC/X]1[44`%%%%`!1110`4444`%%%%` M!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`% M%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`44 M44`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`>2:E_R$;_ M`/Z_;K_T?)5*KNI?\A&__P"OVZ_]'R52KWH?!'_#'\D>0]WZO\PHHHJA!111 M0`4444`%%%%`!7H/A/\`Y!TW_7[)_P"B+:O/J]!\)_\`(.F_Z_9/_1%M7+C/ MX+_Q1.C#?Q/^W7^AT]%%%>2>@%%%%`!7X_?\%VO"/@;QO_P33^-N@_$3XWS_ M`+/WAIM;^%FI/X\U'P!XT^)7PSO]2T;XF>%M5T?X??'7PWX(DLKFV^"7Q0U. MTM?AWX]\3^(]<\/^!_"%KXGM/$WB[4I])TJ72-3_`&!JCJ6G6.KV-YI>J65G MJ6F:E:7.GZCIVH6\5YI]_87L$EM>65]97$V=W;RO!,?C[^QWXI_X)3?L4_LV^*/V?/V?OAG^U=\;;O]K#]F[]EWQY\;/VD/ M%FG_`+#'[/\`H@\866C_`!]_X*5_#7QI\++?4OA?\`L\-JME*?%C?#[_`(*,>/O'GPW\0?L3?MQ_ MM2?%[XV_"3X"?"_P;+\#O%'B'_@H-\$?A)X8_P"";,]]X9_;,^$WQF^(MYI. MG:5\)K_QUH>%[OPKX?N/ M!7Q&\17GA'2O%%MXSU,^)[/Q#8_#WQQ\1)%O_!LO@B/2O[$DT_P)J=@NI6_C MRYO3>7EB3HL<7VB:'US8>`S9Y(`Q@?*<*2%)12@SE@P.X/X7\7!CX@_L MM]R?COX@)Z_]&R?M&\\D_@!P!P.!D@'NZ@@<^OKD^@).`22!D^F=H)`%.HHH M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@` MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBDSSC\O?^O'' MMR.]`"T4W<..O/M[9&?0D=,^H!P2`5!S_GOW'H<=#@GG([4`+1110`4444`% M%%%`'DFI?\A&_P#^OVZ_]'R52J[J7_(1O_\`K]NO_1\E4J]Z'P1_PQ_)'D/= M^K_,****H04444`%%%%`!1110`5Z#X3_`.0=-_U^R?\`HBVKSZO0?"?_`"#I MO^OV3_T1;5RXS^"_\43HPW\3_MU_H=/1117DGH!1110`4444`%%%%`!7@_Q= M_P"2A?LM_P#9=O$'_K,G[1M>\5X/\7?^2A?LM_\`9=O$'_K,G[1M`'O%%%%` M!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`% M%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`44 M44`%%%%`!1136<+PFYCPH)!8@XS@X`'44SS%YQSC(R,8)!(*@Y MQN!5@PSE-I+[1@GS7XL_&?X3_`CP7J/Q%^,WQ#\(_#'P/I4UA:WGB;QIK=CH M.F"_U:_ATK1M+M9;Z:)M0UC7-6N;72M"T;3TNM4UO5+NTTW2[.[O;JW@D`/3 M"P'7/Y'\!Z9/0>I(`Y(IH<'H"><8&"1AMK9`/16R&/3Y3C/&?@7]H_\`;VT+ MX$?"7]H'XLZ3\#/CK\0=+_9YTO0]3\12W7@J;X2>'?%5KK-I->/+_P!G/2/AVWC+X+62_LQ>%]//BE M?7VJ@']*QD4`DY`!P3@D#KR6&5`X)))`7^/:>*7>,$CG!(P,$EAQM'.,Y!!Y MP"#N(P+HO%W[4OQ_N-(UWXF:?XY\-Z)X,F^&?PLB\"^'-' M758[7X8:3X@\!?#C1?'>O>#=1_M*WE\177C#Q;KWB75)M"T;[!KFD69U6WU= M=4_8[^"'B$^)!XKM_BGXUMO%7Q2M/C)J.F^.?VAOV@_&FBZ=XWTZ/5H]+'A# M0O%/Q.U?1O`7@[2UUJ^6P^&?@:Q\.?#:!A87'_")M=:3IDUJ`?2E]JFFZ9"E MQJ5_9Z?!+/!:Q37UU!:12W5U(L5K;1R7$D<;SW,LB101!M\LCK&@+G%>7ZY^ MT%\!O#"WS>)/C7\)?#ZZ9XKMO`FI-K?Q'\':2NG>.+V&[N++P;?O?ZS;K9>* MKRWT^_GM/#UT8M7N8;*[DALW2WE*\-)^QA^R)/<>([R[_9>_9]U"Z\7?$Y/C M5XGGU/X/?#_4WU[XOQ#5Q!\4-4^W^'[@W?CZV'B#7OL_BR0G78CK>L-'?J^J M7S3^FVWP9^$EE]N^R?"WX/+,\A`/,]5_;0_8]T);^36_VK?V;='CTGXJ6? MP+U5]5^.?PPT]-*^-NH+J#V/P>U-KOQ3"-/^*5ZFDZHUI\/[SR?%ES_9U\L. MDN]K.L=6_P#VV_V/-*EUF#4_VHO@%I\WAWXL0?`C7X[WXL^!K9]%^-5T=36V M^%.JB;6T.G^/YVT76%B\*W?E:P[:5J"BTS:3!?I6VL+2S\\VEK:VIN;A[FX- MM`EN;B>0DO-.8MAFG?.9)9"SNV78\X%A4*]3G\6'.3GJS'H>A)R>X4*%`/F. M]_;6_9+TV76(+_\`:&^%%I-X>^+-O\"-,>X$,0=R[6RJD'[ MV#@@\@MG!+)RPV?,32[7`X89YP2,]ARW]XY!R%,8VD@8(!`!\SWW[8W[.]A_ M;(D\;ZI=GP[\7(/@5K:Z/\._B;KSZ=\4KA=2,?AJX31/!VH,(0=(U!)?$2!_ M"]O)`([C6HGF@$M;5/VQ?@GI::Z\D/QLU$>&OBK%\%]8C\._LL?M1^*YH?'T M@U1ECM8?"_P?4_!\!T6\6\^)NEQWWPSL7ETN*\\702:YHB:A]0&,$\X/? M)SD'`Z,"&QE5;YF8Y"X(V+CD_'OA#_A//`OC7P,?$?B?PA_PFGA3Q'X4_P"$ MM\$:C!I'C+PL/$>CWVC'Q'X1U2^L=6LM,\4:&+XZIH.H7FF:G:VNL6UK=W-A M=1H;=@#\=/@-_P`%$?BE\3OVT?%&HZQ87UA^P3\2OBSXG_9`_9W\1ZQ\+_%/ MA-[GX\?"?1)_$5O\5M.^)>NZ+IN@?$/X8?M)>(M+^.WPP\*:CX=UO7O#7AO7 M?@G\%K6QN[7Q=^T#-HEK^W28Q@=B1T(Z''<#CCY<`*5QM^7!K\B6_P""2]Y+ M\$/`?[-L_P#P43_;H_X49\,[;X3V?@?X>Z?X1_X)OZ!:>&8/@;KWA?Q-\*7T M'Q%X;_X)Z:/XUT/4?!>N^"_#&JZ/KVC>*+#Q%;ZAI%O>_P!KM>M-2:E_R$;_\`Z_;K_P!' MR52J[J7_`"$;_P#Z_;K_`-'R52KWH?!'_#'\D>0]WZO\PHHHJA!1110`4444 M`%%%%`!7H/A/_D'3?]?LG_HBVKSZO0?"?_(.F_Z_9/\`T1;5RXS^"_\`%$Z, M-_$_[=?Z'3T445Y)Z`4444`%>!_M,_M-?!K]D+X-^*OCQ\>?%3>$_A]X3_LR MUFFM-+U/Q!K^OZ_K^I6VB>%_!W@[PMH=K?Z]XK\8^*M=O;+1?#OAW1;&ZO\` M4;^[C"HEO%?'_]AGXO?#2P_9LO_P!JR[U&7P?K-M\+ M/#7Q+M&\2Z=\1OA#XWMX8!-\4?A=JFE6/COPKX,O?$W@C2O MB')H=SX&U;Q99Z?K]Q8:D`!/AW\._&'BCX->'?@QXAU*RT+X MF^,?B7IOAGP3X6OKJUEN_$C:=>65]<^^6O[?G[)%[^T!;?LQV?Q=M[OXMWD\ M&G6L%MX.^(4WPZN?$=U\,D^-5MX%@^.,?A-O@?/\2[CX/21_%2'X7Q?$5_B) M)\.I%\:)X8/AS.I#^;^\^`__``6H\7?\$Z/V5/V$O'WPF_:"\:_!3XIZG\3O M#W[7/Q&\&>/_`-D!/VV?`_["6FWL6D_!#]E>[@^+GQZ^!GPWU3XU_%GX=1S> M$?C3\2/[=\5V?@7PCJFS5+/XA>*D\2>#-4]FUC_@F7^U%XP^)6M_`S0?@I=? M#3X#>)O^"CNL_P#!1/P_\==<\=?"C6O"W@'X?ZO_`,$TKG]DK1?V;M?\!:-\ M3?$/Q7U'XS>%_B=/:V>LZIH^B:_\)Y_!MC>>)-,^*NKZJ+;P_<@'[V?LS_MQ M?LP?M@R^*X/V>_B/=^-9_!VF>%/$.J0ZK\/_`(F?#N34O!OCR37(O`?Q'\&) M\3?!W@YOB)\*?')OAOXQ?0M67PUXIU0V%QY?<_%PY^(/[ M+AP>/CMX@SP3_P`VR_M&(OBUKOCWXU^# M;KX8>,?%:Z#\*->7Q7XTV'P)+:>$8_"EA>+^S5^T%-_;]I=6_A2#QO)JK M+;26Q@O/&=WH0@O;AET?[5%9W5L`?3P.1G\NG([$$$@@CD>QYP<@+2`8_'D_ MY]N@]N@`P`M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%` M!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`% M%%%`!1110`44TNH.TG!P3T.,#J<],#N>@RH."RY0N`,D-[@#)'&3P,[B/[J[ MF/\`"#0`^D)`_GQR>_8<\X...<>M(;O-OHN@6$EQJNI MRAELK6;:<>+:?\8_C!\2]6T%_A+\$[S0/!.G_%3Q)X*^)7BO]HR;Q5\'/$*^ M#?#-OI0;QO\`!OX:)X(\3:_\0[+Q7J]_?:)X<;Q]J7P:L9AH%]XDM9]:T.?1 M3K@!].:AJ-AI-A>ZKJMY:Z9IFFVES?ZCJ.H7$-G8V%A9PO<7=]>W=P\<%I9V MMO')<7-S<21PV\"/+,Z*C$?+J_"A/$>N>)M$U;2YO#_AF_\:^*_#UE M8R:YK_AC3=,O-%N-7D\(?LOPW9\`>)_V@_B/XN_:+^*'@6S^(%C#XBUZ6X\` M?#6ZM?B1#?:9KNGG]GKP)J&F?![5['3/#6H7OA+PMK'Q!\._$'Q_I?AR]O[6 MY\>:E<:GJ5W=_4%G86UA:VMA8VUO8V-E!#:VEE91QV]I:6MO$L-O:6T$4:1P MVMO"J100Q+''%%#%%&B19C`!\L7/PL_:$^*]GK*?%;XPV_PF\+^+_AGX5T2; MX9?LY+>VOB_X<^/?MGA_6/'FI:3^U%XAM]/\1>-+&XN-,U3PEX:C-I4'BV/2M7T;TKP%^SQ\&OAGXO\3?$;P?\`#_P_9_$[QOH/@[PU MXY^*VHV[:_\`%;QWHW@#1K#0O"-AXU^).O-J7C/Q/!HUCIL#P)K>M7ZOJ4M[ MK4@;5]0O[VZ]H4%0)-"\"V&KZ'K.F7\4-[IVIZ M7=6M[8W,,<]M-'/'',GVY10`U00,$Y]\`'GDYP`"2F>2ZBD+8&<'O^ M@)Y)(`Z8R3C.,XH`6BF[O8_7MU'XX/7(&,`Y.1BD\Q1CH,G[Q!&,C@ MX/.<;:EJ=U!8:?:0*0IFN;VZ>*V@BRP`>655;.5)'-`&C17AO@']I[]FSXK M>.-8^&/PO_:#^"'Q(^)7A[16\2Z_\//`?Q8\!>+_`!SHGAM+ZRTQ_$6K>$_# M^OZAKVG:$NHZEIU@VKW=A#8"]O[.S-Q]IN88G^>3_P`%#?AKK.L'0?AI\!_V MV_BQJ":A_9DUUH'[&?Q^^'WA6.Y%Y]B9X?B)\?O!GP;^'&I622?.VHZ1XNU" MP\G.X]\1R31Q(\LK"..-7>1W^541`Q9V)Z M*`I(/<F:!^SI^S=\.OBS97NAI?W_COXL?M%R?`_ MP5I&K/>ZC:G0Y8/#'P<^.?CO4IK6VM[34I;JT\%Q:=.FHP6MM?FX@O/(X+XI M_";]J/\`:,_8W^-7P2\=>,?@W\!?C7\9O!?CCX<)XM^&5EXY^,W@OP)X1\:Z M>_A^^N-.?Q#/\#/$NN^+1X9O=;M],U_[/X:LM#UR;2=;_L368-)N-(U8`V/A MC_P4!_9$^,?COP[\._AW\7H-;UWQO-K%O\-=6N_!?Q$\.?#WXPS>'["]U?6( MO@=\6?%'A'1OA9\<)+#1=,U/7ID^$GC+QFW_``C^EZIKR!M(TO4+VV^QP<]B M/8]N/R/X$C/>OP3^$'P)_P""@'CW1/@=\"?VB?!_B/3]/^&'QO\`V:OBQXO^ M+6NZ]^R/9?`KP%I'[*_C+3_B#IOA/]B?PI\`/#FA?'G7K;XRZKX:T/P#XCN? MVE?#WP_/ACX2:IXA;1HCK$-[X<\7_O8O?OR?K]">^.GTX))&2`+1110`4444 M`%%%%`'DFI?\A&__`.OVZ_\`1\E4JNZE_P`A&_\`^OVZ_P#1\E4J]Z'P1_PQ M_)'D/=^K_,****H04444`%%%%`!1110`5Z#X3_Y!TW_7[)_Z(MJ\^KT'PG_R M#IO^OV3_`-$6U2>@%%%%`!3&#$@C'W6') M.,G&/EZ'D`[CRH!"CYV(?10!%Y8Z8&.?EP`N>3TQ@#)!VG(W`-]X$L>63PY# M#G`(SD<8+=%8DY8_(`,J%&4W-+10!$8_0\YZ\Y'7:`0H]ZKP?XN_\`)0OV6_\` MLNWB#_UF3]HV@#WBBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`** M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH MH`**0L!U_P`GL!GJ3SP/QQD9,].#S[8_0\^O;L?;(`M-+`$`]^?R('YY8#'4 MDC`-)O7&@2ZYXA\.?"[P&U^GB'QSXE`DTW2;?2=`L; MB=M^/S'S`%AE0>"02`3>O'J1G;_`!8R M`?EZ\9YXR.AYXK\,_P#@GK^W%^W%\8KZ^^!W[0OP*DTGXYZGX1U_]HFQ\7?$ M'P]K7[/6A>$/A-\1;76S\.O`]Q\(?&/AS1_B[XSU3X6?'/1_%GP$\0ZQ!X0T M"ZN_A9X;^'?QL\8ZAI'B[XJZ+X3U?]&[;X"_%+XB6VD77[1'QXU[7K?4/A;X MB\`?$7X._!#2K?X/?`CQ1JGB?4=;-WXPM+R:3Q7^TEI_B#3_``OJ.E^%;*XT M_P#:&TOP[)+HL_BJS\'Z-J.N/9Z:`=;\1_VGO@]\/-:\6>"?[?D^('QA\'^` M8/B9?_`#X46R?$7X]7?@VZUS3/#>F:]8?"SP_/<^)%TC4=>UBPL++7-3M-.\ M/AOME_=:O:Z7HVL7UAQNLVW[57QAM/&6BZ1J&D?LG^#]2TOX=77P_P#B/I=Q MX?\`BK^T*AU#3K36OB-8>)/AMXP\#ZK\$_AWKFD2W1\'Z#=OXE^/^F2W^GZK MK]YI;VD^G6!^@_`WPZ\$?#/PYHWA'P!X5T+PEX?/%8P$K"]Y-=2J3([-)--+*>U4;1@=,GCT]A[#L.@'`P```#QG MP=\`?A?X&\5>-/'>CZ#J&I>-/'WBY?''B'Q+XR\7>,/'^JQ>(8--U;1['_A% MKCQUK?B0?#_0M,T?7=;TG1/"7@&/PUX2\.Z7K.K6&A:'8VVHWL<_L(C*C"GM MC@!5`Q@!5"D`*`$4?PIW9MQ::B@!%&!CW/3H!V`';`P.,=,XYI::6`./4$_@ M"!W_`-X?U[4;AC/;UZ9Z]"2!SCKTP0>G-`#J:S8XP2<$@#&20"0.2`"<'!)" M\?,PXSQGC[XD?#WX4^%=4\=?%'QUX/\`AMX)T2/S=:\8>/\`Q-HG@[PMH\05 MF\W5/$/B*^T[1].BPK'S;R]AC(&0Q!4GPSQ;^TW;7_PC\#?%[]FOX8>+_P!L M;1OB;)OA1;:!?Z6\6H3'Q=J_COXF_$7P!X0T[P+'-I3VMWJVG:G MKVKW$LL$.B^&M>N94M&`/H7Q=XP\*>`/"OB3QSXY\2:'X.\%^#M$U3Q-XL\6 M^)]5L="\-^&?#NAV,^IZSKVO:YJ<]MIFD:/I>G6T]]J&I7]S;V=G:PR3W$T< M:,P^>/@G^VO^S5^T)XJN/`OPP\?:G=>-$\.3^,].\*>-OAS\4?A)XA\5>"+6 M]L=-N_'7@+1_BWX+\#W_`,1/`MGJ&JZ/97GC7P+!XA\+6EQK6AQW.K1'6M+^ MU_,?QN^%W[;'[7'[+'QQ^'GQ`\"?L_?`7QIJY^%?B_X&^%M#^+WB?XS6^H>* MOA7\1_#OQ;3PS\=_$>I_!?P1X8TKPSXWU/P9H7@OQ-I7A'P?\3=+L?#6N>*+ MJ2[\76_V/2KWY7^#G[''[2GQF_:N_9H^._[1T/[7V@0?LPZGXV\?ZMKW[1G[ M2?P1O9/'_CSQ)X$U#P%H_@/X4?!3]A^]\-?!G3_A!;76O2^./%?C/XF:!X8^ M(GB"?P)X)\'7_@34M$\7^/)H0#]8?C+^U_\`LK?L\74&G?'/]HKX+?"?6;T1 M_P!F>'/'?Q)\(^'?%>M2S1^=;VGA_P`):CJT/B;Q!?W,69+73M$TJ_O[I1FW MMI-R!JGC#]I>RT_X5>"OBU\)O@_\;/VD=-^(5Q:1^%?#/P>\,^%])\5W=C>6 M6HWT&N:I'\%M"*Z<]N=1\5^(M%!N;S3UABECN#(GL&F_#?X=Z3X MP\0?$32/`7@S2_'_`(M2QC\6>.-/\,:+9>,/$\>FZ?9:7ID?B+Q)!8)K6LKI MVDZ=IVF6$>IWMP+#3K*SL+416MM!&G9F-CC#8[''`.64LV&WC("@("#M&5!` M8%0#YN^$'Q*_:"^(L?BFZ^(O[-DO[/ME:Z="W@F#QG\6_`WC_P`5:SK$S7RS M6_BK0?A2/$WA7PW8V!@L))9]'^)7BB2]^U7EMY%O]DBGNO*/"WPV_P""ANN^ M)M`UGXG_`+47[-W@_P`(Z=X@TO4M9^'GP-_9<\6S:[KFBVE];W>I>&[[XN?% MSX_>,[+[/K=LD^GSZGHGP8\-ZG913FZLITN1";?[G$;!^23^?T`Z#@=\``DXR0#Y*^,7[('AKXY^,F\3^-_C5^ MU5I.@G3['3U^&OPD_:6^*_[/W@=!9I(LMU)/\!->^&OCR]N]0:5FU!]0\<75 MO.%BA^RBTACMAU7_``R5^SE=_"/PQ\"?%/PA\'?%'X4>#];'B30/"7QPL[CX M]06OB-=1U75H_$]SJ?QGN?'>N:MXGM[[6]5DM/$.KZI>ZQ:+?W$<%ZELPM:^ MC**`..\'?#[P-\/-(3P_\/\`P9X3\":#'M*:)X,\.:1X8TE&11&K)IVB6=C: M(?*`C)$6X(J*C+L#'K2AZ#!Z@ALX(8\@@'!]3Q\V"#]XL)**`&*FWOD\#>0- MS8'\9`&3G.,8`S@#CD*DG.>Q!/0_H`>>,D.,;$`ZM3Z*`&%20!GD9YRW!;/( M&23C.`-V`"<=`*[]7^8444 M50@HHHH`****`"BBB@`KT'PG_P`@Z;_K]D_]$6U>?5Z#X3_Y!TW_`%^R?^B+ M:N7&?P7_`(HG1AOXG_;K_0Z>BBBO)/0"BBB@`II8+@'//H"?3D@9('/+$;1W M(R,NKY"_;E_;'^''["'[._BC]HCXFZ/XI\3Z7HVL>$O"/AGP;X+L[.Y\3>./ MB'\0/$5CX1\!^$-+NM7NM-\.Z+)K?B35+&UN-?\`$VKZ7H&C61N;Z^NMT4%O M<`'UX#G/L<<]?7D=L@@X.#@C(%+7Y!Z]_P`%H/V7_AI^SO\`LO?&SXZ^#OC7 M\%O'?[6?Q'\+_"GX9_LR^,?!,%K\=;_Q9KWCW0OA]JOB.PTB_P!8TKPUK?P5 M\.77B+1?%4GQQTSQ&WP\\0^#==\*W'AG4M6\9>-/"O@S6/I9?VZ_#MY^TI\9 M/V=]`^!/QQ\1Z1^SE)X1@_:#_:+L]0_9XT?X"?!VY\9_"NU^,NEVOBF3QA\? M_#/QGU2>U\!ZEHNJZRO@CX,^+4TF/7='N;MTTV\&H(`?#_%W_`)*%^RW_ M`-EV\0?^LR?M&U\\?L:_\%&/@]^VMK&J>'_!7@+XQ_"[6_\`A3_PG_:/\"Z5 M\:-"\$:#??%S]FOXZ7?BZQ^$OQ\^'=OX+^(7C]V\!^,;SP/XAMTTSQH/!GQ% M\.RPV`\8>!?#HUG2#>_0OQ<8'X@_LMXS@?'?Q",@$CY?V9?VC5;)7(4*WRDM M@!B!G++D`]ZHI`1G&\,^*_#'C3PYH7C'P=XAT3Q9X1\4:5IVN^&?%/AK5+'7O#OB/0M8M8; MW2-6WFBE<`WZ*H7^JZ;I5C= MZGJE]::9IUA`]S?7VH7,-G:6=O$I>6:YN;B2."&*,*V^22140JP9AM;'SAXP M_;,_9H\&W7Q+TF3XI:?XW\5?!N/PC+\4?AW\%M"\6?M`_%GP1_PGKPCP9%KW MP@^!F@_$3XHVMUXEBN;:]TBT'A%[J\TRXAU:*$Z8_P!KH`^G&<+U]LGT!S@M MZ#@\GCWX.$,B@9/'Y$YSMVX4G+!L)A*^6O$OQV^+-W)\1-+^$_P"R MQ\3O%^M>"=1\'Z=H&J_$3Q'X#^#?P]^(:^*+6:\U35/"VOZEK?BOQ[;:=X'M M5MU\3RZ[\)]+N9;N^33O#-MXCO;;5+?3WZ[H7[8?BJX\?Z=I/CWX"_!K1U\6 M>%O^%9:_IG@CQC\:?%-SX$M8=1?QE%XQTO6O$?PH\-:'XMUJX?1HO#<^EIXL MT;P]9V^JRZC:^(KC4K%=%`/J/>H_B')('._"S2/$/B;1_!>@ZK\1O&OAKP1IVM^,/$,DL.@>%=)O M?$VJ:9;:EXDUR6&2/1]"LI)]5U-T=;*TF,<@3R76OV8(O&5WXN_X6-\>_P!I M?QIH7B+XB>'_`(A^'O"^E?%B7X'6/PW7PTFLII_@#PIX@_9BT3X'>/O$/PUN M3K`?7?#/Q8\8?$F3Q-)I.D/XEU#5S;2^?Z)X(^`GP5^&FL>,?$7P^^$GPT\% M^(OB'XVO?B3X]\0>&O!/A[1]>\;?$'4!?QW7C3Q9K=CI\&I:_P")9+;5-1LX MM9U.XN=0L["\GTVUN(]/&8?!K_"/0/`/Q#\92C6["S.K:W\1M#\&V*:/XCNK#Q3=W-] MX0M?J?R^!TR&)#?W=QP2.H+[P).2""K,#(H(&#_4_3D]3^`H`^6=&_9HU M6_N/!VK_`!@_:!^.WQ<\1>!?B#XB^('AZ>V\:2?!'PL/[7CTB'2?!'B?P#^S M[;_#'PQ\4_A_X4&D"\T7P]\9[;XD-<:KJNM7FN7>KV\VE6&C>8_%S_@G;\"_ M'WP.\%?`#X57&L?LA^"/`7QF\%?'G0D_9;\)?`_PO'/\0O`/B:'QOH-[X@\* M?$OX/?%?X:>*+:3QYI_A_P`>ZJ/$?@35+[4O&?A/POKUS?R7FDH\GWK32X7K M[>F>=V`!G<2=IP`"2>F<'`!^?O@?]A#Q'H'[0?PL_:.^(O[;_P"UM\?O%GP? M\-_$SPEX3\.?$W0?V+/"?A.X\/?%FPT&W\7Z-XAE_9Y_8Z^!GC77=&NM4\)> M#/%46AW?C/\`L4>+/!GAC6KC3[E],6"3]`E7;D>I)Z8Z]>W4G).2222<@$*$ M+J`3G@+NSD8V_P!XDD`#&3DD`X.,XH+@)/A%^RIX&U?XX>)_!^OVLDD5UH7Q.\3>&@OPJ^">I6\D;Q M2Q_&_P"(OPW@6;RX//\`/FACD`/N9FV]B>0./?W.`/Q([`)-8TOP]X?T:TGO\`5]=US4+/2='TJPM59[F^U+4[^:WLK&S@12\UU=31 M0Q)\SNH!(^;?C;X;_:^\<>(M&T/X%_$SX.?`KX=3>'X9_%?C_P`4?#W7/C#\ M9U\03WM]'=Z%X&\(2^)O!_PM\*QV.F+IEW;>-_%6H?%.WNM3GU#3+CX9FQLK M75M1W-`_9I\'7/PJL/A5\=M7U/\`:[L[;Q-'XSOO$?[3?AKX6^-]3U7Q5:ZM M_;>DZP?#?A_X=^$/AKH3^&]0$;^%+;PGX%T"V\-I;P-I:0W">>0#(^#?[8W[ M/?[1WB;Q!X;_`&?O'C?&&#PUI-QJ=_\`$#P)X7\::[\#KB>WO[73AHFB?'^R M\/2?!7Q3XF,]WY[^%O"GCK7?$,&GVUWJ=WIUM8V;3OY1X=\/_P#!1'XI^*]" M\0?$+QS\`_V4?AIIGB#2]6OOA=\'M(U3]HOXN^,M&T^_BO'T+Q)\P\0Z-X3^`?C?5;5+R=O#/Q5M9H;?4)/N^"S@M+>"SM+>WM+.U MABM[:UM8UMX(+>!%C@MX(80D<,,,,:0I%&`@C5455C7RVLH"HP>>2>^.23QG MH/1>=HPH)`!H`^?'7P5\`_$#XNVMO86VA^./B'HZ_$# M4_!<.G64%A%'\.K?QG)KFF?#474$"MJS_#^Q\,S:W=M+?ZS)?ZA7 MR#GD`#G/IC.[[Y/0_,Q'R@X#_.)**`(O+(`P0,9P`-HSD$'`].K!2H<]<*<` M$?`'`4$\8SQU4]0NX'!!96"XP.?F,M%`#5!4:!XQTSP#\2]&\)^(KOPK?1VC7FG_<-,=2Q7!Q@@\Y/3IC!7GKR25QPRMD M8`/YN/A?_P`$?OVB]-_X):?`_P#93\6>,?AK=_'GX??M+_![XN^&V\:^,/&' MC?1?V?OV>_!'[57PT^.0_94\!_&._P#"7B#Q]XKT7P)X#^'.C>&]!\_1]&\+ MZWXLTK2K!AIGA?2-)UF#M/CM_P`$A/B/\:?VRM;^+^E^#_V3?@_HWB7]J`?' MGQ1^V;\-?$/QF/[$?&OA[QAX7D\">);_5M.C\ M07?@W]HCP/\`"*_\%Z%97"_LQP>.YK[Q%>?T**,9Z99LG'?@#/0'H!P2V/N@ ME0,.H`_&+_@FK_P3Z^/_`.S'X^T/X@_M$Z[\')M3^$7[`7[)W_!.+X4V/P5\ M3>-?%-CXS^&7[+6L_$S6D^-/Q#;QU\//`=QX.\<_$";QUI<#?#'P[)XV\/>$ M(M$O6/Q$\7OJMJ='^_?BOX)\'VWQK_9F\=6_A7PW!XWO_C!KV@7OC.'0M+3Q M9>:$G[-?[0-PFBW?B,VC:Q<:2);&UF%@][]F$]I;R^5OCC>/Z@KP?XN_\E"_ M9;_[+MX@_P#69/VC:`/=E!`.<9))X!'TZEN0,#KT`````IU%%`!1110`4444 M`%%%%`!1110`4444`%%%%`!112%L>_3@=>3@=2.]`"T4W>,D<@YZ$8[[0>>@ M9LA"<;\97(YKF/&'CCP9\//#>J>,OB!XM\->!?"&AVIOM;\5>,M=TOPOX;T: MS#*INM7US7+JQTS3+?.]G^R5\*/CO^VMJ!WQVOB#X M%>!X]'^!F*/B19^!/"WQ,U;PS\"_V0_P!K?]IN;PYX&\<>(/'?A?P;K_BS M4/V;_@A\5M(\(0^*M=^&/Q"L/#MGXGU#2=1UIO!^O3:;9W-O82RCSEOV2/VG M_$7^D>-_^"FO[3]A,Q)ET?X,_"?]C#X;^%'W$ET5?&/[-'Q?^(4(PS*C0?$J M$J#YCB2=(98?SC^)/[)'[7/P+_;(^)_Q,^'?C/\`X*K_`!\\$_$[]F7]F;P3 M9?%7X!_%3_@EN_C*V\"-:^' M+>!?`VHZ6NJ^+_B0NL:E!-9>&]/T\`_:#X`?M,_"/]IO1/&NN?">]\=D?#?Q MW)\,_'WA[XG?!OXR?`3Q[X.\<)X+\%?$:/0?$7PU^//@'X:_$'2I;SP'\1O` MWBW3;V[\,Q:;JN@^)]*U#3;V[@G++[UO!&><>O&#G&W!S@[LC&#@=&VGBOPF M_8S_`&>?^"F7A75?VNOBJWQ=U#X::A\:?VG='^(F@?#?]O3X+?LX_%3XE_$# MPUX9_90_9:^"Q\8>./$O_!/OX\^!_A;\.];U+6OA3K7A+18/"3>(+&U\+>#_ M``KXRUKP"GB#Q'K=A=_9S_M2?M1?!^15_:>_8P\4:CX:B`%Q\7OV*_$NH?M2 M^&;>$1@?;/$7P=N_!GPP_:;T^]NTCEE70_A=\)?C?%IS1K;W'B&Y:2VEN0#] M#0E>'KDV/BV M#1-8A77_``+JJ)(T^B?$/PI?_8O%7P]\16RPS27WA[QOHV@:[8K'(U[IUOL; M&5J'[7'[,VGZ]X=\)I\--;\*^$/!\FN>)?$EIH,GACQ!I]P-$TJ_FGUO2+[0+.*YUN+^SR`?1)8`@' MOP/<]<`=2<9/`.`"3@4W>N<9[$D]@%.#ST)!X;&=IP&QN7/RQI_[4/\`PE\' MAB]^&?[/O[2WC?2O&/@#QGXWT?6]:^%LWP-L;*?PL?$UKIG@SQ=HW[2&J_![ MQ]X/\7^.=8\.Q:;X2L=;\$16KVGB/PYXLUB[T?P1J$WB6U98>)_VQ?%R:#+8 M_"7X)_!W2M<^&/B&^U>]^(/Q4\3?$GQU\/\`XOO+K]MX2\/7/PO^'O@G0/`W MCKP%:Q0>'-8\2>(-)_:+\-ZS?G5=7T/2M,M/["L=>UP`^J]X_P#U\'MVZCJ# MR./XL&FO*B#_\=Z[<:NK?%3PO=^/+KXY?$[PCJ?AW2[W3 M+3PEH$'Q.U#3;+4=(_MC7)_$1O6L+: M5XHTWQ/\3T^&T-]IVEGQO8?"_P`+S:S\0=9\-RZIK&DZ7:ZGHWAO4+>\U/5- M.T^T::\O+>"3E;O]IR]U@:I'\+/V?/VA?B7/'\*=$^*/AR^D\#V?PD\-^*1X MCN-$_L;P/::[\=M=^&9T?QZ^G:T^M:UH'B#3--G\+6&BZU:>(_L7B&WLO#U_ M[]X3\"^#/`.BZ5X;\">$?"_@OP[H6C:9X;T30?">@Z7XE:/:6MA8:-H]O+);Z9I=M;QV&GQ2.+2WA5V1NHV<#.#M.5[]CR"=S*AP_"RQ^/WQK_ M`&DKFVU/X3Z5%X/L?%W[3:^,M#F\/_"+P+:6FE>#I-4^"O@/6O`'[2^H>+_% M/Q&^(G@WQ1HECX7TC3-8U?2?.?\`@GAKOP=\8?%/]I;]@+X%?\%#O!OQ+^"6 MA?"OP5\9_@+H_P"PI\0O@>OA'X0>%?'_`(_CO?CQX0\&^)/!=S\6_BG\*_\` MA#_C7;:K;>"/`VO?%75M"\&_L^?'#P%X(\%W6IZUX$NO$VB_T:.IS_#G+;"P MP065NC#:P(YP$93M`4G#;E4(6'H,X&!C:F1@+E</EVJOWU\R@#YKO?V/ M/V<]?F\73^//AM8_%W_A/=%\`Z!XQL?CAJ_B'XU^'M>L?AC_`&)-X+>7PA\4 MM5\6>#M/O-)U7P]I'BA[_1=!TVZU/QE;OXQU26Z\4W%SJTOT3I^E6.EVT-EI MUG9Z=9V\<$4%GI]M'9VD45M##;6\45M`$BCB@M[>"&"-5`@@ABMHSY$:I5]0 M0,'&>>G3VP.PQCCG;]W%``>H M(!!.>3CZ=LX`&>_"@#..2"S!89QS^';Z]^<'!Z9!&=V`3=P.&Y[8P>N!P2,9 MZ\XP`03@8RP'S=0GZ M=I=A=W^H321PV5O/+(B$`^@L_7\`3^>.GU.!2%L=B>^`,G'&2!U.,C(&2>@! M/%?,OQF_:3F^&%IX+D\$?`3]H/\`:1U'Q]IEUK'A[3/@)X1\*ZC9)86Z:7+: MS>(?'7Q+\=_"[X8>$1K$6KP3:/'XI\=:5-J%O;W]Q!`T-A=/&G@OQI^TI\4/ MA7XWU6[^#VB?LO\`Q0DN+RQ^&>B_%SQ#X?\`C?:);_8K":R\1_$+1O@MXWTK M1A')>3W]C<>%/"WQ6O9V6Q6\7Q3"MQ"E`'TWN!QCG()!XP0,=.>^*V@?!KP%K/QH\=6_PX^#OA36M4\. M^+O'7B+QQ\3_`!A+OET_PCX$^'?P_P#&WBJYTS3A#JGB_6-*T;P-8:KX>NO$ M\'B+2M#X6_`?]IC2O'FD_$+XX?MJ>*_B2-*&I&3X/?#/X+_"7X+_``"U2?4M M*O--%SJ6EZQIOQ@^/LTFD27BZEH4(_:.^P6M];6C:K9ZXMNH/"?&7_@F!^Q/ M\<]1\5^+?&OP5T(_%OQ/XDL?&=G\?K.2>Y^/'@3Q=I'B&S\5:+K7PV^)?B$Z M_K/@FTTO7K"SN!X,T?ROAUJVE02>%/$?@[6O"%_J.A7(!XE#^W)^T'\%/B;X M6^"OQH^$$7[7/B?XQ_"75?C?^SKXV_8#\$W%CH/Q$\*^%M<\(:!X\TSQ=H'Q MH^,M_P""?AA9^'+CXE?"V^\-_$K6_P!H>]\"^.]-\;&$)X4OM+L['6_LKPAK M_P"U!\7/A'XVGUWX>^&_V0/B=J>HS:?\.?\`A)/$6B?M(ZCHFB?9M,=?%'CG MPUX*O_!'@^U\3M-)K&FP>%/#OQ/\9Z+9-:Z?K5QXKU:&:?P_5/X'?LFZ'\'? M&WB3XK^)/BO\8?V@_C-XF\+:7X!G^*WQRU7P+<:]HGP\TC4)=9M/`O@_PM\) MOA[\)/A7X*\/SZY/_;/B"3PI\/-'UWQKJ%GHT_C;6O$)\.>&AHOU8BE1@MN. M2``2S98D*NXDDC) M.7444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`! M1110`4444`>2:E_R$;__`*_;K_T?)5*KNI?\A&__`.OVZ_\`1\E4J]Z'P1_P MQ_)'D/=^K_,****H04444`%%%%`!1110`5Z#X3_Y!TW_`%^R?^B+:O/J]!\) M_P#(.F_Z_9/_`$1;5RXS^"_\43HPW\3_`+=?Z'3T445Y)Z`4444`%%%)N`., M\\<=^O`P?7'0X`8< M@DC@CIFO"/BZ?^+@_LMG!Q_PO;Q!VQG'[,G[1N>O3ZG`/4<\T4BL&&0< MCL1@Y'4'C/!&"/4$&EH`****`"BBB@`HHI,]O\]^OH.#R>*`%HIF\?J%ZK]X MG`!()&>^/<`1C;\Q`&&SM8Y(&%+;F^5=Q!``)**YWQ)XO\` M"G@W3X-7\7^)=`\*Z3=:SH'ARVU7Q)K.FZ%IL_B+Q7KFG^&/"^@0WVJW-I;3 M:UXD\2:KIGA[0=+BD>]U?7-0L=(L(+C4;RUMIM_>!Z_P_DW?&U.PT31=)M)M0U M35]8O+;3-,TRPMHVEN;[4+Z]EAMK&TMH5::XN;J6*&"(%Y70*VWX)U'_`(** M?"CQK>7?A[]DGP7\2_VW?%EO;O\`9YT*UN_@AI=_!*]O<+XG_:J\:WOA M?]FW3H]-G20:YH6@_$;Q5\1+6&&"[^)OB2RGNO!GP0^'V@>(_BM\>?' M42,8O-\'?!7X;:5XG^)>NZ:;DQ07GB&V\--X8TC='<:WK&E6>Z[7X*\4?$7Q MS\2;J*+]JW]OKX'_`+*_A/4OB19_"";]G;]B[XDZ5J?Q/N?B;JJW$MI\)/B! M^U3XNTZ#XFOXLELK>\N;C0/@9\(/V=O'7AP:=?W">/=2T=)93[Q\#]0_96_9 M_LM:T;]EK]E7XU7&H:M\:D^$_P`4/$FA_L]?$WPUXS\0^,K/^*(/@M\+KJZA\I](U M?Q[\8_BQJNGFX>'Q3\%K&[LIK";KO!'_``3S^`&E^)-(^(WQI?QI^U[\8](N M)+W2OBI^U9KEG\5;WPWJ;;EFU#X9_#9='T7X$_!.[9)+B-C\%?A5\/I[F":> M/4IK]FFFKTJ'XF?M.>(I;0^&OV7]$\)V=O\`%]O"/B0_''X\^'/"FJ3?"&Q> MT%Y\7/`UC\%O!_[1NF^)-4UB#[=_PB_PT\;Z[\--2G9+$^)?$?A47TBV#+'P M3^USX@DT.X\6_''X3>"(-(^+MQX@U'2/A7\&M4U2?Q1\&K+^SCI/PVU;Q+\2 MO'VOQV/B?4KBVU%_$_C[0?"6FN-/O[33/#FBZ-J&F2^(]5`/J)0B*``L07&`.YMJE2JXNL>+?"WAJ;1K3Q'XET#0+KQ%J<6B^'[?6 MM8T_2I]=UFX8"#2=&AO[F&74]2F+KY-A9"XN9`Z>7&P9:^?]&_9@MXY_#FH> M/?CW^T[\4]9\(_$[5_BCH6J:U\9-4^&,'VO4_P"PUL_!OB3PQ^S=IWP,\!_$ M#X9^'_[!B?2/A_\`$7PGXMT"(+?78]6N`=KP1^RC^S1\.H]"7P?\#? MACIESX7\7>(?'OAW5I_"&E:OXAT/QUXO728_$WC'3/$6MP:CXBLO$VOQ:!H, M&KZ[%J2:G?VVB:+#/=O:Z381VX!@^'/VU?V9O',GP];X8_$D_&;2_BAXM\4> M!_"?BKX$>#/B!\=O`2^(?!8TIO$\?BSXA_!_PKXV\#?#S2=*76]*:3Q+\0O$ M/A?PU<"\06>KW)241_GI^U_\8O&_[:,_P+_8)\&?`_XX?#W2_P!JBX\4>,_V MHI_'&K>%/A9XU\`_L5_"3Q/X7T[QY%J,.@>-/$'BOPP_[2_BCQ#X=^"^@1QV MUAXQF\`ZU\5M=TG3[36/"BBW_:KY-O'GCOPS\,?AEX"\.:YJ'@CQ#XBO?&?BGP3\6]>UBY;XK>"_#GP M^M-!AO)-$\8ZKXY@M-+`.W_8/\>_MO\`BSP=H/P&^,'C#X'^%?C%^Q]KL_P3 M_:K35=%^('QG\9?%/2U\`>&=?^`7Q<^'GC_^WO@9I=HOQ,\':[9:]XT\9ZU\ M,-KZ=X8^S?#WP`^)=Q%\/+OXG_`+57QC\;:KX0 ML_&UIXJL/"&F?#;X1^"/B9)XO@O]/M9?$>C^$/!DOC?2?^$)TZ\6+P!/A+^Q5^S'I_P M?^-DOP/_`&C?&W[%GA;P#!\!_B-XS\,:/X+USP!XL\,^(?A1X7T^]\5:=K7A M'XT^#Y+3P[K4&K^(/AKXS\2^*_AIW4D:WH MO@#]I&?XX_&;Q-^T]X7M/$%UK5WJD,OQ]\=>./%?Q'\;:5=MX@U?3[SPE\3- M;\;>"-2\,7]UX'U;PS?^")G\.GG_``[>_M4_L(^'M.\*>)?A[:_M=?LO>&HC M;Z9XW_9T^&7AOP!^TO\`"W0_.:62Y\=?LS^`[31OAQ\<+!9[FZU#6/$7[-FE M>!?&[R/Y6A?LS>*IVO-3C]E\6?MJZEH7BCQ'X4\+_L9_MN_$VZ\-ZUJNA2:Q MX5^$7@_POX6UFXTJ\GLFO?#?B?XR?$_X6:-K>C7[0/<:7K-G=MIM[9M%=QW( MAFC9O3?C'\9/BWX!T_P/<_#G]DKXP_'?4/%=E>7>M:9X/\=_LY>#'^&T]O;Z M7-#IWC&Z^*OQK\#Q7^H7XU&_M;<_#W_A.;&&XT34/MFH6-K<:9>7X!V?P4^. MWP?_`&BO`UI\2?@A\0O#?Q'\&7=Y>:9)JOAZZ:2?2M;TR3R]9\,>*-'N(K;7 M/"7B_1+IVM/$7A#Q3IFC^)O#E_YFGZQHUA?QR0CUQ3M!!);!))4$\,O_L"_MQ:9I0M_!'B?PY\6 M/AQXATK]H%=$T)I?#OA/]J+PYX*L/&GPU^(W@&34EA\-Q7OBS0M:^)_@;0I; MB^^%OC;P)J-PTU><^%?^"@7[=/PE^,'PI^$'[?W[*7[,O[.G@KQR@\,_#[]H?XY?#_\` MX2O499-#^'7C7XEW]OYY&..O7Z`]B,X^ M\#@@C<"01D9&:^.?B>W[?ESXYUJW^#*_L>Z5\-%:R_X1W6/B=/\`&GQ#XXGC M;3K/[=)KGA[PE!X5T*S==774$L?L/B>_CGT[[)/++:W,)?B'XYMX]/L]2TZ70'N=5M=3T0`^DQ(I!.1@#)Y!Q] M2I(R>P[]N^%+X[-W['^%@I/ZY`ZL/N@GBOG'X/>`/VE_#5WXEN/CA^T1X(^* MT&JZL/`/P!3X.VWA74/M-U+-J<W@+P!_P`)98?#OPMIWA3X>:?I5]\0?B5\2OB) MJ&D^(Y/"'P^\(2^)O"&@W5WH'A'QOXKU'Q;XY\'Z-HO@_48[_4;[2>9^$/[7 M^GZP_P`8O"O[1_A31?V7?BA\`1X(U3XG:-XH^)7AWQ!\-'\%_%*+7&^&_P`3 M?`WQ:O++P7;:]X!\9:MX4\<>%K2Y\6^%?A_XLT_QCX%\6:-K'A#3K>WT?4-9 M\?\`VXO^":'@/]L?Q9X!^+MK\2?B'\,_C=\+[2YT+PIK)\>?&;Q%\&-7\$:Q M)+-XM^'_`(^_9^\,?&/X7^%]4\.>-KQ-"UKQ7K/@'6_AA\2->UGP+\/(M;\? MZKX:\(VGAN;<_9!_X)T?#+]F?PU\0K3Q>)]8\!>"_AW\,=:\0?$;4=#\/^&_%/CGQ_P"/3JOC;X@_$GQ]K'CW MQ_XMU[5?&L]I+H6CZ"`>_?";]LW]DWX^>,+_`,!?`K]H[X,_&KQ5I.E7^M:O MIWPD^(7AKXDP:1I^F7=A8W\FKZKX,U#6M'TN>WN]3L8&L;^_M[YWF/E6TBPW M!B\LUG]MK5[C6=7T'X8?L6?MQ_%Z]T;5-1TB:]L/@_X3^"GAZXNM,O9+*:\T M[7_VL?B;^SOI>LZ.]Q`TUEJVC7-_9:MI^V_T>74+6XM7G^W[2RM[&WM[2S@@ MM+6UC2&"VM8EAMH8HUV)'#`@"11A?NJ@&P\;G7BI?*&.BYP1D!<\@+_=Z,%4 ME>@V*GS(*`/FCXVZK^V#_:/A_3?V;/`?[.5YHFH:7--XH\9_'CXH?$G1M5\+ M:L)XUM]-T?X6_#SX3>);'QO9R6IDEOM0O?C'X$FM;R+[!;V%]!---M M-1L[:\^+/[0GCBZ\&R)JUFUE?3WWP2\`S^`/@#J-X8F9["[O/A7-/H<[_:]` M?2[N)+BO5/!?[/?P&^&WBGQ7XY^'/P2^$/@#QOXZUO6_$WC;QEX*^&O@WPKX MJ\8^)?$MY/J/B+Q#XL\0:#HVGZOXBUO7M1NKF_UG5M5O;K4=4O)Y[F^NIYYY M9&]AHH`AV-@]#U."<#.[=M)"]')^=MN2H`*N26,@7&,\GN??U`]?QR/4G)+J M*``9[\^]%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%` M!1110`4444`%%%%`!1110`4444`%%%%`'DFI?\A&_P#^OVZ_]'R52J[J7_(1 MO_\`K]NO_1\E4J]Z'P1_PQ_)'D/=^K_,****H04444`%%%%`!1110`5Z#X3_ M`.0=-_U^R?\`HBVKSZO0?"?_`"#IO^OV3_T1;5RXS^"_\43HPW\3_MU_H=/1 M117DGH!1110`5^>7_!4[]H[X_?LG?L2?%KXZ?LU?#2;XF_$[PK+X.L5@B\(^ M)OB*G@'PEXF\8Z)X;\:_&"]^&O@Q1XJ^(6E_";PWJNH>.-7\-:-<6)_LG1[[ M6=7U"S\-Z3K:/\3O@EXO MNO"'C;PYJ^D7L5_9>-O#-_J>AZYI,BW M$%U:`'X07?\`P6._:D\,_P#!/S]A3X_^#_`GP)_:J\4_M#?%OX3>!?BY^TW\ M)=1\06W[,7PR^'OC'X__``T^$7VWQEX-UW4?!WQ$\/?M2>*K+XD:/H<_[/\` MIKZCI'PY\"_AGJ M'[(O@7]OSQ+_`,$Y+_PC8^&O%)_:/OOB;X8_8:N_VP;KXTV?Q!N?B5#\,1X% MGUBQ;X:P_#&Y^&8\0I8./&TOQ(CF1O!R?4G@7_@D-^SSX/\`V,/#/[&%SXS^ M*NIZ!9?'_P`'?M4^._B?::IX5TCX@_$OX^>&?C7X?^/VI^*]7MSX1U'P;X>T M#Q5X[\-Z=I^H^$?"7AC1K+3?!T::1H=WINKQGQ#)U^M_\$K/V^*>J^'?$?QBU?]H_7/V:[S6?!./ MB%\0+GQKX]\`/X%TZ?\`X65X8B\$Z#XS@UG467X;^$IM'M$U'\!?V[/^"[O_ M``4%^$/QF\0W6CWO_!.'0/!GP7_;5_:H\$?#'0?B!X4^,4_B_2/`7PC^)OQT M_8\\#^,/C9K^G?M,^&;"75_B-%O!G@^QU5M#^#WC/QE%`@M?"/ M@SQ[_4U^QO\`\$YOA!^Q7K.J>(?!?CWXP_%#6_\`A3WPG_9O\"ZK\9M;\#ZW M?_"/]FOX&77B^_\`A/\``3X>S^"/A[\/\^!/!]]XXU^YBU/QLOC/XBZ_)+8' MQ?X[\1)H^D1V/X'?M"?\$!?VK;3XV?M`'X&?\%9]?^!OPE_X*1?M<_'3XA>/ M/A=I_P"Q]X0\6:AX.O/BS\,?VFO&_B#3+3XFZA\;-,\8ZEI7_",^)_B+X`;3 M_#TO@*PN+7Q[J?B*2S75;?9>`'Z<_LQ?\%YO^"=7Q)_9B^`GQ1^-?[9?[,/@ M'XP^-/@U\&_%/QG^'FC>-BL7PZ^+'COP#HNO^,_`ZZ3=W^NZYIL'AWQ7<:]H ML-MJM_?W>GQZ;]CU+4;B[@EGE]MU3_@MI_P2HTA=:-W^VW\'I#X>UNS\/:JF MG3^(]8EAU2^-YY$=O%I&@7TFHVP&GW;7.HZ:MWIUD(T^VW5NT]NLON7[!W[& MVG_L9?LT?`GX(:[X@\&?%GXB?!?X2:%\%;GXZZ1\)-&^%>O^,_`OA`Q:;X.T MB_TBTU[QEJEM:Z-X3TKPOH=W%?\`C77FUG4/#T7B.]E%]=^3:TH/^";/[%ND M:M!KG@7X+0_!K4[?4XM8BF_9Y\?_`!2_9Q@^WQ7(O0[6/P'\;?#JQ:WEN@&N MK(P?8[V(-;WL-Q:RRP.`>#:M_P`%R?\`@E+HG]O_`&S]L;P/,?#7B6Q\)ZHN MD^$_BCK[G5]1BU":"32H]!\":E)X@T..+3+AK_Q3H"ZGX8TOS=.74]8M'U;2 MUO.?UC_@OG_P2%T+_A*OM_[;7@!SX-\9Z?X"UE=,\(?%C7'GU[4UU9K:[\-I MHGP_U!_&GA%!HM[]O^(7@U=>\`Z49=+75?$UDVNZ(-0^X_C3^S[X\^)_B+3O M%'@']K7]HW]G/4--T>'23I?PDB^`WB'PAJ[07U]?#4==\)_'?X'?&73KC4KE M;XV-[?:.VA7DUC:6:Q7%O=P)>"6Q\!_M.>$O@GJOAC0_CQX+^)GQRBU-+KP[ M\4/C+\(;:S\,3:2VL6$]QHWB?P)\'/$OPV@FO1H<6IV%AXAT*_TB.TU:\LM9 MO/#VJVUA<:-J8!^?FM?\'"O_``1JT/\`X31+C]O'X2W4_@#XA:5\,_$-KI]I MXSN[F;Q%J[:JL&I>%(E\+K_PL'P'9G1KW^V?B?X`/B?X;Z$SZ7%K'BJRFU_0 M(]336/\`@X)_X)&:4/&OV?\`;0^#^NOX%^(^E_#/4H]'\9^%2=8U+4I=7AD\ M4>#)-4UW3(/&_P`.=*DT2^_M3XA>%IM5\*PPR:5=V^I75GK^@W&I?<_P,SHG[0?P]_93'P^_LN\G7XE?!KXQ_%T^,)-9@,"6.GR?!;QO\#ET>WTR_ M1YY+K5Q\?+NZT@VZ1PZ1K#70ELN'\2_MA_$WP1XCU[2/$W_!/_\`;3D\-Z1K M.JZ?I'Q'\$6?[,_Q3\+>*M'L]0GM[#Q)I.A>`/VF->^+=E9ZI9P0:DFG>(OA MGHVM!+N&*6S6ZCN4C`/D[7/^"_'_``3$TL^-H]*_:2^%?C&Z\%^/](\`Q6/A M7X\?LP3W?C5M6_M@'QEX!CUCX[Z*GB3P)I;Z0B:IKTH7&OP:A\5 M/!%WJ?[3FAV-[\.?#JZ-92ZVVOW7AWQO_P`5+H5OH_@C5[^'Q':>'_T%^,?[ M6GP1_9_C\(3?%S4_'WA6W\;:;<:MH]_!\%OC5XQT?3X;);![FW\6>(?`W@#Q M+H'@?4X6U.W`TOQEJ^AZA=*M\;:">+3[][2U\/?VMOV9?BK\//%WQ8\!?'3X M$?##^&_@]\6 M/&6E?%+P==?V]%J?Q+\(W7P1^&7QOU&TT*QN=,TJ.V\,^+M$\+^.M2'B"VCC M\.0ZAIVHZ8CM=_X*:?M5:Y_PFL'P*_X)L_'/XCW>F_$#2M,^'/\`PFOAS]IS M]GZ+QS\,IUU[^V/&OB:7]H/]D+X5:?\`#GQ?:^5X6&C^`I-2\7:7>C6=:_MO MQOX8?PU:1^(/TY\$?M'_`+.WQ*U*TT3X/]5O_`#ET_2/!/Q1\#^*M M1O$@@$LPLM.T'7K^[G2"W*27'DPR*D>)RL4;;QZA=^(O#]C-+:WVN:3:7,`1 MI[:XU&S@N(]X#1--$TL)^V=J5M^UQ_P45_;N\$ M_M)_!;_@FQ^RSXI\/_%RS\423?\`!2GX[?LU_##XP#PQ\7OV#_@3\$?@]X9B M^)'@GXP^,O&7]@?#7P/I7BGX_:;X?^%6K_$/P'X+^/\`\4O#_C'5=.NO&_@> M'2H_V:_X(J>`_P!NKXY?L-'P7\(_^"B'[+?P8^%GP<_:Z_:J\!ZA=_L;_LP> M!OB@R7>E?M#?%;Q9X@\*_"3X@?$;6+OX":;\$/%D/C_1/'7P@N?#7[/VOP6/ MPIU3XM=.U32;[]M?BQ^V?\0-*^*/COX7?L^?`WPK\7W^#]MX47XO M>//B9^T#X?\`V?\`P'I/BOQWX9C\=>%_A3X`UB]\%_$6^\=_%>Z^'MYHOCO4 M=,O]'\$>`=$\/>,?!YN/B(=1U74--TCV/]FG]L?X#_M0_"FV^*/P_P#&>@Z> MFG:+=ZC\1O`^N^)?"2^-O@SJ&AZIKWAOQ7X?^*.F:+X@UK3_``W=^%?%/A'Q M9X>O]4BU2^\+:C<>'-3U+P]KVL:(L6IR@'Q]KW_!'+]G?XKWK:M^U9\8OVN? MVS-9B\?Z!\1]$N/VA/V@-53PWX-UOP[+-=V=AX(^%/P3T/X+_!7PIHUQJ$L% M_?P:+\-;*\NY=,TRWDO?[-@_L^OKR;]B+]E&]M-0TWQ-\$/!?Q!TW5?BA8?& M;^R?BM#J'Q;T72_B;HL&H0^'?$GAC1_B?J'B_3?"$GA:WU&\@\'Z9X7L]+T3 MP?:^7:^&M-TJWM;&&WXGPS_P4K_84\?>)/#_`(3^%G[2OP]^->M>*-;TWP]H MR_`.36/CWI>R0+/J=EH$QJ M4?A7PSH'AF+6]5OM?UF+P_H^FZ,NL:[JDWVC4];U2/3K:V%]J]_<.9[_`%.[ M$M[I:O\8O"'@O0?[2U&'[3<2?"K6?`[^+=? MN=+CTG5!I.G>*]&TF&XN[K3!XC*6R7TT/P0^%_[3/A?7=9\2_M!?M/Z+\9)- M5T8:=:>!OAW\!_#?P1^&/A[4#=V]PVO:1;ZAXL^+?Q8GU)+:*;3+>/6_C#JN MD1VEU-?$?Q5\2KW1;3Q':? M#/X,_!/XR_'KQZ^C:E=WUAI^J7OASX,^!/'%WH.E7M_IFH6T>M>(_P"QM#A: MTN9[O4K:TMY[B/SW0_\`@FW^QMI_B#2_%_BSX1M\/3H@B)]Q M^7[_`,6[KU//4C;G=QN'3&4YC.V@#YIG^+7QJ\=_!*S^(OP4_9_ET_XB:QJ3 M6FE?"S]JKQG<_`*>QT=-7N=.E\1>)]4^'W@G]HC5]$2>S@BUW2O#\GA>36KO M3+J&'6X/#=^9+6.M\$=(_;./B74]=_:0\:?LRCPE<:)/;:+\,?@A\-_BD==T M3Q!)J&GSP:IJOQN\>_%,V/BK1[?3(M2TZ30['X`^"+F[O;JUU9M;AMK)M$N? MI\HQ!SL8\[=X+#!!!';!;)!(&`IV;2%R9`",]^>O?\?IT^@%`'P:?V!O#OB' M6FU[XL_M/_MO_&&Y&J'58-/U']J#QQ\%/#$,BW/VFWLI_!7[)*?LY^"M9TFV M.U?[*\1^'=:L[Q(U34DO-]R]QG?M8_\`!-;]G+]KKXD_#WXY>+[&]\#?M`?" M_P`/:EX+\(?&[P9X6^#OBCQE:^`]6U%M9O/!.J:+\=OA7\9OAMXAT.'69;O6 M-#GUWP#?Z_X0U74]>O\`P1KGAB?Q/XD;5?T$HH`^?_V,O%/B'Q+JCZUXN\=>.?$]PMSXC\8>+M9,-K'=ZKJ;1V]G;6 M>FV6E>'?#6@Z;H7A'P?H/A[P=X>T'P]IOO81LKNVMC!)QU89&5!!V`#D-Q92224PH4RT4`1["0P8[@2W'\(5NJX/7T.2$?$^F7NB^)O"WBG1M/\`$/AOQ%H^I0/;7VE:[H6L6][INKZ7 M>0.UO=:=?V\UKEW$XL-:TF7_1-7T745M=7T>\1[#5+.TO8 MI8$`/3J*C,J#N,#.XDJ-BJH8LP)!"@,N>,C>K$;#NIV\8)Y^49/!Z`9/;DCN M!D]NO%`#J*0'/^?U'J#_`/6ZY%+0`4444`%%%%`!1110`4444`%%%%`!1110 M`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`! M1110`4444`>2:E_R$;__`*_;K_T?)5*KNI?\A&__`.OVZ_\`1\E4J]Z'P1_P MQ_)'D/=^K_,****H04444`%%%%`!1110`5Z#X3_Y!TW_`%^R?^B+:O/J]!\) M_P#(.F_Z_9/_`$1;5RXS^"_\43HPW\3_`+=?Z'3T445Y)Z`4444`%%%%`!11 M10`5X/\`%W_DH7[+?_9=O$'_`*S)^T;7O%>#_%W_`)*%^RW_`-EV\0?^LR?M M&T`>\4444`%%%%`#67<1^IR0<8;TYX)!&""#AL_+@M"$=&]>@`QG.[G'S9.' M/0L^2200HDHH`B",!G";L#KTR`H*[E1--'^"?PATGQ?HL\EUH_BO3?AMX-LO$NEW,UK<6,MQIVNV^C1ZG832 M6-Y>6;S6ES#-):74]HT@@DE63RSQY^P/^PS\4O%NM^/_`(F_L8_LG_$;QYXF MNTO_`!+XU\=_LZ_"'Q?XK\0W\=I#8I?:YXB\0^$-2UC5[Q+2WAMDN=1O;F86 MT,-OYFR*+9]:T4`?E#\9?^"7GACQ)XFU34/@5<_LV?#CP#XKTWP7:^*/@9\: MOV-/A_\`M)?!30/$'P]\'6GPT\)?$OX)>!I_&7PKM?A#\2++X8:5X;^'5[/Y M_C'X?ZAX4\%^#K+_`(5W:W6FZG?:W]?_`+)_[(WP:_8W^$7AOX2?"#PUI=E! MI-G,_B3QDWA[PKHOC#XB>)M4U;5/$GB7QAXSNO".@^'M)N-8\0>*-?U_79+' M2='TGP[HCZM+I7AC1=#T.UL=-MOI^B@"+8V!DC*\9&<$=!N484C&3L*D#.%( M8>85$8]!C"CN#\OW2<$#(P""`"N,`XZ244`(!@>IY)Z]2)A;! M?L5O\3]#DTO7?A=\=-+LW2)[+1?CO\/?B9H^G>3'_9UA:N!(/M:B@#^=?]IK MPG^W3'^V)^S!\#_BOX@\>_M@?#!OV9_VR_B;9:%^R!^TC\:?^":7QR\:3_#_ M`.*?["GA>S\6?$IOAM^T%\/?AE\4/'W@2S^*6JZ/X1T-_B?\'_AEXBM_B+XY M\0OX8\#:EX5\/6.L7?V8?VP?@%^S!^V+^U!\._B=XG_;6_9_^$Q_9F_8N\:: M3X9_;[\??M:?&>Q\"_$W6_BE^W;HGQ0\21_&3XX?$?\`:"\%>!?#GBSPOX5^ M$VE07VE_%VP^'OB^_P#`FN2^&'UC5?!GCFYT[]GOCG^RI^S!^T]%X;@_:4_9 MQ^`O[0MOX-?5)?!]O\);;]FK]G#X"?L\P>,I=+F\70? M`WX/_#WX30^*Y]"34(M"N/$L?@'PYX?BUV?1H]6U5=*DU2.Z;34U34HK(Q)> MW/F@'7?"_P"-OP9^-FA1^)O@S\6_AG\7O#(?AAX]\+>/\`0I(F1&26 M/6/"NK:OI[12(\<>+_&7P2^'&O^,8;F1BSW=KXNU+PW<>)+&\9F M9C=V6IP7.6/[TY);RT_\$R?V3[$%?!=C\??A(@),5M\#_P!LC]L+X)Z5%G(9 M/^$<^%OQU\*^&9H`C,B6MQHTMK&"K1PI+#!+"`??P8''OC'!!Y!/(/(X'<9H M!!Z$'Z<]1G^1!^E?G\?^"?&A6O\`R`/VM?V_O#YYY'[7GQ)\7\'DY'Q*E\;J M^76(Y8;U6/RXW2"6XAF=_P`,-^/H_EM?^"B7[?UK`"2D`\8?LV7VS<=S?Z5J M_P"R]J6H2Y8EOW]Y+MSMC\N()&H!]_DXZ_GV_P`_YZT;AZ_G_G_]1R#R"*_/ M_P#X8B^*<1#V'_!2?]OW3Y\X:?[?^QQK!:/!_=_9_$O[&^N6,?))\V"TAN>2 MHN`A*%1^Q3\9QT_X*>_M_#V73OV",#Z!OV%'(^@(4'A%1,(`#[_W#_/^)P/P MSFFEU7KGMV]3@8SU)[`9+"[3^(?^"=FL7R@J$4P07D%NH4O'%'-+-+(T_LI?M;Z?^\T7_@I_P#M M%ZI*!A8OB%\!?V'=>L&'4&:#P%^S/\*[YRW27R=3MPZX$(MVW.P!^@`8'U[_ M`*=?R[CJ.01D$!"Z@D'/`!)QP`3C)]`.I)P,!L$[7V_`'_"H/^"DVC#=H/[; MG[,WBE8B&2U^*?["7BR_FN1&%O".N^!/"%MJOP_L/BC]JT[]IJ^@U3Q'\ M-_"_P_US0M2T3Q/J7BG0@#]_MPXZ\^Q`[]?Q&/8D`X+#*A@PR#D9(R.1D'!Y M'H00?0@@\BOYN_`'Q[T/]CO]O'X,Z)\2OA=_P4T_9X^'GCG]DC]L"]^(7AW] MHK]H#]IS_@HG\-O$?B_P;\9/V&;3X:_$OPW>>&?VC/VU=-^'WASP/HOB_P"* M.A^)?B)KFF_"/^R9/B3X>T+QLRR^(_"L`_=/X*_M+_L\?M%Z9=:M\!/CG\)_ MC-96!8:J_P`-/B!X7\:7&B3(R1R66OV.@:I?WV@ZC:R.EO>:;J]O9:A:71-O M=VL%SNB`![E13=PZ\D<<@$@YQC&`<]1R,C\CA0<_A_AGD=1]#@^U`"T4`YZ4 M4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110 M`4444`>2:E_R$;__`*_;K_T?)5*KNI?\A&__`.OVZ_\`1\E4J]Z'P1_PQ_)' MD/=^K_,****H04444`%%%%`!1110`5Z#X3_Y!TW_`%^R?^B+:O/J]!\)_P#( M.F_Z_9/_`$1;5RXS^"_\43HPW\3_`+=?Z'3T445Y)Z`4444`%%%%`#&<+C.> M2!P#WSC^70,@8;YLX.TXZ9`/H2`2.,#&&(8J&_E3_X.,?&OQ+^ M'/Q(_9-^*6F?M"^-+'X)_!?2O&/Q*^-7[-7[.'[3.E?`']L/0-&T[6M$O)?V MS_A1X8U"SNM`^,6E_!OPEH7C/PQ'X:^*A?X>)XP\1:#X:CTK5YO'VN-IO.^- M_P!KWXQ?#G]ISXW?M5ZS%\0/BQ\+_B=^T'[W3/&/B[PUXO\2?$BW^,GB+1_C#X%U3Q% MH'B2Z^`>C:"/"OBK7P#^LW>HZGU)]`H!^8GL..O8D`X)Q7A7Q<.?B#^RT?7X M[>(.Q!_Y-D_:-['IZ8/((.17XF_\$9OBE\4];^*T_@;6/C/\7?CIX#\??\$N MO^":7[8WC37OBW\5O'/QMN_"_P"TU^T19_'*/XH3^%_$?C'Q!X@3X>Z#\1[' MP;HVOV_P?T#^ROA_X>G\+F^^'7A#PG83ZW;ZE^Q/Q6UW4V^-?[,WAU_!GB2W MTFV^,.OZE#XXDN_![>%KZ[;]FK]H:/\`L"TLH/%L_CA=6$3(?7J*`/F#X*_L3_L(]3\8_LY_LF?LS?`'Q=K>BR^&=:\4 M_!7X$?"SX6>(M8\-3W]CJDOA[5=:\"^$M`U*_P!#EU+2M*U&;2+BZ>QGOM,T M^YFB>:RMY$?\:OV,_P!EW]H;4K7Q#\7?@CX"\3^-=-\LZ%\3[72CX5^,/A66 M-/+6Y\&_&+P?-H'Q0\&WB1_NX[SPOXMTBZ2/]V9GB/E5].44`?GB?V8/VK/@ MYNE_9G_;,\1>*?#EOF2W^#G[;'AJX_:(\/16J9#Z7X;^.?A_6_AY^TAHEQ%=,^,/PUTE"//U'7OC9\!?AMX)T>":'S/&]]MNW ML_T6()/MP<>XSUSGCIT`((ZGLPQY[\C.#@EEW##`/D,,CNI5NG/%`'`?##XM M_"WXV>#=*^(OP;^(_@;XK^`=<5FT?QI\./%>A>-/"VIB/9YZV.O>';[4-+N9 M+;>HN88[II[=SY?'W MC34OBUX0TWQ/^SI\=]5(DU'X]?LQ>))O@S\2O$%S&9#;O\18]!M9_`GQLLK1 MI7:TT'X[>"?B?X;@?$G]C2.6UOP*GA? M]G3]K*QL8@SJ;OP/XHUFR_9E^,FN%$D>[U/2/'?[+=BH:VM]-\#WSP2R3@'Z M*A@PRI!&2,CGD$@CZ@@@^AI:^2_@O^VS^SO\:_$[_#31_%]]X$^-UK:2WNJ_ ML]_&?P[K_P`'OCOIUO;Y^VWUO\,_B+8Z#XC\4^&[68-"GCGP1;^)O`&HKY5Q MHWBC4+*>VN9?K'>OX`X)[9.`!G^(Y.,+GGCK@4`/HI`<_P"1QW[$CI2T`%%% M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`'DFI?\A&__ M`.OVZ_\`1\E4JNZE_P`A&_\`^OVZ_P#1\E4J]Z'P1_PQ_)'D/=^K_,****H0 M4444`%%%%`!1110`5Z#X3_Y!TW_7[)_Z(MJ\^KT'PG_R#IO^OV3_`-$6U2>@%%%%`!1110!\Z?'K]D?\`9D_:CO\`X9:G M^T5\!OA5\:K_`.#7BO\`X3;X77?Q(\&:-XINO!'B5_LGVJ^T*?5+6X>WM]1? M3M)GU;2&WZ-K-UH>A7.KV%[<:+H\VG[5O^S+^SE:_&J\_:3MOV?_`((VW[1> MH:8NBZA\?;?X5>!8?C7?Z/'I%GX=CTJ^^*<6@1^.+O3?^$=T^PT+[!-K;6J: M-9VVDK$;"WB@3W&B@#QWX2?L]_`CX`6GB>P^`_P2^$/P2LO&_B"Y\6^,[7X1 M_#;P;\.+7Q;XLNU2*Z\4>)K7P?HFCP:_XBNX46.?6]76\U%D2.)YY8P16-\7 M$Q\0?V7.>OQTU\;0,(3_`,,S?M%$C;SM1M@;9N8>8D3GE#O][KP?XN_\E"_9 M;_[+MX@_]9D_:-H`]W&1QG/IQCC\./R`^E+110`4444`%%%%`!1110`4444` M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4 M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!32"2,<#G)'7TQR#QSN MX((*@<@G#J*`/'OC+^S_`/!3]HCPLO@OXZ?"SP)\5O#4-['J6G:9XX\.Z?KX MT35K0-?>&/$VGR1176D>)/#MSI>N:+?Q07^EZA;WMO%<#Y.D_9 M:_:9^!R&X_9(_:KU_6?#=KEK;X`_MH?\)%^T)X#^SC*+IWA#X[C6=-_:?\#3 MF,QHFJ^.?'/Q_P!`TN"WBATWP!&9;J:3]$J:5R<_@1C@CG@CC/!.`<@9SC-` M'YYI^W9K/PD']G_MH_LW?%C]G!H"WVGXK^"M.U;]IC]EZ=0P$NH_\+D^$_A? M_A*_AYX?A8.UQK_[1?P@^!&GQ'8OGS^;#)+]E_#+XM_"SXU^$=/\?_!SXD>` M_BOX%U;/]F>,OAOXN\/^-_"U^519'%IK_AG4-3TNX9$=6=8KIF0$9`W+N[\1 MXQT.WIP!C.0<;0%S@\';T++T*_V?/C+JLB.TL/_``E'C[X0:QX0U?Q_813$3/X=^(S^,/"=ZS2Q MZEH%[;S3PR@'V7O'N!M+$D%0``#SNQC@]^F&!P5-&\>C>N-I!/?C/4X&=H^8 M=",\5_/'_P`%4O@C^T3\*/V/-0?QI^V#\/\`]H#]F>+]I/\`8/3XI^`_V\_@ M_P##%='D\#2?MY?LU#4+/XA?'?X26GP@\%Z+\$=/AX^-%[\5/@5\5SJOP=C\ M:6VNZF=0N/[<7X`\'?M'?L'^%_VPO^"?5Q^R[^PS_P`$_M/^,_A+]I+XIZUX MXU__`()%?%K]AK]H_P`0>,?A6_[!O[9WAO7?#L.D_#!/@5^TI=>#X?$_B'P1 MXUU>#Q3\&],\""X\(65O+K$WQ#D^&_AOQ<`?V.*P8`J^$_P`6M,.M?"OXG?#WXF:, MJ)*VK?#_`,:>&_&>F+%(BR1RM?\`AO4M2M%CDC=)(W:4*Z.C*2&&0#T2BFE@ M.N?3`!)SZ8&3TYXZ#D\8HW#\N2>,`=B>>0>1D9&0^0,XQUSCG&,XYZ8H`=129Z>^<<>E&?K^6?Y9H`6BD!! MZ=C@^Q]#CH?;K2%@#C!R>F!GL3VZ<*>3@$\`Y.*`'44W>IQ@@YQC!!SD9&,' MT!/T!(X%*K!AD9QQU&#R`1D=1P>C`$=Q0`M%%%`!1110`4444`>2:E_R$;__ M`*_;K_T?)5*KNI?\A&__`.OVZ_\`1\E4J]Z'P1_PQ_)'D/=^K_,****H0444 M4`%%%%`!1110`5Z#X3_Y!TW_`%^R?^B+:O/J]!\)_P#(.F_Z_9/_`$1;5RXS M^"_\43HPW\3_`+=?Z'3T445Y)Z`4444`%%%%`!132P!P<]N>@Y.!RT8^+(M&3Q)+X8_M6P_P"$AC\.RWTNEQ:^^C"X_M!=%FU. M";3HM4-O]A>_AFLUG-Q#+&@!NUX/\7?^2A?LM_\`9=O$'_K,G[1M>Z[Q@'G! MSCH<\@#OT;((/3'WB*\)^+A#?$#]EQ@\T4@.?SQ_GT^AYI:`"BBB@`HHHH`****`"BBB@`HI"<=?0GL. MG7J?_K#N12@Y_P`_KQGKU'MUP>*`"BBB@`HHHH`****`"BBB@`HHI"<8]^_' M7(P.3G)[8]#WQD`6BD!SS]?T..W^?7FEH`****`"BBB@`HHHH`****`"BD+` M8SWZ,#ZXXR`@]/_K]`>1U'!'!P?PH`6BBB@`HHHH`****`"BB MB@`HHI"P'4_AD>A(ZD=<''T]C0`M%%%`!1110`4444`%%%%`!1110`QU+=,= M,$-R&'7!&#G&/E/\.XGD`JS0A`Y.3\N20"6"]-QXR>X88(?YA\N$$A8#@Y_( M\?\`UR2`!U)Z`X.!6##(Z?4'Z\@D<'(//4&@"&6WBG@EM[F**X@G1XIX9D66 M&:.0;9%EB=3$ZR+]^,Q[#N8$$$Y^/OB%_P`$\OV%/BKJ)UWQ]^Q]^S=KWBCS M3/#XU/P>\#Z;X\LYRSL;C3?'FC:-IOC'2KHERYN=-URVF\QF??N^8_9%%`'Y M]#_@FK\!-'^?X=?$3]L;X0RJ1Y$/PZ_;I_:\M?#EHJYV+:?#OQ+\9/$_POA5 M,X`_X0ART:QPL3#%&B2?\,;?'[0^?`G_``4R_;*TJW3_`%&A^.?"7[&'Q3T- M2`5'VC4?$O[*,7Q(NP$V)^]^(X<[-[.9'D=_T!HH`_/W_A3'_!1W1`1X;_;H M_9^\4Q)@K'\9/V%M7U^\N`IR4EU#X1?M;?`^TMKB0!5BOH=#DALY@;DZ5?+_ M`**4\C_@J?HN,7W_``3^^).S@C^ROVC/@B+@`8&T?VU^T$+'('3;?@9SEL$/ M^@=%`'Y^_P#"UO\`@IAHIVZW^Q9^R=XF@0?+*/^"8G[1&K*N?/D^$GQV_8G M\811H.-T2?$G]HKX)W]RNX.VV*R,QC9#'%)*SV\/Z"'_`#U_Q'/O32O8<=,8 MW#@=CM9<_GWZ>H!\"K^WS!I(_P"*^_8V_;[\`,I_?!OV:M1^+ODC@$Y_9M\2 M?&Y;C!#*%L#=M*R$P"97B>7P;]JS_@KE\!O@U^S!^TC\5_!B?%+2/BM\+?@! M\8OB1\-O!G[0G[)'[87P3T/Q/\0/!'P]\1^(_!GAS71\4?A#\,)CI&N^)M.T M[1]2:UUK2I&MKMUBU2SD>&[A_7/;R3ZG)YVY.,=OYG)/0G`%>2?'[X+>%/VC MO@5\:?V>O'MSK-IX%^._PF^(WP:\97GANZM+#Q'9^%/BAX-UGP+XCN/#]]J& MGZOI]CK<6BZ[?2:9>76E7]K;7HAEN+"\A$D#@'Y'P?MH?M(IX=\+_%/P#^WK M_P`$T/VO?`>D?M/_`+%?P,^+W@#X!_LK_%+PKX[T'1?VM/VKOA%^SD;FZ\7_ M`/#RCXVP?#/Q/I&F_$C5O&7AR'QC\*];BUV?PG>=S99OSDUS]@/QYXXNO!-K\8/^"B7[;'QE\$>#?BU\%O MC-)\-/&7A?\`X)^>&O"GBOQ;\`?B_P"!_CE\-+7Q)J_PB_80^&7Q&BT:Q^)/ MP\\)ZOJ-KX7\=^&KK5;/3YM'N+UM.OKV";]&T&`<#`SD#TX''08`/`!S@`8P MN``!]%%%`!1110`4444`>2:E_P`A&_\`^OVZ_P#1\E4JNZE_R$;_`/Z_;K_T M?)5*O>A\$?\`#'\D>0]WZO\`,****H04444`%%%%`!1110`5Z#X3_P"0=-_U M^R?^B+:O/J]!\)_\@Z;_`*_9/_1%M7+C/X+_`,43HPW\3_MU_H=/1117DGH! M1110`4444`1OW;(!4`G)P`,G)89'&W=@L6"D;@I((/\`#O\`&V>Q^%7_``7P M^/>L_`N]F_:M_:$^+FC_`!8TG0-*AM?CA\)?VR/V)/C+-^R9K+>$9=$M=4O; M;P[^T/\`L:6WA7PQH]UHYUOPS#\%FUWXS>#)/"VH^)/$_P`/Q MCO9=3C\/2ZT;=M2?0DU.>?4$TIKEK)+V>6ZC@6=FD8`_F8_X(&?\(6/B;XO/ M[/']A#X+G_@FW_P3<7]I)_!JVBZ,W_!1A+'XW)^T$/B0`HU/_AJ-9N/![+^^WQ8T#XSZ_P"-_AEJW@GPI\,-4T+X:>,[GQO! M/XK^*/BOPQK&N7=]\,OB'\.;O29-*T?X-^-++2[>R;QZ-7AU>'6M1DO/[-.F MS:58?;GN[;Y(_P""FW_!1#Q)_P`$^/#?PJUO0_@GX9^)T7Q(E^*ZW?B[XI_& MJY_9Y^#_`(4O/A?\-]1^(.A^`-0^)UK\*?C+/>_&GXX7EBW@GX!?#'_A$[-? MB5XJMM8L%\2Z1"=<^"GPY\#?LS:UJ7QF^/_AS]C2/P M/\._C9X[U+X(1>#_`(M_MCR_&_Q)H?PE^-6JV'PO^*VJ_#C6/A7\*OV:?CAX MW^(T/P9X&B\&^?X]TG7;8`_0P>(?VF@,_\`"I/@7U)_Y.*\ M?@9RV2-W[+C$*Q&Y2QV@,`I*@&G#Q#^TTPR/A)\"L9(_Y.+\?=1P1_R:WP0< M@@\@@BOQ)\1_\%_-&L/`'A?XF:)^S-'?^&O!'[-0_:A_;'MM?^.!\,:_\&O! M/AO]K7Q-^Q=\6M!_9^L(/A!KEM^T_P"+_AM\5_AI\6;WR=>U7]G32/$OA/1? M`-Y9:[9ZW\2[/P[X<_HHMIHKB"*>"6*>":..6">!TDAFAE19(I8GC9XWCD1E M>-T=E="KJQ#`T`>'?\)!^TW_`-$D^!7_`(D5X_\`_H6J/^$@_:;_`.B2?`K_ M`,2*\?\`_P!"U7N]%`'A'_"0?M-_]$D^!7_B17C_`/\`H6J/^$@_:;_Z))\" MO_$BO'__`-"U7N]%`'A'_"0?M-_]$D^!7_B17C__`.A:H_X2#]IO_HDGP*_\ M2*\?_P#T+5>[T4`>$?\`"0?M-_\`1)/@5_XD5X__`/H6J:?$7[30.#\)/@5T MS_R<7X^X'/7_`(Q;X'&,G`)X!S7O-?#O[?W[7>L?L6?!?P]\5])^&VA?$`>( M?B]\-/A5J>L?$#XG/\$?@C\(=)^(&KS:=>_&+]H+XSIX$^*#_"WX/^$Q!%9Z MUXN3X>>*1%X@UOPQHUU9V=CK5SK.E`'9>/[7]J+QIHMCHUIX`^">@2V?C+X= M>*I+VU_:$^(J3W0L M=22)[.;ME\0_M,C_`)I)\"LDDG_C(KQ]DD8!/_)KC$J#A0QYV[<\?,?SX\%_ M\%9=#U/X%?LW?&KXB?LZ_%GP%)\;/V>_C1^T)XK^'.CV'B;XA?$#PCHOPL^( MOPL^#GA'1/ASX6T+P%9>(/C'+^T/\2/C)X!L_P!GF\CT;X>W'Q$\":[!\0DT MW3=-@UFRTOPW1O\`@M5XI^)7[+7[)OQH^#G[)=GKGQE_:P\+?MK?%'1_@1\2 MOC[-\.=$\%_"/]A;5O%&D?%76-9^+>B_!#XG17?Q%U;58/AMHGA'P!%X`L]# MN-<^(6HC5/'VG:%X*NO$&K@'Z]CQ#^TT1D?"3X%?^)%^/O\`Z%K_`/7U'%+_ M`,)!^TW_`-$D^!7_`(D5X_\`_H6JZ+X$_&#P?^T+\$O@_P#'[X>'4F\`?''X M7>`/C!X%;6;(Z;K#>#OB7X3TCQGX9;5M/,UQ]@U-M%UJR:^LA/,MG/_`/Z%JC_A(/VF_P#HDGP*_P#$BO'_ M`/\`0M5[O10!X1_PD'[3?_1)/@5_XD5X_P#_`*%JC_A(/VF_^B2?`K_Q(KQ_ M_P#0M5[O10!X1_PD'[3?_1)/@5_XD5X__P#H6J/^$@_:;_Z))\"O_$BO'_\` M]"U7N]%`'@S>(OVF5Z_"3X%#.3_R<7X^Z#`)Q_PRWG`)&3T&>![/P!\$O#-WXS\'>*/"5MXDL_V@_B%;)`T+7ELS>;'<_;2_:)U?]DS]EWXS?M%Z#\*_$7QKU M7X3^%%\1VWPU\,7KZ3=ZV)-5T_2I[_6=?AT7Q+/X7\$^%[;4)O%OQ#\7P>&_ M$,WA#P#H/B?Q/%H.MOI(TRY^&O@O_P`%8=/^('P5\$?%KQO\'](\(6OBK]JG MXT_L]GQ-\/OBCK/QD^!/BOX/?VJO@/\`&&Q^$?A+5OCG\"4^ M'GPI\2V&@^(=-^&?A=/$/Q)LKKX;Z?=-J8TR\U4`_0U?$/[38X/PD^!1;.2! M^T5X^XR>,_\`&+9VY'(#,3_"K/MR7CQ#^TT?^:2?`KT_Y.+\?=NO3]EOL<@^ MXK\IO!__``7#^'GB']C#]JC]LG6?V9/V@/#%K\`_VD_BC^S;X!^!,_AK7-2^ M.OQ5\1?#WX;^&/B5:ZGXH\%P>&+<_`M9-`U37=<\?VWC234-,^$GA#P=KWB3 MQ7KTMU'-H4?ZP_LR?&(?M$?LW_L__M`CPZ?!X^.GP3^%7QC'A$ZO_P`)!_PB MH^)W@30/&W_"-C7?[,T0ZR-$_MS^S?[5.C:3_:'V8W2Z98)*EI"`0?\`"0?M M-_\`1)/@5_XD5X__`/H6J/\`A(/VF_\`HDGP*_\`$BO'_P#]"U7N]%`'A'_" M0?M-_P#1)/@5_P")%>/_`/Z%JC_A(/VF_P#HDGP*_P#$BO'_`/\`0M5[O10! MX1_PD'[3?_1)/@5_XD5X_P#_`*%JC_A(/VF_^B2?`K_Q(KQ__P#0M5[O10!X M1_PD'[3?_1)/@5_XD5X__P#H6J:?$7[32\?\*D^!6>./^&B_'O4G"CG]ELQ((SG`/O-<;\0_%4_@7P)XV\;6OACQ-XVNO!_A#Q+XIMO!7@NR75/&/C" M;P_HU[JL7A?PEI;S0+J/B;7Y;5-)T&Q,]N+S5[RQMFGC64LH!YN?$/[3)!/_ M``J3X%XQ_P!'$_$$Y`.,`#]EU2,]4=58G`VAMPKC/AM:_M1>`OAWX#\#7GP_ M^"/B:\\&>#/"WA2Z\17'[0?Q`MKG7KCP[H5CH\^MSVA_9EU![6;5IK&2^EMW MOKTP2SO%]KN-GFM^:W[+'_!9'Q#^T+\$OC#\4M=_9CT/POK'P\\2_L=>!?"- MI\-?CUJ'QA^%GC[XJ_ME:WX8\*Z-\`KSXN7/P*^&TWA;]HKX!>-/%WA_PO\` MM0?"B+P+XDOO@_?:_P"';C4=8OO[:\NP]3^"?_!5C4/VH_'W_!1#X=_LS_LG M_$_XC>(_V*/!GP7U;X3V/C#Q)I7P2O/VLO$WQHA^,L.CKX8B^*.C^'K3X:_" M>'5_A+%_9?Q>U^\UQ_%GA76;[Q=X:\#:A;Z9X>TWQP`?H6OB']IIN1\)/@5U MQ_R<5X_Q^!_X9:P?J"1G(Z@@+_PD'[3?_1)/@5_XD5X__P#H6J\+_84_;)OO MVO=#_:)LO$_@/PG\/?B5^RS^U!X__92^+&C?#;XIW'QQ^%\_Q`\`>&_`OBK4 M[CP'\4[GX>?"G4?$%I96/C_3-#\3Z3X@^'/@SQ/X+\;Z1XF\+:WH>W2[/5]6 M^Z@0>G/)'XCK^1XYH`\)_P"$@_:;_P"B2?`K_P`2*\?_`/T+5'_"0?M-_P#1 M)/@5_P")%>/_`/Z%JO=Z*`/"/^$@_:;_`.B2?`K_`,2*\?\`_P!"U1_PD'[3 M?_1)/@5_XD5X_P#_`*%JO=Z*`/"/^$@_:;_Z))\"O_$BO'__`-"U1_PD'[3? M_1)/@5_XD5X__P#H6J]WHH`\&;Q'^TTO7X1_`SGIC]HGQ^I MP/O,H*'Q'^TR=H_X5+\"N20#_P`-%?$#!(95*[O^&7%56#$#:?G;#JHRIV^[ M29[=^",=5'WANY"YSD\%BH;:-V&7\(?@/_P6HOOB;KO[6,?Q'_9:O?A5X4_9 M;_9_^/\`^T#XHOM/^+-]X_\`&WP[MO@=\4_%WP_TWX*_M8>!3\(?!MM^S%^T M9\9?#?A:3XM_"'X4VWBSXP/XR^&D6L^(]%UB[L]"2;50#],_`-M^U%X*T*^T M:[^'WP2U^:\\9?$CQ:E[<_M!?$"TE@M?'7Q$\3^-[715CE_9HO6E@\,6OB.# MPY;W@FC2^MM*AOEM+!;I+*'MAXB_::."/`-EXN M\-2^'%CN)9M?U/PMZM^PA^V;\6/VJ-3^/O@WXS?LWZ5\`O'_`.SWXK\`^#_% M(^'OQKM/VD?A%=^)_&7@+3O&'BCX8V7QATWX=_##2;OXT?`K5KBZ\"_'SP'H MGA_7?#W@/Q"?#K:1\0O&$/B1ETH`^G!X@_:;/_-(_@5_XD5X^_\`H6J7_A(/ MVF_^B2?`K_Q(KQ__`/0M5[JG3CGD^O`SP,$`CC'UZC((-.H`\(_X2#]IO_HD MGP*_\2*\?_\`T+5'_"0?M-_]$D^!7_B17C__`.A:KW>B@#PC_A(/VF_^B2?` MK_Q(KQ__`/0M4?\`"0?M-_\`1)/@5_XD5X__`/H6J]WHH`\(_P"$@_:;_P"B M2?`K_P`2*\?_`/T+5(?$7[30(!^$GP*R/N@QD_P#)K6<#(R>@R`2" M1GWBHW`/7`/`!(&-V28SS@,5;)5+ M+*PG_:$^(L2>&K6S^'W@'P.VBVC3?LTWGVFWFN_!]SXBDN(8=.B%WK]U"]B) MXI;R\^(/`'_!5#Q1XQ_X*)>(OV&-1_9DF\.Z+HGCOXQ>"9?')^*]YJ/Q@\+^ M&/A%\)?"7Q,LOVDOBY^ST_PIL;#X9?LD?&+7/$&]+U'7;FST7!^'/_!97P=\2_P!I+_@G_P#LUZ#^S]\1$UG]N/PMXU\? MW?Q!NI]7T_X:_"'P;9?`/XA?M'?"NT/BK5?`NEV'Q*^)GQ*^&GA7PYXDUGX? M>'GT@?#+0_'-CJ7B'Q#?3C1]+\4`'Z8_\)'^TSU_X5'\"_K_`,-%>/L#C)R1 M^RW@8'.6(!!&TG-.'B']IHYQ\)/@2<'!_P",B_'W!X.#_P`8M<'!!^A!Z&OC M/]F__@IW\//VH_V^/VI/V*/AEX(O[[PY^S!\//"?B:]^/\FO,WA;XC^+]1\< M^)_AYX\\)>`_#P\/11:EH/PW\8>%M;\!:[XZ@\5W-KB@#PC_A(/VF_P#HDGP*_P#$ MBO'_`/\`0M4?\)!^TW_T23X%?^)%>/\`_P"A:KW>B@#PC_A(/VF_^B2?`K_Q M(KQ__P#0M4?\)!^TW_T23X%?^)%>/_\`Z%JO=Z*`/!SXB_:9!Q_PJ7X$YX./ M^&B_'V<$X'7]EON<@>I!`Y%-/B/]ID#/_"H_@7]#^T5X^4G@D?>_9;7&<$#= MM&1R<-?$7Q[^,E_P"( M?`>O>,/@OX=\/^%?BOJ&M7GPV\,_#GXS_%:<^'=$T^#PR^J>)]2LO!P!^BOP M^T7XH'Q_XX\=_$>Q\'^'8==\'_#OPEHGA?P;X[U[QW8VK^#M;^)VL:MX@NM1 MUWX?_#E;*ZUF/QSIMB;.UTF\8P>&XYYM1??%:6WMBL`,<]QC:5`*_*0-P4D$ M@LI.=RG?G80U?C3\(/\`@L=\,_B7\`_@%\>;OX8:\FD?%CP+^UGX\\9Z3\,- M+]#\8VOB.?3M&U'3=6\+67FNN?\%S_AOX2_X)+:?_P5`\6?`?Q5H/B#QAJW MQR\*_"_]DT^+[6_^)7C3Q5\%_BW\7/A_>:%=^(=/\(W,>@P:=X+^#_B;XQ?% MG5K3PMK^F?"7P%HGC&\,OBZ+PQ;7WB``_>,'/3_/_P"KH??(Z@TM<#\*O&W_ M``LKX8_#KXC?V8-%/C_P+X1\:G1Q=G4?[*/BGP_IVM_V;_:+6E@=1^P"]%H+ M\V-E]M6$7(M+=9!"G?4`%%%%`!1110!Y)J7_`"$;_P#Z_;K_`-'R52J[J7_( M1O\`_K]NO_1\E4J]Z'P1_P`,?R1Y#W?J_P`PHHHJA!1110`4444`%%%%`!7H M/A/_`)!TW_7[)_Z(MJ\^KT'PG_R#IO\`K]D_]$6U2>@%%%%`!1110`4444`?FG^WY^P+XL_:^\4_!+XF_##XV^%_@M\4O M@KX-_:9^%]A??$3X*R_'WX>:[\-_VL/AGIWPY^)UM=>`[#XJ?!?6-/\`'FF1 M^'/"^I^!?&MIX\?3M&AA\4:!XA\'^+M$\77EK9^`:;_P1Z7P5\(/AOX.^&_[ M1VI0?%7]GWX]_LF_&W]G+XK?%+X;S?$G2_"=G^R9^RSX,_9'\.?#OXI^!=%^ M)/PXU'XI>'/%_P`/8?C-XFU^Z\/?$#X47FF?$;XUZAK_`(;72='\):5X:OOV MKHH`_GR^(W_!!OP]\2_@5^SW^S9XI^,WPI\7?";X?>"_B'X?^,C?$C]C?X:> M/_BEXA\7?'?XZ)\>?VB_BE^RI\:-1\8V?Q$_8[\7_%G6]8\=^#?L<6K_`!O\ M+>%_`FO>&H]/T&Z\<^!['Q[J7]!$$,5M#%;P1QPP0HL4,,2".*&)!MCABC7" MQQ1(%CCC0*B(H5%50%$M%`!1136<+USTS@`L<="0HRS8.`=H)&1G@T`.HI`< M_F1^7!Z>_'K2,X0$D'`!)V@L<#T1#@D9!&>*0L%ZY_`%CU`X5*O%7P[D^+?P^E\=?#:T\4:$FB?$CX96GCC MX8ZKXP\)ZMX9\;^)HH(-!^)/@77O#WBV/PMXSTO7_M/AI--U#L_VE/VS_P!G MS]DFZ^%6F?&WQ#XYL=>^.'BK5_!'PE\)_#?X(_''X]^-?'GBK0/#UYXLUK1M M!\$?`3X<_$SQ;<7.G>'-/O\`6+AGT:*#['97^!_[6GPZ MN/BI\!/&-_"F@:V;"XTS6K>RGT36=)U"]`/D3_@G]_P`$ MXHOV&H-][\9M1^,FI+\)[+X?6D][X,C\%:=H7B#Q!^T%^T1^TG\9/$WA72H? M%7BD:#H'Q%\=_'G3='T3P.;N_3P1X*^$/P_TJ3Q%XKUU_$7B?6/DRS_X(M>, MO!7[-G[*7PI^$?[6FB>%?C/^RUX:_;A^&FE_&3QG^SK/X^\%^*OA1^WGK7B? M7OBCHLWP;LOCKX*U#1?&_A/4Y/AOJ'P^\9I\6=4T6QO/`NK1:_X$\0:-XTFT M;0OWGWKZ]MWK\OKQGCWZ$GN3G`7#D[&5B`>7?`OX/ M>#_V>/@G\'_@#\/$U)/`'P/^%WP_^$'@=-:OO[3UA?!_PT\):1X+\,KJVI>5 M`=1U-=$T2Q6^OC!#]JN1)-Y4>_:/5*:'4@$9(.""`2&!Z%2,A@1SD$X!!.*0 M.IQ@YSCISC/W>00?Q!P0?4$`@\$`@BEH`** M**`"BFE@"!W()`R,D#K@$@GL.,X)&<4!@<8YR3CMTSD\X)'';)Z'&#F@#Y(_ M;L_9/T[]M[]E?XI?LT:CXSNOAX_CP>"M6T+QM;^'['Q=!X;\8_#/XB^$?BMX M&U'6O!^HWFF6GC+PHOC+P/H47C+P;)K.A-XM\)R:UXGQ=_:4MO MV;O"^$-3^*WQ4UCP9I/P]^%W[.\OA&PTG6?%_CC6/$^N_%SXF>+M=\ M5>1<^'?#.@?JIO&0.2`2`0K8`ZD9Y['[I.0?ND`9)!'/ ML/O8((H`_-;X>_\`!/)_`OP1_P""COP<;XNKJO\`P\#^-O[5?QB;Q$/`1L/^ M%3#]IKX;Z!\/%\.G2AXSNF\>_P#"$IH0U4ZL=3\&KXC-W]@72M`%HMW/]??L MS?!S_AG7]G#]G_\`9]_X2/\`X3'_`(47\$OA3\'/^$N_LEM`_P"$I_X5EX$T M'P5_PD?]@MJNNG1/[;_L3^T_[(.MZQ_9OVG['_:FH>3]KE]K$B,-P(*\_,"" MN%ZG<#@@=R"0IX;!!%5;_4;#2K"]U35+RUT[3--M+B_U'4;^>*SL;"PM(GGN M[Z]N[EXK>UL[6".2>YNIY$@MX$>:5TB4N`"[17P=\$?^"FG[$7[0MA\1=4^& MOQI=-.^%?PATC]H3Q???$CX:?%WX(6I^`&O1>)Y](^._A.;XV>`?A['\1/@K M?0^#O$,L?Q8^'K>*/A^L=E"\OB&-=2THWO4_L\?M^_LI?M3^%?B3XQ^"_P`1 M==U?2_A#HWAOQ-\1M.\9_"7XR_!_QEX:\)^-?!0^(O@?QE+\//C%\/O`7C[4 M/!7CKP1YGB/P-XQTCPUJ'AGQG8VU\/#.JZK<:=?P6P!]D45^>W[/W_!4W]B/ M]IWQK\*/A_\`"7XD^/W\2?'KP7XN^(7P(;XF?LU_M/?`7PY\K_!?QM\>/@W\-?!?Q8;PSI/B31M'[M_$,M@NB65_J%KZ MA\3_`-N/]GCX2?';1OV9_$^H?%O7?C=K?@?PQ\3(_!'PG_9E_::^/#Z+\/?& M7C'Q'X`\-^-/&GB#X'_"'XA^%?A_X;U+Q=X0\2Z0-6\=:YX=M+0Z->WM_):Z M=']K(!]/-(^'F>%_B_\-O''PN\2ZCX9OH= M+\2Z?X?^('AC5?">M7OA[4[BTU"WTW7;73-8NIM(OYK"]AL]02WN)K.\BC:W M?TP'/3GDCCU!P1]000?0\44`?AU^R_\`\$??&?P7^(WPY^)WQ6_:F\._%+5_ M`T/[(GA35/#'PX_9U/P,^'GC/X9?L.?!#XW?#3X`Z-JWA6?XU_%5[3QY8^/_ M`(Q6OQ;\3>.+353X>N)O`/AWP3X.^&_@?2)[W43[G\4O^">/Q9UWXA?\%*OB MW\#_`-K:\^`7Q1_X*`_!K]F+X1>&?'.D_">X\1ZY^S@?V?M(^*/AO6?&GAJ] MM?BKX1O/%7BGQCX>^*>K+X7U&PO/A_?_``Q\1:=IGB:QU#Q)=VL5O'^J5%`' MP-_P3@_8OU7]@?\`9F\-_LTS>(O@GXET'P5>3OX;U;X,?`[QU\$/[5CO[>UG MUSQ#\28?B!^T9^TGKOCWXE>)_$C:QX@\0^-CXKT&RNEU&STBR\*Z=9Z-;O/] M[HI50#@X_NC:,`8`"Y.``,`9/3K2Y&<>V?Z?_JI-XSCTZ^G^<"1@=<`'&3A58[A@.RYZC(!(/,7&OBGXP_P#!1/\`8^^`GQCM/@/\5OBM?>&O MB%(_PDBUM[7X8?%[Q1\/OA_/\>O%>M^"/@O:_%_XR>$?`.O?![X*WGQ/\4>' M-:TSP5:?%SQWX*N->^P27MC%+I\D%W*`?;%%?%7B?_@HA^Q_X._:4L/V2/$? MQ8N]/^.-_P"+_`_PZ?24^&GQ:O\`P%HWQ*^)O@G5_B/\-_ACXK^-VF^!+SX' M^#/B?\0/`NAWOBCP3\./%OQ%T3QMXJTF33)]"T&_.MZ,M_QGQ]_X*E?L6?LS M?$'XH?"_XM^.?BI:>+_@C\.M$^+GQEB\`?LK?M8_&KP]\*/AEXBM-;U#1O'/ MQ&\`?VQ?B]\./V@/&B?&+6=(^-7C/QWI7P_L? M@TGQ$\/^`?A#HMAI^L^(/B%K/PV\4^++^-+?]A_BO^U;^SY\$_AW\._BU\1/ MB7I.G_#3XM>-OA3\/?AMXUT"PUWQWH/C+Q3\<-8TS0?A5!HMYX"TKQ,MQI'C M+4=9TM=.\4L(_"L-G>PZG?ZU::83=C7\-?M&_!KQ?\=OB?\`LS^'?&']H?&[ MX->$/A]X\^)'@G_A'_%%H?#OA/XIR^(H?`>K#Q'?:);>$M9_MQ_">O[K#0-> MU34]*%AG6K+3A`=9M?V%_BM^QGH^@ MZ!X(T'5=>\-:K\2OB[\/OBM9?&K0_%'BZ\\1>$YM9\'7?@.&UTWP5XE^%OB/ M0-7U"ZM]3UN[N]-M+OP[JG-_L>?L6_%7X%_%[X\_M'?M#_M$>'_VBOC[\??` M7[/_`,+O%'B;P'\$Y/V>/`K>$/V=-)\<]L`+7@'P^_:B^!?Q3^+GQ.^!/@/QQ_;WQ6^#?@[ MX4>/OB/X5_X1KQ?IG_"/>$OCAIFN:Q\+M777-9T#3O#>LCQ/IOAS6;HV>@:Q MJFH:$+,1>);31I[FTBGZ;XW?'3X2_LW_``O\5_&;XW>-])^'WPV\%V4=YKGB M+5DO;EFFN[B*PT?0=!T72;74/$'B[QEXHUBYL?#G@KP)X3TK6_&GCGQ7JFC> M$O!^@ZWXFUG2M)O`#UFBOF'X`?MC?L__`+3.M^/?"?PL\2>+[?QW\,/^$?E\ M??#+XL_!WXS_`+//Q:\+Z9XLLY;[PIXDU+X2_M!?#_X8?$I/!OBB*VOX?#GC M:+PK+X1UV_TK6M+TK6KO4M$U:TLOIOS%QGG&`<[3R&`.0,9P`02<8'/]UL`# MZ*;N&,_48XZ@D$A^);>>ZTZP^(_PS^(WP>\:V\5O?76GNNO_ M``U^+?A7P1\1O"ERT]I+)!9>*?"NC7MU9-;ZC;6\NGW5O(_%7B[P1\ M.8/A3X%\5*EQX6\&^)OBMXB\-^$(8M4^]?BI^PGH/C[XX_\`!/;XJ>'?&S>` M_"O[`EW\9TT3X>:?X>NKJ7QSH'Q5_9K\4?LY:7HECXNT_P`5>'[GX?/X+T[Q M%#X@M]5L=&\0W6I?V9'I%JF@/)'K%M]?:3\0]`UKQQXO^'MG8>-X=>\$:9X9 MU;6=1U7X9_$?0O`M]:^+(]0ETN/P?\4-;\*:?\-/B%J5JNFW*^)=&\`^+?$N MK^#99+"'Q?8Z'+JVE)>]ON`./7\>X'09/4X)Q@=R*`/R/_91_P""/?P'_8P_ M;!UC]I?X$^,/B?H/P^/[,7A#]G'P7^S]X@^+W[1/Q&\/^"X_#WC[QQXVU/78 M?$OQ2^._CFWUGPM?Q^+X;#PW\+=0\'#PM\/=8L=7\9^$9;'Q!XO\02S_`*X* M-HQU.22?J?H.WKD^K,>2F\>C8P#G!Q@G'4\<`@G/0>I!`3S4YY'`))R`.!G& M20.5!;/38-Q(4J2`245Y;\6_C9\*?@1X9T[QC\7O'&B^`_#NL^,_!/PZT;4- M;EE0ZSXZ^(_B?3O!G@?PII%G;0W%_J>M^)/$FJV6G6%E8VT\FUY[^<0Z;97M MY;^H@Y&?\_IQ^1(]"10`M%%%`!1110`PH&.>,\#H,\'.W[++;X+:[K-UIOPE M\:?#_P"%O@CQC^S(L?A;X^?#3Q'=Z/XS7X5V%OXN^(.C>,_"=YK?@7Q%XH^' MS^$H+?5I]>;]OZ*`/SZ_9!_8EUG]FW6]"USQ/XO^#FL6W@;]G#P!^S1\+_`/ MP%^`WB3X!_"OX;^#O"'Q"^(_C37K_P`/^&?&7QY_:'\33:CX_P!.\0?#'1O% M+ZGXYO)KS4_A2GB:>[NKOQ7/9:+\-ZU_P07^"GC+]@O2OV1O'GQ8\;ZQ\5O` MO@W]N3PE\(_VC_".N_&KX3VG@6+]N#XN>/OBKXN36_@A\-OV@/#WA3XI>'=- M?Q3X:\-^)/!OQ'\0Z_X>^(FE>#$M]3MM'TG7[[0X/WIHH`\C^`?PCT[X!_!/ MX5?!72=<\0>)M/\`A=X"\+^![?Q#XIU_Q3XGU[6QX=TBUTV35-0UGQKXC\7> M)YVO9;>2X@M=5\3:T^EVKP:3:WKV-C:HGKE%%`!1110`4444`>2:E_R$;_\` MZ_;K_P!'R52J[J7_`"$;_P#Z_;K_`-'R52KWH?!'_#'\D>0]WZO\PHHHJA!1 M110`4444`%%%%`!7H/A/_D'3?]?LG_HBVKSZO0?"?_(.F_Z_9/\`T1;5RXS^ M"_\`%$Z,-_$_[=?Z'3T445Y)Z`4444`%%%%`!1110`4444`%%%%`!7"?$K3? MB1JW@K7[#X1>*_`_@?XC7-M;IX8\5?$GX?:[\5?!&D72WMN]U+X@^'WAGXE_ M!S7?$MM-IHOK6"UT_P")GA22VOI[6^DN[JWMI]-ON[HH`_/[_A6__!4S_H\? M]@#''_.-3]HG^O\`P5?.!GH`<`5^)/[6G[/WQJO_`-N_Q_XI_;6\+_LA?M+V MVH_LD?LO>'OAA\2-2_X-U_VZOV_?A38RZ!\8OVT=2\=^!_!NB?";]JCXUGX- M>/\`14\3>"==^)^J^(/'ZCXF^'/%WPBM=*\':"?AIJ&M^+/ZMZ8RYP1U4@@9 MQDC/!.&('S'.T`D?*25)!`/P+_X)H?!+_@HSX2_9*T?1?AO\8OV0?V?OAO\` M\+W_`&R]8^''PE^)G_!*3]I[X<>(_#'P]\3?ME_'WQ+X%N=-^&&O_P#!0OX+ MZ]\*/A_XH\*:OI'B_P"$WPEUWX=:-K?PL^%FO^#?A_J^H>*M2\.77B[7?OZT M^'/_``5!6ZM7U#]L#]@BZL4N;>2\MK3_`()O?M"V5U/:I*K7$-K>3?\`!52_ MALKF6(,EO>2Z??);2LLSVERJ>2_WNH(&"<\\$]<>_3G\/KDY)=0!^)/_``5/ M^$?[1_Q&_:M_X)%Z]^SAIHLM>^''[4?QEU_Q+\4?$'P3\=?'/X5?";1]3_9F M^(F@VOB3XL>%_`7CWX2W]OH.L7EV/"^C7E]\5/`UFGB;6=*C74=2DV:%J7Y8 M?MJ_\$Q_C/\``SQ)^S/J'B:^B_:\^#OQ@_:S_P""@?[5G[>$]Y^P)\:/VN?@ MA+^T]^T/\'?"?AKX$^)?^'?/P`^/5A\6;GP-X+\!>!?%7PH^%/BR;XC_`!#E M^#WQ-\2:;\1/%OB:/4?&&E:IX8_L#8$XP<`$$\GL0<<8X(SGD9.`P92RENSI MC!QZY'!QDC;A0PY((4=U!7<6H`_D5^&7_!/GXK>-/VI?V3XOVC?AC^TY\>8? M@Y_P06\?>&?#?QI^*/P>\!:%\5M$_:DL?VD_"^J?![2?[7\5_$_XH?`/P3^V M%X+\(:F?$/PZLO$O[0>H7OA?Q3X7T_Q_K/C73HM&U76]+^`/@!^QW^VUX%_X M)T?\%)/V'/B" M+W]HW]FWXH?LB>+?B%X2^&?Q9^/FA?L]_P#"=_#7Q!\8/V9-9NM9^/>AC2?# M?C?X_P#Q>^*7Q7M=8\#_`-]'EG``QP"`.BCH5"@J555YV_(6X7YL9!01G.Z]^Q_X5\'6.@?M(^'OV;/V&_&_QU^,W M[2&N?"+QW\3#X(^)'Q/^%OB3PAX&E^(NN^&_BU?^"?A9XP\&^,(CK?+_``]_ M8B\=_$K]K+]CVRU?]C_XBI_P3._@=XU\."7]G7X%_&']I6R\=:_P##7X+?%3PQ\.;.8>(C-'\. MM`L?'6F:;<_V9;#W(/.>F,#<#@9W6;)7R]WRN"L`.K%C MC//7=GJY'%`'Y*_\$)_!WQ9^'?\`P2A_9"^'_P`;_!GQ!^'GQ&\#>'/B-X/U M'P1\4]!\5>&/'/AGP]X:^-/Q(T;X?Z7JV@>-H+;Q1I=I%\/++PJ_A^VU.WA` M\-R:0]A$FF/9*/UMI%&!@=.,#DX``&/P_P#K]2:6@`HHHH`8ZEONM@XQR`PS MV;!XRN2>,;C@,<#%?+^A>$/VS[?_`(0G_A)?CY^R_JPL/B#K&I?$==#_`&1? MBOX=_P"$K^%=P=(.A^#/!+7_`.VYXG/P^^(6G^5XA_M?XG:\/B;X=UDZKI!L MOA)H`T._'B/ZCHH`_,?]J;QM_P`%"OV=_P!F'QI\7/"WC'X'_'KXF?#V?Q3K MS_#;X4_L)_M#:YKOQ5T?6'T/1/AOX%\&>#_!W[8?Q-\;^%==T#7[Z\U;XC_$ MRTT'XRV]SX1>74]%^"=I=^&[FV\1_G5_P2H>+_%7C[Q/%IGQ\^#?@?Q!^TI\5?A58># M/'WBWQAC]H:+QC86/QH\,ZOXM^+_`,6'TGX.?"SPGX$T+PG>_P!)3*6Z>A&# MG')&=R]&X'`X/4!ANW*;3TSCG<2""/^ M$G^/G[,6KG3_`(@:MJ7Q*;0OV1OBIX;;Q=\+I4T?^P/!_@G[;^VUXH'P]\?Z M:(M>&L?$CQ`/BAX;UT:EI!LOA-X?31;M?$/9:QX;\6WGP$\8^%_C3INC?'WQ M'JG@'Q]I7C3PU\(/"?\`PJ2Q^*>GZKI^NVZ^"O!GAOXB_&CQ%;^%]7\1>'[N MU\*0W/BSXWVNBRZ]-)K5[XG\':1=;=&]P4;01QRS-P/[Q)/0`$DDDG`)SSN; M+,UU+<<8.,D]>#R""K!E968$''H"-VY`#^);]G+P5_P4C^!_[,7[?G[-G[%G MAC]K3]H[]BEO^">%CXD_9N^#W_!2/]D/QA\(_CY^SI\%O#O[5J^!OV?(OB#XNU'2?`2^._@*_P`0-*^&OPQ\-:?!I?C&_NOB MIU?_``2<^'/[1O[(?QR_:]_8S^&W[-7[0?CC]BKXH_"GXMZO\//V^?V@?V3_ M`-K#X;_M(?&+5_A/^SO\"O"'P$_9T\9P_&#P]X"N?AQX0^!_A?6?B#\._A:^ MK?#'1?`/C^31#X<^"NE:'J5AXMLKS^SSRSC`.,%B.20"QR/D`5&"X`P5SR6W M!P7=3&>Q[\YP>O\`$`5*AQR1@!268LK$`T`?S;_\$I?^"=?[1.J_!/\`X)%_ M&G]KKXE:?X:L_P!A+X`^+[SX/?LL:3^S1XR^!GQ/\(_$CXM?#C3/A?=2_M(> M._B1\:_B5J7C.Z^'O@&?QAI^G^&?!_PG^`J7OBKQ+:>(/$"W5EH-MX;_X M*2_"/QSIW[5_QQ^*/['_`()_X*3:1_P4E\=Z-^P)X:_9Y^)_AS3_`(H-_P`$ M_-<\!^%/CAK#^/O#WBGQ)\(7O_@A%X2\.>$I_B-?_'[P1^WL]O>Q/JGA?7?@ M#X=N?^$MGOM9_IK\MBJC<.V<8]<]RV-V M0<;MW0$@9&,8&`HP0#^*']K#]@C]KCXVVW[1_P"PWX%^&/Q=LOBE\2?^"UW[ M3'_!0+PQ\8]0^'?Q`TS]G>#]F3XJ?L3_`!-\*>$=;_X:)_L>+X70^+U\=^.M M&^$LWPJ@\7Q_$NQURVU+5+KPE;>#K7^VD_1;_@DO\)/C%JO[5WPI^-OB/X2_ M&GX0>!_@!_P13_8I_P""?WCK3OC;\*OB%\'M2U;]IKX9?$7QYXO^(^C^#-+\ M=Z-H"_$+PEX#TR73[&3XH^$H/$/PY\0ZAXE2#P'XO\016FL7%M_2,8O3'\6` M>2001@LZO][^,[=S9!)8J2Z^7T)`)4,H+%F)5L=^,,=H!8[VP/O$DT`.08&! MTS@`=!CC:`.%"D;0HR.,Y))I](,C.?7CV']2>I]S2T`%%%%`'S-\;O"G[8NO M^(-)N?V-O%.I1VT&N12:G MIG[17@VVFGU+2KB'2(5T>]M-?^E*8RD^AR"N".QZ_4<#*C;GNW3`!_)!X1\, M_MQZ?\;%UOQ_\?/$_B+]O8?M82QM\./"'[*/[=7@G3[CX9?\+[BL(+RS^*VJ M?MG^/_V)+?\`8:/[.ZG6Y(;GX&WFH6_A^9O#[Z\/VR;2;Q3/_0/XT\!?\%%] M1\6^([WX=_M3_L5>%?`ESK%_-X1\-^-_V!/CIX_\7:'H,EP[:=IGB/QIH?\` MP4G^&NC^*M7L[:WIO@+PC8:C/&+RU\/:9&R6R?:X3!)!`)/8#/ODD')+ M$L>`"<<9W,SD78H7L.@P`!P.``!QW]!G`````!R>B6?C2VM?"Z^)O$'AC5K^ MS\-&W\:W&@^$=7\/6GB#QD4T11K_`(9L=1\<^*)O"'AG?#XE_P"*3U;4/&VI M+%JFAJ?&ZGPY>/XE_EU_X*4?#/\`:1^&_P#P4AO?VK/^"<&D?MR?#?\`;.NA M^R+\._'_`(!NOV!U\6^!?V>-=^ M`O@_4O%6C_%CQ-\?M:^#GB30_"OARTU3X+:1H-_XG7XL^+/ZM6#$Y&,8..N5 M)R,CAES@\$J=N"N"'.U/+]SU!^\P_B)Y.2S<$##,5P,*$%`'\&?[=/PU_;Y^ M%?\`P4?^-?\`P4-^%_[&?Q2_:-_:P\&_M=>/['P'^RE!^R;\?_%'['GB7]FS MX+?LD:[H7[%?[V%SX7\<_%SQ9\:]/\8?$^ M#X-_!_P5\-]>\%>&;R+],=+^"]Y?_`!V^"OA?P9\3/A_8 M^+)+KQ+HWB^#XQR>&-2U_1+?Q)X9M6L9_P"W?Z6MGRX8!N<]\!@=RD`[L%6` M*=?+PH7)4$KL.2<]^!\Q'7=D@G&0=NTC#+C(8*0B@'X+?\%1OV/O$NA?\$Z_ MV*?V2_V7]%^,VLZ=\!OVHO\`@G%X`\*ZUX#\-6_Q&^*'@?X6_!'XB^!_#*_% M+4H9/`_BGPM<7/P_\,:%;^+O$/B/Q3X&U#P+9RZ;/J7B'09?#[7-E)^:'[9O M[%O[>=MXN_X+?:/\+?$7[5_[1.O_`!2_8Z_X)]Z1X3^+OC?X>>!O#OBCXW>` M_!7Q;\=ZS^TQ\$/AO??LZ?#S]E3X;?$#7H/@;+XM\+WGP]\%IIGQ!\4V/C&+ MP-)KD6M>,]!U:T_L7V'M\IRW0DY!/&M^SC\8?&7[$WQ;^-/Q_\`'WAO M2OAO_P`$?_C+\-OA_P#LU_%SP9^S?\.]!\&P_LJ?\$Y?C?\`%/\`:JT_X6^& MOVH?&=WXX\*ZE\>_VO/V;H/#7PF\;:M\8/%OP#_P#@W%^(7PRNM.\;_`[Q[J_B7P[^T3X%_:%^ M"6N^$/AZ\'B7PS]LL/CUI_AKP=J.J^"/!T,1A,(Q9B5 M&]J`/X6_VI?V)?$'C"#_`(*._'+]G_\`83^*UEXB\`_LT?\`!&"^_8$U'2OV M0?BI\-/'_@7QM\,?C!97WQ'O M%'AKPP]U'XA@T_PYK$WG?TD?\%;_`(3?%?X@?"[]E;XF_"SP/XD^*UO^R'^W MM^S3^V%\5/A-X)MX]4^(7Q`^#GP8O_$\OCBS^'GA&='?XB>/_!RZ[8?%/P9\ M-M-FLO$WCC7O`%CH'@A[WQK=>']'U3]754KCGH1W8D@)CJ3G.>?G,AQD;N1M M:8V)`X*Y.[)!X8LS+LV;2N[:F"(M:\<>$=(\'^!/`7Q;TJ+5/AAHOC7QT][XH\(5_/1^ MQ[_P3[\8^,/V_OV;?AI\0OV5?VAO'_["GAC]OS]L;QW!#;GX7^!X=1UY;? MPYXMT.3XCW/B&WE_O3*$G)VD$'((Z].N0>P4<$$%06,G`4",.]`^)/@+XI:-_P4\^/'Q4M M_B[X)_81^(^N3_$/]A+4_AA%HOPA^&'C/_@HIXB_:=\,_L\I^R(GPPN?AY\/ M?#W[*7@OX<>.?C#\)?C3\.M.OK?X;QC2O$WC2Y^S?^"B/ACXDZ1_P5H_9/\` MC58^(_VY?@[\*M`_8B_:"^'_`(@^/W[%7[(FN_M7ZUH_C'Q)\7/ACK&@_#?Q M%H<'[(_[9/AW0[7Q3IFA:CK,MU=_#?3M5C/AZS^R>)M+M[NXL]1_HKVMC&''..>,9&,8X*E6QG`/&6:$;@EB2&)'J`>HR"-+\+WO@7]IGQ=\._P!GGP'X1T[P M#=>*=)\6>#]-MM*\3S?DGI'P5^/Z?\$Y/VI?!WA']FK]ISXL:I^W9_P3%_X- M^-7_`&=M2^#W[/GQ5^+7@GQ(/V;[-;+XR:5JWCWP)X>\1^#/"&O^"K2QMM9N MO"/C'6?#WC34]$U&SUCP]X?_0SUO0M'\2Z-JWASQ%I6F^(/#^OZ M9?:)KNA:W8VVIZ-K6C:K9S:?JFE:KIEY%-97^FZC8W%Q:7UC=02V]Y:S2VLZ M/!(R5G^#?!?A'X=^$_#?@+P!X6\.>!O`_@W1=+\,^$?!G@_0]+\->%/"OAO0 M[6&PT70/#?AW1;.QT;0M%TK3[>"RT[2=*L;2PT^UCCM;.&&"&)5`/XKO^"N? MPO\`$VD?\%%OBC\2OB/\%/BCXA^!GQ'_`&_O^#?W0]&NK+P!XINM*^-=GX.U M3]I2T^)_@#X8ZEY&GZ?X\\7VECJMGH6I^'O#NMS:Q87_`(ATS3;U+"?5(9J7 MX9?L'>)/BG^W7^SF;S]B?XEV/_!-F?\`;+_X*P>-/@U\#_BC^S1\0/!?PR^& MOPH\5_L7_`?0_#]UXK^!?C3PEI$7P+^$GQD_:4\+>.]>^$'PI^)?@[P'8>(O M$=OJ^O:)X!MI?%.GM?\`]GOC?X8_#GXF1>%H/B1X`\$_$&#P/XV\,?$KP5#X MX\*Z)XLB\'_$;P3=-J'@WX@^%EU^RU!?#_CGPEJ+/?>&?%VDBSU[0[IVN=-O MK>?][7;[>D7?ASQQX2^PZ-IWP0MOB)K]M=?#CP1X>TG2O`FGZ;X$\&Z?HFF\EHO[&/Q_ M'_!+O_@H1H/PJ^#'QZT27QQ_P3J_98^%NI_LL>!O^":OQM_9&T3Q9^TKX4\3 M:=>^)_$T?AOXI?M!?&7XP_M,?M8:1X9,OA'X\_'GX?\`PITKX5?%>TTWPEXA MT_Q_XWUG2=8^P_W?;&[$<+@'@$-C`/W2O0M@A5"Y/R,&P%VG(//!Z;CR.0"3 M]XD`Y`)*[N<;@'H`_B$_:T_X)^:W8^/OV^O#N@_L)>+O$'[-OA7]NW_@BG\> M_!?@_P`*?LN>,?B%X;\1>&V\!>'O"?[(_%7B=[C5F^)::N\M\:_MA\+OI$GAO07\/Z=)I&A-HVF'1=)FT*_ M\+RZ7I)LH#INGR>&-4L-+U+PVUG9>1`=`O\`3--O-(V?V?<6%I+;O`FPL>`H MSG:`,],%5VAT4#8AP3E57:=V#P`#(`1UY))/?\!R3T&,XP"[]7^844450@HHHH`****`"BBB@`KT'PG_R M#IO^OV3_`-$6U>?5Z#X3_P"0=-_U^R?^B+:N7&?P7_BB=&&_B?\`;K_0Z>BB MBO)/0"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHII8#&3U]P.Q/A&>"5)VGA]N&P`244A;'K_^K/KC'U.!R.:;O4YQS[CD'G'!]<\8ZD@@9((` M`^BD!!Y!R,D?BI((_`@@_2EH`**:6`ZYZ@>@&3C))P.O;.>F`I!.`,G`QGCKQD=*;YBY4
WR[3GGC&.K*"`/HIN\<=>1N'RG)&,YQC/X8R#@'EE!-PQGMUZC[O M][K]WOGTH`=13-XQD@CC/.`,8!/S9V<`Y.&.0&VYVFC>/?OZ>J@9.=H)W*5! M(8@].HH`?12`YSCL<'V[_P`B#]#2,X7KG/'`&>IV@>@R>!N('7G`.`!U%1F5 M1V8^F!]YCG"KG&20"W'RJ@WN50ABX,#R,XYYP<8&><^AQP>XP1P0:`'44@/Z M?_KI"P7KUQD#(RW(&!DCG)4=AEE&PR#C<3@`9R20.]`#Z*16##(Z?0@^X(."I'0JP#`@@@&D9U7K MW&1[\A0!G@DLRJ!U)(%`#J*16##*\C)'X@D$>Q!!!!P0000"*"0,9XR0,Y`Y M/0 MW&O3J"``.HIF]2`1R"<9QTSS MSG&`1R"<`@C&2R@AD`SP3C^Z,],$\`YR`=VW[[`'8K8P0!]%-5@PR,XSP>Q& M`0RD9#*00002.<'#`@#,J]3C`R2>``.Y)X'\S@XS@X`'44@.>Q')'(QTX/X9 MZ'H>HRI!*T`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`> M2:E_R$;_`/Z_;K_T?)5*KNI?\A&__P"OVZ_]'R52KWH?!'_#'\D>0]WZO\PH MHHJA!1110`4444`%%%%`!7H/A/\`Y!TW_7[)_P"B+:O/J]!\)_\`(.F_Z_9/ M_1%M7+C/X+_Q1.C#?Q/^W7^AT]%%%>2>@%%%%`!1110`4444`%%%%`!1110` M4444`%%%%`!7QA^UK^V/I7[*&N?`C2]7^&/B_P`?VGQL^(#^`VU?PQXC^'&C MVW@J5UTZTTV\UBP\9>-?#FLWQU_7=;T?0-%NK'2SX.AU>[M]&\5^-_"7B7Q# M\.=!\>_9]12=.H4=RP)7!R`>2$RI(;G=D#&!PP`/R+_93_X*>^)?VE?&'[3I M_P"&;;:S^$_[..L_$_P]JNM_"GXR6OQO^/N@^,OASJ^E6>D_#+XV_LK:;\.? M"7Q`^%/Q:^(.CW^L3>'/!'A'6/C'_8/B+P!X^\'_`!#UKP7J5AX8N/%NUX3_ M`."A/QA^,OPY_9RU#X#_`++OA*\^-_[0DG[4NN)\'OCW^TB/A+I7@#X?_LI_ M%-?A'X[U'7?B?\,/@M^T;;ZQXZO_`!;XB^&]A:^%/"?A+4_!L4_BC67B^*=W MI/AK3]7\5VO@%^P3\8O`_P"VEXX_:X^/7Q]\`?&'4-.TCQUX&^#VH^%_@3I? MPO\`BQ?_``^\=Z7\(M-FLOVAO'FG^*M7\/\`C>^\-6/P?\/P6&C?##P/\(_` M6J>*YO$/Q-N_"6F3ZYH'@SX?+IO_``3_`/B]\,?"/[/TG[/?[1OPZ\&?&+X# M:Y^UBMKX_P#BK^SGXB^*_@[Q3\.OVM/BE>?%OQAX-G^''A7]H_X,:IIFJ:!X MGT_X;W&E^*(_B3>Z==S^!6:]\*-::\++1P#SKX=_\%5/%/Q4TKP9\7_!G[/' MA6+]EYOB%^QA\&?C#\0/$OQXU;1_C1\,OC#^VCX3_9V\2>$O#6C_``-TSX#: MYX6\9^$O`$W[5_P0T/Q[XRUSXX_#VZLY+_QMJ6G^%KW3_!L-UKGV'\:OVY/@ MC^SI\1O$G@CXP^)8]#M-#\(?`K6-*MO"GA3XV_%;XI:_XI^/WC[XR_#[P%X3 MTOX9?#3X->*9-;G\5Z[\(-1T;P);^#?%OC/QWXK\4'5_#NJ?#OPLB>"]6^(' MQ?\`#C_@D_XT^$^F>#/A'X._::\.G]F2+QW^Q%\7_C!X#\1_`/4]5^-7Q7^, M'[#WAS]G[1/#OBRR^-=C\==$\&>#-%^*]Y^RS\%;_P")OARX^`?B^6ZT_2?$ MFAZ-KNFVGB>*XTCZK^+'[$9^*'[4FB_M*'XH#1#I5O\`LHVZ>#/^$,&IBX_X M9B^(?[2_CX2IXA;Q98['\;C]HO\`L@YT2<>&O^$1_M%&U[_A(7L-$`.F\-_\ M%"_V1/$_@7XC?$72?BAJ%/&.G^'_#OB+P M)INK>/?`-OXIJS_\%&?V0K2Y^)$-_P#$3Q9I=K\+]`\=^(M8U[5_@9\?M(\( M^+[7X8ZG'H7Q`TOX)>-=3^%]IX1_:+\7^$O$LT/A+6O`?P`UOXE^-[7QE-#X M//AX^)IH]*;YUUW_`()9Z/K^O_!W7+CXTZK8K\/_`-KG]H+]HSQ]I^F>!XK. MW^,'PR^-O[6,'[:VG_L^^()'\6RW&F:5X,^/7@OX(ZS<>--^K'Q5X=\`^+_" M-WX/TC0OBUXFM=,\.\(?\$3?!W@;6/C`_AC6_P!D72='\;>$_P!HK0?!OB+_ M`(=J_LW>(OCW?W_Q_P#$UUXC6S_:D^-OCN^\8+^TG\/O`ECJFL>`K;P9X=\# M?`;5?B#X`O;>P^*7C?QAXEL_^$ON`#Z@U+_@J[^S';?$/X3>&8C\2M,\$^/? M`_[4'C3QU\2O'_P-_:&^%-C\!(?V6+#P?J_CRR^.6@?$?X,^'M4^$`BT+Q+< M>(]0U#XMR_#NVT/P[#X3UZ6/4M)^)WP_N]:],'_!1S]D\>%)?$UQX@^,>F:G M'XZTWX<6GPDUC]D_]K30?VE=7\6ZKX2UCQWIMGX7_90UGX(6?[3/BG2KSP+X M:\7^,;?Q1X9^$NI^%7\+^!O'^NMK:Z3X$\97>B?!6C_\$6KX?"6S^#GB3]H_ M0Y?`FK^'_P!KGX=>)/`OA3X/?$"/X8^`OA%^U/\`"_X1>!5^&W[)W@WXP?M- M_'&^^`'AGX:>*/@KH'Q2\-^$/&/BCX^?"?\`X2'Q?\2O#VA_"SPC\/-=\,^% M/`_4_"3_`(),>-O@`/CI8_%OXG:]XDB^(/BWQB_C63]JOPZG MA7Q'9^$+/P#X8\*^%H/B'X?^)@!]N_"W]NKX2>+OV1/#W[8WC>9O`/PW\3:W MJNBZ/::3!XG^)>M:]?S?%_5/@[\/M%\$^'/"/@]O'GQ`\9_%/Q'!H%CX(^'_ M`(0\$:MXR\0>)O%.E>#_``WH^O:M/9"^X?Q5_P`%6OV'O!F@^'-?USXB?$W_ M`(J/0_BCXF;PQHW[+/[5_B;XC^#?#WP1U?3M"^,.M_%SX5>&O@CJWQ,^!^E? M#'4]9T.#QSJ'QD\)^!+3PS#X@\/7NK36MAKVD7-['I_["WB32/V/?AK^SK8_ M'9)/BK\'OBOH_P`=/!/QTU7X86-UH5U\3_#7QVU+XX:5<^-OA#IWC#1H-:\% MZU=:E=^#?''A;PYX_P#!6K:CX9U'5Y_!/B_X>>(QHFM^'O.?#7_!-G7XM4^, MOC[Q[\?=*\4?%?\`:%^!_P"U7\-OBWXD\,?!VX\%^"[CQ?\`M)O\&M)L?&7@ M7P7J/Q6\9ZGX2\*_#3P-\$/!OA;3_`>L^//&&K>+9UN_$NJ_$>VO)KF.8`]^ M_;1_;!3]EOX7_#[XD:#I?PAUW0_B%XVT_P`+-\3?CK\=T_9U_9=^&VBW_A#Q M/XOL/'/QE_:)M?AK\9;3P#X;\377A[3/A]\.[P^!-8M?&?Q6\>?#[P5'>Z:_ MB>#4;?QW5?V_/B9JNC_#>U^&O[,5M>^.O$_[*&D_M._$[P[\:_C1;?`7PO\` MLZ6?BCQMX5\,^%+'XV>*]2^&OC34?#O@2^T+2_VB?%NH^.[?P=?>([&W^`RZ M5HOPQ\3W7C#4[GP#[5\6/V7/&WB+P[^S7J/PF^)W@;P9\9?V7(IH?AUXP^+' MPBU_XQ_#.>;6OAG=_";Q5J.M_"WPW\8_@OXG.NW_`(0U/6;+PUK>D_%_2+OP M[_;.J6=]_P`)/I6K:CI=[XE\#/\`@GW\1/V9/`WQ,M?@E^TEI.B?%KQ7?_!Z MR\$^.?%WP*TOQ5X$\)_#3X5Z')=?\*3\0?"ZQ^(GAO4O$'PTU#XG>/?V@O'7 MANQ\`_$CX1>)/`>A?$[PM\/M&\275A\.;C7?'0!S^G_\%0H[SX%_LB_%X_L\ M>,-=OOVIOV@O"?P+ENO`/BB#Q9\"_`.D:W^U+H?[,-Q\;+3]H.^\->&]%^(' MPM\9:EKFB?$+]G6#0O"&G_$7X[_#_P`0>'?&5OX%\#>"K3XC^+_AKUWQ0_;I M^*R_M/\`B']DW]F[X"?#7XM_$;PY>Z397>O_`!7_`&B?$'P/\!6U[I7POTGX ML_%C1]4U3P?^SU\?_$MKXD\`^%/BU^RM>Z1HECX.U@^++/X\SZOJU]X!L?`V MF2^.]J']@S4+[X*>%?ASXC^+FE7'C]?VU_AM^W%\2?''AWX8S^&/"/BKX@^# M/VCO#'[0?B7PKX+^&DWQ$UR^\`^$O$=UXN-1?5.?U7]A'XN>'M=\-?%;X)?M"?#?PI^T3IGQ]_:>^+7B;XA_%C]G;Q/ M\5O!'C+P-^TC<1V$7PKO_AUX._:-^".M6C?#/P-X(^`/@SP[XQM?B;(^HP?! M+3+[4O#2OXDN++3`#RGX#OV?VO])^%-WX9^'O@#X1:;\&M<\%?%CPK\/-=^.OPL\,? M$#QWJGQV^&%Y*?CA\3/''PL^'GA#1OA?\-/@[XJEU^[\9 M>*_!W_"/^!M/\'^*/$_CSQ-XOO+CP]-\.=&C/AS5O%?Q-HW_``2`\/V_B']F M2/Q?XT^!?Q0\&_L\_#O]GGPM)XT\=_L?>")_VS9M?_9\\5CXDH?A7^UWX7\> M>&KWX7?"3XM?$VRM/%7Q6^$&N_"CXKW&IZ;XP^,WA7PSX^\*V/Q)TJZ\"?5_ MQJ_8F'Q@_:.\/?M`CXFGP\=`7]EL#PB?!AUHW?\`PS3\:_B;\7V/]N?\)7IG ME?\`":I\2O\`A&U+:-/_`,(TVD#74.N'46TZV`/5-*_;*_9VU;]GO6/VH+/Q MEKD?P>\/ZGKWA_7+O4/AA\5=&^(.C^,/#?CBX^&>K_#O4?@?J_@BP^.%G\4X M_B+;'P/9_"JX^':_$?6/%]WIWA[1O#&H:KJNF6EW\QWO_!6#]E^/XL?"WP2T MOC_2/AWX\_9__:_^.WB[XQ>/?@Q\?/AEH7P4@_8]\7_#'POX_P#"_P`9](^( M?P@\.W'PHNX[;QCXMU+Q%<_%34/`5QX-N_#WPV\/:OI5QJG[1OP33Q7Z5JG[ M%LE[^S-^T;^SW#X]\':I-\>?BS\=OBO;:Q\1/@;X/^+7PZTR?XT_&'6?B[;> M"?'OP7\?:KJWA;XJ>!M/EU./PCXPT^;5_">K^+O#S:E>^&-9^&OBN\T?Q#H7 MP]X9_P""-OB/2/A_\//AY>?M3Q0^'/#?P5_;-^`.JZ+X6^%7Q#G\-^"?AK^U M)=_LUZYX`\-?LK:?\8?VE_CCK/P*\-_L^>-/V4OA?XA\->"OB)XF_:,^'^IZ M7J_Q%\':-X3^'_A76O!^G_#X`^SM=_X*A_L5^%?`>J?$7Q=\1/B+X.TS0O%5 MYX/\1>$_&O[,_P"U'X1^,7AB_P!-\`WOQ4U77?$_P!\2?!K3/CAX;^'ND?#3 M2=3\?:Q\4];^'.G_``QTCPAI>J^(]0\7VNEZ?J%W!VO@O]M3X=>)/C?\6O@= MJ=K<:=XA\#_&[PM\'/A__P`(Q#XF^)>H?$^S\0?LV_`S]HC5?B3G^$=8\)7WC M?1O'8![=XW_;6_9N^&WQGT7X!>,?&^O:=\0]:U7P'X?:XL_A;\6]?^&GA?Q3 M\5=6ET+X6>"?B-\.=2U_P`) M6?A;1-6G\9^$TUGCF_;O^!_BC]F?XX?M1?"W5]1UOX>?!/PGXU\1ZAXK^)GP MX_:!^#OP]UL^"-"O]9U2YT?Q5K/P+\0^)/&/A"PDL[O2=<\7_!KX>_%U=*U2 MSUC0[72-9\3Z5=^'E\U^*?[!?C/Q[\9?'GB#P_\`';0O"/[/WQS^,/[.GQ\_ M:%^$=W\';GQ)\2_%WQ,_9IE^%D?A1/AO\;Q\5-#T3X9>!/&>B_`?X.>'/B+X M:UKX+?$SQ!=Z5H?BZX\#>-O`&O>,;76O"_7:C^P]_:'_``3M\8_L#_\`"S1" M/%GP"^(7P-'Q57P7Y@TU?'FDZ_I9\3#P,WBM1>?V3_;:S)HH\767VM;,0PZM MIAF6:W`)Q_P4K_8MA\=^.?A_J?QTG M7OV>-$\0>*/C3X83X_>+_AUHOP/UCQ;\._"/A3Q%XU\0^%]%^(FI>(1X"T'4 M_&UKI5SX1LY-9'F7A7_@JK^SMXC\4?%VRO\`2/C!H/A?X:VWP$T_0!J7[.W[ M4-O\>_B1XZ^.4/QAU>'P!X7_`&0[WX#6'[2E[J^@^#_A%>_$3S-`^'WB,:Q\ M-+K6/B,MKIW@+PCJGBF3G_B]_P`$L]"^-'PW3X8>)OC-K.F:'-^TE^VO^T#? MZGX>\%Z;!KZ+^V#\+_VG?AU;^']%GU77=7TBRUKX4W?[1D7BO2O$VM:+XDT7 MQ5>^!8-)UCP+:Z7XAG32_%OBW_P2+^(_[1VI:W\2/VE_CS^S)\=OC._C#]G_ M`,8>%[/Q_P#L&6GBC]E>&7X(>#_VA?AK>:-\0_V9_&G[2?B[4_B+I/C3P5^T M9XIU=)X?C3X/\0>"_BSI&A^/?"^NVWAZQM/AY:@'W_H_[?G[)VMZ?IM_IGQ, MU2XDUVW^&USH.B2?"[XNV?C#Q!-\5O&%U\/_``_H_AWP+=^`K?QEKWB;PWX[ MT_5O!OQ?\)Z1H-[XG^`7B?0O$.B_';2?AUJ6@:W!8^T_'+XKZ9\%_A[/X^U5 M]`2RB\6?#+PH3XFU#Q/IFD>?\2OB;X0^&ED&N_!W@;XC:Z;Z2]\7VT6BVT?A M6;2]0UJ33M/U_7/"'AZ[U7QAH/YM_#[_`()8ZE\/KS]FGQ9I_P`:?ASH/Q#_ M`&.;/Q"/V:4^%'[+G@OX%?`_X?7'QN\62>(_VOK2_P#V>OA;XV\/^"_$7AGX MX:3=OX$\&6+WNG>)?@YH&FZ'XME\7_$CXU7GQ`^+7C[["^(/P:^)7[2W[.O_ M``KCXM:QH/P\\:7'Q=\'>,IM1\.>&WU+3QX<^#'[3>A?%+P)$^@2^.]82SUG MQKX#\`>&;#Q"T'C/6+3P_KWB#5K^S_M6UL;?2Y@#SO0O^"I/[#VOGQR]G\6O M$UEIW@'PO\6?&6H^)/$OP*_:"\(>#O%>C?`OQ?I_P]^+\'PB\;>*_A5HGA'X M[^(_AUX_U;2O`7B7P;\$]:^(/C&P\9:A8>%GT-]=NH;*3.3_`(*7?L]ZAXW^ M%5KIFH7LOPF^)OPT^,WB:?XEZUX>^(GA7Q)X,^(GPE_:D_9X_9&N?@QXP^"? MB3X>:=\3/"_C*[^,7QW/A/Q1:^,=,\+ZQ\.=>\'7VF^*?#L-M=7^J:%Y9XW_ M`."6Y\8_#'X8^`8_CM-H^J_"CPA^U-IGAKQ-#\-EO(G\:_'[XY?#[X^^"/%= M_HEQX]`N-'^%WC'X<:):Z[X3;4S+\2](GO;9?$G@:22.6.[\6O\`@G;\8_CM M9>%?$OQ4_:TTK7OC3X6^%'Q8\&V7C?3_`-GO3="\"6OC3QA^U3^S)^U+\--4 MTGX96'Q174+;X5_"G4_V8?"_P[F^'>L_$/Q'\1O'_@O6;RZUSX]V7BZU?Q)J M(!]#?%/]OS]ESX3:CXF\/^(?&OB35/&7A+Q]XB^&6M^#/!7P?^-OQ+\4:=XH M\)_#7X\`/X[\+Z M5XN\=:3KE_;Z3)\Y_"3_`(*W?`#Q9\-/AQXY^)MOK/@[Q3\5M-^$$G@WX._! MKX>?M*_M4?%"Y\1?$G]D/X)?M=Z_X+D\(_"']FZ76M:UOP1X%^,,>I75WX!T MOQQX=F^'VCVGCK6M>\+ZQ-XR^'WP\Y70?^";/[1WACXB^+_V@]$_;'^'-I^T ME\3/'7Q"_A3-^TL?$'A7Q9X: MU_\`9"^'/C#X8_$C7/BMXXM-(L[W6_"_Q%\!?%5+@:V>G_9+_P""7P_98\6_ M"3Q4?CD?'(^%>F^#;#[#_P`*S'A?^W5\)?L)_LU_L4M(]VOC_7SIBZ@?V>C\ M3?*$%]#8'Q>/!P$R^'O^$JUP`]MN_P#@IU^Q'977PV@A^,&J:]IOQ8TKX&:O MX-\8>#OA#\;_`!W\-53]IG6M$T'X!Z/XN^*G@OX;Z]\-OAOXL^*-]XE\/R^% MO!/Q&\5>%/%]SI&L:=XAFT2#P_=PZH_J7Q@_;3_9P^`OCZ#X:?%7QMK?ASQ4 MWPXU?XP:H;/X8_%?Q7X7\(_"G03KR:O\1OB)X^\'>"/$'@+X:>"["X\-ZG83 M^(OB#XE\-:6NJOI.CBX.JZ_H-GJ7XCR_\$^?VN/@SJ?P>_9#^`.G^,/$_P"S MU?>.?^";7CG]H?XY^+_AU\`-,\`^(/$W[$FM?L\0^)?%_@CQ.O[;%_\`'OX? MVOB/X4_LU>!/#3_"=OV.?BG%J?Q3TVT&F?&[P5X/\8>)O&/AW];/VEOV%?#7 M[4.I?'__`(3'QM>:3X9^/O[(Q_95U71-/\,:-JUYX>V>,?%_B^W\?V]SXEEU MGPUXAEL[OQ1##'X.\1>#;[0KP:4\6M2ZIIFJ7.D0`&;J7_!2+]FZ'3_#GB5/ M$6M^%_#J^+OB#X=^(VF?&KX0_M-_`CXN^!=/^'O[./Q4_:5U+6+3X'?$+]GN MQ^)-_P#;?`?PLUK6]*E\8Z9\-O"OB?POIOBB]\">,/&/C31='^'/BWKOA!_P M4-_9+^.'BGP]X'\!?$#Q5#XO\7^(-.\.^$_#GQ`^"7QW^#FK^*+O7OAS\0?B M[X8U/P[8_&#X:>!9];\*>-/AQ\)OBGXM\!>-]+%WX,\?:7\.?'+^#-?UR?PM MKD-A^?ND?\$6;2#X?:MX7/CW]ECX5:YK7B'XKZE=Q?LA?\$_OAQ^RI\+%TSX MA_L2?M`_L@:4DO@/PK\4/$_CKQ'XHT;4OV@_$7Q5UOQ)X\^,OB^QU1]-@\"^ M!_#7PNTO4-0U:7Z,^/7_``37U'XP1_&+5_"W[06J?"?XB^./A)^QMX&^%GQ' MT#X=V&L:U\$_'?[(/C#XY^([+XDZ9::AXKM[/Q3;_$;1/CCK?@3Q#X,NCHL- MIX2;7].E\0:Q%XG9-)`/;-,_X*-_L@:UKO@;0M(^(WBG4X_B%<>&[/1/%UA\ M$/CU=?"W2+SQOXOOO`?P\M/B%\8X?AD_PG^%%S\4?%5G!IOPFA^*/C3P?)\5 MHM?\&:K\.U\3:/X[\%ZAKWA7Q'_X*\_LJ^'?`EGXY^'DW>N>$/VGOC)#\+/#_P`:/ATEQ\"KZ\^,7PH_L_3O&VL^!_'_ M`,*]*\8_#WXK>*_#_A_X5^#O&_\`PEWQ,\%F^\K\3_\`!%_X0O\`'OP;\4OA M]:?LQZ-X/T+3/V7])N[3XM?L0_"+]HGX^^#=._96TSPSX5\)Z/\`LY?M!_$K M6Y=/^"&@^,?A]X&\'>"O%^G:U\'_`(LW.BK9:WXT^%&I?#3XC:\/%^F/?AY9_%L^#/VF?A?X.U+Q?\`%W]FOXU^"=&\`_LM>(OAY\%;KXE_L[_' MSX;_`!C;XK_M`_LW^"_VG]%^"GQ`^.'Q)\.?"3P/\./&WQ+_`&:?"G[%UOK< M$.L^)/$WA+Q3-<>&-'\'`'UAK/\`P5S_`&#=!G\1VMW\2_B??3>&3\4/-/AS M]E+]K?Q;!XCC^!GBH^"/CI<_#>[\+?`O5[7XKV'P.\2J+#XTZA\,9?%ME\)H MY(K_`.(,_AS3IHKIO7]0_P""@/[)NF^.-1\!W'Q*U>6[TRSU&XE\::;\*_C# MK'P5OM1TOP!PN_D_PW_P0[\%^%/B M!JGB72?%?[,TFFZS'K6MWWCS6/V"?A)XC_:]3QIXA^!`M#_`&A=/^'K'0:`/H[Q'_P6`_91 M?0O`6M?#"'XS?$^7QO\`%3]F_P`#0:1;_LR_M7^%MUWX`_\)%XY^#WB.U\">.9?`GQ(\)Z-??#?XBZYX:N?"7A[Q[_`&Q/'&/J MKX__`+:?[.'[,.M:+H'QJ\;:[X=OM8\/ZGXUOKGP]\*OBW\2]#^'WP_T74[' M2]2^*7QK\3?##P'XP\-_`;X3Z9>W_P#I?Q6^-NJ^`/AQ;1:;XBNW\3_9O"7B M>ZTGY=\;?\$XO$VL>)O!7CCP;\>-"\.^+/`/PS_8#\`:%)XF^#EYXN\/37O[ M#_Q8^,/Q(G\0:KI&E_%KP7J5Q;_%&P^+]]X?AT73O$.D2>!KO1K?7)-:\9V] M[-H4/;_M8_L/_$+X^>,?B!XE^%GQ\T#X*V7[0/[.?_#)G[2MIK_P8?XN:UXH M^"]GK7Q"U70;SX+ZR_Q1^'^D_"#XKZ##\9?B_:6GB[QCX5^.'@F]D\4>'[O6 MOA;JA\'Q0:P`:7P`_;LTSXS^+_VWI?$_@8?!SX&?L:^/;[P!>?%WXEGXQ>![ MGQ/)X-\(/XG^*OB_Q#H'Q6^`GPP\`>&?!'A#RVDTS7/!OQF^+[ZOX:6+QEXG MM/`&C:WX3D\3>.6'_!7'X%:U\1?&VAV6B^*O#OPX\`:)\%=?UCQG\5/AI^T_ M\+_B-J4?Q4\!_M@?$;5-)\-?LZ^)/V9_^%KWGB#P]X._9.?Q1X775]+T+P]\ M3O#?C.XN_"GB%=:TGPOX<^)?T$O["_@V^^`_[8W[.WB#Q=K%SX!_:]UGXJRZ MG+X>LQH6O^`/#/Q1^$_AGX42:-HVIZKJ'BN/6M8\.6/AT:OIGB+5;-(;N\GM MH-2T*YM[.;^T/!/"/_!._P"-NK?'C1/VB_VC?VIO`7Q=\?:?XF_9QU?4[#P% M^S->?![P=JFC?L\>`OVR?`UMHL>A:M\?OBW>V]UXW/[6\_B+7]2O-;U6SLM7 M\'ZA;:3HEOHGBG2]*\#@'T5\1/V[_P!G;X??$GX?_#O4/B;X!LV\2:%#\0/% M.O>(K_QQHWA[PM\+-4^"O[1/QJT+QO8>--)^&_B/X8W-Q>>&_P!FSXB:]JFB M^./B+\,X=%^'ND:YXTN-:GOG\"^#_B%XMX1_X*M_LZ>*O%_QDL9M(^+NB>"_ MA9X2_9KU31;W5?V??VG+/XY?$CQI^T?KWQZL-*^'?@_]D/4?@3IO[26NZGH? MAKX)_P#"P;>\\+^`_%B^(?A[K>K_`!#33])\!^!M8\67?@-K_P`$4/!5Q\)7 M^#7B?X^>+M>\+3?%7XWZV-1B\(V.G^)M&^!'C;]BGXJ_L'_`GX#^%=2D\1:C MIVCG]G/X+^.O"L^F^.+[1M:M_'_BKP?K6LZWX(TJ7QW?+I%;XL?\$C/B9^T? M?>)/B'^U!^T%^S9\?/C)+JW[+.O>"[;QW^P?;:_^R[;:G^S7I?[5O@JYC^*G M[,WB[]I7Q;-\5M*^(?P\_:\^(RR6EK\6_`-]X$^*=CX?^)O@_5;6TT?1?!&C M@'U]J_\`P5/_`&'=!N_#%EJ'Q4\8O)XG\%Z!\1IYM+_9[_:2UVP^'O@KQ%\1 M_&GP@_MWXYZIHGPCU+3OV>+;PM\5/AUXZ^'WQ-A^/-U\-[SX0>+O#&K:!\5+ M7P9J%M]G;EOB;_P54_9B^'OQ?\/_``Q_M?7-3TBT\6_';PM\6/B==^`_B]H/ MPX\"#]GKX5_$CXA?$X^!/'][\++CX=_M`^(_`_B7X;7'PM^(G@7X-^-_$/BC MX=^/-1'ACQ5:67C6S@\(7_DW@_\`X)*V'A'X.?'+X5:?\5?AYX;/QS_9'\-_ MLS:@OPD_9>^'OP-^&W@C6-,^-7[4/QHU;QGX$^#OPP\0Z#X5TCPE)>?M+2^% M?#W@*>XN_%L6C>`].USXB_&'XI>/_$WB7QE=0^*_^"6WQ1\3W<_@P_M5>#K? M]GKPYXN_;&\9_"CX8:O^RAX+\>>*O#UY^VCX)^-^A>./#GQ.\5?$/XA>*?A= M\:O`G@OQ'\<_$EUX.\*:_P#`+1;?7/A\+GP!\6;KXF:Q>P_$+3P#])?@3^T/ M\+/VC?"VM>+?A;J7BF6R\,>*K[P/XLT+Q]\,OB?\&?B#X,\7:?I6B:_/X>\; M_"OXR^#_``#\3?!>JS>'/$WAGQ3I]MXI\(Z0VK>%?$OAWQ1I)OO#^NZ3J=Y[ M:#D9P1[$8/K_`)_+J#7YZ_L+?L6>._V+O!.J>`K7XM^`]?\`"'B/XK>+/B)? M?#CP/\,/BQX)^#OPTT+7O#6GV.G?#C]F'P!\1OVHOCQ?_L^^![;QC97?CS5_ M!=AXO\7_``T%[K_B'1OAS\//A9I=]`ME^A*J$&%``[`=````!P.,`<'./N@[ M0``!U%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`>2:E_P`A M&_\`^OVZ_P#1\E4JNZE_R$;_`/Z_;K_T?)5*O>A\$?\`#'\D>0]WZO\`,*** M*H04444`%%%%`!1110`5Z#X3_P"0=-_U^R?^B+:O/J]!\)_\@Z;_`*_9/_1% MM7+C/X+_`,43HPW\3_MU_H=/1117DGH!1110`4444`%%%%`!1110`4444`%% M%%`!1110`5^.'_!3S]GO_AIOX\?L$_"\Z#^R]XC\[Q#^T;KPT[]K[]F'_AKC MX.$Z1\*]-83W7PA_X6S\%#<^(8//+:'X@'CJ(:',97.DZ@URA@_8^F,A;)!V MD@#(R#E3E3P1D`DDJ>&!*MD&@#^7/]J7X@_%']@S4?BG\-/@7X__`&3_`-E7 M3?AC\'/V!K;7]4^$GPQ^`W[#/P\\0/XOB_X*B^+O%7@3X;?$_P"+7P$_;)^" MG[,\7Q&^*O@CP==?#FW_`&NG\5?!/3]:UKQ-\,-&^*/PX^+7[1%I\2=3]V_9 M;_;P^*'Q8^.GPJB\??M8^*_"NKZK\$?A7K'P_P#V0=4_9:^'%_XN_:^\!^(? MV5_'GQ(\4?M=6_AOX5>(/B'XV^'MM=_'+0=6T#3/B+X%_:"\5_L?7.F?#G3O M@IH37_Q.^-W@?XAI_0J48X`QMYSN)8_>4@<\GH<'<%7H4<'Y4V$+A>."<;CR MWR]6VECN^;+DE@3OPS8V@'\=GP)_;L^.?[3'C[X<^$_'W[3'@?\`:1^&/B_X MK?\`!-;XZ^`[_P`-^.?@!XZOOA[XID_;>\$:1XO^'^MVO[.'[/OPJ\$_!CQ] MI'AOQ=\.[_XK?LO:Y\?/VYO&OP._M;X:VE]^TOXDT_QM9^+/B7^Z?[3GQL_: M(^''[5OPG^`W@CQ+=QZ+^U_J7P=TGX/ZI!X5\,7D/PFO/@3XZ\3?$C]M^76M M?U+0M0LI/^%B_LMQ:!;?"2T\76.IOIGQ$TKQ'!M51M5-J#:A7`&[+*Q4F3RN]^"7P[U3XRZ#\?]4T:_P!2^*?A7P!K M/PR\+:QJ'BSQE?:!X8\)^)=;L]?\3+X;\`7.OR?#W0/$WB:[TW2K/Q)X]TGP MK:>.O$&AZ-H?AO5O$-UX:T72]&M0#^7OPK_P4S_;1M--_:)\5?$K]I[X)^'[ MZ+X;_%-O'7P:\'>+?`OQ8^,7["/CJ+]H?X:?!GPI=^+/`6K?L/\`[.G@']D; M3/`5O\0/$,/B+7OV\?VK_P!ICP]K5CHI^/7@?2/B[\+_`(1?%/PIX[]S_85_ M:V_;#_:;^*7A/X)^+?VR8KS2/"W[4/[0>B:A\4/@;>_LU?')OC3\&?A]^S/^ MQ;\=/AY9V/Q?O/V*/@7\.O%G@WQ%XN^-OQ$T!/B9\-_V8?A4?$/@..;0?"^M MZWKNCZ5\8KG^F7RNGS,W+'+,<@-QA>,`A.`V`_!^8M+(Y<(SSSUQG;DLO^%:ZI\#_@MJ'@K]GOPU^S)^TSH_P[\%?$_P"&&A_"_P"% M'ASXT^./$'PM^$-MXC\7>-=`^(GC_P"*.C?$F]L+\Z?X2T&*?3;.S_I@6/`` MR,`AN,CY@&M9\.^./AE\)]!^`WB&X^'WQ*T@>$M2UKX,>!/"7AC4=*\-3 M_"#XK:9XP\3:+\1[WQ!]_P#Q4_:"_:"_9]^-/B']G7XV?\%#/%OP^^"%M\5/ MA'>?$+]NKQ_X"_9'\#>*_@KHWQ%_9U^.GC'3?AK;^)=;^!L'[+OPY\&^.?C! M\)/#>C>$_''QL^%'CC7S_P`)+JGPAA\:ZU\1_B'\+O$/AO\`H5$6!CCDL>1D M@Y)4J>BE%?'6N?&+0=,TC6X_$%I=?!3 M]HG]H/\`9J\2RWT-A?Z^,_`'Q&\"^)?VQ/V&H_ MCGXX^*_A'P?X"^%OB7X0Z!_P6!^`GACQ+J?Q+\'Z[8:7X)\.^`9_AEHOE^,= M(\66D6D6OA^/4$\8O'_`(#_`+47[,WP MX^+3?#FV^$WP_P#V@_'_LYZC\9M+@M=)\,^(M`_IZ^&?PR M\#_!WP#X1^%_PU\.V/A3P+X%T.S\.^&=!L9+RX6QTVR4!?/U'4+F\U;5=0O) M?-U#6=:UJ_U/6]>U>ZO=7UO4M0U2\N[VX[DIG=G!W9!_W?FX(*D,/F8[2-O0 M$'EB`?S8?`_]N;]H+Q3XW_9*\/\`QM_;M^''P_TGQ%<.OPQUOX2_#2W^//A' M_@I%J'_#9UW\%_%/@#0?$'B']E[]G?Q;\3M0^'7P5L?`^H7OQV_8U^%_P=^# M6EW7Q;NOVNM3TGQ7^RSX=TWPS9_/NO\`_!1K]OJW\0_MF3V_[2O[/_A_QQX' M\#_MP7<'[,\7B_3/B9\7OV9+?X(^,-4T'X)_$;6?V<=+_8!\!^)OAAINH6L7 M@.[U;Q7^TK^VI\4?A;\?]/\`B"GB;X%0V5MXG\#^%M'_`*T/+/<@\@G._'?= M@;SMR>A7[H)'S#((J$8YQ@8'((Z8R`$0(4SM4KCT5?BC\/_C_^PCX$^,/B M#4?B9KOPP^"/P_U>/Q)X`^('Q/>X^$]Y\*[GX6:?I^B>'K#2/BA8?%N2]O=3 MD^2/`O[=W[0?P\_96\`>&?V^)#X*\2?"S7OB-X5_9;^-N@_!FSTG1;0>&]5\,?M>?!_]H[XL?LY1 M:%_PF7[0>K7.@^(5U:T_KT\LYR,#`XZ\$8QQZ8W`!2@4,R@-NR$,0Y'5#_`< M%1G@[5VX`88W#)4[?NYDE+`'X-_L$_'O]J[]H_XM?"#1_'W[7.B>*?A]X2^$ M/Q5^(E]K/[/UI\._'O@3]I5/"_[1>N?"[PGJ/B3XU_$#]C'X#GQMX8_X1J&> MPUOQW^R[\*_@Q\.?B1K>C:+XW^%.OV7A"ZO=-UB/]I2V_98T_P#X*._L^^,_ MAKK_`,&M7_;5T7]ISX?VOQ2^%.H:'K.C_MV>._`'CCX8Z3\,AKWPB\?>*/$\ M?B'2/V&_@G\(O%.M_&+XN?#GX9?"G6O@5\2?%G@'Q[?W_P`1/"/QFM?C--XJ M_>G8>,'H&O@/\`M,?\%.(/''Q;\1:KITG[1G[,5O<_$'XX_$"RNM1U M'Q?\5OV>_@Y9Z+H-IJ%^-$\+^'H_$/CKQ;I_ACP)\._!6C^'_"MMJ.L:+X3\ M$>%M/:YM=/D_6N,87OR2<'L3][!.206W$$D]>/EVTT1D=3USG!(SELGO@9_B MP`&.2`F2"]`0#G!9B22`!D\`=`#T``W%F`P"S8!H`=1110`4444`,8$\C'&# MRS`94Y`('&#D\]B%)5\8#E!'&<\YSC!]\XP,YR>`/IG)*T4`%%%%`!3'4MC# M;<=,`9!YRRD[@&`X&5((W*P(8%7T4`1;&``^4XSP=QP6R"%+%N.<`D'"[D`" MOA)%&,^I.3[]@23R3@#J3Z9P!2T4`%%%%`!1110`4444`%%%%`!1110`4444 M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110! MY)J7_(1O_P#K]NO_`$?)5*KNI?\`(1O_`/K]NO\`T?)5*O>A\$?\,?R1Y#W? MJ_S"BBBJ$%%%%`!1110`4444`%>@^$_^0=-_U^R?^B+:O/J]!\)_\@Z;_K]D M_P#1%M7+C/X+_P`43HPW\3_MU_H=/1117DGH!1110`4444`%%%%`!1110`44 M44`%%%%`!1110`4A('^?<#],CCKR,9)Q2U^*;:3Q_\5;ZQ^&OC+PCXR\8V7P1F\+W6LWOP]U#X@>$_$X!^BZN&`*@G M)([9&"P^89RO*D$'#`_*P#`@&\8R,D`'H">02"O^]D$;>H(P<'`/X"+W]I/3+OXB?M#^+?C!\7O$/P1M='A^%WQ&T MCQY\0$UA/`/!>&_^"E/[6WQ+35OC#X*A_9<\(?"D_M!_L'_`#1?V??&W@SXE M:[^TK!J'_!0+]F+]COQ[X1\1^(O&FE_&/P_X:@?X&_%K]JB[\7^-_"MC\'?. M^)'P&^%'CS3-,\1?#3Q%X9?QK>`']`F]?7/WNF#]P@,>#_"QVMG&UN#BE+`9 M]NO3CKU.<#.">2/3K@5^%FE_\%$?VIOC?_PK&R^!^C_`[X:ZCXN^+?[.W[+7 MCJ]^+OPV^)'Q*A^%W[4?B']G/XW?'W]JGPA+I/A/XR_"D>,;+X))HWP=\":; M8:;KFDV]QXR'Q2T;4O&,[II\_AOPL_\`!1G]K/P_\&?V@O%7PXU+]F3PQ;?L MA_#KQM\5OB'I/QMTGX[?$?7_`(W7OCK]L[]L7X'^!],^'GB'6?VE;?7_`(7> M'M$B_9XBFTM_$&H?&6R\<>-/%)^"_@30O@IX5\#Z3?W@!_2,7`ZAN?;U.!^? M8=>BD!B%*[U)QGG@X[@,2%)'8-@XSC/0?,"*_EO^-G[5G[=_PR_9C_:XOM&^ M-'PZ/@WX@_$K_@MU\/?A)KNJ^%?BYJW[0/P>U;]FK5OVPOBOX3\4Z9\7?^%] M:3HQT30O"_P-/B+^T MG\1_C2[_`!N_:A^+W@O7O@QJ^BZ#\2[SX%>"OVR_`'PN^$VD:#XMO+?5/&NN MS_"W]JGP=^RG^S5X97X`Z#X2_;IOOBA_P53;]L7X=_$3PO\`&Q/AC\/?!7Q* M\*_!?QG\*_%X!_5QO`&[G&,YZC'^\/EQR.#C..NWE3NZ M;65LX.:_*[Q1XB\+?%[]BO\`9)^)7[5/Q?\`CQX+U/QIX4^'>LGP3^SO\3_B M1^R_\1OVG?B_XR^&%W>>&O"'A^U^$/B'P'\?+?7O$ZKK/Q"T7X)>$/B/X9CT M8VUX_P`3EU;PY\/]4N-(_/;Q/I'QY\`>#OBMK7QO_:(^/\O[2G[$GPB_X)ZZ MA\.-/T#]IGXM^&/!7B76?'WQ-\132Z?\4_`'@GQ7X/\`AK^TC??%/Q-IFH?L M]^*_&OQI\%^-;CQ[%X.O]3TNVT'6]0U+S`#^ED2*>F>A(!X)"D@D;L#'!*MG M#+\REEYIP<$%AG'/.#C`[CU!'((R".1U%?A'\1[[]JR3XX_\%COA7!^UU9Z1 MXEU;]AK]E+5/V;_$/C375^!OP7_9;U_XZ?$?_@HWX!\)7O@V?3#XGO?#OC+3 MM*\+_#&[\7_&#Q#?>+?&'Q'^+GAZQU:"'PG\,;#X9?!/X7?5'[']Y>?#_P"' MW[3?PH\9QZ[\#_B#\'=7_MCQ[XO\9?ML?M(_M_\`P]\&KXS^%NE>*O#OBW0O MCW^VAIW@SQQ::7X<\-PVNO\`C#X;W?AOPGX+\+7`?5XKB\3Q7>ZU>@'Z9[QT MY/TP>Y!X!)R-I..IP0H+`@&\>C9.,+C+<@'D#[N,@$OM`)&3R*_G`\/?%3QQ M^PGIFK:E^T7K?[36F^//B%^RS\3?%G@SXZ_"C]MS7?\`@H%^R_\`M`^,-*A\ M#Z?8>,M,^'W[9&H?#8?LU?&_3O%/B6#QYX5\$_#KP;\+/V(8_!7Q!CTCQ[\? M?$.FZ#H_A_X8_+/A?XX?&+P3^SA^TE^QG\0=5_;3\2?M3?!G]M;_`()VVWQP M^&GP\_:7^,=[XM\,?#OX[_M!?LZ_!W1_AC\`_P!N'XQ?M+>$?BMXRT[]MCPW MX"^+/[0GA>YOOBW\,_#GP;T;XVZO\#_&NH_#?5OAUJ-YX@`/ZY=ZYQWP21QD M8V\$9R#\XSQA1RQ4%[AC)R.N+-(M8O&GA*R\.?`[Q3X0^*7PU'P=\4^!KSPU+K>O_`!GU;1_B MW:>#=7\9?"M(/AQ=2WINY_#D_P""C7Q6^`.C_$:_\1>&_#'B;0_%7CCXP?!# MX"G7/$_Q-U?Q'X]_;6T;X0_`?QK\`O@QJ.J>-/'_`(EM+33_`(]6/B+XES0Z M+\/M%\+:=HM]\-]6OM%\-W.L^*[X$`_H%WK@'DY[=_O;3P3U!ZK]X'Y2-Y"D MWCT.[\$>@8;]O('\V_B;_@H]^UI\$[ZQEGTWX/W7PL\!_'K]I0 M_M6?$"W\#_&;X[/X;\&?#G]J7Q)\/]4\5:CX.M_VMO$G[1O[,'P8OO"WA3Q1 M%H7QB\)?`3]KWX)_#;Q1J6E^'M<^'_P=^'7@:5]8ZUO^"@_[3&B^"?VF]5^& MEQ^S_P"$=*_9`M/^"BW[2WQ1A^/)_ASI?P> MT3[/>:W!XQT_Q]:Q1W/@H:7QM_;._:4\+_&CXR?\*^NO@%I/P;^`/[4?[(W[ M'?B7X;^.OASX\\4?'7XI>.?VM=*^`5SIWQK^'_C?1/C7X)\*^'?`O@.]_:C\ M'QVGPOO?A+XNU?XEWGP-^-6CP_%CX>S:_8:OX!`/V`WJ,\_=&YN1\J_-R>>F M5(]R"!]UL+GZGG'`)QTZ]QU'7H.3@5_-K'_PTQHO_!$.R\:7?[3_`,11^T?\ M>?C[^S=KDOQZ\->+?C39>)O"E[\9/VX/@7\.;^T\,6_Q5^-GQNOO"FA6GA6\ MOM)N?A[X(U;PI\'9-(O]6T?3/A3HVG:SKUCJ_D_Q1_X*D?&_5?%/@']IGPGK M/V/PE^RS^SO\:_"GQY^"2^*KOPU\*M9_;Q\(_LG?$?XS_''X9_%C4=-M#J%W MX:_9XN-.^#8M[^\M;H:0WB[QIJEMHFGZGI5KG-!D`.#G//IT`)+=?NC`!/0$@-CG'XL^.?&GQ<^*'Q1_92_96_:8_:3 M^'VEZ#X\\>_M<^&OBUX^_8>^(WQ1_9OC^+'Q0^"Z?#SQ1\!OV>6\1Z/\4M>^ M.7[._P`0]4^'7C#QM\5?B%\*O`'[0>K>,_$%U\"KV+_A/KWX3^(_&?PWO_%_ M@)^TY\?/#_Q.LOV/O@Y>_$?X67]K^U/XJ\->,M%_X*27&B_M9_%3]GCX<2_L MJ^'_`-IX^!--^*7P3_;N^)>N?&@^*+^?4]?\*>)?C;\=I?&/PN\+_%/2='NM M*\0>"OAWX&\,:V`?T&^:F<9/\0SM(&5&2`Q`4L.+[' MP)J?PRT^W_9'\9?M%_#7X4_$3XB>%M7\6?M4>.?BKXT\'^%/AI\2[SXK>&?B MS\??V9_V'?$/B+2_A5XB-W^S78/XS^R?#;ZB_P""9O\`P4E^,_[#=:^'/PIU+XL?'_`$+PSIOBV/6O`]E^T9K/@7XC_P#!/K0K/^VO%&IQ M:?K'C']F#5/'/B7XQ/J5KJ5GJ?Q`T739O`0TGPZUS;7`!^V/F+CCDA=Q`*\# M!().=H#8^4D@'UP"0I8`$Y!QUP1QQGG)`&?X;W'_!=#2?A2?`LGP;/[+MO MX<'A&^\,./@1J7A%OVKWT.+X&2W,,D%W8(WPNDS?@5^TM\:O'?[7W[+EI/O'_C76=6@\ M2ZC\&/A3KNOP:]KFK_VAJWPV\!E?)MO!/A"ST,`_IN+@'&')R!PK8&<]3C`Z M$GG@8[O&'/,3CYAR"1SG*C&6&.JC(R1G;D9Q7X6?&/X2?'?X_P#_``42^/GA M[0=*\9>,_A/X!\"?LL6]_%8_\%9?^"@_[!R_#F'QDGQ,N?%>I>"?@]^R3X1U M_P``_%+6]9L=*AU"ZU#QGXG\!ZE<7^E:9H1U:+3YY=2L?%?$?_!07]LKP9\/ MOVLO&OPB3]GBQ\'?LD^"/^"G?[3WCG1_B[X:_:$^+OC+XH:/^R]_P4._;<^% M.E_"WP;XKU+]I+2YOA@/&/P]^!=J]GXFNK7QWX%^$>L2VGACX^``#^CX-D]#^G;KWYVGY3C.&..QP%P,>Y`'*C)/0#)'/4XZ\'VS_.5^T%_ MP5?_`&L_A+\??&>F>&_`7PB\3?LYW_B#]NGX8?"WQ/)\.=8L;33_`(I_L5_L MI_'_`.-6LV6K?$[7/VH?"OQ+^*>I6WQ+_9\O_"7Q$\,^$?V(?`7P<\*0>+9O M"/A;]K7X@^*?`RWWCWT?6/VZ?V\/"_C_`$/]F?7_`!#^QC%\<_BMJO[,VH^` M?C3=?"'XS>'O@1\+O#_QV^`/[=WQVUGP[\2_AQ>?M)7WC'Q]J/A^7]A+6OA_ MH/CS1OBK\*['7M5^+_AW7KKX,0#][?,&>C<9R2I'(;;@!L%B>2 MNT-E0".'CWJ7`ZYYQ^IZ_0<<]\@#+?+7X,_$K]NO]I+3_&>N^%/V=M.^$7Q& M^,'Q/O/V78_`%IX#'Q*_:>\*>-]/\8?LU>)OC+X[U;X&>'/%/[1/[*W[/^J^ M$X(-'76M-^(7B_\`:"_8W\':S\.A+XGN;WXM?&.[^'_PF\<^C_\`!+?]KCXD M_MC>/?&?Q8\<:A]BMO&7["?_``3^^(1\">']>O+KX9:#X\\4_$;]O#PY\0_% M7P^\/)XP\'/@%^RE\6'^`GPG^*%AX(^&O[4]UIWQN'B#6O'A\)I9-\)M(U#2=;C62Z MECYSX2?M)>)OB_\`M_\`AC5O!'Q8\=ZU\"_B5\;M*\1>"?#Y\6>(5\'ZA\./ M&/\`P2K^%?Q@\-VL/A=M3DT>VT:X\1^(3X\32(;2.VB\5:E>>)&2369YM0(! M^[A<`@'()Z#!)ZA<\9XR1D]%R-Q7(I2P`S@XP3VQ@8_BSM&_V;/VV_@E^S?X<^&WA3PU\:M"^//C?7O$O M[(7[/G[4^M>+-9^*/A7]H#0/!&LZ,J_&/Q#X$TGX3:M\%-=T#6[A?#FL>(KB M\;P[_96O?-7Q,_;1_;L\8)\!/`T/Q9_94A\3_''2O^"=_P"TY\,_$OP7\,_& M'PS9^"_#O[1/[6/@3P%_PKWXI6:_'KQ/?_'/X3VGAR;5%N/%VAW_`,$[/]HZ MP&N>'X?"OP>MM)N=3N@#^E/>`0#P3D\E1P.IQG/`P3QP&'OA-X.,9.^,<'@'YB,L`5!-?S8>)?VROV_K'XW'6A\2?V;;W6?@=^S#_`,%/?"FN>`#X M,\2_"CX.?&+XN?`[]I[]F?X9_#7XER1_%#]L#P]X*\"7YM_'_P`.&\/^$?B1 M\3-0_L^*Q^-'P^L/CIX0M_VAK'Q_\&?L#P/^W_\`&D_\$T_VY_VG?&NA>%'_ M`&F?V*?`/[3FH>+/A]XA^"'Q9^`,6A_$/X0_`>#X_P#@CP7\5/@UXU^)?Q*U M#0[N[\)^*O`=YJE]\*OVD/C7\,O'_A/7-,\?_"WXT7>D^+K:P\.@'['EU`SR M<@L,="!CG=]T`Y&"2!@YS@$@\Q'/"D@^6P5P,`_,&.`IP6Y*!@"1^!W MB_\`;S_X*$?#']HNZ^#NM?#;X)?$_P`&_`GQE^S-X'_:2^*/A_PO\)?@-\/O M$%[^U'XSTB#P]JO@WQ-^T-_P4ST+XA_"I?"_A_QSX;\$^!--@_9^_:F_X:.^ M-?@OQ#X1\,ZS\-=9\:Q>%OAOX[#_`,%"W\&Z]X;^,'Q[\+_!H_$CP?\;[O]LG5_P!E3]L;X=Z&_P`3 M/AYH^@WUG^T[^Q-\2M;^+*CX=_$;X1?`J#QYX6\3:8`?TJ;ADCJ1UP1QG&,\ M\9SQGK@]J3S!G&&S@GH>-N=V0.>,#G&&W+M+9K\!O!7[;'_!3?XPZC:_"/P7 MX*_96^'?QW\$_"G]K+QSXYT3XF>"]/\`B8?B/XR^`'CCX,^&/`_PPL_!W[-7 M[?7Q8\+_`+-&M_$./XPOI/C*+QE^T!\>_%/PLU7PM%?W7@CQ+IWB^VL=#Q/% MG_!5W]I+XQS^"KO]A_X3Z#\0_"'QU^(=A\/?@5K=]X"\%^-/$VIW?P^_9H\. M_M!?'V\O/"7Q5_;<_8<\$>--1TS6OB+8_!RR\#6'QB\"^./A[XJ_9_\`VD-? MUOP]\0[+2[#3O#0!_0KO'\^`/4$'!&*=G/\`GK7\V?C_`/;_ M`/VL/CY\&5\<^&_%7P"_9Z\.?#OQ]_P31T'XN^"M!\7R?$'XH?$'Q)^TM\ZOK/P:_:0^!_[0.H_";1OA)J-KXFE^'^CZ38^&?C=;_&-=!^*7@-?B)X7 M\NZU.R_I)3[HZYXSD'=G`ZY`).,`D@'U`.0`!]%%%`!1110`4444`%%%%`!1 M110`4444`%%%%`!1110`4444`%%%%`'DFI?\A&__`.OVZ_\`1\E4JNZE_P`A M&_\`^OVZ_P#1\E4J]Z'P1_PQ_)'D/=^K_,****H04444`%%%%`!1110`5Z#X M3_Y!TW_7[)_Z(MJ\^KT'PG_R#IO^OV3_`-$6U2>@%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!7G'Q7^#_P`*/COX M)U;X9?&[X8?#OXQ?#37Y--EU_P"'OQ4\$^&?B'X(UR31M4M-;TA]7\*>+]+U MG0-2;2]9T[3]6TYKRPF>RU2RLM0M&@N[2&2O1Z*`/F'Q!^Q/^QQXM^%_@?X( M>*_V2_V9/$WP6^&&J/K7PT^$7B'X"_"S6OAC\.]7E.I-)JW@?P%J7A6Y\*>% M=4>36=7D?4-#TBPN9#JFH[W9[VZDFPO"O[#O[-_A;]H#XH_M4-\-?"'B?]H; MXE_$AOB=8?&'QAX'^'>O_$CX3:M/^SG\)/V7]1T'X->/+CP8GB[P1X1UOX)_&SW5T?#FM6WAK3?KNB@#YE^!_[)_PL^"'@/1/!D4- M]\4M7TOXK^/?CUJ'Q,^+6G^#=>^(?B'XZ_$_7?%>O^./B_=W/A_PEX6\)^&_ M&6JS^-_$NE:>GP\\(^"O#?A7PE?KX'\':!X=\'6EEH=K\U?M*?\`!*_]GC]J M+QW\,O$WC:_O_#G@GX81ZLFF?!KP7\'OV/X?"5_)XQ\;ZKXY^*]U:_$SQ;^S M#XP_:?\`AQ=?&V[U632/BY/\#OV@/A0WBO2X6NX_[-\2:KX@U_6/TOHH`\FU M#X#?!'5M*DT+5/@W\*=2T636/B-XB?2+_P"'OA&\TQ_$/QBMO$]G\7-=;3[G M1IK,ZQ\4;3QMXSM?B+J3PR7GCBV\6^)K?Q/-J<.O:JEWYOK?[$?[&?B6\^$F MH^)/V1_V8O$6H?`'2_#V@_`F^UWX"_"S5[SX*:%X2OK74?"FC?"6[U'PM']/\'/HUII%Y:6MQI\-M+;0NGU#10!X3\;?V7_V;/VF=.T+ M2?VD?V>O@9^T%I?A:^O-3\,:9\;OA+X"^*^F^'-1U&WBL]0U#0K#QYH&O6ND M7U]9V\%K=W6GQV]Q<6T45M--)%$@KC5_89_8J37OA1XJB_9`_9:M8007]S//)]444`>?ZK\*OAIKM]XXU/6OA[X%U74_B=X-TSX< M_$O4-2\(Z!J%Y\1/A]HA\7-HW@3QS.AIOA;7YM0T*R7Q MKXN%M80GQ%JINLWX1?!#X-?L_P#@RW^''P&^$OPQ^"/P\M+_`%#5+3P'\(O` M7A7X;>#;74=6E%QJFH6WA?P9I.BZ';W^I7"K-?WD=A]HO)%WW$LCE63U*B@# MY@^'G[$O[&GPC'Q"_P"%4_LC_LQ?##_A;F@W_A?XK#X>?`7X6>"Q\3?#6J_; M3J?ASXA?\(UX4TO_`(370=1.I7YO](\2#4;"\-[>&XMY#_!KX>>,/B%IWA%CJ[-X5L/&7B'P[J/B.T\-E]?UTG0H-333#_;6 MJEK=C?79N/H2B@#Q'XO?LU?L\?M"-X4?X^_`;X+?&]O`M[?ZEX)_X6]\*_`O MQ,_X0W4=4@@MM2U#PFWC30-9;P[?ZA!9V4%]>:4;62]@M((YPR10K'MR?`_X M-2VUI9R?"/X826NG_$#2?BSI]I)X"\*O;6/Q5\/P65IX?^)EG$^D/%:^/]#M M=.T^#2/&,4?_``D6F0V%C!9:E##9P(GJ=%`'SMXR_9$_93^(FK^"O$'C_P#9 ME_9Z\(=,\7>,OB!X*U+6?#=Y> M>%?''BSQ9HFB^)_$WBO1)K/6]?\`$.D:9K&K7EWJ%A9W%N_Q5^R1^RQX[N?` M]YXY_9H_9]\9W7PQ\?>+OBK\-;GQ7\&?ASXAG^'OQ/\`B#XS;XC^/_B/X&FU M?PW>2>$O'GC?XC._Q`\6^,-!>Q\1^(_&K/XGUG5+S67-Z/H:B@#SRS^$WPPL M+K2+^S^&_@"TU#P]XU\6?$GP]?VO@[P_;W>A?$3QW9>)--\;>/M)N(;!)].\ M;>,M-\9>+K#Q;XKLI;?7?$EKXI\20:O?74&NZE#/S6O?LY?L_P#BGXP^$_VB M/$WP+^#?B3]H#P%HC^&O`OQQ\0?#+P3K'Q@\%^&Y5\1B7P[X1^)NH:%<>-?# M.AR#Q?XJ632]'UFUL'7Q/XCW6N_7=4>Z]HHH`\YD^$7PLF\$:;\,IOAK\/IO MAOH]YX?U'2/A_)X+\.-X)TK4/"?B;3_&GA>]TSPFVFMH%A=>&O%VDZ3XI\.W M5I80W6B>)-*TW7=/GAU6SM[R'(MO@!\"[(W[6GP7^$MJ=6\4>/\`QOJQM_AQ MX.A;5/&?Q7L;K2_BCXMU!HM&3[9XF^(^EWM[IGCW7[E9-6\8Z?=W-EXAN]0M MYYHW]=HH`^>_^&2_V7/^%$#]EL_LV_`#_AF89!_9U_X4W\/!\"OC[_BN=XT`#_A,R?%.P:WLO4V_AS^SC^S[\'M!\%>%?A)\"O@U\ M+O#'PVOO$.J?#KPY\.OAAX(\#Z#X"U3Q?'J,/B[4_!>D>%]!TK3_``KJ'BN' M5=3B\1WFA6]A/K*:EJ"ZB]TMU.LOM-%`'RUX4_8>_8P\!V'B_2?`W[(G[+O@ MO2OB#X>^(7A#Q[IOA/X`_"GP[8>./"7Q>A\,6WQ:\+^+['1O"=C;>)/#_P`4 M+7P3X-M_B'HVLI?Z9XUC\)>%U\26FI1>']*BMO:?"?PN^&_@/4]"-#@\,^#+/7+_`$?3[*XU:T\)>&[: M#P]X9M;YIH=`T2*+2M)6TL(8K=>\HH`\XF^#WPGN/"8\!S_##X=3>!QXSB^( MP\&2^"?#4GA,?$*#XDQ_&:#QX/#CZ:VC?\)G#\8(H_BM%XH^Q?VY%\2$7QQ' M?KXH4:M6+I/[/?P&T#5M&\0Z%\$OA%HOB'P[-I%SX?US2/AMX,TS5]"NM`M/ MB)8Z'<:-J=EH<-[ILVC6?Q?^+5II,MG+"VFVOQ1^(L%GY,7C7Q)'J?L-%`'/ M67A3PUINOZ[XJTWP[H.G>)_%%OH]IXF\26.D6%IK_B*U\.I=Q>'K77=7M[>/ M4-7M]#AU'4HM(AU&YN(M-2^NULXXDN9D;S^7]GSX#SZ7XTT.7X)_".31/B3H M7CSPO\1=(D^&_@V33/'WAGXI>*/%OC?XF^&_&FG/HILO%6@?$;QI\0/'GB[Q MYI&O0:AI_B[Q/XT\5Z_X@M]1U;Q%J]Y=>PT4`?,>H?L5_L>ZKXS\8_$;4_V4 M/V9]2^(7Q#NKF^\?>.]0^!/PPO?&7CF^O/#GB#P=>7GC+Q/<^&)-;\47=YX0 M\5^)_"ES=ZW>WMS-X<\2>(=$DD?2];U"SEZKX@_LR?LY?%K1?$OAKXJ_`#X) M_$WPYXSTCP/X?\8:!\0OA7X$\::-XL\/_#+5M7U_X;Z%XETOQ'H&I6.NZ/\` M#_6_$.OZOX*TW5H+VS\+:GKFLZAH4.GWNJW\\_N5%`'SK\3OV1?V5?C=HTWA MWXU?LS?L]?%_0+O6?#7B.]T/XG_!;X<>/]&N_$/@S0-7\)^#]=FTKQ;X;U>R MDU;PIX3U_7?"_AG4989+_0/#NLZGHFEW5MIM]>6]STVC?L\?`7P[>1ZAH'P2 M^$.A:A#J6CZU%?Z/\-?!.FWD6M>'?$/C?Q?X>UF*XLM!@DBU7P_XL^)OQ)\3 MZ)?H1T/2M>\73 MZ9=>+-`O!%MKGB'QMIGQ0U3Q##X-\+3:U=_%70/">A>`_#?Q2N[O4-&OX MM1^(OAKP5X5\*>$-!\7ZK;7^LZ9X8\,>'_#MO.K8O\7_&OQ"UKPWXBU+7_`!_\'?V2OAW9Z9XB\+>*O^$[TSQ=IW@C M]E7]FW]G'X<7OQ#E\;0Z5XHO_BKXF\'>(?BM<:IX<\+^5XXMM/\`#6B:=8_I M-10!X-XG_9:_9H\:W]IJWC']GCX%^+-5L5^+*66I>)OA+X!UZ]LX_CWI(T#X MYI:WFJ^'[NZ@3XT:$B:+\6T@FA7XE:2HTWQE_;%B!;BUX1_9I_9W\`?"'5_V M??`GP#^"G@KX#^(=*\4Z)K_P3\)?"WP-X;^$6N:-XXM[JU\:Z1K7PUT/0-/\ M%ZKI?C&VU#48/%=A>Z)):>(+>_O;;58+N"\N%?V^B@#Q;Q;^SA^SYX^^*7@G MXX>.O@3\&?&?QH^&=NEI\-OB]XK^%_@KQ!\4OA_:I/?7(M/!7Q!U;1+SQ7X6 MM3<:GJ,XM]!U73XA+?WKLDAO+C?R6F?L9?LA:+!\:+;1OV5?V;=)M_VD&N9/ MVB;?2_@9\,-.@^/DMY>ZUJ=X_P`:([7PLB_%%KS4_$GB+4+IO'`UYY[W7M8O M)&:YU._DN?I:B@#R#X;_`+/WP+^#FG^%=(^$7P7^$OPKTGP)X-O^%1>+/@] M\//$?PQ_X3/7_$FN>,M>\6_\('K/AR^\+#Q/K?C#Q-XC\6ZMXA72EUG4O$VO M:SKM[>SZGJM_=7'T!10!\\>(_P!D;]E7QCXH^'_CCQ=^S-^SYXJ\:?";0='\ M*_"SQ=XC^#'PXUOQ/\-/#'AZ\74-`\.?#[7M3\-7>J^"]!T*]'VO1M'\-W>F M:?IMT/M-I!#/ME3V?POX3\,>"=(7P_X.\-Z!X3T&/4=;U:/1/#.C:=H.D1ZG MXDUO4/$GB'44TW2K:TLEU#7O$6K:KK^M7BP"XU36M3U#5+^6YO[RYN9N@HH` M****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`/)-2_Y" M-_\`]?MU_P"CY*I5=U+_`)"-_P#]?MU_Z/DJE7O0^"/^&/Y(\A[OU?YA1115 M""BBB@`HHHH`****`"O0?"?_`"#IO^OV3_T1;5Y]7<^&;NUM["9)[FWAOZZK[R[15+^TM._Y_[+_P*@_^+H_M+3O^?^R_\"H/_BZ.2?\`++_P M%_Y!S1_F7WK^NJ^\NT52_M+3O^?^R_\``J#_`.+H_M+3O^?^R_\``J#_`.+H MY)_RR_\``7_D'-'^9?>OZZK[R[15+^TM._Y_[+_P*@_^+H_M+3O^?^R_\"H/ M_BZ.2?\`++_P%_Y!S1_F7WK^NJ^\NT52_M+3O^?^R_\``J#_`.+H_M+3O^?^ MR_\``J#_`.+HY)_RR_\``7_D'-'^9?>OZZK[R[15+^TM._Y_[+_P*@_^+H_M M+3O^?^R_\"H/_BZ.2?\`++_P%_Y!S1_F7WK^NJ^\NT52_M+3O^?^R_\``J#_ M`.+H_M+3O^?^R_\``J#_`.+HY)_RR_\``7_D'-'^9?>OZZK[R[15+^TM._Y_ M[+_P*@_^+H_M+3O^?^R_\"H/_BZ.2?\`++_P%_Y!S1_F7WK^NJ^\NT52_M+3 MO^?^R_\``J#_`.+H_M+3O^?^R_\``J#_`.+HY)_RR_\``7_D'-'^9?>OZZK[ MR[15+^TM._Y_[+_P*@_^+H_M+3O^?^R_\"H/_BZ.2?\`++_P%_Y!S1_F7WK^ MNJ^\NT52_M+3O^?^R_\``J#_`.+H_M+3O^?^R_\``J#_`.+HY)_RR_\``7_D M'-'^9?>OZZK[R[15+^TM._Y_[+_P*@_^+H_M+3O^?^R_\"H/_BZ.2?\`++_P M%_Y!S1_F7WK^NJ^\NT52_M+3O^?^R_\``J#_`.+H_M+3O^?^R_\``J#_`.+H MY)_RR_\``7_D'-'^9?>OZZK[R[15+^TM._Y_[+_P*@_^+H_M+3O^?^R_\"H/ M_BZ.2?\`++_P%_Y!S1_F7WK^NJ^\NT52_M+3O^?^R_\``J#_`.+H_M+3O^?^ MR_\``J#_`.+HY)_RR_\``7_D'-'^9?>OZZK[R[15+^TM._Y_[+_P*@_^+H_M M+3O^?^R_\"H/_BZ.2?\`++_P%_Y!S1_F7WK^NJ^\NT52_M+3O^?^R_\``J#_ M`.+H_M+3O^?^R_\``J#_`.+HY)_RR_\``7_D'-'^9?>OZZK[R[15+^TM._Y_ M[+_P*@_^+H_M+3O^?^R_\"H/_BZ.2?\`++_P%_Y!S1_F7WK^NJ^\NT52_M+3 MO^?^R_\``J#_`.+H_M+3O^?^R_\``J#_`.+HY)_RR_\``7_D'-'^9?>OZZK[ MR[15+^TM._Y_[+_P*@_^+H_M+3O^?^R_\"H/_BZ.2?\`++_P%_Y!S1_F7WK^ MNJ^\NT52_M+3O^?^R_\``J#_`.+H_M+3O^?^R_\``J#_`.+HY)_RR_\``7_D M'-'^9?>OZZK[R[15+^TM._Y_[+_P*@_^+H_M+3O^?^R_\"H/_BZ.2?\`++_P M%_Y!S1_F7WK^NJ^\NT52_M+3O^?^R_\``J#_`.+H_M+3O^?^R_\``J#_`.+H MY)_RR_\``7_D'-'^9?>OZZK[R[15+^TM._Y_[+_P*@_^+H_M+3O^?^R_\"H/ M_BZ.2?\`++_P%_Y!S1_F7WK^NJ^\NT52_M+3O^?^R_\``J#_`.+H_M+3O^?^ MR_\``J#_`.+HY)_RR_\``7_D'-'^9?>OZZK[R[15+^TM._Y_[+_P*@_^+H_M M+3O^?^R_\"H/_BZ.2?\`++_P%_Y!S1_F7WK^NJ^\NT52_M+3O^?^R_\``J#_ M`.+H_M+3O^?^R_\``J#_`.+HY)_RR_\``7_D'-'^9?>OZZK[R[15+^TM._Y_ M[+_P*@_^+H_M+3O^?^R_\"H/_BZ.2?\`++_P%_Y!S1_F7WK^NJ^\NT52_M+3 MO^?^R_\``J#_`.+H_M+3O^?^R_\``J#_`.+HY)_RR_\``7_D'-'^9?>OZZK[ MR[15+^TM._Y_[+_P*@_^+H_M+3O^?^R_\"H/_BZ.2?\`++_P%_Y!S1_F7WK^ MNJ^\NT52_M+3O^?^R_\``J#_`.+H_M+3O^?^R_\``J#_`.+HY)_RR_\``7_D M'-'^9?>OZZK[R[15+^TM._Y_[+_P*@_^+H_M+3O^?^R_\"H/_BZ.2?\`++_P M%_Y!S1_F7WK^NJ^\NT52_M+3O^?^R_\``J#_`.+H_M+3O^?^R_\``J#_`.+H MY)_RR_\``7_D'-'^9?>OZZK[R[15+^TM._Y_[+_P*@_^+H_M+3O^?^R_\"H/ M_BZ.2?\`++_P%_Y!S1_F7WK^NJ^\NT52_M+3O^?^R_\``J#_`.+H_M+3O^?^ MR_\``J#_`.+HY)_RR_\``7_D'-'^9?>OZZK[R[15+^TM._Y_[+_P*@_^+H_M M+3O^?^R_\"H/_BZ.2?\`++_P%_Y!S1_F7WK^NJ^\NT52_M+3O^?^R_\``J#_ M`.+H_M+3O^?^R_\``J#_`.+HY)_RR_\``7_D'-'^9?>OZZK[R[15+^TM._Y_ M[+_P*@_^+H_M+3O^?^R_\"H/_BZ.2?\`++_P%_Y!S1_F7WK^NJ^\NT52_M+3 MO^?^R_\``J#_`.+H_M+3O^?^R_\``J#_`.+HY)_RR_\``7_D'-'^9?>OZZK[ MR[15+^TM._Y_[+_P*@_^+H_M+3O^?^R_\"H/_BZ.2?\`++_P%_Y!S1_F7WK^ MNJ^\NT52_M+3O^?^R_\``J#_`.+H_M+3O^?^R_\``J#_`.+HY)_RR_\``7_D M'-'^9?>OZZK[SS'4O^0C?_\`7[=?^CY*I5;U!E>_O71E='N[EE92&5E:9RK* MPR"K`@@@D$'(JI7N0^&/^%?DCR7N_5_F%%%%4(****`"BBB@`HHHH`****`" MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`** M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@ M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`" MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`** M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@ M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`" MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`** M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@ M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`" :BBB@`HHHH`****`"BBB@`HHHH`****`/_]D_ ` end XML 19 R39.htm IDEA: XBRL DOCUMENT v2.4.1.9
Note 1: Organization and Significant Accounting Policies: Comprehensive Loss (Policies)
 12 Months Ended
Dec. 31, 2014
Policies  
Comprehensive Loss

Comprehensive Loss – Comprehensive loss is the same as net loss for all years presented.
XML 20 R54.htm IDEA: XBRL DOCUMENT v2.4.1.9
Note 1: Organization and Significant Accounting Policies: Property and Equipment: Schedule of Property Plant and Equipment Useful Life (Details)
 12 Months Ended
Dec. 31, 2014
Equipment | Minimum  
Property, Plant and Equipment, Useful Life 2 years
Equipment | Maximum  
Property, Plant and Equipment, Useful Life 5 years
Equipment Leased to Other Party  
Property, Plant and Equipment, Useful Life 5 years
Furniture and Fixtures  
Property, Plant and Equipment, Useful Life 5 years
Building Improvements  
Property, Plant and Equipment, Useful Life 15 years
Building  
Property, Plant and Equipment, Useful Life 40 years
XML 21 R48.htm IDEA: XBRL DOCUMENT v2.4.1.9
Note 11: Income Taxes: Schedule of Deferred Tax Assets (Liabilities) (Tables)
 12 Months Ended
Dec. 31, 2014
Tables/Schedules  
Schedule of Deferred Tax Assets (Liabilities)

 

December 31,

August 31,

 

2014

2014

2013

Current Asset:

 

 

 

   Accruals and reserves

$        73,000

$         62,000

$         26,000

   Deferred revenue

18,000

33,000

266,000

   Inventories

298,000

90,000

68,000

Valuation allowance

(389,000)

(185,000)

(360,000)

 

 

 

 

 

$                   -

$                   -

$                   -

Long-Term Asset (Liability):

 

 

 

   Deferred compensation

$       601,000

$       601,000

$       601,000

   Research and development and other tax credits

1,929,000

1,896,000

1,804,000

  Net operating loss carryforwards - federal

12,951,000

13,938,000

11,380,000

  Net operating loss carryforwards - state

2,079,000

-

-

   Depreciation and amortization

39,000

8,000

3,000

Valuation allowance

(17,599,000)

(16,443,000)

(13,788,000)

 

 

 

 

  

$                  -

$                  -

$                  -
EXCEL 22 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0`!@`(````(0!P[%.N@0(``&$P```3``@"6T-O;G1E;G1?5'EP97-= M+GAM;""B!`(HH``"```````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````#,VT%OVC`8!N#[I/V'*->) MF#B)32>@AVX[;I76_0`O^2`1B1W9;@?_?DYH454Q$!I2WPL(DGS?BP_/Z65^ MN^W:Z(FL:XQ>Q&DRC2/2I:D:O5[$OQZ^369QY+S2E6J-ID6\(Q??+C]^F#_L M>G)1>%J[15Q[WW]FS)4U=?0HQ8G9TPW#EWPN>G_L1CL8V%47WROKOJ@LQV+9E?XS=_#9FDYP> M]*I1K_D/K%_O-FQ\2V]1E:/(RE%DY2BR9BBR9BBR M9BBR9BBR9BBR9BBR9BBR9BBR9BBR9BBRYBBRYBBRYBBRYBBRYBBRYBBRYBBR MYBBRYBBRYBBR%BBR%BBR%BBR%BBR%BBR%BBR%BBR%BBR%BBR%BBR"A19!8JL M`D56@2*K0)%5H,@J4&05*+(*%%D%BJP215:)(JM$D56BR"I19)4HLDH4626* MK!)%5HDBZPQ%UAF*K+/WDM6'`C6Q\?7_SV(<;%]XI)2;8M?[J+*+BQJZE/PC8C0=3Q0+\>QRI9$P M4P>J/OH\^;*W-$UO>"_F?6*73HQ` MGA,[RW;E0V8+J<_;J)I"RTF#%?.&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E M;',@H@0!**```0`````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````````````````````"\F\UJ MVT``A.^%OH/8>RSO_Z9$SB&ED&N;/H"0UY:)+1FM^N.W[^(6V8%VZH.82\`R MD09[9KZ10AX>?Q[VQ?MC&L1+3H52>WU%ND36+\A]R)%N.1'*,(LLQ M"LKQ;#D>R7&:+,=I*"=GB6IE%Y"<8.:4D\;3/G?#%*O?K]'U)3O9$B9;LI,M M8;(U.]D:)ENSDZUALBT[V18FV[*3;6&R_:S)G@!Y"?=TZ`\SO4%!]_=S%LUT M;2#G'LFQ9#46B9'LST;"ST:RG2.AQ3MT3>HFLK-G! MTC!9AHT(`Q%AV(@P$!&6/;XL'%^.W3L.]HYCM[*#K>S9O>-A[["=C(W,GNT6 MSG;/)I:'Q`IL1`2(B#`K(E);#W']91SRPZKK.\_KPQ!8;'PB,9)M'`F-(]F5 M(V'EJ%F-<\,MA(+;0K.WA8;;0K,;6<-*-NQM8>"VL&R86PASQTZ6P\EB$T)! M0A@VS@W$N67O4HMW*1L2#D+"L[WCH7<\&Q(>0B+,"HDQ_TDM7AYYG5^6YY_0 MP.PX03%L+D`L2+9;)'2+FM4MMRP<."D4>U(H."DTVSH:>L>P)X6!D\*R)X6% MDT*RL2`A%C2[`S4L0<.>%`9."LN>%!9."L?VCH/><6Q(.`@)SX:$AY#P;$AX M"(G`#GJ`00^S,JNI]\U36^^ZRP:<#J'G2O2V06+8V(34E.PP21@FR0Z3A&'2 M[.]*PR]+LWVL,379F+(04Y:-*8LQ-6OSW7`OX^%:9Z]C.(X]&U(>0HJ]_N#X M4^S.4;!S%+MS%.P_>R5X]?IQE\_N555G97'A>"]<9Z:*M%QG MQ=V%\_?M^]\6SJQN9+&6>5FH"^=)U<[KRU]_>?505M^^EN6W&02*^L+9-LW^ MY7Q>IUNUD_6+;VOE%S76Z6:73[W73>>[V16.$>%E]7_ MT2@WFRQ5[\KTL%-%3_FSBR7 M=7.]SAJUOG`BA.6#ZOU0'?9O#UF.J\O`#9SY93?)3]5LK3;RD#>WF-ZS.OSR M0]^/VW^V5GS.U$-]&M2&L\T@[J,_9X6>WK,C`BLEKHLF:Y[$37%T/RNQA*WK-YB9Y\RJ MEQF^5#=KKTV<5=[*7!:I$JOVWS6-\FF4/SU*?)(5EF:KFBR5,+V[>Y?"P;)3SQ9W4GB^Q?C:9>EE5V5V0;RF+! MEB3#-+2,+SYDWP\9H'WB@>S"PC@P$.]4([-ARVEZSI+IA,M>-#QCNY&<#<%8^)- MFI:'5N&NY;ZGPZCZ9E2]&//Z6JOOAU;K&L#TJ%TRM;Z96FO;`"3=G'Q>*P3& M.=GZ#R@Y"?%B^6:$K1DAB4YHR<7D6QBV980D.B%LIJ>B.NZL^MJ/;>ZX7#8A M(',2ZJV7A6>;$)+HA+`OD(CJE$5)V]FT'.YW00CF@=#F;J`\44PP'UHX0BK@;O8ZD\@>2Z;%(Y(TH5K/9/TP6+3PA%8TTK,F>>RB>$(M&FE M/G=L:CCB3BO9CDJ";6I-.UD\HE`+&4\N8I5N>T)$(2BWD]7?[5D*M#[GJ M9\1U'(X8G1;J+9S'Q1F.F#TJV8X0?26NU7#$\+12#P&/D8Y&2$\K]1#`B>JT MC:-N!P.Y6X9<>$C^$G"W"XCKG0$@Z%ZF>E1ZL>S4?-OF(=)C@V$VS605?O+1*# M')M!'C_7_G"($DJ88P2FB5D?;SFAA#E&8!*R/M_VA)CCQ,SQ<,L[O@3A0D\8 M8@3&=&P;)T.<,,0(SA)"$MTA/&&4$1B%;/LFMYZ$F49PEA"WGH2A1G"6$+>> MA*E&<)80-_B$J49PEA"2Z,Q>,-8(C$*V]Q-,XX*Q1F`4LKV@Z`DQU@N-]5RG MBU>\>(.:XMUS^Z%?WH91?'SW,']^_7[Y'P```/__`P!02P,$%``&``@````A M`%P9$.0J!P``&1T``!@```!X;"]W;W)K1W\_=?G.Q4L MNKX\;J"WYZ_/&'A]>F_=+MJZI?@(53MP[V?7^^7ZVZS;XZEMVR M.5+)KVF/9P\?V>=6=VZK<#E\Z'E8\#.7J6-:GP%JX;^?8:':[>E/ES>;E M6)UZ:Z2M#F4/_G?[^MQ=K!TW<\P=R_;+R_ENTQS/8.*I/M3]]\%HL#AN[G]] M/C5M^70`W=]85&XNMHM,V7;/KEV!N91V=:M8KO0)+CP_;&A28:5^T MU6X=?&+WA0B#U>/#,$'_U-5KY_U_T>V;UY_;>OM;?:I@MF&=S`H\-'&L3&C`CY;?AW]=ZV^_7@9#+.`D%`WSQ5'7]Y]J8#!:;EZYO MCO]:B#E3U@AW1@1X[Y[S)5>=^?21#*[!\N7^;%JKC/VWH3!3!DCGXR5=0";!N:B@U7^^IBPA]57 M6)B-0](W$(Z1[(*893!F\\O`:)98+2Z$B0%0=)4%4^[+>GNY+]X;V'A_>6]J M!\#V50YU=4HD`JO)IX@(,5*\@8P"D1X(G?EZ#`R!ZKF?1/C-J46BJ^2,#N1T MH/`&D&L0E_-=,_`Z`-W7F4UBXII%DB&*8BYC18#,!UB<<)%(;"+WB2B.(AX2 M_85/")Y$B1YM('6P)^:K,S!1-YH=0CJUB!S415)$G(1-Y@-,2D4,Y/[SB.DX MTEA\X0-:J_>$R5N$&9@(2_!K4XM889"0=$B"/?,!'4,=Q`9R_[F0D:1`X0-< M*Q]`2Y;Y3\2"*Q&3=2]\0LA$<#W: M0/),:^)E[(]3FX%)*B#QDEK$2P5T(*<#A3>`7-.WN&9@//.*A$1J$3OS0D11 M3%.!#R0Z#@79Y[D/\%@*S<<$.VS(`A%,,BW'R$;B�?\R=^H(D\\NK4,58? M%'+8-CCT,D0D,J;RT'/!!'04V$*!")5(/9K`ZDPEG1U6S-9=/X^K,5QMIG., M6SW-2=QE__,\1\\92Q39=<4'`)9FRNQ\:;8H(VEDKZ;,,E9:K.,XG(CS"15* MR<:H0PQ9,U\(DD9)-N($X%F*K$GTAR)X(CZSI'Q825@$L4[BH\",@@CE:LS+2"B_J1D9:-P&:N)@ZA@O&TY&\LE(X8]@!V_J M)_BTG_#:7UN1'.,JDDQ(OY&AYXIY;9PMN.@YYQ&=@0(!`G+EF(FP-`B8^4'& M#8T;03UF'B?-,E;:7<0C-<;W0&3.BB.$B@B08X#!%AF]'TP4F%#O=H+VB@B;PQ9IT\O\C?":D8\2US5EPJ$9SLPAP]3X0D2:1`SSDPF:0S+,<`;M8#0Z.,Q1CAG(#Z$2),(+S"@(X<0[1F*A M-S4CYE=(&J-DBE/'P)1<.ZJ8B,AF,+ECW(3!SP!DK0L,,"W&-(DEWM2,\&DS MHLD>2AUC?WJ"7/_F6EH[CGEG+1$#:PGG_0L)"24/R<>7FTT:$ M%IK4,7KX%>HN7$Z.+Q.`1$-.@8D\Z\7U#7PT@+7=U)7P:5="CR6I8ZYOGFJS M1D9@=,UM10),M-'GHP&LC30C\QI)/FU*&-TCJ8/L)A):*OBYC>RC##,1W#M- MF)PP\-O'A"DP`VSL93]D]7'Q,QW.X M&1O&5]JGY^!\```#__P,`4$L#!!0`!@`(````(0#P M8:!:Q`(``)('```9````>&PO=V]R:W-H965T+M&V/610]N<%ZS=K]'O7]G='#E2D;8@-6_I&KU3 MB>XWGS^MCER\R(I2Y8!"*]>H4JI;>I[,*]H0Z?*.MO!/R45#%$S%WI.=H*0P MFYK:"WQ_YC6$M<@J+,4M&KPL64Y3GA\:VBHK(FA-%,0O*];)LUJ3WR+7$/%R MZ.YRWG0@L6,U4^]&%#E-OGS>MUR070UYO^&(Y&=M,YG(-RP77/)2N2#GV4"G M.2^\A0=*FU7!(`-MNR-HN48/>)E%R-NLC#]_&#W*WK,C*W[\(ECQC;44S(8R MZ0+L.'_1Z'.AEV"S-]F=F0+\$$Y!2W*HU4]^_$K9OE)0[1@2TGDMB_>4RAP, M!1DWB+52SFL(`'Z=ANG.`$/(FQF/K%#5&H78#>8QCF?`.SLJ5<:T)G+R@U2\ M^6LI?-*R*L%)!<:3"@X^KA*>5&"\JD1!G,SQ!V*)3BHP7E4^G!'D;GR9]55N MC<6S)IN:I421S4KPHP/G`%R4'=&G"B]!^?]%@NIH]D'#9@O8+Z&Q7C+">.#`Q09HD]MMT#!T M)7(N-D2+V4776/5H&7/,S,+3>"$=+VS'"UEO81`LO/GV8#6\1B!U"38<6?EH MD<06-%Y$T-[#;)[ZQ!R'?H1'^:9](HF"T%^,JK'M$_`./PY&;\GZ!,;8#V+_ MB@P<@)-TNP,:'CEPE;75LHAU($FB.(S'3=LGL+^88SRV,;7(M>3;P9[0#_Q) MF\`]K&,S>VR"]EJU1[0C>_J=B#UKI5/3$@KHNPE<`\)>JG:B>&>.Y(XKN`O- M8P7?/@KGU7'3#!*F!D.TW[[W=M)Q1(EV4O`>/CPSGG MWER6MR]M8ST3+BCK5LBS7621KF`E[78K]//'PTV*+"%Q5^*&=62%7HE`M^N/ M'Y8'QI]$38BT@*$3*U1+V2\<1Q0U:;&P64\ZV*D8;[&$)=\YHN<$E_I0VSB^ MZ\9.BVF'#,."7\/!JHH6)&?%OB6=-"2<-%B"?E'37IS8VN(:NA;SIWU_4["V M!XHM;:A\U:3(:HO%XZYC'&\;\/WBA;@X<>O%&7U+"\X$JZ0-=(X1>NXYP*TM$?*!*DID%7LA6?O;@+PC ME2'QCR1P/9)XONVGD1?%_\$2'%G",4OH1TEZA1;'^-(QY5CB]9*S@P6M!\I% MCU4C>PM@5OF$?\T'@E%G[M0A?130`FKZO(Y\=^D\0R&*(^;^'.-/$9MS1#`C MR=^!>`.+`Q8&'Y#MV,?[]3WI5V"H)+(&_6$6#[S:X[W!A+J0RO1F_B`?/9A( M`=[KI2CP"@'5("7RWRP:*0:3Z*#]+/#2>9)C0!"'7C+/<0Q(,S=+H\'M1#IT MP/72%7@N?:;LWF!B+=V#-P^OU4'`[])WF",_!N8W.[%FJJ#Q_;]1\```#__P,`4$L# M!!0`!@`(````(0"X^HM/_P(``'`(```9````>&PO=V]R:W-H965T%<$%9OW;1PG<=TI>LHOU^[?[^]7"3 MN8Z0N*]PRWJR=M^(<&\WGS^M#HP_B880Z8"A%VNWD7)8>IXH&])AL6`#Z>$G M->,=EG#)]YX8.,&5/M2U7N#[B==AVKO&L.37.%A=TY(4K'SN2"^-A),62\@O M&CJ(DZTKK]%UF#\]#S-XUT+=KRC"YV#:K"H*%:BV.YS4:_<.+8O4]38KW9\_E!S$Y+TC M&G;XPFGUC?8$F@UC4@/8,?:DT,=*?02'O8O3#WH`/[A3D1H_M_(G.WPE=-]( MF'8,!:FZEM5;040)#07-(HB5J60M!(#O3D?59D!#\*M^/=!*-FLW3!9QZH<( M<&='A'R@2NDZY;.0K/MK('14&4EPE,#K48*"19#%*$X^8`F/EFAJB8(XS:[( MXIFZ=)L*+/%FQ=G!@=6#Y&+`:I'1$LRJ/]%_^P.-46?NU"%]%&@!,WW9Q$&\ M\EY@$.61N;]D`IO87A*A;R/%.P@:$0]*&.N`WD[K>'^^I_P*ADFZSI@_RI/1 MJVN\-TRD!ZF*WLX_*"8?6%'`>WT4!:]=4(U1XF`>Q3"I;C3R_0@ED1UV:Q%A MDN?)O),V$8<).CNL]+`$UZ=7\#Q]:F>[-TRBT^>P\RBW@>T4R#(_C<\CUJ,H MID">^TF2C08K.NSM]=$5/(]^]IH=,(R)'JNNSI9\.P6"((O2F:&P`!]%V1FP MHB/#3,W7#`>_(=\SWM MA=.2&OX8_44*P^/FD6$N)!OT76_')-SJ]=L&GNP$[@[^`N":,7FZ4`^E\7^% MS3\```#__P,`4$L#!!0`!@`(````(0"AJ\M3^0(``%P(```9````>&PO=V]R M:W-H965TT@TK%14L4#,7.E[V@I#23VL:/@B#U6\(ZUS+,Q2T M[%O:*4LB:$,4Z)-KW=P5O>Z#8LH:I5T/J.FTQ_[;KN"#; M!GR_A`DI3MQF<$7?LD)PR2OE`9UOA5Y[GODS'YA6BY*!`QV[(VBU=!_">8Y= M?[4P^?QE]"`']XZL^>&+8.5WUE$(&]JD&[#E_$E#OY7Z$4SVKV8_F@;\%$Y) M*[)OU"]^^$K9KE;0;02&M*]Y^9I364"@0.-%2#,5O`$!\.NT3*\,"(2\F.N! ME:I>NG'J(1S$(<"=+97JD6E*URGV4O'VGP6%1RI+$AU)X'HD"2,ORE"(T@^P MQ$>69,B21`AG-VCQK2\34TX462T$/SBP]$"Y[(E>R.$ M9*8"6D)/GU[L4#5ZZ0'61@BX6K12+ MP2;H%(7!-,AA'2,<96,K^;".@EEZJ8]T0_MOUZW!8]UHVKVUQ:1&=Q3$E]<: M6YMA.<'AI`'YL(S0P-1(-*S5VT5K\%3T-&R+L:)1D*33L$?U&4[0).QA/4E2 MC,_UD>[T([HU>*I[HFMM,5;W+,,(3;ZES1"`HS2.)U]L/@0D.,+!.]+Q1Z1K M\%AZ$I\3L[$#QWNQP6ZY@6S>W-9SB%':"P`-PQ;DZ M#?0!=/Y?L/H/``#__P,`4$L#!!0`!@`(````(0!I)W?@``0``,@.```9```` M>&PO=V]R:W-H965T6;&>.SUM^>Z+B;V=9EW0HICOP`[#T&G,2^]I0=. MVW510@0J[4['CQOW.UTQFKC>=CTDZ-^27Z3VVY%GAAN!F;W+W_5"!/SNGX,?LL>K_$I??>7DZ]U#N"")2@:V*%\9E#AD% MFX4?*:=<5```GTY=JJD!&A^]+6?3GC1O$BR@A`06Y<^"ROR^5I>ODC[(7 M]7\HHJ,5FOBC"7R/)M1?^&E$H_@++L'H$NHNH1\EZ0P6#^,:TL2R/MNN.W%Q M8.X!N6PS-9/I"IQ5?L)W\P.)4?=\5S<-MX):0E&?ME$0K+TG*$0^:G93C6\J M]E-%0$P)>T-"KQ(/0KC&`;G5XWB[OJ_\2KQQX5/C#Z^^0XP[U"1#=`&)8T)O M3QX4>U.11N$$WU30*`K3ZU,,>JCM?'HEMNFCJR_2HR8>Z._2B!`KLWL4A,,\ M535EVH"!!I-B/IH2VVBQA8::$8VF(:&A#6=):)+$2].%F9)X&<7Q.[F%V3P_ M`"4V`PBL)^]0@OP4V-/$GAB&PH^3.+84S%`$=)FFMQ08V8^_`J_$)CRUG[Q# MS:WN>WN`:0,&2O(5%"4V4:+`?L-0,R8R(D$:6K-X;RC".(W\6XV'>X!I`P;*\BLH2FRA3!*)&DQDE"XGK],G M_[/W_S>X*73?^3D51WF%U3BKWDXT5_%&$J`Q+X MOK5Z[3]5,$L!^[W;VV_RJ_8PGQ^;B<%/++H=19&>3WN$Z1J31[6`^3S8,`R> MRM MZ?-YL`/H/-,%4FU4X>7'7$&'FW;Q3Q7L(X7)K];]^?S8)4S^Q.S1.ZJUDK'Z M]@C3-2:/6MKG\V`C,'GL)1L.&BJ?N*?SP_"-?'ZF4(>5=SV0'\\BN,ENLQ/_ MF76GLI%.Q8^PW22+!*K:X4D$+WK1#IOI@^CA!#'\/,.)D<.NC"Q`?!2B?[U0 M9YWK&73[/P```/__`P!02P,$%``&``@````A`'38&)F?`@``>@8``!D```!X M;"]W;W)K&ULE)5;;]HP&(;O)^T_6+YOSBD'$2H* MZE9IE:9IAVOC.(G5.(YL4]I_O\\VI!`ZB=TDV'GSY/U.9G'W*EKTPI3FLBMP M'$08L8[*DG=U@7_]?+B98J0-Z4K2RHX5^(UI?+?\_&FQE^I9-XP9!(1.%[@Q MII^'H:8-$T0'LF<=/*FD$L3`4M6A[A4CI7M)M&$21;>A(+S#GC!7US!D57'* M-I+N!.N,ARC6$@/^=<-[?:0)>@U.$/6\ZV^H%#T@MKSEYLU!,1)T_EAW4I%M M"W&_QAFA1[9;7.`%ITIJ69D`<*$W>AGS+)R%0%HN2@X1V+0CQ:H"K^+Y)L/A MZ);>1X#N1C?GPT0\;^E3#(E(6L+*7` M,#.0"PU%?EGFZ701OD!EZ$%S[S5P'323Y%RROL3$YXK-46%K#A$,84!J3\/X MN+Q'MU9LW=IR6_OW?N/4VMC9I2*-1M8^D+R[/S,+E;S>K!5#UYVD+9O=GG_Z MWFO<&+F`UN.-S[:_A MZ'&#&@X/8/1[4K,GHFK>:=2R"I!1,(%95_[P\`LC>S&ULE%7;;J,P$'U?:?\!^;U< M0Y*BD*HIZ6ZEKK1:[>79`0-6`2/;:=J_W[$=")?NJGT)\?CX<.9X9MC[R")-RC+:%#'Z]?/^:HTL(7&3X8HU)$:O1*";[>=/FQ/C3Z(D M1%K`T(@8E5*VD>.(M"0U%C9K20,[.>,UEK#DA2-:3G"F#]65X[ONTJDQ;9!A MB/A[.%B>TY0D+#W6I)&&A),*2]`O2MJ*CJU.WT-78_YT;*]25K=`<:`5E:^: M%%EU&CT4#>/X4$'>+]X"IQVW7LSH:YIR)E@N;:!SC-!YSM?.M0-,VTU&(0-E MN\5)'J-;+]HOD+/=:']^4W(2@_^6*-GI"Z?9(VT(F`W7I"[@P-B3@CYD*@2' MG=GI>WT!W[F5D1P?*_F#G;X26I02;CN$A%1>4?::$)&"H4!C^Z%B2ED%`N#7 MJJFJ##`$O^CGB6:RC%&PM,.5&W@`MPY$R'NJ*)&5'H5D]1\#\LY4AL0_DRQ` M_7G?M_UUZ(7+#[#`^[04>%Y8%GZX6K]#BV/RTC8E6.+MAK.3!:4'RD6+52%[ M$3!W_IAL>L?^91@XI4AN%4N,H&?`"P&7_+P-%^[&>8:;2<^8W1RS\L>0NPZB M[D'Q)EW@PNN-C^P[A"H"2*G/"SP?YO7V?7?R%5C)[]Z[,P'@[O.92ITC5L%8 M6C*'3$CVER6KNAZUZ\,9*'`+4]V4^&^V\1P.!1 M(LP;Q@0F03-63+_4A!?DCE25L%)V5",C`&5]M)]FM[XJHTE\YT50W/-X`M-/ MQYW^`$R?%A?D&^8%;815D1Q>Y=HK:$YNYI=92-;J[CTP"7-'_RWA,T.@;5P; MP#ECLENHYN@_7-N_````__\#`%!+`P04``8`"````"$`/W1$H9@"``!P!@`` M&0```'AL+W=O+^3,[][D1UZ MYMH(U1,]4)?JFP#]_/%S=8&0L[2O:J9X7^)4;?+?X^&&^5?K)M)Q; M!(3>%+BU=I@18EC+)361&G@/;VJE);7PJ!MB!LUIY3?)CJ1Q?$TD%3T.A)F^ MA*'J6C!>*K:1O+ECY99@,SG;_>`+ M\$VCBM=TT]GO:ON9BZ:U4.T<`G)QS:K7DAL&"05,E.:.Q%0'!N"*I'"=`0FA M+_Z^%95M"SP!Y4V>Y->@1VMN[(-P3(S8QE@E?P=5LF,%2KJCP'U'2?(H2_/I M3?(?E,F.DKU1THLI)`3F\U122Q=SK;8(>@^WU\:>70>/GR`>T.ETH#Q:.K$#)+[?BQ`6&.,<*YME)HI9!,_4]<)*AU3_> MP2'@V&%?%D_>L,%NF/#0N9+KAJ]XUQG$U,9-;PJ?&U?'@^4^=14^65_!@>.G MDXPO8.`'VO"O5#>B-ZCC-2#C:`H#KL.1$1ZL&OR\K)6%2?<_6SC9.710'(&X M5LKN'UQ_CO\5BS\```#__P,`4$L#!!0`!@`(````(0"6`P/*I`(``'H&```9 M````>&PO=V]R:W-H965TIWN[:.Z9D"Q0;40O[WI%B)-GL MN6R4IIL:ZGZ+$LJ.W-W@BEX*II51A0V`CGBAUS5/R90`TV*>"ZC`V8XT+S*\ MC&;K!)/%O//GM^![<_8;F4KMOVB1?Q,-![,A)A?`1JFM@S[G;@HVDZO=3UT` MWS7*>4%WM?VA]E^Y*"L+::=0D*MKEK^ON6%@*-`$<>J8F*I!`#R1%.YD@"'T MK7OO16ZK#(_&03H)1Q'`T88;^R0<)49L9ZR2?SPH.E!YDOA``N\#290&29Q. M[O^'971@24XL\`\\>,XF'D-4U331$K(\(ESE4 MT)+M:!(9,S MVY+II;4>T[515]#J][@^QY+KD*U[7!C&U!.ZK]O\;B+P```/__`P!02P,$%``&``@````A`$W" M$<6/`P``;@H``!D```!X;"]W;W)K&ULE)9=CZ,V M%(;O*_4_(.XW8+Z)DJPF(=.NM"NMJG9[[8"36`,8V`S7:5N0G! M/'Y]WN/CC]7GMZ9V7@D7E+5K%RU\UR%MR2K:GM;N/W\_?\I<1TC<5KAF+5F[ M[T2XGS>__[:Z,OXBSH1(!Q1:L7;/4G9+SQ/EF318+%A'6OAR9+S!$E[YR1,= M)[CJ.S6U%_A^XC68MJY66/)'--CQ2$M2L/+2D%9J$4YJ+"%^<::=N*LUY2-R M#>8OE^Y3R9H.)`ZTIO*]%W6=IEQ^.;6,XT,-OM]0A,N[=O\RDV]HR9E@1[D` M.4\'.O><>[D'2IM51<&!2KO#R7'M/J'E/G.]S:K/SP]*KF+RWQ%G=OV#T^HK M;0DD&Z9)3<"!L1>%?JE4$W3V9KV?^PGXSIV*'/&EEG^QZY^$GLX29CL&0\K7 MLGHOB"@AH2"S"&*E5+(:`H!?IZ&J,B`A^*U_7FDESVLW3!9QZH<(<.=`A'RF M2M)URHN0K/E70^@FI46"FT@(T=^^!XL@BU&SNB)H'I5O<&T9=9';9WPE5!&!I\`4YG_KZ^7S? MPU>P"O\^[E8W@/;@QPYU3J2A&5HQ1T+?1/8_04:#AA^HG.V"\2&UL`ZLV#23]H44I7Z66L!N"N19 MDOM68HLI$/HHCP-+8C\E4!Y&63!FR'`'J^%Q=PHVW:$LM]QI)M'N_#S-4A/8 M38'8AUW"BKV8`O`YB[*Q:OJ%LS<(!(/$8X8,=\E'W"G8/NOW(6\UH=S!P M&(UI[8&="?AQ;MDOID"8QFED`7L#@-E%XQ"&M_0CWA1L>DNM<;<:N5D+XEG5 M[:8`E-RL*J??PR1*;&`_!0(H[`E@.%.WD\FN_>O=3<&6L\RLN*U&]()#"($U MB]@9!%1YC5OD5+.$WF[05<-_IV;^@`QWV'3^0;YB?:"J&ULE%5=;YLP%'V?M/]@^;U\$TH44K6INDW:I&G:Q[,# M!JQBC&RG:?_]KG%"@+15^H*Q?>[Q\;F7R^KFF3?HB4K%1)MAW_$PHFTN"M96 M&?[S^^'J&B.E25N01K0TPR]4X9OUYT^KO9"/JJ94(V!H589KK;NEZZJ\IIPH M1W2TA9U22$XT3&7EJDY24O1!O'$#SUNXG+`66X:EO(1#E"7+Z;W(=YRVVI)( MVA`-^E7-.G5DX_DE=)S(QUUWE0O>`<66-4R_]*08\7SYK6J%)-L&[OWL1R0_ M3,WK.G[GU$U=8%JO"@8W,+8C2S5Z1ZH6^R^2%=]92\%L2)-)P%:(1P/]5I@E"';/HA_Z!/R4J*`EV37ZE]A_ MI:RJ-60[A@N9>RV+EWNJ:K%=2[!&4'BA7'3&%["^!V?@3@LOV-H-C;QD&3AF26\.28?AF M(%Q!DI_6L9>NW"?(3'[`W%D,/`=,$DPAFW.(/R!<$#RH!B?'JE_/YE&<`1MQ M)KM&[9U=&"N9"SE'A-[K2L"SL1+C7_1F?1T5F:`,PR&#%;%_XK/%Q M?TS07,$L17<6$_7^>$XT]V:ZG9Z*<:)N,57WOB\&/%<5#GY;7RQFY,MH87)R M,CWYLKHQ07,%&PO=V]R:W-H965TQ9C0V3K)1(4;1)S@QNVV@,;0'SL?\^572#NQIF;&]R6:_?O'ZN M5U5--;W\\EXU;DH5S:;N+;%RTQL\W*_LO_Z]G@WMZVZ2A0E7]G? M>6U_N?_YI^6;J)[K`^>-!0IEO;(/37-:.$Z='7B1UA-QXB7\92>J(FW@:[5W MZE/%TVV[J#@ZGNN&3I'FI2T5%M4U&F*WRS,>B^REX&4C12I^3!N(OS[DI[I3 M*[)KY(JT>GXYW66B.('$4W[,F^^MJ&T5V>+KOA15^G0$W^]LFF:==OME(%_D M625JL6LF(.?(0(>>(R=R0.E^N(QV[E?M@GZ.^=OM?9_ MJSZ(MU^J?/M;7G+(-M0)*_`DQ#-2OVX1@L7.8/5C6X$_*FO+=^G+L?E3O/W* M\_VA@7('X`B-+;;?8UYGD%&0F7@!*F7B"`'`OU:18VM`1M+WE>W!#^?;YK"R M_7`2S%R?`=UZXG7SF*.D;64O=2.*?R2I==2+^$H$/I4(\R?>/&!!>(/*5*G` M[W8J[-I0'&FKS5*<-NG]LA)O%K0>!%Z?4FQDM@#A+CW23)^PC_(%B4*1!U19 MV;!G(!4U%/GU?CJ?+9U7*$RF..LAAU'&IF-@%5`V-H%$`QPPT+N`ZOP/+E`% M772_O^Z`LRW/"+EC=$MB$T@T@(0,O:"'/-Z/77Z1#)VGYW=F9&\M.9[L/$S? M9H#$`R31$1(?=)L>WP\V!JK`YH$D:)TQITE<2Q+3(E<(?/3+/!;29;$B181D M=%W2DZ!"Q!\T^]#?9`9P<\BSY[60NWJD+CXTN&Q[U&C==>5?2T2WHI"@W16> MRZ:&BPM_3\R_^_UZ8B>D=D;"AB=-%S>2:=P2@;C/"?<#H\,VBN3U&R0>((F. MD`!GMP2(9!J@1(P`S=VH2'JW^<$Y8?*A,DHRJI*,DH+QU.-107N$?IYZ)%-G M$C&<&;V^4:2P[2(V=UVWCT6Z(@3?'Q`20O#"4&>00L%^NMX.DJD=B1AVC%VY M421IQXM&_!!&!,$:AA-""(D"L*($SP`V/DQ-W"3UG))1;UB*/T$X_? MQ*D];GW^?&!J(.LF)839U1Q%M(LV:B&$W&4G'D()@6CX."FU\"^$*>#9<\"G'+_&I)C+U:8XB M?,?`?17))W;DC6U\RIE'Y*';E/.U43<6W#J&Y=`G953G`%+&X1B6+-CO^&YZQV9!-&;68(73*3&D MNM5@^;,YR0NQ[1FGC\\+V;)I(16D3[B.=7Y1C8=00B`:$^3J/Y<"WC/-GE,0 MZ;G!.X0B^3"ES\,L-(Z[\54LO#?"&`RM\UE3NI970_+2H^#5GF_X\5A;F7C! M:Q\\@O:HO)**IPMX;80I:N!P5?703E<#7\,55GM6,G$/KK9&=-;^`EZ[1_2G MH-\*.;T27$6=TCW_/:WV>5E;1[Z#F-UVVU3R,DM^:=3AXDDT<`G5GC,.<.G( MX1K`G<"8V0G1=%_@EYW^&O/^7P```/__`P!02P,$%``&``@````A`-R4EK5I M!```<@X``!D```!X;"]W;W)K&ULG%==CZ,V%'VO MU/^`>%_`?"0$)5F%P+0KM5)5[6Z?"7$2-(`C3"8S_[[7-B:VR4PG?1DFA^N3 M>^ZYUW:67U^;VGK!':U(N[*1X]D6;DNRK]KCRO[Q_>E+;%NT+]I]49,6K^PW M3.VOZU]_65Y)]TQ/&/<6,+1T99_Z_IRX+BU/N"FH0\ZXA3<'TC5%#Q^[HTO/ M'2[V?%%3N[[GS=RFJ%I;,"3=9SC(X5"5."/EI<%M+T@Z7!<]Y$]/U9E*MJ;\ M#%U3=,^7\Y>2-&>@V%5UU;]Q4MMJRN3;L25=L:M!]RL*BU)R\P\3^J8J.T+) MH7>`SA6)3C4OW(4+3.OEO@(%K.Q6AP\K>X.2'`6VNU[R`OVL\)4J_UOT1*Z_ M==7^CZK%4&WPB3FP(^29A7[;,P@6NY/53]R!OSIKCP_%I>[_)M??<74\]6!W M!(J8L&3_EF%:0D6!QO$CQE22&A*`OU93L=:`BA2O_'FM]OUI90\DK`4ZY$#@J]&2O$=)TK"LE]R8J^6"\[L\AL(:1;!C+RH8IA>44VNIE'<:+I?L"K5`.,>DT M!ND16QG!?&>TF0GD"N""@%$%6&FJ8&WUH`K&PE3([T\E<)/E&RG+"+DD,X%< M`;24H6_4E.]/@*PO"P9CU/K.C>JE(L87O<[*MYT@V03)543+#UKR\_FQX)7M M@]9;`RP\O5;I$*0D.$&R"9*KB)8@^*LF*+>2!SUG+#QSZ6`Z(&,7;`6`()%1 M'(H-<9D(BF!TQJ#`#,K'(/@R34=MAU8+;'?A!:&SIF1:`XB`P-Z5,R<@W2 M#6`'E9+3_S-`G'9P$,B\4AA25CC-`.1-'!BBX*$,D;D_22X]*M+=S.]'W9I; ME\T.P`]D?R?G][9>91.#.[,Y8!)2CKLIE$TA=O_F7'RAR%7_^=^-1/X`(SY4F#!&X. M4WP3)AO(?_HB#1,XR>_@")C$"G?,"6[\Y^*(_RRZ8]52J\8'4.GQO:`3OQG$ MAW[P9D=ZN.MSFT[PVP[#W<=SX.P\$-++#_#5[OAKS^_<= MV\`"V;:)U#P$F!R.SYP9C[.^?:Y*ZXEP05D=(\]VD47JA*6TSF/TX_O]S0I9 M0N(ZQ26K28Q>B$"WF_?OUB?&'T5!B+2`H18Q*J1L(L<124$J+&S6D!I^R1BO ML(1'GCNBX02G^J6J='S773@5IC4R#!&_A(-E&4W('4N.%:FE(>&DQ!+TBX(V MHF.KDDOH*LP?C\U-PJH&*`ZTI/)%DR*K2J*'O&8<'TK(^]F;X:3CU@]G]!5- M.!,LDS;0.4;H>M%^A9S-6OOSDY*3&-Q;HF"G MCYRFGVE-P&PHDRK`@;%'!7U(50A>=L[>OM<%^,JME&3X6,IO[/2)T+R04.TY M)*3RBM*7.R(2,!1H;'^NF!)6@@#XMBJJ.@,,P<_Z>J*I+&(4+.SYT@T\@%L' M(N0]593(2HY"LNJ7`7DME2'Q6Q*XMB2^;WLS=W$%1]!RP+7E".VEYX;!\I\Z M').3MN@.2[Q9=\A MIH+`J*&@MQNI\T:!H66&WBPGF>\,QCH$&^SNOS>J`H_UF,A$SZ1]8'*KUUI??-M=?KAYA1@U9C2;N5,1GI,] M*4MA)>RHQNX<:MU'^Q-AZZN&G,1W<%+H33*-^Q%LUC?P000[Z3R^G45;/0F< MG@@F?H-S\@7SG-;"*DD&TEQ;C59NS@SS(%FCI^:!29CU^K:`HYW`IG5M`&>, MR>X!%G;Z/PN;WP```/__`P!02P,$%``&``@````A`',0]^@0!@``:Q<``!D` M``!X;"]W;W)K&ULK%C;CJ-&$'V/E']`O`_08&QC MC;T:/3!>=4=5'TXZ>/ M^F2\E6U7->>U22S'-,IST>RJ\V%M_OTU>5B:1M?GYUU^:L[EVOQ6=N:GS>^_ M/;XW[4MW+,O>@`CG;FT>^_ZRLNVN.)9UWEG-I3S#+_NFK?,>_FP/=G=IRWPW M+*I/MNLX<[O.J[/)(JS:>V(T^WU5E%%3O-;EN6=!VO*4]_#\W;&Z="):7=P3 MKL[;E]?+0]'4%PCQ7)VJ_ML0U#3J8O7Y<&[:_/D$NC_(+"]$[.$/+7Q=%6W3 M-?O>@G`V>U!=/`X&_5.5[YWT;Z,[ M-N]I6^V^5.<2W(8\T0P\-\T+I7[>40@6V]KJ9,C`GZVQ*_?YZZG_JWG/RNIP M["'=/BBBPE:[;U'9%>`HA+%XOX@,QX$KCQ( M\H('@2L/0MS)MQMWAXTW/#9/;?-NP*:"E'27G&Y1LH)@(O'LUF,I?*\2H`1HD"<:96W" M>DAR!^7[MID%WJ/]!B57<,Y6YQ"5$0H&K2\:-L)`C($$`RD&,@FP0?,H'*KL M?Q!.HU#AXI&W`IB<<)%*P1!+(@S$&$@PD&(@DP!%I:>JO+Z?118I&7:NG,4% MRM&6<5RVEXS(Y M]D(E92,)8BLN0<.57;KB!KQSA!V4K-K!$(^]Q88"YD@P.A0Q9+(LUBB)AJ1X M428!B@`P_GX!E*P*8,@,^IJ4&92^D"\+6"]VX36\0/TXXA2Y:MI:_^GHR_BPI(-223$<4(N/7]1E"R:@1#5",(4AGR90+:A80\[RG&%7 M/,P6\[F/ZB42P:5RF""V"<@2BFCZ#VV99**/#NE0ID"J1W1BD4:RVPV.L/D& M7F_B;EL.@1D""@5K4A7I4*Q#B0ZE.I0ID"J&#B;WBV%CC"*&02BSZ$44$KZ0 M;7-O.7<#%^]SP9D\B">(MS?41A.5,+<\E.QT(DA[!G?1[!I+WI"J973LN=\R M/B3)^6<0L@P5>DCX0MX99SZM:+7118(C6\:7+8<]Y%@SE(I$7Y/J4*9`JGPZ M'MTOGP]3LGP&(?FX11*^\':/G%AB*\43)&537!LCQ%ZD.I0ID.H* M':DD5W[0&MD`ILCG,YG<&CEKTA$1#8IU*-&A5(;#E5S_ M#$(I1N-U2#B+CLIO&Y]X),!S3L0Y'C37<8[01\2)Q9JHBZHI40D+RT&M*)T( M-^Z376-]OXG2^0N;"^T& MONRC#\G3JC*)YI<>$].TPHNP(,_)7\+T(W1#AJ;^";ST=AR//IZ&J$7]+CT*O M\+?N"DY!]#A;;P4'"3K^-%L]@2'Z#]O9"C[1`;?'.\-1YR4_E'_D[:$Z=\:I MW(-&]F7>LL-2_IG.R^JYZ>&0+^QR3U=+[\U/PHQF\ M(].HXT=0T&NKD7Y],`-`T.!)LF\#*9:$``KDL)U!AA"3_YY%*5M"CR>)OEL-$X! MCK;-`X,S`_&3 M^33RALP!,_&=-*QG\CS1Q>)_U^6""@S%1+>RE_D"!-8_D%F4],Q1:+*AH]8HY[6_`O5M>@,:GD%H:-D!KEUF,2PL:KWW;Q5%B;(OS;PP^30$Z,$P)52 M]K)QLQY_P:O?````__\#`%!+`P04``8`"````"$`>./R%%<"``!\!0``&0`` M`'AL+W=OP4FJ-]OVB2G9`F(E:F&/'HJ19).W=:,T M7=50]R'I4W9F^\4-7@JFE5&EC0!'@M';FL=D3(`TFQ8"*G"Q(\W+'+\DDT4/ MD]G4Y_-+\+WIW"-3J?TG+8HOHN$0-K3)-6"EU,9)WPKW"#:3F]U+WX!O&A6\ MI-O:?E?[SURL*PO=SJ`@5]>D."ZX81`H8*(T MB=+O4OII-AP]X(6$NGQ,"VKI;*K5'L'H@7/34C?(R03(+I_^/_.!8-R>%[?) M;P6U@9[N9OWQ<$IVT`AVTKS>:M)KQ?Q6T8NO)8L[DN0B(5#"I0[(MEO'_?Z> M_3LQ=!*CCO_!A>MK?`V:OF^D*WK^_L&B\^#*"G`?M^+$.094Q\KHG96@&?J@ MAUD,GVO!O"M([@C@A+E_"83$`?X2@O5P@,)DM'3-OU*]%HU!-2_!6!P-829T M.#YA857K)V"E+(R]OZW@+<J: M>-JP*F6%K'A,7K@F-YN/']8'J1YUSKGQP*'2,&6NB>,$,U*]S M4>NC6YF,L2N9>MS75XDL:[#8BD*8E\:4>&6R^KJKI&+;`KB?Z8PE1^_F9F!? MBD1)+3/C@UU@"QTR+X-E`$Z;=2J``-ON*9[%Y):N[NB,!)MUTZ`_@A_TR7=/ MY_+P68GTFZ@X=!O6"5=@*^4C2K^F^`B"@T'T0[,"/Y27\HSM"_-3'KYPL[!G+JFN$>I"MP1K(9U&3KZ%C?0@5&-+E%EYC`=H=P#>OSM)DME^O@"7J: MM)H[JX%KIZ&=(H!JNI*@C-.2SC?YF!G%F!F;CJ7G:2;GTTS?DP;%,0'O MKOAY&':^-K/5--NPQS/K)\(63V$+7N;"(#?A:[]L0JN!ZTE1;\#"DH[O*8K= MW%,'UFJ&L%$_T3A8#'(3NK!63A`MJ(^\NN4L,AV!ML157*UXY]X46@O MD7NTF_VWDV9Z=S_`Z*W9CG]G:BSPMC=&ULT` MW$H#0[?YFL-+%HA>VS;_````__\#`%!+`P04``8`"``` M`"$`%WY7$LD"```P!P``&0```'AL+W=OP8`U8Q1K;3M/]^US@A0#HI M>P%L'Q_.N0=?UO>OHD8O3&DNFPR'7H`1:ZC,>5-F^-?/I[L%1MJ0)B>U;%B& MWYC&]YN/']9'J9YUQ9A!P-#H#%?&M"O?U[1B@FA/MJR!E4(J00P,5>GK5C&2 M=YM$[4=!,/<%X0UV#"MU"X/"-=R>,GQ?.OO&%0;(C) M!K"7\ME"O^1V"C;[5[N?N@"^*Y2S@AQJ\T,>/S->5@;23L"0];7*WW9,4R@H MT'A1)X/*&@3`%0ENOPPH"'GM[D>>FRK#L[F7I,$L!#C:,VV>N*7$B!ZTD>*/ M`X565$\2G4C@?B()$R^.DG3Q/RRS$TM\88EN9O&=KZY,.V+(9JWD$<&G!\IU M2^R''*Z`V=9G!E5V;OJ*_:M@8-*2/%B6#,.9@>T:0G[9)$&Z]E\@&7K"/#H, M7'M,&HTAVVN:<(S8G1$V^H8?9=[C]BR!*+Q$YW:Y#N:,GF"K9EM6U1E0> M;/>)H%[];-\8'R*;Z&1^"PVS:R]^OP`-JR4E^T94R1N-:E8`9>"EH$FYEN<& M1K;=@=]+`ZVJ>ZS@S\3@"`0>@`LIS7E@#UC_K]O\!0``__\#`%!+`P04``8` M"````"$`-;3PLJ`"``"I!P``&0```'AL+W=O';`!*N`D>TT[;_?M9U$ M@:1IFH<$XW-/SCG77.:W+TV-GIE47+0I#CP?(];FHN#M.L5_?C_<3#!2FK8% MK47+4OS*%+Y=?/XTWPKYI"K&-`*&5J6XTKJ;$:+RBC54>:)C+>R40C94PU*N MB>HDHX4M:FH2^GY"&LI;[!AF\AH.498\9YG(-PUKM2.1K*8:]*N*=VK/UN37 MT#54/FVZFUPT'5"L>,WUJR7%J,EGC^M62+JJP?=+$-%\SVT7)_0-SZ50HM0> MT!$G]-3SE$P),"WF!0<')G8D69GBNV"6)9@LYC:?OYQMU=$U4I78?I6\^,Y; M!F%#FTP#5D(\&>AC86Y!,3FI?K`-^"E1P4JZJ?4OL?W&^+K2T.T8#!E?L^(U M8RJ'0('&"V/#E(L:!,`W:K@Y&1`(?;&_6U[H*L6CQ(O'_B@`.%HQI1^XH<0H MWR@MFG\.%.RH'$FX(X'?'4D0>N$D#N+D`RRC'4MTS!*%\7ARA1;B?-F8,JKI M8B[%%L'1`^6JH^8@!S-@-OF,(.7S^4`PIN;.%-E20"OHZ?,BCD9S\@R-R'>8 M^U-,V$8R#;2 MF%X.;V1'-WI2@/=Z*0:<8J`Z2$FB@1('26S.@>\^?OT& M/-`_/`D.,G7ZO]P,MI>7M[,WMWN:X6&\7K,!#S1/^H'>.XC+?'(^\_&ULG%3;CMHP%'ROU'^P_+YQ`DFXB+!:A+9=J95652_/QG&(11Q' MMEG@[WML0\1EVZ*^D)C,F9DSYR2SQ[ULT!O71JBVP$D48\1;IDK1K@O\X_OS MPQ@C8VE;TD:UO,`';O#C_..'V4[IC:DYMP@86E/@VMIN2HAA-9?41*KC+3RI ME);4PE&OB>DTIZ4OD@T9Q'%.)!4M#@Q3?0^'JBK!^%*QK>2M#22:-]2"?U.+ MSIS8)+N'3E*]V78/3,D.*%:B$?;@23&2;/JR;I6FJP;ZWBAMSQ,R(<`TGY4".G"Q(\VK`C\ETT6.R7SF\_DI^,ZT6UCOZG=9R[6M85I9]"0 MZVM:'I;<,`@4:*)!YIB8:L``_"(IW&9`('3OKSM1VKK`PSS*1O$P`3A:<6.? MA:/$B&V-5?)7`"5'JD`R.)+`]4B2#*(DC?-_WI);.9UKM$*P,*)J. MN@5,IL#K^AI".N_W!0VYFB=7Y$L!;6`6;_,L36?D#0)D1\SB/4S68PC(]QY` M]]S#W[4=&#QBU&NGD[SG]?X6`9/ZB9X+0=7]0@Y<8*#JA;+T6BA@[_/@2NZ=C"^.+`/+_D7=%U_*3GC\$$#`G^?QZQ<(;'5:^HVO^E>JU:`UJ>`5S MC:,1V-?A?0X'JSJ_VBMEX3WTMS5\=CGL?1P!N%+*G@[NB]%_R.>_`0``__\# M`%!+`P04``8`"````"$`GM<00U(#```H"@``&0```'AL+W=OGDUBP-HD MCFRS[/Y]QS8$VVQ9R@,0^\SAS)FQA]G]2]MXSYAQ0KNY'P>1[^&NHC7IMG/_ MU\_'NXGO<8&Z&C6TPW/_%7/_?O'QP^Q`V1/?82P\8.CXW-\)T4_#D%<[W"(> MT!YWL+.AK$4"'MDVY#W#J%9!;1,F492'+2*=KQFF[!8.NMF0"I>TVK>X$YJ$ MX08)T,]WI.)6#Q?T+:D8Y70C`J`+M=#+G(NP"(%I,:L)9"!M]QC>S/V'>%K&D1\N9LJ@ MWP0?N/'=XSMZ^,1(_95T&-R&.LD*K"E]DM`OM5R"X/`B^E%5X#OS:KQ!^T;\ MH(?/F&QW`LJ=048RL6G]6F)>@:-`$R299*IH`P+@W6N);`UP!+VHSP.IQ6[N MC_(@&T>C&.#>&G/Q2"2E[U5[+FC[1X/B(Y4F28XD\'DDB9,@F61QEO\'R^C( MDIHL:9*-)S=H"75>RJ82";28,7KPH/=`.>^1[.1X"LS2G_2?_H`Q,N9!!JE0 M0',HZO,BRZ)9^`R%J(Z8Y24FL1&K2\3((2G?@,0#2P@I#'F`MV8>;]?WI%^" MH9*^-^A/BWS@53DN-295A91)K]R%TEBPI`#O[5(D>.X#U2`ER\XI:BD:DRNC MBTDV'D69+7;U+J(T$5EJ<^*8T%2UMN M:[O-6!GD:DQM!4N-.2M8Z07M=!S$2O7PYOA>&M&6W/&EW/J#49`7=C8K.1$4-$^9X">3.';$:]N4DEK>N_',@:95LK5+/>CW$>K3%WQ#;DHY[ M#=[`714%8SB`3$]Z_2!HKX;5F@J8T.KK#OZ18:"/`@!O*!6G!]E(PW^\Q5\` M``#__P,`4$L#!!0`!@`(````(0!)7E'H)`0``-<-```9````>&PO=V]R:W-H M965TZ56JJK> MVV="G`0MX`B3S>Z_[]@#!)MTQ>8A"?;QR9DS8WNR_O9>E=8;:T3!ZXU-',^V M6)WS0U&?-O:/?UZ>8ML2;58?LI+7;&-_,&%_V_[ZR_K&FU=Q9JRU@*$6&_O< MMI>5ZXK\S*I,./S":I@Y\J;*6GAL3JZX-"P[J$55Z5+/B]PJ*VH;&5;-'`Y^ M/!8Y2WE^K5C=(DG#RJP%_>)<7$3/5N5SZ*JL>;U>GG)>78!B7Y1%^Z%(;:O* M5]]/-6^R?0EQOY,@RWMN]3"AKXJ\X8(?6P?H7!0ZC7GI+EU@VJX/!40@;;<: M=MS8SV25DM!VMVMET,^"W<3HNR7._/9;4QS^*&H&;D.>9`;VG+]*Z/>#'(+% M[F3UB\K`7XUU8,?L6K9_\]OOK#B=6TAW"!')P%:'CY2)'!P%&H-[4=.N/!\`G!KST3[4DA*V\JOHN75OP@B4M1`0CL2 M']3C/(6O,Q<'W6+X[!83Z@0T7,0S)+@8CG(GS=ILNV[XS8*2`\'BDLD")BM@ MEK;X8"X&,1CU?SY!;)+D6;)L;-@KL%Q`8'6+@?<`L#$@R MI2$Z2=HC9*HA@B$,<'8F$?;7US7*1:;&P-"(F)%&)@Y9ZO&D.#V5*Z_?T?'TN;42K,OT)S(1@]8^D9AX MWGV3HK4:(EA$47BO2X5($3$5N]3%SO-6+M)%1\0P;X<8])8XH5''R7B:.B26 M]3*\C),L1?!4/(%3?[[5"FW*7NA)W74@-#LD/EF:>4\TB!]'=$F-4D\[R`/% M\C(8%<<\OPE>(?KI%9O*$=1O?&H4>]*1]/.QL3[MYA]HEK?$US7CW:)K-K;0 MCB`(CM7[L6R:F3P$&3L@'4#F+4OD-3)2__EV5&BC1JA1CKL.A#5"EZ$?QD;U M)QU$F8D;<#RBG6Y$7BHC@3-+`J\BS5YJ;/J=HM[8F'+?,::3;GHL$ED?U("\ M5;XN$N\B7:1Q$NQD1PNGB5X#D^+M07W_(QMO7#8D'/MH[!0KUIQ8PLI26#F_ MRAZ9PH4XC`[]^S.5#8@QGLB^7HZ[PP2TU9?LQ/[,FE-1"ZMD1Z#TG`6(:+`Q MQX>67U1_NN>H4BX`@``^`8``!D```!X;"]W;W)K&ULE%7;;IPP$'VOU'^P_!ZN>T7+1DG8M)%:J:IZ>?8:`U8P1K8WF_Q] MQWAA+Z3J]@7P<'R8F-)<-BD.O0`CUE"9\Z9,\<\?CS<+C+0A M34YJV;`4OS&-;]M3=4BA8HMKSFYJTCQ4C0Y*ELI"+;&G2_AA-">^YN,:(7G"JI96$\ MH/-=HF/-2W_I`]-ZE7-08&U'BA4IO@N3S03[ZU7GSR_.]OKD&>E*[C\IGG_A M#0.SH4RV`%LIGRWT*;YJ5(*&AR"_K631; M^2]0&7K`W(\Q\^@<\M!#;!TL;]8'CKSA^99-C[!-`)(&7>#YJ:[WZ]VG;\$V M_?Z[]RX`W(.>RU3'B'E\GEHVAL3!.63S#N0H\$P/],[U>BP8.O4D_8@%I2LJ]$E;S1J&8%?"KPYG`NE1M=;F%DVQW&PO=V]R:W-H965T!/L>VQ#-#%5+69`8_O/] MYY8L'T^R04>NC5!MCI,HQHBW3!6BK7+\X_OV88:1L;0M:*-:GN,S-_AQ]?'# MLE=Z;VK.+0)":W)<6]LM"#&LYI*:2'6\A7]*I26U<-05,9WFM/!!LB%I'$^( MI*+%@;#0]S!460K&-XH=)&]M@&C>4`OYFUITYDJ3[!Z*Y:I>FN@;I/R9BR*]L?;O!2,*V,*FT$.!(2O:UY3N8$2*ME(:`" MUW:D>9GCIV2Q'F.R6OK^_!2\-Z_ND:E5_TF+XHMH.30;QN0&L%-J[Z3/A?L) M@LE-]-8/X$6C@I?TT-AOJO_,155;F'8&!;FZ%L5YPPV#A@(F2C-'8JJ!!.`; M2>$V`QI"3_[:B\+6.1Y-HFP:CQ*0HQTW=BL<$B-V,%;)7T&47%`!DEX@<+U` MDC1*9UF23?Y-(2$C7^"&6KI::M4C6!KP-!UU*Y@L@.PJ&T%__EP9E.1BGER0 M#P6U@6D<5Y-TNB1':"&[:-:WFG10$#`?,@#7UQG\W=F)(4.,!N?Q?#)P?7;K MH/'K\,8(HNXW:9F66%.B0-))?1O:XX`!P[IAEP&[[3!L*]`"NW2?)EN' MK0/Z%?9(2K(8RTO2!AO6U8=$(G]\_]_C(W7UVH.(H4,B).5QVZM=KGJ(Q#X? MTSAH>W>&_4L;'I(*QV/,>$S:WIQ([]K6^^]=Q9LJ)!%!L#Z6F[CMA4HEFY6* M]&$8R\L\(3',3;B(L()7$53&`A\!W8A5UJK59B7"-/90C",@>WLRH3Y!0TW2 MV\J(]QB\QDKJ`9^)@29-G!4&.Y[6-$+.99<)=(A9VP,^8WXT)`^4AQB6"B;: M7M7\O,K6U0K>3!`6#?!TVM+$6:]?Y&K9/1+(#LXS+M;K51K;OX`OWU)9E;G4ZGT4IE ML40-R#[6E_`;U69]>\W!&Y#%-Y;P]?O/R\1?E>%G$ M__K#)[_\_'DY$#)H(=&++Y_\]NS)BZ\^_?V[QR7P;8%'1?B01D2B6^0('?`( M=#.&<24G(W&^%<,04V<%#H%V">F>"AW@K3EF9;@.<8UW5T#Q*`->G]UW9!V$ M8J9H"><;8>0`]SAG'2Y*#7!#\RI8>#B+@W+F8E;$'6!\6,:[BV/'M;U9`E4S M"TK']MV0.&+N,QPK')"8**3G^)20$NWN4>K8=8_Z@DL^4>@>11U,2TTRI",G MD!:+=FD$?IF7Z0RN=FRS=Q=U."O3>H<],9&R;,UM`?H6G'X#0[TJ=?L>FT1.[P:3?$45*&'=`X+&(_D%,(48SVN2J#[W$W0_0[^`''*]U]EQ+' MW:<7@CLT<$1:!(B>F8D27UXGW(G?P9Q-,#%5!DJZ4ZDC&O]=V684ZK;E\*YL MM[UMV,3*DF?W1+%>A?L/EN@=/(OW"63%\A;UKD*_J]#>6U^A5^7RQ=?E12F& M*JT;$MMKF\X[6MEX3RAC`S5GY*8TO;>$#6C\S210*:D`XD2+N&\:(9+:6L\]/[*GC8;^AQB*X?$ M:H^/[?"Z'LZ.&SD9(U5@SK09HW5-X*S,UJ^D1$&WUV%6TT*=F5O-B&:*HL,M M5UF;V)S+P>2Y:C"86Q,Z&P3]$%BY"<=^S1K..YB1L;:[]5'F%N.%BW21#/&8 MI#[2>B_[J&:+T5';:S76&A[R<=+V)G!4ALZ%8JNU'N_*J8E+\@58IA_#]31>\G<`6Q/M8>\.%V6&"D,Z7M<:%"#E4H M":G?%]`XF-H!T0)7O#`-005WU.:_((?ZO\TY2\.D-9PDU0$-D*"P'ZE0$+(/ M994FRE)")J(*X,K%BC\@A84-=`YMZ;_=0"*%NJDE:!@SN9/RY M[VD&C0+=Y!3SS:ED^=YK<^"?[GQL,H-2;ATV#4UF_US$O#U8[*IVO5F>[;U% M1?3$HLVJ9UD!S`I;02M-^]<4X9Q;K:U82QJO-3+AP(O+&L-@WA`E<)&$]!_8 M_ZCPF?W@H3?4(3^`VHK@^X4F!F$#47W)-AY(%T@[.(+&R0[:8-*DK&G3UDE; M+=NL+[C3S?F>,+:6["S^/J>Q\^;,9>?DXD4:.[6P8VL[MM+4X-F3*0I#D^P@ M8QQCOI05/V;QT7UP]`Y\-I@Q)4TPP:&PO^-_[V!MMX#`.3WJ';8,.\]WG?WXS'YN;;%]_3OCC1Q@V#B=Z[[.J:$RS" MI1L\3O2_/5@7(UW;Q':PM+TP<";ZJ[/1O[W][6]N-O&KYWQ^3;,1Q&CYW-.G+LY08'^5['Z':O.K[M!GI" MX=I?B!#Q[>AYN[Y8A/[:CMVYZ[GQ*Z.E:_[B^L-C$$;VW`.H+SW37F2TV4&) MO.\NHG`3KN)+(-<)5RMWX911CCOC#E"ZO0FVON7'&VT1;H-XHAOY*2WYY,-R MHE_I6B+R+%P"B#_\M`WC;WZ7_'GWQW?ONO_^^IM__M59_NN'K\J?_?"UWLG8 M$)I@@_TT+[M[R<+'">5.*L'MS2H,B"`]4!-JZ_HY"'\.+/P,G`'$PZ_=WFQ^ MT;[8'ISI(;Q%Z(61%H.503YV)K!])_G&S/;<>>3BUU:V[WJOR6D#3S#'2+_G MNV`F/-E).)R7SQS19#*-$`8G4Q_/4)E\$,G&D_MELG^LD(GC-6CF=8S^.%Y, MBOUR2>-5]HN2#H_AE=N*\(D>YQ/=LB"']+I=5"LUV(F8C6==X'#LTG6 MM_K64*IDG"^6[88,^Y9,538PM-X/[\ZF3OG,ZJ1+T_"Y(@`#3JX670C=/?$] MM/!U#C\Y(W'6,FJM2[RFD11^M,^"8? MZ6P\EDW4L.`EF>C[`;XD$[7@OYDTG:9!:\H"F=/38A9YZM!LLG1<'YU32U%1&,``$X_YH?&4`D*XY8JS.BJ`/`(:#P6C0 M&QLF_,^:I=,CD*W3@:[:J@2!(JL2!(JLRGKXCH3,GT8*+&#V9NG:CV%@>_"VDXW(_NX9"==1X)+)1(^?W,4S,./69I,>.V%Q*@YY M=C"QZS:'9G=H#HRK9&(CB;7O+-VM7Y8NYUUI/U`CZK99<*+#(&>2SGR+I:(. M6B$UG^`(9FIF:<$!X!.92PB.D"%CL6PJ*B,9(28C&2`H(QDA*B.$3E5P99I< MAENXA+=K8,L:=;ML=M3:7ZH)$N`5'M,XIJS/QB$5&FT<(ZK33'F07TJQ,37P MQ;K("DD;1I3E;!A0(67#"%$9>;^IE#B?XF-ZKD"RHV_NZX?!`$;)P`S/3A(L MUC&D9OD=04[$94>6--?B58#D.H!P*%:;;H?\KA#$?C"^JO"F%1@*^L+QO,]8 M8O^QRJLZ+"C=WKRLR+5TV."`%YOQ4CV^A57;]&U2P9,#X%4WR*@=I-GKM??Z M:>O/G+HREK/8ICMG3O.VQ)3$_(?!^%L;.(V:X,=JF@#D^_ M!@]E_,&YA/G+]`?,5Q\1ACV0S\(&")?`_%4O( M,9F4',L32EF7?H'_'BDM+OT>I6:2;\'1"S7#P1X`1[&L2[&J4@PQ.T1:H0(X MV*,""ZJNG)+7J\OYRA1"DBY@*#0":6"?1N1Y)N;GR%X_."\P%4VN)+VLZM=Z`4FVOK'KC#S"6DP%?UC)UK4VS*7K MYP@LQRNB47(VJ6]3Q$,Y;CX[H5:5[PWDEIRE'W-0B608F MDGSN_O_(,B78O\8L\S9[KD;/%W"[4L=0[75"G4):RV3`.D?-E8*SY/[5^CLF M*!IQGKT9:(.H!TN58JLT?*]:ZW%MF!]?5VF^3[*`:OY[:J^&^S.3AA^V2'8. M63LK!]Y!KIM-&MHHJ[8S*&/B7>5L".O5!H>@K`"3@7I,*640_SMQ)1H>44C-:Q02K+7VT#4&$(";5!YLORKJ^.- M:A+Q&SEK"H>D'J5]1'UI*O5_$DO3GDK?5-YK`9?2(H]7;N7`NMB4BDJ`J@-/ M+C""JU93Y:+.JTJXPK4)O+>%!M64;M2'MW.V>IS>CL-7>R'K2*P6):<1`K"G MN"=/6RDUS.=PX"KW8%?]X3H_N6N*OV.H!6PQT;"UB=#/UI#"BBE!9LB6I+*^\1#=S%0W#! MM<*VM(!]XH%]D);0@AO*6M."G54I+=QC5>`RX5)O6UPP)*7%ZWX@J'NSRHYL M-V*!"T46P45I%7;$O6R$%HC"NM_-J+S'&X(>GU`I;`?OB([@ M885".DJH%%;CO;POZ.4)E<)>O'^;@OZ=4"DL!?2(1"9\(&+UA$INHSZO75-0 MNU-[F65=WF&PSHC`@*=B+[8>/*T\Q&>=LZUQ.!\D`N%&:"%*3\[B69O!GL(R*$+I_67MV8,=A]*KA=KB<'&_T@2"Y/X5AKB.>@@&'(H"^@R?#PT/G M-=!+HB'>A[%O;4,FCP5>/7AO3!LR,#I!P_L?WL70A@R,3LCP217[)Q$R'X+U M-K<0GTNQ=(N0^.@&S\Z2]QQ>PP:`%*'TR=G&D9W['Q]2AJ!B/N']\3D-/D6P MV]UW>\9/<#M\ID3<*DAB!WMH$>!_V<9$C3B*$#$$\]*#&\.#2;(@YD@@+!$< M#R%L4,BU%W.KHP^\[@8CR8WET,S-GT[LX:=XWN[+^@ M,ORAB6OXI8(C?LB!_>`$;/GMF=<;#W[N(4J%3<%_+LY-='*0P&&UL[)WK;ES'M>>_#S#OL"$P8!["CY(GF=]_K:K: M=Y)2G-@'&#BQI=ZUJU:M^ZUJ?_[O'ZYFV0_YKWSVZ7*^O MGW[VV6I\F5^-5CN+ZWS.D_/%\FJTYJ_+B\]6U\M\-%E=YOGZ:O;9WN[NP6=7 MH^G\439>;.9KUAT<]!]EF_GT+YO\A?]T,-A]].SSU?39Y^MG7RS&FZM\OLZ` M(WLY7T_7M]GKN2\`W-GC;TZ_R+:>?/[9^MGGG^D5?ZV_EWVUF*\O5[PSR2?U MQU_DXYULT.]E>[O]8?WA5Z,E#W?MX7[]X1\V\_2P\>8]P-;G"MMYEU],5^OE MB$U^/;K*ZZ/>0J&CI;Y*GNS61LCPIGU)<)KKZ:S?)F]8"<7BV4#CM.K MT4S/W^77B^6:64#FU?5HWA@8@0AP%^-/UZ/U9E5?_+N\\5.8X4^+V6:^'BUO MV3LK-X9]O:C/%5[\-I_-MK^?+V[`03Y:(7B3[/5JMCU:6IJK'^D/]E,_UA-,OGZP9-3L:F_U;9,A_G##J;Y;ULGJ^U M09AU<6.[0,]ED\7F;'V^F66C^`I#MO9V>[N[N_7EWX'0-1QS/5JB)Q'.25Z\ M5ENI_N[K^0\`NEA.\Y5!4G_^9GV)"(V#:/C^ZV/>+];(^=UCWBZQ$@)/&ET8 MNI:>:5W2IVM?*A)B-AV=36?3-6`WJ)&0?#VZ%8;KX/)\N0%=I3GJ0[Y>P'0= MK[_8K-:+*Y`R0:^LIDTB?Y&?YVC`"40&MYL\VTZX,46TF->7JR+P#KA:I@[< M$[%_YPIWS(QJO)JN19.5 MWS9(\W89<0,.I>JW=G9W^V+<#(G9Y+_-^L;AXO)LY69@M%E?PI]_S2=PRR+^ M.I5VG!BHBVX[H5UA5]H7ZV5'=RXV..X=]@>]_2%.0?%G6W(P!,*#WM[N7A6> M'C1?7>?C]?2'?-:P,R>3"1R[F",LUZ/I9'LZS\:CZRG"4T?F>[RGU0;]&2#? M&_8&@WY<:[3&C5HU]#%\O;G:N"J8Y.?3\;0QQ!G-)JV1J@&!R72)86S?#WFS MIHO?HNEQR?+U5,Y`A^-VUSMUR$[NUI/UX366*WCMOH$-]GO@"\Z9#QS\0-[M MAKK,X8D_DL34H6@;W0YOE0/#S/7IS-:[SL`Z,?GU,K_,YRNX/_MRL>HTQ,,' MN^D-2_S.=6I3ZY]B<1N*RG[,U@O$LC"1+0KM931(#,2!:\JC24/0YXU57B", MLN#Q>4/MQ0&K-ACCPS*("/Y=0Y/]O!-WP1<8 M3:ZF!WP\:9#[]7R=8P?6P*N1]97:9ZF/"CNP/=97K(\U MV,]R_,8\K)FM1Q^:XB`?&LAYEETO%S],E0.HS_4UWNA,C"'B,/RZ$&G]W#D< M5&NXF5L9[J?9\]%J.OZ(\5],9QO3#)BDJ#X-UVV+<7I?BVOK^25_`6KX!`AXCV;J_` MEF[,4S+_^(F=YK_^7K2]>!7E&&BO:]QVC,_O>Z&\:8]F)]DK0IO3?/G#=-SD MSOO&XT=[9J`.6=>++XC&4GBU.,68C+E,)8=LOU65#%%J9AWH'`[_= MX):*;6`L/)Z6#%1]&?)4XSR?K#(3P`?Q9MK.XR!<(FH3N/I*]0V=3^=D_V2A M[MB0UF(C)1!Q$"U8T!:Q*BG=45^NNK'Y'0FNMZ/;$-/-2;AT)\+2O@'HARGU MENSL-FO;11T4O3AM%05G"_,\I2P5YW1D4@U[;0-[V1F5E?E)1A^". MMZF`=+_WM=#1?YJ]65Z,YD$/FF(\G5[,I_A<*N>$_*,`>+L@>]ZB0S1/0Q6% MR95<^\?F7ZJ$UICB^68UG>?1@V>,_O>6?ZW^JN0;-;G^H\^>?3Y>S-#=<-45 MQ3_[9?F*7*`/>3&:3<^64XT['UU-9[?^\YY^L&I@[C\0TBV6^O$S6\$*AT]7 MUZ,Q6.U(I+(UX++[_ M^]_^`V?CFI+.W__VOY]D-Z.5^"H,\3(*W$6+E58\H?+XY1^XW($=_6WZO.H;X.UK1[&)) M365RA@'Y7JQU%;"RNEVM\ZN5(%GS3)J5A9:9J'V17>H7`%Z.KF]MEV\VR^RK MZ7BY>,^/5__#!:/$#,18ZY,9W.R$7&T0H-5X.;U>&XU_*5;YZ?]F#5#_!7S[ M[$JHNB'RS*@DN!_D",_RJ^O9XG:%-L9#4B"]?;$Q)5B\HBS'!:1>^,NY7!TY M,1!U<0Y9S%<*O'*I-0(_,"#_L`YYM"G)!,J8L`8)$S0M]`A5%&9;+Z=GQ,S9 M`JKR;+(9PS5X=V+1;^931-98Z64U'.PF=J7X.%W0(ZBLW30!0 MU$9A>Y62)<)IJG^A1GF&?!G.HH0*!>=><;Y5Q5EZ7%YH,$C`ODQU8+/M!+OX M-_0#B$`X=;EE%=0>D!,J6@K?)A`NSS4[IE6M!4P,6BLOJ)]`=$2F2NM-2PT+ M@N1A$PU$2#>G>@F33G4$SH,]KCV9JRH]'9`;EDYU=F@4Z,=>I(';IFBC+I/3IF@B]'$PK?^U821+6-Q(#HO;&4 MV]EH_GV,B[JHDLK![U(4^$LHK#OH\;ZK8F\>Q'B$O+)7#'G"/#19D$++1E?J MLS#<@K],`1%$`>VCB916J8V@%`*#-=D@)%JX_&&:WXC>M!\@`*GC)DP-K33, M5!]ZA#>G3L6O1G-RL9:8CZM*"=S;Q4"(@)6DMGQ^*]E:X]10HF=WL@ MX+Z@Q-CT&&93MAT\J,MC='T]$T9D6%D19C17/TYA7'8W3F]@6PPL^S[/;JA8 M87G9RP2MBOLK8SL%*)L'IEG@$^'#"TG>6U'&)1KRA^EBLP(YY4GE^C%LL92M ML!7\)=-K\C5CA6!EJ@DCMI2;";*;2YBKJ`G+Y#G+;Q=@"IN"FI[09#"![ATB MT,YZKXO.CU_.BE,=CG[NQJ@J]R5UI!C_K]109.PO`TIR++?WL,KF*QNM MK)*&;9SD8)<01`0U+U@OQNJ!O7>5TU,@$_/3C]\NEM]3B=_&ZLH$FAK"9YC2 MNSC)+A:+"3^!^PXH;.92XKWPX\647CM##$M`XK>H$W+-_UV7*18R65VHJ*6V&[U=\NS5,<,.ICSV=NR3RNC6:H=_FI, M9@5(64P#LL89QEJR<])FI58,=$1(HAK'5;*J7>RJUE#5O;:IF,(QQJ^9-%%P M(]4$(18KB$WR2?UB,SQ%UU5B>NM7:\'\^ED-TT43[9YI@_U,7G0C1_'.RN-% M`Y=;TN+ECM=>;99$(P2W0;P^6*!;?_GY9CJ;:%-3JH[LU7R.^J!^QQ+QY?KX MX6[[3EZJFHT'K8C;Q,^D,E<.SJ$D7,`%=ND/I=Z@RG%1U0^'3I*MRK$D5J'V MH:&C1_U*1NW?(^@\8:3*IR(-_4@J[DO0V&81SU79BDXI&2)605$4CG:@98%Q MB;(QGI;HXKL[UD+G8'=0J2B/Y0T!*HIA/;7=F0V[@A!$4BJ,,Z)JIY7(B&T+ MRN=K'JL=L\=RZA0FKVQG[@E`U:+C&]&AEY%',U>IJ,CTV5O,0&JI_/4H!H,J M:'H9BL0JGHPR1FD10-O2M[AV9`QOLW>NBWW7OYJ]8:HDA_AK:!6Z`^$#^G8% ML=PA+),%?!LO$K@0,=Z3$&(KX_^7P2>%AS:F`<(4!*6T%E_$\%&J(?1EYB-: M20(?R$)W!`P]E:M9/'7TFY!5?QOT(M-:"20M7;%]!_N]_NX>)NYPOW>X=V33 M;&'MC@^.JOU\KKT)>5!1DH4'9`58WUJ'TLJ!/2Q7N45WX;"_R[39%Z59BR1& M3#94-S4T",DY:'=WS#[L]X:'?=\.G8Y[AP>U[21VJZ2`GKWV+I'W10?)KXDC M@Y=O*EO)7N]G@1]+KIZLGNT[]B_>!@MJ%/R&!(Z;43./K0-[.)&AB*5N&;>C ME9$2`T]GR=.6.(SV2JG@1_AAFY4?K# MWD_I-O,Z+%H'Y"!#@]]"5:LT_"@`]C*-1Q$MU M]^SRROI1V:-C&3-IIDEOD0$"%>)K_XF@#$_>TIX\MKT&.F$@M#US+&35;BZG M2#J>.$:''/8UR7T24&6L1(4:9SYS?.,&`0JF`SJOB1Z-K.^9VC-W,K$/(9^B MWI#A%SC%9LQ>);+RJ+H!UTT`3DC.$Z6K4(=:7F@QJPZ^!.5#U1- M4-WN5'U322@E=+]\>49850YR4R0!E0081Y0\EKU_(G6M859]U"Z4HDQI!J'F MYF.ZN`AH30I;QB@J`9.?_*7!I0P*KEUW/-D[ZN'DU MA97KELXE-XL-7M9H*?JTC\(.ZX.BW#G%"Z4 M-J'X0WY#-I2F415'HNJG*[1;ECZ&?!(E.5F&\2@I]WMD\HE=0]ZA\J*VD#!6 M)%QZ4VNM5&M6,H;9(CM^RGPM@51[-O!42-M^;IEA-`&QL3^=.MVQ,&OGK\)>( MF1/5C"PZ`)A,OA(_8LA:\P;1AC5!FK-,$X"ZHWG9CZP$C(4^C]Y//UXK9^Y, M23!$NI$*B;I&#/D'68@0R2/*%_+GH9LDHZ\#=YMF$6K:2YQ6Y]4W:!NQ M$C"K4\5J@7*TO>?E'!)9TC&T78+P1)WULU=255]YB?QEHT1>4^/M.N@[#&XX MNE^.[6OO/E-.H/C'=/3]0QI-OV\]4]%^T&:+D+Q8XJ[F-M&I_A691"- M1+WCYNEP?UW7S18([ZB%-OM2W(:\V&K@CQ/W>P=&PMW?0.`H0!^SW!GM'O<%^HZ,\#ACT M#@X'O;WCQ@Q1D$TR0M(HI$5-G:7@RSS(4>$)JJ*VQ/@37BA<1M8X1ZVCH=)1 MH?7)^J`L#`N].FGXZG)Z?1U'K_PX4G".6?9\^D' M.5YVP#:A*[SPZC%B)!MF[K?;&Z]UWJKX30NF"`#T2PM%S1"UB/)+?N29P9H\ MJ4*55M?3675&D25NL">\^QC/*BL=+W158"A2AKY_*]JR>?("F+QSRK>4B[W1 M[529(:<"^BMH3ZP1]6<@R0J=^0H:`50OI5'";D!J.EO\;M MUG1UH7/'(1B"1I5P.!3NB6ZL[FM^:5#47G$'\?/)MMW!8NXDZQO%0[I&NKZ$ MW,0=<>5"0N`7ZR:R';T'YH03*>P.B8&WG#N6"@1A8J6/U-_*27:\!YU^E^FY M!DC%E5I"+7`*;2;QU81FX4FE+'$+M05*01AZO0PE'+>*$UG$$!S8>[+`!(F% MC*A".50*,;&0J0X!WQ(Q`"Z)6$]3KUQN]*8IB%71F%OSA=?/*DI(BPLU@K+% M&H/\.KX?JI6B02]ZG/ZY:NB%-,9\K2#+2!PH!G'`L4NE$=741@JQ\=00N*O- M5>E\71L>(-D"CXX6"<7WZ@QIT2!O]Z`\" M6]09W4=$[OX/K4"+X`C09[S7X1*(*UUVL&JS$"NMG+SB8AF+REE&Q M^0M\%_CVW73UO6-0,=RO(NU==#S+_UANI'_$G$HS^V<$5IVN3*( MV%ZCSU1](>"SOLB@P;*PB#,N4%1TO@G#B4DJJD(F@=297"6Z@7$T+O!%"=T= MS%SYDE"/9;'*/&;8B[ZE>`5'*/I2`E##7.AP"*2OAH<(I/&)<5;@_#/KWI0P MMN47[G;U-`M5P&%MY>D'5]Q)TC"G72*LM.X M$BQI%D)::P,M6_BS/2@]F:">,6KV?N\``4^;O?C%#YOPE]*!1FNOW&%]3(T?YC\R=B]55=5 M80`*-7M*S%IN^)(9^%58@O=`?5V%NCA20I06H+989F$G/G0/A'E$W^R<[L2[ M3I0JL(@))`8=),P'^53J.81:NI$EM5:CSJ]&WR.:"8^BD'(.5Z%D9CIR9`=6 MS)OP0RY:Q%K#\2WCD6H3K]@0$?TG_),Q&A*%JH'R!8`*\Z8UX@FTRCMK6T41 MEYDOD-.*#8$I>K>!$YP5#Q:C"HHEW^(E0X\EV(,1LQ-0<*V=/D&+4U'U7H&8 M7U4?0<)4EQ90<:.XTN1+K$-BX5\'PU4!M.)JV2]&.4NJ[7?I!51[Z*A@6SJL MD]Q_MI.$QNE0 MO2Z=*;$_E&O,,-_6?F__>-C;/Z3KRMC'6ILL_57PH\8=]@Z'9![W]Z344)@3 M3U6;D%>2_48(?Q_-S<24% M:)0X=$23PPD7W&JD`Q8C4GOUC>T+@#>$-(U7=3YCIC[<4OI!%4J4J'F*<+VV MF!QJ^5JE4YFH!0M53&LKNT7=Q^*7"2J>KNF;]*JDM07N@/0$1X%ZH`-<.U)A-L[[U[QV M!&V+/E?I4YW"#4!$XHZ**_1(#)GQBO0-^A.EX,TC]K;+=E$^)JD)'N3M<(!. MF`0:XG%P5<#(R3CD@_3&:*;L$P<``BSF/-^!=[Q2->J+F%&M.2L'SYI'((SR M<'#C@8.$K9^B47[/\I)2>\HVC\[LK#,,71V%^5Q34)/)YIT0)!=:GLP'#5CR MSX,VURV)!5J%SM)9=H4_I[I MPW%8^RQ<4FNW8DMP39WO&@US]J%'FJ@P8'PU[_<+<.:770T3%]MT>-$IF! M^L:$I]A0@VPVZB3&IA9!-*[1O7-YFV"/-N#=PWLW<]`[.CJ\<[;LZ/B8)N+C M^J#2P:MVFKQ5@=?%*!R*JD\1ZVM]3D6"U8-&=3-6)ON]`9U"QP==:,\8L$^5 MKGD?NN&B=CBJ#H:-P8, M*X;8WM6(?M\H;U&OC])$DFJOGDEQ5BIH'9#:6W'?-,+BNG3<,F0CN2)L] M;`S7!I/]H?;3PTNZ&,UQKZ(.E!AM';UL!XP=`JP=\ZZ&&GMFR^ M>/KJSJ-;VZVKI%2F][O<^3^B'Y;:9"M/FT>_;U^FNV3DW*%''PM M,=U_FA4WO-90V)Z.#:_!`\6+D7KE_V:UV>BZ5SPQ=%?T^4+-@/B%7^!=JF>@ MV&B$0F!BI'A(W>J';VW#$5IZ1@M$NK%H%U9 M+L$2V6BULA*X(4`7!84(/_!G0:3Z<6_QQ$*GCZ&P)24_#=X"#='7L9S_:+9: M\,B!L:X,'9P3Z@)@U3RSU`:'9";`4H0N02P5B,>C5!"\UFA##T4L3@DKB2B\ M4^F2[)2M]ACQ`#@[!Y;)$F#D,UC[ M++?(V\>!WGM;#70B(9W,=,=-%Y5QPN3:,@B*KM7;#"3]0X?4X ML"87:&\,4'P9@TEJTZ-$TKTNB7TB^";"VD/I8Q@/VH-J%+O>WC7+O'\`<).C4WDFH$CYIL&3Z899.EPHNI M(=0AO>6PO1\"X3TUB*&>L].7+Y+3HNO6K%T%#)6!YQ17E1Q8"0_LL"]DU"6Z MD_R,]GS*_5@.3F=*F^HGLW@`2K@>Y(:^F`O:7\B;88[]=AZ60RON[-)@Q?WW MH"S>7-*=UJ:`3[U@_AZ780>FNG/Y52D#; M?B#N@O$/LJ]23Q(YPJW^\ MW&4YGYE>28WPY;-O$=FT_]@W78+IJ.VPH<#AFE.:"-UAP#\5X)SB!NAS;C^F M`/90+*3NI5\YL_!UNPVJL^H>"U(0[U MW/DB`C\*0 MB)=,*Z@T*E@)XZB0*)PBV%`UD'O,YC0?IJ[%I)]/_,%);&?T2V;5__=._8CA M*PUXD%Z1Z65??ODBO?PVS:]IUGH7TF^6LD'L>1$Z-D2]VE"'!.98T%?&26J, MB\IY=N``+[.HOH3"4#)P(IHXP$T1'A79QEU::2Q(->]"EJ-L^HQP2?^R8&H' M]CDXLS(\ZAT>W3F'>#M89T/PQ&)JIK)/!T8Z)L2TT"_9N?FV!J6D"*BL[%>#!.B<-89`?#JF0"M MWP*N/HVV%G9"NYR&T51"5EK(>3Q]DFT-/*9%2SV>\O>C+K0QOG,13=F&`CQE M$)\X'MHTQ/:]`*\)E'8G!4'#Z0;S00E1J72TBOH8O!,Q^6*Q8T7ZC$N:$`HT M6C@#\!HA5B0*Z776P;L2BRFY]3._\NNYS7FT%XWUM=$ZTD5-=5^MR%%9@\;E6KL MC+?&))``M:PS`*R8XBX!V6""$U$)#[BIG24PL5"JO7(Q5RC!*]:'.4C1P11E M#5[";E);327^-IY,J*KQ#NJUBE93:^-D%FBT1)P=5(B./ZCXQ[3O"%&6O\U$ M#U+!D,-P7^#*=%**1*J:48?O>:XTDAKB%30@L99;;*.]2.-9O2)CD+1ZTF6A M7.1229:U$1SL%_Z7\>-[6+?;%EE0&W6T'\QC\)EB+R\VF:-A%X24?I="41E& M6P(">65F_/27QEJC&.9);R8.VMTYW"]9S/);">PTV%PY\YJW^CM[`WF&X11A M":CT6C*T9]Q]@,,6@B#K0UE-/_@MJTIN@F\@GR!SZZ M55?;TY+O<\/IY87$&.>*D#T;!<$Q6^<(5D:?$UR<(C/?&XAC:P?[MC7#9=I. M_Q6W34IP:B!4W"^YQP^J:K[FN"+$MBB"GK5MB)_Q00J2Y M,,&9$9+BF7+RAO[!K/A%!CJXN+X`SH8;&CI(?)<0HF_()J\Y@1ZT7;ST;'JN MM!AJ*^[8PRE/^\L4!,];GAI],LQ)]$\/E+4HGG$+O/K./%C@`\\6(U!BF&?# MG6,SPG6OK`%R82H*KH`\ZE,_;1?$)G:.+1BKV0(U M!KMV%L&YZS:VH^BO1JO`>&'1-IY[[!W((6T8,&C7V*-ES%B&A.=XNB2S20*' M6&>%3VQ:/7CE./^%!F<'EA%P#'MP9-`4B1R[]5YWHK-"*;MC042RBJWHE"$* M*OP^G,I35Z=8F;DM7BJR:A9@>&<8;ECLE5*N6X+E$8W9']-O\ MQY_P+DP+O%/:B.)]Y-X>GG$(%+CT0N`*-08,O5N.#V-),G"A1A;\8;"O-3+K3/9 MJ":/RY2R$$NFOY4J*$)J:DYDE)8(-TC);-1Q#K88H6$HL[*3!.*2/P][UR^N M$5/CP<=+H%"LYK@+S;\%N#K;5H2HK"#T+3!NU&Y!GG[3P46=QA%7ZV<[%KUZ\H\H*%)$;,(EN[2#DF8GYT>> M7E^N:']-15?S=%U)T&:^LX'AK]`MK#;,WG0G*C7&TY3TIFCS+T)=T=2>'!O+5Q(S MGD_5?%KRB;8-.^^O)/V7\;75W_ MEG5V/&&)9N)7#3'7_IN06)#_;G,GAC4OQP_>N,(1O4QW>CY=IA>!DPF.=>2M M(W4#6$>`U&^Y9!CJV,J3^S5H\JD\/6U1OC.],'(OP3(#7%L+%RV2!H'X$7PP M&6].%`3R7\P;+^7K8E85O:3X41QI+H!<^G`,-WHIMFE#S+5N3E(N/X5$!1F2 M+C,WJ&PY?;,Q.,`ST,V0ZVAG31,JB4G#`X$$VH=G0H(Y-E&WAD1O>5K%32B- M->!BZ5=VRE74"/9;4/,DA3C<18LJ*U)#H8A,^LAO9996"#D>\Z9MPP5)(FH# MUQD"B%(LY2HZR'6*G:'!.R25L;/[FZA_JQF)>()+1L)SV&56<1S%>I!-7R$N MA;Z)N2'^NC1Z@$NW@J34K5Z4&Q/U:$I=I#0LNA,&J'1>F12*#":&(D1MZW(S MY!KX+2N9,:&?B8G8YX'VW_47\N*9G`JUY;^\,&K;KGRKVF M?HPOAP>]@[UR\K]"%KE)K$T$@0X/WI$R(";/V@:9@]U#YA76:P374[4*'1P5 MPE/66+9=.0NAVLXF*L`V=*T_O4?9^J!],V:U_0K]D3-^U@2DK1D-@"GB%+:5 MJ6@\:T(GC5HW087'DWR$@LM3::5I]+6>.<)%5P*8YZ1=4,I%0"5-5Z4N"$GJ M`ET0?1.8+24GAS09NW:_8R+>_8CDI/BFUE:P7^XJ,$5&4(7$=;4A#'<.'^IX M4/=+GD?PJ[R?J]8U9QJXB+P3SW9C[!=,8'9="YN@3J1TOUN.$A?E4"2F=[YF`RM))FIK%#4N"<14=4%YG_% M&*B<_,&JI'QF;)TQ-.E7;_-[6':XS@Q627X@)LRS(4!,O;+6F^>5E=AC5*G6 MW$>%B+:8'L9QJF"@8&.YYS]K#GFZ;N20A1K:GKI2R58@E[<"Y\#)2-%_TF1R M67E%]SOJ!G-R_W]>V8]<*WKZA+RRM%>15W8='_'+E'I<2C/KKV5]6J;.OS+E MK#9^"5FE*/6/YYQ+V_OHY',CZGE?X,H:T-_FMRG M!=ME3R%D/BVLQ!_Q/MFAN9XB4"6U::Z\O4RWM5H(P6R)B@VB?!NZQ^N)RA/B MH"L8/16<*5A8!4%6/OE*9M6L8JKTCM?#8T(416M%\$9/K`%>.U-COXVM0(=7 M1"!G+B6_5%=LY M/@Y_9PT-VLD+-2^1?\O>DR3('G^GN\,;YS;?E!#LF*OBJ'EQ=1V"WQ/TK?-) M_><(=N,!69=SRJ)?Y1+'DV).M^"DJU9UVBG:^I0O;':+G+3+6_NIG!IS M6;Y<9[T(25QQ!#`L-[;/U>I]CBUL'7/[W7!@(K=U>,277G;KWYUKI<#Q4])Z M?P8Y+ZS6JNA%N1$8$"'C;(0RMATOBG0?_>X7'Z5!TMX]C2F-R1D!:&G`>7+4 M`B[UN4F>A_V=_<%O;`O]_LX@9(JM"RX2#^*6/Y37K9L^>O&]P<[PP!??V]LY MWO,T=7UQ^+W`0>?J@^;JZN:*6_;DF78\V-T9L*ABWN9*=F&:2M M@P$'R_C6X->H.C?F__(/"?4-Q4UHO;BYNS:$>#1PWJFIQ!R77,!.]V:\=4CZD1JN60=]/-PKW&4N54ZP MPIWATD*[>CJ\NI/%CW,F+BEGUC]IS2KA#D*7NLE'&P1B,=]X%01P_,G;KH)P M6%8&;2#4)?5KF='^[M/L73B:_):VC]MR5U>[6N85[>;A;YEQ+5TBMS4\&/2& M=*%^G*\7E,)0'R<9'KL9XN*BH^.#\D2M.L&I;:\TE0(4X#B"#FZHV4MAHZZ, M04`I7W$->G$OO_NXH9M2$G#E9_HD4+!N\ZX&DZWWP:X7=X(3I!<9^E)L4BLG M#/=^T]/I!ZV$P:F*K7D;EOHJ]%M([SQ9S;N_?BN M@.".2'*MZE(A2SR:V9H;?6K$:MN50,B-7FW]]KM,7BG`Z_QD4N,&D^_,++^L MFN5>;:7X=5$1)^ZL$_#ZN^%.&M^"_DUK0`M'Y]",:[0X?7O/D'"C1GV6 M4SH\R_RDFXS#_0<1U6$3]3??X=6W7B;H+7[UX7]*MT?0^;'`M#=CS3T#)[JQIO'46.%$MZ*17S*MA';4C6X-2U;;1<8577=Q1D1? M=F!(J5.M-AO(VR-6:C*CP9=P$L*%^F0VZ#4I:I)ZZC^N/V\L%H$K_S=K$/E+ M;M'?MAR$X2Y[_"6MW':LX$D['A.<(D_\S.*=P&0'Z/^N;7<*@M1P:%6%25PL M&IL&I5]33"]]^$-'*.T:('0K.:G)*MN.:J\.Y,->-OWN75)#)1ON'EG!4F7VOV'TQIYIW;9NOT^G:WWBF MP^Z-&=%7'[[?X!?`>A&,/IL!G\Z%?4BJ^#'":$=;-N(`=$_5/^22YNILTM?Z MH*5_OZ%ESNBNR4:KY4X*WSR[-GAET5U5@9W0M^R1:"/E!6WD^*A9+GY1`X]3 M6*VR<^C/>VU?B[/[.SP/VK*\A>X60!;7`^.YVG<3``M#ZM>"V1F>V?1[W8S+ MSURTK].W>J[E6W#@]="SR$_ICN["`0.\>.]PS"^WS3-3=R*2[V#T+E3_RJ]L%]\@QTGHO@P?7&AB9&HY3/U!+:H-$Y' M(LT:X];6+EI&`D@HZ+PAWB(VJW(KE:6Y6SY)&MF_?`.8.0B47!%*LBCJUJXJ MK"I:%,B*.A;KPA^5S*!.L-B19H`+CH8AR[J96L`I=J#O#Z8/&)=_GG#H7.N1 M]]5ET&5?>70K('Q+,SY[K\O%?6CZW*'8O[A0G_**+GYBEW3LJ`T>]\CN/VNG MLZ7DU39:[-5@"$HF@"+2H*[T-^;4R9W08^R$M^\!B,.*[P?HP0MOE;`&A_L) MH`;4#:Y$<7<&487.!Y^MN$0-'8GC-*Y_O4I%*P8[Z(W*\JN%6E06"0CP M"@5Z\KFE^HP6E`F4[.=,V\R"14ZM^D(O=*852_FQ8D$?7"K!F^+BSWD1)V!>UI,`BGZY(OF-5X71K5LH_C*QC M54/\@X^IAVF=CR_GNC2&+0*ZZ1F1.DX9N4*_R;YL.Q@T_8_FVVY?\+J5)C%` M<]R+8DM7@!%19PQ4`;:R8">J(^9&WNKA_#9_=*EA#48*/#(0$_ M@"E*%->&::P=9N1<5;(4S>_IP?G<.,:]Q^?P(AQ%HP!G%I1?!1U8P!'N(XY) MO#0BI10V.(C+6+5"5`KKP&@((,06:)EF[#0.5.D0'T_S['$P MNM[7UJD(JQFHH8%:_6V0*A><%$"H[!+LM#4L4[$S=[VL$JX[B_QR_3+/-=-0 MX$SMZQ%JPW3X9&=@/?M>3HS[_TRI9369!G\]5>3I[[CPW?7.&UCG/1]+H&3CEWX8@8D.E6*99/WCXR-?7VE` MA%KLQ#TCQ6UT^HNUIZ?;__RJ%S[-P&A\$.?7\&KH2^"$(R=FI%$C$WR?<]". M0U>+6UTI(7G0QP2*7VXN:27WTQ*<'5KZM\YY7RC7_A`GTX3O^;M`0LLQC6]) M=V>5;GC1*V7HO(G4*\:RANGZ"R`_Z`T&A[T!49#Y=L61G?B2W=M;(FCQ%2;S M>>31P$GLMD'>EZ9(A,]7^1DI$K*"G"W0Y7X>XRG-QX&0;K(4EQ`;L6W;/_T8 M#W+%I_:S$2@AH3#Y_G$,=`);W3KPEGR0:IGL,O[#(6!DV9H\A<%T.X#>U0\G M'*E=BQ97T_6:6Y9>7.KB;-82Z;"1;C5T!)"E[%*A1#"[FX3+6HGB_9W?T,9F3X1WY@$&96ETS9;85*V4%G/7OM_ M[)W_3ES'DL=?91196BP!"=@F-U$V$L:0^*X#%N!$]T]@`)-@QIIA$OMJ_]AW MV+_V/S^+'V6?9#_?JNX^??KTF1E@-GM7NMK5E5$M:76D3@)338GICK'R&O6D:0W93PX.LX M_309&.&[5J9;SG)$9]!])WH>-M5K+%)U^)N*AJP9L($SFNAWQ38I.?ZJ?#2V M.X-,C,J0O80-;]YIVZYI,HYLX')T!F(BIA:6VVS`S,KZ1=]8#9TCXK-"-H02 M&W?_7='(-V?)+0RLZZS.38>$F1$5`?[PT M5ZZN0N/S"169I9BZ-\)4*_I;8QZQ^U@U)LP6II?"SBSH9HI2QB]G9;C]S6AX MU\(Q!*&GEU/TOR<;G8!,RP/*TUC@C9#"*VA;(V4-+#K8-[I"=C[,U+ MA'_^Y+05!3#GD6D)8NIM=@BU46M$M\,T.1XL/7TJ"N8?SS8^?X+TPL-#\243 M"DJ[P5W"_1.5Z\N&X4:AUD$5)3VE(*LC4.T(7OOSQZW4: M2-@]*7\YI"7RVH6PGNP+F5WE,'$*76+C5@V8;J()G\W&6\R8'@$*\LC8SKX2 MEP#IN<"TX_YL]=33.MJ)/3^M3)Y-K/'>:%B,(Z?EAG!USE":,D*1(8W2B6E3 MV[YI5VS9+-"@Y:7*K6;?',N!/D7#%/V^P&&EQ)+PI[]=J7\*D3P4LT.0:?%S MM!YCZ"$!$=(!:[SX)WT6RX!G[C_)6Z(B6'$>5,Q@`J.0N(T<1%]\@NXBT*Z8 M_#XJ,6::@_#6TED22H-X$V8[TN"-^:R#K3Y7+*0IV0EBO92.4J+278A7>"T^ M4<;MD>KH1_MN=/'YT\;ZQK.@DR#4"M\>H3=:4EK\Q'PVG3A$9T>=/&\A+LBZ M%IT$RQOT6,XY/BDMRW&ENU3C16WJUK!3T6%`./! MXFY#NFX.]^=/,1UZ@.+FPK=GZ#\I M/VF"L]WH7X#*7+&BQN%1`MN/")8XW+%ISC2)PE.&`&)]Q+630 MHR8=J_&,51.EV$'PH8E1T;Z*G_SNV7UWVU2+!\W;3@]M MT>"-NX.'PAS4-B,B34H>Q;PKV1U.5D^_%5G=Z<-=\V5IE::<#BD1.[L')>4> M4*+BA``,TMD+^E!G@K/@2WS#0IR$[\V@.N&*1/+N0;.$.7I,Q.Z0'G\+N]A= MYP)1!0GKY*_C=7AI+.\,12?@QM1[]LDU95)O M6XNA$MU^#J:_#=B3%A6L6,3:%7A)KSM6X"9YP! MU[L-WCTP!AC"5V*0JK(B1*)YX"8RAU'P]*1($S]Y6V;_#"WG5,%X7SMZ5C,W M%JQ/OW:AZ<%)\K*)@W!N$;K1S=3D]:.-T.I(OVMF,(@%:'*5M=R6$1)]MR>\ MTRZ^=*>(?)I2N'A&+.W$!6F5J`YU(8MRV['AXC96\XESX MQMZYF0%<9*$_TY[0UKS^*>JA*Q%@E1ND&!J\"H+-9TX8?Y35\H6N6Z_E+"[9 M"F)ZK.S\YE)58CQDE8Z'?:4J:Q"@5M16R1)@Y.1V.K2W">K%)74[-JBW/G2!N.@.V&A`!-H&X9S;%X693*,;`O@F*P#P,SG\VA M7PR7/LO6[.W%>V85,\L-;?5<#7MEFNZ'[H9YN3@9PNRCFZ9%H\@FY5_N7,P[=BZS2:6`]9C<9 M2M\H#NAW:S=C^NDO:.`PCM3R0,ED7CC2L)]CXL1[8B43!4A"33(C M,\Z(1>'KLM%"G#KCDF(7IA\I!AIC-@;@=M,"W>0`B&"1(Z)`OMOV.BK.*V&-.6)^?4+'*RABEB59E28RZ! M<(IMR1DL?!$K+-0;IJD,CCF3@@WEG!4%$/,W%#"7P1=WMQVKE2UTVTSI)CH- MO8*&.&6CZ0.VM M"$P'$D"!U20:C43OX.MA80?=#:H-JU%&MBFWA;\,2^#6&6TPH[CIJ!5^[)) M;5,F$RE19T_1MHN$,_SBZ0RQ=Y&!5S% M,^3""-6-XN?W)[M=0:"#@3+5LTK_L#*0'VUN5H352BR@V@?/D4D4UV!TX4PZ MY9MV2<6AG*)!%L6Z1.\YU]J@6W"E.D_<7:308W;<.B2`I)8Z6IODBXP!_GEA M1@GY7](NT^OJJ`A+;IJ:;"8FQTA5_Z6]44$+<0PQ7YD4:]C+ MV6_.,>Q=DEU+,G+(O`S6AM.-J9IIO"1APFXM+`6R/.D&/#:ZJ$4BA'F8:NJ- MP@75=,R]"FN%I]V8*45ITZG\["JB[GI1*I^NI%Y19L9BC55'!OM>^(;3` M:7-K\L7LMLU:#=CG+]BQL^V@'5>F34$O)*[5S$&IS#^>$#<;#@[7![^,KL]& MMU@]Y`A=H0MZTIYN1I394@>Z\S15S<.V;574*V&&BZI$K1LR#%^W;=[=`Z,+ MP1!6]FL@LKBZ<5XL6Q7UKF65V.RGL0]TTA=LLH/8H2:T%0R*8CP.[F!FT6.% MDB;!78IBW*]]!E"[F*/SV.QGAS>*FDF2@BDAV4B8]FL6:H7?<`,KHUHS@N#W M33PWUR7C.E-300N&E?9@:*!85>I6ID7+C8;W#?G"9V@1QF.I^6A(KYYT$#L1 MG\:)N#%!K.4%UI-0IHJE0(B?&*>3GH$PR-?O43G.PLO!3/5P9J0Y8W`0J`P= M;A,'#GL7EAIII\?.B+`7Y`.A1A,XH;]"0DJ^<:7-.4#G&F19C!T`.I=[U[1] MXTO;B6[_^S_^<["S5_-K96YXC*_&=*IO";]",WVSIZ3K[64F3^/GTOUV#]9> M>EC0\F#M8?3G'JQ\FJ@BBL5C.NHW?EV#K\?4<[R<(>'_ M;%N/G=S7UE-*AZF.F3K?8^KEB"PPEZ0*5E-I+?WIIMX,./__F7H0ZZ*&7K[O M?V!#SYIE0B7IXLVU\J)Q2)/-]G>1\3<2]Q2#LBG9Q^UV0\KT5NE/4J7@=9(F MHEE-H*>6:)LH*RLGC\N*RRNGCRF&3RX/IR!=61_"-$)$)[RUNI$)WC%`&=FY ME+"(?U`#-">>_P,#M+7\/PW0*4UQEF^`]NNHQS4=-04O*&1345'3_1UZ(#'Y MC1@>?Z&31B"1,"-;_Y"L;=, M6]%US9VI)#:FQQ+1/2J[QVPFBT"8.'3G@ M4+2`"/[UN36X-2^1E4+A&_\L:I=-T5,BO;S)(9;NZE2L>A M];+S;2P28[W!E4(H4).93$9%*8NP5L.[_<3TH[-+:6T4<2"FM[( MGFVT$%>LHA9L$;$UJ5G1RQ4;0LDL>'MUBNL++B\GDGF3PDC^9-YWH!(R*GJ/ ME-YL5=,5?_%^9HWO`PA+)UM`I6;U)M^6S!OE`4?KOG1T#Z*6/'`SK.BSW"QQ4.OH+520!%=GA1!?:5+8>R!EG[&/))LLLR[V+=7HF@[X>C[QKI`'2]Z'<[G?]5M_T_Q\WW*2O'E5(&G.6''4&2JA1%ZRT M+,ZT0%YU,'#M27-Z97M%$)R0.1XN);A6GW"VMS_^_KO;>E&BE]XMQFW\O>VC MYW"DR13*WSYZ8VQU[:MO0FDB)M'_O^9_KK[\_KO)WY5X_*]?;&Q\P7^=C:Y= M8WEWSI_TE_$>+CD?LH-G^'1\I;]>\&`6][Q]N:D_Z-T)=\K^0+AL--8?O[15 M;K\_5%4,G'IV57841F#?(3ZP,\7+B8LR%#G)H/L3(*LC<]V<`?9ZS2\#%RC' MHQ=P%[/ET9Q\`8HRX8H(#3CY$]N!UP:],-ML+"=I3"O6)K9('O(#?Z^41TH; MZ-_U62*+3=_"Q+B`#>T0LCT'M=,;'.>L\I;R`^;E=R"47"X&Q8;$!B=GO+\0 M'W0K5*G%ZHLXX7'J^N6Z*J+$0*MXDT\!:$K@R69]+'QQW84B<[RUG9YZ;:+# MQX6IXJ[&AC.7N66Y'(_>DUVZ]=4S^(&/YFZGT3+.W]'@!7B&4,OXXUKHF7DV MN)Q>#15\#&8QODAEP)P,XH1;_R3Z+SK7,?@5N6I?-I5,CJ$'WO@3+,5U3[M+ M/2'S:'?$L9GCHG/I)D[VH;1!.-J_ZY#]^"!]*NOP#MCH+*=6>.H[*PZG"%N; MZG5?(C?@K+5.?/*N9\*1!5&_4IAXZ,)XEUOFP$4H#-<\[MIDF-$<"J M8\B\*8+CMTE7I`,,-$W>WQFY><0@[':WD2."*["`O1;BS8V;@[(O[[O)V$?\ M=:#2?DH"U&OTL".[8BN3II%MP$;'$6P3\#2Y-0$J`AOBO139-T$9!3=VO_+Y MZY.1]?LB]DQMSDQ9*:`7DJ!(>M4_B[K>@Z!S12'4AHXT M1@T(WD'#CT[`F'88B1*:F%S82WZE=U1PTME*SMVEN*2WP:*0H.1F95TL9T0/ MW7C89(\HBLPR)8$ABG&ZNSXI70)QP&?O0L*)"S]CPT;9EJ$@C<.F7A_LGHRA M)5%43,P!K!ORT1A@#WR'47.T['']\I'7G^F!T9!N/)3UZ%$KG$US*UR2<2O0 M"85!*Q-LQ@EYM_VRE5%D=*[YH[^*#)Q0TH]&RZ M%$!BA2R&QP6L12Q,`[>X1"<'=]63<&$7?7&N>C)N!P&5U^,Z;@[]WA`_/[_Y M565(J(U\]MO;$\NJ3%#^K)2Z)GC$\>R3=FK/T_5@*A0._S/`/!X-AX-C:C-< M$XO4Y9X!XR'U!E.YQQ=PTNO1>VE4"\'Y]8PX^C2TA@#I`_7-/=Z9H7 M5>/?L/5N+AF0+&1PA8;6'SZ684_R^HUT:BZ#DEKI5AS(.0;`>O M2-V($<(7/^R\2K&^QK^B/[NS)&G442;D,:QYB`J/VL2E\ITTA;L(``.DI4SX M0QA_$H9%TCE1^$PJ^D"AWMJUM71\D*-T5BDL$Y6-A2L> M:`S4,^?S)F_+TEN!CY[%X]-JZUZ+3XD"0X2-V6,!L5$4:8U<\L>' MGCRVI8ZO.O&8KQ*2^+7!H!U"!LJ8@U)*1&YUL"WB"YODE0K2E2.9FD_-S0ZI MC)"_U<>RM)%0<8#/Y'K3ANS5+7:YE7Z0-.7&FIXS>7LNTQF8I>U0I#0S+7=J!26!M?K?V;'15>``F4%PGUSP#=0'6\ M:.*3X:_H:$*M:+H#9F.768J?'X%5*O14*[24;IDB%YG?#@[&E^3(ARJ6(H:C MK/IV[C"QO*OS2>6+Y^J?+4-PY748U"E*&W_XKBBQT%D]SE4.O#^X>RECP`]# M"(73*1^W'][^CY8'F#UY$\;M'[MP%DC63KX?KMYOE@=6./,)M!NKD,]`5&7T M\D#)*O+.`"$;M;RE\0^B!"M#D0/2V9A*,0.*^@=+!`@F)0;63QNO?<3REOS% M>U5]A!)<_>I?NQRZ/"!>>B&SXY,/N%SZ`RRN(1&CARA':F$U M'YR>#Y<'H.7D5*J&S0"M[Y/E`57SKO6?7&7T\D#!#2S/?W#@(*!W>&Y)!2O5 MF)B!HUF?+0^X[2$!+KP()N)A,[`0&K5*,>['5N\WRP/KZ.W5^_<1IA_A?Z;< M](-4';\\<-[@../@=DF#EK+DGER4+NQ4WCZY9X[?&XE]=,LP5X+Z@7[`K,O; MFO35<2K@^$K5BOLA[@Y>'B!UX87C)=7YNA!UND14WI__^5`;U;S;=2^:X*M?M&*=NB M_>_`&'@R,7@>+)`C62`Q?HD.CA]?O^:"^=L6)\A"WBW.O;HO;\/?EP9!QZL%*7'6P M\@;'\*..O(]6HZ);HU/>[:G`P55_DYU]"_?*6/"HB4' M>"5YCJ?F@N6,>P15K.*<:7![5Q_P^G8;'CV?7ET/90.\1$-5:03Y'LJI]N]] M8*6[8#XQI2]VO6S`\F`)'5M9?5(;*!$]T*O.]^L*_W%@/I=UKU7UT2-^NA90&>4VU-U!%+PQU MRKO_^5=TXO9MK0R8?Q+TWN^1#U?SJ+C)'8KZYP M.>*H^+C`&M/+==6657QILZ0>.Z)E6A:1.?8Q?6(?P_/,=:P68?L\VS[,&YZ6 M4#J[:OS-'4ZCY`]KS&<9HR]&T]-;F9L5VZ>'/Z&VS*+RUX?LHVH\+7#X M7NY3!M%+%1&]]E?MT8-<0AA7H1@BQAGA0WD.RD&OO>[R*D%KBKK16$/I1EK! M(FCE:-OT`XVS>?N<(^9_&./)*>%JQ#0B547SD:CE&-`Q?:="`$AQ$MM(>*-` M!=LMQ[UB]^7?]B6,>_<]GXV\R-:C3IRT_\Y)V!ID234[F#^O?4,.3XA.S/\` M,8A3-`0DE5[7!TB/T3M_!0.IYVL2S0@^7XN9/E&1/`*%:$%S=5T^6A^HJ8.^ M^ZX(F5,GQ`[,5!`!!Z6F0RLU$`C\I@I9N@AXB2K31>'%^.N0N"LOGF3K,@]#.FW!?3^XO< MH5Q4%=*,>N/<"UM^40)K,W_S+0E;OV*^IN<#;C21P$R2Q,#TS/DT&#\>'-QT M.&KZ[?B/40D"3%BY(U5M-O]-.2'17[RC1R565\Z>P7/%%?[2(RJH^'B$0*[/ MUQY849K(!**'C2P9=I'P48)L6)O=WWX^OGR2PC$X_[.?+=]'T;.D+9;@19?; M1RLQ[<98[^`#V!E#X/X6F*&^ZOAC\`*5\U8A;ALT]_4VSM]WDR2:K2$W*)>! M!Q7*Y?*=DH,5O:0*D7F/\N*;/@MPT45,K1YZ*T]U]@R*Q*H'S&N!ZAV>7#Q\ M58OYV>5\14.0ZV#E#BQKX.&SRVWK@>-5D.K9I@^?=2?5/$O,*/,/5\CYX4N^ MB$U65P=F<_7-N`!!UV`N?-KSU&C3_GEG:>>&#J.B0!U%9B>4YTGK!19?WL$X M+C/`RB%IBMR[70Z*YVM`#9ML8OMOLSBLV2,-OS#/.]#*PS*#<73&)Y":D^=H M^CG/A)ND\'9#ZB7\ZCGN&D!+HY>ZF6O6Y6?[YLN;'2LP=1.&@411G3FY..>S MIR-33[,.JG('6VVZ$H1M?^8;VY6MZLE9:@Z7^F1U4-CY[&2J#`\S%JU'&3KO MU7CN8E;.W!Y(=.VMQ9:@_!\U[&=/<:BX+0G.^-].:`9,A!=:M(0B(;<'R.8C M#TA,!CWZ83^N5]M]R37EC!N1#WG=0,T\R6Z(-`B@#M7,W?'\O20S`8-1;P-Q46$`75_Q=O8+6)+/*F:3V+``QF##D\%)[;>"D26X=VKH4GZ\0QJ> M]#&W>PWKY1#@/Q]LS&9C&2&7D<+FT,N)14=GPIVRWU?KP9JO_<^#3S*54A*T;QM/VR5#GJ:YD=HX;`C MO5*%=DJ\1Z+9V*C2RE:@J2>)IIY5Q\TPDK.?8L'8.V]UL3D6W'+LI]3L:;.Z M)[\G1"_F=XII+FY?8,(GPT$J@=O;&F3^/$$7R"L(5CM^U,?E%12_G$QNO_\? M`0```/__`P!02P,$%``&``@````A`/RUHYXE`P``60L``!@```!X;"]W;W)K M//HB1$.J#0B!DJI6PGGB>R MDM18N*PE#:P4C-=8PB5?>Z+E!.?ZH;KR0M\?>#6F#3(*$]Y'@Q4%S4C*LDU- M&FE$.*FP!/^BI*W8J]59'[D:\^=->Y>QN@6)%:VH?-.BR*FSR=.Z81RO*HC[ M-8AQMM?6%R?R-&DF*&'8)(&`?+F M4YV@OY1LQ;OOCBC9]BNG^7?:$,@VU$E58,78LT*?%/)7VS[C=!U*:'<"42D`IOD;RD1&6049-PP44H9J\``O#LU5:T!&<&O^G-+ M`& ME6BG$K]7Z>O%,X'I/*58XOF4LZT#S0?.18M5*P<34/XX,9`1Q3XH6#\"(0NH MYLM\X$^]%RA`MD,6ITC8)9:G1&2)I!\@P4'%`^<'^Y#2_O85#!5$SM'^459' MN#!(K%M!A;RT;Z3O;G2<@&Q_)PJ>(9`Z.K'2M##(4&<9=@W?RM'RRGIZ?KUC M&VK>W[:"+=O1H2XF@089:]O!ESMK>7EY.3V[W/$,_[S^GA5L>8XMSP89&,\J MU?#J(LOK2'H1Z?@?W.)?P9;_I&MN81#(W:&;$JNOE]>1]"+2\3^\Q;^"+?\# MR[]!+OJ_CJ07D8Y_=;KWWO,4;/D?6OX-W>%:PY7ED>3:( MZ?F1:7F[YZ\CZ46DXS^`L[M_TC5M13"V(M@Q)H1H/`RB)+9#Z,&D72:&`2WT MCYMQ-PAU,/7N'!AL[#(,+8.+'6."".,HLO^XUP`U/JE?^4C!>#?#D3GT6[PF M/S!?TT8X%2E@O_#=(6Q&PO M=V]R:W-H965T&ULG)A=;]LV%(;O!^P_"+J/S4^1"N(4E81N M!39@&/9QK=AR+-2V#$EIVG^_0Y&)>"C;E7?3U/*CX_=\D*_$AP_?#OOH:]5V M=7-Q7__]>E.QU'7E\=-N6^.U2K^7G7QA\>??WIX;=HO MW:ZJ^@@B'+M5O.O[T_URV:UWU:'L%LVI.L(WVZ8]E#U\;)^7W:FMRLUPTV&_ M9(0DRT-9'V,;X;Z=$Z/9;NMU533KET-U[&V0MMJ7/>CO=O6I>XMV6,\)=RC; M+R^GNW5S.$&(IWI?]]^'H'%T6-]_?CXV;?FTA[R_45&NWV(/'R;A#_6Z;;IF MVR\@W-(*G>:<+M,E1'I\V-20@2E[U%;;5?R1WA=,Q\O'AZ%`_]35:^?]/^IV MS>LO;;WYK3Y64&WHD^G`4]-\,>CGC;D$-R\G=W\:.O!'&VVJ;?FR[_]L7G^M MZN==#^V6D)%)['[SO:BZ-504PBR8-)'6S1X$P+_1H3:C`14IOPU_7^M-OUO% M/%E(13@%/'JJNOY3;4+&T?JEZYO#OQ:B+I0-PEP0^.N"4+9@6E*9W!"%NRC" MCR*85'J&EJ7-:RA34?;EXT/;O$8P>Z"\.Y5FDND]1#Y?%RB(83\:>+@%4NZ@ MF5\?6?JP_`KU7SLD.X-@(I\2G&"D.(/0=V0)RM_E0TGGRSJ@\9G%G&JE9*)&!MO=?L$XRRE>BSL0!2($#!_:ERF2+RZ M1;R!`_%!RS.+6/$ZD3I8&;G_/14)IZ%R'P"_)9>FWIC\[+W/P('PH*:91:QP MI83D,AB'W"WJ+?`,'\H.R919Q0T,%T9-A1P1+ M5)*,\VR'!A'0&:TO#`V%[65^\0<:RQ=CX.&G,\>XN=$Z82RH;8X0RIC0*@VV MK`(S@@O"U84&4.-3LP=HH+']B*!\F6,\_YE<*?PK:!ZHL:;YE(X,H;.YHOWIH7$A\4-J.^P5&5 MII*,O^UJCQ`)-NJ9H!ML'X%UR?DE@Z?&D[P,YCT>#G<%>W90Y.-"XOC+T1,?`KO'^HB;C/8(KK#&H#N\D4!QJ;8KA'9XX91R*?7"G\ M*U@.=-B?"C.[`C:FZ]/!S%U!;8,EECGF>FUMG&M,<3T.3B:P2)-,\L/W-#:U M2AE:C6/LJ/-4T0#(?P04&!"$C+L6SL%8V.QER@P=-&)`6';60!\+9I^K&PO M=V]R:W-H965TF#-!*'])\')][SKG77IX_J([<@[%2]R7- MDI02Z(6N9-^4]-?/ZY,S2JSC?<4[W4-)'\'2\]7'#\NM-G>V!7`$&7I;TM:Y M8<&8%2TH;A,]0(]?:FT4=_AH&F8'`[P:%ZF.Y6E:,,5E3P/#PAS#H>M:"KC2 M8J.@=X'$0,<=ZK>M'.R>38ECZ!0W=YOA1&@U(,5:=M(]CJ24*+&X:7IM^+I# MWP_9E(L]]_CP@EY)8;35M4N0C@6A+SW/V9PATVI9273@8R<&ZI)>9(O+@K+5 MKK\<&?#>D@IIO M.O=#;[^";%J'W9ZA(>]K43U>@148*-(D^PTG60()VNP[EIZ2DK$QCJM_@10MJ,*)/F.!/]W)/GD?XM9$#+ZNN*. MKY9&;PG."I:R`_>3ERV0<&\HE(\6WW*(UCS)A627L]V7]F#?66?M9=R&5X@T*?)YD1[\9A'^ M+%8O!S&4661M[@-V!03)1:9&^TM'A/;0]^7GLR?^IAJ!TPNPCR)#W] M?/($";;#)@[#KL`T\`FZSA*A-WZ#9AA>?!O/CHM\[%[\@'MWX`U\XZ:1O24= MU+@T34[1N@F[/SPX/8Q;::T=[MKQML5#&G`@TP3!M=9N_^#/EWCLK_X"``#_ M_P,`4$L#!!0`!@`(````(0#G-B!3)@,``$D)```9````>&PO=V]R:W-H965T M8E6-O;'#:[S("(Y"Q&PSGL7GG;A/7,>W]K@OH M%\%G/OEM\)*>/S&2?2$-AK2A3K("1TJ?I/0QDX^@L[WH_=!5X!LS,IRC4R6^ MT_-G3(I20+E7,"(YL&WV>H]Y"HF"C>6MI%-**P"`;Z,F/B]!UQ[ M#S>T`F\5K2\@L=6HNI#ND4#[':-G`V8>-9/N[&>H2]IK#DH#WZ,F\N:29"EY,[$!>*2&'*?4?Z_E M`"?%$D[65M(>U(,IB0ZR5/C.R#HC@K#1A5SXW6#GPF2N2F<*+IH(9&BR,RT.1XCE:Z&CU M."C-ID-SK"#0N%1SE]F,([R&0XIU#CTBI1DX5F^SLZM=HIJ7'-$U'%*LPH;Z_?&0GG67_%TIVTJ$B#4II(C6?G6@]G:ZJ7DJQS`G.HUE0[P?4J768M0;3BX:2 M^7HZ??N$19UH:K.N,2MP@JN*&RD]R=/*A6&-3\>3],Z3^X8]-L!!UJ("?T6L M(`TW*IQ#5\>*8,$P=12J&T';[B@X4@%'6/>SA+\L&'9+QP)Q3JD8;N0+QC]! M^S\```#__P,`4$L#!!0`!@`(````(0#Q\Y?!@0,``)H*```9````>&PO=V]R M:W-H965T:;*$G5`-T=:59: MC69FGQUP$JN`D>TT[;_?:YP`ALXH?6G#];G'Y]SKK_7C6UU9KX0+RIJ-C19+ MVR)-P4K:'#?VC^_/#[%M"8F;$E>L(1O[G0C[.NUR&3HUI8VN&%;^'@QT. MM"`9*\XU::0FX:3"$O2+$VW%C:TN[J&K,7\YMP\%JUN@V-.*RO>.U+;J8O7E MV#".]Q7X?D,^+F[,OJ8%9X(=Y`+H'"UT[CEQ$@>8MNN2@@-5=HN3P\9^ M0JL\L9WMNJO/3THN8O3;$B=V^8O3\BMM"!0;VJ0:L&?L14&_E"H$R5I8WOA(HB6'@*XM2="/E-%:5O%64A6_Z=!Z$JE2=PKB0?JK^/N MPHT#%(2?8/&O+##OP.*[013?H<71OKHR95CB[9JSBP5+#Y2+%JN%C%;`K.KC M096UF[YBORH85$J1/"F6C0U[!M(%-/EU&R31VGF%SA17S&Z.B5P3DMX@J@^* M-[L%!EYDIN0WA%H$8*GW!34?^_JXWS?Y"JSDW^;=Z0!P]WZF4N>(R#.E97.( MMS0A^0>0P:#A!];._7X4>&,#>2\?(=^<>J-L7] MVA38U#8OO,:$NO`HBD*S:JD>'[1GXX00^>ZD#[DQ'B&4](2&D?`S1A38-!(D M`V^W.7<:,PA-IX%L&LA'`4-;]!EM"FQJFQ=98W21/=?S)]I3/3YHS\8)*/:\ M:%BJG=M\#'#AQ`T'2L.*>CA\<*#^_@!22::E<#DY*W8:,TA.IX%L&LA'`4-C M8FK\O38%-K7-RZTQU\/$CZ/1&NRJEVK`(#X;9\#2BF='XQ@0!P%RA^-5>]%W MOK[,:L*/)"55):R"G=5][L'^ZJ/]4^/)54?")+Y#*[AYYO$,GB9=W.D3X&G0 MXB/Y!_,C;815D0-,M5Q$L`6Y?ESH#\G:[FK=,PF/@N[G"=Z`!.ZTY0+`!\;D M[4/=7/VK,%6(9I/CGS]63R.,C*5-06O5\!R?N,'/LX\?I@>EMZ;BW"(@-";' ME;7MA!##*BZI"53+&WA3*BVIA:7>$--J3HNN2-8D#L,!D50TV!,F^A&&*DO! M^%*QG>2-]1#-:VK!OZE$:RXTR1[!2:JWN_:)*=D"8BUJ84\=%"/))J^;1FFZ MKJ'O8Y12=F%WBSN\%$PKHTH;`(YXH_<]C\F8`&DV+01TX&)'FI)1%V>`_*,F9 MDEY3TC@;CA[P0GQ?74Q+:NELJM4!P=8#YZ:E;B-'$R"[?!)(^?U\(!A7\^** MNE)0&YCI?I9EXRG9PR#863._U\2WBL6](@EO)]W'O_T[ M,?2)4>\_'0]Z;M?CW&O2;I"NZ<7;!\NK!S=6@/NX%2?.,:!Z*]G@30ISKQGZ MH-,X&MU:75R_'P_"-+E]#^?+_8>O'XZ28?@7X(W[X^/W14LW_"O5&]$85/,2 M;(7!$/:Z]H?'+ZQJN_FOE85-W]U6\(WCD%,8@+A4REX6[GCV7\W9'P```/__ M`P!02P,$%``&``@````A`-HNOE8Y`P``@`D``!D```!X;"]W;W)K&ULE%;;CILP$'VOU']`O"_W2Q*%K`)HVY5:J:IZ>7;`!&L! M(]O9[/Y]QS@AX&S;;!X(MH\/Y\P,'M;W+VUC/&/&">T2T[4F+40_5'C%G&+ M]KB#E8JR%@D8LKW->X91.6QJ&]MSG,AN$>E,Q;!BMW#0JB(%SFEQ:'$G%`G# M#1*@G]>DYV>VMKB%KD7LZ=#?%;3M@6)'&B)>!U+3:(O5X[ZC#.T:\/WB!J@X M)N757^<*T-^LA/K\( M/O+)O<%K>OS$2/F%=!B"#6F2"=A1^B2ACZ6<@LWVU>Z'(0'?F%'B"AT:\9T> M/V.RKP5D.P1#TM>J?,TQ+R"@0&-YH60J:`,"X&JT1%8&!`2]#/]'4HHZ,?W( M"F/'=P%N[#`7#T12FD9QX(*VOQ7(/5$I$N]$`O\G$C>T`B^,%^]A\4\LP87% MNYG%5KZ&,.5(H,V:T:,!I0?*>8]D(;LK8#['1[D9(_:W@$&D),E6LB0FO#,0 M"PY)?MZ$D;NVGR$SQ0F3*@Q<1TSLS2'9-8U&DI\1,N?@8+0!H9W:>#N]9[42 M+-7*=$OYJ9J82M.572-\9RX^?P-R43\3"YF\7:P$0]5-PA8LH_FC4X4)1D.9 M/I%/)F92(.6W2Y'@Q`2?8P;#2`M4JC!A-!2!8P5NZ,_%9AK"\P/-3JXA?,`[(I@#?7[AAI%G+IP@WB)W(O;B9B8_GXN7Y MX<,I_>\74&[2381SC:G"C-&_*B-M_:J(M/6+P9E\V>:UX^__\N4F7;Y6PZG" MC/)];3W3UJ-+4:MBT=8G1Z72KSJ>.LI;S/8XPTW#C8(>9#?S(/?C[-AHMYX\ M(;3Y#!KPT*[L<0$:8(_V^"MB>])QH\$54#I6#`7,5`M5`T'[H8'LJ(#6-]S6 M\*6#X4AU+`!7E(KS0![8X[?3Y@\```#__P,`4$L#!!0`!@`(````(0"8O[96 M^`(``,4'```9````>&PO=V]R:W-H965T,`^&RK=*7!`_'Q^?, MC(?U_6M5&B^$"\KJ&#FFC0Q2IRRC]3%&/W\\WBV0(22N,URRFL3HC0ATO_GX M87UF_%D4A$@#&&H1HT+*9F59(BU(A87)&E+#FYSQ"DM8\J,E&DYPUFZJ2LNU M[="J,*V19ECQ6SA8GM.4)"P]5:26FH23$DO0+PK:B(ZM2F^AJS!_/C5W*:L: MH#C0DLJWEA095;IZ.M:,XT,)OE\='Z<==[N8T5) MZDG<"XD'ZB_O7=-=!$X0_@>+?V&!8HWZ0)77F>\9=\A5!.`I=X7Y'SHZ_UZ=_(56,GOSMWJ`'#W?J92 MYXC(&TM+YA#/'D/V[T"N!D=^H'=N]Z/`T*D#^?XR'!^]U1B_][R;!I)I8#\( MC+1!9]ZN38%C!,;[U$93:1H2M7WDAY[O3C*[&P*<,%Q,")+A>]]9!OYR;'X_ M!"R7BT%R1L;@0@R-J];VO"#^2'2E+8:3LI$:?!XGNH_U4?G!5 M:TSB6V<%EW0>3V"*MW&KWP!3M,%'\A7S(ZV%49(&ULE%;; MCILP$'VOU']`O"_W6Z*0U29DVTJM5%6]/#M@@K6`D>UL=O^^8QSN6S7[0L)P M?'S.S.!A<_]2E=HS9IS0.M9MP](U7*HI#6.]5?, M]?OMQP^;"V5/O,!8:,!0\U@OA&C6ILG3`E>(&[3!-3S)*:N0@%MV,GG#,,K: M155I.I85F!4BM:X8UNP6#IKG),4)3<\5KH4B8;A$`O3S@C2\8ZO26^@JQ)[. MS5U*JP8HCJ0DXK4EU;4J77\YU92A8PF^7VP/I1UW>[.@KTC***>Y,(#.5$*7 MGE?FR@2F[28CX$"F76,XC_4'>WT(=7.[:?/SF^`+'_W7>$$OGQC)OI(:0[*A M3+(`1TJ?)/1+)D.PV%RL?FP+\)UI&<[1N10_Z.4S)J="0+5],"1]K;/7!/,4 M$@HTAN-+II26(`"N6D5D9T!"T$O[>R&9*&+=#0P_M%P;X-H1<_%()*6NI6PKE2)QKB0NJ+\^=PPG\FT_>`>+=V6!?0<6S_'#Z`8MIO+5IBE!`FTW MC%XT:#U0SALD&]E>`W.7'^6FS]B_$@:9DB0/DB76X9V!7'`H\O/6#Z*-^0R5 M2:^8W1(3.E/(OH/(.DC>I`L,O/9TR:%#R"8`2[TOR/G8U]OU[N1+L)3?[;M3 M`>#N_`8:Z).,5=N0O5AS&`#>` MYX/5B9?@/5XD>.8E''C;(NP41GFQ0W_UAAL%&;F9K`D\SQW+;6D/$X@;1M$8 M,G$4OL>1!,\=S=IJIS"J9SPKM.SQUJKS%&3D:!Z`<28W:A%*K9I.ZMBM,#OA M/2Y+KJ7T+">/"[W01_NA^.#(-W,6W]EK.".7\02&:!LW^P4PQ!ITPM\0.Y&: M:R7.82O+"*%9F!J#ZD;0IAT"1RI@?+5_"_A:P7#Z6@:`&PO=V]R:W-H M965T>F*>:=EWEFC)G5XWM=66^8LI(T:]N;N;:% MFYP497-VQ^8V8^;+W^L+H2^LA/&W`*'AJWM$^?M MTG%8?L(U8C/2X@;N'`BM$8=+>G182S$JNJ"Z*0/SN5+>O=ZOP>NQK1UW/[D).Z!8M]697\HS.UK3I?OAP; M0M&^`NYW+T1Y[]U=3.SK,J>$D0.?@9TC$YTR+YR%`TZ;55$"@2B[1?%A;3]Y MR\QS;6>SZ@KTO<07IOQOL1.Y_$G+XN^RP5!MZ)/HP)Z05R%]*<02!#N3Z.>N M`_]2J\`'=*[X?^3R%RZ/)P[MCH!(@"V+CQ2S'"H*-C,_$DXYJ2`!^&O5I=@: M4!'TWOU>RH*?UG80SZ+$#3R06WO,^',I+&TK/S-.ZA]2Y%VMI(E_-0D@^^M] M?^;/(R^*?\$EO+K`7T(^2^1VY.)*K*U.*.-JL*+E8L/<@<]8BL9.])3B+ M^H3P*VF&BOVL8%`I8?(D7-8VO#00SJ#+;YLH\5?.&W0FOVJV4XTIV?42T0?A MF_8+HZ^GNV:]0FP"0!JXH.8JU^?][M,78I%^_]RM7`#O@<>@V4T52:"GEDXE M@:M+LD\D(Z#&`WOG?AXAAIVJI!\N8OW16ZD)!^:=N9":"YFRH.4&.U/-K=]# MMVLN@M8V%&`H<616<"LU2;>A/'_NN:Y1P)U4C!2I&N*'_GP2DFF*N1NI"@T+ M7@,3*X8#Z#:6"#*Q0J/T4A-W6`]QK";0;?N=%"A46H0_3R8AF:8(@I]3Q5,J M\<+?IA)!)E5D4$F-I/+\<)+B3@H4*C7"#Z9UR#1!`I_.L?U:IY+?81)!)I/Y MDDB-9`H"]?FR4?*^@J0&+!:3@$R][[D:LD8DYH]/CN7;71)!)E%B=$EJKGO/ MZXH^%E5"28D"I<7XH7BGC)A,ERQNO%6+WR$302;9W""3FIY,VRR22PH4+C5B MJL_4VU'DQN,G0&L5C"]:KV[WJ%/K*).C^:J!@VH\&\?/@H2Y0Y->-?+\?/B$ M4!=XBV"LJ424:Y)U]\4XSUK;>$K_MT M/17SGUAWA@`8OUITQ/\@>BP;9E7X`(]R9PD<4E0.<,L(K>>V-W9M"]=/ MLSUM7]@.8VZ!0LWF]H[S9NHX+-_A"K$Q;7`-D0UM*\3AL=TZK&DQ*N2BJG1\ MUXV="I':5@K3]A8-NMF0'&[UZ(\H.V?#B3KTC>4D8W?`QRCC)ZGG/J MI`XH+68%@0Q$V:T6;^;VHS?-/-]V%C-9H#\$[UGOL\5V=/^E)<4W4F.H-O1) M=&!-Z8M`GPOQ"A8[9ZN?9`=^M%:!-^BUY#_I_BLFVQV'=D>0D4AL6GQDF.50 M49`9^Y%0RFD)!N"O51$Q&E`1]"[_[TG!=W,[B,=1X@8>X-8:,_Y$A*1MY:^, MT^JO@KQ.2HGXG4@([KNX?ZN(HPS)_#+$T6+6TKT%0P-?R1HD1M";@K!(++R8 M&&0DUCR*17(IT`RZ\;:(DG3FO$$%\XY9GC.^3JS.B<#5D6P`\8Z(`RD<\X#B M]/,8;LS!OX"A!;9U]!^F\5%7YKA43"@[())>F2^RW@O-"NC>;D7`@D<%TCONK'8]@9C'C6C_MQ/Z[YAO;?[EO`IN]3:U0)%1-+W]ZD M_[TRONK'@_.\LG[/&9"X5HXS[Z8#S/I!"8F;%^_%86Z]5 M/+['N(`-X['YHU.,,CX*)L*:/M8KC?`FT1F1:40@JG[2T-PG][@7L.%^$NC> MEHI1[F/7ZW^Q&IC_`=D50+,NSF5CUPO@4+B^:XA%9@JAD8)BNI%/_8$&:,0D MU:9:9IGIA!OVZZ!ED>I97'3Z.!%FA(D`;:<"O_&N))XL($ M>5#S^_L@5YFIF-MW!ZEO)J8NRT$/W`@``J0@``!D```!X;"]W;W)K&ULG%9= M;YLP%'V?M/^`_%X^0H`D"JG:5=TJK=(T[>/9`0-6`2/;:=I_OVO?A%+2I,WR M0`(534SN/3"HNVI0$KD\#FMJ;^'[L-92W!!D6\B, M%GKH>>[-/6!:+7,.#DSLCF1%2JZ"Q740$&^UM`']X6RK!K\=58GM5\GS[[QE MD#;,DYF!M1`/!GJ7FTDD2F8?8/&P(FOPAFJZ6DJQ=:!K0%-UU/1@ ML`#FO3.LH_=ZS"IX-"17AB4ET.[@0L'\/*ZBV6SI/4*FV0YSC1BX]IB@1WA0 M35\2E#$LZ>V0]\H&;)1-Z*:4:WPPE)F\+1.>(V/`,&N#XJ?SN.=%9<1,;2<- M_4S/$3+@E(")/J5H-A\)(2:V.<=AF(2^WR->)0G--4S23&X(S7\Z43-H5,'\ MA1^M(B;!"GSXO*T?O]8_K6O`8]V7#D%=Q.R<1T=UDW-T#7BL^](RJ(L8U(6T MC_DU^_UH,;V?MQDTU@_[/%$?,3O]X[[G_Z-O!HWUIR-]Q.!\G_`?0',-`S@] MX18]5HY&RCO0N]'#]G^.-&Y&KY;9P7JVE"E!Z2`QL8_['$\,W%`;)DOVA=6U M:N&PO=V]R:W-H965T&UL ME)==CZ,V%(;O*_4_(.X3,/F:1$E6`VC:E5JI:G?;:T*J]-YHPPM6[WPR#7V/UCD[%O5YYW_]\C)Y\CTN MLOJ8E:RF._^#?MG?6O/(+I<*###7?^1H3.^1YVY,#8*P[]#*$0;L); M`=Z$_ZMN\QSA70)]&_.WNN5+V[8_&N](3]FM%'^R^Z^T.%\$W&D!94YM`'N-8T6F#5G):2`3Z\J<#U!&;-W25<3U:3LD\7#Z08];E@.\N!XD>!IEW2>!;)_F_ M602R(FVQTTQD^VW#[AXL=9@SOV:X<<@&$JK*RCKH6O]7J:'&F.09L^Q\V*-0 M10[]?MN'V^`-.IIWBE@JX%,KB*U(E`+;ATE3(Q``K4:&!IC(WU\$B@S%2*:R MQC)@@D0.R%`QLQ7I4#'7"@L5^CP>%<6P,HT2+736MB*Q5,SU9!(WD!H!"P1: M.QX$Q3L?)JE[M71`I`(^M6)E*Q*E4'5/C8!%!AMP/!F*;;(G^[ZQ5)AD:UN1 M*(4F,P(6V?(1,A3;9,3=`E*R:+?''!X[_9IINYO(ZWUW4R-@@:T>`4.Q`^;L MO%A*9,T.W]N]B5+HFAD!"PT?TX:=_'AOHMA!<_9B+"7S%FH6A63E%DT)-)D1 ML,C6CY"AV"%S/""6$B0[[2<3$DUF4-836M^$N$M.:36D$;`@"3Q/S?JA'<\@ M]N,ZMJ,<7*=.<:?I5U?219:RMNOETSH*'?#4'&6#HCF/;C215FXZ"G&]K=.8 M.Y-!B=;T@&K4`!!F^@`@JNTU&+D^0Z3&K.`04&EZ0"-B5Q"- M>WP%I3EJ]!><:#E&/`Z.] M`T"EZ0&-B%T]M/#Q@-+P+<#!#C8>"O*)1MQ(VD56K>E$RU5(R*+O@@V(3FX` MCO1"Z?\6J&,C,5'/"*.2SFY/M*:OI!HU:#6Z^>.@\AE@@3IV$L-!#->C?&68 MD<7:F4G2"7I7Q[.;7,*:4IZPY$M_19LS36A9B$CNHC8'H*AX70%J[^1QS'Y1[!K>Z0X,`''J/;G!<[:%%[GPRF( M3XP)]0E]_PT``/__`P!02P,$%``&``@````A`%J.[@^9!```O`\``!D` M``!X;"]W;W)K&ULG%==CZLV$'VOU/^`>-^`@7RA M)%>_7MK:Z< M%]KRDC5KETQ\UZ%-P?9E>1^M+NX)5^?M\^7\4+#Z M#"&>RJH4[UU0UZF+^/NQ86W^5('O-Q+E11^[>QB%K\NB99P=Q`3">5+HV//2 M6WH0:;/:E^``T^ZT]+!VMR3.R-3U-JLN0?^4])5KOQU^8J^_M.7^M[*AD&V8 M)YR!)\:>D?I]CQ`,]D:C'[L9^*-U]O207RKQ)WO]E9;'DX#IGH(C-!;OWU/* M"\@HA)D$G8R"52``_CIUB:4!&=-,E)\U% MOEFU[-6!B@.]_)QC_9(8HF!60LBM]##DZ4=I`FL89(M1UBXL%1C.86Y?-M%B MNO)>8#X*Q4G&'&(R=CT#,X9A4QO(-,`#`X,+2*+M`N?VBRXP"KKHOY_TP-56 M8$GN&?V0U`8R#3`D0PGHDF^789]?),/$Z/F=6]E+)">0!8?IVXV0=(1D.F+H M@VJ[7Q^286F`5ZT`9F:N$D72!(Z0=(1D.F((A/G5!?;K^8MSCE$ZY?T,)A(A MFDR%@)+!71C.37>I(BT-TL(D90,)OF:8F=TR,\%U+4YE\9PP^#(4_XTJ"6&Y MR46(,4PK$M&M2"1:=FLT\$ED"DP_>9_9[\-AO&%G;MJY(1LVS5XWDDW=$M%U M*R08UF8Z0C(=,=1@"[^QQWVL"@>9JB0"JO0R6`X)Z"9AITCZ2@@CWR2E-TG6 M>LYNDJ[[C^$0JDYW^+$S))O.)&(X(W9I[!1IUI7.PVSF^[8MDQ$LYB-*9E+" M<*I3#$L$NI#NJ>],'WOK1IGF%&2X"Z-KX^:)-,>MC*M*#^Q)1L?;+##-H5^4(U1CI&UGG<]2VH.0UV/LDL2.*)24_D&XFKGE6ODQ2$"W` MF47*K$C!TO^@(+%5:N9DP_GB'DU4O]4G4D*69ZMY[M1`,I?+CQB5I1RK0)(R M)F1FC.G4G_U@.R'8=#6KGQ2G:M&Z)P4-Y;KK0D*Y7DGI&,H,R"PM;)V:I/^7 M?=E_C8I3D*94(@3VWVN[C^QVC\=+7'XFR^[WMUG7GB$MRCN+/);7M#W2':TJ M[A3L@O<1G,X!E7>E=!K#40*V`@N'.]2V2["%)WBWNL%/@AC.I^,X21C#P7", M;Z-X"Y;&+Y(HAH,:X-[P9;@[G?,C_3UOCV7#G8H>P(O?+9=6WK[D@V!G2"-< M@IB`6U/W\P2W9`H'6'\"23XP)OH'_,!P[][\!P``__\#`%!+`P04``8`"``` M`"$`,26$I"0%```E$P``&0```'AL+W=O:E5:KG=EG2IP$%7`$M&G__=Z+3;`- MDZ3STC0WQX=[[H>O\>K+>UD8;[1NSC8?I]G-&;9:TFKEI/4M$A; M\+\YYJ>F9RNS>^C*M'YY/3UDK#P!Q7->Y.U'1VH:919^/52L3I\+T/U.O#3K MN;LO(_HRSVK6L'T[`SJ+.SK6O+26%C!M5KL<%C9KNU^8C"1.R-*W-J@O0 MCYR>&^E_HSFR\Q]UOON65Q2B#7G"##PS]H+0KSLTP6)KM/JIR\#?M;&C^_2U M:/]AYS]I?CBVD&X?%*&PUZ08S?VZ[!.#&,VW:IQPI32-[;5I6_L=!1%!Q$D>0P&=/8L^(9P>?X'`% M!WP*#N+.G(5/_,^P>((%?.]9R&SA^UZPF-_48_'8=*&.TS;=K&IV-J!^07US M2K$;2`@L&&,7,L4C`NRLMX@NYG`;,<8 M#1'U"$PETL:Z(9$,%@BXJ(#LZ"JP4CZI`EE01?_\;6\89#FJJ*A']$MBW9!( M!L5E*`;9Y>FB[N.+8$B,'-^Y%KTMQSB\?#%\T<@2CRR);%'\@W*[WS\$KTT' MM$H%H,5J*T"2@R-+/+(DLD5Q$/(K.]CO#I_,.;)TGO<9W'(+D=P4%O#DHLXA M@5H)L0`M%=!D7.7)4SX39LG[W?"%;]YA;9;V%Q+KT9CRR) M;%&\P0.!M,==]P;!JC?<`MY(Z?>UP$5B&7P,->+[E^CP_6P2I!52,@D:"DE1 M!M5VOS($J\JX15.V4)V.Q+)E5S+^8NG9*B"^!4BN`!0U!`;/_7(ZM*I'F#1! M2]7?J%_(%;FVZSA:#N+;D$2'P-EPV)%563BU[JX_=%Y+DS"IL@(M#5&_4"E! MR21>3,1-Z$6DYT M!9)<95'5XGR5U%[?'(F8QK(L;@)9?5ZC'C6W9\Q`X@`\[IBH#A^7],OAH562( M::M,GD"?/$0L5/M>'SW3*"T"R2V4J@\'KJ3OUQJ%3VU%MACDJFQMFXH(1[FD M:Y0'LO#@-*-E*QZ!R'P>:/,@T4$![#'!SW**TUG2?*-=Q"R7VX6;E'81*+E= M1J:$R"8U#SA?)9]^+0]B2,NN"I/4V-SBRN=\)QC.)J*-)E%#0#L4WAQ@(VE< M0VZX1'XYP-]82UH?:$2+HC$R]HHO_G/(_<7*+R5B/X13-FQ%FATN*QX[;9I] MBY<8$_BM$\*KVYAGZX;PSC2V/WKA([\,T1_@A?`.`PNLRP]P27%*#_2OM#[D M56,4=`]:[&["U/R:@W]IV:D[]3^S%JXGNG^/L[;_@`RX7 M7)O_`0``__\#`%!+`P04``8`"````"$`U\TPFZ`"``#6!@``&0```'AL+W=O M9#6*=/F-(EB M2F0K3*':*J<_?]R<+2AQGK<%;TPK<_HD';U+456W$ M5LO6!Q(K&^XA?U>KSNW9M#B%3G-[O^W.A-$=4&Q4H_Q33TJ)%MEMU1K+-PWX M?DRF7.RY^YJV$-(03G-`470YF.2QE`";3K7]`D'M(951,ZX/1J(KA7'\H9 M(L>FYF/:T/B0T-M]@JO&_"$"A@Z<_*,OSL>2;RLA>*P4(L=.)@G_6,-_P\)9R>.`%P: MX_&ULK%I=;^/*#7TOT/]@^'UCZ\L? M09*+6)IM+]`"17';/CN.DAAK6X&EW>S^^Y(:CF9(3F([N"]W;XZ.:!X.9PYE MZ^:WG_O=Z$=];+?-X7:<7$W'H_JP:1ZWA^?;\7_^^/IE,1ZUW?KPN-XUA_IV M_*MNQ[_=_?4O-V_-\5O[4M?=""(]7D\F[>:EWJ_;J^:U/L"5I^:X M7W?PY_%YTKX>Z_5C?]-^-TFGT]EDO]X>QC;"]?&<&,W3TW935\WF^[X^=#;( ML=ZM.\B_?=F^MB[:?G-.N/WZ^.W[ZY=-LW^%$`_;W;;[U0<=C_:;Z]^?#\UQ M_;`#W3^3?+UQL?L_5/C]=G-LVN:INX)P$YNHUKR<+"<0Z>[F<0L*L.RC8_UT M.[Y/KDV1CR=W-WV!_KNMW]K@_T?M2_/VM^/V\1_;0PW5AG7"%7AHFF](_?T1 M(;AYHN[^VJ_`OXZCQ_II_7W7_;MY^WN]?7[I8+D+4(3"KA]_576[@8I"F*NT MP$B;9@<)P']'^RVV!E1D_;/_]VW[V+W1M"=(*Y]76.O)]=PIZN@C3#4]+V20BTQR#U& MN1W#MH)RM=`'/^ZR++N9_("UVQ!GI3D)9Y2.@0N%82L)F`"8@(!!!13K3U"! M45"%^_R5`[RL5*3L&.Z62@(F`%C*L-1ARO&6=?5%\NT8_CO4-RED?2TGM=V) MY2L54BG$A`C+#SHLS.^3C8%18%=!$8;,=6<0"5()2+FH]$`:2JT0$R),#'1V M*.;C8B.YS]E]THJ0_B3K.[-42*40$R(LFQG/!DN;P=EWX9[#*#Q-0F"3!'4L M1!T'DE-7*<2$",M\SC/_N(Y(Y@D2$K2H0BJ%F!!AV:"-B[/K$W7$*#Q-0G@= M9Z*.`VFHHT),B+#,ESSSC^N(9)X@(4$=%5(IQ(0(RR:!YI.%1!N]L"'[,#Q1 M@I(@4P?!7@VZ=,ZK6SD6Y!RP%IQE/`L6@4M"IQ"]D117:([=RW;S;=5`6.!$ M*I^!?Y&K81`AR$),D(7R9>][Z301)U<%9`SS+L$H@C_:N2CTDD!4)'F8.8;L MK?/`V>LZ=)58B&5/D&=5CN4APR">$QI(D),[S$[D1K;C/V*56`AK$:SXDJ]X MZ5B0M6?E4\ZJXBPQ;I@XRSL\UXG>$N@\H8^<*-1G(:8OD;U2)L2:]Y;V1HGGBNP&1(K,$GS M,#&:^A@ES70-#(^2SN&YRY>)RT,O"^2=6#=ROE"6A80LL<=+T!/(RK(P'U+% M&,NE8A@>(YDRW5P46N+YHLA`0U$6$J+DJ)`0BYHQZ5?"UYET<5*:+T"9(!D1 M*5U./VA(=,U`G)T\+SVZR7I#S182FJ6M)\2:VPV8L,XBQ8RB"8;'*`IXGAP. M*+Z.:,F!U!/-208>:B)H..++Q")P8+M3O]*081!+*8W.`A=6OP_"C=-!0UHE M(5BLX"B7@T"<)0>!.,N;!Y>(?AQ473;8'\WK>[-!8*_PH"6'`P<%TXZ&*@T9 M!O%/9O@`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`N::C2D&$0 MSS4R2BRADR[\[2G7LX2#N'F)Z:CT+#$QJI\/\$'?C2HI(A!X\].4&\J')`\RQ?U.%&!QG&X@+0)0,!)XX2\M0P M38)\!081#/"?TER*D_GO&[W$L;U?I4.+K"KZW]H,"+JH[H@>6+ MJB#C8P&+"2@N\KR>S3W/04%1-51IR#"(YP2295%QJUU8TP+#B&0)XC657U2Y M&[VD2D.&03Q_X5X?;_Y"NY2#?`*EABH-&0;QG"(N]9F::II*"E?ZTU!=R>!*%ON<'.Z!R2>6&]P#,T7L"B@%9X]=*>!*_Q:KS""?P959 M])XY7)G'KL"%*`[EC%83BAFM90H5@Y^O(OFFH-Z>R#+?%-3#SS/Z'GCMYQI? MZHE<2:$N\/N'O@+O&-]':PR)Q?."0)$X*T@JEM-]?GT/3:P_>(4K%<-AG:++ M!*O4+])DJ`>\B_RZ?J[_N3X^;P_M:%<_P0:8]M\5'NW;S/:/CGZ1?&@Z>`VY M_W'R!=XZK^$ES^D5'.U/3=.Y/R#1R?`>^]W_`0``__\#`%!+`P04``8`"``` M`"$`W<>[1SD+``"I-0``&0```'AL+W=O'Y_OA MO_XHO\R'@]-Y?7A<[]I#F_6C'K3?C>/)9#K>K[>'H=&P M/%ZCHWUZVFZ:HMW\V#>'LU%R;';K,\S_]+)]/3EM^\TUZO;KX_@;FPF M*FU>C!=CT/1P][@%"]#M@V/S=#_\&BWK+!Z.'^ZT@_Z];=Y.P?\/3B_M6W7< M/OYM>VC`VQ`GC,"WMOV.HK\_(H+!8S&ZU!'XQW'PV#RM?^S._VS?ZF;[_'*& M<&=@$1JV?/RS:$X;\"BH&<49:MJT.Y@`_'>PW^+2`(^L?^G/M^WC^>5^F"2C M;#9)(A`??&M.YW*+*H>#S8_3N=W_QPA%5I51$ELE\.F49*-9-%DD,U!R86!B M!\*G&QCYNU\8F-J!\&D'1M?=$>:C[85/-W!Z<8IP50^`3S?%J9_BE0Z:627P MZ>X:>R47[(1MJN\.GV[@Y))GQR:\>K44Z_/ZX>[8O@U@"T(`3Z]KW-#1$I2Y M96)NW2V<]]8-+!A4\A6UW`]A/"R)$RSVGP_)++T;_X0%NK$R*RD348G<2>!J M1+4%!XJ#DH.*@SH`8["Y,QS6Y/_!<-2"AKLIKQSPGHB9E4["#2DX4!R4'%0< MU`$@5L(&"JWLW_TNBB@,^SR(8I0E=/8K(Q.;?8Y!R@4I!%&"E()4@M0A(5;! M[@ZM^N2B12WWPQA<=V'56B&82B"44:?DG5`74T&4(*4@E2!U2(@+($^%+K@< M6!36EKKYK2P)PBA((8@2I!2D$J0.";$!4F=H`X8Q!>$;J0$'L7U-[+,4-A:I8E M0C%Z$TL\^B('Y.RJ-"(B51*5$E44T0-09K?&`,;KWD]JT7F58! MRIX+QLHA&L4%CZ(=&!HND/*ZG/I2HDJBFB!J./8!@>$?1-%V#:%]82.A.\L\ M$JB02$E42E1)5!-$C<&*'ACSR=XELHU!:*5%75QS*X0?72&,YA,:U\)*9;"4 M.JF$2RDO!7&E%F%]%Q:-\(1W?MENOJ]:4`M+JR=L"1P5[`'"-@FA/18%]AB2 MS/0)(YY$[(A1X`$7=O"[`LH*P`>>44"#;V^I35C#`YMZY@['X&[RMN*'D[B7 M8N<*K-!$VQJE\UGDIVF/UU:U<4>V M6,P3EAR4U1(;D7F61?$[$8Q9DW%YRVAI6FLM`JO<;LB=5+!G+$J33DH11`(` MQ]3_/0!:"9NJ:0M(`*()CX`=F$"1##83SUG]4NR$J?JE_/JF9F-9OK#N_FA? MW\O(05;#@S%KAQSR+4`N42&1DJB4J)*H)H@:R;H"W%R?:&ICV2XX1-JAN8BN M["#\0+>"E42E1)5$-4'4<*SS070_V&@HS5:O0>$^"PB]%Q;4Z^]E*W:0JO!A M,59D^`CV`#\@6*DLTKEJ,IK&B^DD^.=W`YT=UL_K9V<+<#@[@]CL6)K,8R/E M9M>U3W0N-Y7G6)9GB^A<%BP?YTX*,K?WY\*7*#JGFXHJ%GV^4FQ1)=%;L$*? MVX'6/_%H,E-?O`R=$5:5*F^*EE$2E1)5$-4'$&#Q\ MA<9\,@-I-72'.D0RT,(77G.&\5(NW102*8E*B2J):H*HX:RL7LY`B2F6D,G= M-%<694$*DJB02$E42E1)5!-$C>DIEFCZC4^TL,JSW>,0C2*K_[F7_$P49;7$)@\# M2Z/H*Y+=BYV4CZ)`RNMR4J5$E40U0=1P++!79U2L+GR56N1S9>ZD/"HD4A*5 M$E42U0118UA!-U&\\<"4R#IO49AN;.6'.NSKZ(3U)84=E\%"]U(+WW7KV"LO MY:-J6P9("GY@Q(IYY0<&4@O6:-9>"M13=]W4<\!3$1%[@R`@;N:YE4H6'2HL M\MY34JB4J!+CZI!02V[J5!+9J5B4TEW*XIF[@>8TF^+9?<:J:N%DX!Y!Z'P_ M8V-NIS#7'6L\FK.$4'HUSK651#5!U"/8PER_KVW#$]98@ZA'@N==-F_9@<8C M43R#KKMK<+5(`4M!KQM_"%<>X6.T:,2?+)1>P%LOU-1$BEB?LM;JR<@C6`Z1!? M9\%V_.HGJ^@"EO(M8LYA*SBW4E!%,!\HC$]DY2Z\E%9B.$A;L MR@N$TV-2=9]4N"NIR[#+"O;(!_&W/5F0)U.#F,M85GBAEWY@:Q)PC$J613B:@A5GFX-CJD ME]0H8TXO[=V#-%1)5!-$O7)3>YC*]M`B,-_%('=2WHY"(B51*5$E44T0-08; MKF"??ZX6HA+6*!C$0LQZ\#RU4N9[PRQ*H@7O>0HK@P?N(/>RY*:\E$FB,5M- M)168C28L%55>X,)]ZCZI]Y,H]F;S4<*V;.4%+OJYNXV7>M?/ M^!V[\'/0T#E'7RYB6@M=Q0X%.U6B0B(E42E1)5%-$-FI\!Q8&/F)1S%:#;/2 M-H9A=Y/R5)N[@=X7A41*HE*B2J*:(&KX3:THO/S/N86PQCSB)N/B6$,?)O7-V8!5_2#%CXF@;F!JWO& M3)?P?FD/GRWAG/E_"NXT]'&[=>^<([@POU/6,B"!B\'::O`)O$"WQ_:"> M*\ETB8_'Y!5X]@46]EV!'\9\[8T^WKY'TPH=W\=QL?3PK^GR*RQ[.:45K*$^ M(U:P@O0"&G=1@A_*O*Z?F[^OC\_;PVFP:YY@:\#O+Z!@'LU/;3O>X[= M)9!MT_0%X<-XSLSXPNKR4;?D05JG3%?0+$DID9TPI>KJ@G[_=G-R3HGSO"MY M:SI9T"?IZ.7Z_;O5WMA[UTCI"3!TKJ"-]WW.F!.-U-PEII<=?*F,U=S#T-;, M]5;R,DS2+9NEZ2G37'4T,N3V+1RFJI20UT;LM.Q\)+&RY1[TNT;U[L"FQ5OH M-+?WN_Y$&-T#Q5:URC\%4DJTR&_KSEB^;<'W8[;@XL`=!D?T6@EKG*E\`G0L M"CWV?,$N&#"M5Z4"!Q@[L;(JZ";+K\XI6Z]"/C^4W+O1.W&-V7^TJORL.@EA MPS+A`FR-N4?H;8DEF,R.9M^$!?AB22DKOFO]5[/_)%7=>%CM)1A"7WGY="V= M@$"!)IDMD4F8%@3`DVB%.P,"X8\%G4%C5?JFH//39'F6SC.`DZUT_D8A)25B MY[S1/R,H"Z(B5Y!VS3U?KZS9$UAN0+N>X^;)(Z MCC2",B`;@9YE3>S"%GE[J@@.W8=88^78W.F4-NR?.8!?=X>SIORQ`H9&3A9# MP!,G9].6KW="\+13K!P[P5OVQ4DX^Z<1G#2ECY6ID>4+(_&*B.=02UO+#[)M M'1%FA\=_!@=HJ`XWTV:&&^ME?9%OPMYGPP>X,7I>RSMN:]4YTLH**-,$K=AX MY\2!-WTX_5OCX:X(KPW\&B2J])ZYTD+6,:&C@'B\3F0JZCPF/W\\WMP2 M3QM6IZR4-8_)*]?D;O7^W7(GU9,N.#<>(-0Z)H4Q3>3[.BEXQ?1(-KR&/YE4 M%3/PJ7)?-XJSU"ZJ2G\W'`+X2 MB9):9F8$<+Y+=,AYX2]\0%HM4P$,4'9/\2PF:QK=TUOBKY96H%^"[W3GW=.% MW'U4(OTB:@YJ0YVP`ALIG]#U&"CW M%!@AL2A]?>`Z`44!9C2>(E(B2T@`GEXE<&N`(NPE)F,(+%)3Q&0R&TWGP82" MN[?AVCP*A"1>LM5&5K^=$[5).2R;V@,S;+54)^30VBS M/)4D9(<@:T2)"6Q4B*]!V>=5&,R6_C.HD;SYW#L?>+8^M/7P(9LV)4BCF])Q M>?:1T1DCHUR8RKTS=,.,CX>97!,&G4'O;O+328OK(CN?T,K=Y1/V`Z'$$]@\ MYWGA(B@UL&GE&DKJG"B`=9SF;5H]56&+7*XJ.MOHK:S.,B0WNP86G?NPSC+I M"AL&M\<9S*\)A<[]4,XR9(#C]:`#PF`Q`L+G*X3K^A&66&$\!BH5B=$4##@YYQ%P1W"E=`P`` M4@L``!D```!X;"]W;W)K&ULE%;+;MLP$+P7Z#\( MO,[ MN'TIB^"9*RUD%1,Z&)*`5XE,1;6)R9_?#UP9M,JI(9>%2;4->*L]0N*HLP&@ZG M8)MN25\:!*%XP`_7K7-1ZCU8FE\"53#UMZZM$EC5` MK$4AS*L%)4&9S!\WE51L78#N%SIFR1[;/O3@2Y$HJ65F!@`7ND+[FF?A+`2D MY2(5H`!M#Q3/8K*B\SLZ(^%R80WZ*_A.M_X'.I>[KTJDWT7%P6W8)]R!M91/ MF/J88@@6A[W5#W8'?JH@Y1G;%N:7W'WC8I,;V.X)*$)A\_3UGNL$'`68031! MI$064`#\!J7`HP&.L)>81$`L4I/'9#0=3*Z'(PKIP9IK\R`0D@3)5AM9_G-) MU!;EL&QI]\RPY4+)70#[#=FZ9GAZZ!R`]S4YA*;*8T5"=0BR0I28P$$%?@W. M/B_'=+((G\&-Y"WGSN7`;Y-#FXP0JFE*@C+:)1VV9\^,R[^,FHP77,+F=L[6[K&?M$:/$(#L]I7;@(MAK4-';U+75)%,!: M2=.F+,]5."*7NXK)EKVQU47ZXJ8^+(J[AMS3XG"1#^\BH*Z:KXI>FRGF]#=E6' M%8%BTF$]TF3I@?YP@=9^@[!`/=;W%NSU.MKI$1/C^C*SM=+*6!F89^S>'V97#-WXX@.1,2K-_0+^::7CY'P``__\#`%!+`P04 M``8`"````"$`/(QB/4T#```\"P``&0```'AL+W=O1C$6Q#B!+7L`_B50Y M,_"HMKXN%6>Q791G?C`<3OVV/+J$+F?J>5?>1#(O@6(C,F'>+"GQ\FCQM"VD8IL,?+_2,8O>N>U#ASX7 MD9):)F8`=+[;:-?SW)_[P+1:Q@(<8-H]Q9.0K.GBGLZ)OUK:!/T5?*]KOSV= MROU7)>+OHN"0;3@G/(&-E,\(?8HQ!(O]SNI'>P(_E1?SA.TR\TONOW&Q30T< M]P0]MN#:/`CF)%^VTD?D_AZ('+L<2'%C@^\`RF@XFL^&(GB?QW8ZLP0=FV&JI MY-Z#J@%)73*L0;H`XGY'8`6Q:P2'!*H:]JKA&%Y6XV"Z]%\@==$!<^\P\%EA M:(7P0;12!K7+E1&,RIA;W,J]"]1E@GZ9T34R"`X)?'YL?C*J>)VRPXQMP=3] MC*\10C!4`;BHE+JI="`*Y5H#S:KM-+()971Y-A%LU:MTNDC7U+1)BX4_`^SI M,L%%37H7`3\U([?]1F9-Q=-*"&XJN4C7"+;B6IU?9@07->E=I&EDWF]DWE0\ M;03!3247Z1K!B5W5%#B$&EY&PWXO%&]U+7VGS5AT2\RUA1X[K3:`!S,% MBV<4W/6'^U-5,'6AIITCK8=>U10LNF7G6!.@H%]/E'U3S,_>&+NL)8%,(6GZ M.=+C\%U45SV3/'?9&\ESH9[CZ6D`='+^?+HM@/;T@-%';VTT,WI5$[#H5O*. MM0':TP?HZ/SY=#N!96J?S_C(];FJ%\`DTVX&AU#M?-RLXE[E.5=;_H5GF?8B MN<,Y)("7#[;%E>S4&DZR42%&T29X9W+;1&-H"YK)_ MGVJJ&KH;7W<>AO%QU9DZ5=W512^^?A9'ZYU5=<[+I>T[GFVQ,N/;O-PO[7^^ M)U^>;*MNTG*;'GG)EO8/5MM?5[_^LOC@U6M]8*RQ@*&LE_:A:4YSUZVS`RO2 MVN$G5L(W.UX5:0,?J[U;GRJ6;ENGXNB./&_B%FE>VL@PK^[AX+M=GK&89V\% M*QLDJ=@Q;2#^^I"?:LE69/?0%6GU^G;ZDO'B!!0O^3%O?K2DME5D\V_[DE?I MRQ%T?_IAFDGN]L.`OLBSBM=\USA`YV*@0\TS=^8"TVJQS4&!2+M5L=W2?O;G MR"=M M!?ZJK"W;I6_'YF_^\3O+]X<&RCT&14+8?/LC9G4&&04:9S063!D_0@#PVRIR ML30@(^EG^_S(M\UA:0<39SSU`A_,K1=6-TDN*&TK>ZL;7OR'1CY1(L1"^.E/0+URJ()]72NR2CL2A`-D'B`;`9(HB):R+`HU)!Q_3M3 M@)M#GKVN.3:7,U("6.>X^@5'JT06?8U(@`VMS30A4T5MX#WI:F,RZA?DZ84];NKUQP_J%1RZ7D14O83,NL+%A"CB!C:)BFAA0][4L,^4 M`XX#60]AK,>'B!H?(F%[>&&S(:0+>#,P251$"T],*TH7O1Z>,-;#0R2$9M9M MA<`W=F]$;K.VO8[#\33PQEV-40+Q:#1&@]J@38`T(V=FM.FD^[Z/933I8]%D MSQZ1+8QUV8@8LHUX(G+#>,/0$S^&;.+I*X<`:?0=OW7J?O5BVJPEG?4=BGTX M&^^O=&NM:R;($&VTO4@Z0C&Z%:%6`WD0AC14?D&*JGQ)E$(%>@]!9R#*"C7,Y@T(02J*OT2#=*C%*?S_5'26:Y&B9!1F(F^ MYR*?''%?SI[.M2.R@;.W*P&,[3K1AHQHLXX/Y,_>D#T],@3OS[ MTT#S@9H&A(PTF-W))\<;&Y6XNOIMR._61D6_BU:Z8C$&W*\8AP9M>2)D*!ZT M)G*\H9BX%,6(7-2"O5@,Z7!*7+32%8MQ05'\5E;1[:#F+UVP*OPO@X_ M-+087W@#]VSMNCS`O2J#>P3/@;:]X[R1'\0_Z&YJ5_\#``#__P,`4$L#!!0` M!@`(````(0"F,,0WV`(``%$(```9````>&PO=V]R:W-H965TJX%T-<#6=WAJNE-[D]D%>NR>WVXX?-4:HG77!N/&"H=4(*8YHX"#0K>$6U+QM>PYM,JHH: M6*H\T(WB-+6;JC*(9K-54%%1$\<0JTLX9)8)QN\E.U2\-HY$\9(:J%\7HM$G MMHI=0E=1]71HKIBL&J#8BU*85TM*O(K%CWDM%=V7H/LE7%!VXK:+$7TEF)): M9L8'NL`5.M9\$]P$P+3=I`(4H.V>XEE"=F%\%T8DV&ZL0;\%/^K.LZ<+>?RL M1/I5U!S2G/Z*$T/^3Q"Q=Y8>"XEZ`( MA<7IZSW7#!P%&C]:(A.3)10`OUXEL#7`$?J2D`@2B]04"9FO_.5Z-@\![NVY M-@\"*8G'#MK(ZH\#A;8HQV5+NZ>&;C=*'CTX;T#KAF+WA#$0GVIR#&V5_RH2 MJD.2';(D!!H5\FMP]GD[C^:;X!G<8&^8.X>!WQ83MH@`JFE+@C*Z)4W;<\J, M8,R,=F$I=R[031--IYG_3QH$@]_=XI=#@0ZSL'9W]2SZB=#B.33/>5VX"8X: MU+1VC2UUH!#(.J#%M%QHD.&PO M=V]R:W-H965T(\;PO>F%;F]%$Z>K'Z^&&Y,_;.U5)Z`@RMRVGM M?91Z60+;TIC-?>PM!5SG96\Z#?IAJ5Q/&>:JY8&ALR>PF'*4@EY M9<16R]8'$BL;[B%_5ZO./;%I<0J=YO9NVYT)HSN@V*A&^<>>E!(MLINJ-99O M&O#]D$RY>.+N%T?T6@EKG"E]!'0L)'KL><$6#)A6RT*!`RP[L;+,Z3K)+A>4 MK99]?7XKN7,'S\359O?%JN*;:B44&XX)#V!CS!U";PH,P69VM/NZ/X#OEA2R MY-O&_S"[KU)5M8?3GH$A])45CU?2"2@HT$3I#)F$:2`!N!*ML#.@(/RAO^]4 MX>NKI34[`CT#DJ[CV(%)!L0O&P(GB%TC.*?0TY"K@T.X7TV2Q9+=0^7$'G,9 M,'`=,,F`8"`Z*(/:ZG51'"O/I0S1(Y-S<>T MV/<+R.?M-L%-8_H0`3\'1EYIB_.QXMM*"!XKA=/W(V!@/4ZI_K.&G M).&+C",`E\;XIP4(L^$WM_H+``#__P,`4$L#!!0`!@`(````(0#Q&SJ/P@P` M`&I"```9````>&PO=V]R:W-H965T>QTE,3:V`MN[V?/O.Q0YX@R'L2-W]R+> M/!Q2,\./EY2EW/SZ8_LZ^M[L#YMV=SO.)K/QJ-FMV\?-[OEV_.\_S"]7X]'A MN-H]KE[;77,[_K,YC'^]^^M?;M[;_=?#2],<1]#"[G`[?CD>WZZGT\/ZI=FN M#I/VK=E!R5.[WZZ.\.O^>7IXVS>KQZ[2]G6:SV;SZ7:UV8U="]?[S[31/CUM MUHUJU]^VS>[H&MDWKZLC^']XV;P=L+7M^C/-;5?[K]_>?EFWVS=HXLOF=7/\ MLVMT/-JNKW][WK7[U9=7B/M'5J[6V';WBVA^NUGOVT/[=)Q`^$?C$&$YZ"W%U,<,G7C0+%SWA[=Q7A$^L^&EOIR[Q73^JU7%U M=[-OWT5G6K9-32,'>C9`V&;>HT<+VK6U6Q4#'P!`PA8CZL&`H_(2P;"LV+'3H`0&) M,XH!+;"*BH&.@2&`Q0"CDL:0GE/8`];X=@P_^Q[(JH+[]N!L(T14/N.Z-^MX01`MB*&'AP8RE MX9WN$&O<18'7?O"$I%\0)8@6Q%#"_(/Y2_VSZ2]@21\XEVTKW'%/8*Z17"^C M7/=&&*\21`MB*&&Q+'@LIW-MC;G+GI!<"Z($T8(82IA_=@?S_Z^;MA7NN",E M6TJO9E&N>Z,^UX)H00PE+)8EC^5TKJTQ=]D3DFM!E"!:$$,)\R^#01PG>SY\ M8'?-<-<1L:%])73)7A\JA@A5J(A=H"4R#/&0K'"1\7,ZYYF3.5@2\6H/B()/ MM41*(BV188B[:;6)N-FMZ#-8@`:N*9G3.!:`1SSU>332L6((4TFD)3(,\9BL M?)&8SJ3>BQU-/=6_;J-29P(IB;1$AB'NII4AXN:%8IIY-:/^.Q2M,=%FH?85 MP0K'G))(2V08XB%9Y2(AGM*!$W;>:7 M%RPW7MNH_[W<$26]*N,QWUN%S`ND,X$,0SPDJV,DI#.9]ZI'/:="Z#,OD,H$ MTA(9AKB;5J*(FS;SERST3NG8:N,17VVJ./.]5(BV188C' M9%7STZD'=8\W-HB"^-02*8FT1(8A[F9"8R_8MMOS4K0Q0\0S'YW+ZV`5,M]K M,R(MK0Q#/*1!$IM+B45$,R\E5EIIB0Q#W,V$Q%Z2>2FQN4<\\_'Q-%AAFI5$ M6B+#$`_):M_GQ[Q72K+:R#UOY=% M*K'Q837OK4+F!=+2RC#$0[+:1T(ZO=#G7BFIYT(\:[0*TT!)I"4R#'$WK7@1 M-VWF\P4L]&?\]9I'_77([F"A#7_7;QD?57-OQ6;",IRPN'-6Q8AS9WSRFD=] M<@@.--BO=4X1NYH=]!!I:648XB$-TJY":AYF0KOL,7[@&:606H:(9SX^HP2KD'G?5@A<2RO#$`]ID.(5 M4O$0!0=JB91$6B+#$'.S3$CE!9GOFN$ZY1&_&;6,SRC!JL^\1%HBPQ`/"?J: M3N/3"EM:Z\ASCTCFT2H@)9&6R##$W4PH;&87IX&#OI02BX@/^OB0$JQ"ZGU; M(4PMK0Q#/*9!$EM*B444'*@E4A)IB0Q#W,V$Q%XRZ*7$E@Y%@SX^I`2KD/F^ M(B(MK0Q#/"0KAT2[S@QZ+YY$HDJ/:.8%4M)*2V08XFXF)#:[&GXWJI0:BX@. M^F(6GUJ"%>992:0E,@SQF`9I;"DU%A%-O=18::4E,@QQ-Q,:>\$M6#NTX_6R ME\JPHR]FX23H[FUBQ1"EDDA+9!CB(0W2V%)J+*+@4RV1DDA+9!AB;E8)C861 M>>YDWE7CRN21_5JO/SL5LW#2=)GV5G8_3JS""8L[9\7NTPM'9:TCGQRB)W-O M!0[`).-72XB>'82GEZM*2IQ'+!.YN$?AK:),A!,/]VV0>%52O!"1T221DDA+ M9!CB;EJE(!UF3REVP1VX;:BCXLEE_ M?6AAP,*"D9BR!3PNVHV(^ZX1KAH>P7D',UHC@N%#)D%T:E%H%9Y>T(AXQ6C3 M;9)66=@?\K"MJ)$5R8:=54/#=LI(E]BY0RQLCY9])A1:T1B%E4&KKB+W/E+9 M1.?`-SA][TAUG3O$W'0(CMW88SJ7>>F2/V&'`9/&^ M$RLNNZ>7J[):%+-(TQ2VQ!J*ME7:&\&]E.XQZ,DR[*BZ86Z"0?`GGP=_>/21 MC)_I(ZG6BZ".?:F\%WY58I\MR9O_Q;^@5MM3WK/;$AYI-LJY:_R.$Y`-W MKMB[3'U'?!RX%68RM\48.<2^CW<:9$2HW M%7.'HA$:;^>\E9^:RZODPN1;(ET`[[[P^:M]0Q")6YCB)=!P@W(RRY;T7W", MIV'0#F4N=R@>16D0*Y2O")%^/,P4MM7WG_;DW$1UK7]HQ2*VWY9_?GAVUGQ7 MXU$4<;PT8<73$6-;(6)//HS%+4WGK'C$=EM!)N1%^YR%VYO0?8Y'42+BI0DK MGDF$:Y[,9E_O7")"+L]H8DXO2<7[C-$(O8[X_(RN2MX#XT+CH*$0W& M5R1[)K1RK^C1MY\6T9[ILOZ26ZFN7;B/`"GK)V&1Q<<@M+)[Q^]WZ14+;:AJ MR"4+K18?+5G]UNTC8H3\D?[]M'YA&R!%W)[Y1%D!#NO]@@&%"*% M5CW1TL@PQ+VWVP@RZF+O/W6ZLF>QZ)Z<1U%W1D>I&JU<=Z9WQFASICN="W#S M^8.M,3:#!O.@82XA[D54]P+CMMD_-W7S^GH8K=MO]B53N"=S=]-C]P;L0[6X MMK<,H"]$R164=/L!4;*$DJ[_XI(2ZL#]ET1K)=2!F[N)DJJ`UKK9';=6E5#2 M37)14D%)=^H5)7,HF:>N4^;@0;<+BNN4X(%;7T0)>`!?%R6\+L$#N&&8*@$/ MX'N.5`GD&GHW45)`'=@BIDJ@#GSEGRJ!7+N=9NQU`;EV\RLN*6?@0;<@BA)X M%=I-T[@D!P_@@;F4!U`''GY*E4"NX1FB5`GD&A[;295`KMW-[MB#`G+M3M%Q M20X>P*/#B=9R\,`IBZ@#'L!#KZDZX`$\.YHJ`0]@I4N50,_!4X^)D@SJP/>A MJ1*H`R\CI$H@U_#\?ZH$>AL>HT^50&_#D^N)DAQZ&Y[_3I1`E62-#&K`6UF) M&AEDVGT[$>.HO50*9AA=A9`F\D7^?;@LJ).P?;#>GN!UF M"7Y?7M_#,BHO_&!G>HI#+R;MH0^370@]F.Q`Z+^N^Z9]_N!-_[?5<_./U?YY MLSN,7ILG6*1GW8EV[_Y6@/OEZ-7W2WN$5_P[(7Z!O^G0P!O*LPEHQE/;'O$7 M"&S:_Y6(N_\!``#__P,`4$L#!!0`!@`(````(0`:Q=BT"@8``%X8```8```` M>&PO=V]R:W-H965T&ULG%G;;N-&#'TOT'\P]&Y;H]$UB+-8 MW=H%6J`H>GE6;#D68EN&I%SV[\L1Q]:0\AIR7^*8.CR:0W*&S.3QR^=A/WLO MF[:JCRM++&QK5A[7]:8ZOJRLO__*YZ$U:[OBN"GV];%<6=_+UOKR]/-/CQ]U M\]KNRK*;`<.Q75F[KCL]+)?M>E<>BG91G\HC/-G6S:'HX&OSLFQ/35EL>J?# M?NG8MK\\%-710H:'9@I'O=U6ZS*MUV^'\M@A25/NBP[6W^ZJ4WMF.ZRGT!V* MYO7M-%_7AQ-0/%?[JOO>DUJSP_KAV\NQ;HKG/>C^%&ZQ/G/W7T;TAVK=U&V] M[19`M\2%CC5'RV@)3$^/FPH4J+#/FG*[LKZ*A]R1UO+IL0_0/U7YT1J_S]I= M_?%+4VU^JXXE1!ORI#+P7->O"OIMHTS@O!QYYWT&_FAFFW);O.V[/^N/7\OJ M9==!NCU0I(0];+ZG9;N&B`+-PO$4T[K>PP+@Y^Q0J=*`B!2?_>='M>EV*TOZ M"R^PI0#X[+ELN[Q2E-9L_=9V]>%?!`E-A22.)H%/32+'ILZH\9["3(0WLJU+X4#T"LLBVA9JYG&]*L?+XJI]X5T"V4 MZ/N3L)W'Y3N4U5ICXFL823')-8Q+,>DUC$80-69 M,;D="P5>6?#3B$5XX>WC%2,FZ"/E1$'`GB?FND,4V1HS6X$N?:T@08&2+&S)N MR`T#$0&GSOTBE!,7P2HJ1@R*@).6[:B$//8":`J,($7$(#+CAIQRA-*5PZ8C M(H/_(U(Y<9'L"(T1,XBT7:8B0<2@(N6&C!MRPT!4J!G/:!:W#T8%YJMG>R5& MS+"V!`VZ\(1T0\%*,^4N&3?DMSB(G.@>.0K,Y;"2BA%CR.&&E!LR-*#@>>AX MPH^8XOPFA`@2T+FG)ZA'Q&.N0M#7ACQ(RC:J5L;Z> M7@@NO6QDR2F+ZF;#,JA`U<`-@=/:F<"V3X4R);$&:26^'0A6HHE&#(E(1Y9L M9,E-"]6B6OC]6K#Q4RUL?(B%.1VHOT/H=)*0YZXOA2U9TT@U9!";C2PYI_&A M15[>1+6JSGZ_5IP'J-;A#?V.BM4?GG#J8MZ45G\T-VK(H"4=6;*1)3!\)U0N-/D)XGOXVANE2GGZX+YP*BRQF.(EUP MYO`@(U@B34PB3(`O9>1ZXW:'F!^W.Y-C[CE!((*`K20G+Q*VJGQ_V.HT#FI" MF!X'G"=H'$8'ICETJ#A(SV4K3`1BAKI.M07S>[7=<9?<)"&BG+MFF1[-9QF6 MNUB#A@4GVH(+%I$#>Y'F.QWY9"-+?HN%:KIK+G&NS25\(VJ0J6DTA8PPF;;H MC2@#'UH[2V]^&T-U03%-+T!'H5FN^+$>:Q#>F5S;B`3@2R\,8#CER<,W(XX#*Q3QQJ$B?K!/M28H012 MXG5M'XY_P2KCCL!8"W==V=OZ@;Z,M_!I[^`P``__\#`%!+`P04 M``8`"````"$`832E<40'``#('0``&````'AL+W=OWI;KELUKOB MD#>+ZE0/:OAKKY&1[7=ENLB MK=;/A^+86B5UL<];L+_9E:=FT'987Z/ND-=?GT_S=74X@8K'ZW'PICP5X&^)D(O!855\- M]//&B.#FY>3N3UT$_JQGFV*;/^_;OZJ7WXOR:=="N!4P,L3N-C_2HEF#1T'- M@BNC:5WMP0#X=W8H36J`1_+OW?\OY:;=K3RA%RKP!0/X[+%HVD^E4>G-UL]- M6QW^LR#6J[)*>*]$@/7]=;[@H6)*WZ!%]EK@N:,6R5407F'+TO+JW)3F;?YP M7UC9>5!T8`O&HCRMP?&Y?WR M&T1FW6/B*2;@&)(,$!,'HS<=!(Y>?$LV($P2`*4S+_"YR^MRO`?S#=B8/SPW MM@+0?>9#39TB`H%-2Z<0X6-(=@'"SA#$!W+G>CX&#)GJF`\I;YL!KSP@?G8M8]0VBPFZ1)J+0(LXF M#X($3/)0D"AF"!)RQ70T:D$RW:P23H=].RH&3&QGQ*NQ MQ?2613R4!)"X`+C,-(EKZ@+@=LV)>S(7P)B0(7NE+*);R!DP(<3Q$D0 MPEPGF96^!\AZ0.<%E&O,C,.KDZU#D_Y$/1CWH-'CR4223B29*\$6FI%WO85V M0*)I(<94M).,69#U^%S`#RT(A(C49#=)$4#),-+D(1E"S+7/!!\[.69HQN3U M#.U0Q0S'3M(SM*">H=12D;))&$)`JU:,%CV":*W""46D0[*0O=*-F1F;#L,K MB\<.6\QT?$+/U((L4Q4%8G1R!TBZ9Z^\'L!"RB+%`!'XQ%49`LR#*'*<9M;>SM-.:,R3Y%/, MW#'.1:CICI(@Q#R$/6BTLH\8TA%Q+SM3.Z\Q4U+_ M,;,@:;=J1M>*I+]N*RM20A(%*0+,>0`Y09(B0Q`><9ANY_F.>9K!?#M/.\XQ M3^+KF%G0T"S!U22W$X+07$RH(ATZ#*!?GHET0<^0$J5]Z:0%HLK)JO%V&^G0 M>,5@@K@Y[D$]12YUP.684+91$@Q\=F(^I8DQ*F):1)0GQFCX?N6K$8.9WK1] M0]ZBXF=U"X3=W9+K:-0D;F7(;7RK70RW_C<=GK=AMW=1;F1G(Y[4,^-*P%V M$/X)P?BP13N)WV56BC'P7NHS1K./8+1BD;.-HWP49(A?R=@.KA MW0W>+GWX-(6WJ@1!(JF@D(A/TO^:,:3->,;V=>7DG7#GU,E[Q/ MQW"N95JY_8P-,UW"40VEZT("6"%]Y_MS'UX7C:'7P+>"<[2\\'SWZK?5]G']]GS;_\^?YK=YO[<_+-\>EZ_; MM_JV_Z/>]W^_^^M?;KYM=Y_W+W5]Z,D(;_O;_LOA\'X]&.Q7+_5FN;_:OM=O MTO*TW6V6!_ES]SS8O^_JY6/3:?,Z&`V'L\%FN7[KMR-<[TX98_OTM%[5:KOZ MLJG?#NT@N_IU>9#\]R_K][T?;;,Z9;C--0/]=U]_VT?_W]B_;;W_;K1__L7ZK16TY M3O8(?-IN/]O0/QXMDLX#ZFV:(_"O7>^Q?EI^>3W\>_OM[_7Z^>4@AWLJ%=G" MKA]_J'J_$D5EF*O1U(ZTVKY*`O+?WF9MIX8HLOS>_/MM_7AXN>V/9U?3^MONP/V\W_VJ#"#=4.,G*#R+^908YT'+N.\J_K6,RO)J-I M.6\^_DC/B>LY"SW+J[(8+L:EY,T=!VW=C8QJ>5C>W>RVWWHR-Z6R_?O2SO3B M6@;S^K4C=(K^3%!1T@YR;T>Y[BB&@B M)B:0GYR_<7Y6_L7(KGMN03CY=+8#8>Z.H-S31.XNR)>LB&@B)B903HGE')?; M!F/*CD1R$U%$-!$3$\C/[B&2I7,A!G;FTFE'P<0=0:UGB=9=4*XYD7K=+(J^@0>/(I49Z08:48&$*9I[>GT-%LS@S0=BM,DI`I" MFI$!A&G*\8O3;!:_\\_&P@Z33!"'<(+,TPG21?GCH_Q8X^Z0:48&$)9DC>AT MY9UMQ1/$H5AY0JH@I!D90)BF]:,H3:M\V(2>[#EVUYXJ[Q`JOTB5[Z*"\H2T M'SX<#`,(2[*>%)7TP:GI'"Q6WJ%8>4*J(*09&4"8IK6F*$VK_/B".>\<+L[? M(5!^-DR5[Z*"\H1T0<@`PI*L0T4E?:"\\[,X?T-)U)Q6F2;U4C0HJ19F0`89K62J(T+UQC[458.AL<@B6@3-=8WS&L9XJ1 M9F0`84G6=J*2/E@5G$G%RI-O52-"BI%F9`!AFM8WHC0O5=[93YR_0ZA\NOB. MNJ@PP0EICC*`L"1K.U%)'RCO3"K.G'RK&A%2C#0C`PC3M!X3I6F5MYNE,Z]L M1ZU5Q=<"'LE"$=;;,KA7<]NO"E%!>3=6V+YICC*`H"2[+8I+.JY\$XU.Z%$X M#RM&BI%F9`!AFM:/(N4_2+-UKUC@L4-QFH041VE&!A"FF3BAG2`7;/G';)$> MX01)-QPAJIL@C#0C`PA+LMYUNO*MTX'R#L7*$U)C0IJ1`81I)JYIE;_@IM.8 M[=0C23`Z-<-6J#TU0U10WHT5G9H<90!A28G#?C#GV4C'G9'ZG"I&BI%F9`!A MFHEK7FA'8[93CU#Y=/<:HGR5BI%F9`!A2=;.3I_SSOPB.QJ3'U:,%"/-R`#" M-!/7;.S('J@S_6C,?NJ1+)'1I$]WY"$J2$^NJSG*`,*:$HO]8-*SDXX=BI<; M0HJC-",#"-*<)+9II;_@MFLS#/JI1ZA\N*1IEYL0U2G/2#,R@+`D:X;;82>>4\6H3KH_=G.^B@O*$=!C+1QE` M6-)9%FN+395GB_51X6`H1IJ1`81I9BSV@NN."5NL0W)+PZM5>22+9ECZY\GE MMPI1OJ,.*.Z87#V:$"4=LTC&:-AD6SGE.]C/[M[7(_I?%2R*3?YJ#`6BI!X>J98 MN8'159*VPI#IL)C.$I4TADC`?#)/3\XD1AZ;*J?AS,?:S]HN3'F[X!#6O@B?UB[Z M/JJMW3['-4D.K$I#AM-%(H_&$'D4K)PD(28)&0^+(GP05I[9@13GKE-3WG\X M!(*429J5#RJ;N2!/PRV&B60*0Q93>?(2OS[1&#&>369IB,&0T6(>AZ`<=EMQ M\E(P=9N0:"EP2.KV5E(Q4HPT(^-1,SRF:;<*49H7N$SD>EKI./"@LLBF.W,4?$^7/[_C/KC=QH MZC9#L3H.Q<>6D/(=0Y1F9`!A^MG]D2S.9UX(3WF#Y)&L7]$A2=;6*D3Y*:P8 M:48&$-:4[(8^\!;>]DP="J)6C!0CS<@`PC3MWB*9.78C>Z[R[18EOF\X=0B5 M#VNR\XQ?)0!A"6=M;>9\M[&HUAY%Q60XBC-R`""-&?)YL,N:/8& M^IG*-\/@KL0C5#Y=TD*4UU0QTHP,("S)[A*BR71\SL]L=)*Y0T'FRD<%I!AI M1@80IIG9`%RB/&\!9@ZA\F'WV<[Y$!64[SIZI#G*`,*2SC+Q&9NX1T'FBI%B MI!D90)AFQL0O49YM?.80*I_NQ$.4EUDQTHP,("S)VN'I<]Z99V2Q,_+3BI%B MI!D90)AFQF(O49X==N90K#QM6:L0%93O.GJD.>>*\1>"%XL5+,NRLNL&&E&!A"6=);# MSMAA/8J59X?E*,W(`((TRU_CL,TPZ%,>X9Q/-OI5B.J49Z09&4!8DGQB/)F. M.VQIHY/,'8J4]U$!*4::D0&$:68<]H)=9?'PV3BZH1S/ER0MGN;$!64[ZS9 M(\U1!A"6=);#VMO-Z9QGA_51X6`H1IJ1`81I9ASVDCG/#ELZA',^O88-45YF MQ4@S,H"PI+,<9A[1ERYC5L,PSZE$>H?'H-&Z(Z MY1EI1@80EG26P\[983V*E&>D&&E&!A"FF7'8"[Y2G+/#>H3*I]>P(2HHSP[+ M4080EB2?>/K>9FZCDSGC4*P\(>4[ABC-R`#"-!.'/;X%DW<$4)H.-6\/:%W3 M1P6D&&E&]A4$S?!-QS;-]I4"[6_A-_7NN:[JU]=];[7]8E\7(#9[=]/A]ET& M#W/[,H-&#VH924MSR4$M8VEIEC=JF?A7(Z0MY?3:&JC,&&J92O)#VF4D?N93(Y29]9$>>:Q'=9!.<:Q'=9"^9 M:Q'=9/N6:Q'=Y/!D6F;21VZJY%JDC]R;R+6(UG([(-667JY%M)8[8YF6 MB;3(8SNY%E%4GI3)M8BB\L!)KD44E0U=IF4J+?+M1JY%M);O"#(M8VF1)QAS M+:*H/#28:Q%%Y=&[7(LH*D^[95HFHJ@\-)9K$47E.:U,RUCZR`8JUR)]Y/'I M7(MH+4\AYUI$:WGP-]A,RTC*2/_*HEUR)]Y-NL7(MH+;_' MR+6(UO*SAER+:"V_),BUB-;R0'ZFI9!*Y6>ON1;)6GYIFFN1K,6X=@\(K5KW_'3 M_G%PW]=^VA[DW3S-5[",5LK'O1 MP9=*&\4B6YT597+@8Z&A(]]KR@"PI,JV4IP0&6/3*B*L@ZS:\N"%TM?7U^2[&S!\^1 M;?3NLY'E5]D)*#9L$V[`1NL[A-Z6&(+%]&CUC=^`[R8J1<6VK?NA=U^$K!L' MNST#0^@K+Q^OA>504*")LQDR<=U"`G"-E,3.@(*P!W_?R=(UN#J>I\EB,@>6 MC;#N1B(EB?C6.JW^[$%[JD"2[4G@OB>9G,>S>3))0?,_)#0DY/U=,\=62Z-W M$?0,2-J>80>F.1"_;@B<(':-X()`3T.N%C;A?I4EBR6]A\KQ/>8J8.`Z8-(! M04%T4`:UTY41C,I86DSE*@0.9;+792;OD4%P0>#ZG/QL,O`&Y8"9^GXY]#-] MCQ"""Y*!BT'IN)0!E$*W/H/29$AG5$WH@-.KB6"O/I0S1(Y-G8]IL>^S.23T M=I_@JC%_B("A`R?_Z(OY6/)M)02/E4+DV`E.XH-&]R=X`;;?YL=58_X0&3MY MV7IACH1SIH2IQ2?1MC;B>HLS(H.3,T2'\;7.L*->QJ?YVC<]'3[`6.E9+;XQ M4\O.1JVH@#*)<8Z8,)C"B].]/]T;[6"@^,<&_A\"#D\2`[C2VCV]@#`=_DBK MOP```/__`P!02P,$%``&``@````A`-#D!UM7!P``7R```!@```!X;"]W;W)K MME(K5=6V M?3FW.OK>P*>AX]?J]/D2]&T97U> M>63J>Y/BG->[\GQ8>7]__O1A[DW:+COOLE-]+E;>MZ+U/JY__NGAM6Z>VV-1 M=!.(<&Y7WK'K+LO9K,V/196UT_I2G.&3?=U460=OF\.LO31%MNLOJDZSP/>3 M69659T]$6#:WQ*CW^S(O:)V_5,6Y$T&:XI1UH+\]EI=61:OR6\)56?/\*KK9T[];<!5!R&1G]P1(Y0QX%7&(.$TF,*#M7F01YYE)4'&P_JV4*G?%D')'R8?8'5S25GXW((9FP5@R\E#TMM M@!G`#!(8LH#5^1^RX%%X%NK^&P48:5F2%4-=0FV`&0"2#,U@2AYO:E5?3H;V M->I+8KN^@A.(]N7EVSH(=1!F(D@?M)NI[YV-P:.LO`"*\$9G2!)(,4B15>F! M-)3:09B)H&2@L\UDWBXV)_>:U9TV$C%*ZR#409B)(#4)5O/.TO(H6*9$H`I& M'6.KC@-)94<=A)D(4IYBY6_7D9.Q0(E$PP[;.@AU$&8B2`TW^A^?73P*EBD0 M8BRW1'!E$UQ9*DD+5/X4D]A`@O*C9.`R-YDIG^S=L,_&RB5D2E=0 M,/0/=2&&(*R)VX?1,%I3!U^]$H.%ON64:V5_:V=#AS`06$-HV$-(L2!V((PIJXU%#U(48@K!6;EV&UBLM(HP.:9+>AV98X(Q_R0J'Y:'$@1B"D,S@ M+N?LV=@Y)61VLH)T$U$78@C"FKCQW5PZ^`YB#PT)64/#'O^*A09[:,^-<98] M_L=9WQG_L,KWY,?95LT%A/,+[?'?WP;V@QC_"_@!@%@EH)@RG_MI[&0F[R6C M+/PDT3V(E^TNUPYM:$U1:EB2>H+:EO(#K.TCTDVTPZ.)B)L7QZ&^*R7W'PV^PM<"U<0=K+MBY$78@A M"&OE]F@LQY46D6:JJ[P)!(0W>Z0;4CS8*99A;R[$)`1JG:[A7GB[3.&(L%O+B>)%&5E$8CA%%2:KG%L[),NMWN5KH>KB$ MK%2U"+&M%2OMOYDNX$@AMG8^Q90T2,)0CTTQ7#$E2H/4US?"V5H>_O:T"EVS MEA"D-?S(H2!C#+@00Q#6Q-W/Z*KWK8"P4-1L$C*42I]%)A0YVV64Y=1\C&4L M'D[QBF??9FBA:]H*,I=#LC1$719#$-9JF>^5%G%-%@XG^\<@+6#K0M2%^*FF MOE!H$J>4XNBL*II#L2U.IW:2UR_\!!)^E%D_#+`X'MV0^9)_&X7VM#\)TB4W M\I%/P@3.5)/13^`:T.5>0^$V8W>!X]G'?B?8=X=CV[XB-AZ`J)'XFQ!N/((_ M1LO'44&;:`DG,:[03;R$,Y$1''(>31DR%L\/@U(XWKUDA^*/K#F4YW9R*O90 M?+__3:L1!\3B32=_=GBJ.SC8[7^!.,)!?@&G8OX4]LN^KCOU!@3-AC\-6/\' M``#__P,`4$L#!!0`!@`(````(0#*8/WXR`4``/X6```9````>&PO=V]R:W-H M965T2]3-%]A>Q)*V7:`%BF+; M/BLR;0NQ3$-2-KM_WZ%(6AQ2L9VT+W%\?#@Z9SCD4%Q^^EX?G6^T:2MV6KED MXKL./95L6YWV*_>OKY\?9J[3=L5I6QS9B:[<'[1U/ZU__FGYRIKG]D!IYT"$ M4[MR#UUW7GA>6QYH7;03=J8G^&7'FKKHX&NS]]IS0XMM/Z@^>H'O)UY=5"=7 M1%@T]\1@NUU5THR5+S4]=2)(0X]%!_K;0W5N5;2ZO"=<733/+^>'DM5G"/%4 M':ON1Q_4=>IR\65_8DWQ=`3?WTE4E"IV_\4*7U=EPUJVZR80SA-";<]S;^Y! MI/5R6X$#GG:GH;N5^T@6>1"YWGK9)^COBKZVVO].>V"OOS35]K?J1"';,$]\ M!IX8>^;4+UL.P6#/&OVYGX$_&F=+=\7+L?N3O?Y*J_VA@^F.P1$WMMC^R&A; M0D8AS"2(>:22'4$`_'7JBI<&9*3XWG^^5MONL')#?T(B/P&V\T3;[G/%([I. M^=)VK/Y'<(B,)&($,@9\JACQ)`KBZ8SP*%=&AG(D?,J1))[$4S^\-3"2`R&\ M&AA.9G$<);/IZ",]X;M/8U9TQ7K9L%<':A.LM>>"5SI9P$B5/R'ZDM&W$@J9 MY$$>>925"XL*DM5"%7Q;!S%9>M]@YDK)V=@<@Y$J!I\F'C8S@5P#/#!P<0&I M_Q]<\"CI5;*!L3P!/./H0YB(X.I9`4PU1HK-O(\SC)J*A]G M#46%_?%><[\_T9F0/P$9_F98>4KDP'E?0O%L'OF8D=UDY-<8V!-O4/=[DNU, MGS,!&9[F6'%*Y$#A*?3#(#"F(KM-R4T*O`L,9QQLB[>J^VW)QJ;;$A"VE1@3 MD1(Y$)6BIDD>LR1+3F@T#0WON8HSQL"^>-.[WY=LD;HO`1F^S,,`/^+SG4[H MF<>)[QO6L]N4_"H%V^(=4;,E6O8[=V;\FT6;1 MWB8@I$FRU*)/$I\,ZU6N#8,SBZ/0*+6<&!P"+V+#IHEM\/9YOPW1;)$-V7]1 M"TJL%B0'@K"A!256"QIE&1G(R0T6\A<8;?]#"Z4/@D\#$C(6BK%-I9(5DGZA M/)!9!.<;8[8RBT2FT\3H![E)2F"/2=Z84WCE>L><]FS#W.58<5DNBJ4M%QO* M$83GP3@*?&P>[!,"E&*_\0X+6R(A_*"5VG!"$]LYK%KA),P_X M"D+[P=2H^71@J0K+;(A?U/7A^VU;Z!<7;^+&J*;-GJ;T>&R=DKWP2S4XQ:V7 M%UC<^&V"$*[\0EX@UB^1N@PT?LEF"W@QLD?`[>%CWU8,_@9N%7N1)A[``T;B M;$#2F*+'".+WTVP&`J6C>+R`UWI;Z"99P$OS"#Y=P.LKX-[E`7#[>"[V]/>B MV5>GUCG2'232[X\2C;B_%%\Z6;Y/K(.+Q[Z2#W#/3.%BQY]`Z>P8Z]07_H#+ MS?7Z7P```/__`P!02P,$%``&``@````A`(]&P`]U`@``#@8``!D```!X;"]W M;W)K&ULE%1=;YLP%'V?M/]@^;T8R%>+(%6RJENE M39JF?3P[Y@)6,$:VTS3_?MFR3>D+8'-\SCWWP_GMDVK)(Q@K=5?0)(HI M@4[H4G9U07]\O[^ZIL0ZWI6\U1T4]`"6WB[?O\OWVFQM`^`(,G2VH(US?<:8 M%0TH;B/=0X=_*FT4=[@T-;.]`5X.AU3+TCB>,\5E1P-#9B[AT%4E!=QIL5/0 MN4!BH.4.X[>-[.TSFQ*7T"ENMKO^2FC5(\5&MM(=!E)*E,@>ZDX;OFG1]U,R MY>*9>UB<;=L.0:9F7$AWXM!,#54%72;:>4[;,A_S\ ME+"W)]_$-GK_T^]+%V#7]?1 M;!%/$H23#5AW+STE)6)GG5:_CJ`C52!)CR3X/I),YI>2L!#0X.^..[[,C=X3 M[!F4M#WW'9AD2/QW0^C$8U<>7%#L:8S58A$>E^DBR=DC9DX<,>N`P>>(>4$P M%!V54>UR90_VRCZU/I1UV#B52<=`7LE,WB+CP07%YTOPL\G(&Y0#9CKTRZF? MZ5N$/+B@*;H8EHK\>?^ M-%L-UP$;?^`X]KR&+]S4LK.DA0HIXVB!5DP8Z+!PNA^F8J,=#N+PV>"]"]AT ML?==:>V>%RC,QIM\^1L``/__`P!02P,$%``&``@````A`+S35=Y[`@``#`8` M`!D```!X;"]W;W)K&ULE%1=;]L@%'V?M/^`>*^Q MG:_5BE.EJ[I5VJ1IVLE0= M>0!CI>Y+FB4I)=`+7G/'[<7'RBQCO<5[W0/)7T"2Z]6[]\M=]KH`>_]3:*.YP:1IF!P.\"H=4Q_(TG3/%94\C0V'. MX=!U+07<:+%5T+M(8J#C#N.WK1SL@4V)<^@4-_?;X4)H-2#%1G;2/0522I0H M[II>&[[IT/=C-N7BP!T6)_1*"J.MKEV"="P&>NKYDETR9%HM*XD.?-J)@;JD MZZRXGE.V6H;\_)*PLT=S8EN]^V1D]47V@,G&:_(7L-'ZWD/O*K^%A]G)Z=MP M`=\,J:#FV\Y]U[O/()O6X6W/T)#W551/-V`%)A1IDGSFF83N,``S!;I M)$/-_Y"P&%#P=\,=7RV-WA&L&92T`_<5F!5(_+HA=.*Q:P\N*=8TQFKQ$AY6 M^6*Z9`^8.;''7$<,CB,F&Q$,14=E5#M?V8.]LD^M#^4Z;AS+Y*_+3-XBX\$E MQ?%O\+/)R!N5(V8:ZN78S_0M0AYI48!KX"%UGB=!; MWUDYUMNX.S;].O?W\')_6JS#8\#&']B,`V_@*S>-["WIH$;*-/'=9V([QX73 M0^B)C7;8AF':XJL+6')I@N!::W=8H#`;W_'5'P```/__`P!02P,$%``&``@` M```A`$$-+,Q2`@``!@4``!D```!X;"]W;W)K&UL ME%3+;MLP$+P7Z#\0O$32DQEG4E:U4' M!7T"0Q^6[]\M3DKO30-@"3)TIJ"-M?T\C@UO0#(3J1XZ?%,I+9G%HZYCTVM@ MI2^2;3Q*DDDLF>AH8)CKMW"HJA(<-HH?)'0VD&AHF47]IA&]N;!)_A8ZR?3^ MT-]Q)7NDV(E6V"=/2HGD\\>Z4YKM6IS[G.:,7[C]X89>"JZ5496-D"X.0F]G MGL6S&)F6BU+@!,YVHJ$JZ"J=KW,:+Q?>GY\"3N;JGIA&G3YJ47X6':#9N":W M@)U2>P=]+-TC+(YOJK=^`5\U*:%BA]9^4Z=/(.K&XK;'.)";:UX^;31?Q$=W@?S#K@,'K@$D'1(QJ!DDHXUK2R_9<.CNPZ^SL/`Z,R5^#R;#+RA<\#X`#V;)W_>R%D\FKZZ]\M@KLKO>K`KSV;_ M=`R8%/'I\!FL1CXTPPN,8<]J M^,)T+3I#6JBP-(GN<0H=@AP.5O4^4CME,8#^ML'_#>!BD@C!E5+V&PO=V]R M:W-H965TXH=EF5]J^(`QGSIPY9R!_.,F6'$`;H;J"QD%$"71< ME:*K"_KC^^;N`R7&LJYDK>J@H&NCP3:6T9!:/N@Y-KX&50Y%LPR2*9J%DHJ.>(=-OX5!5)3BL%=]+Z*PG MT=`RB_I-(WIS89/\+722Z=V^O^-*]DBQ%:VPYX&4$LFSQ[I3FFU;G/L43QB_ M<`^'&WHIN%9&539`NM`+O9WY/KP/D6F1EP(G<+83#55!EW&VFM!PD0_^_!1P M-%?WQ#3J^$F+\HOH`,W&F%P`6Z5V#OI8ND=8'-Y4;X8`OFI20L7VK?VFCI]! MU(W%M*V.5_.5!\2#*!TQ\8@(4=[( M69S,$Y?Q*]%?9G.%0]RC8Y-T_D]3CXDQLA$43_]:[X7XE?2Y2]`U?(2V-82K MO5NW&`,;GXY?PC(9]F9\@9O8LQJ>F*Y%9T@+%99&P1RGT'Z7_<&J?MBJK;*X M@\-M@[\&ULE%3+;MLP M$+P7Z#\0O$-Z.R93?*WT$EFMKONCFO9(<5& MM,*=>E)*))\]UTH;MFEQ[F.:,7[F[@\W]%)PHZVN7(1T<1!Z._-C_!@CTSPO M!4[@;2<&JH(NTMDRH_$\[_WY(>!@+^Z);?3AHQ'E9Z$`S<8U^05LM-YZZ'/I M'V%Q?%.][A?PQ9`2*K9KW5=]^`2B;AQN>X(#^;EFY6D%EJ.A2!.-)IZ)ZQ8% MX)5(X9.!AK!C04?86)2N*>AX&DWNDW&*<+(!Z];"4U+"=]9I^3.`TEY4X.JE MK9AC\]SH`\%U(]IVS(;Q'-_AOS#)@\#I@T@$1HYI!$LJXE/1O>\Z=/=AW]G9Y*:_```` M__\#`%!+`P04``8`"````"$`[/)4;VX"``"?!0``&0```'AL+W=OCO7]=GGRBQC@\U[_4`%7T`2R]7'S\L]]KH0!OS3:*.[P:%IF1P.\#I=4SV9I>LX4EP.-#*5Y"X=N&BG@2HN=@L%%$@,] M=ZC?=G*T1S8EWD*GN+G=C6="JQ$IMK*7[B&04J)$>=,.VO!MCW7?9P471^YP M>$&OI##:ZL8E2,>BT) MB>WT_HN1]3 M(9QLP;IKZ2DI$3OKM/H;05D0%;F"M"ON^&II])Y@NQ%M1^Z')RN1V&O*L;+( M,*G\GTA4YTG6GJ6B.*=XW:*Q=ZNB2)?L#MT0!\PF8O`Y8;()P5#-)`EEG$IZ MW9YC9@_VF='X(&43`Z=I9J^GR=^3QH/1F1/Q17X^\<;,$5,$NT_K*9XF\A8O MWF^Q9\'>8WF3?T7QZ&"4<`"=ZLSF%Y/.)S;CS+S=9@\.V2>?#Y'\L=PX^'&Z M%)@6/D/?6R+TS@]UCF,Q1:=]6\_\_>?QHER'!7@6WQ2'_633!]R/D;?PG9M6 M#I;TT&"J-+E`=29N6#PX/899WVJ'FQ%>._P1`@YOFB"XT=H=#WZ'IU_KZA\` M``#__P,`4$L#!!0`!@`(````(0#.,V=I3P(```8%```9````>&PO=V]R:W-H M965T,&YIMMM7V!6$X<^;,F0.+AY-LR0&T$:K+:1Q$E$#'52FZ M.J??OF[NWE%B+.M*UJH.QY(*9$\>ZP[I=FVQ;E/<Z.W,]^%]B$S%HA0X@;.=:*ARNHRS54K#8C'X\UW`T5S= M$].HXP%-]698P&=-2JC8OK5?U/$CB+JQ MN.TI#N3FRLKS&@Q'0Y$F2*:.B:L6!>"52.&2@8:P4TX3;"Q*V^1T,@NF\V@2 M(YQLP=B-<)24\+VQ2O[PH'@0Y;D&:6MF6;'0ZDAPW8@V/7/AB3,D=II29/,, MH\J_B41UCF3I6'**.<5R@\8>BG0V6X0'=(/_PJP\!J\C)AX1(:H9):&,:TDO MVW/I[,"NL[/+25GY!]=MDI?;3/ZGC0.CWU?BT\F?`WK,$*!G\Z3/&SF+DQC3 M\^_!7-6PZ]&N=#8?)_&S>HSC&D%)]!OD5?@\^J5+T#6\A[8UA*N]RUJ,VQJ? MCI_!,AE",[[`&/:LAB>F:]$9TD*%I5$PQZ1H'V1_L*H?(K55%@,XW#;XOP%< M3!0@N%+*7@[N4QG_8,5/````__\#`%!+`P04``8`"````"$`;RI.7U`"```% M!0``&0```'AL+W=O3 M;,D!M!&J*V@<1)1`QU4INKJ@/[YO[AXH,99U)6M5!P4]@Z&/B_?O\J/2.],` M6((,G2EH8VV?A:'A#4AF`M5#AV\JI26S>-1U:'H-K!R*9!LF430+)1,=]0R9 M?@N'JBK!8:WX7D)G/8F&EEG4;QK1FPN;Y&^ADTSO]OT=5[)'BJUHA3T/I)1( MGCW5G=)LV^+!:&579`.E"+_1VYGDX#Y%ID9<")W"V$PU5 M09=QMDIIN,@'?WX*.)JK>V(:=?RH1?E9=(!FXYK<`K9*[1STJ72/L#B\J=X, M"_BJ20D5V[?VFSI^`E$W%K<]Q8'<7%EY7H/A:"C2!,G4,7'5H@"\$BE<,M`0 M=BIH@HU%:9N"3F;!]#Z:Q`@G6S!V(QPE)7QOK)*_/"@>1'FN0=J:6;;(M3H2 M7#>B3<]<>.(,B9VF"4[F&4:5KXE$=8YDZ5@*BCG%0Q>1TP\(D)4,TI"&=>27K;GTMF!76=GEY.R\@^NVR0OMYG\3QL'1F>NQ*>3 MV"^E/$'MO@-``#__P,`4$L#!!0` M!@`(````(0#1H1@`,P,``+0)```9````>&PO=V]R:W-H965T6WLK!Y>Z\IZP8P3VB2V[WBVA9N,YJ0Y)/;O7X]W][;% M!6IR5-$&)_8;YO;#^O.GU8FR9UYB+"QP:'ABET*TL>ORK,0UX@YM<0._%)35 M2,`M.[B\91CEW:"Z<@//B]P:D<96#C&[QH,6!ENW3!:;W*"70@8[<8+A)[X\?ITG;7JRZ?/P2?^.B[Q4MZ M^L)(_HTT&,*&:9(3L*?T64J?[9Z,=N`GXP*\<%.E;B)SU]Q>10"ICM M.30D^XKSMQ3S#`(%&R>82Z>,5@``GU9-Y,J`0-!K=SV17)2)/8N<^<*;^2"W M]IB+1R(M;2L[\"U]_`AC,L`KFJF MRR9%`JU7C)XL6&^`RULD5Z\?@Z$,)81V5`LZIO^E!/%(DXUT26QX46`XAYE] M68<+;^6^P'1DO69[KO%-Q6Y0R.RE;3HJN,"KH2&]*;2^S((HUL(I=@D5)4)X6RREK1($_85DS#4PPS"Q2V$4FP2JLJ$ M<*X?U;U^.RW2A'WE*D)Y;(YVELN+3HI-0E69$$830BW2A'W%)%SH84:&RUL( MI=@D5)4)X;U^E,I0BS1A7S$)EWJ8(E2GF-JI:\P.>(>KBEL9/TFD]B&'S^D`_BV$?.:]OPGC3'<:X;*,&R@*ZW?WWN46QU,)8[KRTV\>G3MUS[ZUM\_6]*K4WW+0% MJ;Q2FR-:-W:9/T#\%OK?<_UI[)???FN+TO:@Q9!OJ1"MP M).2%4K^=*`2##65TVE?@ST8[X7/V6G9_D?OON+A<.RBW"XZHL?#T$>,VAXR" MS,IRJ5).2@@`_FI505L#,I*]]Y_WXM1=M[J]7KF>:2.@:T?<=FE!)74M?VT[ M4OW+2&B08B+6(`*?@XCEKBS?1>[Z$RKVH`*?@PIR5[[K.FO?@U@>S.\,(^%S M'NE8KN?W+AZ,!-W>_GH>B;@Y'_LW6"[[TL19E^TV#;EKT.^0K?:6T=6#0E"F M-7$F!U.5?E8DJ`X5V5.5K0X+%8:WT%EO.\>S-\8;=$,^<"*5@T3&8630TE/9 M6`82&4@YP`!'DRTHKVR+MAI+[].VJ`JU-084C<#LTY(\C(QQ2"P#B0RD'"!X M@.;B/2POD[$"E`P+0JB`E-^(<2RV(&B"#PH2*TBB("F/"!%#4S\?,25O=0O< MP10Q`7^(`$G%_D MFZ+?>"*-0LF$S&E"OE39="+!,,$>+&G5WHKN4=VUR%\BPC;,A=ZR81FSQ4TU M1',,XA;1VDD62M(VDBZ1927#OB>X77,*>/]JD9-$F M0WB;"A(K2#(@UK1KI#PBQ$=O-MSF^S@^2A;C8PC$QR=5ROQA(/'+#/FNU':+ MI+5(2A9)GDA*%TG^1!+LPU)XWCXEB_89(MD/IJGZYCT,I#4[E,S`\Z6(8X'A MFG`1D+*3"`SXW7>4!2A2$,SCSDM;,(W@WO2\ZYXMVAX@T7L4PQW4#*32)2;,_U'(F22A3;1&B>2'1.#VNNW=E>^\G-B-J6^F"`A(1X M4IB'D>3UC0!WK<"44A:+E,"%YX'83(G(L-?.6J:D(L4*?)XBIH.>^UPZ'J]^ MQ&X)<%R.)T,T0##C"!U4*%:A1(72$>KEQ3#I:<^%^?^J-EP9^.@91/,UG?_( M5,HVL&!;F5F!=/S%\&JA38%$UGPH]$LB66;)Y\LR:]Y567+8(X?=I"O<7/`! MEV6KY>25/F!\:+()98^K@QO"X0Z%DO#$#>'T5G%XC.W[;$G\B#[2%OB1%<)% M4M6)[!#N:RJ^=\(]>^S)$S@AW)9@@#']`(^P6W;!?V3-I:A;K<1G\&CV"[=A MSSCVI2.W_D%Q)!T\O_I_K_#&ULG%?;CJLV%'VOU']`O$_`Y(Z2'(7`M$7C6U1%E=I7)`*[^U/3.TOAY]_VMU)\T8SC)D%"A7=VQECM>\X-,EP&=,9 MJ7$%=RZD*6,&E\W5H76#X[1]J"P;O5+0LH:),YYD;//5M2VRL3_>JU($Y\+R/V! M%G'2:;<7(_DR3QI"R87-0,X11L>9M\[6`:7#+LTA`2^[U>#+WCXB/T(+VSGL MV@+]G>,[5?ZW:$;NOS1Y^BVO,%0;QHF/P)F0-T[]FG(('G9&3[^V(_![8Z7X M$M\*]@>Y_XKS:\9@N)>0B`?ST\\0TP0J"C(S;\F5$E*``?AKE3EO#:A(_-'^ MWO.497M[OIHMU^X<`=TZ8\I>0NP7M"^%I'?/)@'P0 MYB6>PT")@O1%_Z^:0[&YR)&K[&V8=_`XA49Y/RS6RYWS#H.;2$XPYB"=<>H8 M?"2Y;&@"D0(X$*!/`8-CIN"-\F0*KL)3=.\/.F"(Y1F6.T;W2&@"D0)HEJ$7 M5,O3/=W5EY-A8+3Z&M4+!,<3W9%4:8*77 M*I"D=L%HQ_HYZ*%;C#\P?W(O#_OG]?BK/4X$[9A]>Q\<[+N6R"J;XEX_=P,1TBD(IH; M?AY0UKCON^%DW8U`P(TZ_)L^N&AE25(,CI!(132#T#2/&^1DW:!`U'))1'$S M0B(5T=P@6/\?M].R=3\2,BJV-2K6L=1%P_-CYOF`JB(SK6JIUK:+,=11/*2!`\;XW,Y4*7\#;;S3!?]4A\EU$B MB<7PR?4#B:T*5O%^+920D70P(9/*!\6J\@*G9'>4]8>4J'O]I(J>EF]:2MKO M3V@DMS@UEH`@5I?T)%E@HH/",11ID.Z)[U.*I_\W`G*S&TP$<+YNVZ^W=9(( M@M5DV(X\X[053K.,38N?WKFZH36TH8@H#NCBV%CBYHI/N"BHE9`;/WROH;][ M5'P8A$L?MCHHI('#!\.QS6;@`?^0F.`'G@_GI[%.,/?AX#+&CPO_")'&-X*% M#P<)P)W^S?"A4,=7_%O<7/.*6@6^0!:WG3*-^-00%XS4[=9[)@P^$=I_,_@D MQ'#`P/U\(8=T%?T'_D7GX%P``__\#`%!+`P04``8`"````"$`E^\57/P# M``#I#```&0```'AL+W=OWGMZ;67E%'*MSN=&MEZAIJGG*<7.!$,>JKN@[#ZIK31Y^.;>XRXXU^'ZSW"P?8O.;1?BFRCM,\(FN M()PAA"X]!T9@0*3]MJC``4N[UJ'33C]886K9NK'?\@3]7:$;F5UKI,2W7[NJ M^+UJ$60;ZL0J<,3XA5&_%`R"Q<9B]3.OP)^=5J!3=JWI7_CV&ZK.)85R>^"( M&0N+]P21'#(*85:VQR+EN`8!\%]K*M8:D)'LC7_>JH*6.]WQ5][:="R@:T=$ MZ'/%0NI:?B44-]\%R>I#B2!V'P0^AR!P^>!BIU\,C^L76]9JXWFNOUG_KP1# MV.'923*:[;<=OFG0(6"Y#TG6G(LF1$/#)9]%C91@70&&&!@=`%9_`DN6!3F8GA^-`"3 M+5N1/#"&)8D*I#-`D@SEG$N^WX=#?AD9.D[*KY*]2'!LT7$L??$"219(.DY']#'R3K?!ZZP!-G*NHI[DCOF-%TBR0-(Y(@F$;GT\@8S,!0Z%B@1B04>- MDFU;D1SW)&>4G"R0=(Y(`OV/"&1D6:!`0.`@.>X1_I84&V2!I'-$4K/^B!I& MEM4(1$E7(%. M(XN.>Y+/WVV!9WF6XCV1&)N-N?943Q(C"$S?G]I-,A1\Q!`CRX8$HAAR%4,] M21CR_"#P/9F12`S8&NYZDLN[+Y49IN5N)H9DR()Q/2^1F#(K-K9H6>4O$1:C M\T[I',AX/V-8$-DICPN32]K$CF(D[EDV;(UIJSN^8G=@>;S$3Y9GPI_,254. MHTPA,0?#/N_YXECDG]A.Q9TSLAE5BR)C:+9II^K`QBH,&[ M?M`5@2"N?D3B'K&@Y6.`_<@X)'["#*G*BX'<(LOX,[(0S1)7YPPP-(7WX1N2$,-<"- M\0EPT+QD9_1'UIVKEF@U.H%FD^^/3AQ5Q0W%%WYB.V(*1TQ^6<)/"@3#WES! M9CIA3(<;]H#Q1\K^'P```/__`P!02P,$%``&``@````A`.LP;'%5!```DPX` M`!D```!X;"]W;W)K&ULG%==CZ,V%'VOU/^`>-_P M#0E*LDH"TZ[42E6UNWTFQ$G0`(XP,YGY][W7-L0VV6VF+Y/A<'PX]\-UK9W[X^?9K;%NN+]E#4M"4K^YTP^_/ZUU^6 M5]H]LS,AO04*+5O9Y[Z_I([#RC-I"C:C%]+"G2/MFJ*'R^[DL$M'B@-?U-2. M[[JQTQ15:PN%M'M$@QZ/54DR6KXTI.V%2$?JH@?_[%Q=V*#6E(_(-47W_'+Y M5-+F`A+[JJ[Z=RYJ6TV9?CFUM"OV-<3]YH5%.6CSBXE\4Y4=9?38ST#.$4:G M,2^LD3]+TB5Z;\;[$SO?[658<_JI9` MMJ%.6($]I<](_7)`"!8[D]5/O`)_==:!'(N7NO^;7G\GU>G<0[DCB`@#2P_O M&6$E9!1D9GZ$2B6MP0#\M9H*6P,R4KSQWVMUZ,\K.XAG4>(&'M"M/6']4X62 MME6^L)XV_PB2)Z6$B"]%X'<4>7AQ(!?#KUSL>;-Y%(7Q/'G<0BA58,5-Q0O= M^+_#<$1*>(:SHB_6RXY>+6A;")I="MP$7@JZF-H`"B02,2;[1[F&)*/(!E56 M-NPW6,Z@05[78;)8.J]0U%)RME..IS-V`P,KB+*9">0*X$``8Q10%#,*;)`/ M1H$J&,7P_.T`W,+R#'O*+9"B,EE\C>UO!\477 M8OIV$R2;(+F*:/Z@V1[WA^25[4.LMP:8NWJNMI+$7Q2\OKL)DDV07$4T@U#? MQPTBF1L<"K45B`<=-5KV0\/R3I*"L26R"9)+Z00YFL'X(P:1K!L4"!@<+.\D MXH](-D%R%='<)!]Q@V3=C4",=!DMN),DM0W\T-@RV5U2H/=*?I<4CB0M,ASS MRBOLYSL)R7ID`C$BB\9'B4Z5I)B_VWPWF.OW,^U^F'BQ?C_7[D>1?UNOA;+X M2"A(UD,1B!&*864G22*4R`UCLT`Z89&$1C)RC1"&<9*,T6K1>#!(U,J(N3W# MB=>?J_)Y2V'KP0:\4[$`$BU'"XKH87)=6*GOW9L)4;*!E?":+6#01L;VSG1* MXL=!8$RM7*>$B9^XMP?IT>)P>K@/T;P9EH#@SKCC)-+KR/KVU.:])=I\UR;E0U[64XNDAX@3[28A? MZ>5'30;'IK'+Y!Q48U1'HVRI"91Y$RC7(-TK#C/%ZYW&5SW)T:=ZDI#:(A,H M@[,XK\Z-A.V.`PVI#N1':EK9I7T!8_2I'#LF.*;,-V(SPA3*$SA&#!=L/5`";)][PXL$5K.*`:?!)?B M1/XLNE/5,JLF1XC3Y:^C3GQ4B(M>=LR>]O`QP)OG#!]_!(Y4[@S>74=*^^$" M'NV,GY/K?P$``/__`P!02P,$%``&``@````A`%,'JI]0`@``!@4``!D```!X M;"]W;W)K&ULE%3;CM,P$'U'XA\LOV_N[;)5DE5+ M55@))(2X/+O.)+$:QY'M7O;O&<F=:`$N0H3<%;:T= M%F%H>`N2F4`-T..;6FG)+!YU$YI!`ZO&(MF%213-0\E$3SW#0K^$0]6UX+!6 M?"^AMYY$0\M&,R93?*7T$FF=_OACBLY(,56=,(^CZ242+YX:GJEV;;# MN4]QQOB9>SS"9S`V4XTU`5=QHM51L,R M'_WY)N!H+NZ):=7QG1;5!]$#FHUK<@O8*K5ST*?*/<+B\*9Z,R[@DR85U&S? MV<_J^!Y$TUK<]@P'@>!3EN49I:V99F6MU)+AN1)N!N?#$ M"R1VFE*3LO(/+MO\$G+5)OV?-@Z,SER(S]+Y)-]W]I@Q M0%>-LNM&?NWH\;\'[LGGZ6T>/B9%K`B71;`)Y%3Z/?ND2=`-OH>L, MX6KOLA;CMJ:GTV>P3,;03"\PA@-KX"/3C>@-Z:#&TBBXQ]QI'V1_L&H8([55 M%@,XWK;XOP%<3!0@N%;*G@_N4YG^8.4/````__\#`%!+`P04``8`"````"$` M9H9-[$\"```%!0``&0```'AL+W=O3;,D!M!&JRVD<1)1`QU4INCJGW[YN[MY18BSK2M:J#G)Z!D,? MBK=O%D>E=Z8!L`09.I/3QMH^"T/#&Y#,!*J'#M]42DMF\:CKT/0:6#D4R39, MHF@62B8ZZADR_1H.556"PUKQO83.>A(-+;.HWS2B-Q[?L[KF2/ M%%O1"GL>2"F1/'NL.Z79ML6Y3W'*^(5[.-S02\&U,JJR`=*%7NCMS/-P'B)3 ML2@%3N!L)QJJG"[C;)72L%@,_GP7<#17]\0TZOA!B_*3Z`#-QC6Y!6R5VCGH M8^D>87%X4[T9%O!9DQ(JMF_M%W7\"*)N+&Y[B@.YN;+RO`;#T5"D"9*I8^*J M10%X)5*X9*`A[)33!!N+TC8YG6"5_>%`\B/)< M@[0ULZQ8:'4DN&Y$FYZY\,09$CM-$YS,,XPJ_R82U3F2I6/)*>84RPT:>RC2 M6;H(#^@&_X59>0Q>1TP\(D)4,TI"&=>27K;GTMF!76=GEY.R\@^NVR0OMYG\ M3QL'1F>NQ*>3V_&ULG%G?;]LV$'X?L/_!T'MM4?XARXA3Q!*Y%=B`8>BV9T66 M8Z&V94A*T_[W.XJDQ..Q:>*7IO[X\73WW8EW-N\^?CN?)E_+IJWJRS9@TS"8 ME)>BWE>7IVWPSV?Q81U,VBZ_[/-3?2FWP?>R#3[>__K+W4O=?&F/9=E-P,*E MW0;'KKMN9K.V.);GO)W6U_("*X>Z.><=?&R>9NVU*?-]O^E\FD5AN)J=\^H2 M*`N;YBTVZL.A*LJL+I[/Y:531IKRE'?@?WNLKJVQ=B[>8NZ<-U^>KQ^*^GP% M$X_5J>J^]T:#R;G8?'JZU$W^>(*XO[%%7AC;_0=B_EP53=W6AVX*YF;*41IS M,DMF8.G^;E]!!%+V25,>ML$#VXAY&,SN[WJ!_JW*E];Z_Z0]UB^_-=7^C^I2 M@MJ0)YF!Q[K^(JF?]A*"S3.R6_09^*N9[,M#_GSJ_JY??B^KIV,'Z5Y"1#*P MS?Y[5K8%*`IFIM%26BKJ$S@`_T[.E2P-4"3_UO]]J?;=<1O,5]-E',X9T">/ M9=N)2IH,)L5SV]7G_Q2):5/*2*2-P%^/D5QBQ,YC'X33?.5-R]C%G>Y?=W3?TR@=J$R-IK+BN=;<"8U`_RI2T, MBOY(4%!2&GF05K8!O%2PO84J^'J_6*[O9E\ASTADMQ'89Z]TX@E/T$R M@G"""!M!_L'[:_MGSL)W%KVT@AU7"+,2YMB2\))&2RAZ.;%8![4G2NA8)DQ)QF$JQ`Z3(!E!N$:BX004 M-H+\@UIXNW^2C/U3"/AGB^HHGVJ2?3*P]1*+FGE)SE'(O:086Q)>TMC64/@, MFN;;X^_96``-.0JX)YIAK523#9-X[7B=8=9Q)3`P`T/'-0[C0D'1G:6^RXF1I2W-<"3(Q) MZ$B684JRA&\GN,8Y9LQ7BY5+$9@2)6N;@N60DX$EQ^N'%--SA!VW@B!N(T6J M61:448A32!BH-X_=E!W>02AK+"1ITRPX28? MT+\2W,]RVXR?-1ZN6!PY7KPBSN?Z^J,V:S4@.6R[+[D]M^@WFD"9V3A6`*>0 M0!!V7XX/Q/T;OM&H,02]E!JR7TJ6.&=KR@:6*>&,0IQ"`D$X)CDG6#']Y+52 M4P7R7$.CJ"DC4$8A3B&!(.RFG`TL-V\<_YD:,9#_&L+*CV>RKJ:!-2I/(&[, MCUH(!.&0Y`A@A?03Y=7`@#S7T/BTE!$HHQ"GD$`0"HQ M$%;>/=)&UJ`\A3B%!()P2/#$MRL/WVG=X\9`EO(4RBC$*200A-WT#`"W*$]' M`*BB/B2L_#A]JIH?6:/RPT8#<%GM+S=,.&PV]#.ZR![-,F"IU!/QU9 MIL`S"G$*RW]\-L+K%V47K MC'KPJPP-\]GY\J8*,N5- M%(,%.,?`TFS((=S27?.G\L^\>:HN[>14'J`XP_ZGE4;=\ZD/G?X^^EAW<#_7 M?S4]PGUL"=<;X13.QD-==^:#?,!PPWO_/P```/__`P!02P,$%``&``@````A M`"X10YE0`@``!@4``!D```!X;"]W;W)K&ULE%3; MCILP$'VOU'^P_+[<0K(-`E9)H[0KM5)5]?+LF`&L8(QLY[)_WS%N4+;95ML7 MA.',F3-G#N0/9]F1(V@C5%_0.(@H@9ZK2O1-0;]_V]Z]H\18UE>L4ST4]`D, M?2C?OLE/2N]-"V`),O2FH*VU0Q:&AK<@F0G4`#V^J966S.)1-Z$9-+!J+))= MF$31(I1,]-0S9/HU'*JN!8>-X@<)O?4D&CIF4;]IQ6`N;)*_ADXRO3\,=US) M`2EVHA/V:22E1/+LL>F59KL.YS['*>,7[O%P0R\%U\JHV@9(%WJAMS,OPV6( M3&5>"9S`V4XTU`5=Q=DZI6&9C_[\$'`R5_?$M.KT08OJD^@!S<8UN07LE-H[ MZ&/E'F%Q>%.]'1?P19,*:G;H[%=U^@BB:2UN>XX#N;FRZFD#AJ.A2!,D<\?$ M58<"\$JD<,E`0]BYH`DV%I5M"SI;!//[:!8CG.S`V*UPE)3P@[%*_O2@>!3E MN49I&V99F6MU(KAN1)N!N?#$&1([33.6DK/V#ZS;)RVUF M_]/&@=&9*_'I;#'Q^LX>,P;HV3SI\T;.XB1&C_\]F*L:=SW9E:;S/SIZC..: M0/%\.8&\"I]'OW0)NH'WT'6&<'5P68MQ6]/3Z3-8)6-HIA<8PX$U\)GI1O2& M=%!C:13<8^ZT#[(_6#6,D=HIBP$<;UO\WP`N)@H07"ME+P?WJ4Q_L/(7```` M__\#`%!+`P04``8`"````"$`+'!(ZM\#``!I#0``&0```'AL+W=O79 M)`:B3N+(-DWWWT]5G!C;85LP+X0+T*R6@%[4QU7XS]_/G[^$@52TSFG):[8*WYD,OZY_^[2\?,UXU0+$ORD*]MZ1A4&7)]V/- M!=V7,.\W$M.LYVY?!O15D0DN^4&-@"[20H=S?HJ>(F!:+_,"9H"V!X(=5N&& M)"F)PVB];`WZMV`7:7T/Y(E??A=%_J.H&;@-=<(*[#E_P=#O.4*0'`VRG]L* M_"F"G!WHN51_\!9C29(5/&2Q``GT%5X-(` M1^A;^[P4N3JMPNE\-%N,IP3"@SV3ZKE`RC#(SE+QZC\=1#HJ33+I2.!Y@^2# MQ&F7",\NDMBML,8XD;L M^@@L$M*F%A"!7B,:;/9%8\D?%(TL*+H?;ML#UUE,/(5]1)^26H"C$.II*[R] M&'OW,!ALM]V;^N[IF(E>=FC.;H"D-N*H@<+::K#(\>-^(V M79`]&3(?NT$[$V1\M!%'.LBTI7]L)`:W"GO>;8=8M@V0U$:>/C(W![M@: M(;"(C5]D[J]Y$]1+3CO$MIG,KPO14;AX1"$&NPHUXBF<>L4R049AA[@*8Y/F M*,1KUCI?/JX?!KL*->(IG)FAVF-B9X*,P@ZY2^'3(PHQV%6H$4^AMWMW)L@H M[!!7X74S.1X2.)#O-[&-=C5VD"?RBV?C-U86&PO=V]R:W-H965T[QHN7-%W5O2!LCL\]YUQ?EI&#'J&FCV#IY>KMF^5.FSO;`SB"#*.M M:>_<5#%F10^*VT1/,.*75AO%'2Y-Q^QD@#?S(36P/$U+IK@<:6"HS&LX=-M* M`==:;!6,+I`8&+A#_;:7D]VS*?$:.L7-W78Z$UI-2+&1@W2/,RDE2E2WW:@- MWPSH^R$KN-ASSXL3>B6%T5:W+D$Z%H2>>KY@%PR95LM&H@,?.S'0UG2=55H?=/D=#WE?5/%Z#%1@HTB3YN6<2>D`!^"1*^IN!@?"'FN98 M6#:NK^FB3,[?I8L,X60#UMU(3TF)V%JGU:\`RF91@6N6=LT=7RV-WA%L-Z+M MQ/WER2HD]IH6Z"PP1)7_$HGJ/,G:L]04[RD>MQCL_:HHTR6[QS3$'\Q5P.`S M8K*(8*@F2D(9AY*>CV=?V8-]91^7EW(5-@[+Y,^76?Q/&0_&9`[$%XLR\H;* M`5/,<1_Z*8X+A;9CQB\;\Z>PUV@GYE64?Q,+)0,H0[((RM-%U'44*]Z1U\?J MP7/UF&O8.757'M-Z=^\0^[(Y?^B8/NR@GP,CQ1,C8;+"]55@.O@`PV")T%L_ M-3G>N[@;!WJ=^WX\W2^J]3SH+'[`09MX!U^XZ>1HR0`M4J:)MV+"J(:%T],\ M-!OM<,3FUQ[_J(!7+TT0W&KM]@LLS.(_>O4;``#__P,`4$L#!!0`!@`(```` M(0"M[ELD3`(```4%```9````>&PO=V]R:W-H965TW<_K['N$'9S;;: MOB!LQG/FS!F-M7T:AH8W()D)5`\=?JF4ELSB4M>AZ36P"JZ5494-D"[T0F][7H2+ M$)F*K!38@;.=:*ARNHS354+#(AO\^2G@:*[>B6G4\:,6Y6?1`9J-8W(#V"JU M<]"GTFWAX?#F]&88P%=-2JC8OK7?U/$3B+JQ..T9-N3Z2LOS&@Q'0Y$FF,P< M$U84ZQLT]E`D MR4,6'M`-_@>S\AA\CIAX1(2H9I2$,JXEO6[/I;(#N\K.+B=EY3>NRTQ>+S/] MGS(.C'Y?B4^F\Y'75_:8(4#/^DF>%W(63S$\_^[+'1I&/;J5)(L7!3TF1JX1 M%-^_[-;'T<]<@J[A`[2M(5SM7=1B'-:X._X%R\F0F?$#IK!G-7QANA:=(2U4 M>#0*[C%VVN?8+ZSJAT1ME<7\#:\-7C>`GEVS`)6 M,$:V<_O[KG%#DZ:M3E\0AMG9V=F!Q=-)MN0`V@C5Y30.(DJ@XZH479W3KU\V M#V\H,99U)6M5!SD]@Z%/Q>M7BZ/2.],`6((,G-1U:'H-K!R*9!M.HF@62B8ZZADR_1(.556"PUKQO83.>A(-+;.HWS2B M-Q[?L'KF2/%%O1"GL>2"F1/'NN.Z79ML6Y3W'*^(5[.-S12\&U M,JJR`=*%7NC]S(_A8XA,Q:(4.(&SG6BH@SZ5[A,7A7?5F6,`G34JHV+ZUG]7Q/8BZL;CM*0[D MYLK*\QH,1T.1)IA,'1-7+0K`*Y'")0,-8:><3K"Q*&V3TV063.=1$B.<;,'8 MC7"4E/"]L4I^]Z!X$.6Y!FEK9EFQT.I(<-V(-CUSX8DS)'::$IS,,XPJ_R82 MU3F2I6/)*>84RPT:>RC2Z601'M`-_A.S\AB\CIAX1(2H9I2$,JXE_=F>2V<' M=IV=74[*RC^X;O-+R$V;Y'_:.#`Z&PO=V]R:W-H965TX0=EF6VU?$(8S9\XY,Y`]GF1+#J"- M4%U.XR"B!#JN2M'5.?W^;7-W3XFQK"M9JSK(Z1D,?2S>O\N.2N],`V`),G0F MIXVU?1J&AC<@F0E4#QV^J926S.)1UZ'I-;!R*))MF$31/)1,=-0SI/HM'*JJ M!(>UXGL)G?4D&EIF4;]I1&\N;)*_A4XRO=OW=US)'BFVHA7V/)!2(GGZ5'=* MLVV+OD_QE/$+]W"XH9>":V5490.D"[W06\\/X4.(3$56"G3@8B<:JIPNXW0U MI6&1#?G\$'`T5_?$-.KX48ORL^@`P\8QN0%LE=HYZ%/I'F%Q>%.]&0;P19,2 M*K9O[5=U_`2B;BQ.>X:&G*^T/*_!<`P4:8)DYIBX:E$`7HD4;C,P$';*:8*- M16F;G$[FP6P136*$DRT8NQ&.DA*^-U;)GQX4#Z(\UR!MS2PK,JV.!,>-:-,S MMSQQBL1.TP2=>891Y=]$HCI'LG0L.<4]Q7*#P1Z*Z6R>A0=,@__&K#P&KR,F M'A$AJADEH8QK2:_'<^GLP*ZSB\M)6?D'UVV2U]M,_J>-`V,R5^*GDS\->LRP M0"_\3%\V`@XD"!%=*V&-: MF=-'Z>C%^N.'U=[8.U=+Z0DPM"ZGM?==QI@3M=3<1::3+7PIC=7,YTURU-#!D]CTZG>UZMR!38OWT&EN M[W;=F3"Z`XJM:I1_[$DIT2*[J5IC^;8!W0])RL6!NU^8E6S)@6J\*!0K0=F)EF=--DEV>4[9>]?[\4G+OCMZ)J\W^LU7%5]5*,!O: MA`W8&G.'T)L"0["9G>R^[AOPS9)"EGS7^.]F_T6JJO;0[1D(0EU9\7@EG0!# M@2::S)!)F`8*@"?1"D\&&,(? MZ-\!E/1%!:Z^M"ON^7IES9Y`NP'M.HZ')\F`&&N:@K+`,%3Y6I%0'9)LD"6G M<$YANP-C[]?I+%VQ>W!#_,5.(,#N<`!.X0T-T&$Z;"9ZMY_$TV_3'GPT?8&ATO)*WW%:J=:21 M)5#&$1XZ&\9.6'C3]0-@:SR,B_ZUAK^#A&L48P=+8_QA`8G9\+]9_P$``/__ M`P!02P,$%``&``@````A`'FI%J-I`@``=@4``!D```!X;"]W;W)K&ULE%1=;]L@%'V?M/^`>*^Q':==K3A5NJI;I4V:IGT\$WQM MHQIC`6G:?[\++"Q:NJE]L0P^G'ONN0>OKA[52![`6*FGAA993@E,0K=RZAOZ M_=OMV3M*K.-3RT<]04.?P-*K]=LWJ[TV]W8`<`09)MO0P;FY9LR*`12WF9YA MPB^=-HH[7)J>V=D`;\,A-;(RS\^9XG*BD:$V+^'072<%W&BQ4S"Y2&)@Y`[U MVT'.]L"FQ$OH%#?WN_E,:#4CQ5:.TCT%4DJ4J._Z21N^';'OQZ+BXL`=%B?T M2@JCK>YNW\#`[.7T;!O#%D!8ZOAO=5[W_"+(?'$Y[ MB0WYONKVZ0:L0$.1)BN##*%'%(!/HJ1/!AK"'QM:8F'9NJ&AB_-L>9$O"H23 M+5AW*STE)6)GG58_(Z@(HB)7D';#'5^OC-X3'#>B[(H:B;VF!786&9+* M?XE$=9YDXUD:BCG%XQ:-?5A7RWS%'M`-\1MS'3'X3)@B(1BJ29)0QK&DY^TY M5/9@7QF-#U*NX\9QF?+Y,HO7E/%@=.9(?+4X3[RQ[C?JK7%/)@'#%V MD6RJEG^,BI4BZ+02QN#8.3_,LL!I_M]"?RJ43![&'7\RB2@N%JG=.*V8\Q@F M!::']S".E@B]\QDN,05I-UVO3>G=^7N_JC(;C3VAT6_FJF/^;Z%P```/__`P!0 M2P,$%``&``@````A``S9G@(Q`0``0`(``!$`"`%D;V-05=$RV M'AY\Z\!'#2%+)!N8=#7:QN@8QD%NP8A0I(9-X;KU1L1T]!OLA'P7&\`S0JZP M@2B4B`+WP-Q-1#0BE9R0[L,W`T!)#`T8L#%@6E#\W8W@3?CSPI"<-(V.>Y=F M&G5/V4H>PJF]"WHJ=EU7=.6@D?PI?EG>/PZCYMKVNY*`>+^?1H2X3*M<:U`W M>[Y[\TT6PK;"O[-*R<&.20\B@LK2>^Q@=TR>R]N[U0+Q&:&7.2GSDJXH8>2" ME>2UPL?6>)]/0#,*_)MX!/#!^^>?\R\```#__P,`4$L#!!0`!@`(````(0"G MG[SWE0```*D````0````>&PO8V%L8T-H86EN+GAM;#R.00H",1`$[X)_&.;N M9O4@*DD6%'R!/B!D1Q-()DLFB/[>>/'24#14MY[>.<&+JL3"!K?#B$#LRQSY M:?!^NVX."-(J6]2_X27&3H!A:#H;7EI)3X0-G)4!;BWCQ* MS:YUK$\E2R4W2R!J.:G=..Y5[@*TVD,U>#XBQ/X!(?U26:W^(_8+``#__P,` M4$L#!!0`!@`(````(0!?"\KJ"P0```,2```0``@!9&]C4')O<',O87!P+GAM M;""B!`$HH``!```````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M`````````````````````````````````````````````````````)Q836_; M.!"]+[#_P="]D>5\U`UD%5DG00NDVV#MMD>"I<86-S*ID)0WZ:_?H60[ED(R MKF^R.(^.!MI0D=-2 M"IA$SZ"CC]F??Z3W2E:@#`<]P"V$GD2%,=5E'&M6P(KJ$UP6N+*0:D4-_E3+ M6"X6G,&U9/4*A(E'P^%%#$\&1`[YNVJW8=3N>+DVQVZ:2V;]T]_GSQ4ZG*57 M555R1@U&F7WA3$DM%V9P\\2@3./]Q12]FP&K%3?/V3"-]W^F,T9+F.+&V8*6 M&M+XY47Z":A-VCWE2F?IVERN@1FI!IK_PK2-HL%/JL&Z,XG65'$J#+IES=H? MS7-9::.R'U(]Z`+`Z#1&@_9E\[AON__,S[+QJ+'`IZZEW:'U!!>Z/LZY*4%_ M7=Q391PNCSL^-UZT'K<.;5DDJ`UR(PSFBWP6+=M<[GN^B^$O6E+!@,Q>!>@:"J4`@]PA43LSF[C6C9FA!JR:-)$+,I6K2D$!0O,UD#NW&UW(S$CV4,@R MQQH@-X_U(:=079#;4O[7(6CGTM_2`$G(5[6D@O]J--0$;GC MCS7/,9-^HU-R#8;RLHD6ZX]R09J\^B%G9%.KSRU7>$9E,^9'G)//JPJ%'+:Z M0'JP=KLR[6;A/>FG-QC<&(-;@%*0DW]@#:+&$MMM^,)YDZT/Y`O]5RHRK;61 M*TN>%>*M5'Y(,L1M2_0YM\)"O!OQ5&+MB0#D'(-F2!.Y8DS6 MUGAI!1&"7*!C/S4\UA9V@T2$./8J/0DXY:N.MHMM6MZ.^G!%G1YQSMD1F/,C M,!='8-X?@1D?@?G@Q*!8),X#*.*F3;M)[!FY6>L9N6GJ&;EYZ1FYB>@9N3/? M,W*GNF?DSFW/Z+!DXD"Q$W6OGWD;NYN!IB2\&#.F^`PQDUW@]F? MV=[.V&YV>]O47R,3;E0*EXL4$2L6+"92*%Q/H$UZ,^U^[S8%O\`X1ZIN\ M.YC.;;MWO[[CXD%_J^;R&F\@VP\(W9?IK,`+;XY7Z^WZRXOT$WX[4*7=9%I0 ML81\:_-ZP7[N^-Y^T\F2LY/AZ1`'C[UW:;RY$>+7F^Q_````__\#`%!+`0(M M`!0`!@`(````(0!P[%.N@0(``&$P```3``````````````````````!;0V]N M=&5N=%]4>7!E&UL4$L!`BT`%``&``@````A`+55,"/U````3`(```L` M````````````````N@0``%]R96QS+RYR96QS4$L!`BT`%``&``@````A`"RK M^XL)`P``&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`+CZBT__`@``<`@``!D````` M````````````=!\``'AL+W=O&PO=V]R M:W-H965T&UL M4$L!`BT`%``&``@````A`'38&)F?`@``>@8``!D`````````````````$2H` M`'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@` M```A`)8#`\JD`@``>@8``!D`````````````````LC(``'AL+W=O&UL4$L!`BT`%``&``@````A`#LVMKIK!0`` M"Q4``!D`````````````````8SP``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`',0]^@0!@``:Q<``!D````````` M````````Y4D``'AL+W=O&PO=V]R:W-H M965T&UL4$L! M`BT`%``&``@````A`/G;D$T:`P``^PD``!D`````````````````:54``'AL M+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A M`',MLE]N`@``#08``!D`````````````````D5X``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`%>>H4BX`@``^`8` M`!D`````````````````&FD``'AL+W=O&PO=V]R:W-H965T&UL M4$L!`BT`%``&``@````A`'F4%-0E"P``3F,```T`````````````````/W4` M`'AL+W-T>6QE&PO&PO=V]R:W-H M965T&UL4$L!`BT`%``&``@````A`!G$L9OQ!0``MA<``!@` M````````````````3=P``'AL+W=O&UL4$L!`BT`%``&``@````A`.&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`-HNOE8Y`P``@`D``!D````````` M````````Y>X``'AL+W=O&PO=V]R:W-H M965T&UL4$L! M`BT`%``&``@````A`%=A2Y6Z`P``_PL``!D`````````````````[O@``'AL M+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A M`.#@>[QV!````A```!@`````````````````Q0,!`'AL+W=O&UL4$L!`BT`%``& M``@````A`#$EA*0D!0``)1,``!D`````````````````00T!`'AL+W=O&UL4$L!`BT`%``&``@````A`-W'NT&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A``SZ%-9>`P``4@L``!D````` M````````````/S$!`'AL+W=O&PO=V]R M:W-H965T&UL M4$L!`BT`%``&``@````A`*8PQ#?8`@``40@``!D`````````````````)#X! M`'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@` M```A`!K%V+0*!@``7A@``!@`````````````````"%$!`'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A M`+S35=Y[`@``#`8``!D`````````````````HG\!`'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`/\"WH)3`@``!@4` M`!D`````````````````9X&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`&\J3E]0`@``!04``!D````````````` M````'(\!`'AL+W=O&PO=V]R:W-H965T M&UL4$L!`BT` M%``&``@````A`$I/SSE(!```J0X``!D`````````````````ZYD!`'AL+W=O M&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`%,' MJI]0`@``!@4``!D`````````````````*:&PO=V]R:W-H965T```9`````````````````#:L`0!X;"]W;W)K&UL4$L!`BT`%``&``@````A`"X10YE0`@``!@4``!D` M````````````````7+,!`'AL+W=O&PO M=V]R:W-H965T&UL4$L!`BT`%``&``@````A`*WN6R1,`@``!04``!D````````````````` MKKP!`'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``& M``@````A`/KE(\>F`@``M`8``!D`````````````````/L0!`'AL+W=O v2.4.1.9
Note 8: Deferred Revenue (Details) (USD $)
Dec. 31, 2014
Aug. 31, 2014
Aug. 31, 2013
Details      
Deferred Revenue $ 54,218us-gaap_DeferredRevenue $ 96,043us-gaap_DeferredRevenue $ 783,708us-gaap_DeferredRevenue
XML 24 R55.htm IDEA: XBRL DOCUMENT v2.4.1.9
Note 1: Organization and Significant Accounting Policies: Warranty Reserve (Details) (USD $)
 4 Months Ended 12 Months Ended
Dec. 31, 2014
Aug. 31, 2014
Aug. 31, 2013
Details      
Warranty Reserve $ 65,102us-gaap_ProductWarrantyAccrual $ 75,728us-gaap_ProductWarrantyAccrual $ 50,968us-gaap_ProductWarrantyAccrual
Warranty Expense $ 13,410us-gaap_ProductWarrantyExpense $ 41,471us-gaap_ProductWarrantyExpense $ 80,276us-gaap_ProductWarrantyExpense
XML 25 R78.htm IDEA: XBRL DOCUMENT v2.4.1.9
Note 12: Stock-based Compensation (Details) (USD $)
 4 Months Ended 12 Months Ended
Dec. 31, 2014
Aug. 31, 2014
Details    
Granted 1,450,000us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross 127,000us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
Exercise price, lower limit $ 0.44us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit  
Exercise price, upper limit $ 0.51us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit  
Grant date fair value per share $ 0.22us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue  
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition 1 year 1 month 24 days  
Unrecognized stock-based compensation expense $ 1,078,000us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized  
Closing stock price $ 0.36fil_ClosingStockPrice  
XML 26 R46.htm IDEA: XBRL DOCUMENT v2.4.1.9
Note 7: Stockholders' Equity: Schedule of Stockholders' Equity Note, Warrants or Rights (Tables)
 12 Months Ended
Dec. 31, 2014
Tables/Schedules  
Schedule of Stockholders' Equity Note, Warrants or Rights

 

 

Shares

 

Weighted- Average Exercise Price

Weighted-Average Remaining Contract Term (Years)

 

 

 

 

 

 

 

 

 

 

Outstanding as of August 31, 2013

5,457,305

$

2.93

-

Granted

4,400,000

 

1.10

-

Exercised

-

 

-

-

Forfeited or expired

-

 

-

-

 

 

 

 

 

Outstanding as of August 31, 2014

9,857,305

$

2.11

4.02

Granted

-

 

-

-

Exercised

-

 

-

-

Forfeited or expired

-

 

-

-

 

 

 

 

 

Outstanding as of December 31, 2014

9,857,305

$

2.11

3.69

 

 

 

 

 

Exercisable as of December 31, 2014

5,457,305

$

2.93

2.62
XML 27 R33.htm IDEA: XBRL DOCUMENT v2.4.1.9
Note 1: Organization and Significant Accounting Policies: Stock-based Compensation (Policies)
 12 Months Ended
Dec. 31, 2014
Policies  
Stock-based Compensation

Stock-Based Compensation - Stock-based compensation is measured at the grant date based on the value of the award granted using the Black-Scholes option pricing model, and recognized over the period in which the award vests.  For stock awards no longer expected to vest, any previously recognized stock compensation expense is reversed in the period of termination.  The stock-based compensation expense is allocated to the various categories of operating costs and expenses in a manner similar to the allocation of payroll expense. 
XML 28 R79.htm IDEA: XBRL DOCUMENT v2.4.1.9
Note 12: Stock-based Compensation: Schedule of Assumptions Used (Details)
 12 Months Ended
Dec. 31, 2014
Details  
Expected volatility 62.96%us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
Expected term, years 7 years 2 months 26 days
Risk-free interest rate 2.07%us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
XML 29 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 30 R73.htm IDEA: XBRL DOCUMENT v2.4.1.9
Note 11: Income Taxes (Details) (USD $)
 4 Months Ended 12 Months Ended
Dec. 31, 2014
Dec. 31, 2013
Aug. 31, 2014
Aug. 31, 2013
Details        
Income tax provision       $ 2,000us-gaap_IncomeTaxExpenseBenefit $ 1,938us-gaap_IncomeTaxExpenseBenefit
Valuation Allowance 389,000us-gaap_DeferredTaxAssetsValuationAllowance   185,000us-gaap_DeferredTaxAssetsValuationAllowance 360,000us-gaap_DeferredTaxAssetsValuationAllowance
Liability Valuation Allowance 17,599,000fil_LiabilityValuationAllowance   16,443,000fil_LiabilityValuationAllowance 13,788,000fil_LiabilityValuationAllowance
Operating Loss Carryforward $ 40,701,000us-gaap_OperatingLossCarryforwards      
XML 31 R57.htm IDEA: XBRL DOCUMENT v2.4.1.9
Note 1: Organization and Significant Accounting Policies: Revenue Recognition: Schedule of Revenue Recognition (Details) (USD $)
 4 Months Ended 12 Months Ended
Dec. 31, 2014
Dec. 31, 2013
Aug. 31, 2014
Aug. 31, 2013
Details        
Product Sales $ 470,875us-gaap_SalesRevenueGoodsGross $ 986,900us-gaap_SalesRevenueGoodsGross $ 3,019,525us-gaap_SalesRevenueGoodsGross $ 1,934,826us-gaap_SalesRevenueGoodsGross
Disposable devices 409,787fil_DisposableDevices 501,565fil_DisposableDevices 1,568,481fil_DisposableDevices 1,109,750fil_DisposableDevices
Service contracts and other 109,346fil_ServiceContractsAndOther 100,597fil_ServiceContractsAndOther 375,747fil_ServiceContractsAndOther 330,116fil_ServiceContractsAndOther
Equipment rental 125,900us-gaap_OperatingLeasesIncomeStatementLeaseRevenue 95,200us-gaap_OperatingLeasesIncomeStatementLeaseRevenue 364,600us-gaap_OperatingLeasesIncomeStatementLeaseRevenue 298,600us-gaap_OperatingLeasesIncomeStatementLeaseRevenue
Total revenues $ 1,115,908us-gaap_Revenues $ 1,684,262us-gaap_Revenues $ 5,328,353us-gaap_Revenues $ 3,673,292us-gaap_Revenues
XML 32 R76.htm IDEA: XBRL DOCUMENT v2.4.1.9
Note 12: Stock-based Compensation: Stock Incentive Plan (Details) (USD $)
 12 Months Ended
Dec. 31, 2014
Details  
Shares available for grant 6,337,300us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
Annual retainer, non-employee directors $ 60,000fil_AnnualRetainerNonEmployeeDirectors
Annual retainer, audit committee chair 65,000fil_AnnualRetainerAuditCommitteeChair
Annual retainer, cash portion 30,000fil_AnnualRetainerCashPortion
Annual retainer, audit committee chair cash portion 35,000fil_AnnualRetainerAuditCommitteeChairCashPortion
Annual Retainer, Paid in Common Stock $ 30,000fil_AnnualRetainerPaidInCommonStock
Annual Retainer, Options Granted 30,000fil_AnnualRetainerOptionsGranted
Shares available for grant, Director Plan 1,750,000fil_SharesAvailableForGrantDirectorPlan
XML 33 R81.htm IDEA: XBRL DOCUMENT v2.4.1.9
Note 13: Supplemental Cash Flow Information (Details) (USD $)
 4 Months Ended 12 Months Ended
Dec. 31, 2014
Dec. 31, 2013
Aug. 31, 2014
Aug. 31, 2013
Details        
Income tax provision       $ 2,000us-gaap_IncomeTaxExpenseBenefit $ 1,938us-gaap_IncomeTaxExpenseBenefit
XML 34 R77.htm IDEA: XBRL DOCUMENT v2.4.1.9
Note 12: Stock-based Compensation: Schedule of Stock Based Compensation (Details) (USD $)
 4 Months Ended 12 Months Ended
Dec. 31, 2014
Dec. 31, 2013
Aug. 31, 2014
Aug. 31, 2013
Stock-based compensation $ 192,844us-gaap_ShareBasedCompensation $ 284,167us-gaap_ShareBasedCompensation $ 844,628us-gaap_ShareBasedCompensation $ 1,134,811us-gaap_ShareBasedCompensation
Cost of Sales        
Stock-based compensation 11,776us-gaap_ShareBasedCompensation
/ us-gaap_IncomeStatementLocationAxis
= us-gaap_CostOfSalesMember		   61,427us-gaap_ShareBasedCompensation
/ us-gaap_IncomeStatementLocationAxis
= us-gaap_CostOfSalesMember		 67,119us-gaap_ShareBasedCompensation
/ us-gaap_IncomeStatementLocationAxis
= us-gaap_CostOfSalesMember
Research and Development Expense        
Stock-based compensation 32,349us-gaap_ShareBasedCompensation
/ us-gaap_IncomeStatementLocationAxis
= us-gaap_ResearchAndDevelopmentExpenseMember		   183,371us-gaap_ShareBasedCompensation
/ us-gaap_IncomeStatementLocationAxis
= us-gaap_ResearchAndDevelopmentExpenseMember		 212,569us-gaap_ShareBasedCompensation
/ us-gaap_IncomeStatementLocationAxis
= us-gaap_ResearchAndDevelopmentExpenseMember
Selling, General and Administrative Expenses        
Stock-based compensation $ 148,719us-gaap_ShareBasedCompensation
/ us-gaap_IncomeStatementLocationAxis
= us-gaap_SellingGeneralAndAdministrativeExpensesMember		   $ 599,830us-gaap_ShareBasedCompensation
/ us-gaap_IncomeStatementLocationAxis
= us-gaap_SellingGeneralAndAdministrativeExpensesMember		 $ 855,123us-gaap_ShareBasedCompensation
/ us-gaap_IncomeStatementLocationAxis
= us-gaap_SellingGeneralAndAdministrativeExpensesMember
XML 35 R71.htm IDEA: XBRL DOCUMENT v2.4.1.9
Note 9: Major Customers and Foreign Sales (Details) (USD $)
 4 Months Ended 12 Months Ended
Dec. 31, 2014
Aug. 31, 2014
Aug. 31, 2013
Details      
Customer One 41.53%fil_CustomerOne 23.46%fil_CustomerOne 30.36%fil_CustomerOne
Customer Two 11.30%fil_CustomerTwo 22.92%fil_CustomerTwo  
Export Sales $ 630,857fil_ExportSales $ 3,381,563fil_ExportSales $ 1,470,619fil_ExportSales
Export Sales to Certain Countries as a Percentage of Total Sales 53.00%fil_ExportSalesToGermanyAsAPercentageOfTotalSales 46.00%fil_ExportSalesToGermanyAsAPercentageOfTotalSales 30.00%fil_ExportSalesToGermanyAsAPercentageOfTotalSales
Percentage of Accounts Receivable Due From One Customer 36.00%fil_PercentageOfAccountsReceivableDueFromOneCustomer 68.00%fil_PercentageOfAccountsReceivableDueFromOneCustomer 72.00%fil_PercentageOfAccountsReceivableDueFromOneCustomer
XML 36 R25.htm IDEA: XBRL DOCUMENT v2.4.1.9
Note 1: Organization and Significant Accounting Policies: Cash and Cash Equivalents (Policies)
 12 Months Ended
Dec. 31, 2014
Policies  
Cash and Cash Equivalents

Cash and Cash Equivalents – Cash and cash equivalents consist of cash and investments with original maturities to the Company of three months or less.  As of December 31, 2014 and August 31, 2014, we had $25,000 in a restricted bank account.

 
XML 37 R50.htm IDEA: XBRL DOCUMENT v2.4.1.9
Note 12: Stock-based Compensation: Schedule of Assumptions Used (Tables)
 12 Months Ended
Dec. 31, 2014
Tables/Schedules  
Schedule of Assumptions Used

 

 

Expected volatility

62.96%

Expected dividends

0.00%

Expected term

7.24 Years

Risk-free interest rate

2.07%
XML 38 R42.htm IDEA: XBRL DOCUMENT v2.4.1.9
Note 3: Detail of Certain Balance Sheet Accounts: Detail of Accounts Receivable (Tables)
 12 Months Ended
Dec. 31, 2014
Tables/Schedules  
Detail of Accounts Receivable

 

 

December 31,

August 31,

 

2014

2014

2013

 

 

 

 

Accounts receivable:

 

 

 

 

 

 

 

   Trade receivables – non-related party

$       293,182

$       364,170

$       890,985

   Other receivables

1,890

22,717

28,984

   Allowance for doubtful accounts

(20,000)

(20,000)

(20,000)

 

 

 

 

 

$         275,072

$       366,887

$       899,969
XML 39 R75.htm IDEA: XBRL DOCUMENT v2.4.1.9
Note 11: Income Taxes: Schedule of Deferred Tax Assets (Liabilities) (Details) (USD $)
Dec. 31, 2014
Aug. 31, 2014
Aug. 31, 2013
Details      
Accruals and reserves $ 73,000us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals $ 62,000us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals $ 26,000us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
Current Deferred Revenue 18,000us-gaap_DeferredTaxAssetsDeferredIncome 33,000us-gaap_DeferredTaxAssetsDeferredIncome 266,000us-gaap_DeferredTaxAssetsDeferredIncome
Current Inventories 298,000us-gaap_DeferredTaxAssetsInventory 90,000us-gaap_DeferredTaxAssetsInventory 68,000us-gaap_DeferredTaxAssetsInventory
Valuation Allowance (389,000)us-gaap_DeferredTaxAssetsValuationAllowance (185,000)us-gaap_DeferredTaxAssetsValuationAllowance (360,000)us-gaap_DeferredTaxAssetsValuationAllowance
Deferred Compensation 601,000us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits 601,000us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits 601,000us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
Research and development and other tax credits 1,929,000us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment 1,896,000us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment 1,804,000us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment
Net Operating Loss Carryforwards 12,951,000us-gaap_DeferredTaxAssetsOperatingLossCarryforwards 13,938,000us-gaap_DeferredTaxAssetsOperatingLossCarryforwards 11,380,000us-gaap_DeferredTaxAssetsOperatingLossCarryforwards
Deferred Tax Assets, Operating Loss Carryforwards, State and Local 2,079,000us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal    
Long Term Depreciation and Amortization 39,000us-gaap_DeferredTaxLiabilitiesNoncurrent 8,000us-gaap_DeferredTaxLiabilitiesNoncurrent 3,000us-gaap_DeferredTaxLiabilitiesNoncurrent
Liability Valuation Allowance $ (17,599,000)fil_LiabilityValuationAllowance $ (16,443,000)fil_LiabilityValuationAllowance $ (13,788,000)fil_LiabilityValuationAllowance
XML 40 R37.htm IDEA: XBRL DOCUMENT v2.4.1.9
Note 1: Organization and Significant Accounting Policies: Shipping and Handling (Policies)
 12 Months Ended
Dec. 31, 2014
Policies  
Shipping and Handling

Shipping and Handling – We bill our customers for shipping and handling charges, which are included in net sales.  The cost of corresponding shipping and handling expense is reported in cost of sales.
XML 41 R52.htm IDEA: XBRL DOCUMENT v2.4.1.9
Note 1: Organization and Significant Accounting Policies: Organization and Business (Details)
 12 Months Ended
Dec. 31, 2014
Details  
Entity Incorporation, State Country Name Delaware
Entity Incorporation, Date of Incorporation Jul. 03, 1986
XML 42 R67.htm IDEA: XBRL DOCUMENT v2.4.1.9
Note 7: Stockholders' Equity (Details) (USD $)
Dec. 31, 2014
Aug. 31, 2014
Aug. 31, 2013
Details      
Preferred stock shares authorized 10,000,000us-gaap_PreferredStockSharesAuthorized 10,000,000us-gaap_PreferredStockSharesAuthorized 10,000,000us-gaap_PreferredStockSharesAuthorized
Preferred stock par value $ 0.001us-gaap_PreferredStockParOrStatedValuePerShare $ 0.001us-gaap_PreferredStockParOrStatedValuePerShare $ 0.001us-gaap_PreferredStockParOrStatedValuePerShare
Common stock shares authorized 80,000,000us-gaap_CommonStockSharesAuthorized 80,000,000us-gaap_CommonStockSharesAuthorized 80,000,000us-gaap_CommonStockSharesAuthorized
Common stock par value $ 0.001us-gaap_CommonStockParOrStatedValuePerShare $ 0.001us-gaap_CommonStockParOrStatedValuePerShare $ 0.001us-gaap_CommonStockParOrStatedValuePerShare
XML 43 R61.htm IDEA: XBRL DOCUMENT v2.4.1.9
Note 3: Detail of Certain Balance Sheet Accounts: Detail of Inventories (Details) (USD $)
Dec. 31, 2014
Aug. 31, 2014
Aug. 31, 2013
Details      
Parts and supplies $ 1,004,164us-gaap_InventoryRawMaterials $ 1,369,960us-gaap_InventoryRawMaterials $ 1,353,614us-gaap_InventoryRawMaterials
Work-in-process 951,519us-gaap_InventoryWorkInProcess 880,751us-gaap_InventoryWorkInProcess 990,668us-gaap_InventoryWorkInProcess
Finished goods 569,965us-gaap_InventoryFinishedGoods 228,478us-gaap_InventoryFinishedGoods 201,488us-gaap_InventoryFinishedGoods
Reserve for obsolete inventories (750,000)us-gaap_InventoryValuationReserves (150,000)us-gaap_InventoryValuationReserves (100,000)us-gaap_InventoryValuationReserves
Inventories, net $ 1,775,648us-gaap_InventoryNet $ 2,329,189us-gaap_InventoryNet $ 2,445,770us-gaap_InventoryNet
XML 44 R47.htm IDEA: XBRL DOCUMENT v2.4.1.9
Note 11: Income Taxes: Schedule of Income Tax (Provision) Benefit Computed at Federal Rates (Tables)
 12 Months Ended
Dec. 31, 2014
Tables/Schedules  
Schedule of Income Tax (Provision) Benefit Computed at Federal Rates

 

 

Four Months Ended December 31,

Years Ended August 31,

 

2014

2014

2013

 

 

 

 

Income tax benefit at federal statutory rate

$         1,281,000

$     2,428,000

$     2,805,000

Stock-based compensation

(66,000)

(287,000)

(335,000)

State income taxes, net of federal benefit

124,000

236,000

272,000

Research and development credit

33,000

99,000

106,000

Valuation allowance

(1,360,000)

(2,480,000)

(2,905,000)

Other

(12,000)

2,000

55,062

 

 

 

 

 

 $                     -

$           (2,000)

$           (1,938)
XML 45 R9.htm IDEA: XBRL DOCUMENT v2.4.1.9
Note 3: Detail of Certain Balance Sheet Accounts
 12 Months Ended
Dec. 31, 2014
Notes  
Note 3: Detail of Certain Balance Sheet Accounts

Note 3:  Detail of Certain Balance Sheet Accounts

 

Details of certain balance sheet accounts are as follows:

 

 

December 31,

August 31,

 

2014

2014

2013

 

 

 

 

Accounts receivable:

 

 

 

 

 

 

 

   Trade receivables – non-related party

$       293,182

$       364,170

$       890,985

   Other receivables

1,890

22,717

28,984

   Allowance for doubtful accounts

(20,000)

(20,000)

(20,000)

 

 

 

 

 

$         275,072

$       366,887

$       899,969

 

Inventories:

 

 

 

 

 

 

 

   Parts and supplies

$    1,004,164

$    1,369,960

$    1,353,614

   Work-in-process

951,519

880,751

990,668

   Finished goods

569,965

228,478

201,488

   Reserve for obsolete inventories

(  750,000)

(150,000)

(100,000)

 

 

 

 

 

$    1,775,648

$    2,329,189

$    2,445,770

 

Accrued liabilities:

 

 

 

 

 

 

   Warranty reserve

$         65,102

$        75,728

$        50,968

   Training and installation reserve

2,038

4,716

5,528

   Accrued taxes payable

50,462

59,745

44,677

   Payroll, commissions, legal and other

987,550

726,339

472,707

 

 

 

 

 

$    1,105,152

$      866,528

$      573,880

 

 
XML 46 R62.htm IDEA: XBRL DOCUMENT v2.4.1.9
Note 3: Detail of Certain Balance Sheet Accounts: Detail of Accrued Liabilities (Details) (USD $)
Dec. 31, 2014
Aug. 31, 2014
Aug. 31, 2013
Details      
Warranty Reserve $ 65,102us-gaap_ProductWarrantyAccrual $ 75,728us-gaap_ProductWarrantyAccrual $ 50,968us-gaap_ProductWarrantyAccrual
Training and Installation Reserve 2,038fil_TrainingAndInstallationReserve 4,716fil_TrainingAndInstallationReserve 5,528fil_TrainingAndInstallationReserve
Accrued taxes payable 50,462us-gaap_AccruedIncomeTaxes 59,745us-gaap_AccruedIncomeTaxes 44,677us-gaap_AccruedIncomeTaxes
Payroll, commissions and other 987,550us-gaap_AccruedSalariesCurrent 726,339us-gaap_AccruedSalariesCurrent 472,707us-gaap_AccruedSalariesCurrent
Accrued liabilities $ 1,105,152us-gaap_AccruedLiabilitiesCurrent $ 866,528us-gaap_AccruedLiabilitiesCurrent $ 573,880us-gaap_AccruedLiabilitiesCurrent
EXCEL 47 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%\T.#,U8F,R-%]C-C1D7S1E-#E?.&9B,5\T9#1A M-C5D964S8S@B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O3PO>#I.86UE/@T* M("`@(#QX.E=O#I% M>&-E;%=O#I.86UE/DYO=&5?,U]$971A:6Q?;V9? M0V5R=&%I;E]"86QA;CPO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DYO=&5?-%]05]A;F1?17%U:7!M96YT/"]X.DYA;64^ M#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O#I7;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I. M86UE/DYO=&5?-U]3=&]C:VAO;&1E#I%>&-E;%=O#I7;W)K#I7 M;W)K#I7;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DYO=&5?,3)?4W1O8VMB87-E9%]#;VUP96YS871I;SPO M>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DYO=&5?,31?0V]M;6ET;65N='-?86YD7T-O;G1I M;CPO>#I.86UE/@T*("`@(#QX.E=O#I.86UE/@T*("`@(#QX.E=O M#I%>&-E;%=O#I.86UE/DYO=&5?,39?4W5B#I7;W)KF%T:6]N7V%N9%]3:6=N:68Q/"]X.DYA;64^#0H@("`@/'@Z5V]R M:W-H965T4V]U#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DYO M=&5?,5]/#I7;W)KF%T:6]N7V%N M9%]3:6=N:68T/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E M;%=O#I.86UE/@T* M("`@(#QX.E=O#I% M>&-E;%=O#I.86UE/DYO=&5?,5]/#I7;W)KF%T:6]N7V%N9%]3:6=N:68W/"]X.DYA M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DYO=&5?,5]/#I7;W)KF%T:6]N7V%N9%]3:6=N:68Q,#PO>#I.86UE/@T*("`@(#QX.E=O M#I%>&-E;%=O#I.86UE/DYO=&5?,5]/#I%>&-E;%=O M#I7;W)KF%T:6]N M7V%N9%]3:6=N:68Q,SPO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DYO=&5?,5]/#I%>&-E;%=O#I7;W)KF%T:6]N7V%N9%]3:6=N:68Q M-CPO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I7;W)KF%T:6]N7V%N9%]3:6=N:68Q.3PO>#I.86UE/@T* M("`@(#QX.E=O#I% M>&-E;%=O#I.86UE/DYO=&5?,U]$971A:6Q?;V9? M0V5R=&%I;E]"86QA;C$\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DYO=&5?-%]05]A;F1?17%U:7!M96YT7SPO M>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DYO=&5?,3%?26YC;VUE7U1A>&5S7U-C:&5D=6QE M7SPO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O M#I.86UE/@T*("`@ M(#QX.E=O#I%>&-E M;%=O#I.86UE/DYO=&5?,3)?4W1O8VMB87-E9%]# M;VUP96YS871I;S,\+W@Z3F%M93X-"B`@("`\>#I7;W)KF%T:6]N7V%N9%]3:6=N:68R,#PO>#I.86UE M/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DYO=&5?,5]/#I%>&-E;%=O#I7;W)KF%T:6]N7V%N9%]3:6=N:68R,SPO>#I.86UE/@T*("`@(#QX.E=O M#I%>&-E;%=O#I.86UE/DYO=&5?,5]/#I%>&-E;%=O M#I7;W)KF%T:6]N M7V%N9%]3:6=N:68R-CPO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DYO=&5?,E],:7%U:61I='E?1&5T86EL#I.86UE/@T*("`@ M(#QX.E=O#I%>&-E M;%=O#I.86UE/DYO=&5?,U]$971A:6Q?;V9?0V5R M=&%I;E]"86QA;C0\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DYO=&5?-%]05]A;F1?17%U:7!M96YT7S$\+W@Z M3F%M93X-"B`@("`\>#I7;W)K#I%>&-E;%=O#I. M86UE/@T*("`@(#QX.E=O#I7;W)K5]$970\+W@Z3F%M93X- M"B`@("`\>#I7;W)K5]!<'(\+W@Z3F%M93X-"B`@("`\>#I7;W)K5]38V@Q/"]X.DYA M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O M#I%>&-E;%=O#I.86UE/DYO=&5?,3%?26YC;VUE7U1A>&5S7U-C:&5D M=6QE7S,\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I. M86UE/DYO=&5?,3)?4W1O8VMB87-E9%]#;VUP96YS871I;S8\+W@Z3F%M93X- M"B`@("`\>#I7;W)K#I%>&-E;%=O#I. M86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I!8W1I=F53 M:&5E=#XP/"]X.D%C=&EV95-H965T/@T*("`\>#I0#I%>&-E;%=O7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@ M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M M;#L@8VAA2!);F9O'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^1&5C(#,Q+`T*"0DR,#$T/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^ M9F%L2!#96YT3PO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^,#`P,#,R,#$W-#QS<&%N/CPO'0^ M+2TQ,BTS,3QS<&%N/CPO'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$2!# M=7)R96YT(%)E<&]R=&EN9R!3=&%T=7,\+W1D/@T*("`@("`@("`\=&0@8VQA M2!&:6QE'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^,C`Q-#QS<&%N/CPO'0^1ED\ M2!0=6)L:6,@1FQO870\+W1D/@T*("`@("`@("`\=&0@8VQA'0^1&5L87=A2!);F-O'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5]. M97AT4&%R=%\T.#,U8F,R-%]C-C1D7S1E-#E?.&9B,5\T9#1A-C5D964S8S@- M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-#@S-6)C,C1?8S8T9%\T M930Y7SAF8C%?-&0T838U9&5E,V,X+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$6%B;&4\+W1D M/@T*("`@("`@("`\=&0@8VQA'0^)FYB'0^)FYB'0^)FYB'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA M'0^)FYB'0^)FYB'0^)FYB2!S=&]C:R!S:&%R97,\+W1D/@T*("`@("`@("`\=&0@8VQA7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@ M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'!E;G-E'!E;G-E*3PO M=&0^#0H@("`@("`@(#QT9"!C;&%S"!P'0O M:F%V87-C3X-"B`@("`\ M=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'1087)T M7S0X,S5B8S(T7V,V-&1?-&4T.5\X9F(Q7S1D-&$V-61E93-C.`T*0V]N=&5N M="U,;V-A=&EO;CH@9FEL93HO+R]#.B\T.#,U8F,R-%]C-C1D7S1E-#E?.&9B M,5\T9#1A-C5D964S8S@O5V]R:W-H965T'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!A;F0@;W1H97(@87-S971S/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$;G5M<#XX,#4L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@ M8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/"$M+65G>"TM/CQP('-T>6QE/3-$;6%R9VEN M+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN.C!I;CMM87)G:6XM M8F]T=&]M.BXP,#`Q<'0^/&(^3F]T92`Q.B9N8G-P.R9N8G-P.T]R9V%N:7IA M=&EO;B!A;F0@4VEG;FEF:6-A;G0@06-C;W5N=&EN9R!0;VQI8VEE6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP M:6X[;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0^)FYB'0M:6YD96YT M.BXU:6X^/&(^3W)G86YI>F%T:6]N(&%N9"!"=7-I;F5S2`R,#$U+"!W92!C:&%N9V5D M('1H92!N86UE(&]F('1H92!#;VUP86YY('1O(%!E2!T:&%T M(&1E=F5L;W!S+"!M86YU9F%C='5R97,L(&UA7-T M96T@96UP;&]Y'1E;G-I=F4@:6YT96QL96-T=6%L('!R;W!E65A65A6QE M/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN.C!I M;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[=&5X="UI;F1E;G0Z+C5I;CX\8CY! M8V-O=6YT2!B87-I2!U M2!W&-E'0M:6YD96YT.BXU:6X^/&(^4')O<&5R='D@86YD($5Q=6EP;65N M=#PO8CX@)B,Q-3`[(%!R;W!E6QE/3-$)W=I9'1H.C$R-BXQ<'0[<&%D9&EN9SHP:6X@-2XT<'0@ M,&EN(#4N-'!T)SX@/'`@6QE/3-$)W=I9'1H.C0U+C!P M=#MP861D:6YG.C!I;B`U+C1P="`P:6X@-2XT<'0G/B`\<"!S='EL93TS1&UA M'0M86QI9VXZ65A6QE/3-$)W=I9'1H.C$N-S5I;CMP M861D:6YG.C!I;B`U+C1P="`P:6X@-2XT<'0G/B`\<"!A;&EG;CTS1')I9VAT M('-T>6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[=&5X M="UA;&EG;CIR:6=H=#XT,"!Y96%R6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[ M;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[=&5X="UI;F1E;G0Z M+C5I;CY%>'!E;F1I='5R97,@9F]R(&UA:6YT96YA;F-E(&%N9"!R97!A:7)S M(&%R92!E>'!E;G-E9"!W:&5N(&EN8W5R2!A;F0@97%U:7!M96YT(&%R92!R969L96-T M960@:6X@;W!E6QE/3-$;6%R9VEN+7)I9VAT M.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M M.BXP,#`Q<'0^)FYB'0M:6YD96YT.BXU:6X^5&AE(&-O2!A;F0@97%U:7!M96YT('-O M;&0@;W(@;W1H97)W:7-E(')E=&ER960@87)E(')E;6]V960@9G)O;2!T:&4@ M86-C;W5N=',@86YD(&%N>2!R96QA=&5D(&=A:6X@;W(@;&]S6QE/3-$;6%R9VEN M+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN.C!I;CMM87)G:6XM M8F]T=&]M.BXP,#`Q<'0[=&5X="UI;F1E;G0Z+C5I;CX\8CY0871E;G1S/"]B M/B`F(S$U,#L@4&%T96YT(&-O'!E;G-E9"!A6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F M=#HP:6X[;6%R9VEN+71O<#HP:6X[;6%R9VEN+7)I9VAT.BXQ<'0[;6%R9VEN M+6)O='1O;3HP:6X[;6%R9VEN+6QE9G0Z+C%P=#MM87)G:6XM8F]T=&]M.BXP M,#`Q<'0^)FYB2!R97-E65A2!E>'!E;G-E('=A'0M:6YD M96YT.BXU:6X^/&(^26YC;VUE(%1A>&5S/"]B/B`F(S$U,#L@5V4@86-C;W5N M="!F;W(@:6YC;VUE('1A>&5S('5S:6YG('1H92!A2!M971H;V0L(&1E9F5R"!AF5D(&9O"!C;VYS M97%U96YC97,@871T&ES=&EN9R!A"!B87-E2!D:69F M97)E;F-E6QE/3-$;6%R M9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN+71O<#HP:6X[ M;6%R9VEN+7)I9VAT.BXQ<'0[;6%R9VEN+6)O='1O;3HP:6X[;6%R9VEN+6QE M9G0Z+C%P=#MM87)G:6XM8F]T=&]M.BXP,#`Q<'0[=&5X="UI;F1E;G0Z+C5I M;CXF;F)S<#L\+W`^(#QP('-T>6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G M:6XM;&5F=#HP:6X[;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[ M=&5X="UI;F1E;G0Z+C5I;CX\8CY);F-O;64@*$QO65A6QE/3-$;6%R9VEN+7)I9VAT M.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M M.BXP,#`Q<'0[=&5X="UI;F1E;G0Z+C5I;CXF;F)S<#L\+W`^(#QP('-T>6QE M/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN.C!I M;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[=&5X="UI;F1E;G0Z+C5I;CY4:&4@ M8V]M<'5T871I;VX@;V8@9&EL=71E9"!E87)N:6YG&5R8VES92!O9B!S=&]C:R!O<'1I;VYS(&%N9"!W87)R86YT M&-L=61E9"!F6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R M9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[=&5X="UI;F1E;G0Z+C5I M;CY3:6YC92!W92!H860@;F\@9&EL=71I=F4@969F96-T(&]F('-T;V-K(&]P M=&EO;G,@86YD('=A'0M:6YD96YT.BXU:6X^ M)FYB'0M:6YD96YT.BXU:6X^/&(^4W1O8VLM0F%S960@0V]M<&5NF5D(&]V97(@=&AE('!E'!E;G-E+B9N8G-P.SPO<#X@ M/'`@F4@'0M:6YD96YT.BXU:6X^ M)FYB6QE/3-$;6%R9VEN+6QE9G0Z,3DN-G!T.V)O M6QE/3-$)W=I9'1H.C$S-"XY M<'0[8F]R9&5R.FYO;F4[<&%D9&EN9SHP:6X@-2XT<'0@,&EN(#4N-'!T)SX@ M/'`@86QI9VX],T1C96YT97(@6QE/3-$)W=I9'1H M.C$S,BXT<'0[8F]R9&5R.FYO;F4[<&%D9&EN9SHP:6X@-2XT<'0@,&EN(#4N M-'!T)SX@/'`@86QI9VX],T1C96YT97(@6QE/3-$)W=I9'1H.C8X+C=P=#MB;W)D97(Z M;F]N93MB;W)D97(M8F]T=&]M.G-O;&ED('=I;F1O=W1E>'0@,2XP<'0[<&%D M9&EN9SHP:6X@-2XT<'0@,&EN(#4N-'!T)SX@/'`@86QI9VX],T1C96YT97(@ M6QE/3-$)W=I9'1H.C8V+C)P=#MB;W)D M97(Z;F]N93MB;W)D97(M8F]T=&]M.G-O;&ED('=I;F1O=W1E>'0@,2XP<'0[ M<&%D9&EN9SHP:6X@-2XT<'0@,&EN(#4N-'!T)SX@/'`@86QI9VX],T1C96YT M97(@6QE/3-$)W=I9'1H.C8X M+C=P=#MB;W)D97(Z;F]N93MP861D:6YG.C!I;B`U+C1P="`P:6X@-2XT<'0G M/B`\<"!S='EL93TS1&UA6QE/3-$)W=I9'1H.C8V+C)P=#MB;W)D97(Z;F]N93MP861D:6YG.C!I M;B`U+C1P="`P:6X@-2XT<'0G/B`\<"!S='EL93TS1&UA6QE/3-$)W=I9'1H.C8V+C)P=#MB;W)D M97(Z;F]N93MP861D:6YG.C!I;B`U+C1P="`P:6X@-2XT<'0G/B`\<"!A;&EG M;CTS1')I9VAT('-T>6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F M=#HP:6X[=&5X="UA;&EG;CIR:6=H=#XF;F)S<#L\+W`^(#PO=&0^(#QT9"!W M:61T:#TS1#@X('9A;&EG;CTS1'1O<"!S='EL93TS1"=W:61T:#HV-BXR<'0[ M8F]R9&5R.FYO;F4[<&%D9&EN9SHP:6X@-2XT<'0@,&EN(#4N-'!T)SX@/'`@ M86QI9VX],T1R:6=H="!S='EL93TS1&UA'0M86QI9VXZ6QE/3-$)W=I9'1H.C$U-2XY<'0[8F]R9&5R.FYO;F4[<&%D M9&EN9SHP:6X@-2XT<'0@,&EN(#4N-'!T)SX@/'`@6QE/3-$ M)W=I9'1H.C8V+C)P=#MB;W)D97(Z;F]N93MP861D:6YG.C!I;B`U+C1P="`P M:6X@-2XT<'0G/B`\<"!A;&EG;CTS1')I9VAT('-T>6QE/3-$;6%R9VEN+7)I M9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[=&5X="UA;&EG;CIR:6=H=#XD("8C M,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.SDX-BPY,#`\+W`^ M(#PO=&0^(#QT9"!W:61T:#TS1#@X('9A;&EG;CTS1'1O<"!S='EL93TS1"=W M:61T:#HV-BXR<'0[8F]R9&5R.FYO;F4[<&%D9&EN9SHP:6X@-2XT<'0@,&EN M(#4N-'!T)SX@/'`@86QI9VX],T1R:6=H="!S='EL93TS1&UA'0M86QI9VXZ'0M86QI9VXZ6QE/3-$)W=I9'1H.C8X+C=P=#MB;W)D97(Z;F]N93MP M861D:6YG.C!I;B`U+C1P="`P:6X@-2XT<'0G/B`\<"!A;&EG;CTS1')I9VAT M('-T>6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[=&5X M="UA;&EG;CIR:6=H=#XT,#DL-S@W/"]P/B`\+W1D/B`\=&0@=VED=&@],T0X M."!V86QI9VX],T1T;W`@'0M86QI9VXZ'0M86QI9VXZ6QE/3-$)W=I9'1H.C8V+C)P=#MB;W)D M97(Z;F]N93MP861D:6YG.C!I;B`U+C1P="`P:6X@-2XT<'0G/B`\<"!A;&EG M;CTS1')I9VAT('-T>6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F M=#HP:6X[=&5X="UA;&EG;CIR:6=H=#XS-S4L-S0W/"]P/B`\+W1D/B`\=&0@ M=VED=&@],T0X."!V86QI9VX],T1T;W`@6QE/3-$)W=I9'1H M.C8V+C)P=#MB;W)D97(Z;F]N93MB;W)D97(M8F]T=&]M.G-O;&ED('=I;F1O M=W1E>'0@,2XP<'0[<&%D9&EN9SHP:6X@-2XT<'0@,&EN(#4N-'!T)SX@/'`@ M86QI9VX],T1R:6=H="!S='EL93TS1&UA'0M86QI9VXZ6QE/3-$)W=I9'1H.C8V M+C)P=#MB;W)D97(Z;F]N93MB;W)D97(M8F]T=&]M.G-O;&ED('=I;F1O=W1E M>'0@,2XP<'0[<&%D9&EN9SHP:6X@-2XT<'0@,&EN(#4N-'!T)SX@/'`@86QI M9VX],T1R:6=H="!S='EL93TS1&UA'0M86QI9VXZ6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM M87)G:6XM;&5F=#HP:6X[=&5X="UA;&EG;CIR:6=H=#XD)B,Q-C`[)B,Q-C`[ M("8C,38P.R8C,38P.S$L,3$U+#DP.#PO<#X@/"]T9#X@/'1D('=I9'1H/3-$ M.#@@=F%L:6=N/3-$=&]P('-T>6QE/3-$)W=I9'1H.C8V+C)P=#MB;W)D97(Z M;F]N93MB;W)D97(M8F]T=&]M.F1O=6)L92!W:6YD;W=T97AT(#$N-7!T.W!A M9&1I;F'0@,2XU<'0[<&%D9&EN9SHP:6X@-2XT<'0@,&EN(#4N-'!T M)SX@/'`@86QI9VX],T1R:6=H="!S='EL93TS1&UA'0M86QI9VXZ6QE M/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[=&5X="UA;&EG M;CIR:6=H=#XD)B,Q-C`[)B,Q-C`[)B,Q-C`[(#,L-C7-T96US M+CPO<#X@/'`@6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP M:6X[;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[=&5X="UI;F1E M;G0Z+C5I;CY2979E;G5E(&9R;VT@=')A:6YI;F<@6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[ M;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[=&5X="UI;F1E;G0Z M+C5I;CY2979E;G5E(&9R;VT@97%U:7!M96YT(')E;G1A;"!U;F1E6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN M.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0^)FYB'0M:6YD96YT.BXU:6X^3W5R M(')E=F5N=64@6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[ M;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0^)FYB'0M:6YD96YT.BXU M:6X^4V%L97,@=&\@9&ES=')I8G5T;W)S(&%R92!R96-O9VYI>F5D(&EN('1H M92!S86UE(&UA;FYE6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R M9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[=&5X="UI;F1E;G0Z+C5I M;CX\8CY#;VYC96YT2!O9B!T2P@=V4@<&5R9F]R;2!O;F=O:6YG(&-R961I="!E=F%L=6%T:6]N M6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G M:6XM;&5F=#HP:6X[;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[ M=&5X="UI;F1E;G0Z+C5I;CX\8CY!9'9E'!E;G-E('=A2X\+W`^(#QP M('-T>6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R M9VEN+71O<#HP:6X[;6%R9VEN+7)I9VAT.BXQ<'0[;6%R9VEN+6)O='1O;3HP M:6X[;6%R9VEN+6QE9G0Z+C%P=#MM87)G:6XM8F]T=&]M.BXP,#`Q<'0^)FYB M'0M M:6YD96YT.BXU:6X^/&(^4VAI<'!I;F<@86YD($AA;F1L:6YG/"]B/B`F(S$U M,#L@5V4@8FEL;"!O=7(@8W5S=&]M97)S(&9O2!A8V-E<'1E9"!A8V-O=6YT:6YG('!R:6YC:7!L97,@6QE/3-$;6%R9VEN M+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN+71O<#HP:6X[;6%R M9VEN+7)I9VAT.BXQ<'0[;6%R9VEN+6)O='1O;3HP:6X[;6%R9VEN+6QE9G0Z M+C%P=#MM87)G:6XM8F]T=&]M.BXP,#`Q<'0^)FYB'0M:6YD96YT.BXU:6X^/&(^ M0V]M<')E:&5N'0O:F%V87-C M3X-"B`@("`\=&%B;&4@ M8VQA'!A;F0@'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/"$M+65G>"TM/CQP('-T M>6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN M.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0^/&(^3F]T92`S.B9N8G-P.R9N M8G-P.T1E=&%I;"!O9B!#97)T86EN($)A;&%N8V4@4VAE970@06-C;W5N=',\ M+V(^/"]P/B`\<"!S='EL93TS1&UA'0M:6YD96YT.BXU:6X^)FYB6QE/3-$;6%R9VEN+6QE9G0Z+C5I;CMB;W)D97(M8V]L;&%P M6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP M:6X^)FYB6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F M=#HP:6X[=&5X="UA;&EG;CIC96YT97(^/&(^075G=7-T(#,Q+#PO8CX\+W`^ M(#PO=&0^(#PO='(^(#QT6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP M:6X^)FYB'0@,2XP<'0[<&%D9&EN9SHP)SX@/'`@86QI9VX],T1C96YT97(@ M6QE/3-$)W=I9'1H.C8S+CAP=#MB;W)D M97(Z;F]N93MB;W)D97(M8F]T=&]M.G-O;&ED('=I;F1O=W1E>'0@,2XP<'0[ M<&%D9&EN9SHP)SX@/'`@86QI9VX],T1C96YT97(@6QE/3-$=VED=&@Z-C,N-S5P=#MB;W)D97(Z;F]N93MP861D:6YG.C`^ M(#QP(&%L:6=N/3-$6QE/3-$=VED=&@Z M-C,N.'!T.V)O6QE M/3-$=VED=&@Z,36QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[=&5X M="UA;&EG;CIR:6=H=#XF;F)S<#L\+W`^(#PO=&0^(#QT9"!W:61T:#TS1#@U M('9A;&EG;CTS1'1O<"!S='EL93TS1'=I9'1H.C8S+C6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM M87)G:6XM;&5F=#HP:6X[=&5X="UA;&EG;CIR:6=H=#XF;F)S<#L\+W`^(#PO M=&0^(#QT9"!W:61T:#TS1#@U('9A;&EG;CTS1'1O<"!S='EL93TS1'=I9'1H M.C8S+CAP=#MP861D:6YG.C`^(#QP(&%L:6=N/3-$6QE/3-$=VED M=&@Z-C,N-S5P=#MP861D:6YG.C`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`^(#PO=&0^(#QT9"!W:61T:#TS1#@U M('9A;&EG;CTS1'1O<"!S='EL93TS1'=I9'1H.C8S+C6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM M87)G:6XM;&5F=#HP:6X[=&5X="UA;&EG;CIR:6=H=#XF;F)S<#L\+W`^(#PO M=&0^(#QT9"!W:61T:#TS1#@U('9A;&EG;CTS1'1O<"!S='EL93TS1'=I9'1H M.C8S+CAP=#MP861D:6YG.C`^(#QP(&%L:6=N/3-$6QE/3-$)W=I9'1H.B`Q-S8N-C5P=#L@<&%D M9&EN9SH@,#LG/B`\<"!S='EL93TS1&UA6QE/3-$)W=I9'1H.B`V,RXX<'0[(&)O'0@,2XU<'0[('!A M9&1I;F6QE/3-$)W=I9'1H.B`V,RXW-7!T M.R!B;W)D97(Z(&YO;F4[(&)O6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM M;&5F=#HP:6X[;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[=&5X M="UA;&EG;CIJ=7-T:69Y.W1E>'0M:6YD96YT.BXU:6X^)FYB6QE/3-$;6%R9VEN+6QE9G0Z+C5I;CMB;W)D M97(M8V]L;&%P6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G M:6XM;&5F=#HP:6X^26YV96YT;W)I97,Z/"]P/B`\+W1D/B`\=&0@=VED=&@] M,T0X-2!V86QI9VX],T1T;W`@6QE/3-$ M=VED=&@Z-C,N-S5P=#MP861D:6YG.C`^(#QP(&%L:6=N/3-$8V5N=&5R('-T M>6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[=&5X="UA M;&EG;CIC96YT97(^)FYB6QE/3-$=VED=&@Z-C,N-S5P=#MP861D:6YG M.C`^(#QP(&%L:6=N/3-$6QE/3-$=VED M=&@Z-C,N.'!T.W!A9&1I;F'0M86QI9VXZ M6QE/3-$=VED=&@Z M,36QE/3-$=VED=&@Z-C,N-S5P=#MP861D:6YG.C`^ M(#QP(&%L:6=N/3-$6QE/3-$=VED=&@Z-C,N M.'!T.W!A9&1I;F6QE/3-$=VED=&@Z,36QE/3-$=VED M=&@Z,36QE/3-$=VED=&@Z-C,N.'!T.W!A9&1I;F6QE M/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN+7)I M9VAT.BXP-6EN.W1E>'0M86QI9VXZ6QE/3-$=VED=&@Z-C,N M.'!T.W!A9&1I;F6QE/3-$ M;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X^)B,Q-C`[)B,Q-C`[ M(%)E'0M86QI9VXZ6QE/3-$)W=I9'1H.C8S+C6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G M:6XM;&5F=#HP:6X[=&5X="UA;&EG;CIR:6=H=#XH,34P+#`P,"D\+W`^(#PO M=&0^(#QT9"!W:61T:#TS1#@U('9A;&EG;CTS1'1O<"!S='EL93TS1"=W:61T M:#HV,RXX<'0[8F]R9&5R.FYO;F4[8F]R9&5R+6)O='1O;3IS;VQI9"!B;&%C M:R`Q+C!P=#MP861D:6YG.C`G/B`\<"!A;&EG;CTS1')I9VAT('-T>6QE/3-$ M;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[=&5X="UA;&EG;CIR M:6=H=#XH,3`P+#`P,"D\+W`^(#PO=&0^(#PO='(^(#QT6QE/3-$;6%R9VEN+7)I9VAT M.C!I;CMM87)G:6XM;&5F=#HP:6X^)FYB6QE/3-$;6%R9VEN+7)I9VAT M.C!I;CMM87)G:6XM;&5F=#HP:6X[=&5X="UA;&EG;CIR:6=H=#XF;F)S<#L\ M+W`^(#PO=&0^(#QT9"!W:61T:#TS1#@U('9A;&EG;CTS1'1O<"!S='EL93TS M1'=I9'1H.C8S+C6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[=&5X="UA M;&EG;CIR:6=H=#XF;F)S<#L\+W`^(#PO=&0^(#QT9"!W:61T:#TS1#@U('9A M;&EG;CTS1'1O<"!S='EL93TS1'=I9'1H.C8S+CAP=#MP861D:6YG.C`^(#QP M(&%L:6=N/3-$6QE M/3-$)W=I9'1H.B`Q-S8N-C5P=#L@<&%D9&EN9SH@,#LG/B`\<"!S='EL93TS M1&UA6QE/3-$)W=I M9'1H.B`V,RXX<'0[(&)O'0@,2XU<'0[('!A9&1I;F'0@ M,2XU<'0[('!A9&1I;F6QE/3-$;6%R9VEN+7)I9VAT.C!I M;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN+7)I9VAT.BXP-6EN.W1E>'0M86QI M9VXZ6QE/3-$;6%R9VEN+7)I9VAT.C!I M;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP M,#`Q<'0[=&5X="UA;&EG;CIJ=7-T:69Y.W1E>'0M:6YD96YT.BXU:6X^)FYB M6QE/3-$;6%R9VEN+6QE9G0Z M+C5I;CMB;W)D97(M8V]L;&%P6QE/3-$;6%R9VEN+7)I9VAT M.C!I;CMM87)G:6XM;&5F=#HP:6X^06-C6QE M/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[=&5X="UA;&EG M;CIC96YT97(^)FYB6QE/3-$;6%R M9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[=&5X="UA;&EG;CIC96YT M97(^/&(^(#PO8CX\+W`^(#PO=&0^(#PO='(^(#QT6QE/3-$;6%R9VEN+7)I9VAT.C!I M;CMM87)G:6XM;&5F=#HP:6X^)FYB6QE/3-$;6%R9VEN+7)I9VAT.C!I M;CMM87)G:6XM;&5F=#HP:6X[=&5X="UA;&EG;CIR:6=H=#XF;F)S<#L\+W`^ M(#PO=&0^(#QT9"!W:61T:#TS1#@U('9A;&EG;CTS1'1O<"!S='EL93TS1'=I M9'1H.C8S+C6QE M/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[=&5X="UA;&EG M;CIR:6=H=#XF;F)S<#L\+W`^(#PO=&0^(#QT9"!W:61T:#TS1#@U('9A;&EG M;CTS1'1O<"!S='EL93TS1'=I9'1H.C8S+CAP=#MP861D:6YG.C`^(#QP(&%L M:6=N/3-$6QE/3-$=VED=&@Z-C,N.'!T.W!A9&1I;F6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP M:6X[;6%R9VEN+7)I9VAT.BXP-6EN.W1E>'0M86QI9VXZ6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F M=#HP:6X^)B,Q-C`[)B,Q-C`[(%1R86EN:6YG(&%N9"!I;G-T86QL871I;VX@ M6QE/3-$=VED=&@Z-C,N.'!T.W!A9&1I;F6QE/3-$;6%R9VEN M+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN+7)I9VAT.BXP-6EN M.W1E>'0M86QI9VXZ6QE/3-$;6%R M9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X^)B,Q-C`[)B,Q-C`[($%C M8W)U960@=&%X97,@<&%Y86)L93PO<#X@/"]T9#X@/'1D('=I9'1H/3-$.#4@ M=F%L:6=N/3-$=&]P('-T>6QE/3-$=VED=&@Z-C,N.'!T.W!A9&1I;F6QE/3-$=VED=&@Z-C,N-S5P=#MP861D:6YG.C`^(#QP(&%L:6=N M/3-$6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X^ M)B,Q-C`[)B,Q-C`[(%!A>7)O;&PL(&-O;6UI'0@,2XP<'0[<&%D9&EN9SHP)SX@/'`@86QI9VX] M,T1R:6=H="!S='EL93TS1&UA6QE/3-$=VED=&@Z,36QE/3-$=VED=&@Z-C,N.'!T.V)O'0M86QI9VXZ'0M86QI9VXZ6QE/3-$ M;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[=&5X="UA;&EG;CIR M:6=H=#XF;F)S<#L\+W`^(#PO=&0^(#PO='(^(#QT6QE M/3-$)W=I9'1H.B`V,RXW-7!T.R!B;W)D97(Z(&YO;F4[(&)O6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM M87)G:6XM;&5F=#HP:6X[;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q M<'0^)FYB3X-"CPO:'1M;#X-"@T*+2TM+2TM/5]. M97AT4&%R=%\T.#,U8F,R-%]C-C1D7S1E-#E?.&9B,5\T9#1A-C5D964S8S@- M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-#@S-6)C,C1?8S8T9%\T M930Y7SAF8C%?-&0T838U9&5E,V,X+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!A;F0@17%U:7!M96YT/"]B M/CPO<#X@/'`@6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP M:6X[;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[=&5X="UI;F1E M;G0Z+C5I;CY02!A;F0@97%U:7!M96YT(&-O;G-I6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM M87)G:6XM;&5F=#HP:6X[;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q M<'0[=&5X="UI;F1E;G0Z+C5I;CXF;F)S<#L\+W`^(#QT86)L92!B;W)D97(] M,T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0T M.3$@6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[ M=&5X="UA;&EG;CIC96YT97(^/&(^1&5C96UB97(@,S$L/"]B/CPO<#X@/"]T M9#X@/'1D('=I9'1H/3-$,36QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F M=#HP:6X[=&5X="UA;&EG;CIC96YT97(^/&(^,C`Q-#PO8CX\+W`^(#PO=&0^ M(#QT9"!W:61T:#TS1#@U('9A;&EG;CTS1'1O<"!S='EL93TS1"=W:61T:#HV M,RXW-7!T.V)O'0M86QI M9VXZ8V5N=&5R/CQB/C(P,30\+V(^/"]P/B`\+W1D/B`\=&0@=VED=&@],T0X M-2!V86QI9VX],T1T;W`@6QE/3-$=VED=&@Z,36QE/3-$=VED=&@Z-C,N.'!T.V)O'0M86QI9VXZ'0M86QI9VXZ6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[=&5X="UA M;&EG;CIR:6=H=#XF;F)S<#L\+W`^(#PO=&0^(#PO='(^(#QT6QE/3-$;6%R9VEN+7)I M9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X^)B,Q-C`[)B,Q-C`[($5Q=6EP;65N M=#PO<#X@/"]T9#X@/'1D('=I9'1H/3-$.#4@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$=VED=&@Z-C,N.'!T.W!A9&1I;F6QE/3-$ M;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN+7)I9VAT M.C,N-W!T.W1E>'0M86QI9VXZ6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM M87)G:6XM;&5F=#HP:6X^)B,Q-C`[)B,Q-C`[(%)E;G1A;"!E<75I<&UE;G0\ M+W`^(#PO=&0^(#QT9"!W:61T:#TS1#@U('9A;&EG;CTS1&)O='1O;2!S='EL M93TS1'=I9'1H.C8S+CAP=#MP861D:6YG.C`^(#QP(&%L:6=N/3-$6QE M/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN+7)I M9VAT.C,N-W!T.W1E>'0M86QI9VXZ6QE/3-$;6%R M9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN+7)I9VAT.C,N M-W!T.W1E>'0M86QI9VXZ6QE/3-$=VED=&@Z,36QE/3-$;6%R9VEN+7)I9VAT M.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN+7)I9VAT.C,N-W!T.W1E>'0M M86QI9VXZ6QE/3-$=VED=&@Z-C,N-S5P=#MP861D:6YG M.C`^(#QP(&%L:6=N/3-$6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G M:6XM;&5F=#HP:6X[;6%R9VEN+7)I9VAT.C,N-W!T.W1E>'0M86QI9VXZ6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP M:6X[;6%R9VEN+7)I9VAT.C,N-W!T.W1E>'0M86QI9VXZ6QE/3-$ M=VED=&@Z-C,N-S5P=#MP861D:6YG.C`^(#QP(&%L:6=N/3-$6QE M/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X^)B,Q-C`[)B,Q M-C`[($)U:6QD:6YG("AH96QD(&9O6QE/3-$=VED=&@Z-C,N.'!T M.W!A9&1I;F6QE/3-$;6%R9VEN+7)I9VAT M.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN+7)I9VAT.C,N-W!T.W1E>'0M M86QI9VXZ6QE/3-$=VED=&@Z-C,N.'!T.W!A9&1I;F6QE/3-$;6%R9VEN+7)I9VAT M.C!I;CMM87)G:6XM;&5F=#HP:6X^)B,Q-C`[)B,Q-C`[($QA;F0F(S$V,#L@ M*&AE;&0@9F]R('-A;&4I/"]P/B`\+W1D/B`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`^ M(#QP(&%L:6=N/3-$6QE/3-$;6%R9VEN+7)I9VAT.C!I M;CMM87)G:6XM;&5F=#HP:6X^)B,Q-C`[)B,Q-C`[($QE6QE/3-$=VED=&@Z-C,N-S5P=#MP861D:6YG M.C`^(#QP(&%L:6=N/3-$6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G M:6XM;&5F=#HP:6X^)B,Q-C`[)B,Q-C`[($QE'0M86QI9VXZ'0M86QI9VXZ M6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM M87)G:6XM;&5F=#HP:6X[=&5X="UA;&EG;CIR:6=H=#XH,2PV.34L-C8X*3PO M<#X@/"]T9#X@/"]T6QE/3-$=VED=&@Z-C,N M-S5P=#MP861D:6YG.C`^(#QP(&%L:6=N/3-$6QE/3-$=VED=&@Z-C,N.'!T.W!A9&1I;F'0M86QI9VXZ6QE/3-$;6%R9VEN M+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X^)FYB6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[ M;6%R9VEN+7)I9VAT.BXP-6EN.W1E>'0M86QI9VXZ6QE/3-$ M;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN+7)I9VAT M.BXP-6EN.W1E>'0M86QI9VXZ6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM M;&5F=#HP:6X[;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[=&5X M="UI;F1E;G0Z+C5I;CY$97!R96-I871I;VX@97AP96YS92!T;W1A;&5D("0T M,RPR.#`@9F]R('1H92!F;W5R(&UO;G1H2X\+W`^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5]. M97AT4&%R=%\T.#,U8F,R-%]C-C1D7S1E-#E?.&9B,5\T9#1A-C5D964S8S@- M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-#@S-6)C,C1?8S8T9%\T M930Y7SAF8C%?-&0T838U9&5E,V,X+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0M:6YD96YT.BXU:6X[8F%C M:V=R;W5N9#IW:&ET93Y);B`R,#$T+"!O=7(@0F]A7!EF%B M;&4@=F%L=64@;V8@:6YV96YT;W)Y(&%N9"!O=&AE7-I2P@97%U:7!M96YT+"!A;F0@;W1H97(@ M87-S971S(')E;&%T960@=&\@=&AE(&AY<&5R=&AE7!E.B!T97AT+VAT;6P[ M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@ M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E M>'0O:'1M;#L@8VAA6QE/3-$;6%R9VEN+7)I M9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN.C!I;CMM87)G:6XM8F]T M=&]M.BXP,#`Q<'0^)FYB'0M:6YD96YT.BXU:6X^4&%T96YT(&-O'!E;G-E(&%S(&EN8W5R65A'!E;G-E('=A M2X\+W`^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^ M#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\T.#,U M8F,R-%]C-C1D7S1E-#E?.&9B,5\T9#1A-C5D964S8S@-"D-O;G1E;G0M3&]C M871I;VXZ(&9I;&4Z+R\O0SHO-#@S-6)C,C1?8S8T9%\T930Y7SAF8C%?-&0T M838U9&5E,V,X+U=O'0O:'1M;#L@8VAA3PO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/"$M+65G>"TM/CQP('-T M>6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN M.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0^/&(^3F]T92`W.B9N8G-P.R9N M8G-P.U-T;V-K:&]L9&5R6QE/3-$;6%R9VEN+7)I9VAT.C!I M;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP M,#`Q<'0^)FYB6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F M=#HP:6X[;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0^)FYB'0M:6YD M96YT.BXU:6X^3VX@3V-T;V)E2`D,3DN,B!M:6QL:6]N+"!I M;F-L=61I;F<@<')O8V5E9',@9G)O;2!T:&4@97AEFEN9R!T:&4@,C`Q M,B!3:&5L9B!296=I&EM871E;'D@)#DN,"!M:6QL M:6]N(&9R;VT@=&AE2!O9F9E2!O9B!T:&4@'0M:6YD96YT.BXU M:6X^)FYB6QE M/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN.C!I M;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[=&5X="UI;F1E;G0Z+C5I;CY/;B!! M<')I;"`Y+"`R,#$S+"!W92!E;G1E2!!9W)E96UE;G0F(S$T M.#LI('=I=&@@4F]T:"!#87!I=&%L(%!A2!T:&4@4&QA8V5M96YT($%G96YT(&EN(&-O;FYE8W1I;VX@=VET:"!T:&4@ M07!R:6P@,C`Q,R!/9F9E2!R97!R97-E;G1A M=&EO;G,L('=A2!U6UE;G1S('1H92!0 M;&%C96UE;G0@06=E;G0@;6%Y(&)E(')E<75I2!U2`D-2XP(&UI;&QI;VXN)FYB&5D(&-O;6)I;F%T:6]N M"!M;VYT:',@86YD(&]N92!D87D@9F]L;&]W:6YG('1H92!C;&]S:6YG M(&1A=&4@;V8@=&AE($%P&5R8VES92!P&5R8VES86)I;&ET>2!O9B!T:&4@ M=V%R2!O=VX@;6]R92!T:&%N(#0N.24@;V8@;W5R(&-O;6UO;B!S=&]C M:RX\+W`^(#QP('-T>6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F M=#HP:6X[;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0^)FYB'0M:6YD M96YT.BXU:6X^5V4@86=R965D('=I=&@@96%C:"!O9B!T:&4@<'5R8VAA2!B92!E>'1E;F1E9"!I;B!C97)T86EN(&-I2!A9W)E96UE;G0@=&\@:7-S=64@;W(@86YN M;W5N8V4@=&AE(&ES2!S96-U6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM M87)G:6XM;&5F=#HP:6X[;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q M<'0[=&5X="UI;F1E;G0Z+C5I;CY792!A;'-O(&%G6QE/3-$;6%R9VEN+7)I9VAT.C!I M;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP M,#`Q<'0^)FYB6QE/3-$=VED M=&@Z.3@N,38E.VUA6QE/3-$;6%R9VEN+7)I9VAT M.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M M.BXP,#`Q<'0^:7-S=64@;W(@2`F(S$T-SMW96EG:'1E9"!A=F5R86=E)B,Q-#@[(&%N=&DM9&EL M=71I;VX@<')O=FES:6]N.R!O6QE/3-$ M=VED=&@Z-2XW)3MP861D:6YG.C`^(#QP('-T>6QE/3-$;6%R9VEN+7)I9VAT M.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M M.BXP,#`Q<'0^)FYB6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[ M;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0^96YT97(@:6YT;R!A M;GD@86=R965M96YT("AI;F-L=61I;F2!S96QL M('-E8W5R:71I97,@870@82!F=71U6QE/3-$;6%R9VEN+7)I M9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN.C!I;CMM87)G:6XM8F]T M=&]M.BXP,#`Q<'0[=&5X="UI;F1E;G0Z+C5I;CY792!A;'-O(&%G6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM M87)G:6XM;&5F=#HP:6X[;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q M<'0[=&5X="UI;F1E;G0Z+C5I;CY792!A;'-O(&%G&EM871E;'D@ M)#0N-B!M:6QL:6]N+"!A9G1E'!E;G-E2!U6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP M:6X[;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0^)FYB'0M:6YD96YT M.BXU:6X^5&AE($%P2`Y M+"`R,#$T+"!T:&4@0V]M<&%N>2!E;G1E2!R96%S;VYA8FQE(&5F9F]R=',@8V]N2!S86QE2!I;F1E;6YI9FEC871I;VX@2!T:&4@0V]M<&%N>2!O;B!A($-U2`Y+"`R,#$T+B9N8G-P.R9N8G-P.U1H6QE M/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN.C!I M;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[=&5X="UI;F1E;G0Z+C5I;CY/;B!* M=6YE(#(U+"`R,#$T+"!T:&4@0V]M<&%N>2!A;F0@8V5R=&%I;B!I;G-T:71U M=&EO;F%L(&EN=F5S=&]R"!M;VYT:',@86YD(&]N92!D87D@9F]L;&]W:6YG('1H92!C;&]S:6YG(&1A M=&4@;V8@=&AE($IU;F4@3V9F97)I;F<@86YD('=I;&P@&5R8VES92!P2!O=VX@;6]R92!T:&%N M(#0N.3DE(&]F('1H92!#;VUP86YY)B,Q-#8[28C,30V.W,@ M&-E<'1I;VYS+"!I="!W M:6QL(&YO="P@=VET:&EN('1H92`W-2!D87ES(&9O;&QO=VEN9R!T:&4@8VQO M2!A9W)E M96UE;G0@=&\@:7-S=64@;W(@86YN;W5N8V4@=&AE(&ES2!S96-U'0M:6YD M96YT.BXU:6X^)FYB6QE/3-$ M=VED=&@Z.36QE/3-$=VED M=&@Z-"XX)3MP861D:6YG.C`^(#QP('-T>6QE/3-$;6%R9VEN+7)I9VAT.C!I M;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP M,#`Q<'0^)B,Q-C`[)B,Q-C`[)B,Q-C`[("8C,30Y.SPO<#X@/"]T9#X@/'1D M('=I9'1H/3-$.34E('-T>6QE/3-$=VED=&@Z.34N,B4[<&%D9&EN9SHP/B`\ M<"!S='EL93TS1&UA2!T:6UE(&%F=&5R('1H92!I;FET:6%L(&ES&5R8VES92!O&-H86YG92!P2!R96QA=&5D M('1O('1H92!B=7-I;F5S2!O28C,30V.W,@8V]M;6]N('-T;V-K+"!O=&AE2!S96QL('-E8W5R:71I97,@870@82!F=71U6QE M/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN.C!I M;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0^)FYB'0M:6YD96YT.BXU:6X^5&AE($-O M;7!A;GD@:&%S(&%L2!E86-H(&]F('1H M92!P=7)C:&%S97)S(&%G86EN2X\+W`^(#QP('-T>6QE/3-$;6%R9VEN M+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN.C!I;CMM87)G:6XM M8F]T=&]M.BXP,#`Q<'0^)FYB6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN M.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[=&5X="UA;&EG;CIJ=7-T:69Y M/B9N8G-P.SPO<#X@/'`@3MT97AT M+6EN9&5N=#HN-6EN/B9N8G-P.SPO<#X@/'1A8FQE(&)O6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F M=#HP:6X[;6%R9VEN+6QE9G0Z."XX<'0[=&5X="UI;F1E;G0Z+3@N.'!T/B9N M8G-P.SPO<#X@/"]T9#X@/'1D('=I9'1H/3-$,3DE('9A;&EG;CTS1&)O='1O M;2!S='EL93TS1"=W:61T:#H@,3DN,S8E.R!B;W)D97(Z(&YO;F4[(&)O'0@,2XP<'0[('!A9&1I;F'0@,2XP<'0[('!A9&1I;F6QE/3-$;6%R9VEN+7)I9VAT.C!I M;CMM87)G:6XM;&5F=#HP:6X[=&5X="UA;&EG;CIC96YT97(^/&(^5V5I9VAT M960M($%V97)A9V4@17AE6QE/3-$)W=I9'1H.B`R M,"XT,B4[(&)O6QE/3-$)W=I M9'1H.B`Q.2XS-B4[(&)O6QE/3-$)W=I9'1H M.B`R+C$X)3L@8F]R9&5R.B!N;VYE.R!B;W)D97(M8F]T=&]M.B!S;VQI9"!W M:6YD;W=T97AT(#$N,'!T.R!P861D:6YG.B`P.R<^(#QP('-T>6QE/3-$;6%R M9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X^)FYB6QE/3-$)W=I M9'1H.B`Q-BXQ,B4[(&)O6QE M/3-$)W=I9'1H.B`Q.2XS-B4[(&)O6QE/3-$)W=I9'1H.B`R M+C$X)3L@8F]R9&5R.B!N;VYE.R!P861D:6YG.B`P.R<^(#QP('-T>6QE/3-$ M;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X^)FYB6QE/3-$ M)W=I9'1H.B`Q-BXQ,B4[(&)O'0@,2XP<'0[('!A9&1I;F6QE/3-$)W=I9'1H.B`Q.2XS-B4[(&)O6QE/3-$;6%R M9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN+7)I9VAT.BXR M:6X[=&5X="UA;&EG;CIR:6=H=#XU+#0U-RPS,#4\+W`^(#PO=&0^(#QT9"!W M:61T:#TS1#(E('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,BXQ M."4[(&)O6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F M=#HP:6X[=&5X="UA;&EG;CIC96YT97(^,BXY,SPO<#X@/"]T9#X@/'1D('=I M9'1H/3-$,C`E('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,C`N M-#(E.R!B;W)D97(Z(&YO;F4[('!A9&1I;F6QE M/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN+6QE M9G0Z."XX<'0[=&5X="UI;F1E;G0Z+3@N.'!T/D=R86YT960\+W`^(#PO=&0^ M(#QT9"!W:61T:#TS1#$Y)2!V86QI9VX],T1B;W1T;VT@6QE/3-$)W=I9'1H.B`R+C$X)3L@8F]R9&5R.B!N;VYE.R!P861D M:6YG.B`P.R<^(#QP('-T>6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM M;&5F=#HP:6X^)FYB6QE/3-$)W=I9'1H.B`Q-BXQ,B4[(&)O6QE/3-$;6%R M9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[=&5X="UA;&EG;CIC96YT M97(^+3PO<#X@/"]T9#X@/"]T6QE/3-$)W=I9'1H.B`T,2XY,B4[(&)O'0M:6YD M96YT.BTX+CAP=#Y%>&5R8VES960\+W`^(#PO=&0^(#QT9"!W:61T:#TS1#$Y M)2!V86QI9VX],T1B;W1T;VT@6QE/3-$)W=I9'1H.B`R M,"XT,B4[(&)O'0@,2XP<'0[('!A9&1I M;F6QE M/3-$)W=I9'1H.B`R,"XT,B4[(&)O6QE M/3-$)W=I9'1H.B`Q.2XS-B4[(&)O6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM M87)G:6XM;&5F=#HP:6X[;6%R9VEN+7)I9VAT.BXR:6X[=&5X="UA;&EG;CIR M:6=H=#XF;F)S<#L\+W`^(#PO=&0^(#QT9"!W:61T:#TS1#(E('9A;&EG;CTS M1&)O='1O;2!S='EL93TS1"=W:61T:#H@,BXQ."4[(&)O6QE M/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[=&5X="UA;&EG M;CIC96YT97(^)FYB6QE/3-$;6%R M9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN+6QE9G0Z."XX M<'0[=&5X="UI;F1E;G0Z+3@N.'!T/D]U='-T86YD:6YG(&%S(&]F($%U9W5S M="`S,2P@,C`Q-#PO<#X@/"]T9#X@/'1D('=I9'1H/3-$,3DE('9A;&EG;CTS M1&)O='1O;2!S='EL93TS1"=W:61T:#H@,3DN,S8E.R!B;W)D97(Z(&YO;F4[ M('!A9&1I;F'0M86QI9VXZ6QE/3-$)W=I9'1H.B`Q M-BXQ,B4[(&)O6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[ M=&5X="UA;&EG;CIC96YT97(^-"XP,CPO<#X@/"]T9#X@/"]T6QE/3-$)W=I9'1H M.B`T,2XY,B4[(&)O'0M:6YD96YT.BTX+CAP=#Y'6QE/3-$)W=I M9'1H.B`Q.2XS-B4[(&)O6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM M;&5F=#HP:6X[;6%R9VEN+7)I9VAT.BXR:6X[=&5X="UA;&EG;CIR:6=H=#XM M/"]P/B`\+W1D/B`\=&0@=VED=&@],T0R)2!V86QI9VX],T1B;W1T;VT@6QE/3-$;6%R9VEN M+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[=&5X="UA;&EG;CIC96YT97(^ M+3PO<#X@/"]T9#X@/'1D('=I9'1H/3-$,C`E('9A;&EG;CTS1&)O='1O;2!S M='EL93TS1"=W:61T:#H@,C`N-#(E.R!B;W)D97(Z(&YO;F4[('!A9&1I;F6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM M;&5F=#HP:6X[;6%R9VEN+6QE9G0Z."XX<'0[=&5X="UI;F1E;G0Z+3@N.'!T M/D5X97)C:7-E9#PO<#X@/"]T9#X@/'1D('=I9'1H/3-$,3DE('9A;&EG;CTS M1&)O='1O;2!S='EL93TS1"=W:61T:#H@,3DN,S8E.R!B;W)D97(Z(&YO;F4[ M('!A9&1I;F'0M86QI9VXZ6QE/3-$)W=I9'1H.B`R+C$X)3L@8F]R9&5R M.B!N;VYE.R!P861D:6YG.B`P.R<^(#QP('-T>6QE/3-$;6%R9VEN+7)I9VAT M.C!I;CMM87)G:6XM;&5F=#HP:6X^)FYB6QE/3-$)W=I9'1H.B`Q-BXQ M,B4[(&)O6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[=&5X="UA M;&EG;CIC96YT97(^+3PO<#X@/"]T9#X@/"]T6QE/3-$)W=I9'1H.B`T,2XY,B4[ M(&)O'0M:6YD96YT.BTX+CAP=#Y&;W)F96ET960@;W(@97AP:7)E9#PO<#X@ M/"]T9#X@/'1D('=I9'1H/3-$,3DE('9A;&EG;CTS1&)O='1O;2!S='EL93TS M1"=W:61T:#H@,3DN,S8E.R!B;W)D97(Z(&YO;F4[('!A9&1I;F'0M86QI9VXZ6QE/3-$)W=I9'1H.B`R+C$X)3L@8F]R9&5R.B!N;VYE.R!P861D:6YG M.B`P.R<^(#QP('-T>6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F M=#HP:6X^)FYB6QE/3-$)W=I9'1H.B`Q-BXQ,B4[(&)O6QE/3-$;6%R9VEN+7)I M9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[=&5X="UA;&EG;CIC96YT97(^+3PO M<#X@/"]T9#X@/"]T6QE/3-$)W=I9'1H.B`T,2XY,B4[(&)O'0M:6YD96YT.BTX M+CAP=#XF;F)S<#L\+W`^(#PO=&0^(#QT9"!W:61T:#TS1#$Y)2!V86QI9VX] M,T1B;W1T;VT@6QE/3-$)W=I9'1H.B`R+C$X)3L@8F]R9&5R.B!N M;VYE.R!B;W)D97(M=&]P.B!S;VQI9"!W:6YD;W=T97AT(#$N,'!T.R!P861D M:6YG.B`P.R<^(#QP('-T>6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM M;&5F=#HP:6X^)FYB6QE/3-$)W=I9'1H.B`Q-BXQ,B4[(&)O'0@,2XP<'0[('!A9&1I;F6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP M:6X[;6%R9VEN+7)I9VAT.BXR:6X[=&5X="UA;&EG;CIR:6=H=#XY+#@U-RPS M,#4\+W`^(#PO=&0^(#QT9"!W:61T:#TS1#(E('9A;&EG;CTS1&)O='1O;2!S M='EL93TS1"=W:61T:#H@,BXQ."4[(&)O'0@,2XU<'0[('!A9&1I;F6QE/3-$)W=I9'1H.B`Q-BXQ,B4[(&)O'0@,2XU<'0[('!A9&1I;F6QE/3-$)W=I M9'1H.B`R,"XT,B4[(&)O'0@,2XU<'0[('!A9&1I;F6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R M9VEN+6QE9G0Z."XX<'0[=&5X="UI;F1E;G0Z+3@N.'!T/B9N8G-P.SPO<#X@ M/"]T9#X@/'1D('=I9'1H/3-$,3DE('9A;&EG;CTS1&)O='1O;2!S='EL93TS M1"=W:61T:#H@,3DN,S8E.R!B;W)D97(Z(&YO;F4[('!A9&1I;F6QE/3-$;6%R9VEN+7)I9VAT.C!I M;CMM87)G:6XM;&5F=#HP:6X[=&5X="UA;&EG;CIC96YT97(^)FYB6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G M:6XM;&5F=#HP:6X[;6%R9VEN+6QE9G0Z."XX<'0[=&5X="UI;F1E;G0Z+3@N M.'!T/D5X97)C:7-A8FQE(&%S(&]F($1E8V5M8F5R(#,Q+"`R,#$T/"]P/B`\ M+W1D/B`\=&0@=VED=&@],T0Q.24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W=I9'1H.B`Q.2XS-B4[(&)O'0@,2XU<'0[('!A9&1I;F'0M86QI9VXZ6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP M:6X^)#PO<#X@/"]T9#X@/'1D('=I9'1H/3-$,38E('9A;&EG;CTS1&)O='1O M;2!S='EL93TS1"=W:61T:#H@,38N,3(E.R!B;W)D97(Z(&YO;F4[(&)O6QE/3-$;6%R9VEN+7)I9VAT.C!I M;CMM87)G:6XM;&5F=#HP:6X[=&5X="UA;&EG;CIC96YT97(^,BXY,SPO<#X@ M/"]T9#X@/'1D('=I9'1H/3-$,C`E('9A;&EG;CTS1&)O='1O;2!S='EL93TS M1"=W:61T:#H@,C`N-#(E.R!B;W)D97(Z(&YO;F4[(&)O6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM M;&5F=#HP:6X[=&5X="UA;&EG;CIC96YT97(^,BXV,CPO<#X@/"]T9#X@/"]T M3X-"CPO:'1M;#X-"@T*+2TM+2TM/5]. M97AT4&%R=%\T.#,U8F,R-%]C-C1D7S1E-#E?.&9B,5\T9#1A-C5D964S8S@- M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-#@S-6)C,C1?8S8T9%\T M930Y7SAF8C%?-&0T838U9&5E,V,X+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6QE/3-$;6%R M9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN.C!I;CMM87)G M:6XM8F]T=&]M.BXP,#`Q<'0[=&5X="UI;F1E;G0Z+C5I;CY792!H879E(&5N M=&5R960@:6YT;R!C97)T86EN('-E6UE M;G0@:6X@861V86YC92XF;F)S<#LF;F)S<#M792!R96-O9VYI>F4@=&AE6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[ M;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0^)FYB'0M:6YD96YT.BXU M:6X^07,@;V8@1&5C96UB97(@,S$L(#(P,30L($%U9W5S="`S,2P@,C`Q-"!A M;F0@075G=7-T(#,Q+"`R,#$S+"!W92!H860@9&5F97)R960@'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA65A6QE M/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN.C!I M;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0^)FYB'0M86QI9VXZ:G5S=&EF>3MT97AT M+6EN9&5N=#HN-6EN/D%S(&]F($1E8V5M8F5R(#,Q+"`R,#$T+"!T:&4@:&EG M:&5S="!A8V-O=6YT(')E8V5I=F%B;&4@9'5E(&9R;VT@;VYE(&-U2`W,B4@;V8@=&]T86P@86-C;W5N=',@3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\T.#,U M8F,R-%]C-C1D7S1E-#E?.&9B,5\T9#1A-C5D964S8S@-"D-O;G1E;G0M3&]C M871I;VXZ(&9I;&4Z+R\O0SHO-#@S-6)C,C1?8S8T9%\T930Y7SAF8C%?-&0T M838U9&5E,V,X+U=O'0O:'1M;#L@8VAA6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F M=#HP:6X[;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[=&5X="UI M;F1E;G0Z+C5I;CY792!H860@65A2!T&EM871E;'D@-#(E+"`X)2!A;F0@,R4@;V8@=&]T86P@2P@9G)O;2!T:&5S92!R96QA=&5D('!A M7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T* M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA&5S/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\(2TM96=X+2T^/'`@6QE/3-$;6%R9VEN+7)I9VAT M.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M M.BXP,#`Q<'0[=&5X="UA;&EG;CIJ=7-T:69Y/B9N8G-P.SPO<#X@/'`@&5S+B8C,38P.R`\+W`^(#QP('-T M>6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN M.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[=&5X="UI;F1E;G0Z+C5I;CXF M;F)S<#L\+W`^(#QP('-T>6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM M;&5F=#HP:6X[;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[=&5X M="UI;F1E;G0Z+C5I;CY4:&4@:6YC;VUE('1A>"`H<')O=FES:6]N*2!B96YE M9FET(&1I9F9E'0M M:6YD96YT.BXU:6X^)FYB6QE M/3-$8F]R9&5R+6-O;&QA<'-E.F-O;&QA<'-E/B`\='(@86QI9VX],T1L969T M/B`\=&0@=VED=&@],T0R-3(@=F%L:6=N/3-$=&]P('-T>6QE/3-$=VED=&@Z M,3@X+CEP=#MP861D:6YG.C`^(#QP('-T>6QE/3-$;6%R9VEN+7)I9VAT.C!I M;CMM87)G:6XM;&5F=#HP:6X^)FYB6QE/3-$=VED=&@Z.30N-G!T.W!A9&1I M;F'0M86QI9VXZ8V5N=&5R/CQB/C(P,30\+V(^/"]P/B`\+W1D M/B`\=&0@=VED=&@],T0Y-2!V86QI9VX],T1T;W`@6QE/3-$)W=I9'1H.C'0M86QI9VXZ8V5N=&5R/CQB/C(P,3,\+V(^/"]P M/B`\+W1D/B`\+W1R/B`\='(@86QI9VX],T1L969T/B`\=&0@=VED=&@],T0R M-3(@=F%L:6=N/3-$=&]P('-T>6QE/3-$=VED=&@Z,3@X+CEP=#MP861D:6YG M.C`^(#QP('-T>6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP M:6X^)FYB6QE/3-$=VED=&@Z.30N-G!T.W!A9&1I;F'0M86QI9VXZ6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN M+7)I9VAT.BXQ:6X[=&5X="UA;&EG;CIR:6=H=#XF;F)S<#L\+W`^(#PO=&0^ M(#QT9"!W:61T:#TS1#DT('9A;&EG;CTS1'1O<"!S='EL93TS1'=I9'1H.C

6QE/3-$;6%R M9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN+7)I9VAT.BXQ M:6X[=&5X="UA;&EG;CIR:6=H=#XF;F)S<#L\+W`^(#PO=&0^(#PO='(^(#QT M6QE/3-$;6%R9VEN+7)I M9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN+7)I9VAT.C,N-W!T.W1E M>'0M86QI9VXZ6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[ M;6%R9VEN+7)I9VAT.C,N-W!T.W1E>'0M86QI9VXZ6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F M=#HP:6X[;6%R9VEN+7)I9VAT.BXP-6EN.W1E>'0M86QI9VXZ6QE/3-$=VED=&@Z-S`N.#5P=#MP861D M:6YG.C`^(#QP(&%L:6=N/3-$6QE/3-$=VED=&@Z.30N-G!T.W!A9&1I;F'0M86QI9VXZ6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP M:6X[;6%R9VEN+7)I9VAT.C,N-W!T.W1E>'0M86QI9VXZ6QE/3-$=VED=&@Z.30N-G!T.W!A9&1I;F6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM M;&5F=#HP:6X[=&5X="UA;&EG;CIR:6=H=#XH,BPT.#`L,#`P*3PO<#X@/"]T M9#X@/'1D('=I9'1H/3-$.30@=F%L:6=N/3-$=&]P('-T>6QE/3-$=VED=&@Z M-S`N.#5P=#MP861D:6YG.C`^(#QP(&%L:6=N/3-$6QE/3-$=VED M=&@Z,3@X+CEP=#MP861D:6YG.C`^(#QP('-T>6QE/3-$;6%R9VEN+7)I9VAT M.C!I;CMM87)G:6XM;&5F=#HP:6X^3W1H97(\+W`^(#PO=&0^(#QT9"!W:61T M:#TS1#$R-B!V86QI9VX],T1T;W`@6QE/3-$;6%R9VEN M+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN+7)I9VAT.BXP-6EN M.W1E>'0M86QI9VXZ6QE/3-$)W=I9'1H.C'0M86QI9VXZ6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F M=#HP:6X[=&5X="UA;&EG;CIR:6=H=#XD)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q M-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[("@R+#`P M,"D\+W`^(#PO=&0^(#QT9"!W:61T:#TS1#DT('9A;&EG;CTS1'1O<"!S='EL M93TS1"=W:61T:#H@-S`N.#5P=#L@8F]R9&5R.B!N;VYE.R!B;W)D97(M8F]T M=&]M.B!D;W5B;&4@=VEN9&]W=&5X="`Q+C5P=#L@<&%D9&EN9SH@,#LG/B`\ M<"!A;&EG;CTS1')I9VAT('-T>6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G M:6XM;&5F=#HP:6X[=&5X="UA;&EG;CIR:6=H=#XD)B,Q-C`[)B,Q-C`[)B,Q M-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[ M("@Q+#DS."D\+W`^(#PO=&0^(#PO='(^(#PO=&%B;&4^(#QP('-T>6QE/3-$ M;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[=&5X="UI;F1E;G0Z M+C5I;CY$969E'0@ M,2XP<'0[<&%D9&EN9SHP:6X@-2XT<'0@,&EN(#4N-'!T)SX@/'`@86QI9VX] M,T1C96YT97(@6QE/3-$)W=I9'1H.C

6QE/3-$)W=I9'1H.C(Q.2XW-7!T.W!A9&1I M;F6QE/3-$;6%R9VEN+7)I M9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X^0W5R6QE/3-$;6%R9VEN+7)I9VAT M.C!I;CMM87)G:6XM;&5F=#HP:6X[=&5X="UA;&EG;CIR:6=H=#XF;F)S<#L\ M+W`^(#PO=&0^(#QT9"!W:61T:#TS1#DT('9A;&EG;CTS1'1O<"!S='EL93TS M1"=W:61T:#HW,"XV-7!T.W!A9&1I;F6QE/3-$)W=I9'1H M.C'0M86QI9VXZ6QE/3-$)W=I9'1H.C(Q.2XW-7!T.W!A9&1I;F6QE/3-$)W=I9'1H.C6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[ M;6%R9VEN+7)I9VAT.BXP-6EN.W1E>'0M86QI9VXZ6QE/3-$)W=I9'1H.C(Q.2XW M-7!T.W!A9&1I;F6QE/3-$ M;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X^)B,Q-C`[)B,Q-C`[ M($EN=F5N=&]R:65S/"]P/B`\+W1D/B`\=&0@=VED=&@],T0Q,#(@=F%L:6=N M/3-$=&]P('-T>6QE/3-$)W=I9'1H.C6QE/3-$)W=I9'1H.C6QE/3-$)W=I9'1H.C6QE/3-$)W=I9'1H.C'0@,2XU<'0[<&%D9&EN9SHP:6X@-2XT<'0@,&EN(#4N M-'!T)SX@/'`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`[($YE="!O<&5R871I;F<@;&]S69O6QE/3-$;6%R9VEN+7)I9VAT.C!I M;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN+7)I9VAT.BXP-6EN.W1E>'0M86QI M9VXZ6QE M/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN+7)I M9VAT.BXP-6EN.W1E>'0M86QI9VXZ6QE/3-$)W=I9'1H.C6QE M/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN+7)I M9VAT.BXP-6EN.W1E>'0M86QI9VXZ6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F M=#HP:6X[;6%R9VEN+7)I9VAT.BXP-6EN.W1E>'0M86QI9VXZ'0@,2XP<'0[<&%D M9&EN9SHP:6X@-2XT<'0@,&EN(#4N-'!T)SX@/'`@86QI9VX],T1R:6=H="!S M='EL93TS1&UA'0M M86QI9VXZ'0@,2XP M<'0[<&%D9&EN9SHP:6X@-2XT<'0@,&EN(#4N-'!T)SX@/'`@86QI9VX],T1R M:6=H="!S='EL93TS1&UA'0M86QI9VXZ'0@,2XP<'0[<&%D9&EN9SHP:6X@-2XT<'0@,&EN(#4N-'!T)SX@/'`@86QI M9VX],T1R:6=H="!S='EL93TS1&UA'0M86QI9VXZ6QE/3-$)W=I9'1H.C(Q.2XW-7!T.W!A9&1I;F6QE/3-$)W=I9'1H.C6QE/3-$)W=I9'1H.C6QE/3-$)W=I9'1H M.C'0@,2XU<'0[<&%D9&EN9SHP:6X@-2XT<'0@,&EN(#4N M-'!T)SX@/'`@86QI9VX],T1R:6=H="!S='EL93TS1&UA6QE/3-$)W=I9'1H.C6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP M:6X[;6%R9VEN+7)I9VAT.C,N-W!T.W1E>'0M86QI9VXZ"!L87=S(&EN(&5F M9F5C="P@;W5R(&9U='5R92!E87)N:6YG2!T:&%N(&YO="!T M:&%T(&]U'0M:6YD M96YT.BXU:6X^)FYB'0M:6YD96YT.BXU:6X^26X@861D:71I;VX@=&\@=&AE(&1E M9F5R"!A2!H M87,@=6YR96-O2`D M,BPV,#`L,#`P(&%T=')I8G5T86)L92!T;R!T:&4@9&EF9F5R96YC92!B971W M965N('1H92!A;6]U;G0@;V8@=&AE(&9I;F%N8VEA;"!S=&%T96UE;G0@97AP M96YS92!A;F0@=&AE(&%L;&]W86)L92!T87@@9&5D=6-T:6]N(&%SF4@=&AE M(&5X8V5S6%B;&4N)FYB28C M,30V.W,@;F5T(&]P97)A=&EN9R!L;W-S(&-A6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM M87)G:6XM;&5F=#HP:6X[;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q M<'0^)FYB'0M:6YD96YT.BXU:6X^07,@;V8@1&5C96UB97(@,S$L(#(P,30L('=E M(&AA9"!A(&YE="!O<&5R871I;F<@;&]S69O'!I MF5D+CPO<#X@/'`@6QE/3-$;6%R9VEN M+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN.C!I;CMM87)G:6XM M8F]T=&]M.BXP,#`Q<'0[=&5X="UI;F1E;G0Z+C5I;CY792!P97)F;W)M(&$@ M"!P;W-I=&EO;B!W:6QL(&)E('-U2UT:&%N+6YO M="!T:')E2!H860@;F\@=6YR96-O M9VYI>F5D('1A>"!B96YE9FET('1H870@=V]U;&0@869F96-T(&ET6QE/3-$ M;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN.C!I;CMM M87)G:6XM8F]T=&]M.BXP,#`Q<'0^)FYB'0M:6YD96YT.BXU:6X^5V4@8VQA6UE;G0@;V8@:6YC;VUE('1A>&5S(&EN(&]U"!P;W-I=&EO;G,N/"]P/B`\<"!S='EL93TS1&UA"!R971U'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/"$M M+65G>"TM/CQP('-T>6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F M=#HP:6X[;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0^/&(^3F]T M92`Q,CHF;F)S<#LF;F)S<#M3=&]C:RU"87-E9"!#;VUP96YS871I;VX\+V(^ M/"]P/B`\<"!S='EL93TS1&UA&-E<'1I;VX@;V8@=&AE($%U9&ET($-O;6UI M='1E92!#:&%I65A&5R8VES92!P'!I65A M6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN M.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[=&5X="UI;F1E;G0Z+C5I;CY3 M=&]C:RUB87-E9"!C;VUP96YS871I;VX@8V]S="!I'!E8W1E9"!T;R!V97-T+"!A M;GD@<')E=FEO=7-L>2!R96-O9VYI>F5D('-T;V-K(&-O;7!E;G-A=&EO;B!E M>'!E;G-E(&ES(')E=F5R'!E;G-E M(&%S(&9O;&QO=W,Z/"]P/B`\<"!S='EL93TS1&UA'0M:6YD96YT.BXU:6X^)FYB6QE/3-$;6%R9VEN+6QE9G0Z-2XT<'0[8F]R9&5R+6-O;&QA<'-E M.F-O;&QA<'-E/B`\='(^(#QT9"!W:61T:#TS1#(R-R!V86QI9VX],T1T;W`@ M6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G M:6XM;&5F=#HP:6X^)FYB6QE/3-$)W=I9'1H M.B`Q-#$N-S5P=#L@<&%D9&EN9SH@,&EN(#4N-'!T(#!I;B`U+C1P=#LG/B`\ M<"!A;&EG;CTS1&-E;G1E6QE/3-$)W=I9'1H.B`Q-S`N,#5P=#L@<&%D9&EN9SH@,&EN(#4N-'!T M(#!I;B`U+C1P=#LG/B`\<"!S='EL93TS1&UA6QE/3-$)W=I9'1H.B`W,"XY<'0[(&)O6QE/3-$)W=I9'1H.B`W,"XY<'0[(&)O6QE/3-$)W=I M9'1H.B`W,"XX-7!T.R!B;W)D97(Z(&YO;F4[(&)O'0@,2XP<'0[('!A9&1I;F6QE/3-$)W=I9'1H M.B`W,"XY<'0[(&)O6QE/3-$;6%R9VEN+7)I M9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN+7)I9VAT.BXP-6EN.W1E M>'0M86QI9VXZ6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM M;&5F=#HP:6X[;6%R9VEN+7)I9VAT.BXP-6EN.W1E>'0M86QI9VXZ6QE/3-$;6%R9VEN M+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X^0V]S="!O9B!S86QE6QE/3-$ M)W=I9'1H.B`W,"XY<'0[('!A9&1I;F6QE/3-$;6%R9VEN M+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN+7)I9VAT.BXP-6EN M.W1E>'0M86QI9VXZ6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN M+7)I9VAT.BXP-6EN.W1E>'0M86QI9VXZ6QE/3-$)W=I9'1H.C6QE/3-$;6%R9VEN+7)I M9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN+7)I9VAT.BXP-6EN.W1E M>'0M86QI9VXZ6QE/3-$)W=I9'1H.C6QE/3-$)W=I9'1H.C'0@,2XP<'0[<&%D9&EN9SHP M:6X@-2XT<'0@,&EN(#4N-'!T)SX@/'`@86QI9VX],T1R:6=H="!S='EL93TS M1&UA6QE M/3-$)W=I9'1H.C$W,"XP-7!T.W!A9&1I;F6QE/3-$;6%R9VEN+7)I M9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN+7)I9VAT.BXP-6EN.W1E M>'0M86QI9VXZ6QE/3-$)W=I9'1H.C$W,"XP-7!T.W!A9&1I;F6QE/3-$ M;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN+7)I9VAT M.BXP-6EN.W1E>'0M86QI9VXZ'0@,2XU<'0[<&%D9&EN9SHP:6X@-2XT M<'0@,&EN(#4N-'!T)SX@/'`@86QI9VX],T1R:6=H="!S='EL93TS1&UA6QE/3-$)W=I9'1H.C6QE/3-$;6%R M9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN+7)I9VAT.BXP M-6EN.W1E>'0M86QI9VXZ6QE/3-$;6%R9VEN+7)I9VAT.C!I M;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP M,#`Q<'0[=&5X="UI;F1E;G0Z+C5I;CXF;F)S<#L\+W`^(#QP('-T>6QE/3-$ M;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN.C!I;CMM M87)G:6XM8F]T=&]M.BXP,#`Q<'0[=&5X="UI;F1E;G0Z+C5I;CY$=7)I;F<@ M=&AE(&9O=7(@;6]N=&AS(&5N9&5D($1E8V5M8F5R(#,Q+"`R,#$T+"!W92!G M&5R8VES92!P65A'0@=&AR964@ M>65A6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X^)FYB M3PO<#X@ M/"]T9#X@/'1D('=I9'1H/3-$,3(Q('9A;&EG;CTS1&)O='1O;2!S='EL93TS M1"=W:61T:#H@.3`N-#5P=#L@<&%D9&EN9SH@,#LG/B`\<"!A;&EG;CTS1&-E M;G1E'0M86QI9VXZ8V5N=&5R/C8R+CDV)3PO<#X@/"]T9#X@/"]T6QE/3-$)W=I9'1H M.B`R-C$N-#5P=#L@<&%D9&EN9SH@,#LG/B`\<"!S='EL93TS1&UA'0M:6YD96YT.BTX+CAP=#Y%>'!E8W1E9"!D:79I9&5N9',\+W`^(#PO=&0^ M(#QT9"!W:61T:#TS1#$R,2!V86QI9VX],T1B;W1T;VT@6QE/3-$)W=I9'1H.B`R-C$N M-#5P=#L@<&%D9&EN9SH@,#LG/B`\<"!S='EL93TS1&UA'0M:6YD M96YT.BTX+CAP=#Y%>'!E8W1E9"!T97)M/"]P/B`\+W1D/B`\=&0@=VED=&@] M,T0Q,C$@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Y,"XT-7!T M.R!P861D:6YG.B`P.R<^(#QP(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$;6%R M9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[=&5X="UA;&EG;CIC96YT M97(^-RXR-"!996%R6QE/3-$)W=I9'1H.B`R-C$N-#5P=#L@ M<&%D9&EN9SH@,#LG/B`\<"!S='EL93TS1&UA'0M:6YD96YT.BTX M+CAP=#Y2:7-K+69R964@:6YT97)E'0M86QI9VXZ M8V5N=&5R/C(N,#6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R M9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[=&5X="UI;F1E;G0Z+C5I M;CY4:&4@97AP96-T960@=F]L871I;&ET>2!R871E('=A2!O9B!O=7(@8V]M M;6]N('-T;V-K+B9N8G-P.R9N8G-P.R9N8G-P.U1H92!E>'!E8W1E9"!T97)M M('=A'!E&5R8VES92!A;F0@9F]R9F5I='5R97,N)FYB M2!4 M2!9:65L9"!#=7)V92!2871E2!R969E2!428C,30X.R!R M871E(&EN(&5F9F5C="!A="!T:&4@=&EM92!O9B!G'0M86QI9VXZ'0M:6YD96YT.BXU:6X^56YR96-O M9VYI>F5D('-T;V-K+6)A'!E;G-E(&5X<&5C M=&5D('1O(&)E(')E8V]G;FEZ960@;W9E2!O9B!T:&4@=&EM92UB87-E M9"!S=&]C:R!O<'1I;VX@87=A'0M:6YD M96YT.BXU:6X^)FYB'0@,2XP<'0[('!A9&1I;F6QE/3-$ M)W=I9'1H.B`Q-2XW)3L@8F]R9&5R.B!N;VYE.R!B;W)D97(M8F]T=&]M.B!S M;VQI9"!W:6YD;W=T97AT(#$N,'!T.R!P861D:6YG.B`P.R<^(#QP('-T>6QE M/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X^/&(^5V5I9VAT M960M($%V97)A9V4@)B,Q-C`[17AE6QE/3-$)W=I M9'1H.B`Q."XV-"4[(&)O6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM M;&5F=#HP:6X^/&(^06=G'0M:6YD96YT.BTX+CAP=#XF M;F)S<#L\+W`^(#PO=&0^(#QT9"!W:61T:#TS1#$V)2!V86QI9VX],T1B;W1T M;VT@6QE/3-$;6%R9VEN+7)I M9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[=&5X="UA;&EG;CIC96YT97(^)FYB M6QE/3-$;6%R M9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[=&5X="UA;&EG;CIC96YT M97(^)FYB6QE/3-$)W=I9'1H.B`Q."XV-"4[(&)O6QE/3-$)W=I9'1H.B`Q+C`E.R!B;W)D97(Z(&YO;F4[('!A9&1I M;F6QE/3-$;6%R9VEN+7)I9VAT.C!I M;CMM87)G:6XM;&5F=#HP:6X^)FYB6QE/3-$)W=I M9'1H.B`Q+CDV)3L@8F]R9&5R.B!N;VYE.R!P861D:6YG.B`P.R<^(#QP(&%L M:6=N/3-$6QE/3-$)W=I9'1H.B`Q+C`E.R!B;W)D97(Z(&YO M;F4[('!A9&1I;F'0M86QI9VXZ6QE/3-$)W=I9'1H.B`Q,2XW."4[(&)O6QE/3-$;6%R9VEN M+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[=&5X="UA;&EG;CIR:6=H=#XF M;F)S<#L\+W`^(#PO=&0^(#PO='(^(#QT'0M:6YD M96YT.BTX+CAP=#Y'6QE/3-$)W=I9'1H.B`Q-BXV."4[(&)O6QE M/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN+7)I M9VAT.BXR:6X[=&5X="UA;&EG;CIR:6=H=#XQ,C'0M86QI9VXZ6QE/3-$)W=I9'1H.B`Q,RXW M-"4[(&)O6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[ M=&5X="UA;&EG;CIR:6=H=#XQ+C$Y/"]P/B`\+W1D/B`\=&0@=VED=&@],T0Q M."4@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q."XV-"4[(&)O M6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[=&5X="UA M;&EG;CIR:6=H=#XF;F)S<#L\+W`^(#PO=&0^(#QT9"!W:61T:#TS1#$E('9A M;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,2XP)3L@8F]R9&5R.B!N M;VYE.R!P861D:6YG.B`P.R<^(#QP(&%L:6=N/3-$'0M86QI9VXZ6QE/3-$)W=I9'1H.B`Q-BXV."4[(&)O M6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN M+7)I9VAT.BXR:6X[=&5X="UA;&EG;CIR:6=H=#XM/"]P/B`\+W1D/B`\=&0@ M=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT@'0M86QI9VXZ6QE/3-$)W=I9'1H.B`Q,RXW-"4[ M(&)O6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[=&5X M="UA;&EG;CIR:6=H=#XF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#L@ M+3PO<#X@/"]T9#X@/'1D('=I9'1H/3-$,3@E('9A;&EG;CTS1&)O='1O;2!S M='EL93TS1"=W:61T:#H@,3@N-C0E.R!B;W)D97(Z(&YO;F4[('!A9&1I;F'0M86QI9VXZ6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G M:6XM;&5F=#HP:6X[=&5X="UA;&EG;CIR:6=H=#XF;F)S<#L\+W`^(#PO=&0^ M(#QT9"!W:61T:#TS1#$Q)2!V86QI9VX],T1B;W1T;VT@6QE/3-$)W=I9'1H.B`S-BXR)3L@8F]R9&5R.B!N M;VYE.R!P861D:6YG.B`P.R<^(#QP('-T>6QE/3-$;6%R9VEN+7)I9VAT.C!I M;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN+6QE9G0Z."XX<'0[=&5X="UI;F1E M;G0Z+3@N.'!T/D9O'!I6QE/3-$)W=I9'1H.B`Q M-BXV."4[(&)O6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R M9VEN+7)I9VAT.C$Q+C,U<'0[=&5X="UA;&EG;CIR:6=H=#XH-#6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM M87)G:6XM;&5F=#HP:6X[=&5X="UA;&EG;CIR:6=H=#XF;F)S<#L\+W`^(#PO M=&0^(#QT9"!W:61T:#TS1#$S)2!V86QI9VX],T1B;W1T;VT@6QE/3-$)W=I9'1H.B`Q+C`E M.R!B;W)D97(Z(&YO;F4[('!A9&1I;F6QE/3-$)W=I9'1H.B`Q,2XW."4[(&)O M6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[=&5X="UA M;&EG;CIR:6=H=#XF;F)S<#L\+W`^(#PO=&0^(#PO='(^(#QT'0M:6YD96YT.BTX+CAP=#XF;F)S<#L\+W`^(#PO=&0^(#QT9"!W M:61T:#TS1#$V)2!V86QI9VX],T1B;W1T;VT@6QE M/3-$)W=I9'1H.B`Q+CDV)3L@8F]R9&5R.B!N;VYE.R!P861D:6YG.B`P.R<^ M(#QP(&%L:6=N/3-$'0M86QI9VXZ6QE/3-$)W=I9'1H M.B`Q."XV-"4[(&)O6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F M=#HP:6X[=&5X="UA;&EG;CIR:6=H=#XF;F)S<#L\+W`^(#PO=&0^(#QT9"!W M:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,2XP M)3L@8F]R9&5R.B!N;VYE.R!P861D:6YG.B`P.R<^(#QP(&%L:6=N/3-$6QE/3-$)W=I9'1H.B`Q-BXV."4[(&)O6QE/3-$;6%R M9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN+7)I9VAT.BXR M:6X[=&5X="UA;&EG;CIR:6=H=#XS+#@V,BPY,C`\+W`^(#PO=&0^(#QT9"!W M:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,2XY M-B4[(&)O6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[ M=&5X="UA;&EG;CIR:6=H=#XF;F)S<#L\+W`^(#PO=&0^(#QT9"!W:61T:#TS M1#$S)2!V86QI9VX],T1B;W1T;VT@'0M M:6YD96YT.BTX+CAP=#Y'6QE/3-$)W=I9'1H.B`Q-BXV."4[(&)O M6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN M+7)I9VAT.BXR:6X[=&5X="UA;&EG;CIR:6=H=#XQ+#0U,"PP,#`\+W`^(#PO M=&0^(#QT9"!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W M:61T:#H@,2XY-B4[(&)O6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM M;&5F=#HP:6X[=&5X="UA;&EG;CIR:6=H=#XF;F)S<#L\+W`^(#PO=&0^(#QT M9"!W:61T:#TS1#$S)2!V86QI9VX],T1B;W1T;VT@6QE/3-$)W=I9'1H.B`Q+C`E.R!B;W)D M97(Z(&YO;F4[('!A9&1I;F'0M86QI M9VXZ6QE/3-$)W=I9'1H.B`Q,2XW."4[(&)O6QE/3-$ M;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN+7)I9VAT M.BXQ:6X[=&5X="UA;&EG;CIR:6=H=#XF;F)S<#L\+W`^(#PO=&0^(#PO='(^ M(#QT'0M:6YD96YT.BTX+CAP=#Y%>&5R8VES960\ M+W`^(#PO=&0^(#QT9"!W:61T:#TS1#$V)2!V86QI9VX],T1B;W1T;VT@6QE/3-$;6%R9VEN+7)I M9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[=&5X="UA;&EG;CIR:6=H=#XF;F)S M<#L\+W`^(#PO=&0^(#QT9"!W:61T:#TS1#$S)2!V86QI9VX],T1B;W1T;VT@ M6QE/3-$)W=I9'1H.B`Q."XV-"4[ M(&)O6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[=&5X M="UA;&EG;CIR:6=H=#XF;F)S<#L\+W`^(#PO=&0^(#QT9"!W:61T:#TS1#$E M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,2XP)3L@8F]R9&5R M.B!N;VYE.R!P861D:6YG.B`P.R<^(#QP(&%L:6=N/3-$'0M86QI9VXZ'0M M86QI9VXZ'0M86QI M9VXZ6QE/3-$)W=I9'1H.B`Q,RXW-"4[(&)O6QE/3-$ M;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[=&5X="UA;&EG;CIR M:6=H=#XQ+C4T/"]P/B`\+W1D/B`\=&0@=VED=&@],T0Q."4@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q."XV-"4[(&)O6QE/3-$;6%R9VEN M+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[=&5X="UA;&EG;CIR:6=H=#XF M;F)S<#L\+W`^(#PO=&0^(#QT9"!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O M;2!S='EL93TS1"=W:61T:#H@,2XP)3L@8F]R9&5R.B!N;VYE.R!P861D:6YG M.B`P.R<^(#QP(&%L:6=N/3-$'0M86QI9VXZ M6QE/3-$)W=I9'1H.B`Q-BXV."4[ M(&)O6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R M9VEN+7)I9VAT.C$T+C)P=#MT97AT+6%L:6=N.G)I9VAT/B9N8G-P.SPO<#X@ M/"]T9#X@/'1D('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W=I9'1H.B`Q+CDV)3L@8F]R9&5R.B!N;VYE.R!P861D:6YG.B`P.R<^(#QP M(&%L:6=N/3-$'0M86QI9VXZ6QE/3-$)W=I9'1H.B`Q M."XV-"4[(&)O6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP M:6X[=&5X="UA;&EG;CIR:6=H=#XF;F)S<#L\+W`^(#PO=&0^(#QT9"!W:61T M:#TS1#$E('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,2XP)3L@ M8F]R9&5R.B!N;VYE.R!P861D:6YG.B`P.R<^(#QP(&%L:6=N/3-$'0M86QI9VXZ6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R M9VEN+7)I9VAT.C$T+C)P=#MT97AT+6%L:6=N.G)I9VAT/C4L,3,Q+#DQ.3PO M<#X@/"]T9#X@/'1D('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W=I9'1H.B`Q+CDV)3L@8F]R9&5R.B!N;VYE.R!B;W)D97(M8F]T=&]M M.B!D;W5B;&4@=VEN9&]W=&5X="`Q+C5P=#L@<&%D9&EN9SH@,#LG/B`\<"!A M;&EG;CTS1')I9VAT('-T>6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM M;&5F=#HP:6X[=&5X="UA;&EG;CIR:6=H=#XD/"]P/B`\+W1D/B`\=&0@=VED M=&@],T0Q,R4@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q,RXW M-"4[(&)O'0@,2XU<'0[('!A9&1I;F6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM M87)G:6XM;&5F=#HP:6X[=&5X="UA;&EG;CIR:6=H=#XD/"]P/B`\+W1D/B`\ M=&0@=VED=&@],T0Q,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H M.B`Q,2XW."4[(&)O'0@,2XU<'0[('!A9&1I;F'0M86QI9VXZ6QE/3-$)W=I9'1H.B`S-BXR)3L@8F]R9&5R.B!N;VYE.R!P861D:6YG M.B`P.R<^(#QP('-T>6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F M=#HP:6X[;6%R9VEN+6QE9G0Z."XX<'0[=&5X="UI;F1E;G0Z+3@N.'!T/D5X M97)C:7-A8FQE(&%S(&]F($1E8V5M8F5R(#,Q+"`R,S`Q-#PO<#X@/"]T9#X@ M/'1D('=I9'1H/3-$,38E('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T M:#H@,38N-C@E.R!B;W)D97(Z(&YO;F4[(&)O6QE/3-$)W=I9'1H.B`Q+CDV)3L@8F]R9&5R.B!N;VYE.R!B;W)D97(M8F]T M=&]M.B!D;W5B;&4@=VEN9&]W=&5X="`Q+C5P=#L@<&%D9&EN9SH@,#LG/B`\ M<"!A;&EG;CTS1')I9VAT('-T>6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G M:6XM;&5F=#HP:6X[=&5X="UA;&EG;CIR:6=H=#XD/"]P/B`\+W1D/B`\=&0@ M=VED=&@],T0Q,R4@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q M,RXW-"4[(&)O'0@,2XU<'0[('!A9&1I;F6QE/3-$;6%R9VEN+7)I9VAT.C!I M;CMM87)G:6XM;&5F=#HP:6X[=&5X="UA;&EG;CIR:6=H=#XD/"]P/B`\+W1D M/B`\=&0@=VED=&@],T0Q,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I M9'1H.B`Q,2XW."4[(&)O'0@,2XU<'0[('!A9&1I;F'0M86QI9VXZ2!T:&4@:&]L9&5R6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R M9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0^)FYB7!E.B!T M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT M96YT/3-$)W1E>'0O:'1M;#L@8VAA6QE/3-$;6%R9VEN M+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN.C!I;CMM87)G:6XM M8F]T=&]M.BXP,#`Q<'0^)FYB'0M:6YD96YT.BXU:6X^5V4@<&%I9"!N;R!A;6]U M;G0@9F]R(&EN=&5R97-T(&1U6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN M.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[=&5X="UI;F1E;G0Z+C5I;CY7 M92!H860@;F\@;F]N+6-A65A'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0M:6YD96YT.BXU:6X^)FYB'0M:6YD96YT.BXU:6X^3VX@2F%N=6%R M>2`Y+"`R,#$U+"!W92!E;G1E2!A="`D,S4P+#`P,"P@=VET:"!A(')E=FEE=R!A="!L96%S="!A;FYU M86QL>2!B>2!T:&4@0V]M<&5N65A2!O9B!C M;VUP96YS871I;VX@;V8@0T5/)B,Q-#8[2P@=VAI8V@@28C,30V.W,@8V]M;6]N('-T;V-K(&]N($YO=F5M8F5R(#$P+"`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`Q<'0^)FYB'0M:6YD96YT.BXU:6X^5&AE($-O;7!A;GDF(S$T-CMS(&9O M6UE;G0@86=R965M96YT+B9N8G-P.R9N8G-P.U!U2!R96%S;VX@*&]T:&5R('1H86X@9F]R(&-A=7-E*2P@=&AE($-O M;7!A;GD@=VEL;"!P87D@=&\@37(N(%=O;&-O='0@86X@86UO=6YT(&5Q=6%L M('1O(&AI2!A=V%R9',@=VEL;"!I;6UE9&EA=&5L>2!V97-T(&%N M9"!B96-O;64@97AE6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R M9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0^)FYB'0M:6YD96YT.BXU:6X^ M3VX@4V5P=&5M8F5R(#$V+"`R,#$T+"!T:&4@0V]M<&%N>2!E;G1E2!A;FYU86P@ M:6YC96YT:79E(&)O;G5S('!R;V=R86US+"!E;7!L;WEE92!B96YE9FET('!L M86YS(&%D;W!T960@;W(@;6%I;G1A:6YE9"!B>2!T:&4@0V]M<&%N>2P@86YD M('1H92!#;VUP86YY)B,Q-#8[2!I;G-U"!Y96%R2!T:&4@0V]M<&%N>2!O=&AE2!I2!R96%S;VX@;V8@:&ES M(&1E871H+"!H:7,@97-T871E('-H86QL(')E8V5I=F4@:&ES('-A;&%R>2!T M:')O=6=H('1H92!E;F0@;V8@=&AE(&UO;G1H(&EN('=H:6-H(&AE(&1I960@ M<&QU2!T97)M:6YA=&5S M(&AI;2!W:71H;W5T(&-A=7-E.R`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`Q<'0[=&5X="UI;F1E;G0Z+C5I;CXF;F)S<#L\+W`^(#QP('-T>6QE M/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN.C!I M;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[=&5X="UI;F1E;G0Z+C5I;CY/;B!$ M96-E;6)E2!I65E("AI;F-L=61I;F<@;65D:6-A;"!I;G-U65A2!F;W(@=&AE M(#$R+6UO;G1H('!E2!P65A6UE;G1S(&9O7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^/"$M+65G>"TM/CQP('-T>6QE M/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN.C!I M;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0^/&(^3F]T92`Q-3HF;F)S<#LF;F)S M<#M296-E;G0@06-C;W5N=&EN9R!06QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R M9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0^)FYB2`R,#$T+"!&05-"(&ES2US<&5C:69I8R!G=6ED86YC92P@86YD(&-R96%T97,@82!4;W!I M8R`V,#8@/&D^4F5V96YU92!F&-H86YG92!F;W(@=&AO2!T:&4@9F]L;&]W:6YG('-T97!S M.CPO<#X@/'`@6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP M:6X[;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0^)FYBF4@2!S871I6QE/3-$;6%R M9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN.C!I;CMM87)G M:6XM8F]T=&]M.BXP,#`Q<'0[=&5X="UI;F1E;G0Z+C5I;CY!4U4@,C`Q-"TP M.2!I'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0M:6YD96YT M.BXU:6X^)FYB'0M:6YD96YT.BXU:6X^3VX@2F%N=6%R>2`Q-2P@,C`Q-2P@=&AE M($-O;7!A;GD@96YT97)E9"!I;G1O(&%N(&5M<&QO>6UE;G0@86=R965M96YT M('=I=&@@:71S($-L:6YT;VX@12X@0V%R;F5L;"P@2G(N+"!T;R!S97)V92!A M2`Q-BP@,C`Q M-2P@=&AE($-O;7!A;GD@96YT97)E9"!I;G1O(&%N(&5M<&QO>6UE;G0@86=R M965M96YT('=I=&@@0F5N:F%M:6X@0F5C:VAA;2!T;R!S97)V92!A'0M:6YD96YT.BXU:6X^ M)FYB'0M:6YD96YT.BXU:6X^169F96-T:79E($9E8G)U87)Y(#$V+"`R,#$U+"!T M:&4@0V]M<&%N>2!E;G1E'0M:6YD96YT.BXU:6X^)FYB M'0M M:6YD96YT.BXU:6X^169F96-T:79E($9E8G)U87)Y(#$W+"`R,#$U+"!T:&4@ M0V]M<&%N>2!E;G1E2`R,"P@,C`Q-2P@4&5R'0M:6YD96YT.BXU M:6X^)FYB'0M:6YD96YT.BXU:6X^3VX@1F5B2!N;W1E('=I=&@@86X@87-S M970@;&5N9&5R+"!I;B!T:&4@86UO=6YT(&]F("0W-3`L,#`P+B8C,38P.R8C M,38P.R!4:&4@;F]T92!I2!P87EM96YT2`R-"P@,C`Q-BX\+W`^(#QP('-T>6QE/3-$;6%R9VEN M+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN.C!I;CMM87)G:6XM M8F]T=&]M.BXP,#`Q<'0[=&5X="UI;F1E;G0Z+C5I;CXF;F)S<#L\+W`^(#QP M('-T>6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R M9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[=&5X="UI;F1E;G0Z+C5I M;CY4:&4@0V]M<&%N>2!H87,@979A;'5A=&5D(&]T:&5R(&5V96YT6EN9R!B86QA M;F-E('-H965T6QE M/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN.C!I M;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0^)FYB7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAAF%T:6]N(&%N9"!" M=7-I;F5S'0M:6YD M96YT.BXU:6X^/&(^3W)G86YI>F%T:6]N(&%N9"!"=7-I;F5S2`R,#$U+"!W92!C:&%N M9V5D('1H92!N86UE(&]F('1H92!#;VUP86YY('1O(%!E2!T M:&%T(&1E=F5L;W!S+"!M86YU9F%C='5R97,L(&UA7-T96T@96UP;&]Y'1E;G-I=F4@:6YT96QL96-T=6%L('!R;W!E'0O:F%V87-C M3X-"B`@("`\=&%B;&4@ M8VQA'0M:6YD96YT.BXU M:6X^/&(^1FEN86YC:6%L(%)E<&]R=&EN9R!097)I;V0@)B,Q-3`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`Q<'0[=&5X="UI;F1E;G0Z+C5I;CX\8CY# M87-H(&%N9"!#87-H($5Q=6EV86QE;G1S/"]B/B`F(S$U,#L@0V%S:"!A;F0@ M8V%S:"!E<75I=F%L96YT2!O M9B!T:')E92!M;VYT:',@;W(@;&5S3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\T.#,U8F,R-%]C-C1D M7S1E-#E?.&9B,5\T9#1A-C5D964S8S@-"D-O;G1E;G0M3&]C871I;VXZ(&9I M;&4Z+R\O0SHO-#@S-6)C,C1?8S8T9%\T930Y7SAF8C%?-&0T838U9&5E,V,X M+U=O'0O M:'1M;#L@8VAAF%T:6]N(&%N9"!3:6=N M:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S.B!!8V-O=6YT'0^/"$M+65G>"TM/CQP('-T M>6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN M.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[=&5X="UI;F1E;G0Z+C5I;CX\ M8CY!8V-O=6YT2!B87-I2!U2!W7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@ M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^/"$M+65G>"TM/CQP('-T>6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G M:6XM;&5F=#HP:6X[;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[ M=&5X="UI;F1E;G0Z+C5I;CX\8CY);G9E;G1OF%B;&4@=F%L=64N)FYB7!E.B!T97AT+VAT;6P[ M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@ M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E M>'0O:'1M;#L@8VAA'0M:6YD96YT.BXU:6X^ M/&(^4')O<&5R='D@86YD($5Q=6EP;65N=#PO8CX@)B,Q-3`[(%!R;W!E6QE/3-$)W=I9'1H.C$R M-BXQ<'0[<&%D9&EN9SHP:6X@-2XT<'0@,&EN(#4N-'!T)SX@/'`@6QE/3-$)W=I9'1H.C0U+C!P=#MP861D:6YG.C!I;B`U+C1P="`P M:6X@-2XT<'0G/B`\<"!S='EL93TS1&UA'0M86QI9VXZ65A6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X^ M)FYB6QE/3-$)W=I9'1H.C$N-S5I;CMP861D:6YG.C!I;B`U+C1P="`P:6X@ M-2XT<'0G/B`\<"!A;&EG;CTS1')I9VAT('-T>6QE/3-$;6%R9VEN+7)I9VAT M.C!I;CMM87)G:6XM;&5F=#HP:6X[=&5X="UA;&EG;CIR:6=H=#XT,"!Y96%R M6QE/3-$;6%R9VEN+7)I M9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN.C!I;CMM87)G:6XM8F]T M=&]M.BXP,#`Q<'0[=&5X="UI;F1E;G0Z+C5I;CY%>'!E;F1I='5R97,@9F]R M(&UA:6YT96YA;F-E(&%N9"!R97!A:7)S(&%R92!E>'!E;G-E9"!W:&5N(&EN M8W5R2!A M;F0@97%U:7!M96YT(&%R92!R969L96-T960@:6X@;W!E6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[ M;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0^)FYB'0M:6YD96YT.BXU M:6X^5&AE(&-O2!A;F0@97%U:7!M96YT('-O;&0@;W(@;W1H97)W:7-E(')E=&ER M960@87)E(')E;6]V960@9G)O;2!T:&4@86-C;W5N=',@86YD(&%N>2!R96QA M=&5D(&=A:6X@;W(@;&]S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'1087)T7S0X,S5B M8S(T7V,V-&1?-&4T.5\X9F(Q7S1D-&$V-61E93-C.`T*0V]N=&5N="U,;V-A M=&EO;CH@9FEL93HO+R]#.B\T.#,U8F,R-%]C-C1D7S1E-#E?.&9B,5\T9#1A M-C5D964S8S@O5V]R:W-H965T'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!297-E6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN M.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[=&5X="UI;F1E;G0Z+C5I;CX\ M8CY787)R86YT>2!297-E'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/"$M+65G>"TM/CQP('-T>6QE M/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN.C!I M;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[=&5X="UI;F1E;G0Z+C5I;CX\8CY) M;F-O;64@5&%X97,\+V(^("8C,34P.R!792!A8V-O=6YT(&9O"!R871E'!E8W1E9"!T;R!A<'!L>2!T;R!T87AA8FQE(&EN8V]M92!I;B!T:&4@>65A M'!E8W1E9"!T;R!B92!R96-O=F5R960@;W(@"!A"!R871EF5D M(&EN(&EN8V]M92!I;B!T:&4@<&5R:6]D('1H870@:6YC;'5D97,@=&AE(&5N M86-T;65N="!D871E+CPO<#X\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/"$M+65G>"TM/CQP M('-T>6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R M9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[=&5X="UI;F1E;G0Z+C5I M;CX\8CY);F-O;64@*$QO65A M6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F M=#HP:6X[;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[=&5X="UI M;F1E;G0Z+C5I;CXF;F)S<#L\+W`^(#QP('-T>6QE/3-$;6%R9VEN+7)I9VAT M.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M M.BXP,#`Q<'0[=&5X="UI;F1E;G0Z+C5I;CY4:&4@8V]M<'5T871I;VX@;V8@ M9&EL=71E9"!E87)N:6YG&5R8VES M92!O9B!S=&]C:R!O<'1I;VYS(&%N9"!W87)R86YT&-L=61E9"!F6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G M:6XM;&5F=#HP:6X[;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[ M=&5X="UI;F1E;G0Z+C5I;CXF;F)S<#L\+W`^(#QP('-T>6QE/3-$;6%R9VEN M+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN.C!I;CMM87)G:6XM M8F]T=&]M.BXP,#`Q<'0[=&5X="UI;F1E;G0Z+C5I;CY3:6YC92!W92!H860@ M;F\@9&EL=71I=F4@969F96-T(&]F('-T;V-K(&]P=&EO;G,@86YD('=A7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@ M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M M;#L@8VAA2!P'!E M;G-E7)O;&P@97AP96YS92XF;F)S<#L\+W`^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\T.#,U8F,R-%]C-C1D7S1E-#E?.&9B M,5\T9#1A-C5D964S8S@-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO M-#@S-6)C,C1?8S8T9%\T930Y7SAF8C%?-&0T838U9&5E,V,X+U=O'0O:'1M;#L@8VAA MF%T:6]N(&%N9"!3:6=N:69I8V%N="!! M8V-O=6YT:6YG(%!O;&EC:65S.B!2979E;G5E(%)E8V]G;FET:6]N("A0;VQI M8VEE'0^/"$M+65G>"TM/CQP('-T>6QE/3-$;6%R M9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN.C!I;CMM87)G M:6XM8F]T=&]M.BXP,#`Q<'0[=&5X="UI;F1E;G0Z+C5I;CX\8CY2979E;G5E M(%)E8V]G;FET:6]N/"]B/B`F(S$U,#L@5V4@7-T96US+"9N8G-P.W!A6QE/3-$)W=I9'1H.C$U-2XY<'0[8F]R9&5R.FYO;F4[<&%D9&EN9SHP M:6X@-2XT<'0@,&EN(#4N-'!T)SX@/'`@6QE/3-$)W=I9'1H.C8V+C)P M=#MB;W)D97(Z;F]N93MB;W)D97(M8F]T=&]M.G-O;&ED('=I;F1O=W1E>'0@ M,2XP<'0[<&%D9&EN9SHP:6X@-2XT<'0@,&EN(#4N-'!T)SX@/'`@86QI9VX] M,T1C96YT97(@6QE/3-$)W=I9'1H.C$U-2XY<'0[8F]R9&5R.FYO M;F4[<&%D9&EN9SHP:6X@-2XT<'0@,&EN(#4N-'!T)SX@/'`@'0M86QI9VXZ6QE/3-$ M)W=I9'1H.C8X+C=P=#MB;W)D97(Z;F]N93MP861D:6YG.C!I;B`U+C1P="`P M:6X@-2XT<'0G/B`\<"!A;&EG;CTS1')I9VAT('-T>6QE/3-$;6%R9VEN+7)I M9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[=&5X="UA;&EG;CIR:6=H=#XD)B,Q M-C`[("8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.S0W,"PX M-S4\+W`^(#PO=&0^(#QT9"!W:61T:#TS1#@X('9A;&EG;CTS1'1O<"!S='EL M93TS1"=W:61T:#HV-BXR<'0[8F]R9&5R.FYO;F4[<&%D9&EN9SHP:6X@-2XT M<'0@,&EN(#4N-'!T)SX@/'`@86QI9VX],T1R:6=H="!S='EL93TS1&UA'0M86QI9VXZ6QE/3-$)W=I9'1H.C$U M-2XY<'0[8F]R9&5R.FYO;F4[<&%D9&EN9SHP:6X@-2XT<'0@,&EN(#4N-'!T M)SX@/'`@'0M86QI9VXZ6QE/3-$)W=I9'1H.C8V+C)P=#MB;W)D M97(Z;F]N93MP861D:6YG.C!I;B`U+C1P="`P:6X@-2XT<'0G/B`\<"!A;&EG M;CTS1')I9VAT('-T>6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F M=#HP:6X[=&5X="UA;&EG;CIR:6=H=#XU,#$L-38U/"]P/B`\+W1D/B`\=&0@ M=VED=&@],T0X."!V86QI9VX],T1T;W`@6QE/3-$)W=I9'1H M.C8V+C)P=#MB;W)D97(Z;F]N93MP861D:6YG.C!I;B`U+C1P="`P:6X@-2XT M<'0G/B`\<"!A;&EG;CTS1')I9VAT('-T>6QE/3-$;6%R9VEN+7)I9VAT.C!I M;CMM87)G:6XM;&5F=#HP:6X[=&5X="UA;&EG;CIR:6=H=#XQ+#$P.2PW-3`\ M+W`^(#PO=&0^(#PO='(^(#QT6QE/3-$)W=I9'1H.C8X+C=P=#MB;W)D97(Z;F]N M93MP861D:6YG.C!I;B`U+C1P="`P:6X@-2XT<'0G/B`\<"!A;&EG;CTS1')I M9VAT('-T>6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[ M=&5X="UA;&EG;CIR:6=H=#XQ,#DL,S0V/"]P/B`\+W1D/B`\=&0@=VED=&@] M,T0X."!V86QI9VX],T1T;W`@'0M86QI9VXZ6QE/3-$)W=I9'1H.C8V M+C)P=#MB;W)D97(Z;F]N93MP861D:6YG.C!I;B`U+C1P="`P:6X@-2XT<'0G M/B`\<"!A;&EG;CTS1')I9VAT('-T>6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM M87)G:6XM;&5F=#HP:6X[=&5X="UA;&EG;CIR:6=H=#XS,S`L,3$V/"]P/B`\ M+W1D/B`\+W1R/B`\='(@86QI9VX],T1L969T/B`\=&0@=VED=&@],T0R,#@@ M=F%L:6=N/3-$=&]P('-T>6QE/3-$)W=I9'1H.C$U-2XY<'0[8F]R9&5R.FYO M;F4[<&%D9&EN9SHP:6X@-2XT<'0@,&EN(#4N-'!T)SX@/'`@6QE/3-$;6%R9VEN+7)I9VAT M.C!I;CMM87)G:6XM;&5F=#HP:6X[=&5X="UA;&EG;CIR:6=H=#XQ,C4L.3`P M/"]P/B`\+W1D/B`\=&0@=VED=&@],T0X."!V86QI9VX],T1T;W`@6QE/3-$;6%R9VEN+7)I9VAT.C!I M;CMM87)G:6XM;&5F=#HP:6X[=&5X="UA;&EG;CIR:6=H=#XY-2PR,#`\+W`^ M(#PO=&0^(#QT9"!W:61T:#TS1#@X('9A;&EG;CTS1'1O<"!S='EL93TS1"=W M:61T:#HV-BXR<'0[8F]R9&5R.FYO;F4[8F]R9&5R+6)O='1O;3IS;VQI9"!W M:6YD;W=T97AT(#$N,'!T.W!A9&1I;F6QE/3-$)W=I9'1H.C8X M+C=P=#MB;W)D97(Z;F]N93MP861D:6YG.C!I;B`U+C1P="`P:6X@-2XT<'0G M/B`\<"!S='EL93TS1&UA6QE/3-$)W=I9'1H.C8V+C)P=#MB;W)D97(Z;F]N93MP861D:6YG.C!I M;B`U+C1P="`P:6X@-2XT<'0G/B`\<"!S='EL93TS1&UA6QE/3-$)W=I9'1H.C8V+C)P=#MB;W)D M97(Z;F]N93MP861D:6YG.C!I;B`U+C1P="`P:6X@-2XT<'0G/B`\<"!S='EL M93TS1&UA6QE/3-$ M)W=I9'1H.C8V+C)P=#MB;W)D97(Z;F]N93MP861D:6YG.C!I;B`U+C1P="`P M:6X@-2XT<'0G/B`\<"!A;&EG;CTS1')I9VAT('-T>6QE/3-$;6%R9VEN+7)I M9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[=&5X="UA;&EG;CIR:6=H=#XF;F)S M<#L\+W`^(#PO=&0^(#PO='(^(#QT'0@,2XU<'0[<&%D9&EN9SHP:6X@-2XT<'0@,&EN(#4N M-'!T)SX@/'`@86QI9VX],T1R:6=H="!S='EL93TS1&UA'0M86QI9VXZ6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[ M=&5X="UA;&EG;CIR:6=H=#XD)B,Q-C`[)B,Q-C`[)B,Q-C`[(#$L-C@T+#(V M,CPO<#X@/"]T9#X@/'1D('=I9'1H/3-$.#@@=F%L:6=N/3-$=&]P('-T>6QE M/3-$)W=I9'1H.C8V+C)P=#MB;W)D97(Z;F]N93MB;W)D97(M8F]T=&]M.F1O M=6)L92!W:6YD;W=T97AT(#$N-7!T.W!A9&1I;F'0@,2XU<'0[<&%D M9&EN9SHP:6X@-2XT<'0@,&EN(#4N-'!T)SX@/'`@86QI9VX],T1R:6=H="!S M='EL93TS1&UA'0M M86QI9VXZ6QE/3-$;6%R9VEN+7)I9VAT M.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M M.BXP,#`Q<'0[=&5X="UI;F1E;G0Z+C5I;CXF;F)S<#L\+W`^(#QP('-T>6QE M/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN.C!I M;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[=&5X="UI;F1E;G0Z+C5I;CY2979E M;G5E(&9R;VT@<')O9'5C="!S86QEF5D('=H96X@82!P M=7)C:&%S92!O&5D(&]R(&1E=&5R;6EN86)L92P@86YD(&-O;&QE8W1I M;VX@:7,@2!A7-T96T@2XF;F)S M<#LF;F)S<#M3;VUE('-A;&5S(&]F('-YF5D('=H96X@=&AE('1R86EN:6YG M(&AA7-T96US(&1O(&YO="!R97%U:7)E('-P M96-I9FEC(&-U&-E<'0@:6X@8V%S M97,@=VAE6QE/3-$;6%R9VEN M+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN.C!I;CMM87)G:6XM M8F]T=&]M.BXP,#`Q<'0[=&5X="UI;F1E;G0Z+C5I;CXF;F)S<#L\+W`^(#QP M('-T>6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R M9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[=&5X="UI;F1E;G0Z+C5I M;CY2979E;G5E(&9R;VT@=&AE('-A;&4@;V8@9&ES<&]S86)L92!D979I8V5S M(&ES(')E8V]G;FEZ960@=VAE;B!A('!U6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM M;&5F=#HP:6X[;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0^)FYB M'0M M:6YD96YT.BXU:6X^4F5V96YU92!F2!A6QE/3-$;6%R9VEN+7)I9VAT.C!I M;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP M,#`Q<'0[=&5X="UI;F1E;G0Z+C5I;CY2979E;G5E(&9R;VT@F5D(&]N(&$@6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F M=#HP:6X[;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0^)FYB'0M:6YD M96YT.BXU:6X^4F5V96YU92!F2!I6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F M=#HP:6X[;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[=&5X="UI M;F1E;G0Z+C5I;CY$969E3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\T.#,U8F,R-%]C-C1D M7S1E-#E?.&9B,5\T9#1A-C5D964S8S@-"D-O;G1E;G0M3&]C871I;VXZ(&9I M;&4Z+R\O0SHO-#@S-6)C,C1?8S8T9%\T930Y7SAF8C%?-&0T838U9&5E,V,X M+U=O'0O M:'1M;#L@8VAAF%T:6]N(&%N9"!3:6=N M:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S.B!#;VYC96YT'0^/"$M+65G>"TM/CQP('-T>6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G M:6XM;&5F=#HP:6X[;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[ M=&5X="UI;F1E;G0Z+C5I;CX\8CY#;VYC96YT2!O9B!T2P@=V4@<&5R9F]R;2!O;F=O:6YG(&-R M961I="!E=F%L=6%T:6]N'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'!E;G-E9"!A'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/"$M+65G>"TM/CQP('-T>6QE/3-$;6%R9VEN+7)I M9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN.C!I;CMM87)G:6XM8F]T M=&]M.BXP,#`Q<'0[=&5X="UI;F1E;G0Z+C5I;CX\8CY3:&EP<&EN9R!A;F0@ M2&%N9&QI;F<\+V(^("8C,34P.R!792!B:6QL(&]U'!E;G-E(&ES(')E<&]R M=&5D(&EN(&-O7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@ M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^/"$M+65G>"TM/CQP('-T>6QE/3-$;6%R9VEN+7)I9VAT.C!I M;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP M,#`Q<'0[=&5X="UI;F1E;G0Z+C5I;CX\8CY57!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T* M#0H\:'1M;#X-"B`@/&AE860^#0H@("`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`Q<'0^)FYB6QE/3-$;6%R9VEN+6QE9G0Z.#8N,W!T.V)O6QE/3-$)W=I9'1H.C$N-S5I M;CMP861D:6YG.C!I;B`U+C1P="`P:6X@-2XT<'0G/B`\<"!A;&EG;CTS1')I M9VAT('-T>6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[ M=&5X="UA;&EG;CIR:6=H=#XR("8C,34P.R`U('EE87)S/"]P/B`\+W1D/B`\ M+W1R/B`\='(@86QI9VX],T1L969T/B`\=&0@=VED=&@],T0Q-C@@=F%L:6=N M/3-$=&]P('-T>6QE/3-$)W=I9'1H.C$R-BXQ<'0[<&%D9&EN9SHP:6X@-2XT M<'0@,&EN(#4N-'!T)SX@/'`@6QE/3-$)W=I9'1H M.C$N-S5I;CMP861D:6YG.C!I;B`U+C1P="`P:6X@-2XT<'0G/B`\<"!A;&EG M;CTS1')I9VAT('-T>6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F M=#HP:6X[=&5X="UA;&EG;CIR:6=H=#XU('EE87)S/"]P/B`\+W1D/B`\+W1R M/B`\='(@86QI9VX],T1L969T/B`\=&0@=VED=&@],T0Q-C@@=F%L:6=N/3-$ M=&]P('-T>6QE/3-$)W=I9'1H.C$R-BXQ<'0[<&%D9&EN9SHP:6X@-2XT<'0@ M,&EN(#4N-'!T)SX@/'`@'1U6QE/3-$)W=I M9'1H.C$N-S5I;CMP861D:6YG.C!I;B`U+C1P="`P:6X@-2XT<'0G/B`\<"!A M;&EG;CTS1')I9VAT('-T>6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM M;&5F=#HP:6X[=&5X="UA;&EG;CIR:6=H=#XU('EE87)S/"]P/B`\+W1D/B`\ M+W1R/B`\='(@86QI9VX],T1L969T/B`\=&0@=VED=&@],T0Q-C@@=F%L:6=N M/3-$=&]P('-T>6QE/3-$)W=I9'1H.C$R-BXQ<'0[<&%D9&EN9SHP:6X@-2XT M<'0@,&EN(#4N-'!T)SX@/'`@6QE/3-$)W=I9'1H.C$R-BXQ<'0[<&%D9&EN9SHP:6X@ M-2XT<'0@,&EN(#4N-'!T)SX@/'`@6QE/3-$)W=I9'1H.C0U+C!P=#MP861D M:6YG.C!I;B`U+C1P="`P:6X@-2XT<'0G/B`\<"!S='EL93TS1&UA'0M86QI9VXZ65A3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R M=%\T.#,U8F,R-%]C-C1D7S1E-#E?.&9B,5\T9#1A-C5D964S8S@-"D-O;G1E M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-#@S-6)C,C1?8S8T9%\T930Y7SAF M8C%?-&0T838U9&5E,V,X+U=O'0O:'1M;#L@8VAAF%T:6]N(&%N9"!3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S.B!2 M979E;G5E(%)E8V]G;FET:6]N.B!38VAE9'5L92!O9B!2979E;G5E(%)E8V]G M;FET:6]N("A486)L97,I/&)R/CPO'0^/"$M+65G>"TM/B`\<"!S='EL93TS1&UA'0M:6YD96YT.BXU:6X^)FYB6QE/3-$ M;6%R9VEN+6QE9G0Z,3DN-G!T.V)O6QE/3-$)W=I9'1H.C$S-"XY<'0[8F]R9&5R.FYO;F4[<&%D9&EN9SHP M:6X@-2XT<'0@,&EN(#4N-'!T)SX@/'`@86QI9VX],T1C96YT97(@6QE/3-$)W=I9'1H.C$S,BXT<'0[8F]R9&5R.FYO;F4[<&%D M9&EN9SHP:6X@-2XT<'0@,&EN(#4N-'!T)SX@/'`@86QI9VX],T1C96YT97(@ M6QE/3-$ M)W=I9'1H.C8X+C=P=#MB;W)D97(Z;F]N93MB;W)D97(M8F]T=&]M.G-O;&ED M('=I;F1O=W1E>'0@,2XP<'0[<&%D9&EN9SHP:6X@-2XT<'0@,&EN(#4N-'!T M)SX@/'`@86QI9VX],T1C96YT97(@6QE M/3-$)W=I9'1H.C8V+C)P=#MB;W)D97(Z;F]N93MB;W)D97(M8F]T=&]M.G-O M;&ED('=I;F1O=W1E>'0@,2XP<'0[<&%D9&EN9SHP:6X@-2XT<'0@,&EN(#4N M-'!T)SX@/'`@86QI9VX],T1C96YT97(@6QE/3-$)W=I9'1H.C8X+C=P=#MB;W)D97(Z;F]N93MP861D:6YG M.C!I;B`U+C1P="`P:6X@-2XT<'0G/B`\<"!S='EL93TS1&UA6QE/3-$)W=I9'1H.C8V+C)P=#MB M;W)D97(Z;F]N93MP861D:6YG.C!I;B`U+C1P="`P:6X@-2XT<'0G/B`\<"!S M='EL93TS1&UA6QE M/3-$)W=I9'1H.C8V+C)P=#MB;W)D97(Z;F]N93MP861D:6YG.C!I;B`U+C1P M="`P:6X@-2XT<'0G/B`\<"!A;&EG;CTS1')I9VAT('-T>6QE/3-$;6%R9VEN M+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[=&5X="UA;&EG;CIR:6=H=#XF M;F)S<#L\+W`^(#PO=&0^(#QT9"!W:61T:#TS1#@X('9A;&EG;CTS1'1O<"!S M='EL93TS1"=W:61T:#HV-BXR<'0[8F]R9&5R.FYO;F4[<&%D9&EN9SHP:6X@ M-2XT<'0@,&EN(#4N-'!T)SX@/'`@86QI9VX],T1R:6=H="!S='EL93TS1&UA M'0M86QI9VXZ6QE/3-$)W=I9'1H.C$U M-2XY<'0[8F]R9&5R.FYO;F4[<&%D9&EN9SHP:6X@-2XT<'0@,&EN(#4N-'!T M)SX@/'`@6QE/3-$)W=I9'1H.C8V+C)P=#MB;W)D97(Z;F]N M93MP861D:6YG.C!I;B`U+C1P="`P:6X@-2XT<'0G/B`\<"!A;&EG;CTS1')I M9VAT('-T>6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[ M=&5X="UA;&EG;CIR:6=H=#XD("8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C M,38P.R8C,38P.SDX-BPY,#`\+W`^(#PO=&0^(#QT9"!W:61T:#TS1#@X('9A M;&EG;CTS1'1O<"!S='EL93TS1"=W:61T:#HV-BXR<'0[8F]R9&5R.FYO;F4[ M<&%D9&EN9SHP:6X@-2XT<'0@,&EN(#4N-'!T)SX@/'`@86QI9VX],T1R:6=H M="!S='EL93TS1&UA'0M86QI9VXZ'0M86QI9VXZ6QE/3-$)W=I9'1H M.C8X+C=P=#MB;W)D97(Z;F]N93MP861D:6YG.C!I;B`U+C1P="`P:6X@-2XT M<'0G/B`\<"!A;&EG;CTS1')I9VAT('-T>6QE/3-$;6%R9VEN+7)I9VAT.C!I M;CMM87)G:6XM;&5F=#HP:6X[=&5X="UA;&EG;CIR:6=H=#XT,#DL-S@W/"]P M/B`\+W1D/B`\=&0@=VED=&@],T0X."!V86QI9VX],T1T;W`@'0M86QI9VXZ'0M86QI9VXZ6QE M/3-$)W=I9'1H.C8V+C)P=#MB;W)D97(Z;F]N93MP861D:6YG.C!I;B`U+C1P M="`P:6X@-2XT<'0G/B`\<"!A;&EG;CTS1')I9VAT('-T>6QE/3-$;6%R9VEN M+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[=&5X="UA;&EG;CIR:6=H=#XS M-S4L-S0W/"]P/B`\+W1D/B`\=&0@=VED=&@],T0X."!V86QI9VX],T1T;W`@ M6QE/3-$)W=I9'1H.C8V+C)P=#MB;W)D97(Z;F]N93MB;W)D M97(M8F]T=&]M.G-O;&ED('=I;F1O=W1E>'0@,2XP<'0[<&%D9&EN9SHP:6X@ M-2XT<'0@,&EN(#4N-'!T)SX@/'`@86QI9VX],T1R:6=H="!S='EL93TS1&UA M'0M86QI9VXZ6QE/3-$)W=I9'1H.C8V+C)P=#MB;W)D97(Z;F]N93MB;W)D97(M M8F]T=&]M.G-O;&ED('=I;F1O=W1E>'0@,2XP<'0[<&%D9&EN9SHP:6X@-2XT M<'0@,&EN(#4N-'!T)SX@/'`@86QI9VX],T1R:6=H="!S='EL93TS1&UA'0M86QI9VXZ6QE M/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[=&5X="UA;&EG M;CIR:6=H=#XD)B,Q-C`[)B,Q-C`[("8C,38P.R8C,38P.S$L,3$U+#DP.#PO M<#X@/"]T9#X@/'1D('=I9'1H/3-$.#@@=F%L:6=N/3-$=&]P('-T>6QE/3-$ M)W=I9'1H.C8V+C)P=#MB;W)D97(Z;F]N93MB;W)D97(M8F]T=&]M.F1O=6)L M92!W:6YD;W=T97AT(#$N-7!T.W!A9&1I;F'0@,2XU<'0[<&%D9&EN M9SHP:6X@-2XT<'0@,&EN(#4N-'!T)SX@/'`@86QI9VX],T1R:6=H="!S='EL M93TS1&UA'0M86QI M9VXZ6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G M:6XM;&5F=#HP:6X[=&5X="UA;&EG;CIR:6=H=#XD)B,Q-C`[)B,Q-C`[)B,Q M-C`[(#,L-C'0O:F%V87-C3X- M"B`@("`\=&%B;&4@8VQA6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM M87)G:6XM;&5F=#HP:6X[;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q M<'0[=&5X="UA;&EG;CIJ=7-T:69Y.W1E>'0M:6YD96YT.BXU:6X^)FYB6QE/3-$;6%R9VEN+6QE9G0Z+C5I M;CMB;W)D97(M8V]L;&%P6QE/3-$;6%R9VEN+7)I9VAT.C!I M;CMM87)G:6XM;&5F=#HP:6X^)FYB6QE/3-$;6%R9VEN+7)I9VAT M.C!I;CMM87)G:6XM;&5F=#HP:6X[=&5X="UA;&EG;CIC96YT97(^/&(^075G M=7-T(#,Q+#PO8CX\+W`^(#PO=&0^(#PO='(^(#QT6QE/3-$;6%R9VEN+7)I9VAT.C!I M;CMM87)G:6XM;&5F=#HP:6X^)FYB'0@,2XP<'0[<&%D9&EN9SHP)SX@/'`@ M86QI9VX],T1C96YT97(@6QE/3-$)W=I M9'1H.C8S+CAP=#MB;W)D97(Z;F]N93MB;W)D97(M8F]T=&]M.G-O;&ED('=I M;F1O=W1E>'0@,2XP<'0[<&%D9&EN9SHP)SX@/'`@86QI9VX],T1C96YT97(@ M6QE/3-$=VED=&@Z-C,N-S5P=#MB;W)D97(Z M;F]N93MP861D:6YG.C`^(#QP(&%L:6=N/3-$6QE/3-$=VED=&@Z-C,N.'!T.V)O'0M86QI9VXZ6QE/3-$=VED=&@Z,36QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G M:6XM;&5F=#HP:6X[=&5X="UA;&EG;CIR:6=H=#XF;F)S<#L\+W`^(#PO=&0^ M(#QT9"!W:61T:#TS1#@U('9A;&EG;CTS1'1O<"!S='EL93TS1'=I9'1H.C8S M+C6QE/3-$;6%R M9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[=&5X="UA;&EG;CIR:6=H M=#XF;F)S<#L\+W`^(#PO=&0^(#QT9"!W:61T:#TS1#@U('9A;&EG;CTS1'1O M<"!S='EL93TS1'=I9'1H.C8S+CAP=#MP861D:6YG.C`^(#QP(&%L:6=N/3-$ M6QE/3-$=VED=&@Z-C,N-S5P=#MP861D:6YG.C`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`^(#PO=&0^ M(#QT9"!W:61T:#TS1#@U('9A;&EG;CTS1'1O<"!S='EL93TS1'=I9'1H.C8S M+C6QE/3-$;6%R M9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[=&5X="UA;&EG;CIR:6=H M=#XF;F)S<#L\+W`^(#PO=&0^(#QT9"!W:61T:#TS1#@U('9A;&EG;CTS1'1O M<"!S='EL93TS1'=I9'1H.C8S+CAP=#MP861D:6YG.C`^(#QP(&%L:6=N/3-$ M6QE/3-$)W=I9'1H M.B`Q-S8N-C5P=#L@<&%D9&EN9SH@,#LG/B`\<"!S='EL93TS1&UA6QE/3-$)W=I9'1H.B`V,RXX M<'0[(&)O'0@,2XU<'0[('!A9&1I;F6QE/3-$ M)W=I9'1H.B`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`^(#PO=&0^(#PO M='(^(#QT6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X^)B,Q-C`[ M)B,Q-C`[(%!A6QE/3-$=VED=&@Z-C,N.'!T.W!A9&1I M;F6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP M:6X[;6%R9VEN+7)I9VAT.BXP-6EN.W1E>'0M86QI9VXZ6QE/3-$;6%R M9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X^)B,Q-C`[)B,Q-C`[(%=O M6QE/3-$=VED=&@Z-C,N.'!T.W!A9&1I;F6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[ M;6%R9VEN+7)I9VAT.BXP-6EN.W1E>'0M86QI9VXZ6QE/3-$ M=VED=&@Z-C,N.'!T.W!A9&1I;F6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X^)B,Q M-C`[)B,Q-C`[($9I;FES:&5D(&=O;V1S/"]P/B`\+W1D/B`\=&0@=VED=&@] M,T0X-2!V86QI9VX],T1T;W`@6QE/3-$;6%R9VEN+7)I9VAT.C!I M;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN+7)I9VAT.BXP-6EN.W1E>'0M86QI M9VXZ6QE/3-$=VED=&@Z-C,N-S5P=#MP861D:6YG.C`^(#QP M(&%L:6=N/3-$6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP M:6X[;6%R9VEN+7)I9VAT.BXP-6EN.W1E>'0M86QI9VXZ6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP M:6X[=&5X="UA;&EG;CIR:6=H=#XH)B,Q-C`[(#6QE/3-$)W=I9'1H.C8S+CAP=#MB;W)D97(Z;F]N93MB;W)D M97(M8F]T=&]M.G-O;&ED(&)L86-K(#$N,'!T.W!A9&1I;F6QE/3-$=VED=&@Z-C,N-S5P=#MP861D:6YG.C`^ M(#QP(&%L:6=N/3-$6QE/3-$=VED=&@Z M-C,N.'!T.W!A9&1I;F'0M86QI9VXZ6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM M;&5F=#HP:6X^)FYB6QE/3-$;6%R9VEN+7)I M9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN+7)I9VAT.BXP-6EN.W1E M>'0M86QI9VXZ6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM M;&5F=#HP:6X[;6%R9VEN+7)I9VAT.BXP-6EN.W1E>'0M86QI9VXZ'0O:F%V87-C3X- M"B`@("`\=&%B;&4@8VQA6QE/3-$=VED=&@Z M-C,N.'!T.W!A9&1I;F6QE/3-$=VED=&@Z-C,N.'!T M.W!A9&1I;F6QE/3-$=VED=&@Z M-C,N-S5P=#MP861D:6YG.C`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`@86QI9VX],T1R M:6=H="!S='EL93TS1&UA6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[ M;6%R9VEN+7)I9VAT.BXP-6EN.W1E>'0M86QI9VXZ6QE/3-$ M)W=I9'1H.C8S+CAP=#MB;W)D97(Z;F]N93MB;W)D97(M8F]T=&]M.G-O;&ED M('=I;F1O=W1E>'0@,2XP<'0[<&%D9&EN9SHP)SX@/'`@86QI9VX],T1R:6=H M="!S='EL93TS1&UA6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP M:6X^)FYB6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM M87)G:6XM;&5F=#HP:6X[=&5X="UA;&EG;CIR:6=H=#XF;F)S<#L\+W`^(#PO M=&0^(#QT9"!W:61T:#TS1#@U('9A;&EG;CTS1'1O<"!S='EL93TS1'=I9'1H M.C8S+C6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[ M=&5X="UA;&EG;CIR:6=H=#XF;F)S<#L\+W`^(#PO=&0^(#QT9"!W:61T:#TS M1#@U('9A;&EG;CTS1'1O<"!S='EL93TS1'=I9'1H.C8S+CAP=#MB;W)D97(Z M;F]N93MP861D:6YG.C`^(#QP(&%L:6=N/3-$6QE/3-$)W=I9'1H.B`Q-S8N-C5P=#L@<&%D9&EN M9SH@,#LG/B`\<"!S='EL93TS1&UA6QE/3-$)W=I9'1H.B`V,RXX<'0[(&)O'0@,2XU<'0[('!A9&1I M;F'0@,2XU<'0[('!A9&1I;F6QE/3-$)W=I9'1H M.B`V,RXX<'0[(&)O'0@,2XU<'0[('!A9&1I;F6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM M;&5F=#HP:6X[;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0^)FYB M7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\ M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!A;F0@17%U:7!M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\(2TM96=X+2T^(#QP('-T>6QE/3-$;6%R9VEN+7)I9VAT M.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M M.BXP,#`Q<'0[=&5X="UI;F1E;G0Z+C5I;CXF;F)S<#L\+W`^(#QT86)L92!B M;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED M=&@],T0T.3$@6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F M=#HP:6X[=&5X="UA;&EG;CIC96YT97(^/&(^1&5C96UB97(@,S$L/"]B/CPO M<#X@/"]T9#X@/'1D('=I9'1H/3-$,36QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G M:6XM;&5F=#HP:6X[=&5X="UA;&EG;CIC96YT97(^/&(^,C`Q-#PO8CX\+W`^ M(#PO=&0^(#QT9"!W:61T:#TS1#@U('9A;&EG;CTS1'1O<"!S='EL93TS1"=W M:61T:#HV,RXW-7!T.V)O'0M86QI9VXZ8V5N=&5R M/CQB/C(P,3,\+V(^/"]P/B`\+W1D/B`\+W1R/B`\='(@86QI9VX],T1L969T M/B`\=&0@=VED=&@],T0R,S8@=F%L:6=N/3-$=&]P('-T>6QE/3-$=VED=&@Z M,36QE/3-$=VED=&@Z-C,N.'!T.V)O'0M86QI9VXZ'0M86QI9VXZ6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[ M=&5X="UA;&EG;CIR:6=H=#XF;F)S<#L\+W`^(#PO=&0^(#PO='(^(#QT6QE/3-$;6%R M9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X^)B,Q-C`[)B,Q-C`[($5Q M=6EP;65N=#PO<#X@/"]T9#X@/'1D('=I9'1H/3-$.#4@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$=VED=&@Z-C,N.'!T.W!A9&1I;F6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN M+7)I9VAT.C,N-W!T.W1E>'0M86QI9VXZ6QE/3-$;6%R9VEN+7)I9VAT M.C!I;CMM87)G:6XM;&5F=#HP:6X^)B,Q-C`[)B,Q-C`[(%)E;G1A;"!E<75I M<&UE;G0\+W`^(#PO=&0^(#QT9"!W:61T:#TS1#@U('9A;&EG;CTS1&)O='1O M;2!S='EL93TS1'=I9'1H.C8S+CAP=#MP861D:6YG.C`^(#QP(&%L:6=N/3-$ M6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R M9VEN+7)I9VAT.C,N-W!T.W1E>'0M86QI9VXZ6QE M/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN+7)I M9VAT.C,N-W!T.W1E>'0M86QI9VXZ6QE/3-$=VED=&@Z,36QE/3-$;6%R9VEN M+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN+7)I9VAT.C,N-W!T M.W1E>'0M86QI9VXZ6QE/3-$=VED=&@Z-C,N-S5P=#MP M861D:6YG.C`^(#QP(&%L:6=N/3-$6QE/3-$;6%R9VEN+7)I9VAT.C!I M;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN+7)I9VAT.C,N-W!T.W1E>'0M86QI M9VXZ6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM M;&5F=#HP:6X[;6%R9VEN+7)I9VAT.C,N-W!T.W1E>'0M86QI9VXZ6QE/3-$=VED=&@Z-C,N-S5P=#MP861D:6YG.C`^(#QP(&%L:6=N/3-$6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X^)B,Q M-C`[)B,Q-C`[($)U:6QD:6YG("AH96QD(&9O6QE/3-$=VED=&@Z M-C,N.'!T.W!A9&1I;F6QE/3-$;6%R9VEN M+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN+7)I9VAT.C,N-W!T M.W1E>'0M86QI9VXZ6QE/3-$=VED=&@Z-C,N.'!T.W!A M9&1I;F6QE/3-$;6%R9VEN M+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X^)B,Q-C`[)B,Q-C`[($QA;F0F M(S$V,#L@*&AE;&0@9F]R('-A;&4I/"]P/B`\+W1D/B`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`^(#QP(&%L:6=N/3-$6QE/3-$;6%R9VEN+7)I M9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X^)B,Q-C`[)B,Q-C`[($QE6QE/3-$=VED=&@Z-C,N-S5P=#MP M861D:6YG.C`^(#QP(&%L:6=N/3-$6QE/3-$;6%R9VEN+7)I9VAT.C!I M;CMM87)G:6XM;&5F=#HP:6X^)B,Q-C`[)B,Q-C`[($QE'0M86QI9VXZ6QE/3-$;6%R9VEN+7)I9VAT M.C!I;CMM87)G:6XM;&5F=#HP:6X[=&5X="UA;&EG;CIR:6=H=#XH,2PV.34L M-C8X*3PO<#X@/"]T9#X@/"]T6QE/3-$=VED M=&@Z-C,N-S5P=#MP861D:6YG.C`^(#QP(&%L:6=N/3-$6QE/3-$=VED=&@Z-C,N.'!T.W!A9&1I;F'0M86QI9VXZ6QE/3-$ M;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X^)FYB6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F M=#HP:6X[;6%R9VEN+7)I9VAT.BXP-6EN.W1E>'0M86QI9VXZ6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN M+7)I9VAT.BXP-6EN.W1E>'0M86QI9VXZ'0O:F%V87-C M3X-"B`@("`\=&%B;&4@ M8VQA6QE/3-$=VED=&@Z,3`P+C`E.V)O6QE/3-$)W=I9'1H.B`T,2XY,B4[(&)O'0M:6YD96YT.BTX+CAP M=#XF;F)S<#L\+W`^(#PO=&0^(#QT9"!W:61T:#TS1#$Y)2!V86QI9VX],T1B M;W1T;VT@6QE/3-$;6%R9VEN+7)I9VAT M.C!I;CMM87)G:6XM;&5F=#HP:6X[=&5X="UA;&EG;CIC96YT97(^/&(^4VAA M6QE/3-$)W=I9'1H.B`R+C$X)3L@8F]R9&5R.B!N;VYE.R!B;W)D M97(M8F]T=&]M.B!S;VQI9"!W:6YD;W=T97AT(#$N,'!T.R!P861D:6YG.B`P M.R<^(#QP('-T>6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP M:6X^)FYB6QE/3-$)W=I9'1H.B`Q-BXQ,B4[(&)O'0M86QI9VXZ8V5N=&5R/CQB/E=E M:6=H=&5D+2!!=F5R86=E($5X97)C:7-E(%!R:6-E/"]B/CPO<#X@/"]T9#X@ M/'1D('=I9'1H/3-$,C`E('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T M:#H@,C`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`S,2P@,C`Q,SPO<#X@/"]T9#X@/'1D('=I9'1H/3-$,3DE('9A M;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,3DN,S8E.R!B;W)D97(Z M(&YO;F4[('!A9&1I;F'0M86QI9VXZ6QE/3-$)W=I M9'1H.B`Q-BXQ,B4[(&)O6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F M=#HP:6X[=&5X="UA;&EG;CIC96YT97(^+3PO<#X@/"]T9#X@/"]T6QE/3-$)W=I M9'1H.B`T,2XY,B4[(&)O'0M:6YD96YT.BTX+CAP=#Y'6QE/3-$ M)W=I9'1H.B`Q.2XS-B4[(&)O6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G M:6XM;&5F=#HP:6X[;6%R9VEN+7)I9VAT.BXR:6X[=&5X="UA;&EG;CIR:6=H M=#XT+#0P,"PP,#`\+W`^(#PO=&0^(#QT9"!W:61T:#TS1#(E('9A;&EG;CTS M1&)O='1O;2!S='EL93TS1"=W:61T:#H@,BXQ."4[(&)O6QE/3-$)W=I9'1H.B`R,"XT,B4[(&)O6QE/3-$)W=I9'1H.B`Q.2XS-B4[ M(&)O6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R M9VEN+7)I9VAT.BXR:6X[=&5X="UA;&EG;CIR:6=H=#XM/"]P/B`\+W1D/B`\ M=&0@=VED=&@],T0R)2!V86QI9VX],T1B;W1T;VT@6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM M87)G:6XM;&5F=#HP:6X[=&5X="UA;&EG;CIC96YT97(^+3PO<#X@/"]T9#X@ M/'1D('=I9'1H/3-$,C`E('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T M:#H@,C`N-#(E.R!B;W)D97(Z(&YO;F4[('!A9&1I;F6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R M9VEN+6QE9G0Z."XX<'0[=&5X="UI;F1E;G0Z+3@N.'!T/D9O'!I6QE/3-$)W=I9'1H.B`Q.2XS-B4[(&)O6QE/3-$;6%R9VEN+7)I9VAT M.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN+7)I9VAT.BXR:6X[=&5X="UA M;&EG;CIR:6=H=#XM/"]P/B`\+W1D/B`\=&0@=VED=&@],T0R)2!V86QI9VX] M,T1B;W1T;VT@'0@,2XP<'0[('!A9&1I M;F6QE/3-$;6%R9VEN M+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[=&5X="UA;&EG;CIC96YT97(^ M+3PO<#X@/"]T9#X@/'1D('=I9'1H/3-$,C`E('9A;&EG;CTS1&)O='1O;2!S M='EL93TS1"=W:61T:#H@,C`N-#(E.R!B;W)D97(Z(&YO;F4[(&)O'0@,2XP<'0[('!A9&1I;F6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP M:6X[;6%R9VEN+6QE9G0Z."XX<'0[=&5X="UI;F1E;G0Z+3@N.'!T/B9N8G-P M.SPO<#X@/"]T9#X@/'1D('=I9'1H/3-$,3DE('9A;&EG;CTS1&)O='1O;2!S M='EL93TS1"=W:61T:#H@,3DN,S8E.R!B;W)D97(Z(&YO;F4[('!A9&1I;F'0M86QI M9VXZ6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[=&5X M="UA;&EG;CIC96YT97(^)FYB6QE/3-$)W=I9'1H.B`R,"XT,B4[(&)O M6QE/3-$)W=I9'1H.B`T M,2XY,B4[(&)O'0M:6YD96YT.BTX+CAP=#Y/=71S=&%N9&EN9R!A6QE/3-$)W=I9'1H.B`R M+C$X)3L@8F]R9&5R.B!N;VYE.R!P861D:6YG.B`P.R<^(#QP('-T>6QE/3-$ M;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X^)#PO<#X@/"]T9#X@ M/'1D('=I9'1H/3-$,38E('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T M:#H@,38N,3(E.R!B;W)D97(Z(&YO;F4[('!A9&1I;F6QE/3-$)W=I9'1H.B`R M,"XT,B4[(&)O'0M86QI9VXZ6QE/3-$)W=I9'1H.B`R+C$X)3L@8F]R9&5R.B!N;VYE.R!P861D:6YG M.B`P.R<^(#QP('-T>6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F M=#HP:6X^)FYB6QE/3-$)W=I9'1H.B`Q-BXQ,B4[(&)O6QE/3-$;6%R9VEN+7)I M9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[=&5X="UA;&EG;CIC96YT97(^+3PO M<#X@/"]T9#X@/"]T6QE/3-$)W=I9'1H.B`T,2XY,B4[(&)O'0M:6YD96YT.BTX M+CAP=#Y%>&5R8VES960\+W`^(#PO=&0^(#QT9"!W:61T:#TS1#$Y)2!V86QI M9VX],T1B;W1T;VT@6QE/3-$)W=I9'1H.B`R,"XT,B4[ M(&)O6QE/3-$)W=I9'1H.B`R,"XT,B4[(&)O6QE/3-$)W=I9'1H.B`Q.2XS-B4[(&)O6QE/3-$;6%R9VEN+7)I M9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN+7)I9VAT.BXR:6X[=&5X M="UA;&EG;CIR:6=H=#XF;F)S<#L\+W`^(#PO=&0^(#QT9"!W:61T:#TS1#(E M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,BXQ."4[(&)O'0@,2XP<'0[ M('!A9&1I;F6QE/3-$;6%R9VEN+7)I9VAT.C!I M;CMM87)G:6XM;&5F=#HP:6X[=&5X="UA;&EG;CIC96YT97(^)FYB6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G M:6XM;&5F=#HP:6X[;6%R9VEN+6QE9G0Z."XX<'0[=&5X="UI;F1E;G0Z+3@N M.'!T/D]U='-T86YD:6YG(&%S(&]F($1E8V5M8F5R(#,Q+"`R,#$T/"]P/B`\ M+W1D/B`\=&0@=VED=&@],T0Q.24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W=I9'1H.B`Q.2XS-B4[(&)O'0@,2XU<'0[('!A9&1I;F'0M86QI9VXZ6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP M:6X^)#PO<#X@/"]T9#X@/'1D('=I9'1H/3-$,38E('9A;&EG;CTS1&)O='1O M;2!S='EL93TS1"=W:61T:#H@,38N,3(E.R!B;W)D97(Z(&YO;F4[(&)O6QE/3-$;6%R9VEN+7)I9VAT.C!I M;CMM87)G:6XM;&5F=#HP:6X[=&5X="UA;&EG;CIC96YT97(^,BXQ,3PO<#X@ M/"]T9#X@/'1D('=I9'1H/3-$,C`E('9A;&EG;CTS1&)O='1O;2!S='EL93TS M1"=W:61T:#H@,C`N-#(E.R!B;W)D97(Z(&YO;F4[(&)O6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM M;&5F=#HP:6X[=&5X="UA;&EG;CIC96YT97(^,RXV.3PO<#X@/"]T9#X@/"]T M6QE M/3-$)W=I9'1H.B`T,2XY,B4[(&)O'0M:6YD96YT.BTX+CAP=#XF;F)S<#L\ M+W`^(#PO=&0^(#QT9"!W:61T:#TS1#$Y)2!V86QI9VX],T1B;W1T;VT@6QE/3-$;6%R9VEN+7)I9VAT.C!I M;CMM87)G:6XM;&5F=#HP:6X[=&5X="UA;&EG;CIC96YT97(^)FYB6QE/3-$;6%R9VEN+7)I M9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[=&5X="UA;&EG;CIC96YT97(^)FYB M6QE/3-$)W=I9'1H.B`R,"XT,B4[(&)O6QE/3-$)W=I9'1H.B`T,2XY,B4[(&)O'0M:6YD96YT M.BTX+CAP=#Y%>&5R8VES86)L92!A6QE/3-$)W=I9'1H.B`R+C$X)3L@8F]R9&5R.B!N;VYE.R!B M;W)D97(M8F]T=&]M.B!D;W5B;&4@=VEN9&]W=&5X="`Q+C5P=#L@<&%D9&EN M9SH@,#LG/B`\<"!S='EL93TS1&UA3X-"CPO:'1M;#X-"@T*+2TM+2TM M/5].97AT4&%R=%\T.#,U8F,R-%]C-C1D7S1E-#E?.&9B,5\T9#1A-C5D964S M8S@-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-#@S-6)C,C1?8S8T M9%\T930Y7SAF8C%?-&0T838U9&5E,V,X+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R"`H4')O M=FES:6]N*2!"96YE9FET($-O;7!U=&5D(&%T($9E9&5R86P@4F%T97,@*%1A M8FQE'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/"$M+65G>"TM/B`\ M<"!S='EL93TS1&UA'0M:6YD96YT.BXU M:6X^)FYB6QE/3-$8F]R9&5R M+6-O;&QA<'-E.F-O;&QA<'-E/B`\='(@86QI9VX],T1L969T/B`\=&0@=VED M=&@],T0R-3(@=F%L:6=N/3-$=&]P('-T>6QE/3-$=VED=&@Z,3@X+CEP=#MP M861D:6YG.C`^(#QP('-T>6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM M;&5F=#HP:6X^)FYB6QE/3-$=VED=&@Z.30N-G!T.W!A9&1I;F6QE/3-$)W=I9'1H.C'0M86QI9VXZ8V5N=&5R/CQB/C(P,3,\+V(^/"]P/B`\+W1D/B`\ M+W1R/B`\='(@86QI9VX],T1L969T/B`\=&0@=VED=&@],T0R-3(@=F%L:6=N M/3-$=&]P('-T>6QE/3-$=VED=&@Z,3@X+CEP=#MP861D:6YG.C`^(#QP('-T M>6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X^)FYB6QE M/3-$=VED=&@Z.30N-G!T.W!A9&1I;F6QE/3-$;6%R M9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN+7)I9VAT.BXQ M:6X[=&5X="UA;&EG;CIR:6=H=#XF;F)S<#L\+W`^(#PO=&0^(#QT9"!W:61T M:#TS1#DT('9A;&EG;CTS1'1O<"!S='EL93TS1'=I9'1H.C6QE/3-$;6%R9VEN+7)I9VAT M.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN+7)I9VAT.BXQ:6X[=&5X="UA M;&EG;CIR:6=H=#XF;F)S<#L\+W`^(#PO=&0^(#PO='(^(#QT6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM M87)G:6XM;&5F=#HP:6X[;6%R9VEN+7)I9VAT.C,N-W!T.W1E>'0M86QI9VXZ M6QE M/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN+7)I M9VAT.C,N-W!T.W1E>'0M86QI9VXZ6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R M9VEN+7)I9VAT.BXP-6EN.W1E>'0M86QI9VXZ6QE/3-$=VED=&@Z-S`N.#5P=#MP861D:6YG.C`^(#QP M(&%L:6=N/3-$6QE/3-$=VED=&@Z.30N-G!T.W!A9&1I;F'0M86QI9VXZ6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN M+7)I9VAT.C,N-W!T.W1E>'0M86QI9VXZ6QE/3-$=VED=&@Z.30N-G!T.W!A9&1I;F6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[ M=&5X="UA;&EG;CIR:6=H=#XH,BPT.#`L,#`P*3PO<#X@/"]T9#X@/'1D('=I M9'1H/3-$.30@=F%L:6=N/3-$=&]P('-T>6QE/3-$=VED=&@Z-S`N.#5P=#MP M861D:6YG.C`^(#QP(&%L:6=N/3-$6QE/3-$=VED=&@Z,3@X+CEP M=#MP861D:6YG.C`^(#QP('-T>6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G M:6XM;&5F=#HP:6X^3W1H97(\+W`^(#PO=&0^(#QT9"!W:61T:#TS1#$R-B!V M86QI9VX],T1T;W`@6QE/3-$;6%R9VEN+7)I9VAT.C!I M;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN+7)I9VAT.BXP-6EN.W1E>'0M86QI M9VXZ6QE/3-$)W=I9'1H.C'0M86QI9VXZ'0M86QI9VXZ6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[=&5X M="UA;&EG;CIR:6=H=#XD)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[ M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[("@R+#`P,"D\+W`^(#PO M=&0^(#QT9"!W:61T:#TS1#DT('9A;&EG;CTS1'1O<"!S='EL93TS1"=W:61T M:#H@-S`N.#5P=#L@8F]R9&5R.B!N;VYE.R!B;W)D97(M8F]T=&]M.B!D;W5B M;&4@=VEN9&]W=&5X="`Q+C5P=#L@<&%D9&EN9SH@,#LG/B`\<"!A;&EG;CTS M1')I9VAT('-T>6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP M:6X[=&5X="UA;&EG;CIR:6=H=#XD)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[ M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[("@Q+#DS."D\ M+W`^(#PO=&0^(#PO='(^(#PO=&%B;&4^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X- M"@T*+2TM+2TM/5].97AT4&%R=%\T.#,U8F,R-%]C-C1D7S1E-#E?.&9B,5\T M9#1A-C5D964S8S@-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-#@S M-6)C,C1?8S8T9%\T930Y7SAF8C%?-&0T838U9&5E,V,X+U=O'0O:'1M;#L@8VAA6QE/3-$ M)W=I9'1H.C(Q.2XW-7!T.W!A9&1I;F6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X^ M)FYB6QE/3-$)W=I9'1H.C'0@,2XP<'0[<&%D9&EN9SHP M:6X@-2XT<'0@,&EN(#4N-'!T)SX@/'`@86QI9VX],T1C96YT97(@6QE/3-$)W=I9'1H.C6QE M/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[=&5X="UA;&EG M;CIR:6=H=#XF;F)S<#L\+W`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`P,"D\+W`^(#PO=&0^(#QT9"!W M:61T:#TS1#DT('9A;&EG;CTS1'1O<"!S='EL93TS1"=W:61T:#HW,"XV-7!T M.V)O6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP M:6X[=&5X="UA;&EG;CIR:6=H=#XH,3@U+#`P,"D\+W`^(#PO=&0^(#QT9"!W M:61T:#TS1#DT('9A;&EG;CTS1'1O<"!S='EL93TS1"=W:61T:#HW,"XV-7!T M.V)O6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP M:6X[=&5X="UA;&EG;CIR:6=H=#XH,S8P+#`P,"D\+W`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`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`[)B,Q-C`[($1E<')E8VEA=&EO;B!A;F0@86UOF%T:6]N/"]P/B`\ M+W1D/B`\=&0@=VED=&@],T0Q,#(@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W=I9'1H.C6QE/3-$)W=I9'1H.C6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R M9VEN+7)I9VAT.C,N-W!T.W1E>'0M86QI9VXZ6QE/3-$ M)W=I9'1H.C6QE/3-$)W=I9'1H.C6QE/3-$)W=I9'1H.C6QE/3-$)W=I9'1H M.C6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G M:6XM;&5F=#HP:6X[;6%R9VEN+7)I9VAT.BXP-6EN.W1E>'0M86QI9VXZ'0@,2XU<'0[<&%D9&EN9SHP:6X@-2XT<'0@ M,&EN(#4N-'!T)SX@/'`@86QI9VX],T1R:6=H="!S='EL93TS1&UA'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$6QE/3-$)W=I9'1H.B`Q-S`N,#5P=#L@<&%D M9&EN9SH@,&EN(#4N-'!T(#!I;B`U+C1P=#LG/B`\<"!S='EL93TS1&UA6QE/3-$)W=I9'1H.B`W M,"XY<'0[('!A9&1I;F'0@,2XP<'0[('!A9&1I;F'0@ M,2XP<'0[('!A9&1I;F6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN M+7)I9VAT.BXP-6EN.W1E>'0M86QI9VXZ8V5N=&5R/CQB/C(P,3,\+V(^/"]P M/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!W:61T:#TS1#(R-R!V86QI9VX],T1T M;W`@6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM M87)G:6XM;&5F=#HP:6X^)FYB6QE/3-$)W=I9'1H M.B`W,"XX-7!T.R!B;W)D97(Z(&YO;F4[('!A9&1I;F6QE/3-$)W=I9'1H M.B`Q-S`N,#5P=#L@<&%D9&EN9SH@,&EN(#4N-'!T(#!I;B`U+C1P=#LG/B`\ M<"!S='EL93TS1&UA6QE/3-$)W=I9'1H.B`W,"XY<'0[('!A M9&1I;F6QE/3-$)W=I9'1H.C$W,"XP-7!T M.W!A9&1I;F6QE/3-$;6%R M9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X^4F5S96%R8V@@86YD(&1E M=F5L;W!M96YT/"]P/B`\+W1D/B`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`@86QI9VX],T1R:6=H="!S M='EL93TS1&UA'0@ M,2XU<'0[<&%D9&EN9SHP:6X@-2XT<'0@,&EN(#4N-'!T)SX@/'`@86QI9VX] M,T1R:6=H="!S='EL93TS1&UA6QE/3-$)W=I9'1H.C'0@,2XU M<'0[<&%D9&EN9SHP:6X@-2XT<'0@,&EN(#4N-'!T)SX@/'`@86QI9VX],T1R M:6=H="!S='EL93TS1&UA'0M:6YD96YT.BXU:6X^)FYB7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X^)FYB3PO<#X@/"]T M9#X@/'1D('=I9'1H/3-$,3(Q('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W M:61T:#H@.3`N-#5P=#L@<&%D9&EN9SH@,#LG/B`\<"!A;&EG;CTS1&-E;G1E M'0M86QI9VXZ8V5N=&5R/C8R+CDV)3PO<#X@/"]T9#X@/"]T6QE/3-$)W=I9'1H.B`R M-C$N-#5P=#L@<&%D9&EN9SH@,#LG/B`\<"!S='EL93TS1&UA'0M M:6YD96YT.BTX+CAP=#Y%>'!E8W1E9"!D:79I9&5N9',\+W`^(#PO=&0^(#QT M9"!W:61T:#TS1#$R,2!V86QI9VX],T1B;W1T;VT@6QE/3-$)W=I9'1H.B`R-C$N-#5P M=#L@<&%D9&EN9SH@,#LG/B`\<"!S='EL93TS1&UA'0M:6YD96YT M.BTX+CAP=#Y%>'!E8W1E9"!T97)M/"]P/B`\+W1D/B`\=&0@=VED=&@],T0Q M,C$@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Y,"XT-7!T.R!P M861D:6YG.B`P.R<^(#QP(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$;6%R9VEN M+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[=&5X="UA;&EG;CIC96YT97(^ M-RXR-"!996%R6QE/3-$)W=I9'1H.B`R-C$N-#5P=#L@<&%D M9&EN9SH@,#LG/B`\<"!S='EL93TS1&UA'0M:6YD96YT.BTX+CAP M=#Y2:7-K+69R964@:6YT97)E'0M86QI9VXZ8V5N M=&5R/C(N,#'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0@,2XP<'0[ M('!A9&1I;F6QE/3-$)W=I9'1H.B`Q-2XW M)3L@8F]R9&5R.B!N;VYE.R!B;W)D97(M8F]T=&]M.B!S;VQI9"!W:6YD;W=T M97AT(#$N,'!T.R!P861D:6YG.B`P.R<^(#QP('-T>6QE/3-$;6%R9VEN+7)I M9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X^/&(^5V5I9VAT960M($%V97)A9V4@ M)B,Q-C`[17AE6QE/3-$)W=I9'1H.B`Q."XV-"4[ M(&)O6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X^/&(^ M06=G'0M:6YD96YT.BTX+CAP=#XF;F)S<#L\+W`^(#PO M=&0^(#QT9"!W:61T:#TS1#$V)2!V86QI9VX],T1B;W1T;VT@6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G M:6XM;&5F=#HP:6X[=&5X="UA;&EG;CIC96YT97(^)FYB6QE/3-$;6%R9VEN+7)I9VAT.C!I M;CMM87)G:6XM;&5F=#HP:6X[=&5X="UA;&EG;CIC96YT97(^)FYB6QE M/3-$)W=I9'1H.B`Q."XV-"4[(&)O6QE/3-$ M)W=I9'1H.B`Q+C`E.R!B;W)D97(Z(&YO;F4[('!A9&1I;F6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F M=#HP:6X^)FYB6QE/3-$)W=I9'1H.B`Q+CDV)3L@ M8F]R9&5R.B!N;VYE.R!P861D:6YG.B`P.R<^(#QP(&%L:6=N/3-$6QE/3-$)W=I9'1H.B`Q+C`E.R!B;W)D97(Z(&YO;F4[('!A9&1I;F'0M86QI9VXZ6QE M/3-$)W=I9'1H.B`Q,2XW."4[(&)O6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM M87)G:6XM;&5F=#HP:6X[=&5X="UA;&EG;CIR:6=H=#XF;F)S<#L\+W`^(#PO M=&0^(#PO='(^(#QT'0M:6YD96YT.BTX+CAP=#Y' M6QE/3-$)W=I9'1H.B`Q-BXV."4[(&)O6QE/3-$;6%R9VEN+7)I M9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN+7)I9VAT.BXR:6X[=&5X M="UA;&EG;CIR:6=H=#XQ,C'0M86QI M9VXZ6QE/3-$)W=I9'1H.B`Q,RXW-"4[(&)O6QE/3-$ M;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[=&5X="UA;&EG;CIR M:6=H=#XQ+C$Y/"]P/B`\+W1D/B`\=&0@=VED=&@],T0Q."4@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q."XV-"4[(&)O6QE/3-$;6%R9VEN M+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[=&5X="UA;&EG;CIR:6=H=#XF M;F)S<#L\+W`^(#PO=&0^(#QT9"!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O M;2!S='EL93TS1"=W:61T:#H@,2XP)3L@8F]R9&5R.B!N;VYE.R!P861D:6YG M.B`P.R<^(#QP(&%L:6=N/3-$'0M86QI9VXZ6QE/3-$)W=I9'1H.B`Q-BXV."4[(&)O6QE/3-$;6%R9VEN M+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN+7)I9VAT.BXR:6X[ M=&5X="UA;&EG;CIR:6=H=#XM/"]P/B`\+W1D/B`\=&0@=VED=&@],T0Q)2!V M86QI9VX],T1B;W1T;VT@'0M86QI9VXZ M6QE/3-$)W=I9'1H.B`Q,RXW-"4[(&)O6QE/3-$;6%R M9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[=&5X="UA;&EG;CIR:6=H M=#XF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#L@+3PO<#X@/"]T9#X@ M/'1D('=I9'1H/3-$,3@E('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T M:#H@,3@N-C0E.R!B;W)D97(Z(&YO;F4[('!A9&1I;F'0M86QI9VXZ6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[ M=&5X="UA;&EG;CIR:6=H=#XF;F)S<#L\+W`^(#PO=&0^(#QT9"!W:61T:#TS M1#$Q)2!V86QI9VX],T1B;W1T;VT@6QE/3-$)W=I9'1H.B`S-BXR)3L@8F]R9&5R.B!N;VYE.R!P861D:6YG M.B`P.R<^(#QP('-T>6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F M=#HP:6X[;6%R9VEN+6QE9G0Z."XX<'0[=&5X="UI;F1E;G0Z+3@N.'!T/D9O M'!I6QE/3-$)W=I9'1H.B`Q-BXV."4[(&)O6QE/3-$;6%R M9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN+7)I9VAT.C$Q M+C,U<'0[=&5X="UA;&EG;CIR:6=H=#XH-#6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP M:6X[=&5X="UA;&EG;CIR:6=H=#XF;F)S<#L\+W`^(#PO=&0^(#QT9"!W:61T M:#TS1#$S)2!V86QI9VX],T1B;W1T;VT@6QE/3-$)W=I9'1H.B`Q+C`E.R!B;W)D97(Z(&YO M;F4[('!A9&1I;F'0M86QI9VXZ6QE/3-$)W=I9'1H.B`Q,2XW."4[(&)O6QE/3-$;6%R9VEN M+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[=&5X="UA;&EG;CIR:6=H=#XF M;F)S<#L\+W`^(#PO=&0^(#PO='(^(#QT'0M:6YD M96YT.BTX+CAP=#XF;F)S<#L\+W`^(#PO=&0^(#QT9"!W:61T:#TS1#$V)2!V M86QI9VX],T1B;W1T;VT@6QE/3-$)W=I9'1H.B`Q M+CDV)3L@8F]R9&5R.B!N;VYE.R!P861D:6YG.B`P.R<^(#QP(&%L:6=N/3-$ M6QE/3-$)W=I9'1H.B`Q."XV-"4[(&)O M6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[=&5X="UA M;&EG;CIR:6=H=#XF;F)S<#L\+W`^(#PO=&0^(#QT9"!W:61T:#TS1#$E('9A M;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,2XP)3L@8F]R9&5R.B!N M;VYE.R!P861D:6YG.B`P.R<^(#QP(&%L:6=N/3-$'0M86QI9VXZ6QE/3-$)W=I9'1H.B`Q-BXV."4[(&)O6QE/3-$;6%R9VEN+7)I9VAT.C!I M;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN+7)I9VAT.BXR:6X[=&5X="UA;&EG M;CIR:6=H=#XS+#@V,BPY,C`\+W`^(#PO=&0^(#QT9"!W:61T:#TS1#$E('9A M;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,2XY-B4[(&)O6QE/3-$ M;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[=&5X="UA;&EG;CIR M:6=H=#XF;F)S<#L\+W`^(#PO=&0^(#QT9"!W:61T:#TS1#$S)2!V86QI9VX] M,T1B;W1T;VT@'0M:6YD96YT.BTX+CAP M=#Y'6QE/3-$)W=I9'1H.B`Q-BXV."4[(&)O6QE/3-$;6%R9VEN M+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN+7)I9VAT.BXR:6X[ M=&5X="UA;&EG;CIR:6=H=#XQ+#0U,"PP,#`\+W`^(#PO=&0^(#QT9"!W:61T M:#TS1#$E('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,2XY-B4[ M(&)O6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[=&5X M="UA;&EG;CIR:6=H=#XF;F)S<#L\+W`^(#PO=&0^(#QT9"!W:61T:#TS1#$S M)2!V86QI9VX],T1B;W1T;VT@6QE/3-$)W=I9'1H.B`Q+C`E.R!B;W)D97(Z(&YO;F4[('!A M9&1I;F'0M86QI9VXZ6QE/3-$)W=I9'1H.B`Q,2XW."4[(&)O6QE/3-$;6%R9VEN+7)I9VAT M.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN+7)I9VAT.BXQ:6X[=&5X="UA M;&EG;CIR:6=H=#XF;F)S<#L\+W`^(#PO=&0^(#PO='(^(#QT'0M:6YD96YT.BTX+CAP=#Y%>&5R8VES960\+W`^(#PO=&0^(#QT M9"!W:61T:#TS1#$V)2!V86QI9VX],T1B;W1T;VT@6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G M:6XM;&5F=#HP:6X[=&5X="UA;&EG;CIR:6=H=#XF;F)S<#L\+W`^(#PO=&0^ M(#QT9"!W:61T:#TS1#$S)2!V86QI9VX],T1B;W1T;VT@6QE/3-$)W=I9'1H.B`Q."XV-"4[(&)O6QE/3-$;6%R M9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[=&5X="UA;&EG;CIR:6=H M=#XF;F)S<#L\+W`^(#PO=&0^(#QT9"!W:61T:#TS1#$E('9A;&EG;CTS1&)O M='1O;2!S='EL93TS1"=W:61T:#H@,2XP)3L@8F]R9&5R.B!N;VYE.R!P861D M:6YG.B`P.R<^(#QP(&%L:6=N/3-$'0M86QI M9VXZ'0M86QI9VXZ'0M86QI9VXZ6QE/3-$)W=I9'1H.B`Q,RXW-"4[(&)O6QE/3-$;6%R9VEN+7)I9VAT M.C!I;CMM87)G:6XM;&5F=#HP:6X[=&5X="UA;&EG;CIR:6=H=#XQ+C4T/"]P M/B`\+W1D/B`\=&0@=VED=&@],T0Q."4@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W=I9'1H.B`Q."XV-"4[(&)O6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM M87)G:6XM;&5F=#HP:6X[=&5X="UA;&EG;CIR:6=H=#XF;F)S<#L\+W`^(#PO M=&0^(#QT9"!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W M:61T:#H@,2XP)3L@8F]R9&5R.B!N;VYE.R!P861D:6YG.B`P.R<^(#QP(&%L M:6=N/3-$'0M86QI9VXZ6QE/3-$)W=I9'1H.B`Q-BXV."4[(&)O6QE/3-$;6%R M9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN+7)I9VAT.C$T M+C)P=#MT97AT+6%L:6=N.G)I9VAT/B9N8G-P.SPO<#X@/"]T9#X@/'1D('=I M9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q+CDV M)3L@8F]R9&5R.B!N;VYE.R!P861D:6YG.B`P.R<^(#QP(&%L:6=N/3-$6QE/3-$)W=I9'1H.B`Q."XV-"4[(&)O6QE M/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[=&5X="UA;&EG M;CIR:6=H=#XF;F)S<#L\+W`^(#PO=&0^(#QT9"!W:61T:#TS1#$E('9A;&EG M;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,2XP)3L@8F]R9&5R.B!N;VYE M.R!P861D:6YG.B`P.R<^(#QP(&%L:6=N/3-$'0M86QI9VXZ6QE/3-$;6%R M9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN+7)I9VAT.C$T M+C)P=#MT97AT+6%L:6=N.G)I9VAT/C4L,3,Q+#DQ.3PO<#X@/"]T9#X@/'1D M('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q M+CDV)3L@8F]R9&5R.B!N;VYE.R!B;W)D97(M8F]T=&]M.B!D;W5B;&4@=VEN M9&]W=&5X="`Q+C5P=#L@<&%D9&EN9SH@,#LG/B`\<"!A;&EG;CTS1')I9VAT M('-T>6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[=&5X M="UA;&EG;CIR:6=H=#XD/"]P/B`\+W1D/B`\=&0@=VED=&@],T0Q,R4@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q,RXW-"4[(&)O'0@,2XU<'0[ M('!A9&1I;F'0M86QI9VXZ6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP M:6X[=&5X="UA;&EG;CIR:6=H=#XD/"]P/B`\+W1D/B`\=&0@=VED=&@],T0Q M,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q,2XW."4[(&)O M'0@ M,2XU<'0[('!A9&1I;F'0M86QI9VXZ6QE/3-$)W=I M9'1H.B`S-BXR)3L@8F]R9&5R.B!N;VYE.R!P861D:6YG.B`P.R<^(#QP('-T M>6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[;6%R9VEN M+6QE9G0Z."XX<'0[=&5X="UI;F1E;G0Z+3@N.'!T/D5X97)C:7-A8FQE(&%S M(&]F($1E8V5M8F5R(#,Q+"`R,S`Q-#PO<#X@/"]T9#X@/'1D('=I9'1H/3-$ M,38E('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,38N-C@E.R!B M;W)D97(Z(&YO;F4[(&)O6QE/3-$)W=I9'1H M.B`Q+CDV)3L@8F]R9&5R.B!N;VYE.R!B;W)D97(M8F]T=&]M.B!D;W5B;&4@ M=VEN9&]W=&5X="`Q+C5P=#L@<&%D9&EN9SH@,#LG/B`\<"!A;&EG;CTS1')I M9VAT('-T>6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F=#HP:6X[ M=&5X="UA;&EG;CIR:6=H=#XD/"]P/B`\+W1D/B`\=&0@=VED=&@],T0Q,R4@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q,RXW-"4[(&)O'0@,2XU M<'0[('!A9&1I;F'0M86QI9VXZ6QE/3-$;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM;&5F M=#HP:6X[=&5X="UA;&EG;CIR:6=H=#XD/"]P/B`\+W1D/B`\=&0@=VED=&@] M,T0Q,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q,2XW."4[ M(&)O'0@,2XU<'0[('!A9&1I;F'0M86QI9VXZ'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^1&5L87=A2!) M;F-O3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\T.#,U8F,R-%]C-C1D M7S1E-#E?.&9B,5\T9#1A-C5D964S8S@-"D-O;G1E;G0M3&]C871I;VXZ(&9I M;&4Z+R\O0SHO-#@S-6)C,C1?8S8T9%\T930Y7SAF8C%?-&0T838U9&5E,V,X M+U=O'0O M:'1M;#L@8VAA7!E.B!T97AT M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^ M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT M/3-$)W1E>'0O:'1M;#L@8VAAF%T:6]N(&%N9"!3 M:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S.B!02!A;F0@ M17%U:7!M96YT.B!38VAE9'5L92!O9B!02!0;&%N="!A;F0@17%U M:7!M96YT(%5S969U;"!,:69E("A$971A:6QS*3QB'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2P@4&QA M;G0@86YD($5Q=6EP;65N="P@57-E9G5L($QI9F4\+W1D/@T*("`@("`@("`\ M=&0@8VQA65A&EM=6T\ M+W1D/@T*("`@("`@("`\=&0@8VQA'0^-2!Y96%R'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$2P@4&QA;G0@86YD($5Q=6EP;65N="P@57-E9G5L($QI M9F4\+W1D/@T*("`@("`@("`\=&0@8VQA65A'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$2P@4&QA;G0@86YD($5Q=6EP;65N="P@57-E9G5L M($QI9F4\+W1D/@T*("`@("`@("`\=&0@8VQA'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$2P@4&QA;G0@86YD($5Q=6EP;65N="P@57-E9G5L($QI9F4\+W1D M/@T*("`@("`@("`\=&0@8VQA3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\T.#,U8F,R-%]C-C1D M7S1E-#E?.&9B,5\T9#1A-C5D964S8S@-"D-O;G1E;G0M3&]C871I;VXZ(&9I M;&4Z+R\O0SHO-#@S-6)C,C1?8S8T9%\T930Y7SAF8C%?-&0T838U9&5E,V,X M+U=O'0O M:'1M;#L@8VAA'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$2!297-E7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T* M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAAF%T:6]N(&%N9"!3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC M:65S.B!);F-O;64@*&QO&-L M=61E9"!F'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$&-L=61E9"!F M&EM=6T\+W1D/@T*("`@("`@("`\=&0@8VQA3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT M4&%R=%\T.#,U8F,R-%]C-C1D7S1E-#E?.&9B,5\T9#1A-C5D964S8S@-"D-O M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-#@S-6)C,C1?8S8T9%\T930Y M7SAF8C%?-&0T838U9&5E,V,X+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0O M:F%V87-C3X-"B`@("`\ M=&%B;&4@8VQA'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2`H1&5T86EL'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X- M"@T*+2TM+2TM/5].97AT4&%R=%\T.#,U8F,R-%]C-C1D7S1E-#E?.&9B,5\T M9#1A-C5D964S8S@-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-#@S M-6)C,C1?8S8T9%\T930Y7SAF8C%?-&0T838U9&5E,V,X+U=O'0O:'1M;#L@8VAA'0O M:F%V87-C3X-"B`@("`\ M=&%B;&4@8VQA3X-"CPO:'1M;#X- M"@T*+2TM+2TM/5].97AT4&%R=%\T.#,U8F,R-%]C-C1D7S1E-#E?.&9B,5\T M9#1A-C5D964S8S@-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-#@S M-6)C,C1?8S8T9%\T930Y7SAF8C%?-&0T838U9&5E,V,X+U=O'0O:'1M;#L@8VAA'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA M'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2P@4&QA M;G0@86YD($5Q=6EP;65N="P@1W)O'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0O M:F%V87-C3X-"B`@("`\ M=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X- M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\T.#,U8F,R-%]C-C1D M7S1E-#E?.&9B,5\T9#1A-C5D964S8S@-"D-O;G1E;G0M3&]C871I;VXZ(&9I M;&4Z+R\O0SHO-#@S-6)C,C1?8S8T9%\T930Y7SAF8C%?-&0T838U9&5E,V,X M+U=O'0O M:'1M;#L@8VAA3H@07!R:6P@,C`Q,R!/9F9E7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T* M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$&5R8VES92!0&5R M8VES86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM M/5].97AT4&%R=%\T.#,U8F,R-%]C-C1D7S1E-#E?.&9B,5\T9#1A-C5D964S M8S@-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-#@S-6)C,C1?8S8T M9%\T930Y7SAF8C%?-&0T838U9&5E,V,X+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R7!E M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@ M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'!O3X- M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\T.#,U8F,R-%]C-C1D7S1E M-#E?.&9B,5\T9#1A-C5D964S8S@-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z M+R\O0SHO-#@S-6)C,C1?8S8T9%\T930Y7SAF8C%?-&0T838U9&5E,V,X+U=O M'0O:'1M M;#L@8VAA2!T'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S3X-"CPO:'1M;#X-"@T*+2TM+2TM M/5].97AT4&%R=%\T.#,U8F,R-%]C-C1D7S1E-#E?.&9B,5\T9#1A-C5D964S M8S@-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-#@S-6)C,C1?8S8T M9%\T930Y7SAF8C%?-&0T838U9&5E,V,X+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R&5S("A$971A:6QS*2`H55-$("0I/&)R/CPO'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^)FYB'0^)FYB'0O M:F%V87-C3X-"B`@("`\ M=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$"!2871E(%)E8V]N M8VEL:6%T:6]N(&%T($9E9&5R86P@4W1A='5T;W)Y($EN8V]M92!487@@4F%T M92P@06UO=6YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$L M,C@Q+#`P,#QS<&%N/CPO"!2871E(%)E8V]N8VEL:6%T M:6]N+"!487@@0W)E9&ET+"!297-E87)C:"P@06UO=6YT/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$;G5M<#XS,RPP,#`\"!2871E(%)E8V]N8VEL:6%T:6]N+"!#:&%N9V4@ M:6X@1&5F97)R960@5&%X($%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT M4&%R=%\T.#,U8F,R-%]C-C1D7S1E-#E?.&9B,5\T9#1A-C5D964S8S@-"D-O M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-#@S-6)C,C1?8S8T9%\T930Y M7SAF8C%?-&0T838U9&5E,V,X+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R&5S.B!38VAE9'5L92!O9B!$969E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$"!C"!!'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!686QU871I;VX@ M06QL;W=A;F-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#$W M+#4Y.2PP,#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0O:F%V87-C3X-"B`@ M("`\=&%B;&4@8VQA3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\T.#,U M8F,R-%]C-C1D7S1E-#E?.&9B,5\T9#1A-C5D964S8S@-"D-O;G1E;G0M3&]C M871I;VXZ(&9I;&4Z+R\O0SHO-#@S-6)C,C1?8S8T9%\T930Y7SAF8C%?-&0T M838U9&5E,V,X+U=O'0O:'1M;#L@8VAA'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA M'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$65E(%-E65A7,\7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA3PO=&0^#0H@("`@("`@(#QT9"!C M;&%S'!E8W1E9"!T97)M+"!Y96%R'0^-R!Y96%R'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA M&5R8VES92!P'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'!I'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$&5R8VES92!P'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$&5R8VES M92!P'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^-R!Y96%R'0^-B!Y96%R'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$&5R8VES86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$&5R8VES86)L92!O<'1I;VYS+"!W96EG:'1E9"!A=F5R86=E M(&5X97)C:7-E('!R:6-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M M<#XD(#,N,SQS<&%N/CPO'0^-2!Y96%R'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`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`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'1087)T I7S0X,S5B8S(T7V,V-&1?-&4T.5\X9F(Q7S1D-&$V-61E93-C."TM#0H` ` end XML 48 R43.htm IDEA: XBRL DOCUMENT v2.4.1.9
Note 3: Detail of Certain Balance Sheet Accounts: Detail of Inventories (Tables)
 12 Months Ended
Dec. 31, 2014
Tables/Schedules  
Detail of Inventories

 

Inventories:

 

 

 

 

 

 

 

   Parts and supplies

$    1,004,164

$    1,369,960

$    1,353,614

   Work-in-process

951,519

880,751

990,668

   Finished goods

569,965

228,478

201,488

   Reserve for obsolete inventories

(  750,000)

(150,000)

(100,000)

 

 

 

 

 

$    1,775,648

$    2,329,189

$    2,445,770

XML 49 R29.htm IDEA: XBRL DOCUMENT v2.4.1.9
Note 1: Organization and Significant Accounting Policies: Patents (Policies)
 12 Months Ended
Dec. 31, 2014
Policies  
Patents

Patents – Patent costs are expensed as incurred.
XML 50 R28.htm IDEA: XBRL DOCUMENT v2.4.1.9
Note 1: Organization and Significant Accounting Policies: Property and Equipment (Policies)
 12 Months Ended
Dec. 31, 2014
Policies  
Property and Equipment

Property and Equipment – Property and equipment are stated at cost less accumulated depreciation.  Depreciation is determined using the straight-line method over the following estimated useful lives of the assets.

 

Equipment

 

2 – 5 years

Rental equipment

 

5 years

Furniture and fixtures

 

5 years

Building improvements

 

15 years

Building

 

40 years

 

Expenditures for maintenance and repairs are expensed when incurred and betterments are capitalized.  Gains and losses on sales of property and equipment are reflected in operations.

 

The cost and accumulated depreciation of property and equipment sold or otherwise retired are removed from the accounts and any related gain or loss on disposition is reflected in net income or loss for the period.
XML 51 R56.htm IDEA: XBRL DOCUMENT v2.4.1.9
Note 1: Organization and Significant Accounting Policies: Income (loss) Per Common Share (Details) (USD $)
 4 Months Ended 12 Months Ended
Dec. 31, 2014
Aug. 31, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 14,989,224us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount 13,720,225us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
Minimum    
Antidilutive Securities Excluded from Computation of Net Income, Per Outstanding Unit, Amount 0.44us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfNetIncomePerOutstandingUnitAmount
/ us-gaap_RangeAxis
= us-gaap_MinimumMember		 0.99us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfNetIncomePerOutstandingUnitAmount
/ us-gaap_RangeAxis
= us-gaap_MinimumMember
Maximum    
Antidilutive Securities Excluded from Computation of Net Income, Per Outstanding Unit, Amount 7.95us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfNetIncomePerOutstandingUnitAmount
/ us-gaap_RangeAxis
= us-gaap_MaximumMember		 7.95us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfNetIncomePerOutstandingUnitAmount
/ us-gaap_RangeAxis
= us-gaap_MaximumMember
XML 52 R44.htm IDEA: XBRL DOCUMENT v2.4.1.9
Note 3: Detail of Certain Balance Sheet Accounts: Detail of Accrued Liabilities (Tables)
 12 Months Ended
Dec. 31, 2014
Tables/Schedules  
Detail of Accrued Liabilities

 

Accrued liabilities:

 

 

 

 

 

 

   Warranty reserve

$         65,102

$        75,728

$        50,968

   Training and installation reserve

2,038

4,716

5,528

   Accrued taxes payable

50,462

59,745

44,677

   Payroll, commissions, legal and other

987,550

726,339

472,707

 

 

 

 

 

$    1,105,152

$      866,528

$      573,880

 

 
XML 53 R30.htm IDEA: XBRL DOCUMENT v2.4.1.9
Note 1: Organization and Significant Accounting Policies: Warranty Reserve (Policies)
 12 Months Ended
Dec. 31, 2014
Policies  
Warranty Reserve

 

Warranty Reserve – We provide limited warranties to our customers for products sold.  Estimated future warranty obligations are accrued each period.  As of December 31, 2014, August 31, 2014 and August 31, 2013, the accrued warranty reserve was $65,102, $75,728 and $50,968, respectively.  During the four months ended December 31, 2014, total warranty expense was $13,410.  During the fiscal years ended August 31, 2014 and 2013, total warranty expense was $41,471 and $80,276, respectively.
XML 54 R31.htm IDEA: XBRL DOCUMENT v2.4.1.9
Note 1: Organization and Significant Accounting Policies: Income Taxes (Policies)
 12 Months Ended
Dec. 31, 2014
Policies  
Income Taxes

Income Taxes – We account for income taxes using the asset and liability method.  Under the asset and liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases.  Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.  The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.
XML 55 R8.htm IDEA: XBRL DOCUMENT v2.4.1.9
Note 2: Liquidity
 12 Months Ended
Dec. 31, 2014
Notes  
Note 2: Liquidity

Note 2:  Liquidity

 

                As of December 31, 2014, we had cash and cash equivalents of $5,594,578, and total current assets of $7,745,352.  We do not believe these resources will be sufficient to fully execute our current strategy through at least December 31, 2015.  Our current strategy involves significant efforts to expand sales of our MicroThermX product.  To become profitable we will need to significantly increase the revenues we receive from sales of our MicroThermX products.  We do not expect that sales of the MicroThermX products will increase sufficiently to cover our total costs of operations in 2015.  We believe additional funding will be required during 2015.

 

If we are unable to raise sufficient additional funds in 2015, we will need to significantly reduce our expenses, and evaluate other business arrangements, including collaborative arrangements, partnerships, or sale of assets, to allow continued operations.  Significantly reducing our expenses would negatively affect our efforts to expand our marketing and sales presence, our research and development programs, and our ability to hire and retain qualified personnel.
ZIP 56 0001096906-15-000323-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001096906-15-000323-xbrl.zip M4$L#!!0````(`#FC4IZ8``,Y<"``1`!P`8G-D;2TR,#$T,3(S,2YX M;6Q55`D``XEP&E6)).,?>/))L'AL*#$ELP;BE38I#W*7W]5I!Y-LDF1(BD) MV)TO(Y/=5;^NKE<_^=W?OLQ]Z85&S`N#=V?D7#Z3:#`)72^8O3OS6#BR+-T> MD;._??]?__G=7T8CZ3$*W61"76F\E)[")'Z./'=&I2<:O7@3RJ2$057I]N:' MJX\L\6(JL7`:OSH1?2-=N2].@%6OP_DBB6DDW0=!^.+$P)N]@3\FYV_@W6(9 M>;/G6/KF^EM)D65KI,A$E_[G\?&WZP]$)1_^;EYK'W[6/]W]?ON_Y]+KZ^LY M=6=.E'([GX1S:31"L%_&D2]!ZP)V&81!D,S?G3W'\>+RX@*KX-OS,)I=N'%T M$2\7]`(*C:`4C;S)659/7`$@J1=>P&)LRZKD9<)&,\=9;&I,'39.2Z]>0"VB MC60R4LFZ"A)TO4T-GKYQD;U<%W5IH1RCD_-9^'(!+P24IYZ_*3YF[GR"4DG+ M$87C[WO!YUP37]44`+%M^R)]NVE='%7*PKZ`M^N"#:2S/AZ[+"- MF$$A-868=1V3E=@TDGFB)D)1Q-)>DUZ'_3L/[Y#D)R9=I'16JG)YY?OA M*Y*_"Z.;,!G'T\2_FDS")(C91SJAWHLS]NEU$D4TB"673KRYXX.RWG^X.Y,F M81#3+_%'Y'1+M#,I";SLKU^>;LZ^!_BR_-W%7JR&`7E/--E"K3Q]H.J@0!]! M.R@\=I_BHJ?8B:G[#\=/Z".-GI[!B[;H;^:N*YU]+Y^#QF]1-N/5 M,SR!`(>$F+YG5Q"APLC[$Z).8\EE-<^^)W+VKPI4D4-/8,IR&@S0/6,)@`$O M>1E@T(BCA#:03,%A[4>Y;/C]4J\08@/J#TF,_AUSH"%$TY!\%_DT9M%,2)"O MSNR6M31`X`1#YYU0[45#:=02RS> MP7P4W22*SJMM@707QK5Z8>C:L&R%&J`"&MT8B'%=9UNF83=N\(T7T4F*<-F2A MTA%B6M8)8J[3UQXQ9QZM++@GZ'W MS+$V!"D&T;1&0OTA"AF#KIYZG3)V6;4Y=AS1_9C5]I]I&IK>/S-QWVFJK?$6 MTYE;K75JA%B:NIO;1\JH$TV>P5AOH%/],#7/VR\+&K`.MF@H(%N;#VF!$];9N$2N?=#5%]$1]'W+1'V@`6:D/Y:_IEE_D#12>VR0]0B[2[<*Y5*!N"O6P,RUFH)K8.HQ%K*,YUG6\; MEDX4LS7G^V`2SNE/$./V[^F1:L+8S]0%S+?DN[&OZ^Z10HAL&V1X]L(^'YE$ M`R]K#-(A^31,;DF@BGX/(&J3 M4L+/^`P/HB(YT6QR$!3U\\<*/_74"$4Z1?8A#,*\]G3.0$::HEG%J;A*/KU! MJG48JJ4=#9'8AQ`]-UEX($CU?B4WK=8"T1!*I!H6X>0S*)`ZU=%413XLC(IT MU#`.!*-VX*/J_!IE,QS;J(1+.-?`S`L2J+$*6V'`WM-I&-&LW"?G"V6W7R!E M#2/7"YQH>1_3.0-6"#,*TPRW>P2#%,:P5%OFG>9@,$]#'#M2*MDP-/*O)X[* M%`^>*_]"XMB1F^FAUGM79?V'6V%_D:.RJ0OW6B M`%K&UGNWWCO,FW#=H#1%SF\9&\GG_-R]D$ M=48_)/,QC1ZFI0VX^_J5[49#P[)SVRU;<1X&Y78FGBCFR@V=FFV8IX:Y M0G5^:?33DG?7[\,C[TO)&R-,]N\^A M[]*(X4:.>%F_)5A!5/]\BF__P&.K;,3ML2XO=9@F-_-*&Y*G4XJD5EL`-6+HAMZW8FDR[G[; M#\NAFU&G6YINVBHN-IYP4\J8+553S2-@WGW^:$^[0'62M;V[07!^:3TU0EWD M3P.63AOV[YN(JEFD&`=*?/,+)S3>9Z&^38)@*3HQ^(7C',].J4$+)X$CC>%R ME#;=I)NF:LO\<8*!P1POF6RM*YIN*)9=BDI]I'7MG$#Y,&@/:5W3CCEB6L>/ M>INF=>3$TKJ*-NQ,Z^Q32^M:=<8VK9--4G0NPZ9UD$9JEM6W8NFZ9K0/PAF6 M0S>C-JTS5"*KZDDW18#9@&ST")B;I'5[V06JDZ'LD=;QN#JG=7OHCZ5I$!2' MRNHJ`.V,U";1E-RN@?ZRNA8^`J^-&"Y]:=-+AJK:FCY@5E<$<[RLKK6NZ(II M$M.4!\CJVOF`\BTC/61U33NF=5:WAWOA%XJ:ICZV`AYF*/=2`:C!K')ARUI? M[N66:,=W+7D0]6Y%MTQ-;F$Z'8`QV)P:8,*2YO;N3)KHQH"MIUAEM MWQMK%(MNG'PTW:O;)LG(S9-.T9L^ILR[S8S=T$0&?U"/#;Y_B#SS[-@^C MV/NS98`HS[ZHBL5U/\1I?BPJ*7E#HXUR.U^@-B+?NEGB87C%&N]P8I*H6?X"SEDM?>&JM597W09,^NI\O'"_"(V?7(,]9 MEW/$EJSG[SL6TN\,H4Y'=/F`"(1]T1X!A$?,CN@-S?Z_#\J70G=)=>`?Y\B; M<.L97EV'V3I13@*=N#,U*W=<^0CP:J.@(4,<-'K%AT=0@SB,.MU(.-(,3;?K M<'%L^@)4?Y!4L71B'@>14+4,0[=J-6L`/+6ZI!&+J/T`RB[QR^ZQ[QIK==M4 M:S6\S*QG=+7QAECUO7@H=&+WI9IRK14.CJY6XTS;KG<2K>&MO=VCL^P8-35; M-VJQ%5CU":Q6X4PE?X/#X7&)4U#%U"SY2,!JM4Q5=,.H=6RMD44PZOG)<\:> M[W6[N7>DJ):Q,_\IL.L97^U-'9JJ[!+=0=!5Z)RM&)IU5'SUDQ2:3:Q=UMH. MWW7"XG!.HQN:#NTZZ!XAM7I79-0KKMI4S=95K393.P0T\9TQ)@2%VJ@P*+1: M70-;T.5:!]P2V\WJTR&=+RV%Q#)_Q\T.3GWBJKTAQ%#46CT;'I=X9&"9AG$L M@=7JF&[(6GT\J$/V@<:X*^4Q"E\\E[KOE[\PZD*2M[Z(Y&H2>R^=`ZIFF(J6 M7_)HR'40L/5+0K)L$'XC[VF`%0=;W2:&:NLG`[9^8@0_O:9W!PLI(4[;L4_A MU>2/Q(OH^J+G1]^!,4G@]G$!N:[R,Q/-60Z"M'8&GJC\3/-I(!5?NZ3K?*`^ M,M+:&^!TU5"Z(XW"":5N>JD+?GWD83J`4!69C^,M6#:Q_^SJN[["0,&FFO,< M!.J.?0$YHSH-J!7["52=OR;VR%#K1_UYL]H3*J_CN-B)'^]\F')[:7K8E-R8 M5Y_(&IV"ZX[L0QC3[G-+IB;KBA@.SR"'XB-=K#SIP[0YBAT+:8J9NUY=S*$' M&+5&J,FFJ;6$4:'^=UX`?=F;S\W+ISG/0:#6VYYA6_KN^'`HK*VL<4^L6`=B M,OZ'::;.8KCN"[C+UW5[N[\`7OF:\FC.6^16[ M.M*]8*CH,-4P+/YV[P/@$'\$SK9M?F6U,8YT,3A;!=ZO)RP#(M.6<9E>!W85 M0B=X7-(>C*?XJF?38=\53Z[,**J&MX55_;VZU<(Y_SVZ@JB71E7 M-!4DRV^D&HRY>`Z6Y#>O-.%>6.G:TY0TA?!?F!32[,BV0N"VD?LTVT"LQ9^_ M4F7=;L>;VR"QGZ0);C:3.:9EBAT85GE\'7(./A;WS+3BD\J:JO+'DWI[O2*ME=^6ZZ2DIQ]\<7?=BQV^X MFB(0;?F@^VX6/2*JZ('RK1X'1B6.&:4;Y%JBRITMW\<0P14'NWGT"*FB$P07N1P85L4Y MG-*M@2UAM;ZNHI2?RY9A*D/=TE$YCX076AD#7R19GI.!;-FRBY?^57/E_0$Z!QHQ^_ MNRB6*U7.UJ5N`_<&#*Y,19&)-B+*"*\OJ:RV(7H%KUQ\?><[LS*Q*4B&9G1R M)3?U;R%OCI5U39$5T/-.X]-'/]WZD25$ASQXJNJ5@2[S05:?4_BGL!X M496%5^`8EJW@<;EF7`J`'I.Q[TWN_-#9%1[_6RE%9\.48=RL\*PY>@5.=YY/ MHVL0R2R,!+WT!)RA@/21+O#F"Q`'WH[@!$N>>HY&4;19#VSJ/\5.G+`RH]\I MR\E*6*U`^Q^AGP2Q$V4`!$0_A#S-0O$"L5^I[_\8A*_!$^0S(<3']#J*:!?1 MBFHEN]^JX!T\$6!%R\_;?*%*!+_VX[=_&8WH[,MH]/4L?HM_+R06+WWZ[FMG$;*W: M><$HPJ^R7,I>L'[@TRG_-_]J',9Q.+\\!X=#%G%&9DU\C#]P)EPBEU\[\\7; M8,P6;[>_>)%(8*H2US)IVS1IW3:D>3%>4[]8X"]IV%9L40_*\2WVU,@#QQS$ ME^>Z%P@$69+6^X1!JLDXL4@IWK^"XWPK\8$ES+X7^4::AM&<1OY2>O]T(_U, M71"UGR_Q3?Q,UV0T\^W*(:T?6&^_E5X=)GG!9%6)NO"'A)52;97"J71#?><5 M7+`$W/^>`#/UC41LRS@7ZZX MC"3LFIGTC$]P3==9+(6M?T@BZ6=O$H6?H-#\-^Q)EBPVFO=7"."9OEVL'L^Q M\*OS`DT;^YDJ9!`D.E_XX9))Z=U*#%Z,9@EN.I.V56A`HUDJO;0RC$X]AAMW MH)GA%(!ZZ%T+4GS&BBM)04%04QHP#YYYX%T@>H'00`R+U7;R5&8N)B[>.$%M M@/;!.S>9Q&RM)[]`0`5*J;J`M&\3K)M6O&*><]Z'H8WB<,'_F94_1T/+FU^1 MA*!(`PL](2>QB1U<4I%%)-XW;#W&NH?7%H<=-DWCF+2$V`@JXZ+3@&=KNM&& M[C0*Y])5,DM8+*D$U>J&3BA^P@O^?"/1Z93B_D::$L">GR)UR-+B9X:$@5VN M`@9I7OL^894-7R]`YY6I?'."*JI?NODRK93:/WH+0+5(P',P,&V/09+G)"ZJ MY;FT!7#E^Y+C_A\T+XW!TC<049F7[D$'UP9^#;Q2@)A0*+A:@B^X"M]*`:!A M#%W;!K'CH45LPST2P5;`H\0')OCGYON^J57@VXG#GJ6I'[ZR5FU/NW9,:8`. MVT^@4%&^8K8M.@R\Y1*D$`,;8().,17NRF&OR2-!@6JAP(H4]5/U`*=I\+A3 M+E63]`>W9TZ<%6R*IQI%M\6EE7)CSTW6A;STS$6F_:]>_"R%T!BP2!]Z'8)E MMGJ&H8^+S6G/1Y2N]09ZW@U&A4\H/3U/WUKMJI.V&0+'6?8H.55(-`JV0\`30'#.7.1)$K^*&R3B> M)CY'E($N8%(39AKRXM%75#,8:X,/VDX]9*195BQ55G#I4-,3Z^K/3N#,TM'8 M!D4*"2A$+TI[E^%+!%*^-C:=0%4=BBTRAC!!$$(Z"3I M%W#(:=XJ.8N%CQ+"S`TXSM((--V0$.*ME_DK&"]D@S.&%TFZ65\:9^66:;9?#K@X+IW3)=AD`XA(.*ZN!0#/?;OV-+&OOG+ MRH39XZ,3K<=)2:JB+`T9ZSK8)2Q.QXC9.$@"4P$_CR$FQ%`3K<9:0A7`KV!@ M][L45&&.BRHK&T%"3O;%V(S.G,;/H5B/?@VCS]#*T0(/HK$,*^24'GL&??U'$L9OY>P_:4)]GRT+-P7+?\1@`_16L9YRKH M0L9GA$'763!ZN?ZQ!9J!BB#/\&;!BCA2R'YM2T!4]=SX>56"&-8*P`M?$>Q' M@"NM>$D4(S6353M0B))^KBUB:?.K@*I=YVPKYQ5Z*_J+V/W_]MZTQW$C21C^ MO`L\_X$+M#%M@"7S%N7Q#E!]S?8^MKO>[O;Z\:<%2TI5<4R1&AY57?/KWXC( M3!X2*8DZ*8F+6;=*(C,C(^/.R(BF]3A:V^58]D`[RFH:*6G%/]MCL>"9'50E(R"9RRD^#J:)#'#]BP\:('1B MWAQ@B=D4@^4\":8X0#U]%.-X6X;!1(HN(7::@DLKT)A$P02#J!'FR3S["2(U M]6DC"<$S4-L3GFL@PK'%L0F>-\:,3_>`(58\;,2F>-B[JNBHA)&KRDYAI-2G M3G?Y&_+(>T[)$GVTLE6T$C:@\<29_RB"Y16VY7EDQ+0]OKN]P[][,::BORB? M^;%!_5;_SF2VC1+X,\KR>N8OBA,+2F41%_8YR^7)82@&:D7S^SQJ/,W(,WV6 ML$3WH%QEHDQ,H@$+]"O,&S_F?+QYUH&Z>*Q1DX9@JE((T4PY*)73%,=6==I44%]2B#OW+=I^@W`$V'L*8=$'!."U=*V< M\U,>OL4LEJY:0YTOT]548^@L+K.;S'TF*7V\):ORU?O&&D3L M[[E:))X2FBW%%\I'IGC`PFT<<2GG9=7)Z6\`5+SF1164/+\JC;.)(YS*D_(8 M&(_^'T*TOXKD,L[.^"+F'H%%P'-TO91GC](Y#`B-B3^%.?AO8-<]8SI;6DD- M3&2>/*62O%22.Z9`JR)GKPF\/$N@(%J""K-(ZG,KWFVXZAG=WLP/R\".)0L$ MWXHI?P3YB'\549(')>?"S[1VL8\B;9;S*?SQ_.B#?`/T`__!LC'[.7ZI8$EJ M63GR/D"#PV6X&"XX7GF%6[D,\.EH:4GLC7"C)07C$_]JMF#B!UE*Y@V_6GP@_$M9HRKS(.,,*2>AJ@'EG%'BW>S;V,E1097R@M5B#$&Z9 MKL>#"=8TF)>&3<^,5,<9J>[0;8^5T>@`6-G,CB[;Q>K&6+IB0?C%Q]"?R/T. M(T4B)3=25LJ7-B0K-RF7,YOM*([,M>,*<5L6TU6IZW,1F^`M-TR<@]$DL6TS MWE732F[TT#7P&^HWKU0:VM^4DE?Y0UQACLL/P9;DAKO("'U`?:<,))+9K^< M!V]FU'LG']#$YR(0G\0$:M!;8)['%:\`!U`IA%I*V2[!P(>H8$:Z_639/^$- MS,F"-8^HH`S!YIS"KY0RV(#[T@R86#_V!+`T2R+90,,6)T MF8^2\$LB,R\,45S[,S_P8CF:&%X&I[V7.`H"^>9@O]1\O>Z';&3WF=,5HKLQ MAI'3'A$7OI6K8SR+P6U:N':KBBB_J-G*;^K*`P&QS_+1`BMSS%I7Y7D%2Q*B M)77A7"*FI"X5KQOX(=FGI?O`E.\>Q2E=LH_!7:WGQ$]TL8_6DE^P8A,I+_+, MV!^[)[1KLF#U`V3!ZJ.!LR(+5OSP8QB%.V?$&EK[DV/;'HQR\`B*KAZ+N_D> M1+@YC[]DTA5"I@42A\-] M(=%`Y)P!$O\@$_?]HHF[$?9VRK*Y:&XT#0.ZK6G"<0;&Y>"MB(;L\HG\TA[]IT1_3_VG0W\5]5(> M;<80O4H[J$KKYM+VPG?]THZ1.-OC8$,<7(<@N^/)8SQ3M\.R[,`4\:JL_790 MG=904]VA?;VL]6HG](U<1QUIVA6C;XUE9JJ:/E)MXYHI;`V*='5D6JIK.%W3%2L+$ZS;6-2/`U%1=[TW']PLY M')=T<'<(P6'8)_!;SPU+(ULU>B2MDT".I3H]EM9@R1BY:[!T'7*Z/X?JSZ'Z MI77,B.R/E_*7OT:G-AXG5"N^JLSL;BFSVHAV[3F*#LX)6IKN2D;LATE9-PU5-V^P1N>O)GC,T56.TBB*/5]&LVU=C/I?OMLS+&0P+ M!1/H/K%7W'\EHE'@(^_H)-MGJ.*^*K6=HQYTO*P6[PJ7/YX\^O.Y?#IA08`W MIOC5:9AVZG_CI2%D@7?<'W[C1?8#D66TL!$G_/J"Y2"RN*&*Q"]8$$R`P->& M5V4_##X-W@PX*#1]Y(>`?PQ:I(TD:\396T5C4=Y/WK'/D MT;-82SXN;OU@Y]P$;^CP&UZ\Q4S]7?!E6"=1^0XX_)N`(1`TWVC[.*T\@P#E M]\NUX&U1%Q&R4"5-PG_@RO?S;C%Y2J;Q3% MD:JXO*>K>M,L'*=17%^!Z`O6>,BKW\D.A]CG2V)$WHE:7!V^U-3E,YA%SE^^8YW"N/H6+B]5=R^DC>RJ=53Z0JFZ!`D&\30C5\)'K7VH:NQ M(-=`\O+V/BK'B*ALLG#S,J>N?)"9;C1)GO&5;+4?FU!7C53/LT3!G M8^QYFA?&HDMI\Y1*'M*427ZO>8$P"6\HHW#.F*59'%+?D#D^PG&-ZXE9A5TF M$>,D1T1`S403>6.:B59$]4N,Z`:L*J9*.%_RWF\H8?R\>>M5WT+^W'1YL>:N MX@X27PY1]/@[KH@73:2QC$&UK)LLH2$(?%(IXN`I,+,_RV:ER^QU>`E14H8" M*&H]1R2<8X;SF&"I:RJW6:4N*:/R-K6"H(HN6]0O+&:\/%:.R%S64'$L7B>! M!'0A;RLR,!^_H#8I#3'/8 MCF^B*9T"<6KW:##87BU0M+)00";(=<)Y7O_2#@Q0ZP MTEX\(>V>S:T)QZ8J[1!JO;X$]VU\JY4U(R)")A'9H!+B3QA[:D+(4 M'WC(-PO?-W56D\5&\QGR:J*5UMU97LF0'D(^XA*O9BJRA?QET*YI2[_(/4?Q4A5'4?:#,"H*;`#J\NUE8')G"2O9!=>$P;P^I.0,4I%2YT[8'`M3YTYB M7JRRHC!*V5U`D@Q[42>\,Z^T`_/J1N5*Y9S^J3#;@GG.K<.NEE/LU/[A;+R[ M;%87RYA%6PH:?P"Q*LOM_ M8/FJC+AEO#C-F$\3PS2R;@AV5@4%'_N\\?A2%]0FOQL)1'0I'X/-S(WG>ZQ. MQ)*$NBI+,2HFY?)QL5IS?25ETH6@.-$+>.:1A0BME/`AHHH\?$2&99)$H6;I M'1?N0C@IM@H2;`1K:C*?TTBY'?&^9-4XRJW^F-D7M`B_ESL=%&TDNL$ M60A+75%YOXZO&^>O%/ZV'=76K#9%]D2G6$-S5&TTDG_8JF49.Q12[&FQ57$\ M&7Y'9/X7_">0#87JBG*AXU-3MS\I#_(H!A%!V`I]EFD2VVX079;K?N;]0ZBL M88S[&O'2B/5S5&K0H4O-QY9#B/&[21#=#ESF%/(;-Q+>YVWNA?ZYP^X[A9%2 MF#I?9`'VA@+U7RG\7'FYIGJ[#/NA"8$UYLD/^VWP9:`\L%`H,QX;9Q.IAT2( M$T5@0*$/BCGB:47H/?"@%U@R,^]/EK6K;K(15AZ-V2-L#=:K MQ0+L]=Q1?8XJ3"]4A47!F7B_`/4#S^]&4U$#_] MD"4W#YXW__%3_."%_K](T(#[1NG`],=M.+GC"*,_/TUS^56(KW9&4L[AMDZ2Y:_@ABK&CW7R(`>_(-1+HZR%&7>N M-[3O3TIC=R)1`YL<0HHGX8=R[7IX[96MVB-+M8Q;X[(DBJ]20+0$+$)WR9[0&[_$T8SI%-N#J=9JA:F;? MV#A#E4;&(I\1#S12]O`"`\51]O"(N@^#Y>G2`NU*+?BZ(<#3C0)P=LL'S5@% M'-0<#SE^FY-O7#Z$_\4?QQ%8'_'L_\G@6,7VQ'P(:FD!/TY]7O3TF?%EAHR? M79:FXSY63-'^4M("QN=D5$X$\=8`D=2CG9=GYO9(/@1.5#<$AS*'I]@2WD6& M^KW0_(((J#IR43`9#1^PMQ91CR:_V'S,/\/GX.5IQDURN?_YV:ZP./@H%R8J M5NCXCU/<XV[B=E:?P7`.,:O2Q$LHHDED*7$BHU)$(HW'" MH,5V9^4&EP7%?%D&GG)O2N"+'B$A>_"XQRZM;7IHB84ICD#-/:3WQYF!VSMC MQC,.\`\O'G-A.`&"#2)^O`<,\A![,X$T?%1VK<)<,C^6G40IXOA/,(`!>CSI M`6Q@SD$PJ#,K5FGVB@GP)9N#*S*C(\8W7H#!S"^/C*7%>TDW30*SUB1XAV@* M*/3-8L*86)1"JU*$991_E6(ZK6^E M#)V!4\G4/N4])+MU8KHY<%<"?[S2G[M7[MY7^7-C.+!7;^GQL%($OS?"R6Z7 MLJZ5_+>_2'Q"RMBZQ/`V6!K:/9HNG)B.41VY%S!LP^T^U:W>@PB+RU_R>6WR MQ3"Q=#Q+.5"+/M3IS.5SIN?AYO;O.2^S^YMY,:S:[VG/H)>XF9?%H(L'D5\7 M,XS+.0N+5R=>SI\8JNDHFKV2/M941%ASQFN,3%5WV]3OZ*J<."+2L+@M'8C]WF,7^%9AWP.8M:\-3=4T[?LN'!E<$T(N MB4`N2Y#TGNPYV0$=6&;W-W.!0B]P8O:#,OBT$7[;([+Y;E M_O#>E7]U)SSKFT5HFJ7JSJJC@7/A]W:(6=/,75=-!VWZ_D!YD6!,VU0=_7K/ MDGZ/XC_!E[J9Q]&8)=+5)&C'P=QU)<;B#-6*>3=YW/T^1QGM:&!J/C#%]>7^[D^4[_W MVRYH,R^+09=.87E'ZA>J\QL_L?/?[FU-V36)#)M^A@Q2[QLV+_!>*)AT912@J99S=4:'/<+V.E>VU9:E.L-5MQ(O MF]OOO)SF9\DV"9%50+VX`6\#PF6(CII/'^G&M1'RD=TAZIM'Z5B MT5GC:6@XJFF>]GCH#-!D#0UUJ%V/3.K+71]%7%S^DL]KD_L$EJ,(_,O+!]!5 M7;-5W>X+F!P^,*BXCK,F'-"3\'XP;0]-U76[D>2R@10[[HQ%2\)GZ2R&R]OV8CRXF2`]ME@U^-M=2%EJ._0V'=H[)Q#TNVF>GV'QHZAZ9R) MJ>_0V`>Z^FCF56SR93'Q8FRBZE_NL.=<;._'=MY/*`=XJWJIIW4TTM9,U=T] M<6`]:HZ>,;$[;BS'W4?X\!+)QM)TU=57U2ZZ;)GRF4)X1;SF^FC$=M61M7/: MQ!G*C6,M_.PV_+(Y_D,6AWZ:Q8P"M5/_&W[>N8;/^9&!"0:#8>R<5GR&C'^T ME7=ORS55Z/SN"CG_Y@IYWK;4H7F%++]VW5?"\:\? M63"A"GZ)%["=B["='R&,;`>KK5TAZQ]MY>>WY9?-_#^#@5_Z\R0BH-,Y\.L( MR+"L(\J,'E4]45V@5-K+*55[NNC2EA\3#\<^H^PL(LZ>('HQ<`$VJ*EJ#EBA M*T^8+M7Q@+6[MFJ95^AZP-)U6[57EG>]+/Y>RB3)A\YB-?:K4 MU`V?L",]'U37TE3=.AJSGPU:]*$Z=$8=B4IU!2O.R,8>8WV+D$M2$T>/!ES% M2KN_I7VIA6,)\8N[JH[5%L!N<(?'"B-<%VX-9PAJ]@BXO3ZR-?519^HI[*EI MR/%NJK\K>5$*^S9G8<*4-$J]`%RL5Y:I&JY&![K\9GT6*[,H3!\3A<%H$Z5\ M\5C!ZX*4\9F_KQNVZAK\2_C#575#ST=[85XLQRFNZA:CX+TZ%6OPSMDX]9]8 M\#(HT%34B6A3[J%2)^(V25CZ,0\:O7T$U)5J2G2J-(3]8XGD"YCW4P!Z#8<1 MTO=0:F*1"/]Z#Q[00QQEX>3'YT<_+94@^!@2&:@*$MR;R(LG6-SAG0^DFD9` M-!.6LGCFAUB^]=%+%1_^ERA^2'1USX"2?+RLR7A1B#L6)PS(.X$=9H]1`/(P M`1I5)D!4_`F>'@!?L?!'E^0N!YQ-D^9Q]$D&Z=*`#.O*?L.*P#Z M"9%R8>9G/WVD2>9`I#0W\W%0)6%!H``_"%!PQI9PJ,HSIEE[P(EM$N+(F%0 M+KJ;*!ZR=!:(J,LEBA'M#44,K!XI`!3>!44H!8&5,S(Q3O'(U M"GV2V,E7J19Q8W7[%9=7]O61@>0L@2"$*:PO9C1,L6Q);DE"3XJZ)1,VAIW! M03@=%YNVM&'PT&=VGS1<5SY1GVT@N2"'[B0$V4^Q?E%>^O*@$$ MS*-TCD)*_T-Q7B_-500(-^HA]/\%P"OS*":VR!>.J_+D5V5H-EU/C5Y8(]XK MJN!CF'KA@P\(IK>2KE<*S`"T+T'F(H]Q,P-R=)[#R2B$CTQLI7\N"0->-'BP)^" M[,_FR!S`#0S60$I2'_*55*1N"<(<,&&W4,!!^\/'# MET<63)7/[,%'Z4GB[4L*0K*X=>3G[')MC/,I5#Z!MX0$3>2KC4!^*UD(@C=. M0($DA+NXC+M$XHZ$/-BC@8>4S*93+K#1!D1!_^7]VUSH^TF286U&I,LR':J+ MK`#F.N\9!H9^PD)4N1-V#^9WDF&,R@_%J>Y]2FP&@(*Z%/H-]./#`X`*CZ#: MS+C1#.;H0%-F?A`@\*\1&BDSAW_%!2NKZ$,^ZO[U^UK._)WX:AXP!(NTH^!H MP`:Z*0!/Y*],XFG%_XAN+QWY".R6W@K:/3:1% MO[#"BY,EJ]GE"YNG7`,8+@E\@US,J8^QK,U9!QVR\^$2W=B)2\I21I=(PSG6 MCKQ>QC2QY:/W5.;-]#E:PYKK82$FN05'("#]#F_%4?;PV&@#M^7246D+)$,2 M)PJ`5?13P$H':LL">&'"DG'LWZ/;S8+HN6S,`P)FWHNP^'V0(_`XC0-N!,-8 M$@W#76N8(F'@_%!#9&1R3A8)DIT_QM@$1FO!H::8U#T&BT)X8(QQA4<6\HYH MW$DOC>/%`O(&E^J6![+`7\$!7Z2;7QIAC(X-CRGPR$@M)Y7FR>\4H0X#S)(+ MD27`%;)(,/!=$.`2@*'F1%*\]D`@8R22)=$)$`W?>G,?)<^=%Z63XJ#ED4`$9#$JI119__G1'W,667B#0TDAN`Q#DQ0+\9(HI&@D M2.TH3DEXD-9Z8+G&0V9%WN&ZR5(UQU8URRAY,6A2E76AB"X(PP1>`@#'CQ@0 MY6.8\+ZK#MV58Z",$_*$D#^A,P,8ZCX`/I?\NX3Q&HI>H_B^UN`*-1K\ZZ44R:6!_'!SB$:+*9`^&8A:F6NCFD@;JC4.I*]BZ`P-T"BS%+&8E.[X5B(+40H?EXCU;7 M/S,_YF_/O#_IW$D$9Q$.,GA*0%\3/]PB;J,ZI4Y4+@X'<%O]-$.2`CV,QU8) MG4XO*/X28>4:K5'WW\DG:K5_&ZFZK-Z?RT1+)\\5EQ'V?#9('>4`5:6["C0[1=<&>"(#!`"'@I1.Y.'@$MOEA[K%R4FN_G,U)MJ^ MN]:8I'_$@:12R,KQ7#)/K`L6FIA+;&Y2V_F987[:-/>O\/E*'( M_!-,`IL)@X@G9_``'-_`9`ZR%2,]]-?$1X48(JF7J80>YUN)2TY\H$5%N(!,>HV@!+.$,I/$S!IMQDN#9**1FUZ\@%K9J`5?F:M&1QY%HA&>1< MLFWCZK95=TT\Y)5LLO\!?X*TRF?42%\+,:L6MIDPL68,\_N\LBQ&\I'VUX$[ M4FVPFP=L0#5ROVM,3!^Y`]WYKK(@=S!:OHC2]G:9_5U=EORJFRKV8/C=P=N& MM$D37^HK(FAJU.*.R\AJC8>1-3!7(>)`A)D+1>%_O*"Q^P32U2?[L'"51(+L MZ]OOR603CR5TREF<9,:H'QXI\!B3N1@+HY];9SPY.,%L*A`HI.%!,/P08>)$ MC+/D+I34'^)<)`*#`)Y"Y`DC#"Q*;A2L\HQ26A$_^"!KDR1^""M"![$DY,GO MJ5\Y3?SZC0CU;K#PZE)+*I2',3!@DR)H233#XR6JRTRV]=8@XO2$3'PW&E,D M4+[%CU30V8HI)@$@4#;L$X4C>#@6[204O_E?I41/1.I]!@H;XW4B%@HTA<%' M-.H7<:Z*_29SJ^SR>J684B'*G^EV"QX.P;*\!U82X!C&NIGX`?GS/#J%2/\K M`'&HN[%[EUX'UR;*)"#3Q_Z<%\\H'B+,)=\O.AW7TIMX/[Z)/\4M MYH9.:7]+_JINR"A86T]579P,K!$@(\J(H4P*7'LU*!L$-2<<0G5RZ?.`!GG_(Y.GL]6S1UX:-P4..(I,P2S;.&%07G(WZG+3E]+.+0_JJ1+%? MP,RA>Q-]FIA,$T.4C/)KD:7+']5#8Y`7Z0W\?/,+=WT_2E7[Q0LP5:`Q=>SK M+RORQG[Y^7_XL_C_,/.`IXP5K\,#Z_*>?A.I"QAJ(%AR#4/!UC$=B7#CATZK M4*GPC%>,BN!A+?PK+ZZ]4B9Y``9#O:5$KR*E8GVV;^W@B!Q^H.-A M_+=8'BV-BP:$$",P=-13DP,SJTV1X M2H[+N:0J&17.RBK@H!:#?@]\G8SV4=4+G'8208@L7 M**MI5$J;PWWS"&Z@.MSG6)P;FP.M*5$LOQ,AEUX)XQ$.908X#5\AAF8XU7*Z M';Y(J4WY0=9BZEQ--@=)`6J?%(J\AJ4IN'$NR(&(%E]L3J#B/MV`+GIC+^MUCA.[CI0/G3)&4]>D+1<'CQ5H M*AE@BV;L_G+5U*7D,ENUA:XO&-HGI=DRNH>`803C#W.^5>0YY'\IKN2T[I5$!LI^2\(LK7?%E%*@#B[4F>1%.* M#S=,S%=8"E_78`Q$#$="'`6J"#^)U8.0O"_M-X+0M$*.";T`!XT7IH>]I=#O5\;?<%5E6QE4K!.M*["L/ST_K\_"&]@;Y=U4I>H0$ MNDVJ;FR:\A+PR&+O+0J?I?3U#8P+,\Z<^VL)%G+@O$=%%5'R%`[JQT]?^5# M5EYRF`2SLFAJFVG6IWZMK4!XF(P?C&$L9?SP+023Z5`);TLJF$)E2L0?U7G*[^+R-+Q3U5JVA>.EZU]U9>[J"ODU%"XG2JTK`&4XG2SW0(B]KX+9Y"80K? M5W!LE-=_8'#^^XUPO$'W/*/NTO)1=$3MU)>K(S9=_^%);@LLG%3>[X%0.B+O MSYL&]B6ASPL+O0SMC@P5\@.PMJOPZ`9M'4;*7K``O70"V+,1?#%X.J@07H/> M;LKA3Z6@((_V52-OYIF8N'OJN6OXJUKNVJIE#U53LR],%K^Z9AL6IFU!Y)=G MO=[L*B^=D\K+Y=D/*B__CLDXJ[TT!$+=9O=/HAX MP.L7'1&/)UG_CN+1'-@G%(]ULQ]4/,H`?C<$9/WRCRX@5Y'0L03C[I306<&X M?I>/+AB.)Q4[N/A>*BY*Q0]1/&5T<8_2P.?87.1T8<^VQR97*T7WBJ\S%+4' MHY>+D<>7@Z%>:'?JA*JS4KA3YU$7(VD[(R(Z=J#?92ST$K/M69+5"])BWI'J M=N8L:9]RM!MG22<2'(!L_9H%IS70C%YDGNEQ4D<$8Q\MO43)V$=+>YG8GR'U M4K&7BKU4[*7B^9XA]0*R%Y`=D1&]@.P%9%?.:[:Y*-$1P7GZ>YQ[P-H9RMC# MD,SEG0I=&I[ZG/KUYT9+)8).)])%;LTJS#73VF'UTY_N8;XQ@CHAC%PO'M1.U-!1\SF,]_@ M0]Z/ZC`:-I"3UL`]I9RLG?X8YUR\(<[9F[T-^#NZW7NZ._I[QMSE&[X;D,PE MW?@_/S0YFR9SE8J>__1#EMP\>-[\QR]83%@T]7I/A=E_C5+VSD^P_'46LZ\P M]9L`GOG;__GW?_M)OO6.\3K7G[$!15;W.'6I@#\^L^E__N4/W?K+WQ"$_[BY M80_?;FY()6TKNLL_K2U+C:M1W!_KVBC)12AB%82C:VO^^3M3'KTG5FWA*6NI M)RQ^PBXH8U&4LMSSL52H'5N&\#Y,SV*T&'2D_X15^;T7V<#/FSQA-?:F;LCP M2O00^O^B-ED)_DV;`BKW2;13"?QIWIFJF/WB:JNOJA9>;X"HM66^%TH$J7QS M)MB$CY.]P##O)FRIANZJRJN1HVJ620.\&KJF.M1<[`N-#6A2V-'@T+7L6];P M+@39>I%4D6!OHQ!%*6^N_ME/_NRZ#!O5RK!?O'\`\[VECCO4K0'V[4,4@U(* ME2_8$_LJA=J[5I7M<\[@3<2Q=<-SA$*-L#C.<4L=?'%<<%5L\SO"M:X/3-&G MG?K[2JDU*#4<*T'37#N_-1"&.;`<#H1AH.O4!,2BUML`&G,9&NPS*Z$H@#`U M=$TVG/F*"/#]-VHLS[%'S4%>.::&P7[9@60CNB0I;*JFJZNV(X2RKEI#377T MD1R)]V])7S0\R^.*HNF4CF2;3D)HV`Q`,Y((W'D<96./8U@0,0.K@ M5!'PV+V\(MC%FTGIU8%2$-9MW47"'>:N[J[CKH&DCM;J0#+W!M+06`=2C8FZ MBJ-9*4%>9"2H*8H":=]T3W=$#>/T>%)&2 M@%CRI_X8NWXF10R)QIIQ`(6K_B;R8NHV_8[ZDD9Q8U-K\OHYB&1 M5ZYJ&@8G.\-2X8U%,I*MQ1>VE[J;UTC)%D*O(BP_AF`AL*_>M\Y+1[U6.G+X MP?+Z=CROO4,=\QJ;5_H<+ZGWK6@.3.+2P'*FTBD:F6[>NG@;6>=3>^-Y[%// MQRFU,<;^RVEI4AP_2;''@+5ZH&WFUL6!=<.'T"&C38[#<27"7'H.V M,ZPY4&KJ*KAX;M^VR[)A&W6G;*L:F^BNBQ6S]]2B>,?T%L-I"_[(PHRV%=`? M/G-#ZHX/:`K^PDW!]\NF8*/*6(40=R2I+4(RE`MIO\N6/AC:'4$4]4P3*"K$ M_T;XV:D'^=5RQ[IB>_>!!R;8PC6`$Q)(GK33DEU&=EL$#37:WJM!D+4%@C!O MXAPQ9/82Y<3Z=D^I:OK>;]YM+2C.?=U;\_^Y+?Q2V/ICX;!))ZW1![LRQG^U M]V-`735 MBV/K=;:XKIJ.=@7FN&JYK9?9579>N\NG<,CMV^_U8G6-PX%G]W M&D]K3=MC*?NSQI(-TF7C.]J-93?,M64W]B%F5D]X'F>'ZRJ(U"[LP%KFJ(>( MIT-`*[XX[@'C)2%E/\4I]RHO]ED6L"O)2]VK)FD/''L]^=`YT=Y/+\M9SD>] M/=FBNO@!S+!.$,$1#ZEK-_QU:WOX`*9>OQ.X$W3385-7M53QI[U`7E5?0980 MP;P1+TE8FBBO`]^[]P.Z+?:]XL6L>I^"7V;#H!'NU0+\>TZ0KUDE+6#F% M'2`Y?F2V)7I#'RVD3?NA0E`J^:=3*E6MM84P=,B2:K6@XV5MEA/F:>VM\^5= M27R[Y\N;G47349/F>ZXIN&;[.$>GZ.>HZ>-.C[@><4=*Q^^TK'HK[JO>HCVV M:&$=7EYM2QA=B;9MS4+]PL]DX1?,^[6^XNUX'&=>P(L"8NF,^$E4%NBJ]7^< MX[T]>>K*L&V&S_EPVBGP6<*LUSN"\4#P83B\TJD+C8PBR(HUBO[>GD#Y&O<#@V<]:CP>_RS25%^^OX(DT>ON[@E)J]-_#76@"H:1^.=(5X1:O?#TXN0B[HZ M,O92-^DL.'(]-MS17@K%G04VUI:64EUM7;'`JY`QRJ]8.7+.L'EB^*`$49(H M8R^.7Z91_.S%DT2YD54E>ZE"E&.H(_MZ%/U:=)AX+(I3 M_U]]'"B?V.SEAYRX-TARHKA>6^00*:,;"HJSSO'3AZH]VD_BZ(8L=-[HXW^-N*H4C[_%.Q7LW#?3M5G>4_UW^26SP`(QQ?;Z)0MWS MC"M*H7Y]9$H6I/X,>]W%#+:8A_IDS=-)3:E4/X&OYXR&4Q6@Q;D7PX=L#J_A M._AHX#TG^!.;3MD8?HRR6)EF:18SA7EQ"/2D2:#$D+R3[<)PE(N M?:E@G3E5>4:`Q\A"$\5#7ER,0N![K\3=3,5[\/PP296Q*#-6LS`.4/-0A<.> MCX;]``-,T4TQ1;=FS-HE(=+]<`SH3O`#(:UNTFD4B\*S@+U9%*:/B8)HGRRC M`U`1P!8FRCR&O8S]X$5)(\)Z]6R(U4/T,12XQ.<:P"&,/S/8P2RD@KJ$21BG_'<&I(ZAG/\!>BH+^V&1P,G;H M`$?"5J#`)]P#AIN8,/"3%`G_/GJ"G<&GWD:SN1>^*(]>`CN4LT:I-S9QDC>? MQ]$W8GC8H%>&ZF@:I^DTC?W[+)5[2S/[P+_`+T",]RQ]9HP3JS>+LC#-ZR+[ M(="'+QIN,\J78M\P>Y011]$;1$4T,L`#<&5C3EU)$N%Q`T,5FS[""/4M5P4"`(2SAFI/0*IJ>`4U(F7*YB+"'$,B/GF+?Q@S>7T1>\NC%K`:\8D4) M/#_VLH2)GW@4KPH0)R0:"KS';(ZG M-+#J>18#(3%:J]]$!\BEWI/G!\7:"28AH`5HN'5^0G_!F#'MD1_FA)&,`<-L M(F@AD<0@T"N4KN7\-=E@7W"T+,'1[AG02;V(`NQG]PG[9P;T!90KA07?5;FR M0I3(99.0XI2-F^;-_=0+#BQA.B505BG01P\5WIH-JM)*-)WB111!*T!5](.@ MF67Y8FGJD*>9PH2/_OA1;M_(-!(5/-`=`&:-5.Y]Z88K$/@:=\L`2J3AK M""YZ#EF`(R,,:A](A28ZIF^ND<"A_^%&0P9^#.@BK+=4Y5PZQ#$ M%S:6`V>I?PP]UBDJ^YTI@"!`R(QD\I//GA%[9+D`*<2X?9C$G#13)PN&$FIDH2.%7BUK M2=IJ+BT\Q)V`?C MR`NPG88"_DB"&SV-HQGM0`:#Q6#V$&,#Z9>;K".M(3$4%(9/4#,.]@CV%F*> M)#`^Q[F5O_U:V)S?MW,CZPBG^IV9JTJ@%@^KTG)+B"\5#+%BI=P+(ZLC`ZD6 MHSBHBKTK(X^I'U1LW9B!/`YSY?W;X,M`YCTK_P!QD$S\<2[^GX!PHBSAI%#Y MN5[J5$:KF32G/Q0OMW<$)P' M14(@RNC_&@&9Z,:/=;3QA1Q+KI?>+MYMK"N[?\F,^0GDZ]=''RS7VQFG;F2W MSXP8;:+HHY&K$,(4("%X'67N70`6T&MD"VEJ#_^*W\F_W+]^+TVQ?X$DQ`U'8;!Y$+XSQJM]A%-X4WSP_1@KX%D_^ M!`9A\9,_9HD,5`B=WAAN0TC!)H)A^8)5.5*21]G*T$KH\#=T$QX>8O:`0@A^ M@F4S?@3T_3B.P`SG!YB1)ZUJ@5_FPLDBX.3$4 M/B'L!=KR,85^>3DVDO+>^+%"E[!Q8E!R863P:%[V)F^S"=B30*/@9J;PRMM' MSX^!#(BD_438V@S1\,JA$GF-1#7VDD>%HCW%\)5(%`6].;BO7YDT6$[B37!\ MCT#,/7^BV-IW2OH,G,47BHI2Y0N3@PIC+)^/7@/NA2_!?I?<70D&*5%8'K!V M;7>@:F-$Q#(=X$B5G>.L"A2PO!E1EB8H'_)-D5`+7LR!4-"-0Q^-Q6,_81@W M1QC_B5LO9,H4D`/,&O\)WC]Z+:R$[V*I7LH#8B@=TISK*;PHP-Q,0'!?F/PA ML#(5C+$D8W!Q,S"@HB>@0P^,J2=V0\`+RX0<*AY`R5U+N?*R;.'NG?"Z4*1- M4[S)RD+A0N6&T43(.(*\$>[*9E2E*L5YZ^6FK@YMOAE<;N(Z[UF!I.L1>E\: M@MSP1\(C#]Q9GTCB(ASQS>%OB;T&NJ%`VZ1*GQX%I01B525+I)?])O!@XB_C MQR@`_`M*1B5CV`]%+*68",FW7@M^B&+))?PN$CA0 M>%R&)W[@K(V%JX0#J.1`SC%2`"8_Q7=S&/@0%4S)\P4_H+PE.@>SW.08\?2:>5'?]SKPB\?J$@XMXAD^!.)-)&B!\?B MH3PT:U!=)O[,#[Q8CB:&%YH)?/XX"H+B>"@17363Q6I&'3CSVW-;SW(*B:WO MN]EG>1S12-8=Z$LI(HL)=\:P;<*=/M0&VIJ\E%40'#.?=^N&RENOK3S/]CWC M5F=9-;:10V-9^84'4=\O!2T:/=V5'4-'DJ[7=PQ=DP&%34/796IV&+E_D*7$ MT5JD%.W6:[1GVHV9=GUZW>I&Z.VO;'28%K=NM-FCME,]3->TC+\TQ&[5X[27 MD0=DY+V04H&;JBV<[T2XPL+`IA! M51Y82)EG=(ML,O-#/TECRDH^OPA-!^A*MUQUN%(378VXP6N'KGF$2EMG(&Y< MVU9UP[Q:<=/1<%$'**,#APUI-#]/8;N_R-&&0N;JD'?94NEKE+:I7'X8,Z>; M%31V=-<5?62HKF7UR-T1N6M*AP"*5<=P3R?^+@;/NJJ;ENKJJ]SCXY5;Z7:U MAW>MKD#21329_.PI*0I=GEIK\=3:8D5+MRQ*]R@PG;N:^)PH,.A#?D?OE3:P M+'P)/MAZ,>@<\_LP>9=\7!HGHENCOD@#Q1&*%&N9=AXB%>,-57%ELS&Q^)D" MJ;BV)_"D'\H)KK3J&TJ!I;QLGO!:`,137Y/%ZR68A@V+,`Q1;090["5)-A,_ M9Z6\T6IR;%$`A?)B%Z_)^DD)MA)`="?L,7H.>26#Q:S&B?_4>`I?R)G]YAV6 M27FG?$*R)5:?>&%XL$GT&8X^L"J2;-7`1RW[:>B-4(^TK@"]_DA2-PF+1IUW89A`+>G];3R:9T@LK]ZDAD.#`LA5*; M>SI932>?_>3/FRG:L'GIA[A=6Z7+H!ACH`TW%2H+GMT/((H/Y6-URJO[2I>` MERP57BT&79+"=ZCDN442K?.JWUH*J^%"O+M:9)2Q/B\['/ M1+'+LA=5^(KH0H%3-V4^5E5J]N/B>EZAJ\[X,WX65ZZIA%->"N1K3#*2LN?+\%)P_KABF_8!TH M1*8>R(U6D3^)I-^EZE)N MA>XJ3E3>2_OK#F/U6R'2W8H&W8%CG0/.),H^Y^;96ZSYZX$U]Q7MM-?DX7Z_ M%>:,/9*@,1@>E*=WQ.=M7J[E(U9,#A-_K&!WO\U(;H,H@8%GS%NIAE51@@WT M0NW,!PT7G%13;+K^P^N`;;"P%1(P)'YP&MAQ8>96*S,'0^N2MG=?JNB\L;`= MD6N=I_'M%J8O*<8.+.V@"FUW7^?X.NU3EE(5=C2PN&?_A79G)_3H^A/FH^A1W1A2;NOIM>@!$;)G67(X=7H2 M'.B#-A=!#ZA.SX<"#J1.SPKM5>]YJMZJ!-5[9;QW9?R!IXYBZEXL^I:<0B]O=^9^--(#/C#M ME3FG5JE)M8+7H,'1IJK3W M6J_&:^T/:@^M8ONLJ3YKJE>N?=94KXQ[9=PKXSYKZARRIJR!L3II2G=U<)'U M/FGJBM6X/K#;G,'T:KE7R[U:[M5RGT:UN9[M$ZEZ1=LG4O7JME>WO;H]:&K5 M4AGHDSO%:UOW=4];VZH.Z!NUJJZP'V7=0=1UJY+562'(&!BGJ'=U5C@:#K3# MEX+3SAA!I\@)ZR""^LRQPQYK4Z>%.AO"[(V(+<[%#75DFZKMMDD^ZDV(WH18 MN@\P,-OD+UZE"6$/S%5=M7L3HC8Q0` M`=,8@!3XYF8&=/V2-U%_]'A[+='A2SXNVP+2CWZ4U*+@P!5>F?`RG43PC M#!$VZ[J_7'*_N]^!GSU_HH01-A',PI1:4N;M+'=H4)8F`"K/`IA7!N^."-^_TM61Z2X!59[ENH@'929L M%A@(-V-DJJD?>N&8HM>`+C]\PJZ5^-%ZFJJ1B)M*L:KHBV8S M/R79>!M.L,T6P,Q@92PIWNVH`+1J!6!I182ORIHN5_;58`D_^!0HF=_AM@./`*`-0T''(@D#Y[WB@4E?H.^!4'P'C MM/OHLZGR_AL;9R!6F/)I.@5#,5Z8JC1!8POG"D3(QE,_GG%#UIO/(P"(?@!; M;P&"]Y]4^I"P^`F-5'C"4V9<=I5;[Q:?&BS>-Y$73\BN]<%@3:,XD0,+@[JT M$GS>"T/LQHR&M))X`6X)6*"O3'XS4BU:.#_Y[!E_"IB7I.*UX$4:PV7;4.&R M(65,=KU=!FI##(IVUPFI2*`("6T49F0NO](YG/0[J0`_!NBHHRW\S'("XDCP MEM]4,3_8PXFPHS5\P-;'W*&(6315\Y$3!MLYJ1FZ=BD?IV67A'HT!PR[;U._ M7I#W\!$D9 M=OD&$9%-J)MQY17X>X&N_)">\$*?MQR?>S&Y=U7PI:_%1TT>@:0XJ/=,R1+> MOCID#U'JHP?Y2YRSC54MFK5VGLR%_>4$2%4SFB3[4U(,:C3!LU.Y/ M_<5FU0#>/(O'CR@S=-72.`LFU+!6D`988>(=+R7V0J$V!P#I*>P[A*_?2 M<_^\R9LOCPL??H6=YVVT-.FZXYOH/I<][V<0I@_\^GLC6J073FR!5B;"#>X\ M^/4^((1YL.V<]?GN@B`"31$G7NRS1(),D]1.\1MHP5B*WQ+^Y3<^FJ*IGP:< MY(%94G_LSWG81"$"(GG#,!81LJD/O!UX(3#V'/NU`MJX9(&M!"!`XV!'UQ3^ MOPA72'HD9P-T@1RP7A3?3B8^8H1B+T`>"6%';DUE#>"Y!-D$`9VP60CD,N;$ M/>47+[`=/48WDFCL\W;SJ%$F;,IX6@HH6@04B,#S"?`)!HW@FZ1`#VE#("[@ M%83A$=`%IH3/=Q>'JX@41,1$*IJ"?NC[B*OV\M>![]W[`7(SS)G!%B*E$DL0 M>)'HDEOR,U+LCEN+"YQBRA4*R(6(."GQOPEO@_=1+X\"[HV4GTN#;<7"I"Q\ M0!%#FI)3+%-!A/H-G^;[-/9`VI(JY.^B&^X%[)()-9;M/L`"B8HEA^&+2YVAY,XJ-6*D>JE1?P6X)AV@JD,@7\4*0 M&`''O30M!`67%\JW#9U9QO$`6OHP*9!V!WU0FRYD7S,4GC MTJ"UBZPLUP-3W@,G%*>G7M91H+SV<%53$H4BY%S!R/=*-!YGL2!G(/PYH'K) M3"&94D@`Y&D1:/!G,S9!R1:\+#"X@`5M(PZ+JKSVOZ_P1KX5"2T?08BRE)/2 M7Y$=7_OP1DE8T(-)R?KD8)=X5)@@J#:$#,\74\<^*FV*5'\\$(6J"/::;(%< M=T8A+%;*%UB4A;JK`0F_K!"%;:0>ADE049!9!:X6NE.^ M1Z+S1O[J;`>6PKA,B2!]PR\3<<-0G%R M]F8AHB2I[G]4>IZ$I<3^#3_:J%K9L9#;E6^G<32CG0'1+:0P,38.!V.K0!RP MYR'!&;.'+*#75&%&L6]C3J:!ST-K)4%."D&".D?\P*@3H!68`+BJ/!EQZ:K9 MHGB#"4]ZZ'&"P[$:&Q?/#]A2@`+#`^@'_)<'8F2B?!XHOT?!&*92`7V!#X:Z MGSS"3I0MHZ0VS*!D\^;C,K!U<4?P1`OD<@@._]+[M0R!H`F`N'P84S20RW4, M:;`59W3W,C@P61D<^!0JM^`@!(KAEHU]29[5V!'XQ"GZ13D?UQF0WU>W MA%"(UAY,5)Z_P?`#)1PC`"6[2,W#]3+P+\P4X7X+#=5&)3715H,OV4!>)<=] M%8D]/T;"E.82*W]>$:3`SD17WM4Y&6W:K\\%P? MU7E5A>I5JV*?/U:2\2)NQAVFKVS\&/KC!H?IZUJ'J3@R1@#(0F]RZ29D%^0! M!$.%E;CN2H.NF$>:7D7T"FT]+G9SD$;T!)`X!* M#J?])S]@#^)T.K<>O*18"U@5K_E@R,JH%,;D0`F#O=F;S(&K0IX[CKF!2FCX M6LUZ$J:_<->$=22UIV[<<(M(J)VRKH(EX5/1QEHGW[T%8O&JFDC(,"5+I+DM MP.9;,1['&1)@%E):S),G7#'AG*;^C#NX!4"J2)GE+IRWI+70_0D][NH^^O<^ M25)4`J0-Q)/P%1DN6:,AOHE1^SM8F-Y+*2@,$"^"(U"-LV1S1`$E\WJ%L\H= M+5`4893ZTY?<=`,,H>$:\P40F>53Y49@F4)XSJK(=U/ MJEDE=1G#K9)_*WG#O[+GV_$8_2UXY2Z.0O@XYO[:'6E3_M^.9@[;M9G#G]F8 M%%2^+J6ZL,N-[BW,V*HP\C$^@0HAA\`KMF9>V1KEF<4L-^!:9M[S,)^'IO0, M9&F,L40?E-,8$ZTH*W>:QQC)C:4I+RX*OL(6^1@JOX" M4/CR&WU[HXV4W-C[#$(-I2G):_);`97".7Z;@:D\PVA8;N[Q**<'2)WPO02I M61[7HWA%HHA`,KI`W.GPR6&@V'+"0\OCZF1C.1FI19"SR93Q$!2Y@R*EF3[7 MCR)E#L2<#+H4%(F## MD#L]3><@^4&$'Q8>,>(Y#LX)L\,3Y]%3GJ,A:\^5R$00M[+TG9 M//GQTLCH4#/>I-%\^6KY,AB+(YCV8`3$O0;6+[`7BOZC\I'"5M,724,6C^&IWUY/NRV,8@ M:S+U28/7X^&:M'+9Y$07.C\EXPE&%(Z)&1V[H?M!OC:X_0PF"-]%58H8$ETW]V?YR[EM2"JW.O1`>>_%H.10U#HB?(8/3>Z,]R6!/7-S>WB>)><*A%"*^&H]@IRVZA`):3P);M/ MP%"%A]\_L7*MAF[%#IR&L@L2>(5#WP>Q%^[3"H:PM\@,*C)^EF[.JOSJ[(J, MP?HKM)=_'+,"A/>Y;/O`[F.^.\YNN_.&A?_P0,K`A_&?C]ZLLB/_@PJWV!80 M)+^"K'M4;L'T`]D6*E^\`/V`?D_VNB=?H\E$^9K%89"%DS4;\IDES(OI"BF& MR)Y8$,WIV++?E(5-&>ZV*?\-MMA_10^!'Z[9D;\'T3UHZ%^\^$\Z[^AW8F$G M#$WNQ!W&ORBE,@8C2IP_S7BX%]4&9I7Q)$'&BV*-2P]B*$1D_,"C`7OP\)8` M_QVL*&]&OD)Q0EHS67%B6F"*XE[%6V^^O%-^$4>(I3<'Q:M*7>`;0T4$@@`1 M4_69--#*]P2^,.[<&)8A@TGO6(!I+DSY.UW1K\RK_.P]+^;#O?O[VY\W/_O% MISD/Y)';A8RGR@7I-3O`U\1/M4K+G5")I#0_@Z0T"UZO#`WC.'KR@JO6Y&!? M%?Q@U4HFLGPPJT7$`Y,HIJ-*)H(P(0]B`^7CWJK2\Q7A0+P//^0%*0:U)S-$ MH3@:YO+!5/%28FCE'@_S)O\$:"G83H%FL`ZGX&#S$QOX1&FQ#=6L\E/>^"Y@7F1(69EU2L?H8UZ+ M@T[-0=U1_"%Y9+PF#*5O%HLMOTRQ7Z`5?O,FQ0.1KQCCX4<8G\F9IEV+@%)T M[>;_UHJS7R,!;G[NEQ1^G%@"IPU:PN0?69)*2;<$?KU7C>>2/'L/RU5TI'AB MHZM=/>/W4BJO^&DN@O_)23SQ58P@7?-/\8,7^O_R\@.L-UGBARPIN>'E=+,: M':Z*"XX@*1ITM;J40%Z5;W0WQ4M*RJU(%_Z2"KK-E3+,_M\93&923E1]692/ M9:DC:U%QU3@I=.7"?3@@S9KEE27J[XR$GJ<$_A1/)7T6CF4MG%`4F`#<3A*\-S'63O6,GHDM\CXRE" ML3=_J;_[!@SVBS^.(Y`U\>S_X4XFV;R4I#"T1!5"\?4,'W[&V)=WSW,S!0C" M'*=;CF-*6[W!DS9`8O$*VD@/A#UZ&6V/A%&>:A)-`5`Z\%[`(L79!*;@09%M M]D0595F`)V@9O\P"#(2)NW1))$EC_SY#:H#UP6]8OBB/-_\64F=8(A?`]OL, MWZ47;Q/?JX^Y+7%IA8D_4"&G.YX:U%7V+>YP?<[#H`+D$M<6O"QQ+WF!!S6+ MBE5,W(DI1'(17B7#/"^LB!M>R0BIQGTW3"$9+!A$Q;Q^47>UQ8"FO'>C[1*U8_SVT.X"GY!BJRMJ-`2=.LIPTLL6"DSB)Z35FLO M*AN+),')(G[KIVVQ893VAY[%/5TBHP#[4RY*Y?"46;A,6HBPFOI=-;Q99KZE MBL.8<@?_O`?S`HPG1/UO(9JKL8_>7?T3/'[>63ZF>L,4=<4/);CKU7#^.!$* M*QY7!,U2S2[Y$"^R*@\KP$R/8#$^YD?.4`3RHJL+1>AH0V/&)#E0.DW24%FJ MONHVE[[50JRDB#%C[)5A4XDQ3*%0BLT#4S;\4V:K=<3FVXWD*M3[F>YOT96/ M+J1Y;D*9XE@J40K8ZVD2O`C,2I:/Q_GC9#.-/9"7_(IO3GU`EQ%5QN0>,V6" M80@01"ZZ%?QZ*8H2;"603K.@-&A2%(K/2UF*5/6HW"%OQJ&AQZ2K"V_Z]93\ MBQ=Z#SSF**'@-?0P5X9N"L]BCJGWP:1X0"0Q"P,.*R=+# M!*"8S$A^7LFO5.&,#\)#DT/49Z.OQ#EF4(-AA?=H^5'V!..I$]!^XXB,++^I M>@(>A3^QO!`>S5+&?:GH17D2'A$88QN("9]15MAOL-)%F$$-1<)`\+G'Q`"B=9\&-,961;J^CYU*[@V\COGNEHW). MXA0($S9[.,VA:LSA;7J24Z:4)1,J MX0H>70`>-W(I];QHO&:GZDOCM[$$16V MN1.>&I8H2$$3HA:D4[!S8:.[LJN90]\0`RD_R^2S"S1*1,\U6HDX)XP9[ M->]*#S0R%I@='F+C)L!T,\Y95#)W(;&S(+LL8:BO`A#%^<4EGH%]^D0EWB.& M]PX2[7XTT>IGS((@F7O8+:#F%]%(:.&7&O!Y5SQG8,Y3V:,(%:`W3]B/\D,! MJ&P36.X_A"/P3\43BTWPW+HF2FDT;^Z@9#@#O=P0">2//;#FJ9)_6H"JW>:4 MS@`K!+U14RA':[LCIN:?G\Z3G-YD?\(SM M&0;B2]=_>W(^4W+6>WH.'WH2/F<2MK16)'S8!J^=RD9ZCS4?)V2!\%,[BH1A M%9$Q-TEB-O?\F$?@1(%($=KU0RKO.Q%U8+!&L>@=1^'^N9]BF*LA]/MW7A@+ MW@RB!`]E,>4`<]G%]=NF`(NX7\OS0XH3S--',8Y]"5J45VL*+JU`8X+EQF75 ML&<_0:2F5+*+(W@684=<.NP7L=7B"(.7B^;38=E/.A:$#<3MF_C)7-;Y])/J M3F'84[3#E&_(,V=Q::LN]+AI5'$A@I]ZX0.>;-Q2@.N#CYDA/^,A1,?/@.\` MK8TGOOQ'$<^N,"-/G")6;`C@KD%(]2Z9J*UPQ_-K?O=BK/3WN8OBO,!2O;(ZPD@3^2)38XKVN)*-M?H"OUK9173@T4*64H)ER4"IG%XZMZIJAXB&& M.C10LB#B7I5^_;N9RN<("5K]@)N9%1 MA*)9[N=<.E&D?'NR&O(ZT"L.%HL[%\TOJE3=FNP8;$/D9>$%E!!7F2-1G#KS;<-4SYB5T-8'O`EB&I-/Q+=Z\DIU026C:FV\4L%2U+#R9'O.?Z?Z*X8E4!)L5)*X]&I MN!:#9LD&"Z7FB..\>G&Q.+)C\FWWPX4%B;IQO&RTK)[(ZP0`FO)"C@UJN9Z) M*YS^WHOQBGQRQ^(OV&7QS!C^]<]@Z7V/":E4M!]V@U;1D#]$=NULGA6)DIBH M,Y8X?QW08'->ZI:Z1E+C2;^4"H2X?V:X-#2,1/Y!F(F>NWD_RU(&B:AXEG># MO/J[*0M;,/$#N@3%!"4>"/]2/*C\?A&O(%)J#5I.<21V>^;EC&+T7W)?1529 MIG34"_S^9D714O)@GLU%7;YE6X9" MJ;T)/)CHR_@QHN#J/"_D1??-H@D+5!'GSK_B0 MU_07G2*`>T3KBK(]CP.H%$XLI1*78.!#5#`C/6RRR9^H<.>"'5ZMEMWH&R1- MN"_-X(D::!-Y+^()3`V`4L$O'R*9&2TBT'FB*45:91LE2B>=>6&(4MN?^8&7 M5QD7P\M`K?<21T$@WUQ3>WH+7EFX@T#%S4J%2\_%JZBIN=H835@N]YEK63QG M0+0OW+94102;'-<)XQ1+@Y+UEJA9!I@<3A<%](-!`Y9X#$/\AR?;]HN6Z$ MO9TR2"Z:&T>M*<9Q!\.%I0F9*$0Y=K7"2<))](P;J^BM$U".1U7H^&S#@&YK MFG"<@7$Y>%O=%V+33^1N]N@_)?I[ZC\=^JNHE_)H,X;H5=I!55HWE[87ONN7 M=HRDT!X'&^+@.@292+OA6:@=EF4'IHA79>VW@^JTAIKJ#NWK9:U7.Z%OY#KJ M2-.N&'UK+#-3U?21:AO73&%K4*2K(]-27<.Y>MG^;BFP?[T"WM)&ZM`=7B_; MV)JNVLX5RPUQ5"O8Z1.,7<099ZKT9BE+4URLCD3A,:Y7> MO'3^T#35'EVQDC#QIHIUS0@P-577>]/Q_4(.QR4=W!U"XZB@W."EJ9[4O/@7%%:.21P7$LU'*-'Y&Z(M%73<%73-GM$ M[GJRYPQ-U1BMHLCC5>OJ]CW%S^6[+?-R!L-"Z0*Z)NP5UUJ):*C_(+4+DFT: M5'$-E;J-4>LQ7C**-P/+'T\>_?E$-V`^#3X,W`PX*31_Y(>`?`]=L M&L4P(?Y$X%,==>I\D4:\1Q+OKBCQPKM6-](WOF1,7LUO^,D&FF4 M-CX+4S^HCHC;*!&@XC[Q9WAMKQF_H%1]HZ@K5,7E/5V]FV;A&!L$U"[G"Y9N MR"N[R<9VV$1*8D3>B5I<';[4U-POR<:/V-\(;UK1[F&+,GZ9CK>AXNA8N+U5 MW+Z2%ZVIX5#I2J7H1",;D=!%7@D>M9"A&Z\@U["A*K6143E&1(V1A9N4.77E M@^0L)-N4-=]2E#CC_5F1@/GY!;5(:;DI"5[I% MC1>&%WA?J*IREQA25L75_G(?\,*,X-?\J3_\-]'\3(Y*-D%*Q2;)2,*:)%>\ M$XM7N\&&0O'JA:62``%VP:V3RO=^$/#B!5CS+IZ0=L[9B;^6\]DUH;ATQ5TB MC=>KX!4_RE5+2,B0B81V:`2XD\8>VI"R*!YXR#<+WS>U`)-U.O,9\D*VH)YSJW#ADZ+:^J+5/OY1E2OA-?Q_NPG?[Z%I?HI?NIL'9(* MS(@J#K."0!-&E@J2?"BUM08VR&9%(;MYA(6=X2>P;Y+L_A]87BHCLA\O3C/F MT\0"-PE96V"3PT)\WIYZJ6UFDP.-.RUZ68_!^.56\#V6#6))0DUZI3P4DW)! MMUBQN+Z:,"DUT(!HSC_S$$&$YD;X$%&I'#XBP_I%HEBQ=',+NS^C)(Y,ST%Y$ M:D"'5&.*RE(W*L6.1?JDN`3>N0"ZK4,,"RZ%C5%Y9/R((]B$!'FK%!=_NKN[H;US;%H`*07Z'O58*;5_8#%]D;FFLK@,A*$NQOKG MY)G\-O@R4!Y8*+0"CQ87C>=N7CB31^<%'90JG*\H;`Z.PQC4#19:)YHCJ*@?3,,[?!:JERB+H]5A M0Q;A7JO'+7R+TK&BK,$XS#YO6)UF0(CUBR6)>Y5P&=+$">HZY M6CZH$O6"[3R#;7\$X$!2\I+;G#W.1;95%J!@L?!Z`J\^1]60%RJ8HJS*V\H` M*0M%,\!%MX_I^RWGHN^^W?#ED?3<]UON^RV? M.0EOW6_YIQ]:N]G56&_I31$Z_XK)NQYE$R7B:+)%8*0K&8=]"?VSNEG:E]#O M2^AO@\2^A'YG[WF?<3'LOHCX=GCK2^A?"/I[ZC\=^JNH[TOH=TBE=7-I?7V/ M_2VM"_4]>AQZ+`OH=^7T-]-MO+%/NZC6(,!_;J+3T>5HK[$1OA9#<;^5K)?_NXS@DI8^N,[VVP-+1[-%TX M,1TC6;T7,&S#[>Y*'O->A,7E+_F\-OEBF%@Z7J5BT#]VQEP^9WH>;F[_GO,R MN[^9%\.J_9[V#'J)FWE9#+H88_VZV&JA7"QRL1G,R_D30^6!@6;O$J!>=V-[ M9*JZV^8XI:MRXHA(PUP?#/3UA+8YSMR1IH[<5?<8+EN&?<(<];(,NS+JT56@ M@&L3,X:A#O4V:=F7L-.&"XQN72VCW\H.2E0?'T^XTVD6Y&U[.A#[O0^\\9^M MPKX',&M?&YJJ:=KW73@RN":$7!*!7)8@Z3W9<[(#.K#,[F_F`H.6IWYD-*EN M8NN2!>`/P:DK)SP+OMTAC6[-XL_,EZP/9`QM51L>)9#1;T01"'%4MU5UAI[X M=P^DC-21,]I0ZJY.-VV=,MJ0>OHQ?&)A&L4O;[$79IA^;9EGVEX&]VFFBSKS MG.U?23\^2[IS4;T\WZ9W5"]H,R^+01=-QCLO%I62 MDFP^#_RK.WQ:?ZU0TRQ5=U:=6IP+O[=#S)JRG[IJ.NAN]&?=BP1CVJ;JZ-=[ MS/5[%/\)OM3-/([&++DV@3*R==765SGA%RDN7%=3AW:;2HP7L=DC376<57?W M+YO5/_BAGSRRB?(019-KXW2;]%^;^JL7P>F&X:K6L$V]BDO8;$/35@^B0*6,L4O@G,G#?1W*3>AA+.AW2>R5)&C'PY`5MYF4QZ-)YL!?'7IB^*#&/(9__ M=F]K5._42;7XY-BJKO6%&;;,DL>&6,:U'5_M"WFVIHZN^+S[:^SY(^$=8B?M*99NA:N91HE==6K2E#E?VD[O$C;95>Z7,O&RVER&#U/O&$F7N MO5!8Z\HH0%.M5LTU+H+7[9$ZM`Z=XM.UK;8LU1FNNKIYV=Q^Y[W$41"HRCB: MS?PDP48;JA*P!R_8IJ=PUPIU'RDSTAVJ]LJVU%TO^WXAQU#TSD3 M4]_SL(^*]*&OJ]CDRV+B14JMX`:1VZLC7P\G<_ M95Z/FJ,?K^^.&\MQ]Q%KND2RL31==?55)7N?3,^9&!"0:#8>R<@WJ&C'^T ME7=ORS55&"K\*^3\FROD>=M2A^85LOS:=5\)Q[]^ M9,&$"L\E7L!VKAUV?H0PLATL$G:%K'^TE9_?EE\V\_\,!G[ISY.(@$XG3*\C M(,.RCB@S>E3U1'6!4FDOIU3MZ:)+6WY,/!S[C+*SB#A[@NC%P`78H*:J.6"% MKCQANE3'`];NVJIE7J'K`4O7;=5>697TLOA[R?E@25(<*V+$T?/CBSEA7"/: M"06O5Q\^E^^"V'LIZ-X-$7'2N.M)MW[5^JZ`V;WQ.)ME@9>RB3)A\YB-?2KK MTPV?L".M"E37TE3=.AJSGPU:]*$Z=$8=B4IU!2O.R,;66'UGBTM2$T>/!ES% M2KN_I?V]_&,)\8N[UXQ7\\%N<(?'"B-<%VX-9PAJ]@BXO3ZR-?715I?OBXOI MZV^8-W2Y^)+";X]1`!A.\*7TY=IJ/3=<@J0S*8:]S?GGT9+)RRVNO MQC:(,P:Z>T"\'<_.TIVMZ,89Z,9%T,WO!`>;W"BW3RSV'ICR_AN+QW["E+O8 M'[.M*$K;BJ2T@75A.)4H_G'R_$8XW<)*, MP>A$.J)VZLO5$9NN__`DMP463BKO]T`H'9'WYTT#^Y+0YX6%7H9V1X8*^0%8 MVU5X=(.V#B-E+UB`7CH![-D(OA@\'50(KT%O-^7PIRQ-4B^DZTA>HD13I:@! MI^1UFKIOXNXIM&JLC*S:JF4/55-K4=#D+&3QJVNV86':%D1^>=9KBP2I>GGI MG%1>+L]^4'GY=SRG8)..2,6ZQ1]=*EJJA5?XV]PS.J!4W)4>.F*A;K/;!Q$/ M^D!OL[&'%(\G6?^.XM'$P^*3B<>ZV0\J'F4`OQL"LG[Y1Q>0+5*L#R88=Z>$ MS@K&];M\=,%P/*G8P<7W4G%1*GZ(XBGS,04_BA7V;>[')Q&06QZ;7*T4W2N^ MSE#4'HQ>+D8>7PZ&>J'=J1.JSDKA3IU'78RD[8R(Z-B!?I>QT$O,MF=)5B]( MBWE'JMN9LZ1]RM%NG"6=2'``LEM<6+D\P6D-M%5]2GN1V>7CI(X(QCY:>HF2 ML8^6]C*Q/T/JI6(O%7NIV$O%\SU#Z@5D+R`[(B-Z`=D+R*ZL3&;W;/XE"='VY:!ZDA6_NG.E_:+ MN/,YA3H=O]C;@[^AV[^GNZ.\9#P];^_!!EL?(+T/QCHKP'^IM4#0I: M>\MRJKH[DM06(1G*A;3?93#"6O2]."RBJ/2I0%&1HKX1?G;K['*MW+'_UCZ' M)9#<]F[)+J/:%@2K$#34:'NO!D'6%@AR#],SZ^`8,GN)/4]_[`?K6 M@N+-^6>A6SJIXJ7*E,&`M@+8$POS=(H?E%B<,:N MC/'7--II_PF['KEZNU)J9R%)UG5FWAB3BJ%:AML20VSUZ#H4J03 MA99N[KT$/#F04W,6)BW;VYZ))%K3\^LU]K-OU:VZJW)CQ1H-=]AVD5UE_16K M-,VUC<& MQI5HZ\\L85X\?E2\$+O1/[$@HJ:1RCAFDZMC.+R\JL,X6UU73T:[`'%UIJVQU+V9XTE&Z3+QJE6C=FSYMKLV7V(F=43GL?9 MX;I$X-J%'5C+'/40\70(:,47QSU@O"2D[.>.Z5[EQI5![X-CK MR8?.B?9^>EDZ@CKV&OVYM#Q_`U.MW`G="5T>F MNZFKNCIQOWW*?4/N_CLV97',)C#";9*P-+D-)S_[WCT,DOHLV2IM?\\Y\S6; M3'MJ#ZRBC4_1SU(QRIT=AW6E:] MS<`L"U.%K+(?CRZOMB6,K@3@MF:A?N%GLO`+YOU:]_%V/(XS+T@H12=F"8N? M6-)IZ_\X)WY[)6>.PR4OG)R1E.`L$Y!,+ MLS893IH'!$Z*U M'@\XL;..'BY87NR6-'T&H>-#I.6:[N@89\['C7@>`E&ZNS9[N4<44=3ZK/T+ M%D(G/+;JMF8Z;H"TQ\M5X*47)(%Z&\EKFJ+]]?08Y$;P3V>.F-XY.<)VY9PJQ> MT*SI4'`>YP0[Z4W%T=I64ZQEP768/(L`>X_)HY=BW!*3UR;^&LM"X=\1%J2@ M\K.\2-3NAZ<7(1=U=63LI93267#D>FRXH[W4CCL+;*RM-J6ZVKKZ@579NBRU2'KMLGD>XC]VL+:=1MO;V_(^$M6*E' M34=1XFTKAR'N\4SW?30-]JTN1 MMJH@VE"%]/UL'D0OC'UA\9,_9E\>O9B]P=:1;TMI5[?@3H_ITZ&;8T8':2#MH;75T%P3!]I]_9`;==6GF?[.GRK-5=C M:;X/418KOP![/2;*>R#UB;)[%=:1I.OU55C7:!4LQ+K.^NTPJW]DR[,=.N-UEV:_MS5K2X=?'2'K6=J@N[8Q.FQEY0$;>"REU M.-BYUU9/%XJC_;9^NA`D'5((K;.33R2'T$W''O*)%[2IM;:+*#HCJMGM]HJN MJ\.ATR-UOU>"=-4"#CMX+-3=F]-Z%E@=JKH^.MBIV<%$XIZD8-.MJI/S;@<( MRS14TUI%&E>#"=TU57.HGU[V=``7AFZHMG.]$N,+"P*8054>6(AWHG@J\F3F MAWZ2XE6'IQ8YAEV)T'2`KG3+58EXV\RY9*7Z.TS6WPPY@YWYQ_4I;!W(_*IMZ+W?#+B& M/+O;),EF^;N"CWM0Q]$:H1UI7@%Y_XJ6;@Q8[M/FMB,:-JYUP*_'`_W8'[H(\ MN*&OBAG>?YNS<)8T7&AF,,1LYW/:5L M2"D@;^=_2>&-3WRH MVW$*TC]]V<96[^8%%TE#NUYPT5$U-,:E-%`=WS5Z"V7G>"//P=+)J5XC'YSO MMN`/TQD8W]7'P%?/OIVP$,ZVL;/+L=5B=6?@N-^MB$VLB\ZN0\G!I0=.0_G% MQ+M.=0XXDRC[S&:>'V(]P[<@]F-OG"K4`^,UF3W?;X4Y M8X\D:`R&!^7I'?%Y^_`0LP>P=)2/@#T_3/RQ@E6:-B.Y#4Q'`^/:6ZF&5:;C M!GJA=N:#VI`GU12;KO_P.F`;+&R%!(R3')P&=ER8N=7*S,'0NJ3MW9J%"(;B)7@_Y0N;I_Q2NZXJ M^:W"[BN[/1W$&BO/82V5TG&';9!R7-VW%Y2L.H@^#]UX@*4;8*"?B4X\P.J[ MKQ&[B(!CJ\XNX&!/YPT'T[%'/WOX>^R!=3GIA!Y=?^QP%#VJ&\-V]<(/ID4/ MB)`]RY+#J=.3X$`?M+E\CX4<"!U>CX(.)PZ[2X.>G6ZE/+!CTYZA5J: MMT7-TEZ57IHJ/6R-VU[U]JKW3%5O58+JO3+>NS+^$,53YF,"9A0K[-O+_=Z^4SUN5#N6T'0^..A5:Z]:>]6ZG"!5]*10\FKVO<:E>4W5 M=0QU9/0'NU>L<(V!>\5>K#,PC2M5LFUR`\]2M[8))V_:8*Y7L@]]AE1=>HQJ MV5J?(W7=JE0;6"VZ&ER:*NV]UJOQ6ON#VD.KV#YKJL^:ZI5KGS75*^->&??* MN,^:.H>L*6M@K$Z:TET=7&2]3YJZ8C6N#^PV9S"]6N[5[7T?:)5+VZ[=5MKVX/FEKUCHUYZ:D3)E>U;!?4/6UMJSJ@;]2JNL)^E'4' M4=>M2E9GA2!C8)RBWM59X6@XT`Y?"DX[8P2=(B>L@PCJ,\<.>ZQ-G1;J;`BS M-R*V.!RE[&V5A&K_\ZLW8-4NEK=Q=&G+7>"% MZ6TX>?_/S)_/P&#Y+6'3+/C9GRZM]'_OYNS-R]>7.;O)G_[?SU[XP&Y^\4-_ MELW^\K<[XX]B8S:8XY`P>=\$3/;I8?J9(55^C3ZECRR^\V#`D\+U(8M#/\UB M!F]^\+_AI^2D`+W)_``ET\?9/(Z>&+Z'`.FGAPB@L+3=H)ADX_1W+\8K(R_8 M_C%,F#)A8W_F!F^U:;SQ&.R; M-7)'AF$58.\%IEU6^2M+44',&`Q9"FW_!J"W7?""'BCM5S*1`/_E;]K`VG[] M:Z'M&"J$^FE`Q7`PLKN)BFUHOT%P)+/[(F%&?M[%$V2O\=1DFRO?:VAY@Y+P->/OS,(`J=F'0A@^X\T M[5@@U%H`IJ:/;./P:%AE`^@CTW(-9R,8IG[PXSL_`6<3W;YW[,D?LUV(0!L- MW>%//]0.N^V$J[;T&PW2NY>I[GG'E=NJ`5%M;-^,7%N,7LK-F M`@8XN50[V-,:$)+#YVT:?LY>6@/K<-.OVK739`D^B;( METS^"7PO4`3A`SG4"=<$%%_)O6PA`G:@",.N"-C-YSP(J"MU@6UT#])Z0G,L MIT.@KB)*`S3L'D`5W^V@9W1=!TIT"TCDD%O,LU(&@;`W'&.?\]32@&T:KFF; M>YEGI51QAJ8Q6K>>V\D3BU,_@8W=.2@#VEDK>[9+0^\T\RJ<&IJC51R+_4Z] MDD\TV[*,C:=^ZR6/(-/Q'XR9/8&Y%H*43]]ZM);S;(\L> MECADHTFJ&$D2EB9OLSAFJSV=FNF'0\LV[3(*RH,M4/68`3A@TB3DTF1)"E(D M7DGE-3,:(U-W*Y1=/^S.B9V1ZZUX72W01`]>^&8?8CB=U%VGTZSX'8\1J<[ M*=YIB=T;L&#*VG:S2?8,5\->=`2VVHW;!VQ+/__*TE^C<+R5,#3`?1N69>'J MT?<%2:.@`)H&L36:.2,MH/F8PC&2QK%+Y^]YU_`Z(Q]F+JM"-,T2W=* M?%X[Z&[3-FR$;CJP=NW`4]?'%,#8=/3M5OU[%/_Y,;R+HS%;':6JP?;(UFU] M5#-M9=`=YVU`M^MJ0UL_^-RU^!Z--."Z[>;^X(=^\L@F%+EK:P4BA=DU\U8& MW7'>1G7M6L.Z->]W[@8#7+?<+>=&0Y@BZI]9PN*GUD81"/N*^FD>>`_S-XF6 MX\)0+V.TW6``N=]6E@^'MF/5;3N,M=4D3:0-3C38OGN=J)Z.+7#BAG5(7)QH MX:0?U&B<>4%+!#JVKI7LE/HQ=YRV`:5#>VBX!Y^Z%LFV-G(VFQJ#L5]CS\<3 M5_"E/X9)Z@5!F9;;6H::Z?(8[^IA]S![`]ZMH8PR'P&">O3;QN8X*)F)<<8F M/.+XU?O66DK;FN543?*%\7:8K@'5]FAHV0>;LA:WEN4,AVVG_.(%7NRS+2,_ M(W=HV]K2G`N#[CAODQ`Q'-,<'7SN>E0/C:&VC.L-YO[9]^[]@,[VMT.YKFM@ M5R]3\_+`NT_?9%P[CEV6WP>%H%Z,#$VP\-M"T)BSN/8,_GU].FN-)6:Z9;9? M/>.>@!.[M!&`EN/:"ZKW&`":FP.HZ:ZN'QG`ANVMR59>I$-W9&G=V>ZN`MRX M_=T$^/WZ)/&E3"#3,)R3$T*'05TD@3^VK;5SI+&L$?^-_"FF9.\)Y8[*6VPMI6/U)J"FZ4V@-RKT?KE4IZE\O%S# MMIUA5<:.,1B)G6P]:P&O^$WT4MWFF3YR#T-O:S$CC'0]9WII?KF9S;CB13RQF#F!5]9/-L#Z"",`&9KH!FU M,+>:>=L-KB?YTVSN@L]Y+AM;!9MOJCG`V,7>-K54S7/[3:U(^)H16VYJN<+H MMIO:3KJ79MQ^4[<"FV^J,7"VY=1%T`NGEAOE&]PFKO MAKW+&-YM!?Z2K-96/P*$.2[;SG40()M,;FW@N!T#M&G/A\9.@$K]*?0F/O*9 MT1$39H/YNX@T2Q_95NF`KG&*?0"R2NJ-1N[(:0O',@:K#V^9/&Q6:E9N.,F^ M`6M**S:-E?=FCP1;P]T<0]L1<7DB/KP4A6,_X$=%^=>B6,0;%K*IG]ZF']@$ MC/<`@[L97@(JWH>)=JBF8KCZPE6M/<)UJA6OK`UB&>[EK7AE29+%T\*CK_C7 M*)PPO%F%QUUB]/JRY&^C9+N*LCQ+P7$V66@[<(Z]P%7$>V.XP_-?X2IBO3'- MC8AU_RND<[/;]>K1.NUB9+:9KX<$"OE(_F1CQT?*!7BC@T/`\+ M-'SQ-F83']5\PKQX_+@]89CF)M`NSW@(.%?1PFC4'3A71A*TC6AV.T#?/F+Y MWH^A#.K!`SQC([_,GE>9V4%SZ<1VZ]?0`IJC+FZUUK+05Q=SZ\#`*XB`MO6RE?*MX!PB2K@@_Q.F#>R M9@9FUO+*!*WKDU3USG9S'ACLAG"`8YP#Z/7&B7-PT.47G/#:AH'YDXX7O/F./;$@VN9"F3XR1NN$P^3$;@W/6]IZK4UQE63]V`QBWV<1/\:J7GZ:,O7WT_)6!OCHH M[`8H:H9N``)[;]SA]<_55\5J)C>;4%`:O(+?GL-U67!ZPQDV$%2;GR/\ MK^SYA/83OGJ#)^T@)#"+<]FP'):;$]?/O3-XE:Z;;KET_H'`6[VY93_O*9B+:,`27QJF=7A(5^_S9I#J+JA'_<1[OAFHAF[8SJGW M_PL+`C!^_LY"S`7#DXG)#"OJIV@4/80=K0BI6I8;MUC`LEISX M+9RPF&P<;G.@AD\JEQ&I\?3/T3.+^2-%'OM M'N\'UOUXFV4S%8.Y+/:CR<)%46X_>BG[`#;]VDZ$F^*IG-9_9/#W@[I\N-LD MR68<$!3#8RR[$F'C`HQ4K,O9_J/V2I)CC-::R7L%<1DE]^OGNV\S'UXMUI>6 M_K>[X1_&+X;S;F&U!YG]'$*4;YTEP0\57^)R^2F+\ M[4[_0__%L$HD<5S@CH.7MD=JJA2P]M*HHPTXU?=SEPB*M)C^@OEY;KK;1.LXC2$;U M/LD!X&NW_F07C;_QIC=[#0O5B]9ZK@URW3!'C;V*)Z6 MX#K4JK?71FOHQ=TCO6P([WY5L4W MN-VYBK<6.H)>C8[?,)C5QN&^3!V_AH*PO'VEY&ROXUM0F#ZPUX9++U['-]3X MPY+TK6SL<]?O*^L+&O:UZ_:%>-#P#UV_(,U>*JNX+<<8(]NTW7V$B)M@.M2* M#\`QYF#]Z>S>8=TKQS3/V421:R*H-EK#QAYY9@L(B[**093`[[PT_0[[C)7: M1%G%Q1'K;_E6"]CLYF,!3):$CCU'[XY2U;63BS M+EO=7DQMJXS6/-.T[4R&MF*F*9])#*'XDV5JA]__[2>@5S^E2W_PAS_!/Z<^ MB-9D_`CT_9]_>4S3^8\__/#\_#Q(V'CP$#W]\/;C_P6B@O\S#4T?@G%6O,;' M_*$TZ$_SW"*%/T!_Q'2F",#KUHTVND&[N/B6/\7"2?&,;MR8.@XYR9_XZ8=B MT)]^$$M<6BYB[!1K]+$!>YA6H)??;0[]'R>"?G&']`/ND(S6G'R7-'?+79*G M'R=>@;G]"G();G9#*)@;"`5S>Y);C'^=PW)S^MQFN17=>/+E&AOM[IZ6^[]? MTO?_1+,MN2DEM!\.";!6]D"W-W_Z=A\'$_]']FT>^&,__85Q=\6'7Q,P"__S M+[E]B9?H\!UL'I>^(+11B(&RVV\^^"ORL1+\?*R??JB=XF^`60'#.6S+[60B M+AQX\[/<%U@`Y3YX0;X./_6"2]HC<3%C\MZ+T5M)SG*?%A=QAAOT$3:H%VH; MFT3&+D;=(J9[.742M'^-F9=D\Z^$CHGM7@D=+>!G]9*\C7MW\$A=P[;T8K_[>]1+K6YLT,=>J+71 M(CL=?/5RJA-H[\W38V*[%_2'QOE"'95>OFRC9@^<6=.X1SU[=&.#WNM6;P,= M/$6KBN5>/AT=Y;WMKDZI% MW?SBA_XLFW6+U@FT*ET+.,_03JE'N_?M/-#.X3Q+M%?BF#VUGR1\W%/[<=". MELS=G+UY^?HR9S=H(E"+E6YA_"Z.8"WI"]8P3/%FL@23@UW=B_S'3EDP,EK6 MX_IH]TYZ7&]NVVZ-ZP;Y\3/#*Y]?(^I%>@>"Z^42,+^\JG.1,?U^=$L.]?MQ M\"77+Z;ATZG?@U/*HWX%CIW0N\L";S`^P9LS' MV3R.GG@9L#/>@;KE=)P'^ATXI1:6X%X`QCNN;7M,'UNB])@^I.3XV0LG9XQA M!+_C$J/'\*$E18_A_5^9LK31J<_:805X2+F'L_:5C1P[13@24I%L(@%>3%;+ MH3__D^%^;]KLS5%K.?5[TVIO#EX]9ZONK^>W3>6%L"<61*0YQ7HN4.#U&W>F MTK#?N#,5E9LV[#V_G=QP91/^I3F;J<`7R0!+*.YA\? MN-SVFMWO8B)R]W;_H$G_)]C]/DWK3':L3V3I_A[UB1;GLT<7L"]GN!W4QU?VC6:VN"J*?7<(?.J[0\_.Z.(V^YN?1):A#W^$7W[Z07Y)`^!+U;=E M%[+*``E]N?;=2D;PGWIL<$*'#_\_4$L#!!0````(`#

&UL550)``.) MG-S4U'V`MH:DN<)$.X7W^2P9PQEC%I*#(O(=B[TG[[22NM MO.;MNX?`MZ;`.*;DNN)43RL6$)=ZF(RN*YA3^^+B_-)V*N]^>_'\[4^V;749 M]4(7/&LPM_HT%&.&O1%8?6!3[`*W0BY5K=N;#XT>#[$`B].AF"$&KZR&-T5$ MJ39I,`D%,*M%")TB(?OFK^07M_I*WIO,&1Z-A?5S\Q?K[/3TPCX[=BP5/7CQ_]BP2OGK@>$UA5H_%G=J7 MC^V^.X8`V9APH5`M%#F^XM'U-G4C7`6ZM+02ZIL=B]GJDNVL[B0$55,[^F!#9>D%Y_+RLA;=34K+YCRQ$D^V?EY; MW$Q)XQQS5IZ5;#Y;T,FH#ST86NKS^&?D1U6WY?:QX>!!`/ MO+@#9=(C3%:=+7OSJ9OLH>*K4499)8F@DO3^$/%!Y-&0VR.$)E%G-?`%CZ]$ M6.U39SFL7BXO?VUP+CN/6_;1`/SK2NIF[4"FN2X-B>`]<`%/T<"'>Q#-D#$@ M0F=PGDH21H+/!EM'A)@;MR[_C$$W$ MV%RN$7\@/P0-7<5TS>6M(/9L`L\,(;!%IM)JRN9RS&EX6A,QEXYU)-E>KQOB M]8X8`UM`R0]I&8+F,I"%*IN'UX;P(/>Y$V!BWI5+L9!S6[5EC+(W4[/Q<6LU"\`J/++U\:5C2X34[#V^&7-``V`U,*,?; MMDDZZ7*0I,5J=M)^`T.0AGH]D/N#<$NLTPB7@R`=4K.3^7LJ(`[/&E;61,K! MQ3JJTFQ@9+[0%]3]-J:^-)&KO$',MV]GLM4,8BH7UY[V"R6"7,[%MP<"80+> M+6)$YK-<`@F#,,H@9"C$+M9%^0**922RB#_,7JL;GH<7IG41]EJDB298(+]) M@X"2R`FZ#?!VQ3(R6L0?9J_NRE0L@NCDB7A-2H0`>;?LZ,*0*9BR^IX2=Y<$-B%_ M!)PET6?3=GD,([5([NB<&C)`NVS)T=9E(DNRC/1D(M:P9,J!\B<&B(=LOI6D M#,$RZ@9=_YFW'/WY]V%VW<@_@G#_W& M/8Y_ZL!YGATWW];2"-OR^_>])M`7,D1$&71GJ-Y/83`&PO$4VI0_^K6!_$;W M_1I!?N^'2O>YZ`R7>VUMKI^4.512A!FX0IDBO=>6`Q8\N3/H26^"%U=,=MBJ M5E*7*NW8RJ$G<"8]:]G2KFXQNP@B40PTCT!I3_/3AO'\Y,(U^Q'*TDS]9%G>/M1`BMT9Q2?>(G)YA-5B&%W<,JZ* M-W#H89:F8FV$[>`'L\-T-%?ZR`<>G])I7\+(%#6:I4QL9H?JI:5W$N1Z.6U^ M1,B0-YF9')2[Q.>]9RN(C^]\.GN:+&75V`_-3E:]'J@^#(0R06Y@IUAB>3__ M+/>U+;(*H`U7X"G.&>`[-'#(D[\6YR%X-R&3)G6!8>I%Z??B\AUE\:\XY!T* M%F[CT%-[=U*3DW]'?YF]?LJE7YVYP`TL/ELD?I-%/Z3S=AD.JQ49OE';/SJTT,FZ\Q%68X0_78&,[RCMDE:]$X;`43A)G: M`C7'B(VTD5@C7&X6=1XPNUKM`\)$G9YWR`WF45V3M+,SS`VZ^3KE9G&+/\Q^ MZUQ"7YR)*`3ZC7U"IMQDI?`^H@[OAQ:E31BX./*(_-^'R-'$:P14YN#_1M>U M]6D%5,M-93'O%"@[/&0QBGXASW]5:[M>N*U&2:Q7&ZXKLPPQN*Q\;OIF>*U'*:Q6ZJ3KHPN6F]8^-VPR_&UX#*5`O> MJ\H-510$A.?MI33"Y291YP$-<_5LYK3/=98WU!_U<[KRRG]02P,$%`````@` M-S!_1J?0/#K6#@``!_@``!4`'`!B=`^/#EK0>1^;`Y[;9#_P/Y_`'_MOLC:+QQ&_]N?^7 MUO'1T47[^*A[UOKWX^.O_4_=D^ZGO__8/_UT?_9T\Z_K_QRV7EY>#J$[!C2T M=NB0::O=%F`Q\KY\$/\\`P9;W$V/7;Z;^/[L0Z39?)NY]?[NZ$S@5/01A[SA5?1@PQ]8.'W=\0)_9(P MV0_>T>WS2C244697D M(/'(@H7N^_?O.^&O\=0\.]=?)8_G?M:)?MQ*C7+@K)CE:GX3R0FH0PF&`SAJ M+3Y^'MPF[2'/[[AHVEFDZ0",W[5"L!_\MQF\?,?0=(;A\KL)A:-,'$O@@OXS M0?SW(K=.94P3#H0ZP3-L\V^A)]X_A1C3957VX4C$&!?(>)DWDKQDBE` M*@E.9*T`;9A1>PJGSY"JA+J1;PSG$N0VPF0=T@D!(I?^=D6<@'ON+__O>>ZU MYR/_[=8;$3H-Z[QB[,)">YEY"%(Z[QA^7E"0A\2W=_S/#:/PU8>>"]VE68%? MG7\5.?P(L*C7AA,(?;8K69N9U,Q*IK'*[C_RGH'G3Z"/'"!124MPL9FC3F(R M+>_"TM`'/A0ED#V,1'^)PHFH<.;PCK"="TU^IC5S)6V\*EU#GSA?)@2[O%M[ M_95W"]]4\)62JT;"4JP+XPOKF#AQDP=8]#X)/8B[>!!O?T:`/8T6L"'GJ,W%'UHKWZ*9+O$%?YKYHVS<]DNP.+O,843+-I'9IF,BZP`,T#H?, M!'"`#UJ$\B*UB/RBGL,'AW@^+[37.,SE\H#!L?A@2L8M-Z["[DR&?.EIZY-M MNQM8H%E>08Q+F.%RMG1-E>:WKAYQHI"B3G6X)\U[M;@/4^*%;GT1"%@`7TK?EO24C9#DU0?TY4X,:?$`/H69ZF M2W)J3I)5&\JC'WC+/Q;VK]<)C4'>CJ@R(2<2&BT]V5QO1@%)]ZQK^X830"&[ M92R`;A;[\21-X'W#)>M:L;!81.BN`LKKE$=($7'_`7``HZ]O"%U.YN6]$-)Y M-$&SAB- MH`#9)TP,^)UVS\_.S[:TVC$3PUKM4CB%CKM2IK"94Z5CY*T2-1=9_5]INJ1/ M87-:7=GSDXO3BXN*FBXRL;@VW966=*W.3&JEY"W<%#1%S2J'568Z5S>D&=UIM15B0JV`PD_$A]T'.@8>^F]8)?0\=XC&'AHA M!WA^SW%(X/FB)T8PFZ4&6G4ACN_0UP"Y%1:69.:GE<)TN]7Y M.;D2X]:8OPB0B@'L^"JIA3:*RJ>4):VW31TIFW-B;6*O(]9R)6D@- MO>E9:^6S$$)U`L]NIS.`J#K:XAEJ)2O#<'6*SA]YZZ;LK5WEII6<-*O5F?E1 MW6K#XHRU\E4`H#IU%U>01Z`4N@,XAUX`U?"6R%4K:7G6JS/V_A[\SB/X@/D\ M1J&,5XD\H(>\XS,$6%67K\"&5C;EL2CH71\-(.8UA/L(>&OS1`&/O9UP:YJB MKG1V_GK[S5(X%/#9C4+I)_"J+!K9R%(O:UFF%1!U'%:TB4$?19QEY:Z7/@D4 M"I@\&0:S632$`?`R"E>Q,ZFD&;W>!Q*^U'<2``9,S@N&01(GN'+4L@UZSR#?(`KP,!'L`9H?YJ M"8!!F0LAV:MS&>B:A1;]"='N\?_$&,"T66!ZY9XN6PM&B* M.:QG#`W*FP/&7FGE0&N6]=8370%"^4>#>J:AL%?(`K2:%4R;^C`H92X<>S65 MA:U;W&@VPJ2>6P@LEC`;J6;5_@DHY3^\#2"#=&ZRHD>6! M:Y9X,67.@R@RCO@R*&\.&'NEE0.M>P2)>&*(GX:)'T9]"EWD#Q#[8G(0J1"3 MO2*7PJY[*,F=\U`+B3.`>5(>>4V)X?>X")&].I=`KKLMGJ#9+(+U-^"YV.RR M\SPT]JHKB5JSLI\9?!A=,Q]-><3-NX-/$_A(X0PL*YO51,5ZNX-!Y:N@M;=D M*/)*>RN_=:*GT=8]"XN]JDMAMF#\61Q[[P:8%]'EKX\81.\U."A\7!OC3_YF[&BM!-,>\M-57>J%Q*9'5++),F)597E M0`D2ZW:7E4&L5\W8[*HI&9,0K-4O%ZKVUY`&T+U#X!EA3I`Y_3*16"NC#.+J M:J9NDTSV!^*_JI1P=_/F-Y.6A5E=K)2==6L0R=_$(XNY4_9`!^)R+*7OGSHX MIOMH`\R.1*GDG^$'N?([T>7H;D]_P9RM``/1-BOM+NK M$I&Y75<*D=>F\G+W)_^ZQQCT64U-YN[F;="O'$P%8F7L/MNJ+A*_*U6L&@8K M=NN5QZI#.UZ$@FEX0)$8.G7UBI9NW#*U"D'6*)/X]B&T/2`8CPA]`52/1GF6 M[1!($J'F<;F,34=1/&/1_JTE('O'VN2!:U\UMQI:,"=K"@A[I"9]R M;YF3>;+&@VBEK@,L46REI(Z38MT5+[5*:\Q?'#:)7\2G_Q>R(/_@32 M\&A#N5."]46__>B(`LYDYV*V-IWRW$GG^;:BR% MZ3`J47`2,EC;-RM%M`U!CBS7C0Q9[L$KF@;37#TVTQAM&U(*3UR-+6^L*_OW MG*U"MC?26,WVIC?6!18-O)A98H2\[(A1[,D&W$(E18#<>[V_FXHCJG@WE;H3 M;\Q-NV4`L7<2K1BP]BGS]*-13,Z?YR.R5]PBY/N)SWW,W)3@81\SVTCT/F;> MQ\S[F-E6MO` M>KP_)KI?8<>K-Q4]M`POU>3=@+A;$8G6U1XE_5I=@LT=>PA\Y@-/S*-_YHJI M+"?%9OYX14:"6KG:<#^N8W1_`065_-)>3C"/\S!6(`D#V M*B\/O+K$ZVO1E0J5S%8KW;GFJY-6[60:I42K@6+S@2+%D/4*6M=^LHH8K)6P M[MUDU'@&J4J5K!O^P$_^TFG_6X[V8FJ_6Z[_6Z[ M_6Z[_6X[:U[=_6X[2UZ\_6Z[_6X["V79[[:S7:'];KO&2M?$W79WP'-SI8HE M:*(F]'#S5@7K_(;87]S^3PVPCA==W".U0`T6A> M?(/LK%06LYOIF'4]Q)[C!-,`9Q25K MJ8RJ["T66SV5UO5=,[%^@EG*YS[2`#7S79;KL.X7+W%$2AG:Z4>RR4,I>3 MO^G[.G3Q^=E#<_X'P,,)Q*,!'".VN#]Y5?W737D)"*95V0UJ+<+U9A1A_MS) MPV@$*?+&=_$YH/V`^F7(1Q=`]H1"-O2'`BM?/R9G22G%I2`I6W1\-8#B$ M$(ZN/_$7A0%'^*CX_H)",WI7R)>!HX#D^&U-:GE-R]G<353UL[?S767UT5X9 MD@TWAU6'7IO0>9>:Z5!5QKX-$I;$J4"OO.N7.$0>SO!X1PQHJI6IM%E[+J4J M@E>C*`57S.F12!*$'8))@MVO;R^`&M56ZUD#84G,462O:\][HA'KV7-=;MQB MV`QONVZ1)&4D-/:U>K*!;-AA;I*S1JY)KU/F,\;(S$6D+O2+)G. MZ/RW5&&,*Y?BIW5OF#@^DW,PZ7GN%9Q#3,+9TNM7T3LH.$Q-XLEFZ27%A74K MD880\SS'O_`PET>U8K&,.^5$1S,R<[B`G_^FEZ-40-7!,:GG:5 MB#.R8*&UL550)``.)W/DN)'GW]Z(_0Y8 M[X2[)Z(TW9KN&??(]FY4ZS&KIIP^K#<%SOJ&AG=!QKE]LTP?R,$!"!M'R:]'\#^W04X) MZV:2_^7W]T6Q/GKS!CYZOLWB;]+L[@WC\>Y-U?#W__Q/O_L=;WSTG$=['SR] MJYH?OOFOGSY=+^_I0W`0)7D!O1(?YM%1SG__*5WR?AFP)-(6\/\.JF8'\*N# MPV\/WAU^\YR'-4%74;QE'M89`JJ<.6I^46CC\X8D571'.\ZAX6=.__#Z/ M'M8Q_7WYN_N,KKK)Q5GV!KY_D]"[H*`AJ/('4.7A]Z#*?RU__2FXI?'O";3\ M?'4NE>R'/5KBHS>N9+RD692&I\DP81M?.Y;ZN@BR`B%W[7MGDM^PI9$.DKGV MI3MITR*(ATF[^U)(*Y9/^,4G]M.>T/2YH$E(PTILH*.8QYP-7RF`<$4Y7=9I MOHIAO4RS5W5-O*JO(ZL@O^4T-_G!71"L^?KVAL9%7OT&]HGW!V\/RP7R7\M? M__TXS8O%ZCJ(:?X3?;BE6R:\=W]Y)6_WIBXP--X3.:-YNLF6M$&._?-W+6NN MLE<:E0&]5[!S,=*P'=/DX//UJW\#HB1=$4[VSV]VO)O2SK,E2;.09N7&7A<^ MR);5+]B/&G'*%F^6*5N.U\5!)1G_?)6E#RHE5FQ3G6K>3`./$[JB6<9F0/`\ MSW-:Y.R'ZG>GSVN:Y&S6YNQX0_-Y$LZ7RVP3Q+D$0P.)H8&&ZP0&C14M$B0A MR4H>OJ$2IYXF=&T,L@F^X2QW4!WC.&;92>_OQYN\2!]H=O.4-@#1_.M@5$G8 MH!:MDAQA]'Q!AZ2;U7`KU>E^?;JBCS39-(=+ULK:BM)@B\%`19*4-'W!@:;+ MLNG?J>KA\WJQ*>"^`S?OGX,L"Y*BN:%)]SNMJPF_Y*@2/MES9`92H>!F$5FQGAC/C- M9R@Y:\V41/49%1&5XZ$$` M#9C^PF(0Q;B1)6-'UB4_>&5;5;Q(L&6F0IT?72RV!N6Q^CG%[.JOJ^;T&PI> MAX>$X`7VA?PFG2_9)I%1Z=8A.RN8$\`?&7H+BSHY,&GNXMN3IXGRXRR43FAXM_S9+YY-,?., M5=2<<#UA.?G9=,%6@Z#8VYWGMWF1L8-*OS.JBM!89U4#X5$O.W".6\7I4TX` M'22MV-6.<4>^(7>XJ@S/<\8#[0[;UT6Z_!5,F#0\V61,-.%5\[<@WE#QZ[,T MJ_SX)+#N1P.-Z$$BXWPK'A[2A'"^1'`@C,76O='F!C-:YQYI=IN6OD<=?12= MBT3G5JQSN4'GIIBD@Q34G)\(Q+J9A=ILMU'V6$I?:#J9Q[-1VBLF`F%>C`&#NS0"V3):RH( M?^T;D,STT`16G]%Q![0;.'IOLA>^0E[?!YETU^]JB8:4@CT&1Q59DO-M+N>$ M?8.1HN]-[&AU[PXPGZ+@-HK%638)N4#W:9_XG:RXL7F0=%F]Y1F>8M]G&)6F>JI.<7Z`=2?^:8Q M01A_/OK\LVEN^'0^_WC^Z?SF_/2:S"].R/7-XOBO_['X=')Z=5VB\_0_/Y_? M_/*EH5-G:!@VG([/K<(?^GB39?+GH8Z&=LZGGC='50J8^\57=+H$2Y;5S3F<5Y!!OA6X\?T:S2H>HJ)Y;V!)G#64MC1O/N1YJP M;3J&L.;P(4HB,#D4T6/UE*%.L-"/!GXV#1$9]?PI&,Y(R9);3_>95D%-WID1 M!BFKA?[A`^P.R1\W40SQG$JH-AJAL=C-%`.VBJ)O0.KN:1,I*OVZ@\+6K5>) MA68K-!@D;%$G9%^=LR5];>)!J6.'N]SRGH:;F"Y6W1LYM[J76W7IV/?"G45N MZ'/QD0GVJVSKPQ/&[X?6.H?S$8)G><&&7*5QO$HS.`#Y!EQ[VFKMDI:QX-!C M9$^*Z\UZ'?-#K>8A4OL9WI?$4#"4`P#PR-]4H^?="/L> MD%^F<;1\T:VQB@_P<<-:89`YM,1+SXZ-;^C2*Z`59VPX'"X3`3X\1`6/]&)W MD^,T`5<\FBPCFI]$^3).+D6PJ:?X\';4U`\;-\=D3HSPJ.3 M0`1RGK"3Y@,_87F'W9YJ:J%VT(!.&;VZ"X_B_BB:`Z3Y]R-$LVI$Q27$J\(^ MHV07]NE=L%QOG>C#/8W&SVG8IW#)_Y3FBJPCM38V@C7;++&Y0]B$MYT:9)B0 MVNP?("D_5##JZXS>L\LOF,=U'9@H5K2MA(XP4!DZ7*ZSCS3GIQ]O(W&;W)W+ZTJ4/OCCCB4YBK)$T[? MEQG@3)&VW;P,085=B:]H$40)S>:;,"J$:;.@]/@^B)J^#F;?6%BE#42RL&9G M)9<9"8`/7#(%([($3K[@MY=:VNNY\5`YM?2Q.\Q-\'Q%H=]1'/&9<4(A"39' M/@2ARA#$E5Y`9?Y_UC&R9SPCG/B-SKU+F M#]-=AR&P]PA/#M[MK\N[U$>:T%54S(LS&H*?(Z2-V3"17G;?LQ'NA_&!/,:: M"K@NNY@Q)"A(*0S92M/\Y@N;1#BM&\XU&TB;P!H%9M7C(,M>2G\8$] M>Y14&#L&*2!/ZO1MFO21G3#+9SJP+Y.:UJ3ZD-K6-!!S:_=/8,Y>!4\_L7') M(GF%PNZV5BS^4A$PTP*BP,L\-/"Z[:'GB;+K7>9^C?J=.D3MWM[$>B]/'URS?`]=5&AY/3@'%S6/%PZ[JR6-7M*V5>"*@R02W!Z`:1O<^G:R^`9U2SIKE7"TB87)LY-WU`X9 MEIU<1/U> MW5K9:F8AF*2;,2Z!F*#IW5HFZVP[7$2E9I>HX(\JX6F0)6R!S.?+Y>9APX\% M)W05+2,Y3K0?6D".J7#(<*2**@D%6?]09:J(-L[Z#=-8+E)S=J0,X5AY0O-E M%O%WX<;(2YNA7*14C%&HJ>B2&F%?<*/K>-U#2J_RL3!1ICH\8[>3(/Z%!MEI M$IZTWY*435'8T`F`.HF7:50%<0+4"2-/@+Y/,-'IH`X5LU&8VKE*9(V?;XK[ M-(M^H^'GA&FS%F4.5>[RO<1[O$;LY_6:9ORG3]&#=-L;E>5(+E9V%6(ALUV9 M97)&-L""Q$#>ESGA4I5F?E9C@&NXJU4IS6,0Q1#L?)9F/X)?[4F4T24C`<(T M`&KZ%G`T)*CZ\H-0=<)J1BA)`\EIF/D,)MJ:5&_9)=QN"F904[W%3[;JIE8N)0$HFHI9*_X MFC!&I*HC#0Q]0YZA0EHI6OL,E,NE;ELLZ.6&7D%,4WW`Y47!/*J`%WN=WGE"GG?IZ$)^P@'*?< M9-6HO][:X%7?6-C2#43"W68$`VZ,#'[7QX+@,C,F+Q:J\:6G\ M`[O;6@AY48B`BV_)"UCB,E\]!I4];\>R:+7OWJ-4;5VQ\`[29(3!@RCZ7J'! M9JCI$"D-ZM.;B#JEIZO&<#.UO_,9$WJ_PJX:KAWM;>%7+@K*)2&(V=&M2!E0 M=D65/31":Y4@`9!N0!R7?.?J+D6[H,JB[\VF=LJ^2P1`0\@WO*@ZVUGK7:EN MEYX$I7,#=]%BD%UDD&2"ACSC565.E'H4&'ULP;.@CY`X#X.2$\EY*22V.I%' M'[.J]5-)V[V@_\"YPV2[Z#Q$RNT7JF\@4?D)&G\F`B%C.D2)F6S+8$82RF\" M01RG3P'#`W?>"]/-;;':Q"2H/F%-OOKV[>SMV[>^0=1$:TU@FH_CN-EQ2Y97 M=)UFD$V$)]YIGL6TS2UDRU4+@O)N%EES*X^]+0>1LTTNB:#,MRS M^"1=;GCFR"04[&HE3"1&">//4+[%?01#^9*4?(07G@"3AV5<^JJD[E/KG`"9F486/P?6@`\W]::!@/%AD*Z_C)5>RC57D?`')%6=28^T3;`?KK8Y7 MY%@[M6F`FSRO\!#17&O-Z&ILPXZA$`)E-PM>V-_CF4CFGN>P-_*+00JV3E]@ M9Z:'#IN$=C19K7*S`Z31G&T?',4[;W,(CMUH0Y&8H MZG*S)2L!S]JUH.T;K'0Z:#]QFXS&U`E55%:J=N.1DIA8>>>NI8%=>IP&5JT! MLZPAMNZ/(K2':^X\S]FI[2S-(,?F!2T6J\5JQ2ZR8)')`<+?O_OP_L.'C@OD M`"*H&^1PH7%'*Q$%Q=^Y!5_"&/.B[-O7Q[3D7M;AA,=&)L&,B>`+"G$*K-\E MLZ(1![\(E]3\$ MZS3_$Z&NV7H]M*\(9J/B,O)NFT9"@J1Z"PMQ=2UV>&_MV"SQAR-9#7RV M#06>)NZOU>EVF)\$$%-?1`PJCIX%4<9=[N;LP/$@GA3!^'.6T6VM>46]NO'Y M3E=&MZ]J4#%DVSQVA) MN_MYD2:/3$X:\B[E?,VL_QVN!!=I\0LMRK0?O]%0,F''XX?/Q#&V*C`3]'.2 M;>D)S^P.NPBA(B[1MVD[NF9;R4#;T&5PR>01$A_FE_E>47:6##L-"-" M%-^PBU:E/`,V"A8>U+,P2U-L_/EX-2Y&2%Q<\=HO<^$;>/MJQ+C2A2]YTLY1((&ET:=H2/81$!7O7=(GKZ.2X]2:A,OK00YF0LG@6?7,]S3_501CO@J>=@N45@5/#P!G8, M@:C]B-T7DZ7<%4WUA17$:<3!(JTDS\^7RSH#'P>447T(S&QGT9R"KI'^NW M,@I8WMY:$4BI*+B#8IE"K\P%2PZJ:(*2">$)F?P+9-%J15884C-"'MRCY;D_ ME9^,=U^VE`MT[XY,=Z4@&>!\0Y>)*HPOQQ-F#!7UE'8G1^#$)O-)"OENY#=A MQ37*3=\6W.&*FCX^IN"K9):D#7'-:- MSP#2SVS6@U8*AO(X2),[`LFOR`E=9W09B;D#:_;\`F=@L:%3^2,T%B53/O8MV/TK`-M1;2?7Q#KW)#+"`Z") MT,CK4/D4&-+=4Z!W`='#%*-_"30?3IU<&&.#;H+W^\4*)#Z+TR?=G%-^8N]- M7R&0E==]GD$(6!#.PS=`F^A!^H2N'1G7)EIVSBHK=9;G4:5QMMW:DEE6*H8% M@VS!#M[KZMQMWPX[3/0?A.@)O8.W;8T-UK@'TYE?I5KH-KQJ@#11G5CI$WZ] MC=VZL#9P+A*T+!M586TB?;#(!HEE^L@]C5]!1]^516P]<(\2U;Y%ACJ%8TI7 M:YMN4%UB6'-]*BN\1YRZ?ZA1*D'A\B0?C,F\4-2)Z"6-;?N?6$Q$W^%\\F5Y MG6B2T9N,B/.J!C4[B%%A@X[VMFH;R$5!7>(%<9\SI6G[+REKH!L+AV#*<]I* MR]#X(QXF>TSP1[.`T[-Y(.LOH<%)3"_F))C=ZVH+H!U#/G+53UZ+(3Y/0OK\ M5]JL=B!O9Z/.9S=KU(-Z6>!34":<-&&T?4&!MO,=)3U5BA\+&U452%$%ZS0) M3]H9&>7M4-A0LD8=DZKBG8(R8:3)B4>D!SNL#A/DDT07]$B MB!+*:RM-/US.Y@I(6Z1Z/A2$SB2RWN M".R'ZGWO/OJ:BHBZYE6]AW1<3W`O)/O<9_X,08$8J"680?[#Q MQ\]\L`JE3[']AMM:2F!9]?.!-9S[D;.9*'A01S"`;N4,WDI`:B*(:)HOK\KS M('4J4@DC@.'TE:21.>:"%MK0+]U7-EY,3,1"OIMP%F3'8T88%_8_6SZ^H+6G M6CJ>4\R'RR'VXCA]"EBGS]+L)-W<%JM-;)S`RO!C/!)["8D"9,6)K-*,5+Q( M!TZ]@V4O';70.6`D7=K3MCG$SEBGCS=YP4XOF>RZ)FUNP7*F%@3U7I@%(:T! M+"<'L`H>7-$8_`3)99`5WKS-F"JD;4PR&9KAQ\R3*%^G?#,_H5#;I"N+?[L- MZD`H98FZ=V^)DE!0]67DE5VNG\0T:G;H3K^YS>G_;,!H^$=Z MG2@8S$#F5G+X_1'9<2&"C2_8,59#RXG>;$A<^ENR3L*-`F[-4+&,H7T9I_DF MTT;'&GUJP1/37$`TZ'XX(C\%_PVUH:OUG+^+L+,$NXTE?E5$&J*@MLMFWR&< MS'_3')<&']KVZQP3DQ^.R-9X7;+S#8+FVM!X>7H$OW8T;$-6N?U9\]T(<=`2 MT>R'/K-#W+[;L>58)`O],HY*PG;/CTAOB8KTP=U*6`Z_N-2B`(3_/]L\X2GU M@A:+U6+%>'(C9E[DB]7W[SZ\__!!!`MTW&\&DT)=@[`=L!`;(JJ:">YP^."1 MI+,JN61:RL"CCGB@Z5=,CAD3A%VTA2R^P-:&/NM7,3N(<%PO6QW"9#=NR7:P MTL<@YD9$$V"YDG7-O1^OBR`K9*N[OV*?)M(MJ8_0DUQV#6+`?`C\XHX.NZ1D MQTRD.VEJ:TEC.^$74B%0![,M45CZHP3L"&DF$L.FQ3W-?(Z!D&JD,R9",RXN M[?;<=,TMUWQ[D1KLF^TL6.HEK''GC"I>69CDUT"=Y#Z:-Z3];UODE;IW'=ZE MB0_<:V,IV,MB'&`9UEX&E(X5^S5`8)-@?&.IIPL%TX4LRN'AT@)2;BWRG.I[ M32S8-=H,<28,02^BN9>)TKOZV[ZWRS3L>D'3)4O;;V1I2;.:H.SZ^O3FVC<0 M=/>S>T&PDV[)-.1KS@Y>(1R^SN+@KC%2[;^C@KXZ6:'&NB)(@*(O8R[M:CWN M2Z%6QX:+VR"GX9Y[.'@:WO$D8!]?=DTN@Q?XU?PIR,(S=F#G58X88CCB[3XA1;@+W^7 M1+^QWG/#U%F:E;^"=K)IZE@(]-2=1FFHZ5Q*3$J1A3'P@.-T+WB)NQ8+N8D0 M?+;W=\(O^4QNMB049"?YK`J%!\?0FO2^K1G3#%US'9D2\(ZW^U:WVJOEQ^9J MN1`+Y(\\`N$\$9UJA"[P/T*F@NW2JCH#.)3"SL'`O=HPRPNG2D*(&ULQNJ+N M)EG33*2B\VT1F$C#G:>)J9`Y_"V>L0/W+L9CL6H[P9]L*+@N+Q):>;MUO,'W M)H%Z>Q\J,&9&['B"1;PC0((PO@08$\9YZQGHRTS!J*W^M(X;:$0\91F^QF=! MZY6\JP4NZK&;'2J0L8I,+&GZA`Q)=_<"#57J1:3`6&=1S'[[KG++N&2C]=7&]MK@JXUUL<2@KB3H"XB4_6Q5&Y/KUAT( M/FZB.&0@/7^`I/:BYH,2$8H/T/#0"X/R`2NIDSIYWY"C5T$31J8#X@Y39YLL MB8I-1N=)R!8[^$F-*<4':$SIA<%@:DM=Q->4]'T#E5X'35"9CH@[4&T#*33O MM^UV:`A)6>,2.15!%'L'%6E?FPC1Z-D=,*0EUW7Q508?HJ%C+AP&2_4*EQ5' MOB!MV?D&,W.]-''7=]2&W_QV]3"E/#_G=+6)/T6KKI1(_;Y'W?@&B6H=<9SG M/NZ(8$N`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`=-?^4!DG.G6T2=MQ@^\C.9UV;'AM!$7^?Q'<' M[T4C"7CP#=`6=-6Z-=H:>X?>@5&^#&)Q394@>J\)W@.P@R'*YT\H-8@9U'BI M2/!TY]1]`UQ7SUN>?E)=.SV!;`_3'+^7P8NBRHVTN8VSAE(0Y`&C=AE*("7V M6E#W#38Z+73LM@;C,79%;P'D7VB0G;'?-&\^JI96ZGQ+V*,VMZKDMZ!-@#CA MU'U!C($"NDJ!*P=@W.>_FO>->,->;(J\8*?AMOW%\",+CX,F0EEX*ZR[3\W* MY*RDQLHG5)DKIOV8:#Y)[4^':8\G1?6*R2+14'%>`G:F5?;6ME M`Q?(->^C5UX/G<@K9VO&:,('E06[W09P\`0OMN,@RUY6:<9S=I@^K"@HV']@ MT8N+M31O.7"_/K+'PQ=,(M2C?;`P'OH>`8"%>4N5DNW-&N)<,N@F>R%*6@O0>TH<:TJ.XUUL/W\M-GN,;SHE@W MZ8\T>PB2EWD^KV>2X*F0>(N.G;W?]ZA]?I"HJ*,C9R@JAI$B)<(`8:(L)*&[2*J-`ZZ#;=>SL\[G=M!,& M@MK..,$0NJZ23BS%N;3NE>T3&H>H2YEGPGA@)WB4/HN2*+^GX8]I*CVC2AK; M>Y3N%`)I">8$R1U0]`5<9OV6ODDKM.\PX3.-HV73KMD04'Q-GI5,H3V)&F)\I^0\U%KYAUXZJ6J%W%@'@=M)AB[7.X2)'S21ZDW=42C2`%>PQ^N&L#]QY-!8,TL5K, M%"FVLJ1I7]FGP+NB_TVT:V'C#NL\U/LR2U>1S(>BW@*-[0YVN,!_`,9#D-U% MRE3PCL148MA4UBFPV]'?)F:E,'#H%!1E=%GPJM:+U2>X<(7S)+RBD/NABME: M9-MH+0F>^U+!NP0-$QOU4E-6-J?;3)I@!_$G&112-2W7'\R03IOB3NY`;OK5 M*$GN++N02[+.Y3_N*4'\;)?.F6M,8_8:O% M0*UX)6D2EK1]`Y2F[ZW'9I,Q<`<@@[@ZN[%TMN/G+CR.F#.)DG,?&2>B8>"& MDJU3<>>"\GR+U=ZO&D/8XT,+D4^FPEF(?MJC.R/`#`Y8>[_V!5?]%=2.@NHW M?.-B\&<:QW]-TJ?DFAWMTH2&YWF^:;UJZ-M;0)Q&%`M``PX'OP(+4O$@@HE_ M\-)HHXTJHY%QG,UQ2'GT1541G6;+*(OZ*0)82=^([3A">IW03Q7J7V MQN8YA21VLD%.HSY<4,*6+4F%)#/RU'SGR2H1R+*4@11,`E\FH0=CT)F#`BCP9*;NDC3Z8990"JL"V0[&'. M!%OJW*NH;`T8%J/?2E[E5K,MJLOWI0YP]_O>;OR;B:BV`^!*GJ1B6I9>?@TN M!]QF^[5/B!VD,F40G/GP.O1&`$_6708VJ2M"LQG>#T'"&`,Z3K.69,\[,ZVL MTZTG?*6Z)XB1W!X8(-H]>U2X%DL_L!KT[R('MC(R.9(HQ%Z7G0SQ!,\BIE,?02EI M;JGLH5P0#+8$;<*(^[@$J?O=7>10-P(3`*A/&*[B$WM`&C/P]O#PB'P1J.H5 M=VLZ+![DXC='6R\2XV7G'Q.-[X^^]#+G/6`Z?#P=.I?0`E(F,%$?HY"&'U_8 M9A^>)ULOZ?FRB!ZC0AXNV8,`WC&EM[#8H(\E9-O8,"X\DG>;JC#8,K)Y\1FG M>TK':'0?)_'9Z:VGED?/0-`Z?!ZO[@RP:/#$N.LT@2O$_#F2EBU4?H-_D@=;3K/FH3!>L=Q+%FT):ZEO6VGK`7D.,D4+V2BZ^H4NC M#%W87N>@3!"X=_H,_@=R6WFKG;V@O29K5-`[SX2YVPZ7$.'`SZRTY#)*`-^0 M+BAW>%P_)@WF:^I"&LK7#:4)L,_C7W)Q/=VN^_R75_21)AN9_W8/`O9FB[&P MV#W=YRBH_MJ0HK#GV$T;^\2=/V7[O>*#42*>]H49(=@IX@Q\PYY>%28A3ET# MXU%1]KQ7]>N&X\J>,X#LUN-0@O&+N-M7%R[&FQ=W[W#1I967RAIX^3:S)E!S M[ZKP8\'2H[DOZ^%9$&7P*@UI,SU[^E,2,#;IA7;`L=.NGS/Q.$F3RA[ MV0H=[/VYQ9)79H*BO"U%_:ML6_\J`);<*,1YDB4P%7;PM6#KRPP8JBYY::P^ M`SO!V_P5!6VPN<'G&;]&S9/P$^,<;]NH4G?VHF+O!;^?V*CE>K6B\#I!:Z_Z M!)81LB_#3+@=<4L/EV//"V!&Y@]0!\87G",5*G40&`*$R5%_D28A#3=LE&]C M6MJVNO&GGRIIQR+I"B:I_Q5U=NE@8R5U"J/G"W8DW:P?*:3J=%FE<)W19=25 M"*.SB87J@FV&F*&OTZM6&5\@H.ISN_:?3,L.JUTLEYN'30P._W5QV,\QY?>U M)&3K,SOA_L9_+W7,D@#)&GE\_0S+'45=JW:R0.:GK3"^@=BVSEIU.49!Q_"= M\"83P9Z,]GF2%T$H_=),&-1#?*#<\:-1]EUH$7:%(43G0`8A)2TM\E$\EUQ7I^PH5-!'15F M@^!P`TZ**`0')';!NJ;+3<:=)T^?E_&&W07.6!_AW+\I.'87JPM:B,O#)3M# M[D+//R=1(>Y1LHW8-AO\ACQ2QW'VSIU,9"<4J:02V;QK4\AHB^AW6[M03ZV3$^^S<71%=IZG7,# MKNDJAD))WX)^8FM.J"R0J__.>K50J6@H_ZTOHT:HM.^Z"J&:<9D\[@N2!N28 MN*\N`F/%?2F$M1+W];H,BOJ:)X;(W4=^(3MH%ODUO)<>Q7XI-&48^Z4%KKNY M63[5AU6$A[*0H*0Q>LZIA;!E-SRAJV@9>7>I4'>^B2B3(7"9+C[91GN(*TCY MN#"_S;FQ0+:@:[^SD%C>4#1\FJM(//*^+H-[/F-Z'K(L@*V;%!VK$9N:5W4<(M\>S**DA]`;T]3:0YPA1]I6!`-NGE M%$M++TVUBI_TGXE?@,=YZ5-_EF8K&A4;!C=X>7M>1V5!PS'C3T:5:3HO=9LJ MQ2RUI0#L,)EF$-,:9?^(`2LN1L&:[[M]9%M+N;W'8Y?_N`QTZGCN[/>]S:3: M9J)BIDXKBW8C]W`]),UA?BC39?<;6X=-JR*0KHGP7YRY['&TWQ#]O M2IFC+``[JOQ\=H7+([X8O2$*G_ M#I\NR%0T.QDK!!=2I$38E#@CWZ!FK)-6_J!^X^5!)LV/+S>,MR(!FLF7X^7- M;(N'7-\XFQGAC/:S9UBT7@OGX/]@"T3,2_SDA5F&=,./ M+5B8^@B)`F;)B2^6%2_O$-E+'6V;3/]!H*)<2R'W]QR-29_J'8)WF?R*"MW<@[:N==M;302/I])2YI#3,P7,7 M4FA!F;_%ZI@G"N7"R\^8FN]LG##-1,-Z.:U+1L(AG!W_21Z(;;U*F`K1V6?,"- MDBRKL/ZPY&6W/IJ5GIG52;/1P8D27Q@JJ2.K12]P(E)6['8>D<3S+.6YF-C6 MO%A593%Y7,)B]?[P^^^^_Z[C?7(`$5P"C,%"H_RIQ'E$!,((OH0Q)L!Y1A)V MEF%[05J54A4YKMEOOF(2S)@(OJ`3I\"]#!S(87?H%KB35.D!V&R&=_:3,+:` M0WXNGI&OOGG[]I"L@XP\`H,9^?!V]O8M_V^5>3C8%/=I!F%&,_+NA]D?#]_- MOGO_MOXS-U:\>\\^^G[V[=MO]U,6SPC[>2T2%\7>W1)E&F[YE"G'MB\4<[K\ MYBY]?!/22*"0_=`$'_O5WT^3@ET[+S>W<;0\B].@>7;N;C,8=DJ6J`2]`5^+U] M2I]H)GZ*'B+9?7Q4EB/Y?-I5"&K%V_/5G)$86)`8R/LR$URJTLPONC."FDP+K8R75^D217] M?Q)E[*R<9DW,&'YD,:NU2B@+)X1=+NLD30YHR8F$%2M?<-1/,?*LU?KAFOHX M8>`6?[$!MZK%JERI'X,H!B\"=G/G+L:]CA(6V$T7.F*H")PK@+A^5[3)*LW( M'5#W96JXTJ*UJ(Y>>'*9"%:41+H)GD6.C5U!KC3/>=@:&WOH0+Z7_ULRW0:3 MLY!@%M<1S'2I>/.LV(+[C&SY$Q"`[$G02B_OV[3":K.=YM8&+AR&C=12CBY6 MS3PT$O!K/L*'DQ@)A3H?U3A4%2Y]@Z:9%EJ1)3W&QFGFY6P#^5-TM3DZ&MK( MABQACLQ/`E1)`03).GB!76*GX22+9^,N4F9NJ[BN;,6XJL48) M>/,.5F:Z4$2]Z<=HZIN:,(?Q?,I+=K:-'BDWC2GSZPVA--+]RDA\U-4);(8= MA4Y\PRI"/69WHA[#Z])0^LAD2;,7L]53VMR"B50M",X^*FA[F(!.U^VV.=1D M`!SZFNZ+H4D*)FN-]R%5BX'R%P72'B)'T^66`ZB)ZETF#'UB)TG(7,TV>79^ M2=B/2U'(5DAJMA[U)F,A>>@PP='Q'H??'4%M,7C>V0E`]B7P#:-#E=5.LHD9 M9H?&PW9`BF9%5'V!-P'JQ<'"TCO(&?2Y98LS'0,?\RGKTG#V)^0PO[)--/+T M>JLX?2HC.[K2#_N7MG.PJH;G(9X:VVV/^-*F]"D*;J&,M3Q+N-&G(\1ZR`4< M(=HC*`V&\8[;N/$>`WN'BOCHV4D_8C[DBM)'?>B`ZD%&9]D6(FT_7@9G&]/K M!O+5B[I$ MG#EJ*I14JTB3;]_/WKT[W`:5%#S$R>:<&-@-LRT%W9LIYH5<(\T)H8.5PQW=Q4#9[]9[F5[W8T5%G:3+#=AA MSM@=.HA%'MXS]KOF"5[=%A4EI14!Y".A'D":?O"V:,E%`/GS(<",*ULJ7'][^49@^$Q>U$#:=_)GK3@F"%-M[B8+.+N+5T)PC924(J4<0S9TT8 M.`%4XL!1@'"!9D2(Y-O$L*KGED7$/I:F2!%^R0[^RV@=Q#=LF\GA'9MM.>5" M9YXJW(R*Q93AO<1&^1;74H>7]$E9B=U+%^-A&I)G$1\PL@[?&0.HU;58E9%M M3#+9`V.[(?YE4?*[H*D"@>#R(N/FYP=!G-O3('Z[K>>WS3*=[CL;=;K MF%_3(-%/#.ETK^\I+7;N6;EVS>M#`K_@#1`8[0;Z[H@=>=D5)(8U[YAF'AI@ND=JHNNQ.Q.9@>DV22[J9[E"RQJB^L)EA6B8. MRF)>2S;=SB?M&\(-E*'("ZT>''<(J[E[EP\6$F!U-$3C2($V_LI`V MW4@LE">42*2^QZ?*8U:R(L#+%USU5$T[WWJ/(1L7<7]+8\:7G2G.HIBVLK/* MVUE`E82U!1QM*1-!VC_82/K>!HI2[U^DQ]K/-+J[+V@X?V2'W3NZE_=:9F%Q MQ-TG[S83-5GS>7LJF9%`<"-T+\^[+_-G(C6/Z!MG#L?A'G-MKA_I793`*_UB M)=P<&Y`V_0KE/]=#+!3.2Z^Y/;S?5IS`PKGVRM.SIVKJ7G6]A\RU"?,F>`:7 M@F3)3MA\SAS?PY0Y3UHN6N"?+695'*=/\#2EM%2B"%LR2-KH'.KLLUJ):E2D MK&$`"8.OX`2]+]:,",$@=+PCN3#92D>VXOGJ]V1/\=T6.GNP&KYZUZ(7?@Y@ MBVFE"):U0JW."K:V0EXJNKZ@2M/M^DJK5?<4'FXM4$*BZYTYXP:D-?=TZT?- MHL?;H&[8\GSK6A!?U[A[ER,`J3>Y/QQB_-V!O^Y$=LR./FDOP:3+([YF0\`_X1" MLK?*/B3PCY<#!$9-+%K`"WUG-7'(!`=SC/]`=]+8?*$:J[_*MRO;G9[D87>` MXEHOO8.A[3(T;YW1I;B"L9]C6JY2]<(;DIEK]*F%(#US`5$I-&I\.$*#&@.; M4]):A\S2$`WNUS1AB.:Z:<;!DV]%FW@-A!A$L' M[ZVD)QN03>QP0JAM#ZYI]A@MI3E3>Q*QX/(]1.@Q8%_Q\`[7.%6UW<"'#[`[ M+`NO='A[3!-V6#M)'X)(=O[I;HM&IE($E(&8$R9;RK[A3-GQ)IP,E.]P!:3< M4?A'FM`LB.',$3Y$202A#?!JI$Y<:_@Q?L7K)23*ZBLXS M/^6TUK8!0^C0D@L9>>&\L`V?3>[*Z&N9T57Q!=X^JA<'M\WF_`"9L]NV=UNI M0=];ID33L7`8.5H]Q+(-^R3=W!:K35Q%\T+ME^@17C#4GN3]:.`C2X>(C(HT MK1CR&MQAR1(2RGL9]#Q(/ZWPT^%CZOBVLA>#J+J1[#>T<^OH9(Z/=]UYOU1,5X?% M!K/R?5^;FK^K);[(H)P]9I'9DJWRV7_US=NWAV0=9"*9[I_(X=O9V[?\O^VX MO1E)TNJWD;!]P*4@W?E3^H8\A1I;10MUP^BT,CG?;B]%`6_-&:R[L8T*Y0HA M4*>JDK+'!

\H4J[5_Y1!H)KD'(H/1@@*':.J0BVLTKO2"GH-Z.,KI\ZN M44O]L?5SN4QSGJ/&//.+_%.;B5^T`F(`MY?YRKO+7Q\M*+*[:,:IWNM/["?V MN^I7['\@PSS[S?\'4$L#!!0````(`#6B?4"D``!<8`P`5`!P`8G-D M;2TR,#$T,3(S,5]P&UL550)``.))A\*CNW_H1J,!-/[RU\=5>+(!.(8H^NG9 MZ8M7STY`Y*,`1HN?GL$8/7___MV'YZ?/_OI?__;'O_S[\^K]\]>O3M^= M_._-S3^FUZ=O3J__YX?IV^O/[^XO_GG^?R].OG[]^@($"P]GO;WPT>KD^7-* M;`BC7W^D_WGP8G!"V(SBG[Y;)LGZQY[QJG\O^36@.PXI$045(?++'3\+Z5A%^%F9X6=-ALDP^T74Q>0A3K#G)[MV0N\! MA#\]4Z[V4I?$\C"+@?]B@38O`P`S"=$_,O*?OSHM-.9/Y-,O>?>W8`%IKU%R M[:U`C6!NL3*!920GN$JLA_U=D^3/#,9GW%%>E'BY)B8R2I[[2Q@&N]ISC%8: M`MP1@00\$/M,J$%K6M$+GYT@'`"<&_Y!Y+]CY)XTRY![Y6?'Y%UEC2WGUT/+ M^09@B`@/P9F7B`1>+>>HY&O,LB%X,Q0$$T)20,FZ"+T%0_35WQT3>8TYMJC? M#B7JG.PI(0=[X2691!__!K9^$_@8?Y M-H=;U#$@^"RSL?A^8'5`JQ6*[A+D_WJW),S'LS2A'C5=V_%U0U3),7Q4Q,!& MZH=AD;J`(>2>63&F"LBNYCQA0' M![;!5O7[D-L9B'T,UQR0F,4<@X3-*@>`_6+]+R\;_%V1#X=M'W[T0KH)>;<$ M((G;[A-6&^E]0[#:W2%C<^[%#QG@:?Q\X7GK?("",(EW7^HCM?C\2V;V*(2S M^06,"#F0^`HHAH*=0JVJ!ZE<>[8F<4QD*F&@5LB0\K5!@BH@C]6>=@X/Q:(( M8BA!4B]K&!GV8&IBT.BBF7KPD!I[^<_Y;"C=>2.B-)\G4PW@+H\7?O3"M MNX!Z=:V`BC/6RH@I2L(Z!">^3WW4^!;X@%#]$()KD!3\\G1*5,45O,1\][2+ MWR5,MR`D]CVX\7`"0:R+&+NVN^!QI-'348#V.%Y&&T(8(DM"P`.K4L051*I\ M]70LH+W89\D2X`HS'.$S"KH"`8O'G@X'=.2[J?ALSHA?2?(T:'!"N)@#4BRX MROGF4IF1F*#$"[.2IC"[P6@-<+*](:O+;#E/_)LU75CP;9BPBBN(BOGNZ03! MH:HEU"G3HE<924V=$GG-SBG3%?0>8`BIET($D!U/6:*0\!-3821;R7I6N;JC MP0=U\5CGHI=(5XM-""H81D]WD'(0M#]^L5M(W'A;NHI06T75"MN#E<;*JOB"-,T3M`*X#.P MIK.J1#EXI9U"A,NR==&&L\(EO04;$*626853V"EH>`Q;%WY0GDY-(E]'R4KEG4)5P+9UX8@29W(=0$@>46GL%(1A'5F[1X#+T[Q5JI'C().H<-BE!^'4/4$/^2>8`06]#"+45_P M%B0>C$!P[N&(.#_QQ/?359H=LB&K$.A#GG.A4-$II%4$85V0F$](2)-#WPD[NEU1;'/:R2;7O;G+. ME3NHM"](.">O8\JM#4/TE9)V@?`92A^2>1HV3[%*MCBUVC!X]4L9N8J_JR8=W@"<9:%16N1S*[N&J:I,K%N%5@G/\P=-TF2),/P= M!$H@-BJY#5Y3!M8M/ED$9[D[=``K*AP#6#O>K=L?9Q'+3U*F6NL8(%/(469P M55F*/6G.;RHU7<-/21H]903L!$/%:4U4PV',5">Q M@],&=A3MSFE5"7<7)5W#A#:G3TI@L`11##?@"L6M4W6( M&^T]FB+NWM1=54(KV%,F.53`*VUL_R([(B5+V=$H9C@R*I%Y=6.BSJ%U,9'L M2NJ=%X)X=V*->V.06=0P&+PQU+AUVV#1.B0*XBX(?]6K\F*]8)1W`!,!L]9% MFF9K0!.-18LK,KL27Z>J_]G'@AV>XJ@WX`!T.N*P+@"U8U`RU[B`PQ,KAY]J ML&8W=8KB9#8O6),X!NRR[G@''%[MLW]T_LR)W>N^Q.`):AC&1SC`&EX#CVL+ MG8?])+JE1/,-7+V<*W@P.+1.4\X@!GZ243>;9S-A,(F"6R("0GB16&&&]RD5 M.!CIMN(*@MK2L,VYQR'+)5S!J\(5?Q?* M.;3V4^WYXQI$L30XQ"_OCA\HX-DZ"WA+!$F$0/-HGI%1&J+,5!>$O=?:PP97J/.44'`PNC\A#W'.7S]ET M.T^&8JFDDSB6.3TB[_$:1:C*8B$5B1.-ZD@`^M.&]+4Q'%VF3^G^#)* M`!&R*/TRL[AAE)2'7STM,YMWZ]S)+"3*95(4"^97N/BW/[]QY!?/Y(9$9XAI&'MY=D:HEI MNB)2D[`49L*2F.'^>G1GONU5[D?DF^WY+Y3O(UF$\V.RO-*NC0L&O]:=-[\& MB73E4RWC#@HUWOCGQYW3IUVR@]U%AH]>#'T.>NRR[J#(X=6ZT^9U.L]@F";< MVP"\TN[BLN>WIV?JVR/S,X"+)2%MLB&S\@)$.BIJR MX2Q+7UD';C$:52\OZK;B/,!\^7`@/AWLSD@SDT@7ET88K0YZ:X31OZG<0_NG M/UIDIE2I:RRI4D';4N7+@G,.>%WIE"$=6$R2/D MK3/$=6R!JC*ZF)BP6;8.HM)%SL^`S@K<0VWU;XDXEN+)BXZ\!H M+-CI7+*\8=LP8P.S)R[ MLQ23J?7@-Z<7=.3`HALKAS^/;T^W??OZNAU;(1XVBU&:`4 MR;9"ZS!:TA62S'Q>!S7UC:$J3A'6*JYR.+;?OWG_]OW[`U$M&C&.I\BFMA5, MATO'KM#J1!,K31TAF!@0T3`&B.).T:`G2+&PU7C)&K4LKZMR1 M/#7Y*YW&,WA^ZX`XRB^G;D#`I%QP7JO5NOP\,OLREF8DQ1GLJC2+3F)U`%O_ MB6');'D1HJ_=)(3=-S9L(MA]M\9/\NQ)43_`TZQB;KZCM-Q@M($$DH_;+V2. MOHSV]U4G?@(W^3-3DIN<^@W9HOH"!&MSJ+:HK#OIX)Q_TWZ`:OL_1@^@_"O- M[Z+&]^@6^"CR80@J5-^C;A2UEZX<4^5^Q&W=(9DS0+#P888$^3L$&211,%DA MG,#?18M-I:J&4>]3:2KI\Y3$>/BNJ$4OW'YSNVM#C:5.]N=:;-MN`'Y`I@]+ MN!_M&FR8:,7+#.[7?O)@1+F>16 M02*TH:#5RZ%F\.0AX9L>+`9G(/^WS&DV#N7/VBC6=VQ]H"$8ZRQRD_;F2\'* M>#*JFK]]J3=FQ;BR9&-==*!)-LU=%9'>^(_4B.L<%X@5:5BW"F%Y8LV3A@8Y_>YH'>`PQ5`G&:C1S/%,H4D74.+W^NN/&VK2;173U[ M%58P>-6FT;UHCBH:QN07IX2J)WGIC(9ZU>,<$`T!'1[,LGI,3,GBDBPC\1G( MEO/J(Z)1\0C'0U,XAV>`M'HTG!4LB-^LD=<[PK'0$,WA*499[#]@6,O,COP&40-70<+H-05-9=#2M;-7HPB)!. M+%OI[IN"^6?7L],**`QDGM'GB,>Z;;PRS=&=;MTZ@P?/%4>![8Z`CNB9P@ISV250/^A*X4-64/0K:SL M8&X]Q,49*5I-..9.Z8GGB![Z8#,^(3J"\9:H0W9H6VM`U.L>Q4AH"(1_N]S1 M7&.]#P2+[D%W.11ZO^#>RTWI,QC[(8I3#*A_OI5$A01U3#UYF=) MSE,4Q42DP4[H-R6@9_/"/_/"I_OQ3_S((-KSRY',X&08-H0*8Z?R(NG@*$G" M&@.8Q-=7D)C\X("W8;CM#6S,2CV/EJHU$WLA,FCC<"&LXI8%$'-O7EO?G-$4 M]2'QZP"FN>H_>B$-EMXM`=@9FH[\%J6>!M9P)9I&W6]_IS==D[%"9S,O+,OV MB52IAZ'5A%NV04\ZYFW%V]W.>7G3O!OCP&YZ8&O`)F)4_T.VM-@G+=1=`:TF MW%)_/>F85_]W3Y>6NU'Z-$"/H0@OSVK/A&KU'1+<95D85YY?^CNT65YPP.K M-(N$4;L[S)--A:RNX^KUW=)T#;F8U_?WM0MPW2A[H]6!-;W1_ZCF!R3NK(A2 M7;\5*KJEV"J2,*_1'SY[_T)X=\^Q%,>&(=-35 MF2!^^T,?`.)3,FK]`7<,V#)55WZ=%MRR`5JRL<`4G.;Y1.^]Q\Y.!%::'%KA M*YV/.GY(DIARIZB?$KHOD]M(5O*']BJ6];A8!E:8$#>E(_[[&Y17$9SA%==6A)I M-T.;%"E!IM728=NR$V=9Q!IGZY2KNV4MU*5B@5EX2[,2P/S=`7IE"F4G^T'4 MX84A81=#FP,A,:,I."`PR!6K3HA0JQ''S(*FA"PP#N_HPP.5&S\81>1//[\A MU)%]D/4RM(F0T3-:B0.27GSEB36[3+;-_RNS$]K-N&4I]*5D@:WX_BY]B,%O M*>G@?-.A=6BV.[0]:%(P6H`#KN1492F_?\,K[Y9."_BV0'EUKLW7RGY,8QB! M.#:894!&D* MD\#@TC%+LD\Z<`O6]+'BW7NS!DV)E"2;;8F4^-&8:!-_0>#PPER.'(HK1=PQ M(%7.'#,=G+1OY@R'A"";S8:$]-%HM-H7:4KT2T203S#TZ98A7^9;P6[)`8VZ M8Y@.E9YCIJSYR*M!,R8@QF83)B![-%\MCGONI!BKQ6,%%=PQ.R*N'3,II2>' M#=H2%A4V&Q$6O:/U:'&0-!>CXEX.M[@[EH//L6-V@Y6`R*`!$9)CLR41$CZ: M%'WB>:F*U$R,30O^N==B&8% M'@[(A!VD?K*3K-"TB.NX8U8DO#MF4DKW3(T&59I4V&Q*6/2.9J2%EU*(436H MPBGNCO'@<^RDW;A",7V5K'@#E-X5-&Y$!"39;U$$Q(_F19OXF-!4. MPVCD=$FOB32+'69 MFG\CJ^6.L9'R[YC!N5O"]3K7C__VHB`T^^:[B!J;#8V([M'(M`CR-,1)E4W- MUBA6=L?DJ$K#,+39;$S[5HZUH M$<\I"3,_N9!3J.8'*5=WQ[ZH2\0QR\.Z]'/G+T&0AL2B:T&9-WUOSD#BP7`VGQ([[<'HHT=,M0_NE@#L=##>%6GF MG.G2NG5"R<`&K!.:1QO5J8W:R9GB$U\AHG[T-=P\(!@M2M)7ME?Z+3IMNUH( MT"T[5DI[8\J`-4FPV'(UB1U-5JO9)4MUI8R03C5N6A_P_ M3D%P!;T'&))UBCD#Q*7$8CO$I7DT1UU[4"PY:SE,X@:<-DER\9@W2F_5HK_E M7[NT1.V[']C\M"=TM#E]ICEKG>#,:1NC(@[SMN6'['[H$H6DYYB2F&R?-*;Y M&ZU2)$*)9_@6+I9)IUY/=^0,;'NZ(WRT19WZ/XJR5W:'=-MST'(=(#SS!NWT MM)2SI[STW.5CP6@#8]+Q1Q"!.4SH@8XT`<$DN0"$6"^\I0?'.MWIZY*BH3?U MNJ1]M&R=6K;S^1SXR?X8$D&#"IMNFT8^6/6HDFG[5L;$5IKXL[` M'&`,`O(YSX/94V2J??=V&"\%0D=+U:FE:DB<+(?:!Z3T6G/:/FD*S@+3])J= M;ZCF4C9^[]0^'4;#T$;J,&I'2]6M3T6&'-H"<`?P!M*="U8*HTF8T9)=3BI. MJ?T.@OPIPNQ&KH;#U7%_3EN[SH7O@CTD=CU=9232BW#!L(:0W;EU%I!-YFCZ MNMTH9`A98Y=06-MILR01C,5&AG[-\^W=HC"<(_S5P\-8&%'/MI@7$8VC;>DV M",^]$=WXB.@?]B@38O`P!S6LD?=1+)IU_.B023+8TBXC7"A99Y M"9A2V>+MM;>JWP=4K67:_HCN.BMS+K$F!M`Y(R3FVU/[3VH`L2HZB!&3?S9, MKVTU^J43ZN8,/8,(FXT[@]QORJ!W\-[OW[TPS?-WYL^&\5+C""K8;#!4^'7, M.SPX*8(Y\](9Z38;I7ZT;-7'6SM7"[E@LNI\]>1V]G#R^>/V MGO0]>82\R42EIF&(V*-*Z:1SF7UW0*,TGZ&5!^M+!YV:IC-:J8](M3/K)9GP MD3PAG.8'%JYRB7$YR=A(`(Y!5M+8PV$[_CZ#U0/`'+SKI=S$ML&K9%EH$(TK M0&.;]VB6+`&^\0BO:OAPZSF.&%\>;`S?F,/P(L413(BWF*49>*1_Q4+P!!7< M1$TD`39<;\W!]3$E[!.7_7*UQFB3)]<5PB6HX"9<(@FPX7IG'BXEB(X"%C$4 MWYN#XM:+%B+/_NEWZ_WW$BO6^009;<+A7BYA6-2-,=&0LG@X.^E#?X817*4K M(4;5,C:C5./&.GWX[#W*I5TI8[6TJ]Q8Y\WN;><5C,`E^9-G[1D%K3?[+.;X M"#AGE_1S^>K4M`7=QL!4"N4.&0_*XO:)J4(+4 M3W9"S#('48WAV1!681>V6WA\'I'/6F/Q_)$>HA1,!ZS"#D*YY].Y$T'T&F_V MF`O`4[1:H2@[`FOR>)"8(IMG`1GMXW0P[K;;O-O^+47>3(MYC+Q9[,6,D;YF`,.4)E:Z`WZ*LV0EYX]^F!)7]X((*T\35MSB/_=P M1-Q3ZHUF?NAD11U6#MS=M&W+"!%&[SH2HW6.A29?UR`IWED$>)8F<>)%=&/X M2P23+D>*O)MC'#0*PG4L5J#WLIBY"$([.FV.*[3C:(PVJ/E#7KB7\">$@O@3 M1C'7)V(7=B+ZP.&SPUF,_0@H&?AK%%./[0S0[$-UV;++V"Q2#E<=+JPXSZGF MZ9NF*,I(HCGKLH.K#(%RB]HN5SZ/UJVD9FM`+P)'B^P4<1']?7(FZ,="WSC6 M1*,!FV%K(P_KSNL6E'%#G[N?70#BB1?).5O;7,Q)L`$X@3'Y1(K>$,Z165]2 M0I#-3J.$]-$[5%M2/TE1O)?-*.B"J6#Q9_[)J29S\K95Q`H\:5^6C>8<]L=VIINR'%[D7N2B7LP%&)J\67<4@N9@_TJ-S@7"9RA] M2.9IV#0UO"E4K;(+4*G*P;J88)/(:Y!P4'C4^K7.*]H1>P`C&2Q!DV]T:)ZR:#DA9Q"KR,)_,;HII1)IR"\L.$)J-T'%(L=DGY M1(^>Z7@SVY6;V>S#8/>8#/Y\<_\RBA,O#,LS$^-(F*2"S3"I\&N=VUH8G])+ MR?SH3[V@S6"(^+/.52V(O".3!`U,2/8@V84=`J/!IW7G[)I3LA(FC/(.P<+B MUKPG^E;M&8'RKYVZGP?T/[#/>0"EHZ,YYGRP.>?#^,+"^,+"^,*"@W?!QQ<6 M;%KLC2\LK-*3'6\X`D:,/\R?5P3H$Q57FR0KAI+C9S!TP_"V";IJW&N[NA6G= M`HQ+*_\XDK"*$WB*F39_:)ZY]]'_/I!-.SWC7HX6P66SQ*&U4L2%?9PJ3^8S M)+Q[FO`[U45&NP-K((."4>_4K]D_26^Z]/""?^B(7=@%7>3Q:5XKO[\A,_[^ M_&E'*EEO=&!]K'<_*J.:,I9\<'HW+O&B!7P(09XU@J>4XDI.**>$;_-*^L-= M0GA8HI#T'%,?K^,L0X+V!U9=`26C%BNN2(L@8R;)+/MW/$F3)<+P=Q!PUZ3" M2BYHL8QO"T_$E`F^\?`,9\OO(,N)M,O>WEDO:-ZBI]^&$V+\U>DR@H+KJRGF(0%K==:\6\ M]G[2H#'T[M%-BOVE%X.&M\>RE3K5;8="3Q:]OYW1(&='S`V&/G7@+N`C"`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`J/I952(ZX@B"*P4<0@3GDOYO%+NV"NG(Y/3R=LD6/G^WB9H3/ M_++R_K6W_6O$DBBAJ*8+."M)X/"4?)U@SEX%[1[:V$JQDY6V&2\II_Q8@(-Z M.5L#>ODJ6ERA.)YZ&&_G"'_U,/<)4$$%FU%5X;?'UR:']J6>SE?N/]Y@M($Q MZ;B88*9HM4[I-F1R`0BC7GA+:.[1"3N8))/>V\'$CVZ?GMM'%B\H\HD-SC#F M^$A[4=.;HRE]AO2I/A&^S%GLI`\7C%['4K5N[<_A[QI1,Y#Z"4V14_"8W>3X M2%]-H/I*OF0EIRB6+BT.:MOA4:(K1>N27W#XRFZ;3Z+@BO0QUY*?=<^:<)@ZR^>O9#GD[=LS`5STE9. MUJW-&XSL/N2:IHILK9:3$-8YMVZEW*#X,MH022"\587IJ8*3")7XM6ZI.^Z@ M'K"&,;BP5;#DY2`:L>:%ZWC`K,=KT$F4->1EW0*686&RI#?Q/A1#Z#\#&Q`B MT2-&I96WF0<))C3OQ0+D+Y$_%;GQMO33 MA,XIURE]?WPV+QYWV!"ATYL.%PAGF9LX?/?6G`R*N6VEZ+1K.$6``R.>T^X5Z5@EO4D2`PJ+.Z6M.N\]IXQC^-, M[29VNI9@2%REENV"5^+::1PZXKX)PA MFE]5#YZBCF&`%$:;`EH[_@]/)_`F-_L)P#$P>FF97C0B4PE-_O49T-@4!]UF M.;<09?!IW9DQ]EY]<5!#B(Y*3;?P4I+%X>D#K-'#.Q"2-A>?0$2OB])SJ,$* M1L5[KIO=94&QCNJUX=9XT)2/=4?7GA@E2^1+\B?/RV$4M-ZY83%W>/H5>W23 MN=NCM2]F#8:-X2??UK(A,3=O-3Q(A,"R","XPA]F7[PO7;H[LKJ2N74+P$[9_;)>#SW$ZEU^A/`T&/P MVQYN`YSZF9+E.XP6F:>0N06,@R?-,C:CPN'*@E0LT@,2DSA.5_GD^(44&O@T M":=W2X)(4CK'Z%*__O3>$2O)G^YB^,2F_1V%I!EZN4F0>W6(GFTV3(,B8&O=/&7G45$;!9FL2)%P5D MJ?(1+&!$7X*?S?,@`V,=IE++9GNAS'GO=TI%W=<"D968.0N4MDU9CU1K&1V/ M>S#NJ-NWHV[S7E1\R):'R-*8H.`HQEV7B%BW_W2HUET@/`X=*W;F.I=Y[[L(F]TC2.U)9VTV#JQD/E47*-\_PX/8W, M9C_?PFAC2->Z9)$=\FC`XJGV_HV-MC96S&#FRM81?BGGMX!>&R7?IRC*!)]Z M(0W]O^YZJ^4`2IP9FT,CU&'*3NMLY25A%D8Q]/L\J\GOSYDQUX^T94E*W1M: MA8FGUP1[=>2:_7P+0XDA7*%-,?H18B^7D9SA%<]7)=7[6WHHS.J=!W]:9GQX5D]\Z#Y\*Q.PJ\/ M^6B-P,)+BK+#F86W>?+A;`-W$@5T9B03)(C\SI^G5>EI:'.@0M/1FP)1DF*Z M`KCS0@]OIP`QSF2Q2MFLSES.!GI?*\[7`L``00E#@``!#D!``#M'5USV[CQN9WI?T#S M4"4SD679EF.[\=TH_DC=R5D:V>E=I].YH4A(0H\B=``IV_WU78`?(B4"I"0H M5CK(0RP)P.X"N]A=+!;`QQ^?ISZ:8\8)#2X;[8/#!L*!2ST2C"\;A-/FV5GG MO-EN_/C#G_[X\<_-)NHSZD4N]M#P!3W0*)PPXHTQ>L!L3ES,4<2A*;JY_MP= M\(B$&'$Z"I\?-OP_0T]/3`?;& M#I/8#EPZ1MF8A.'LHM42C9Z'S#^@;-SR0M8* M7V:X!96:4`LSXC;B=H4&3\>R.I#4;OWRTY<'"3^I>!'QYMAQ9EF#D<.'LGI2 M`,W:)\W#=O.XG389$3^K/N3>U!7$RWKMHT4M#Y.LEB298_=@3.6`2>=+#3B@O3JC7&+AVWT&%C'-X[4\QGCHMK]'"% MXCPEQRU1/'0X!L'T\10'X2UETVL\@"8=1D!1] M62!.03C,78&R(@(`A,XP"PGFV?B^:9GIDH='ZW8)FI"`[&N'?&>X;H>@"?;W ML2^NXZ_;%VCB1OZ.Q4W`>(0^(/'AZ^`N@[>J-F*JB,=^?8!)(#4"[XT>0NK^ M-J&^!Z;LYG7DZ)RV3*JI6Q1E3K\T2(TL:)3^ES-B:0=>$ MNS[E$M,%9IU/\ MZ#QC+AQA+_)Q;Y3]"",X)V))\0D'T+TPVH/\3Q&+^ M9ZBMG)CS[:JD8R-@&IDX,^S=64DPI#&27[CPP(/ M13Q`PD,2(,I#M!Q;'?\/JP'5Q5I]M4PT2>8$[[&!V.>K"`.80Z"+`2CDX<.% M.L1;C`O M7%W6:ZQS"([*Q>'\`DG0*(,MK4`"'4GPUC'0\?4X'IS>Z`HS^!!\CO^6KO<`SW$089!M.HX[:M2SUX#7.?
#M14:T>G<36<.86+- M7#&U2VKJ0J`*S=V!>9W!L;/:8$Z=4)9?*.=]S,!3FH+_-G&8V5WR2B2ZB)IB MKV3#?#MI&MX"*/X.`3$HI@9)T$Q,195\E%?611$4 M>Q\G%R@%)7F<`;,LJK69_34@XOBMXX/M\T<#/"8\9$FZ8Q+TK%#@VP'5Z7I% MX$B_*Y[A1A(YRF//!7*MB=A1_I3)U&L%:(W,=$RN[%:SIZS0&!(:(^*AW;A1 M':M97Q`LLTTOW\PF4BB`ZRR+PFDTN3BTJF)G&_F+"/)JF4GSLQEFG74RIY1* MM_^+0>[2_``KEAJQ/'Z(9K/XE@_'%^'<6Y\^W04CRJ;Z;='*AKJ5C6HW`[11 M'FP<7Q:`40ZRY6/-Q>5BZI:55JB-+2#JS)#BK*!R35NQT=9VG@(D2+`Q<)/2$XBK7^+0 M)%@5ACT2#@C_S;`456'129/11(D\)=+625J0(,;*U9896EW.HZF\*X!_A4K; MIF:5@]/9+M6QU=HY63F42."T^^NO$T&I$)V=(]8E=:@NTOAV\1,KDYN'3ZJ\ M[+KM-1)RIDH'J!5,L:ZQ,9V37&]EU)59AJG+\#3I!F=7=5D?17D!:CI=,^-#NN#<: M808#NGYND!*$+E"NT.;Z3"")"0E4*,5E#?PN;ELTG`RZ"E=GZ$UNJ1;N6[2Z M02J&7=CE*SS5ZP MJL>ABSJ9]!.JLK^MZ3"ZY:Z/,VT.4!<_4H2SM]QPMS&A=0^MI[QP]NVQ"'$B/T:*W.<3OK-(P9HF6ZGX2#WUAPSNN53AT M+HK)>[]76J246*]TYP)ETK.I0*%S;$P>:].(DU5/!6FB;B1S]Y*_PKN`P0Q? MRG-`Z]36A3OCW:RD=?ZC]"\D*)OJ:7#&/TR(>#Q/1"/_!D/LFSZ/HH.O"W:: M#&&D-,C:*176;-1W4FOYG=I\[IH/^EA.:"\#J'%?@)8+BE2!PD4!E@5&UE<; M/:15`Z!N):]*E=UVO6;7\C6NOZWPD5`$+G'\ M`9Y1)DLP(]0SZ@A5(M$MI$U>D9L1@C)*4$R*=8F,G>^M_^[:EE!U.\0*<[_A MB5[[\-KN-I.D7=[!_4%%N+KUELDLTN)M=..Z25OG*\2CR MOY"1T1U*8\3H_""3=F^MW2Q)]]*>5DPZ$K1;!6@N`%5ZZL)L#$J/0J<63>Y@ MJ-^MLRIRTW=,[^3Q*3+'8L)N\X9I*2#=YJ@JHE7C_=(,EU0S5I?4>7^ZZN%I M;=Q+L7&T>'':CGRM/-7U,UOK+%,4,TF7R&KGC.9)E[[#H)\3'((M\A7ONQ3K MZ#;DCO6/O:`"),N-FEE;F]RM4FQK/Z&7?Y;!UNP'&[W-; M?1C/;@R8#A::DYE5H#IA4:QS3(0*K9!L=F*@:C53IZV&Y6>JI6W5^0%K,M;T MFM=PE[6K&`7#='ZRY=#*H=OE"X049W-7JNE\Y).*,[HK5P99ONSD5?'UUZ>; M8M!%AA0'LW;[<+G5R1HS>_H0#3G^/8+NWLQUT:22FKIM>55"\JFX6".%@V)` MEC'KO@J_V5OR6A.J..M4YQ%YR[\=;!B:O0I%AT`WC4U>,:D*L]@MGC5>1Z[[ M++)VKBM"827O(5N6&+@.;]/-MRIXNB7L#N[7LWZ4^3=QMQ8-/5B=+[[!.]MU M7\6UDJ*1E,,!!O38ZSM@"Q]AM<(=5TZS*EFH;*CCMBJD=2AN-I1@D82+\H`M M)_)S@/L,S)[TZ M.DNF7T3\C*YIML&ORVLSN>0!&H5P9E0B$B"@$^4(%>6+

YZ.C_X[KH8\L1 MQTU'5'R#+T%`8V+E=S(5ARX0AVD]=;Y05Y9<-A(Q?GIZ.G@>,O^`LC%(\N%Q M2WQKDH"'8L^M*7YJMH^:Q^V#9^XU4.!,,9\Y+M9`2!LW6NL2X(6L%4*W6D$T MQ8RX`OVY0-\^K85^N?TV%-#@?ELB:-#%NJQ!$=MJFY'# MA[)-Q)MCQYE)%=8\;`.7&RKB))[2ABWLASS]I;D`%5-<08H$R[%[,*;SEH=) M;5*6VX@/"N0XOG`8.4/Q!JD;7C9"%F$83.+[PFREWP73+AL".KF`FJ!T[D!M MB&D&I$30F(21(.0SH]$LK4B@2@/%GV?R5-.C!.-%L29J"*W<&!'_5]T5!=V$ MM)C#EXUZ=?>J>_G<@$*.UG+?:E0L=DS7D2D-P)EF+T:Z$I<-8_HN&ZY\&F'1 MP^1:-)F]"^MX+,+`XCK<>QSV1NGMEE>4B_V\D_9IY[23=GF3EO7'@(NKT;A1 M9JY/L+R?C6_>X;3]]\_ZT^.SD[.S348B;?G=L#XF>'/6%]M_4];'3DI8R7E8 MN8,;)^\3N1--_-@]2UXC3CM=5>L;QE[W3EFSAC?/&/F$@Y+$.+"NB3;'%^0G?9D@X:OR9.4H,_B M?^QEO5C^>?]YL=R#]1K5YX&'75CM^3OLX`!\33F)1?:9\$,BQW_$;+J.W*T) MXS5%,&&-0+BL%DJ+]E\44T8:[!9'"HSZWHDV1"](.M, MX:=]H.WQB2[3)G_:3[_UYEFLNV4^R6)RYWYZS1'-$?)(/X-$.L%+EW?[,2J0 MW-[HD8(KI:*^3J-OU[^5J9PG:?4\Q76$;QF=@EBG4I3V^$W>WB8%[ST M0J>7?SA^%(I7 MGHMZI/V(N1.8OSERBV'`]=J\IJU8H32E4]H'L'2WY%DF@@U)D$BHHHO5#?>J MGXEP%K#4O`Y$*EF` MV3T-;J8SG[Y@?$T8=D/*>-':ZFM^!UWL1F`&XI.B(<97$X>P\AZ65OP..BAV M2?KB@LR4]+JKWJJK=(7;*P70KO MZ^N\JH`Q0````(`#FC4IZ8``,Y<"``1`!@```````$```"D@0````!B`Q0````(`#`L``00E#@``!#D!``!02P$"'@,4````"``W,']&I]`\ M.M8.```'^```%0`8```````!````I(%6K@``8G-D;2TR,#$T,3(S,5]D968N M>&UL550%``.)[T``&)S9&TM,C`Q-#$R,S%?;&%B M+GAM;%54!0`#B7`:575X"P`!!"4.```$.0$``%!+`0(>`Q0````(`#6B?4"D``!<8`P`5`!@```````$```"D@2_Z``!B`L``00E#@``!#D!``!02P$"'@,4````"``W,']& MG2DARMP0``#.U```$0`8```````!````I('.(P$`8G-D;2TR,#$T,3(S,2YX M`L``00E#@``!#D!``!02P4&``````8`!@`:`@``]30! #```` ` end XML 57 R32.htm IDEA: XBRL DOCUMENT v2.4.1.9
Note 1: Organization and Significant Accounting Policies: Income (loss) Per Common Share (Policies)
 12 Months Ended
Dec. 31, 2014
Policies  
Income (loss) Per Common Share

Income (Loss) Per Common Share – The computation of basic income (loss) per common share is based on the weighted average number of shares outstanding during each year.

 

The computation of diluted earnings per common share is based on the weighted average number of shares outstanding during the year, plus the common stock equivalents that would arise from the exercise of stock options and warrants outstanding, using the treasury stock method and the average market price per share during the year.  Common stock equivalents are not included in the diluted loss per share calculation when their effect is anti-dilutive.  Options and warrants to purchase 14,989,224 shares of common stock at prices ranging from $0.44 to $7.95 were excluded from the calculation of diluted earnings per share for the four months ended December 31, 2014 because their effect was anti-dilutive.  Options and warrants to purchase 13,720,225 and 9,669,878 shares of common stock at prices ranging from $0.99 to $7.95 were excluded from the calculation of diluted earnings per share for the years ended August 31, 2014 and 2013, respectively, because their effect was anti-dilutive.

 

Since we had no dilutive effect of stock options and warrants for the four months ended December 31, 2014 and 2013 and the years ended August 31, 2014 and 2013, our basic weighted average number of common shares outstanding is the same as our diluted weighted average number of common shares outstanding.

XML 58 R40.htm IDEA: XBRL DOCUMENT v2.4.1.9
Note 1: Organization and Significant Accounting Policies: Property and Equipment: Schedule of Property Plant and Equipment Useful Life (Tables)
 12 Months Ended
Dec. 31, 2014
Tables/Schedules  
Schedule of Property Plant and Equipment Useful Life

 

Equipment

 

2 – 5 years

Rental equipment

 

5 years

Furniture and fixtures

 

5 years

Building improvements

 

15 years

Building

 

40 years
XML 59 R53.htm IDEA: XBRL DOCUMENT v2.4.1.9
Note 1: Organization and Significant Accounting Policies: Inventories (Details) (USD $)
Dec. 31, 2014
Aug. 31, 2014
Aug. 31, 2013
Details      
Reserve for obsolete inventories $ 750,000us-gaap_InventoryValuationReserves $ 150,000us-gaap_InventoryValuationReserves $ 100,000us-gaap_InventoryValuationReserves
XML 60 R72.htm IDEA: XBRL DOCUMENT v2.4.1.9
Note 10: Related Party Transactions (Details) (USD $)
 4 Months Ended 12 Months Ended
Dec. 31, 2014
Dec. 31, 2013
Aug. 31, 2014
Aug. 31, 2013
Details        
Sales to related parties $ 463,423us-gaap_RevenueFromRelatedParties $ 16,686us-gaap_RevenueFromRelatedParties $ 419,549us-gaap_RevenueFromRelatedParties $ 99,896us-gaap_RevenueFromRelatedParties
Related party trade accounts receivable, net $ 13,471us-gaap_AccountsReceivableRelatedPartiesCurrent   $ 8,322us-gaap_AccountsReceivableRelatedPartiesCurrent $ 24,201us-gaap_AccountsReceivableRelatedPartiesCurrent
XML 61 R2.htm IDEA: XBRL DOCUMENT v2.4.1.9
Balance Sheets (USD $)
Dec. 31, 2014
Aug. 31, 2014
Aug. 31, 2013
Current assets:      
Cash and cash equivalents $ 5,594,578us-gaap_CashAndCashEquivalentsAtCarryingValue $ 8,130,416us-gaap_CashAndCashEquivalentsAtCarryingValue $ 9,450,528us-gaap_CashAndCashEquivalentsAtCarryingValue
Accounts receivable, net of allowance for doubtful accounts of $20,000 275,072us-gaap_AccountsReceivableNetCurrent 366,887us-gaap_AccountsReceivableNetCurrent 899,969us-gaap_AccountsReceivableNetCurrent
Related party trade accounts receivable, net 13,471us-gaap_AccountsReceivableRelatedPartiesCurrent 8,322us-gaap_AccountsReceivableRelatedPartiesCurrent 24,201us-gaap_AccountsReceivableRelatedPartiesCurrent
Inventories, net 1,775,648us-gaap_InventoryNet 2,329,189us-gaap_InventoryNet 2,445,770us-gaap_InventoryNet
Other current assets 86,583us-gaap_OtherAssetsCurrent 146,319us-gaap_OtherAssetsCurrent 200,028us-gaap_OtherAssetsCurrent
Total current assets 7,745,352us-gaap_AssetsCurrent 10,981,133us-gaap_AssetsCurrent 13,020,496us-gaap_AssetsCurrent
Property and equipment, net 1,140,871us-gaap_PropertyPlantAndEquipmentNet 1,267,661us-gaap_PropertyPlantAndEquipmentNet 1,319,880us-gaap_PropertyPlantAndEquipmentNet
Total assets 8,886,223us-gaap_Assets 12,248,794us-gaap_Assets 14,340,376us-gaap_Assets
Current liabilities:      
Accounts payable 598,466us-gaap_AccountsPayableCurrent 548,897us-gaap_AccountsPayableCurrent 521,417us-gaap_AccountsPayableCurrent
Accrued liabilities 1,105,152us-gaap_AccruedLiabilitiesCurrent 866,528us-gaap_AccruedLiabilitiesCurrent 573,880us-gaap_AccruedLiabilitiesCurrent
Note payable   33,279us-gaap_NotesPayable  
Customer deposits 41,667us-gaap_CustomerDepositsCurrent 41,781us-gaap_CustomerDepositsCurrent 317,480us-gaap_CustomerDepositsCurrent
Deferred revenue - current portion 54,218us-gaap_DeferredRevenueCurrent 96,043us-gaap_DeferredRevenueCurrent 730,593us-gaap_DeferredRevenueCurrent
Total current liabilities 1,799,503us-gaap_LiabilitiesCurrent 1,586,528us-gaap_LiabilitiesCurrent 2,143,370us-gaap_LiabilitiesCurrent
Deferred revenue - net of current portion     53,115us-gaap_DeferredRevenueNoncurrent
Total liabilities 1,799,503us-gaap_Liabilities 1,586,528us-gaap_Liabilities 2,196,485us-gaap_Liabilities
Commitments and contingencies         
Stockholders' equity:      
Preferred stock, $.001 par value; 10,000,000 shares authorized, no shares issued and outstanding         
Common stock, $.001 par value, 80,000,000 shares authorized, 39,713,540, 39,713,540 and 34,006,202 shares issued, respectively 39,714us-gaap_CommonStockValue 39,714us-gaap_CommonStockValue 34,007us-gaap_CommonStockValue
Additional paid-in capital 63,587,400us-gaap_AdditionalPaidInCapitalCommonStock 63,394,556us-gaap_AdditionalPaidInCapitalCommonStock 57,739,056us-gaap_AdditionalPaidInCapitalCommonStock
Treasury stock, 24,331 shares at cost (234)us-gaap_TreasuryStockValue (234)us-gaap_TreasuryStockValue (234)us-gaap_TreasuryStockValue
Accumulated deficit (56,540,160)us-gaap_RetainedEarningsAccumulatedDeficit (52,771,770)us-gaap_RetainedEarningsAccumulatedDeficit (45,628,938)us-gaap_RetainedEarningsAccumulatedDeficit
Total stockholders' equity 7,086,720us-gaap_StockholdersEquity 10,662,266us-gaap_StockholdersEquity 12,143,891us-gaap_StockholdersEquity
Total liabilities and stockholders' equity $ 8,886,223us-gaap_LiabilitiesAndStockholdersEquity $ 12,248,794us-gaap_LiabilitiesAndStockholdersEquity $ 14,340,376us-gaap_LiabilitiesAndStockholdersEquity
XML 62 R45.htm IDEA: XBRL DOCUMENT v2.4.1.9
Note 4: Property and Equipment: Schedule of Property and Equipment (Tables)
 12 Months Ended
Dec. 31, 2014
Tables/Schedules  
Schedule of Property and Equipment

 

 

December 31,

August 31,

 

2014

2014

2013

 

 

 

 

   Equipment

$    1,503,845

$    1,468,528

$    1,401,811

   Rental equipment

58,940

58,940

58,940

   Furniture and fixtures

303,226

303,226

300,061

   Building improvements

-

54,736

54,736

   Building (held for sale)

956,000

956,000

956,000

   Land  (held for sale)

244,000

244,000

244,000

 

 

 

 

 

3,066,011

3,085,430

3,015,548

   Less equipment impairment

 (     85,000)

-

-

   Less accumulated depreciation

(1,840,140)

(1,817,769)

(1,695,668)

 

 

 

 

 

$    1,140,871

$    1,267,661

$    1,319,880
XML 63 R6.htm IDEA: XBRL DOCUMENT v2.4.1.9
Statements of Cash Flows (USD $)
 4 Months Ended 12 Months Ended
Dec. 31, 2014
Dec. 31, 2013
Aug. 31, 2014
Aug. 31, 2013
Cash flows from operating activities:        
Net loss $ (3,768,390)us-gaap_NetIncomeLoss $ (2,106,641)us-gaap_NetIncomeLoss $ (7,142,832)us-gaap_NetIncomeLoss $ (8,251,691)us-gaap_NetIncomeLoss
Adjustments to reconcile net loss to net cash used in operating activities:        
Depreciation and amortization 43,280us-gaap_DepreciationDepletionAndAmortization 40,364us-gaap_DepreciationDepletionAndAmortization 125,824us-gaap_DepreciationDepletionAndAmortization 132,153us-gaap_DepreciationDepletionAndAmortization
Stock issued for services     180,000us-gaap_StockIssuedDuringPeriodValueIssuedForServices 180,002us-gaap_StockIssuedDuringPeriodValueIssuedForServices
Stock-based compensation 192,844us-gaap_ShareBasedCompensation 284,167us-gaap_ShareBasedCompensation 844,628us-gaap_ShareBasedCompensation 1,134,811us-gaap_ShareBasedCompensation
Loss (gain) on disposition of assets 33,827us-gaap_GainLossOnDispositionOfAssets   (30)us-gaap_GainLossOnDispositionOfAssets  
Impairment of inventory and other assets 805,000us-gaap_AssetImpairmentCharges 50,000us-gaap_AssetImpairmentCharges 50,000us-gaap_AssetImpairmentCharges  
Decrease (increase) in:        
Decrease (increase) in receivables (33,334)us-gaap_IncreaseDecreaseInAccountsReceivable 95,124us-gaap_IncreaseDecreaseInAccountsReceivable 548,961us-gaap_IncreaseDecreaseInAccountsReceivable (601,326)us-gaap_IncreaseDecreaseInAccountsReceivable
Decrease (increase) in inventories (46,459)us-gaap_IncreaseDecreaseInInventories (328,517)us-gaap_IncreaseDecreaseInInventories 66,581us-gaap_IncreaseDecreaseInInventories (41,813)us-gaap_IncreaseDecreaseInInventories
Decrease (increase) in other current assets 59,736us-gaap_IncreaseDecreaseInOtherCurrentAssets 51,881us-gaap_IncreaseDecreaseInOtherCurrentAssets 53,709us-gaap_IncreaseDecreaseInOtherCurrentAssets (79,959)us-gaap_IncreaseDecreaseInOtherCurrentAssets
Increase (decrease) in:        
Increase (decrease) in accounts payable 49,569us-gaap_IncreaseDecreaseInAccountsPayable (57,272)us-gaap_IncreaseDecreaseInAccountsPayable 27,480us-gaap_IncreaseDecreaseInAccountsPayable 325,663us-gaap_IncreaseDecreaseInAccountsPayable
Increase (decrease) in accrued liabilities 238,624us-gaap_IncreaseDecreaseInAccruedLiabilities (84,323)us-gaap_IncreaseDecreaseInAccruedLiabilities 292,648us-gaap_IncreaseDecreaseInAccruedLiabilities 149,182us-gaap_IncreaseDecreaseInAccruedLiabilities
Increase (decrease) in customer deposits (114)us-gaap_IncreaseDecreaseInCustomerDeposits 95,347us-gaap_IncreaseDecreaseInCustomerDeposits (275,699)us-gaap_IncreaseDecreaseInCustomerDeposits 292,500us-gaap_IncreaseDecreaseInCustomerDeposits
Increase (decrease) in deferred revenue (41,825)us-gaap_IncreaseDecreaseInDeferredRevenue (46,237)us-gaap_IncreaseDecreaseInDeferredRevenue (687,665)us-gaap_IncreaseDecreaseInDeferredRevenue 560,423us-gaap_IncreaseDecreaseInDeferredRevenue
Net cash used in operating activities (2,467,242)us-gaap_NetCashProvidedByUsedInOperatingActivities (2,006,107)us-gaap_NetCashProvidedByUsedInOperatingActivities (5,916,395)us-gaap_NetCashProvidedByUsedInOperatingActivities (6,200,055)us-gaap_NetCashProvidedByUsedInOperatingActivities
Cash flows from investing activities:        
Purchase of property and equipment (35,317)us-gaap_PaymentsToAcquirePropertyPlantAndEquipment (21,330)us-gaap_PaymentsToAcquirePropertyPlantAndEquipment (75,599)us-gaap_PaymentsToAcquirePropertyPlantAndEquipment (35,362)us-gaap_PaymentsToAcquirePropertyPlantAndEquipment
Proceeds from disposition of assets     2,025us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment  
Net cash (used in) investing activities (35,317)us-gaap_NetCashProvidedByUsedInInvestingActivities (21,330)us-gaap_NetCashProvidedByUsedInInvestingActivities (73,574)us-gaap_NetCashProvidedByUsedInInvestingActivities (35,362)us-gaap_NetCashProvidedByUsedInInvestingActivities
Cash flows from financing activities:        
Net proceeds from the sale of common stock     4,636,579us-gaap_ProceedsFromIssuanceOfCommonStock 4,583,437us-gaap_ProceedsFromIssuanceOfCommonStock
Proceeds from note payable     74,052us-gaap_ProceedsFromNotesPayable  
Payments on note payable (33,279)us-gaap_RepaymentsOfNotesPayable   (40,774)us-gaap_RepaymentsOfNotesPayable  
Net cash provided by financing activities (33,279)us-gaap_NetCashProvidedByUsedInFinancingActivities   4,669,857us-gaap_NetCashProvidedByUsedInFinancingActivities 4,583,437us-gaap_NetCashProvidedByUsedInFinancingActivities
Net increase (decrease) in cash and cash equivalents (2,535,838)us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease (2,027,437)us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease (1,320,112)us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease (1,651,980)us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease
Cash and cash equivalents, beginning of period 8,130,416us-gaap_CashAndCashEquivalentsAtCarryingValue 9,450,528us-gaap_CashAndCashEquivalentsAtCarryingValue 9,450,528us-gaap_CashAndCashEquivalentsAtCarryingValue 11,102,508us-gaap_CashAndCashEquivalentsAtCarryingValue
Cash and cash equivalents, end of period $ 5,594,578us-gaap_CashAndCashEquivalentsAtCarryingValue $ 7,423,091us-gaap_CashAndCashEquivalentsAtCarryingValue $ 8,130,416us-gaap_CashAndCashEquivalentsAtCarryingValue $ 9,450,528us-gaap_CashAndCashEquivalentsAtCarryingValue
XML 64 R59.htm IDEA: XBRL DOCUMENT v2.4.1.9
Note 2: Liquidity (Details) (USD $)
Dec. 31, 2014
Aug. 31, 2014
Dec. 31, 2013
Aug. 31, 2013
Aug. 31, 2012
Details          
Cash and cash equivalents $ 5,594,578us-gaap_CashAndCashEquivalentsAtCarryingValue $ 8,130,416us-gaap_CashAndCashEquivalentsAtCarryingValue $ 7,423,091us-gaap_CashAndCashEquivalentsAtCarryingValue $ 9,450,528us-gaap_CashAndCashEquivalentsAtCarryingValue $ 11,102,508us-gaap_CashAndCashEquivalentsAtCarryingValue
Total current assets $ 7,745,352us-gaap_AssetsCurrent $ 10,981,133us-gaap_AssetsCurrent   $ 13,020,496us-gaap_AssetsCurrent  
XML 65 R35.htm IDEA: XBRL DOCUMENT v2.4.1.9
Note 1: Organization and Significant Accounting Policies: Concentration of Credit Risk (Policies)
 12 Months Ended
Dec. 31, 2014
Policies  
Concentration of Credit Risk

Concentration of Credit Risk – Financial instruments that potentially subject us to concentration of credit risk consists primarily of trade receivables.  In the normal course of business, we provide credit terms to our customers.  Accordingly, we perform ongoing credit evaluations of our customers and maintain allowances for possible losses.

 

We have cash in the bank and short-term investments that exceed federally insured limits.  We have not experienced any losses in such accounts.
XML 66 R65.htm IDEA: XBRL DOCUMENT v2.4.1.9
Note 5: Impairment (Details) (USD $)
 4 Months Ended 12 Months Ended
Dec. 31, 2014
Dec. 31, 2013
Dec. 31, 2014
Aug. 31, 2014
Details        
Impairment of inventory and other assets $ 805,000us-gaap_AssetImpairmentCharges $ 50,000us-gaap_AssetImpairmentCharges $ 805,000us-gaap_AssetImpairmentCharges $ 50,000us-gaap_AssetImpairmentCharges
XML 67 R22.htm IDEA: XBRL DOCUMENT v2.4.1.9
Note 16: Subsequent Events
 12 Months Ended
Dec. 31, 2014
Notes  
Note 16: Subsequent Events

Note 16:  Subsequent Events

 

On January 15, 2015, the Company entered into an employment agreement with its Clinton E. Carnell, Jr., to serve as President and Chief Executive Officer.

 

Effective February 16, 2015, the Company entered into an employment agreement with Benjamin Beckham to serve as Vice President of North American Sales.

 

Effective February 16, 2015, the Company entered into an employment agreement with Todd Turnlund to serve as Vice President of Research and Development.

 

Effective February 17, 2015, the Company entered into an employment agreement with Jen Hoglin to serve as Vice President of Global Marketing.

 

Effective February 20, 2015, Perseon Corporation amended its certificate of incorporation to change its legal corporate name to “Perseon Corporation” from “BSD Medical Corporation.”   The name change was effected pursuant to Section 242 of the Delaware General Corporation Law (the “DGCL”).  Under the DGCL, the amendment to the Company’s certificate of incorporation to effect the name change did not require stockholder approval.

 

On February 24, 2015, the Company executed a promissory note with an asset lender, in the amount of $750,000.   The note is secured by the Company’s headquarters and manufacturing facility.  During the one year term of the note, monthly payments of interest only at Prime Rate plus 6.0% are required, with the principal due on February 24, 2016.

 

The Company has evaluated other events occurring after the date of our accompanying balance sheets through the date of the filing of this Transition Report on Form 10-K.  No other material subsequent events requiring adjustment to our accompanying financial statements were identified.

 
XML 68 R36.htm IDEA: XBRL DOCUMENT v2.4.1.9
Note 1: Organization and Significant Accounting Policies: Advertising and Promotion (Policies)
 12 Months Ended
Dec. 31, 2014
Policies  
Advertising and Promotion

Advertising and Promotion – Advertising and promotion costs, which are principally included in sales expenses, are expensed as incurred.  Advertising and promotion expense was $56,504 for the four months ended December 31, 2014, and $206,099 and $205,442 for the years ended August 31, 2014 and 2013, respectively.
XML 69 R24.htm IDEA: XBRL DOCUMENT v2.4.1.9
Note 1: Organization and Significant Accounting Policies: Financial Reporting Period (Policies)
 12 Months Ended
Dec. 31, 2014
Policies  
Financial Reporting Period

Financial Reporting Period – We have changed our fiscal year end for financial reporting from August 31 to December 31, effective for the four months ended December 31, 2014.  The financial information for the four months ended December 31, 2013 provided for comparative purposes is unaudited.  All adjustments (consisting only of normal recurring adjustments) necessary for the fair presentation of our results of operations and our cash flows for the four months ended December 31, 2013 have been included.  The results of operations for the four months ended December 31, 2014 may not be indicative of the results for our fiscal year ending December 31, 2015.
XML 70 R68.htm IDEA: XBRL DOCUMENT v2.4.1.9
Note 7: Stockholders' Equity: April 2013 Offering (Details) (USD $)
Apr. 09, 2013
Details  
Sale of Common Stock and Warrants 4,065,042fil_SaleOfCommonStockAndWarrants
April 2013 Offering to purchase common stock shares 3,048,782fil_April2013OfferingToPurchaseCommonStockShares
April 2013 Offering Purchase Price Per Fixed Combination $ 1.23fil_April2013OfferingPurchasePricePerFixedCombination
April 2013 Offering Warrant Exercise Price (per share) $ 1.65fil_April2013OfferingWarrantExercisePricePerShare
XML 71 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 72 R7.htm IDEA: XBRL DOCUMENT v2.4.1.9
Note 1: Organization and Significant Accounting Policies
 12 Months Ended
Dec. 31, 2014
Notes  
Note 1: Organization and Significant Accounting Policies

Note 1:  Organization and Significant Accounting Policies

 

Organization and Business – Perseon Corporation, formerly BSD Medical Corporation, (the “Company”) was incorporated in the State of Delaware on July 3, 1986.  In February 2015, we changed the name of the Company to Perseon Corporation.  We are a life sciences company that develops, manufactures, markets and services groundbreaking medical systems to treat cancer using heat therapy.  Our MicroThermX® microwave ablation system employs precision-guided microwave energy to ablate diseased soft tissue.  We have developed extensive intellectual property and distribute our products in the United States, Europe and Asia.

 

Financial Reporting Period – We have changed our fiscal year end for financial reporting from August 31 to December 31, effective for the four months ended December 31, 2014.  The financial information for the four months ended December 31, 2013 provided for comparative purposes is unaudited.  All adjustments (consisting only of normal recurring adjustments) necessary for the fair presentation of our results of operations and our cash flows for the four months ended December 31, 2013 have been included.  The results of operations for the four months ended December 31, 2014 may not be indicative of the results for our fiscal year ending December 31, 2015.

 

Cash and Cash Equivalents – Cash and cash equivalents consist of cash and investments with original maturities to the Company of three months or less.  As of December 31, 2014 and August 31, 2014, we had $25,000 in a restricted bank account.

 

 

Accounts Receivable – Trade accounts receivable are carried at original invoice amount less an estimate made for doubtful receivables based on a review of all outstanding amounts on a monthly basis.  Management estimates an allowance for doubtful accounts by identifying troubled accounts and by using historical experience applied to an aging of accounts.  Trade accounts receivable are written off when deemed uncollectible.  Recoveries of trade receivables previously written off are recorded when received.  Interest is not charged on trade receivables that are outstanding beyond their due date.

 

Inventories – Parts and supplies inventories are stated at the lower of cost or market.  Cost is determined using the average cost method.  Work-in-process and finished goods are stated at the lower of the accumulated manufacturing costs or market.  We maintain a reserve for obsolete inventories to reduce excess and obsolete inventories to their estimated net realizable value.  The reserve was $750,000 as of December 31, 2014, $150,000 as of August 31, 2014, and $100,000 as of August 31, 2013.

 

Property and Equipment – Property and equipment are stated at cost less accumulated depreciation.  Depreciation is determined using the straight-line method over the following estimated useful lives of the assets.

 

Equipment

 

2 – 5 years

Rental equipment

 

5 years

Furniture and fixtures

 

5 years

Building improvements

 

15 years

Building

 

40 years

 

Expenditures for maintenance and repairs are expensed when incurred and betterments are capitalized.  Gains and losses on sales of property and equipment are reflected in operations.

 

The cost and accumulated depreciation of property and equipment sold or otherwise retired are removed from the accounts and any related gain or loss on disposition is reflected in net income or loss for the period.

 

Patents – Patent costs are expensed as incurred.

 

 

Warranty Reserve – We provide limited warranties to our customers for products sold.  Estimated future warranty obligations are accrued each period.  As of December 31, 2014, August 31, 2014 and August 31, 2013, the accrued warranty reserve was $65,102, $75,728 and $50,968, respectively.  During the four months ended December 31, 2014, total warranty expense was $13,410.  During the fiscal years ended August 31, 2014 and 2013, total warranty expense was $41,471 and $80,276, respectively.

 

Income Taxes – We account for income taxes using the asset and liability method.  Under the asset and liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases.  Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.  The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

 

Income (Loss) Per Common Share – The computation of basic income (loss) per common share is based on the weighted average number of shares outstanding during each year.

 

The computation of diluted earnings per common share is based on the weighted average number of shares outstanding during the year, plus the common stock equivalents that would arise from the exercise of stock options and warrants outstanding, using the treasury stock method and the average market price per share during the year.  Common stock equivalents are not included in the diluted loss per share calculation when their effect is anti-dilutive.  Options and warrants to purchase 14,989,224 shares of common stock at prices ranging from $0.44 to $7.95 were excluded from the calculation of diluted earnings per share for the four months ended December 31, 2014 because their effect was anti-dilutive.  Options and warrants to purchase 13,720,225 and 9,669,878 shares of common stock at prices ranging from $0.99 to $7.95 were excluded from the calculation of diluted earnings per share for the years ended August 31, 2014 and 2013, respectively, because their effect was anti-dilutive.

 

Since we had no dilutive effect of stock options and warrants for the four months ended December 31, 2014 and 2013 and the years ended August 31, 2014 and 2013, our basic weighted average number of common shares outstanding is the same as our diluted weighted average number of common shares outstanding.

 

Stock-Based Compensation - Stock-based compensation is measured at the grant date based on the value of the award granted using the Black-Scholes option pricing model, and recognized over the period in which the award vests.  For stock awards no longer expected to vest, any previously recognized stock compensation expense is reversed in the period of termination.  The stock-based compensation expense is allocated to the various categories of operating costs and expenses in a manner similar to the allocation of payroll expense. 

 

Revenue Recognition – We recognize revenue from the sale of medical systems, disposable devices related to the systems, parts, and accessories, and equipment rental, training, and service support contracts.  Our revenues consisted of the following:

 

 

Four Months Ended December 31,

Years Ended August 31,

 

2014

        2013

        2014

        2013

 

 

 

 

 

Product sales

$        470,875

$       986,900

$    3,019,525

$    1,934,826

Disposable devices

409,787

501,565

1,568,481

1,109,750

Service contracts and other

109,346

100,597

375,747

330,116

Equipment rental

125,900

95,200

364,600

298,600

 

 

 

 

 

Total

$     1,115,908

$    1,684,262

$    5,328,353

$    3,673,292

 

Revenue from product sales is recognized when a purchase order has been received, the cancer treatment system has been shipped, the selling price is fixed or determinable, and collection is reasonably assured.  Most system sales are F.O.B. shipping point; therefore, shipment is deemed to have occurred when the product is delivered to the transportation carrier.  Most system sales do not include installation.  If installation is included as part of the contract, revenue is not recognized until installation has occurred, or until any remaining installation obligation is deemed to be perfunctory.  Some sales of systems may include training as part of the sale.  In such cases, the portion of the revenue related to the training, calculated based on the amount charged for training on a stand-alone basis, is deferred and recognized when the training has been provided.  The sales of our cancer treatment systems do not require specific customer acceptance provisions and do not include the right of return except in cases where the product does not function as warranted by us.  To date, returns have not been significant.

 

Revenue from the sale of disposable devices is recognized when a purchase order has been received, the devices have been shipped, the selling price is fixed or determinable, and collection is reasonably assured.  Currently, our customers are not required to purchase a minimum number of disposable devices in connection with the purchase of our systems.

 

Revenue from training services is recorded when an agreement with the customer exists for such training, the training services have been provided, and collection is reasonably assured.

 

Revenue from service support contracts is recognized on a straight-line basis over the term of the contract, which approximates recognizing it as it is earned.

 

Revenue from equipment rental under an operating lease is recognized when billed in accordance with the lease agreement.

 

Our revenue recognition policy is the same for sales to both related parties and non-related parties.  We provide the same products and services under the same terms for non-related parties as with related parties.

 

Sales to distributors are recognized in the same manner as sales to end-user customers.

 

Deferred revenue and customer deposits include amounts from service contracts as well as cash received for the sales of products that have not been shipped.

 

Concentration of Credit Risk – Financial instruments that potentially subject us to concentration of credit risk consists primarily of trade receivables.  In the normal course of business, we provide credit terms to our customers.  Accordingly, we perform ongoing credit evaluations of our customers and maintain allowances for possible losses.

 

We have cash in the bank and short-term investments that exceed federally insured limits.  We have not experienced any losses in such accounts.

 

Advertising and Promotion – Advertising and promotion costs, which are principally included in sales expenses, are expensed as incurred.  Advertising and promotion expense was $56,504 for the four months ended December 31, 2014, and $206,099 and $205,442 for the years ended August 31, 2014 and 2013, respectively.

 

Shipping and Handling – We bill our customers for shipping and handling charges, which are included in net sales.  The cost of corresponding shipping and handling expense is reported in cost of sales.

 

Use of Estimates in the Preparation of Financial Statements – The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ from those estimates.

 

Comprehensive Loss – Comprehensive loss is the same as net loss for all years presented.

 

 
XML 73 R3.htm IDEA: XBRL DOCUMENT v2.4.1.9
Balance Sheets Parenthetical (USD $)
Dec. 31, 2014
Aug. 31, 2014
Aug. 31, 2013
Balance Sheets Parenthetical      
Allowance for doubtful accounts $ 20,000us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent $ 20,000us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent $ 20,000us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent
Preferred stock par value $ 0.001us-gaap_PreferredStockParOrStatedValuePerShare $ 0.001us-gaap_PreferredStockParOrStatedValuePerShare $ 0.001us-gaap_PreferredStockParOrStatedValuePerShare
Preferred stock shares authorized 10,000,000us-gaap_PreferredStockSharesAuthorized 10,000,000us-gaap_PreferredStockSharesAuthorized 10,000,000us-gaap_PreferredStockSharesAuthorized
Preferred stock shares issued         
Preferred stock shares outstanding         
Common stock par value $ 0.001us-gaap_CommonStockParOrStatedValuePerShare $ 0.001us-gaap_CommonStockParOrStatedValuePerShare $ 0.001us-gaap_CommonStockParOrStatedValuePerShare
Common stock shares authorized 80,000,000us-gaap_CommonStockSharesAuthorized 80,000,000us-gaap_CommonStockSharesAuthorized 80,000,000us-gaap_CommonStockSharesAuthorized
Common stock shares issued 39,713,540us-gaap_CommonStockSharesIssued 39,713,540us-gaap_CommonStockSharesIssued 34,006,202us-gaap_CommonStockSharesIssued
Treasury stock shares 24,331us-gaap_TreasuryStockShares 24,331us-gaap_TreasuryStockShares 24,331us-gaap_TreasuryStockShares
XML 74 R17.htm IDEA: XBRL DOCUMENT v2.4.1.9
Note 11: Income Taxes
 12 Months Ended
Dec. 31, 2014
Notes  
Note 11: Income Taxes

Note 11:  Income Taxes

 

The income tax provision of $2,000 and $1,938 for the years ended August 31, 2014 and 2013, respectively, is comprised of a current provision for state income taxes. 

 

The income tax (provision) benefit differs from the amount computed at federal statutory rates as follows:   

 

 

Four Months Ended December 31,

Years Ended August 31,

 

2014

2014

2013

 

 

 

 

Income tax benefit at federal statutory rate

$         1,281,000

$     2,428,000

$     2,805,000

Stock-based compensation

(66,000)

(287,000)

(335,000)

State income taxes, net of federal benefit

124,000

236,000

272,000

Research and development credit

33,000

99,000

106,000

Valuation allowance

(1,360,000)

(2,480,000)

(2,905,000)

Other

(12,000)

2,000

55,062

 

 

 

 

 

 $                     -

$           (2,000)

$           (1,938)

Deferred tax assets (liabilities) are comprised of the following:

 

December 31,

August 31,

 

2014

2014

2013

Current Asset:

 

 

 

   Accruals and reserves

$        73,000

$         62,000

$         26,000

   Deferred revenue

18,000

33,000

266,000

   Inventories

298,000

90,000

68,000

Valuation allowance

(389,000)

(185,000)

(360,000)

 

 

 

 

 

$                   -

$                   -

$                   -

Long-Term Asset (Liability):

 

 

 

   Deferred compensation

$       601,000

$       601,000

$       601,000

   Research and development and other tax credits

1,929,000

1,896,000

1,804,000

  Net operating loss carryforwards - federal

12,951,000

13,938,000

11,380,000

  Net operating loss carryforwards - state

2,079,000

-

-

   Depreciation and amortization

39,000

8,000

3,000

Valuation allowance

(17,599,000)

(16,443,000)

(13,788,000)

 

 

 

 

  

$                  -

$                  -

$                  -

 

The ultimate realization of the deferred tax assets is dependent, in part, upon the tax laws in effect, our future earnings, and other events.  As of December 31, 2014, we recorded a valuation allowance of $389,000 against current deferred tax assets, and a valuation allowance of $17,599,000 against net long-term deferred tax assets.  The increase in the valuation allowance for the four months ended December 31, 2014 relates primarily to our operating losses.  In recording the valuation allowance, we were unable to conclude that it is more likely than not that our deferred tax assets will be realized.

 

In addition to the deferred tax assets listed above, the Company has unrecorded tax benefits of approximately $2,600,000 attributable to the difference between the amount of the financial statement expense and the allowable tax deduction associated with stock-based compensation.  As a result of net operating loss carryforwards, the Company was not able to recognize the excess tax benefits of share-based compensation deductions because the deductions did not reduce income tax payable.  Although not recognized for financial reporting purposes, this unrecorded tax benefit is available to reduce future income and is incorporated into the disclosed amounts of the Company’s net operating loss carryforwards, discussed below.  If subsequently realized, the benefit will be recorded to contributed capital.

 

As of December 31, 2014, we had a net operating loss carryforward available to offset future taxable income of approximately $40,701,000, which will begin to expire in 2029.  If substantial changes in the Company’s ownership should occur, there would be an annual limitation of the amount of the net operating loss carryforward which could be utilized.

 

We perform a review of our material tax positions in accordance with recognition and measurement standards established by authoritative accounting literature, which requires a company to determine whether it is more likely than not that a tax position will be sustained upon examination based upon the technical merits of the position.  If the more-likely-than-not threshold is met, a company must measure the tax position to determine the amount to recognize in the financial statements.  Based upon our review and evaluation, during the four months ended December 31, 2014 and 2013 and the years ended August 31, 2014 and 2013, we concluded the Company had no unrecognized tax benefit that would affect its effective tax rate if recognized.

 

We classify any interest and penalties arising from the underpayment of income taxes in our statements of comprehensive loss in other income (expense).  As of December 31, 2014, August 31, 2014 and August 31, 2013, we had no accrued interest or penalties related to uncertain tax positions.

 

We file income tax returns in the U.S. federal jurisdiction and various state jurisdictions.  U.S. federal income tax returns from the year ended August 31, 2011 through the period ended December 31, 2014 are subject to examination.

 
XML 75 R1.htm IDEA: XBRL DOCUMENT v2.4.1.9
Document and Entity Information (USD $)
 12 Months Ended
Dec. 31, 2014
Mar. 30, 2015
Jun. 30, 2014
Document and Entity Information      
Entity Registrant Name Perseon Corp    
Document Type 10-K    
Document Period End Date Dec. 31, 2014    
Amendment Flag false    
Entity Central Index Key 0000320174    
Current Fiscal Year End Date --12-31    
Entity Common Stock, Shares Outstanding   39,689,209dei_EntityCommonStockSharesOutstanding  
Entity Filer Category Smaller Reporting Company    
Entity Current Reporting Status Yes    
Entity Voluntary Filers No    
Entity Well-known Seasoned Issuer No    
Document Fiscal Year Focus 2014    
Document Fiscal Period Focus FY    
Entity Public Float     $ 26,701,152dei_EntityPublicFloat
Entity Incorporation, State Country Name Delaware    
Entity Incorporation, Date of Incorporation Jul. 03, 1986    
XML 76 R18.htm IDEA: XBRL DOCUMENT v2.4.1.9
Note 12: Stock-based Compensation
 12 Months Ended
Dec. 31, 2014
Notes  
Note 12: Stock-based Compensation

Note 12:  Stock-Based Compensation

 

Our Third Amended and Restated 1998 Stock Incentive Plan (the “Plan”) authorizes the granting of incentive stock options to certain key employees and non-employees who provide services to the Company.  The Plan, as amended, provides for the granting of options for an aggregate of 6,337,300 shares.  The options vest subject to management’s discretion.

 

Effective February 4, 2009, our Fourth Amended and Restated 1998 Directors Stock Plan (the “Director Plan”) provides an annual retainer of $60,000 to each non-employee director with the exception of the Audit Committee Chairman who is to receive $65,000.  The cash portion of the compensation of $30,000 ($35,000 for the Audit Committee Chairman) is paid 50% twice each year, with $30,000 of compensation paid in common stock of the Company once each year.  Prior to February 4, 2009, the Director Plan granted each non-employee outside director 30,000 options each year at an exercise price equal to the fair market value of the common stock at the date the option was granted.  The options vest according to a set schedule over a five-year period and expire upon the director’s termination, or after ten years from the date of grant.  The Director Plan, as amended, allows for an aggregate of 1,750,000 shares to be granted.

 

Stock-based compensation cost is measured at the grant date based on the estimated value of the award granted, using the Black-Scholes option pricing model, and recognized over the period in which the award vests.  For stock awards no longer expected to vest, any previously recognized stock compensation expense is reversed in the period of termination.

 

The stock-based compensation expense has been allocated to the various categories of operating costs and expenses in a manner similar to the allocation of payroll expense as follows:

 

 

Four Months Ended December 31,

Years Ended  August 31,

 

2014

2014

2013

 

 

 

 

Cost of sales

$       11,776

$       61,427

$       67,119

Research and development

32,349

183,371

212,569

Selling, general and administrative

148,719

599,830

855,123

 

 

 

 

Total

$    192,844

$     844,628

$  1,134,811

 

During the four months ended December 31, 2014, we granted a total of 1,450,000 stock options to employees with exercise prices ranging from $0.44 to $0.51 per share and with one third vesting each year for the next three years.  The weighted average estimated grant-date fair value per share of these stock options was $0.22, and our assumptions used in the Black-Scholes valuation model to determine this estimated fair value are shown below:

 

 

Expected volatility

62.96%

Expected dividends

0.00%

Expected term

7.24 Years

Risk-free interest rate

2.07%

 

The expected volatility rate was estimated based on the historical volatility of our common stock.   The expected term was estimated based on historical experience of stock option exercise and forfeitures.  The risk-free interest rate is the rate provided by the U.S. Treasury for Daily Treasury Yield Curve Rates commonly referred to as “Constant Maturity Treasury” rate in effect at the time of grant with a remaining term equal to the expected option term.

 

Unrecognized stock-based compensation expense expected to be recognized over an estimated weighted-average amortization period of 1.15 years is approximately $1,078,000 as of December 31, 2014.

 

A summary of the time-based stock option awards as of as of December 31, 2014 and August 31, 2014 and changes during the four months ended December 31, 2014 and the year ended August 31, 2014 is as follows:

 

 

Shares

Weighted- Average  Exercise Price

Weighted-Average Remaining Contract Term (Years)

Aggregate Intrinsic Value

 

 

 

 

 

 

 

Outstanding as of September 1, 2013

4,212,573

$

2.85

 

 

 

Granted

127,000

 

1.19

 

 

 

Exercised

-

 

      -

 

 

 

Forfeited or expired

(476,653)

 

2.18

 

 

 

 

 

 

 

 

 

 

Outstanding as of August 31, 2014

3,862,920

 

2.88

6.32

$

-

Granted

1,450,000

 

0.46

 

 

 

Exercised

-

 

      -

 

 

 

Forfeited or expired

(181,001)

 

1.54

 

 

 

 

 

 

 

 

 

 

Outstanding as of December 31, 2014

5,131,919

$

2.25

7.03

$

-

Exercisable as of December 31, 23014

2,953,586

$

3.30

5.31

$

-

 

The aggregate intrinsic value in the preceding table represents the total pretax intrinsic value, based on the Company’s closing stock price of $0.36 as of December 31, 2014, which would have been received by the holders of in-the-money options had the option holders exercised their options as of that date.

 
XML 77 R80.htm IDEA: XBRL DOCUMENT v2.4.1.9
Note 12: Stock-based Compensation: Stock Option Rollforward (Details) (USD $)
 4 Months Ended 12 Months Ended
Dec. 31, 2014
Aug. 31, 2014
Aug. 31, 2013
Details      
Options Outstanding, beginning of period     4,212,573fil_OptionsOutstandingBeginningOfPeriod
Outstanding beginning of period, weighted average exercise price     $ 2.85fil_OutstandingBeginningOfPeriodWeightedAverageExercisePrice
Granted 1,450,000us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross 127,000us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross  
Granted, weighted average exercise price $ 0.46us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice $ 1.19us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice  
Forfeited or expired (181,001)us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod (476,653)us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod  
Forfeited or expired, weighted average exercise price $ 1.54us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice $ 2.18us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice  
Outstanding, End of Period 5,131,919us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber 3,862,920us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber  
Outstanding, weighted average exercise price $ 2.25us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice $ 2.88us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice  
Outstanding, weighted average remaining contract term 7 years 11 days 6 years 3 months 25 days  
Exercisable 2,953,586us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber    
Exercisable options, weighted average exercise price $ 3.30us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice    
Exercisable options, weighted average remaining contract term 5 years 3 months 22 days    
XML 78 R4.htm IDEA: XBRL DOCUMENT v2.4.1.9
Statements of Comprehensive Loss (USD $)
 4 Months Ended 12 Months Ended
Dec. 31, 2014
Dec. 31, 2013
Aug. 31, 2014
Aug. 31, 2013
Revenues:        
Sales $ 526,585us-gaap_OtherSalesRevenueNet $ 1,572,376us-gaap_OtherSalesRevenueNet $ 4,544,204us-gaap_OtherSalesRevenueNet $ 3,274,796us-gaap_OtherSalesRevenueNet
Sales to related parties 463,423us-gaap_RevenueFromRelatedParties 16,686us-gaap_RevenueFromRelatedParties 419,549us-gaap_RevenueFromRelatedParties 99,896us-gaap_RevenueFromRelatedParties
Equipment rental 125,900us-gaap_OperatingLeasesIncomeStatementLeaseRevenue 95,200us-gaap_OperatingLeasesIncomeStatementLeaseRevenue 364,600us-gaap_OperatingLeasesIncomeStatementLeaseRevenue 298,600us-gaap_OperatingLeasesIncomeStatementLeaseRevenue
Total revenues 1,115,908us-gaap_Revenues 1,684,262us-gaap_Revenues 5,328,353us-gaap_Revenues 3,673,292us-gaap_Revenues
Cost of revenues:        
Cost of sales 334,455us-gaap_OtherCostOfOperatingRevenue 795,034us-gaap_OtherCostOfOperatingRevenue 2,563,921us-gaap_OtherCostOfOperatingRevenue 2,161,967us-gaap_OtherCostOfOperatingRevenue
Cost of related party sales 257,125us-gaap_RelatedPartyCosts 7,654us-gaap_RelatedPartyCosts 313,156us-gaap_RelatedPartyCosts 87,694us-gaap_RelatedPartyCosts
Cost of equipment rental 3,929us-gaap_DirectCostsOfLeasedAndRentedPropertyOrEquipment 3,929us-gaap_DirectCostsOfLeasedAndRentedPropertyOrEquipment 11,788us-gaap_DirectCostsOfLeasedAndRentedPropertyOrEquipment 11,788us-gaap_DirectCostsOfLeasedAndRentedPropertyOrEquipment
Total cost of revenues 595,509us-gaap_CostOfRevenue 806,617us-gaap_CostOfRevenue 2,888,865us-gaap_CostOfRevenue 2,261,449us-gaap_CostOfRevenue
Gross margin 520,399us-gaap_GrossProfit 877,645us-gaap_GrossProfit 2,439,488us-gaap_GrossProfit 1,411,843us-gaap_GrossProfit
Operating costs and expenses:        
Research and development 627,769us-gaap_ResearchAndDevelopmentExpense 701,549us-gaap_ResearchAndDevelopmentExpense 2,229,043us-gaap_ResearchAndDevelopmentExpense 2,281,854us-gaap_ResearchAndDevelopmentExpense
Selling, general and administrative 2,819,205us-gaap_SellingGeneralAndAdministrativeExpense 2,237,057us-gaap_SellingGeneralAndAdministrativeExpense 7,308,643us-gaap_SellingGeneralAndAdministrativeExpense 7,403,273us-gaap_SellingGeneralAndAdministrativeExpense
Impairment of inventory and other assets 805,000us-gaap_AssetImpairmentCharges 50,000us-gaap_AssetImpairmentCharges 50,000us-gaap_AssetImpairmentCharges  
Total operating costs and expenses 4,251,974us-gaap_OperatingExpenses 2,988,606us-gaap_OperatingExpenses 9,587,686us-gaap_OperatingExpenses 9,685,127us-gaap_OperatingExpenses
Loss from operations (3,731,575)us-gaap_OperatingIncomeLoss (2,110,961)us-gaap_OperatingIncomeLoss (7,148,198)us-gaap_OperatingIncomeLoss (8,273,284)us-gaap_OperatingIncomeLoss
Other income (expense):        
Interest income 5,672us-gaap_InvestmentIncomeInterest 8,167us-gaap_InvestmentIncomeInterest 22,491us-gaap_InvestmentIncomeInterest 32,225us-gaap_InvestmentIncomeInterest
Other income (expense) (42,487)us-gaap_OtherNonoperatingIncomeExpense (3,847)us-gaap_OtherNonoperatingIncomeExpense (15,125)us-gaap_OtherNonoperatingIncomeExpense (8,694)us-gaap_OtherNonoperatingIncomeExpense
Total other income (expense) (36,815)us-gaap_NonoperatingIncomeExpense 4,320us-gaap_NonoperatingIncomeExpense 7,366us-gaap_NonoperatingIncomeExpense 23,531us-gaap_NonoperatingIncomeExpense
Loss before income taxes (3,768,390)us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest (2,106,641)us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest (7,140,832)us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest (8,249,753)us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
Income tax provision       (2,000)us-gaap_IncomeTaxExpenseBenefit (1,938)us-gaap_IncomeTaxExpenseBenefit
Net loss and comprehensive loss $ (3,768,390)us-gaap_NetIncomeLoss $ (2,106,641)us-gaap_NetIncomeLoss $ (7,142,832)us-gaap_NetIncomeLoss $ (8,251,691)us-gaap_NetIncomeLoss
Net loss per common share: Basic $ (0.09)us-gaap_EarningsPerShareBasic $ (0.06)us-gaap_EarningsPerShareBasic $ (0.20)us-gaap_EarningsPerShareBasic $ (0.26)us-gaap_EarningsPerShareBasic
Net loss per common share: Diluted $ (0.09)us-gaap_EarningsPerShareDiluted $ (0.06)us-gaap_EarningsPerShareDiluted $ (0.20)us-gaap_EarningsPerShareDiluted $ (0.26)us-gaap_EarningsPerShareDiluted
Weighted average number of shares outstanding: Basic 39,689,000us-gaap_WeightedAverageNumberOfSharesOutstandingBasic 34,006,000us-gaap_WeightedAverageNumberOfSharesOutstandingBasic 34,967,000us-gaap_WeightedAverageNumberOfSharesOutstandingBasic 31,414,000us-gaap_WeightedAverageNumberOfSharesOutstandingBasic
Weighted average number of shares outstanding: Diluted 39,689,000us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding 34,006,000us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding 34,967,000us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding 31,414,000us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding
XML 79 R12.htm IDEA: XBRL DOCUMENT v2.4.1.9
Note 6: Patents
 12 Months Ended
Dec. 31, 2014
Notes  
Note 6: Patents

Note 6:  Patents

 

Patent costs are expense as incurred.  In prior years we had certain patents recorded net of accumulated amortization.  The patents were being amortized on a straight-line basis over their estimated legal life, up to a period of 17 years.  Amortization expense was $0 for the four months ended December 31, 2014, and was $0 and $4,032 for the years ended August 31, 2014 and 2013, respectively.
XML 80 R11.htm IDEA: XBRL DOCUMENT v2.4.1.9
Note 5: Impairment
 12 Months Ended
Dec. 31, 2014
Notes  
Note 5: Impairment

Note 5:  Impairment          

In 2014, our Board of Directors determined that it is in the best interest of Perseon shareholders to divest of our assets related to the hyperthermia product line    In connection with our plans to either sell or divest the assets related to the hyperthermia product line, we analyzed the carrying value and estimated net realizable value of inventory and other assets related to the hyperthermia product line as of December 31, 2014.  As a result of this analysis, during the four months ended December 31, 2014, we recorded an impairment charge of $805,000 for inventory, equipment, and other assets related to the hyperthermia product line.  These impairment expenses are the result of our assessment of the decrease in the estimated realizable value associated with assets related to the hyperthermia product line.  The inventory reserve was also increased by $50,000 in the corresponding year ended August 31, 2014, to recognize a portion of the devaluation of inventory related to the hyperthermia product line.
XML 81 R23.htm IDEA: XBRL DOCUMENT v2.4.1.9
Note 1: Organization and Significant Accounting Policies: Organization and Business (Policies)
 12 Months Ended
Dec. 31, 2014
Policies  
Organization and Business

Organization and Business – Perseon Corporation, formerly BSD Medical Corporation, (the “Company”) was incorporated in the State of Delaware on July 3, 1986.  In February 2015, we changed the name of the Company to Perseon Corporation.  We are a life sciences company that develops, manufactures, markets and services groundbreaking medical systems to treat cancer using heat therapy.  Our MicroThermX® microwave ablation system employs precision-guided microwave energy to ablate diseased soft tissue.  We have developed extensive intellectual property and distribute our products in the United States, Europe and Asia.
XML 82 R19.htm IDEA: XBRL DOCUMENT v2.4.1.9
Note 13: Supplemental Cash Flow Information
 12 Months Ended
Dec. 31, 2014
Notes  
Note 13: Supplemental Cash Flow Information

Note 13:  Supplemental Cash Flow Information

 

We paid no amount for interest during the four months ended December 31, 2014 and the years ended August 31, 2014 and 2013.  We paid no amount for income taxes during the four months ended December 31, 2014.  During the years ended August 31, 2014 and 2013 we paid $2,000 and $1,938 for income taxes. 

 

We had no non-cash financing and investing activities during the four months ended December 31, 2014 and the years ended August 31, 2014 and 2013.
XML 83 R15.htm IDEA: XBRL DOCUMENT v2.4.1.9
Note 9: Major Customers and Foreign Sales
 12 Months Ended
Dec. 31, 2014
Notes  
Note 9: Major Customers and Foreign Sales

Note 9:  Major Customers and Foreign Sales

 

During the four months ended December 31, 2014, we had sales to two foreign customers totaling 41.53% and 11.30% of total revenues.  During the year ended August 31, 2014, we had sales to two foreign customers totaling 23.46% and 22.92% of total revenues.  During the year ended August 31, 2013, we had sales to one customer totaling 30.36% of total revenues.  

 

Export sales were $630,857 in the four months ended December 31, 2014, and $3,381,563 and $1,470,619 in the years ended August 31 2014 and 2013, respectively.

 

                During the four months ended December 31, 2014, export sales to Germany and Belgium combined were approximately 53%.   During fiscal year 2014, export sales to Taiwan and Belgium combined were approximately 46% of total sales.  During fiscal year 2013, export sales to Belgium and Germany combined were approximately 30%.

 

As of December 31, 2014, the highest account receivable due from one customer was 36% of total accounts receivable.  As of August 31, 2014, the highest account receivable due from one customer was approximately 68% of total accounts receivable.  As of August 31, 2013, the highest account receivable due from one customer was approximately 72% of total accounts receivable.
XML 84 R60.htm IDEA: XBRL DOCUMENT v2.4.1.9
Note 3: Detail of Certain Balance Sheet Accounts: Detail of Accounts Receivable (Details) (USD $)
Dec. 31, 2014
Aug. 31, 2014
Aug. 31, 2013
Details      
Trade Receivables - Non-Related Party $ 293,182us-gaap_ReceivablesFromCustomers $ 364,170us-gaap_ReceivablesFromCustomers $ 890,985us-gaap_ReceivablesFromCustomers
Other Receivables 1,890us-gaap_OtherReceivables 22,717us-gaap_OtherReceivables 28,984us-gaap_OtherReceivables
Allowance for Doubtful Accounts Receivable (20,000)us-gaap_AllowanceForDoubtfulAccountsReceivable (20,000)us-gaap_AllowanceForDoubtfulAccountsReceivable (20,000)us-gaap_AllowanceForDoubtfulAccountsReceivable
Accounts Receivable, Net, Noncurrent $ 275,072us-gaap_AccountsReceivableNetNoncurrent $ 366,887us-gaap_AccountsReceivableNetNoncurrent $ 899,969us-gaap_AccountsReceivableNetNoncurrent
XML 85 R13.htm IDEA: XBRL DOCUMENT v2.4.1.9
Note 7: Stockholders' Equity
 12 Months Ended
Dec. 31, 2014
Notes  
Note 7: Stockholders' Equity

Note 7:  Stockholders’ Equity

 

The Company has 10,000,000 authorized shares of $.001 par value preferred stock.  As of December 31, 2014, August 31, 2014 and 2013, there were no shares of preferred stock outstanding.  The Company also has 80,000,000 authorized shares of $.001 par value common stock.

 

Shelf Registration Statements

 

On October 1, 2009, a universal shelf registration statement was declared effective by the SEC for the issuance of common stock, preferred stock, warrants, senior debt, subordinated debt and units up to an aggregate amount of $50.0 million (the “2009 Shelf Registration Statement”).  We completed four stock offerings utilizing the universal shelf registration statement during calendar year 2010, and we received total net proceeds of approximately $19.2 million, including proceeds from the exercise of warrants issued in the stock offerings.

 

On September 28, 2012, we filed a universal shelf registration statement with the SEC for the issuance of common stock, preferred stock, warrants, senior debt, subordinated debt and units up to an aggregate amount of $50.0 million (the “2012 Shelf Registration Statement”).  On October 11, 2012, the 2012 Shelf Registration Statement was declared effective by the SEC.  We have completed two stock offerings utilizing the 2012 Shelf Registration Statement from April 2013 through December 31, 2014, and we received total net proceeds of approximately $9.0 million from these offerings, as more fully described below.  We may periodically offer one or more of these securities in amounts, prices and terms to be announced when and if the securities are offered.  At the time any of the securities covered by the registration statement are offered for sale, a prospectus supplement will be prepared and filed with the SEC containing specific information about the terms of any such offering.

 

April 2013 Offering

 

On April 9, 2013, we entered into a placement agency agreement (the “Agency Agreement”) with Roth Capital Partners, LLC (the “Placement Agent”), pursuant to which the Placement Agent agreed to use its reasonable efforts to arrange for the sale of up to 4,065,042 shares of our common stock and warrants to purchase up to 3,048,782 shares of our common stock in a registered direct public offering (the “April 2013 Offering”).  The Placement Agent was entitled to a cash fee of 6.5% of the gross proceeds paid to us for the securities sold in the April 2013 Offering.  We also reimbursed the Placement Agent for all reasonable and documented out-of-pocket expenses incurred by the Placement Agent in connection with the April 2013 Offering, not to exceed the lesser of (i) $35,000 or (ii) 8% of the gross proceeds of the April 2013 Offering, less the Placement Agent’s placement fee.

 

The Agency Agreement contains customary representations, warranties and covenants by us.  It also provides for customary indemnification by us and the Placement Agent for losses or damages arising out of or in connection with the sale of the securities being offered.  We agreed to indemnify the Placement Agent against liabilities under the Securities Act of 1933, as amended.  We also agreed to contribute to payments the Placement Agent may be required to make in respect of such liabilities.

 

Also on April 9, 2013, we and certain institutional investors entered into a securities purchase agreement (the “Purchase Agreement”) in connection with the April 2013 Offering, pursuant to which we agreed to sell an aggregate of 4,065,042 shares of our common stock and warrants to purchase a total of 3,048,782 shares of our common stock to such investors for aggregate gross proceeds, before deducting fees to the Placement Agent and other estimated offering expenses payable by us, of approximately $5.0 million.  The common stock and warrants were sold in fixed combinations, with each combination consisting of one share of common stock and a warrant to purchase 0.75 shares of common stock.  The purchase price was $1.23 per fixed combination.  The warrants became exercisable six months and one day following the closing date of the April 2013 Offering and will remain exercisable for five years thereafter at an exercise price of $1.65 per share.  The exercise price of the warrants is subject to adjustment in the case of stock splits, stock dividends, combinations of shares and similar recapitalization transactions.

 

The exercisability of the warrants may be limited if, upon exercise, the holder or any of its affiliates would beneficially own more than 4.9% of our common stock.

 

We agreed with each of the purchasers that, subject to certain exceptions, we will not, within the 30 trading days following the closing of the April 2013 Offering (which period may be extended in certain circumstances), enter into any agreement to issue or announce the issuance or proposed issuance of any securities.

 

We also agreed with each of the purchasers that while the warrants are outstanding, we will not affect or enter into an agreement to affect a “Variable Rate Transaction,” which means a transaction in which we:

 

•

issue or sell any convertible securities either (A) at a conversion, exercise or exchange rate or other price that is based upon and/or varies with the trading prices of, or quotations for, the shares of our common stock at any time after the initial issuance of such convertible securities, or (B) with a conversion, exercise or exchange price that is subject to being reset at some future date after the initial issuance of such convertible securities or upon the occurrence of specified or contingent events directly or indirectly related to our business or the market for our common stock, other than pursuant to a customary “weighted average” anti-dilution provision; or

 

 

•

enter into any agreement (including, without limitation, an equity line of credit) whereby we may sell securities at a future determined price (other than standard and customary “preemptive” or “participation” rights).

 

We also agreed with each of the purchasers if we issue securities within the 12 months following the closing of the April 2013 Offering, the purchasers shall have the right to purchase all of the securities on the same terms, conditions and price provided for in the proposed issuance of securities.

 

We also agreed to indemnify each of the purchasers against certain losses resulting from our breach of any of our representations, warranties, or covenants under agreements with each of the purchasers, as well as under certain other circumstances described in the Purchase Agreement.

 

We closed the April 2013 Offering on April 12, 2013 and received net proceeds of approximately $4.6 million, after deducting placement agent fees and the offering expenses borne by us.

 

The April 2013 Offering was completed using the 2012 Shelf Registration Statement, pursuant to a prospectus supplement filed with the SEC.

 

May 2014 Offering

 

On May 9, 2014, the Company entered into an At-the-Market Issuance Sales Agreement (the “ATM Agreement”) with MLV & Co. LLC (“MLV”).  Under this sales agreement, we could issue and sell from time to time, up to $8,000,000 of common stock.  These shares are registered under the 2012 Shelf Registration Statement .  MLV would act as sales agent, using commercially reasonable efforts consistent with its normal trading and sales practices.  The Agreement provided that our common shares would be sold at market prices prevailing at the time of the sale of our common stock, at no discount to market and no warrants attached.  We were not obligated to make any sales under the sales agreement.  We paid MLV a commission rate of 3.0% of the gross proceeds from the sale of common stock sold through MLV as sales agent under the sales agreement, reimbursed MLV for certain expenses incurred in connection with entering into the sales agreement, and provided MLV with customary indemnification rights. The full terms and text of the sales agreement was filed by the Company on a Current Report on Form 8-K on May 9, 2014.  Through June 22, 2014, the Company sold 46,622 shares of common stock at an average price per share of $1.074, for gross proceeds of $50,068.  The ATM Agreement was terminated on June 22, 2014.

 

June 2014 Offering

 

On June 25, 2014, the Company and certain institutional investors entered into a securities purchase agreement (the “June Offering”) in which the Company agreed to sell, pursuant to a securities purchase agreement (the “Purchase Agreement”), an aggregate of 5,500,000 shares of its common stock and warrants to purchase a total of 4,400,000 shares of its common stock to such investors for aggregate gross proceeds of approximately $5.2 million, and net proceeds of approximately $4.7 million, after deducting placement agency fees and other costs associated with the transaction.  The common stock and warrants were sold in fixed combinations, with each combination consisting of one share of common stock and a warrant to purchase 0.8 shares of common stock.  The purchase price was $0.95 per fixed combination.  The warrants will become exercisable six months and one day following the closing date of the June Offering and will remain exercisable for five years thereafter at an exercise price of $1.10 per share.  The exercise price of the warrants is subject to adjustment in the case of stock splits, stock dividends, combinations of shares and similar recapitalization transactions.  The exercisability of the warrants may be limited if, upon exercise, the holder or any of its affiliates would beneficially own more than 4.99% of the Company’s common stock.  The warrants are contingently puttable at the option of the holders upon the occurrence of a fundamental transaction (as defined in the warrant agreements).  The Company considers that all of the fundamental transactions are within the Company’s sole control, and that the probability of any fundamental transaction occurring and the put being exercised are both remote.

 

Under the Purchase Agreement, the Company has agreed with each of the purchasers that, subject to certain exceptions, it will not, within the 75 days following the closing of the June Offering enter into any agreement to issue or announce the issuance or proposed issuance of any securities.  The Company also agreed with each of the purchasers that for a period of four years from the date of the Purchase Agreement, the Company will not affect or enter into an agreement to affect a “Variable Rate Transaction,” which means a transaction in which it:

 

    •

issues or sells any convertible securities either (A) at a conversion, exercise or exchange rate or other price that is based upon and/or varies with the trading prices of, or quotations for, the shares of common stock of the Company at any time after the initial issuance of such convertible securities, or (B) with a conversion, exercise or exchange price that is subject to being reset at some future date after the initial issuance of such convertible securities or upon the occurrence of specified or contingent events directly or indirectly related to the business of the Company or the market for the Company’s common stock, other than pursuant to a customary “weighted average” anti-dilution provision; or

 

 

•

enters into any agreement (including, without limitation, an equity line of credit) whereby the Company may sell securities at a future determined price.

 

The Company has also agreed to indemnify each of the purchasers against certain losses resulting from its breach of any of its representations, warranties, or covenants under agreements with each of the purchasers, as well as under certain other circumstances described in the Purchase Agreement. The transaction closed on July 1, 2014 and the net proceeds were transferred to the Company.

 

Warrants

 

A summary of the outstanding warrants issued in our stock offerings as of December 31, 2014 and August 31, 2014 and changes during the four months ended December 31, 2014 and the year ended August 31, 2014 is as follows:

 

 

Shares

 

Weighted- Average Exercise Price

Weighted-Average Remaining Contract Term (Years)

 

 

 

 

 

 

 

 

 

 

Outstanding as of August 31, 2013

5,457,305

$

2.93

-

Granted

4,400,000

 

1.10

-

Exercised

-

 

-

-

Forfeited or expired

-

 

-

-

 

 

 

 

 

Outstanding as of August 31, 2014

9,857,305

$

2.11

4.02

Granted

-

 

-

-

Exercised

-

 

-

-

Forfeited or expired

-

 

-

-

 

 

 

 

 

Outstanding as of December 31, 2014

9,857,305

$

2.11

3.69

 

 

 

 

 

Exercisable as of December 31, 2014

5,457,305

$

2.93

2.62
XML 86 R14.htm IDEA: XBRL DOCUMENT v2.4.1.9
Note 8: Deferred Revenue
 12 Months Ended
Dec. 31, 2014
Notes  
Note 8: Deferred Revenue

Note 8:  Deferred Revenue

 

We have entered into certain service contracts and other agreements for which we have received payment in advance.  We recognize these revenues over the life of the agreements.

 

As of December 31, 2014, August 31, 2014 and August 31, 2013, we had deferred revenue of $54,218, $96,043 and $783,708, respectively.

 
XML 87 R16.htm IDEA: XBRL DOCUMENT v2.4.1.9
Note 10: Related Party Transactions
 12 Months Ended
Dec. 31, 2014
Notes  
Note 10: Related Party Transactions

Note 10:  Related Party Transactions

 

We had sales of $463,423 during the four months ended December 31, 2014, and $419,549 and $99,896 during the years ended August 31, 2014 and 2013, respectively, to entities controlled by a significant stockholder and member of the Board of Directors.  These related party transactions represent approximately 42%, 8% and 3% of total sales for each respective period.

 

As of December 31, 2014, August 31, 2014 and August 31, 2013, receivables include $13,471, $8,322 and $24,201, respectively, from these related parties.
XML 88 R64.htm IDEA: XBRL DOCUMENT v2.4.1.9
Note 4: Property and Equipment (Details) (USD $)
 4 Months Ended 12 Months Ended
Dec. 31, 2014
Aug. 31, 2014
Aug. 31, 2013
Details      
Depreciation Expense $ 43,280us-gaap_Depreciation $ 125,824us-gaap_Depreciation $ 128,121us-gaap_Depreciation
XML 89 R66.htm IDEA: XBRL DOCUMENT v2.4.1.9
Note 6: Patents (Details) (USD $)
 4 Months Ended 12 Months Ended
Dec. 31, 2014
Aug. 31, 2014
Aug. 31, 2013
Details      
Amortization expense $ 0us-gaap_AmortizationOfIntangibleAssets $ 0us-gaap_AmortizationOfIntangibleAssets $ 4,032us-gaap_AmortizationOfIntangibleAssets
XML 90 R63.htm IDEA: XBRL DOCUMENT v2.4.1.9
Note 4: Property and Equipment: Schedule of Property and Equipment (Details) (USD $)
Dec. 31, 2014
Aug. 31, 2014
Aug. 31, 2013
Property, Plant and Equipment, Gross $ 3,066,011us-gaap_PropertyPlantAndEquipmentGross $ 3,085,430us-gaap_PropertyPlantAndEquipmentGross $ 3,015,548us-gaap_PropertyPlantAndEquipmentGross
Equipment Impairment (85,000)fil_EquipmentImpairment    
Accumulated depreciation (1,840,140)us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment (1,817,769)us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment (1,695,668)us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
Property and equipment, net 1,140,871us-gaap_PropertyPlantAndEquipmentNet 1,267,661us-gaap_PropertyPlantAndEquipmentNet 1,319,880us-gaap_PropertyPlantAndEquipmentNet
Equipment      
Property, Plant and Equipment, Gross 1,503,845us-gaap_PropertyPlantAndEquipmentGross
/ us-gaap_PropertyPlantAndEquipmentByTypeAxis
= us-gaap_EquipmentMember		 1,468,528us-gaap_PropertyPlantAndEquipmentGross
/ us-gaap_PropertyPlantAndEquipmentByTypeAxis
= us-gaap_EquipmentMember		 1,401,811us-gaap_PropertyPlantAndEquipmentGross
/ us-gaap_PropertyPlantAndEquipmentByTypeAxis
= us-gaap_EquipmentMember
Equipment Leased to Other Party      
Property, Plant and Equipment, Gross 58,940us-gaap_PropertyPlantAndEquipmentGross
/ us-gaap_PropertyPlantAndEquipmentByTypeAxis
= us-gaap_EquipmentLeasedToOtherPartyMember		 58,940us-gaap_PropertyPlantAndEquipmentGross
/ us-gaap_PropertyPlantAndEquipmentByTypeAxis
= us-gaap_EquipmentLeasedToOtherPartyMember		 58,940us-gaap_PropertyPlantAndEquipmentGross
/ us-gaap_PropertyPlantAndEquipmentByTypeAxis
= us-gaap_EquipmentLeasedToOtherPartyMember
Furniture and Fixtures      
Property, Plant and Equipment, Gross 303,226us-gaap_PropertyPlantAndEquipmentGross
/ us-gaap_PropertyPlantAndEquipmentByTypeAxis
= us-gaap_FurnitureAndFixturesMember		 303,226us-gaap_PropertyPlantAndEquipmentGross
/ us-gaap_PropertyPlantAndEquipmentByTypeAxis
= us-gaap_FurnitureAndFixturesMember		 300,061us-gaap_PropertyPlantAndEquipmentGross
/ us-gaap_PropertyPlantAndEquipmentByTypeAxis
= us-gaap_FurnitureAndFixturesMember
Building Improvements      
Property, Plant and Equipment, Gross   54,736us-gaap_PropertyPlantAndEquipmentGross
/ us-gaap_PropertyPlantAndEquipmentByTypeAxis
= us-gaap_BuildingImprovementsMember		 54,736us-gaap_PropertyPlantAndEquipmentGross
/ us-gaap_PropertyPlantAndEquipmentByTypeAxis
= us-gaap_BuildingImprovementsMember
Building      
Property, Plant and Equipment, Gross 956,000us-gaap_PropertyPlantAndEquipmentGross
/ us-gaap_PropertyPlantAndEquipmentByTypeAxis
= us-gaap_BuildingMember		 956,000us-gaap_PropertyPlantAndEquipmentGross
/ us-gaap_PropertyPlantAndEquipmentByTypeAxis
= us-gaap_BuildingMember		 956,000us-gaap_PropertyPlantAndEquipmentGross
/ us-gaap_PropertyPlantAndEquipmentByTypeAxis
= us-gaap_BuildingMember
Land      
Property, Plant and Equipment, Gross $ 244,000us-gaap_PropertyPlantAndEquipmentGross
/ us-gaap_PropertyPlantAndEquipmentByTypeAxis
= us-gaap_LandMember		 $ 244,000us-gaap_PropertyPlantAndEquipmentGross
/ us-gaap_PropertyPlantAndEquipmentByTypeAxis
= us-gaap_LandMember		 $ 244,000us-gaap_PropertyPlantAndEquipmentGross
/ us-gaap_PropertyPlantAndEquipmentByTypeAxis
= us-gaap_LandMember
XML 91 R34.htm IDEA: XBRL DOCUMENT v2.4.1.9
Note 1: Organization and Significant Accounting Policies: Revenue Recognition (Policies)
 12 Months Ended
Dec. 31, 2014
Policies  
Revenue Recognition

Revenue Recognition – We recognize revenue from the sale of medical systems, disposable devices related to the systems, parts, and accessories, and equipment rental, training, and service support contracts.  Our revenues consisted of the following:

 

 

Four Months Ended December 31,

Years Ended August 31,

 

2014

        2013

        2014

        2013

 

 

 

 

 

Product sales

$        470,875

$       986,900

$    3,019,525

$    1,934,826

Disposable devices

409,787

501,565

1,568,481

1,109,750

Service contracts and other

109,346

100,597

375,747

330,116

Equipment rental

125,900

95,200

364,600

298,600

 

 

 

 

 

Total

$     1,115,908

$    1,684,262

$    5,328,353

$    3,673,292

 

Revenue from product sales is recognized when a purchase order has been received, the cancer treatment system has been shipped, the selling price is fixed or determinable, and collection is reasonably assured.  Most system sales are F.O.B. shipping point; therefore, shipment is deemed to have occurred when the product is delivered to the transportation carrier.  Most system sales do not include installation.  If installation is included as part of the contract, revenue is not recognized until installation has occurred, or until any remaining installation obligation is deemed to be perfunctory.  Some sales of systems may include training as part of the sale.  In such cases, the portion of the revenue related to the training, calculated based on the amount charged for training on a stand-alone basis, is deferred and recognized when the training has been provided.  The sales of our cancer treatment systems do not require specific customer acceptance provisions and do not include the right of return except in cases where the product does not function as warranted by us.  To date, returns have not been significant.

 

Revenue from the sale of disposable devices is recognized when a purchase order has been received, the devices have been shipped, the selling price is fixed or determinable, and collection is reasonably assured.  Currently, our customers are not required to purchase a minimum number of disposable devices in connection with the purchase of our systems.

 

Revenue from training services is recorded when an agreement with the customer exists for such training, the training services have been provided, and collection is reasonably assured.

 

Revenue from service support contracts is recognized on a straight-line basis over the term of the contract, which approximates recognizing it as it is earned.

 

Revenue from equipment rental under an operating lease is recognized when billed in accordance with the lease agreement.

 

Our revenue recognition policy is the same for sales to both related parties and non-related parties.  We provide the same products and services under the same terms for non-related parties as with related parties.

 

Sales to distributors are recognized in the same manner as sales to end-user customers.

 

Deferred revenue and customer deposits include amounts from service contracts as well as cash received for the sales of products that have not been shipped.
XML 92 R51.htm IDEA: XBRL DOCUMENT v2.4.1.9
Note 12: Stock-based Compensation: Stock Option Rollforward (Tables)
 12 Months Ended
Dec. 31, 2014
Tables/Schedules  
Stock Option Rollforward

 

 

Shares

Weighted- Average  Exercise Price

Weighted-Average Remaining Contract Term (Years)

Aggregate Intrinsic Value

 

 

 

 

 

 

 

Outstanding as of September 1, 2013

4,212,573

$

2.85

 

 

 

Granted

127,000

 

1.19

 

 

 

Exercised

-

 

      -

 

 

 

Forfeited or expired

(476,653)

 

2.18

 

 

 

 

 

 

 

 

 

 

Outstanding as of August 31, 2014

3,862,920

 

2.88

6.32

$

-

Granted

1,450,000

 

0.46

 

 

 

Exercised

-

 

      -

 

 

 

Forfeited or expired

(181,001)

 

1.54

 

 

 

 

 

 

 

 

 

 

Outstanding as of December 31, 2014

5,131,919

$

2.25

7.03

$

-

Exercisable as of December 31, 23014

2,953,586

$

3.30

5.31

$

-
XML 93 R21.htm IDEA: XBRL DOCUMENT v2.4.1.9
Note 15: Recent Accounting Pronouncements
 12 Months Ended
Dec. 31, 2014
Notes  
Note 15: Recent Accounting Pronouncements

Note 15:  Recent Accounting Pronouncements

 

                No new accounting pronouncements were adopted during the four months ended December 31, 2014 that had a material impact on our financial statements.

 

In May 2014, FASB issued ASU 2014-09 Revenue from Contracts with Customers. The amendments in ASU 2014-09 affects any entity that either enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of nonfinancial assets unless those contracts are within the scope of other standards (e.g., insurance contracts or lease contracts). This ASU will supersede the revenue recognition requirements in Topic 605 Revenue Recognition and most industry-specific guidance, and creates a Topic 606 Revenue from Contracts with Customers.

 

The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve that core principle, an entity should apply the following steps:

 

 

Step 1: Identify the contract(s) with a customer.

Step 2: Identify the performance obligations in the contract.

Step 3: Determine the transaction price.

Step 4: Allocate the transaction price to the performance obligations in the contract.

Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation.

 

ASU 2014-09 is effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. Early application is not permitted.  We have not yet determined how our financial statements will be affected by the adoption of ASU 2014-09.
XML 94 R26.htm IDEA: XBRL DOCUMENT v2.4.1.9
Note 1: Organization and Significant Accounting Policies: Accounts Receivable (Policies)
 12 Months Ended
Dec. 31, 2014
Policies  
Accounts Receivable

Accounts Receivable – Trade accounts receivable are carried at original invoice amount less an estimate made for doubtful receivables based on a review of all outstanding amounts on a monthly basis.  Management estimates an allowance for doubtful accounts by identifying troubled accounts and by using historical experience applied to an aging of accounts.  Trade accounts receivable are written off when deemed uncollectible.  Recoveries of trade receivables previously written off are recorded when received.  Interest is not charged on trade receivables that are outstanding beyond their due date.
XML 95 R49.htm IDEA: XBRL DOCUMENT v2.4.1.9
Note 12: Stock-based Compensation: Schedule of Stock Based Compensation (Tables)
 12 Months Ended
Dec. 31, 2014
Tables/Schedules  
Schedule of Stock Based Compensation

 

 

Four Months Ended December 31,

Years Ended  August 31,

 

2014

2014

2013

 

 

 

 

Cost of sales

$       11,776

$       61,427

$       67,119

Research and development

32,349

183,371

212,569

Selling, general and administrative

148,719

599,830

855,123

 

 

 

 

Total

$    192,844

$     844,628

$  1,134,811

 
XML 96 R41.htm IDEA: XBRL DOCUMENT v2.4.1.9
Note 1: Organization and Significant Accounting Policies: Revenue Recognition: Schedule of Revenue Recognition (Tables)
 12 Months Ended
Dec. 31, 2014
Tables/Schedules  
Schedule of Revenue Recognition

 

 

Four Months Ended December 31,

Years Ended August 31,

 

2014

        2013

        2014

        2013

 

 

 

 

 

Product sales

$        470,875

$       986,900

$    3,019,525

$    1,934,826

Disposable devices

409,787

501,565

1,568,481

1,109,750

Service contracts and other

109,346

100,597

375,747

330,116

Equipment rental

125,900

95,200

364,600

298,600

 

 

 

 

 

Total

$     1,115,908

$    1,684,262

$    5,328,353

$    3,673,292
XML 97 R5.htm IDEA: XBRL DOCUMENT v2.4.1.9
Statements of Stockholders' Equity (USD $)
Common Stock
Additional Paid In Capital
Treasury Stock
Accumulated Deficit
Total
Balance at Aug. 31, 2012 $ 29,778us-gaap_StockholdersEquity
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember		 $ 51,845,035us-gaap_StockholdersEquity
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_AdditionalPaidInCapitalMember		 $ (234)us-gaap_StockholdersEquity
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_TreasuryStockMember		 $ (37,377,247)us-gaap_StockholdersEquity
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_RetainedEarningsMember		 $ 14,497,332us-gaap_StockholdersEquity
Balance - Shares at Aug. 31, 2012 29,777,522us-gaap_SharesIssued
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember		   24,331us-gaap_SharesIssued
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_TreasuryStockMember		    
Common Stock Issued For Services 164us-gaap_StockIssuedDuringPeriodValueIssuedForServices
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember		 179,838us-gaap_StockIssuedDuringPeriodValueIssuedForServices
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_AdditionalPaidInCapitalMember		     180,002us-gaap_StockIssuedDuringPeriodValueIssuedForServices
Common Stock Issued For Services - Shares 163,638us-gaap_StockIssuedDuringPeriodSharesIssuedForServices
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember		        
Common Stock Issued For Cash, net of offering costs of $416,565 4,065fil_CommonStockIssuedForCashNetOfOfferingCostsOf416565
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember		 4,579,372fil_CommonStockIssuedForCashNetOfOfferingCostsOf416565
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_AdditionalPaidInCapitalMember		     4,583,437fil_CommonStockIssuedForCashNetOfOfferingCostsOf416565
Common Stock Issued For Cash, net of offering costs of $416,565 - Shares 4,065,042fil_CommonStockIssuedForCashNetOfOfferingCostsOf416565Shares
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember		        
Stock-based compensation   1,134,811us-gaap_ShareBasedCompensation
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_AdditionalPaidInCapitalMember		     1,134,811us-gaap_ShareBasedCompensation
Net loss       (8,251,691)us-gaap_NetIncomeLoss
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_RetainedEarningsMember		 (8,251,691)us-gaap_NetIncomeLoss
Balance at Aug. 31, 2013 34,007us-gaap_StockholdersEquity
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember		 57,739,056us-gaap_StockholdersEquity
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_AdditionalPaidInCapitalMember		 (234)us-gaap_StockholdersEquity
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_TreasuryStockMember		 (45,628,938)us-gaap_StockholdersEquity
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_RetainedEarningsMember		 12,143,891us-gaap_StockholdersEquity
Balance - Shares at Aug. 31, 2013 34,006,202us-gaap_SharesIssued
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember		   24,331us-gaap_SharesIssued
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_TreasuryStockMember		    
Common Stock Issued For Services 161us-gaap_StockIssuedDuringPeriodValueIssuedForServices
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember		 179,839us-gaap_StockIssuedDuringPeriodValueIssuedForServices
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_AdditionalPaidInCapitalMember		     180,000us-gaap_StockIssuedDuringPeriodValueIssuedForServices
Common Stock Issued For Services - Shares 160,716us-gaap_StockIssuedDuringPeriodSharesIssuedForServices
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember		        
Common Stock Issued For Cash, net of offering costs of $638,488 5,546fil_CommonStockIssuedForCashNetOfOfferingCostsOf638488
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember		 4,631,033fil_CommonStockIssuedForCashNetOfOfferingCostsOf638488
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_AdditionalPaidInCapitalMember		     4,636,579fil_CommonStockIssuedForCashNetOfOfferingCostsOf638488
Common Stock Issued For Cash, net of offering costs of $638,488 - Shares 5,546,622fil_CommonStockIssuedForCashNetOfOfferingCostsOf638488Shares
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember		        
Stock-based compensation   844,628us-gaap_ShareBasedCompensation
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_AdditionalPaidInCapitalMember		     844,628us-gaap_ShareBasedCompensation
Net loss       (7,142,832)us-gaap_NetIncomeLoss
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_RetainedEarningsMember		 (7,142,832)us-gaap_NetIncomeLoss
Balance at Aug. 31, 2014 39,714us-gaap_StockholdersEquity
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember		 63,394,556us-gaap_StockholdersEquity
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_AdditionalPaidInCapitalMember		 (234)us-gaap_StockholdersEquity
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_TreasuryStockMember		 (52,771,770)us-gaap_StockholdersEquity
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_RetainedEarningsMember		 10,662,266us-gaap_StockholdersEquity
Balance - Shares at Aug. 31, 2014 39,713,540us-gaap_SharesIssued
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember		   24,331us-gaap_SharesIssued
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_TreasuryStockMember		    
Stock-based compensation   192,844us-gaap_ShareBasedCompensation
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_AdditionalPaidInCapitalMember		     192,844us-gaap_ShareBasedCompensation
Net loss       (3,768,390)us-gaap_NetIncomeLoss
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_RetainedEarningsMember		 (3,768,390)us-gaap_NetIncomeLoss
Balance at Dec. 31, 2014 $ 39,714us-gaap_StockholdersEquity
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember		 $ 63,587,400us-gaap_StockholdersEquity
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_AdditionalPaidInCapitalMember		 $ (234)us-gaap_StockholdersEquity
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_TreasuryStockMember		 $ (56,540,160)us-gaap_StockholdersEquity
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_RetainedEarningsMember		 $ 7,086,720us-gaap_StockholdersEquity
Balance - Shares at Dec. 31, 2014 39,713,540us-gaap_SharesIssued
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember		   24,331us-gaap_SharesIssued
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_TreasuryStockMember		    
XML 98 R10.htm IDEA: XBRL DOCUMENT v2.4.1.9
Note 4: Property and Equipment
 12 Months Ended
Dec. 31, 2014
Notes  
Note 4: Property and Equipment

Note 4:  Property and Equipment

 

Property and equipment consist of the following:

 

 

December 31,

August 31,

 

2014

2014

2013

 

 

 

 

   Equipment

$    1,503,845

$    1,468,528

$    1,401,811

   Rental equipment

58,940

58,940

58,940

   Furniture and fixtures

303,226

303,226

300,061

   Building improvements

-

54,736

54,736

   Building (held for sale)

956,000

956,000

956,000

   Land  (held for sale)

244,000

244,000

244,000

 

 

 

 

 

3,066,011

3,085,430

3,015,548

   Less equipment impairment

 (     85,000)

-

-

   Less accumulated depreciation

(1,840,140)

(1,817,769)

(1,695,668)

 

 

 

 

 

$    1,140,871

$    1,267,661

$    1,319,880

 

Depreciation expense totaled $43,280 for the four months ended December 31, 2014 and totaled $125,824 and $128,121 for the years ended August 31, 2014 and 2013, respectively.
XML 99 R58.htm IDEA: XBRL DOCUMENT v2.4.1.9
Note 1: Organization and Significant Accounting Policies: Advertising and Promotion (Details) (USD $)
 4 Months Ended 12 Months Ended
Dec. 31, 2014
Aug. 31, 2014
Aug. 31, 2013
Details      
Advertising and Promotion Expense $ 56,504us-gaap_AdvertisingExpense $ 206,099us-gaap_AdvertisingExpense $ 205,442us-gaap_AdvertisingExpense
XML 100 R82.htm IDEA: XBRL DOCUMENT v2.4.1.9
Note 14: Commitments and Contingencies (Details) (USD $)
Dec. 31, 2014
Details  
Annual base salary - CEO $ 350,000fil_AnnualBaseSalaryCeo
Annual base salary - CFO $ 200,000fil_AnnualBaseSalaryCfo
XML 101 R69.htm IDEA: XBRL DOCUMENT v2.4.1.9
Note 7: Stockholders' Equity: Schedule of Stockholders' Equity Note, Warrants or Rights (Details) (USD $)
Dec. 31, 2014
Aug. 31, 2014
Aug. 31, 2013
Details      
Outstanding Warrants 9,857,305fil_OutstandingWarrants 9,857,305fil_OutstandingWarrants 5,457,305fil_OutstandingWarrants
Weighted Average Exercise Price of Warrants Outstanding $ 2.11fil_WeightedAverageExercisePriceOfWarrantsOutstanding $ 2.11fil_WeightedAverageExercisePriceOfWarrantsOutstanding $ 2.93fil_WeightedAverageExercisePriceOfWarrantsOutstanding
Warrants Granted 4,400,000fil_WarrantsGranted    
Weighted Average Exercise Price of Warrants Granted   $ 1.10fil_WeightedAverageExercisePriceOfWarrantsGranted  
Weighted Average Remaining Contractual Term of Warrants Outstanding 3.69fil_WeightedAverageRemainingContractualTermOfWarrantsOutstanding 4.02fil_WeightedAverageRemainingContractualTermOfWarrantsOutstanding  
Exercisable Warrants 5,457,305fil_ExercisableWarrants    
Weighted Average Exercise Price of Warrants Exercisable $ 2.93fil_WeightedAverageExercisePriceOfWarrantsExercisable    
Weighted Average Remaining Contractual Term of Warrants Exercisable 2.62fil_WeightedAverageRemainingContractualTermOfWarrantsExercisable    
XML 102 R27.htm IDEA: XBRL DOCUMENT v2.4.1.9
Note 1: Organization and Significant Accounting Policies: Inventories (Policies)
 12 Months Ended
Dec. 31, 2014
Policies  
Inventories

Inventories – Parts and supplies inventories are stated at the lower of cost or market.  Cost is determined using the average cost method.  Work-in-process and finished goods are stated at the lower of the accumulated manufacturing costs or market.  We maintain a reserve for obsolete inventories to reduce excess and obsolete inventories to their estimated net realizable value.  The reserve was $750,000 as of December 31, 2014, $150,000 as of August 31, 2014, and $100,000 as of August 31, 2013.
XML 103 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.1.9 Html 73 235 1 false 15 0 false 4 false false R1.htm 000010 - Document - Document and Entity Information Sheet http://bsdmc.com/20141231/role/idr_DocumentDocumentAndEntityInformation Document and Entity Information true false R2.htm 000020 - Statement - Balance Sheets Sheet http://bsdmc.com/20141231/role/idr_BalanceSheets Balance Sheets false false R3.htm 000030 - Statement - Balance Sheets Parenthetical Sheet http://bsdmc.com/20141231/role/idr_BalanceSheetsParenthetical Balance Sheets Parenthetical false false R4.htm 000040 - Statement - Statements of Comprehensive Loss Sheet http://bsdmc.com/20141231/role/idr_StatementsOfComprehensiveLoss Statements of Comprehensive Loss false false R5.htm 000050 - Statement - Statements of Stockholders' Equity Sheet http://bsdmc.com/20141231/role/idr_StatementsOfStockholdersEquity Statements of Stockholders' Equity false false R6.htm 000060 - Statement - Statements of Cash Flows Sheet http://bsdmc.com/20141231/role/idr_StatementsOfCashFlows Statements of Cash Flows false false R7.htm 000070 - Disclosure - Note 1: Organization and Significant Accounting Policies Sheet http://bsdmc.com/20141231/role/idr_DisclosureNote1OrganizationAndSignificantAccountingPolicies Note 1: Organization and Significant Accounting Policies false false R8.htm 000080 - Disclosure - Note 2: Liquidity Sheet http://bsdmc.com/20141231/role/idr_DisclosureNote2Liquidity Note 2: Liquidity false false R9.htm 000090 - Disclosure - Note 3: Detail of Certain Balance Sheet Accounts Sheet http://bsdmc.com/20141231/role/idr_DisclosureNote3DetailOfCertainBalanceSheetAccounts Note 3: Detail of Certain Balance Sheet Accounts false false R10.htm 000100 - Disclosure - Note 4: Property and Equipment Sheet http://bsdmc.com/20141231/role/idr_DisclosureNote4PropertyAndEquipment Note 4: Property and Equipment false false R11.htm 000110 - Disclosure - Note 5: Impairment Sheet http://bsdmc.com/20141231/role/idr_DisclosureNote5Impairment Note 5: Impairment false false R12.htm 000120 - Disclosure - Note 6: Patents Sheet http://bsdmc.com/20141231/role/idr_DisclosureNote6Patents Note 6: Patents false false R13.htm 000130 - Disclosure - Note 7: Stockholders' Equity Sheet http://bsdmc.com/20141231/role/idr_DisclosureNote7StockholdersEquity Note 7: Stockholders' Equity false false R14.htm 000140 - Disclosure - Note 8: Deferred Revenue Sheet http://bsdmc.com/20141231/role/idr_DisclosureNote8DeferredRevenue Note 8: Deferred Revenue false false R15.htm 000150 - Disclosure - Note 9: Major Customers and Foreign Sales Sheet http://bsdmc.com/20141231/role/idr_DisclosureNote9MajorCustomersAndForeignSales Note 9: Major Customers and Foreign Sales false false R16.htm 000160 - Disclosure - Note 10: Related Party Transactions Sheet http://bsdmc.com/20141231/role/idr_DisclosureNote10RelatedPartyTransactions Note 10: Related Party Transactions false false R17.htm 000170 - Disclosure - Note 11: Income Taxes Sheet http://bsdmc.com/20141231/role/idr_DisclosureNote11IncomeTaxes Note 11: Income Taxes false false R18.htm 000180 - Disclosure - Note 12: Stock-based Compensation Sheet http://bsdmc.com/20141231/role/idr_DisclosureNote12StockBasedCompensation Note 12: Stock-based Compensation false false R19.htm 000190 - Disclosure - Note 13: Supplemental Cash Flow Information Sheet http://bsdmc.com/20141231/role/idr_DisclosureNote13SupplementalCashFlowInformation Note 13: Supplemental Cash Flow Information false false R20.htm 000200 - Disclosure - Note 14: Commitments and Contingencies Sheet http://bsdmc.com/20141231/role/idr_DisclosureNote14CommitmentsAndContingencies Note 14: Commitments and Contingencies false false R21.htm 000210 - Disclosure - Note 15: Recent Accounting Pronouncements Sheet http://bsdmc.com/20141231/role/idr_DisclosureNote15RecentAccountingPronouncements Note 15: Recent Accounting Pronouncements false false R22.htm 000220 - Disclosure - Note 16: Subsequent Events Sheet http://bsdmc.com/20141231/role/idr_DisclosureNote16SubsequentEvents Note 16: Subsequent Events false false R23.htm 000230 - Disclosure - Note 1: Organization and Significant Accounting Policies: Organization and Business (Policies) Sheet http://bsdmc.com/20141231/role/idr_DisclosureNote1OrganizationAndSignificantAccountingPoliciesOrganizationAndBusinessPolicies Note 1: Organization and Significant Accounting Policies: Organization and Business (Policies) false false R24.htm 000240 - Disclosure - Note 1: Organization and Significant Accounting Policies: Financial Reporting Period (Policies) Sheet http://bsdmc.com/20141231/role/idr_DisclosureNote1OrganizationAndSignificantAccountingPoliciesFinancialReportingPeriodPolicies Note 1: Organization and Significant Accounting Policies: Financial Reporting Period (Policies) false false R25.htm 000250 - Disclosure - Note 1: Organization and Significant Accounting Policies: Cash and Cash Equivalents (Policies) Sheet http://bsdmc.com/20141231/role/idr_DisclosureNote1OrganizationAndSignificantAccountingPoliciesCashAndCashEquivalentsPolicies Note 1: Organization and Significant Accounting Policies: Cash and Cash Equivalents (Policies) false false R26.htm 000260 - Disclosure - Note 1: Organization and Significant Accounting Policies: Accounts Receivable (Policies) Sheet http://bsdmc.com/20141231/role/idr_DisclosureNote1OrganizationAndSignificantAccountingPoliciesAccountsReceivablePolicies Note 1: Organization and Significant Accounting Policies: Accounts Receivable (Policies) false false R27.htm 000270 - Disclosure - Note 1: Organization and Significant Accounting Policies: Inventories (Policies) Sheet http://bsdmc.com/20141231/role/idr_DisclosureNote1OrganizationAndSignificantAccountingPoliciesInventoriesPolicies Note 1: Organization and Significant Accounting Policies: Inventories (Policies) false false R28.htm 000280 - Disclosure - Note 1: Organization and Significant Accounting Policies: Property and Equipment (Policies) Sheet http://bsdmc.com/20141231/role/idr_DisclosureNote1OrganizationAndSignificantAccountingPoliciesPropertyAndEquipmentPolicies Note 1: Organization and Significant Accounting Policies: Property and Equipment (Policies) false false R29.htm 000290 - Disclosure - Note 1: Organization and Significant Accounting Policies: Patents (Policies) Sheet http://bsdmc.com/20141231/role/idr_DisclosureNote1OrganizationAndSignificantAccountingPoliciesPatentsPolicies Note 1: Organization and Significant Accounting Policies: Patents (Policies) false false R30.htm 000300 - Disclosure - Note 1: Organization and Significant Accounting Policies: Warranty Reserve (Policies) Sheet http://bsdmc.com/20141231/role/idr_DisclosureNote1OrganizationAndSignificantAccountingPoliciesWarrantyReservePolicies Note 1: Organization and Significant Accounting Policies: Warranty Reserve (Policies) false false R31.htm 000310 - Disclosure - Note 1: Organization and Significant Accounting Policies: Income Taxes (Policies) Sheet http://bsdmc.com/20141231/role/idr_DisclosureNote1OrganizationAndSignificantAccountingPoliciesIncomeTaxesPolicies Note 1: Organization and Significant Accounting Policies: Income Taxes (Policies) false false R32.htm 000320 - Disclosure - Note 1: Organization and Significant Accounting Policies: Income (loss) Per Common Share (Policies) Sheet http://bsdmc.com/20141231/role/idr_DisclosureNote1OrganizationAndSignificantAccountingPoliciesIncomeLossPerCommonSharePolicies Note 1: Organization and Significant Accounting Policies: Income (loss) Per Common Share (Policies) false false R33.htm 000330 - Disclosure - Note 1: Organization and Significant Accounting Policies: Stock-based Compensation (Policies) Sheet http://bsdmc.com/20141231/role/idr_DisclosureNote1OrganizationAndSignificantAccountingPoliciesStockBasedCompensationPolicies Note 1: Organization and Significant Accounting Policies: Stock-based Compensation (Policies) false false R34.htm 000340 - Disclosure - Note 1: Organization and Significant Accounting Policies: Revenue Recognition (Policies) Sheet http://bsdmc.com/20141231/role/idr_DisclosureNote1OrganizationAndSignificantAccountingPoliciesRevenueRecognitionPolicies Note 1: Organization and Significant Accounting Policies: Revenue Recognition (Policies) false false R35.htm 000350 - Disclosure - Note 1: Organization and Significant Accounting Policies: Concentration of Credit Risk (Policies) Sheet http://bsdmc.com/20141231/role/idr_DisclosureNote1OrganizationAndSignificantAccountingPoliciesConcentrationOfCreditRiskPolicies Note 1: Organization and Significant Accounting Policies: Concentration of Credit Risk (Policies) false false R36.htm 000360 - Disclosure - Note 1: Organization and Significant Accounting Policies: Advertising and Promotion (Policies) Sheet http://bsdmc.com/20141231/role/idr_DisclosureNote1OrganizationAndSignificantAccountingPoliciesAdvertisingAndPromotionPolicies Note 1: Organization and Significant Accounting Policies: Advertising and Promotion (Policies) false false R37.htm 000370 - Disclosure - Note 1: Organization and Significant Accounting Policies: Shipping and Handling (Policies) Sheet http://bsdmc.com/20141231/role/idr_DisclosureNote1OrganizationAndSignificantAccountingPoliciesShippingAndHandlingPolicies Note 1: Organization and Significant Accounting Policies: Shipping and Handling (Policies) false false R38.htm 000380 - Disclosure - Note 1: Organization and Significant Accounting Policies: Use of Estimates in The Preparation of Financial Statements (Policies) Sheet http://bsdmc.com/20141231/role/idr_DisclosureNote1OrganizationAndSignificantAccountingPoliciesUseOfEstimatesInThePreparationOfFinancialStatementsPolicies Note 1: Organization and Significant Accounting Policies: Use of Estimates in The Preparation of Financial Statements (Policies) false false R39.htm 000390 - Disclosure - Note 1: Organization and Significant Accounting Policies: Comprehensive Loss (Policies) Sheet http://bsdmc.com/20141231/role/idr_DisclosureNote1OrganizationAndSignificantAccountingPoliciesComprehensiveLossPolicies Note 1: Organization and Significant Accounting Policies: Comprehensive Loss (Policies) false false R40.htm 000400 - Disclosure - Note 1: Organization and Significant Accounting Policies: Property and Equipment: Schedule of Property Plant and Equipment Useful Life (Tables) Sheet http://bsdmc.com/20141231/role/idr_DisclosureNote1OrganizationAndSignificantAccountingPoliciesPropertyAndEquipmentScheduleOfPropertyPlantAndEquipmentUsefulLifeTables Note 1: Organization and Significant Accounting Policies: Property and Equipment: Schedule of Property Plant and Equipment Useful Life (Tables) false false R41.htm 000410 - Disclosure - Note 1: Organization and Significant Accounting Policies: Revenue Recognition: Schedule of Revenue Recognition (Tables) Sheet http://bsdmc.com/20141231/role/idr_DisclosureNote1OrganizationAndSignificantAccountingPoliciesRevenueRecognitionScheduleOfRevenueRecognitionTables Note 1: Organization and Significant Accounting Policies: Revenue Recognition: Schedule of Revenue Recognition (Tables) false false R42.htm 000420 - Disclosure - Note 3: Detail of Certain Balance Sheet Accounts: Detail of Accounts Receivable (Tables) Sheet http://bsdmc.com/20141231/role/idr_DisclosureNote3DetailOfCertainBalanceSheetAccountsDetailOfAccountsReceivableTables Note 3: Detail of Certain Balance Sheet Accounts: Detail of Accounts Receivable (Tables) false false R43.htm 000430 - Disclosure - Note 3: Detail of Certain Balance Sheet Accounts: Detail of Inventories (Tables) Sheet http://bsdmc.com/20141231/role/idr_DisclosureNote3DetailOfCertainBalanceSheetAccountsDetailOfInventoriesTables Note 3: Detail of Certain Balance Sheet Accounts: Detail of Inventories (Tables) false false R44.htm 000440 - Disclosure - Note 3: Detail of Certain Balance Sheet Accounts: Detail of Accrued Liabilities (Tables) Sheet http://bsdmc.com/20141231/role/idr_DisclosureNote3DetailOfCertainBalanceSheetAccountsDetailOfAccruedLiabilitiesTables Note 3: Detail of Certain Balance Sheet Accounts: Detail of Accrued Liabilities (Tables) false false R45.htm 000450 - Disclosure - Note 4: Property and Equipment: Schedule of Property and Equipment (Tables) Sheet http://bsdmc.com/20141231/role/idr_DisclosureNote4PropertyAndEquipmentScheduleOfPropertyAndEquipmentTables Note 4: Property and Equipment: Schedule of Property and Equipment (Tables) false false R46.htm 000460 - Disclosure - Note 7: Stockholders' Equity: Schedule of Stockholders' Equity Note, Warrants or Rights (Tables) Sheet http://bsdmc.com/20141231/role/idr_DisclosureNote7StockholdersEquityScheduleOfStockholdersEquityNoteWarrantsOrRightsTables Note 7: Stockholders' Equity: Schedule of Stockholders' Equity Note, Warrants or Rights (Tables) false false R47.htm 000470 - Disclosure - Note 11: Income Taxes: Schedule of Income Tax (Provision) Benefit Computed at Federal Rates (Tables) Sheet http://bsdmc.com/20141231/role/idr_DisclosureNote11IncomeTaxesScheduleOfIncomeTaxProvisionBenefitComputedAtFederalRatesTables Note 11: Income Taxes: Schedule of Income Tax (Provision) Benefit Computed at Federal Rates (Tables) false false R48.htm 000480 - Disclosure - Note 11: Income Taxes: Schedule of Deferred Tax Assets (Liabilities) (Tables) Sheet http://bsdmc.com/20141231/role/idr_DisclosureNote11IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesTables Note 11: Income Taxes: Schedule of Deferred Tax Assets (Liabilities) (Tables) false false R49.htm 000490 - Disclosure - Note 12: Stock-based Compensation: Schedule of Stock Based Compensation (Tables) Sheet http://bsdmc.com/20141231/role/idr_DisclosureNote12StockBasedCompensationScheduleOfStockBasedCompensationTables Note 12: Stock-based Compensation: Schedule of Stock Based Compensation (Tables) false false R50.htm 000500 - Disclosure - Note 12: Stock-based Compensation: Schedule of Assumptions Used (Tables) Sheet http://bsdmc.com/20141231/role/idr_DisclosureNote12StockBasedCompensationScheduleOfAssumptionsUsedTables Note 12: Stock-based Compensation: Schedule of Assumptions Used (Tables) false false R51.htm 000510 - Disclosure - Note 12: Stock-based Compensation: Stock Option Rollforward (Tables) Sheet http://bsdmc.com/20141231/role/idr_DisclosureNote12StockBasedCompensationStockOptionRollforwardTables Note 12: Stock-based Compensation: Stock Option Rollforward (Tables) false false R52.htm 000520 - Disclosure - Note 1: Organization and Significant Accounting Policies: Organization and Business (Details) Sheet http://bsdmc.com/20141231/role/idr_DisclosureNote1OrganizationAndSignificantAccountingPoliciesOrganizationAndBusinessDetails Note 1: Organization and Significant Accounting Policies: Organization and Business (Details) false false R53.htm 000530 - Disclosure - Note 1: Organization and Significant Accounting Policies: Inventories (Details) Sheet http://bsdmc.com/20141231/role/idr_DisclosureNote1OrganizationAndSignificantAccountingPoliciesInventoriesDetails Note 1: Organization and Significant Accounting Policies: Inventories (Details) false false R54.htm 000540 - Disclosure - Note 1: Organization and Significant Accounting Policies: Property and Equipment: Schedule of Property Plant and Equipment Useful Life (Details) Sheet http://bsdmc.com/20141231/role/idr_DisclosureNote1OrganizationAndSignificantAccountingPoliciesPropertyAndEquipmentScheduleOfPropertyPlantAndEquipmentUsefulLifeDetails Note 1: Organization and Significant Accounting Policies: Property and Equipment: Schedule of Property Plant and Equipment Useful Life (Details) false false R55.htm 000550 - Disclosure - Note 1: Organization and Significant Accounting Policies: Warranty Reserve (Details) Sheet http://bsdmc.com/20141231/role/idr_DisclosureNote1OrganizationAndSignificantAccountingPoliciesWarrantyReserveDetails Note 1: Organization and Significant Accounting Policies: Warranty Reserve (Details) false false R56.htm 000560 - Disclosure - Note 1: Organization and Significant Accounting Policies: Income (loss) Per Common Share (Details) Sheet http://bsdmc.com/20141231/role/idr_DisclosureNote1OrganizationAndSignificantAccountingPoliciesIncomeLossPerCommonShareDetails Note 1: Organization and Significant Accounting Policies: Income (loss) Per Common Share (Details) false false R57.htm 000570 - Disclosure - Note 1: Organization and Significant Accounting Policies: Revenue Recognition: Schedule of Revenue Recognition (Details) Sheet http://bsdmc.com/20141231/role/idr_DisclosureNote1OrganizationAndSignificantAccountingPoliciesRevenueRecognitionScheduleOfRevenueRecognitionDetails Note 1: Organization and Significant Accounting Policies: Revenue Recognition: Schedule of Revenue Recognition (Details) false false R58.htm 000580 - Disclosure - Note 1: Organization and Significant Accounting Policies: Advertising and Promotion (Details) Sheet http://bsdmc.com/20141231/role/idr_DisclosureNote1OrganizationAndSignificantAccountingPoliciesAdvertisingAndPromotionDetails Note 1: Organization and Significant Accounting Policies: Advertising and Promotion (Details) false false R59.htm 000590 - Disclosure - Note 2: Liquidity (Details) Sheet http://bsdmc.com/20141231/role/idr_DisclosureNote2LiquidityDetails Note 2: Liquidity (Details) false false R60.htm 000600 - Disclosure - Note 3: Detail of Certain Balance Sheet Accounts: Detail of Accounts Receivable (Details) Sheet http://bsdmc.com/20141231/role/idr_DisclosureNote3DetailOfCertainBalanceSheetAccountsDetailOfAccountsReceivableDetails Note 3: Detail of Certain Balance Sheet Accounts: Detail of Accounts Receivable (Details) false false R61.htm 000610 - Disclosure - Note 3: Detail of Certain Balance Sheet Accounts: Detail of Inventories (Details) Sheet http://bsdmc.com/20141231/role/idr_DisclosureNote3DetailOfCertainBalanceSheetAccountsDetailOfInventoriesDetails Note 3: Detail of Certain Balance Sheet Accounts: Detail of Inventories (Details) false false R62.htm 000620 - Disclosure - Note 3: Detail of Certain Balance Sheet Accounts: Detail of Accrued Liabilities (Details) Sheet http://bsdmc.com/20141231/role/idr_DisclosureNote3DetailOfCertainBalanceSheetAccountsDetailOfAccruedLiabilitiesDetails Note 3: Detail of Certain Balance Sheet Accounts: Detail of Accrued Liabilities (Details) false false R63.htm 000630 - Disclosure - Note 4: Property and Equipment: Schedule of Property and Equipment (Details) Sheet http://bsdmc.com/20141231/role/idr_DisclosureNote4PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails Note 4: Property and Equipment: Schedule of Property and Equipment (Details) false false R64.htm 000640 - Disclosure - Note 4: Property and Equipment (Details) Sheet http://bsdmc.com/20141231/role/idr_DisclosureNote4PropertyAndEquipmentDetails Note 4: Property and Equipment (Details) false false R65.htm 000650 - Disclosure - Note 5: Impairment (Details) Sheet http://bsdmc.com/20141231/role/idr_DisclosureNote5ImpairmentDetails Note 5: Impairment (Details) false false R66.htm 000660 - Disclosure - Note 6: Patents (Details) Sheet http://bsdmc.com/20141231/role/idr_DisclosureNote6PatentsDetails Note 6: Patents (Details) false false R67.htm 000670 - Disclosure - Note 7: Stockholders' Equity (Details) Sheet http://bsdmc.com/20141231/role/idr_DisclosureNote7StockholdersEquityDetails Note 7: Stockholders' Equity (Details) false false R68.htm 000690 - Disclosure - Note 7: Stockholders' Equity: April 2013 Offering (Details) Sheet http://bsdmc.com/20141231/role/idr_DisclosureNote7StockholdersEquityApril2013OfferingDetails Note 7: Stockholders' Equity: April 2013 Offering (Details) false false R69.htm 000700 - Disclosure - Note 7: Stockholders' Equity: Schedule of Stockholders' Equity Note, Warrants or Rights (Details) Sheet http://bsdmc.com/20141231/role/idr_DisclosureNote7StockholdersEquityScheduleOfStockholdersEquityNoteWarrantsOrRightsDetails Note 7: Stockholders' Equity: Schedule of Stockholders' Equity Note, Warrants or Rights (Details) false false R70.htm 000710 - Disclosure - Note 8: Deferred Revenue (Details) Sheet http://bsdmc.com/20141231/role/idr_DisclosureNote8DeferredRevenueDetails Note 8: Deferred Revenue (Details) false false R71.htm 000720 - Disclosure - Note 9: Major Customers and Foreign Sales (Details) Sheet http://bsdmc.com/20141231/role/idr_DisclosureNote9MajorCustomersAndForeignSalesDetails Note 9: Major Customers and Foreign Sales (Details) false false R72.htm 000730 - Disclosure - Note 10: Related Party Transactions (Details) Sheet http://bsdmc.com/20141231/role/idr_DisclosureNote10RelatedPartyTransactionsDetails Note 10: Related Party Transactions (Details) false false R73.htm 000740 - Disclosure - Note 11: Income Taxes (Details) Sheet http://bsdmc.com/20141231/role/idr_DisclosureNote11IncomeTaxesDetails Note 11: Income Taxes (Details) false false R74.htm 000750 - Disclosure - Note 11: Income Taxes: Schedule of Income Tax (Provision) Benefit Computed at Federal Rates (Details) Sheet http://bsdmc.com/20141231/role/idr_DisclosureNote11IncomeTaxesScheduleOfIncomeTaxProvisionBenefitComputedAtFederalRatesDetails Note 11: Income Taxes: Schedule of Income Tax (Provision) Benefit Computed at Federal Rates (Details) false false R75.htm 000760 - Disclosure - Note 11: Income Taxes: Schedule of Deferred Tax Assets (Liabilities) (Details) Sheet http://bsdmc.com/20141231/role/idr_DisclosureNote11IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetails Note 11: Income Taxes: Schedule of Deferred Tax Assets (Liabilities) (Details) false false R76.htm 000770 - Disclosure - Note 12: Stock-based Compensation: Stock Incentive Plan (Details) Sheet http://bsdmc.com/20141231/role/idr_DisclosureNote12StockBasedCompensationStockIncentivePlanDetails Note 12: Stock-based Compensation: Stock Incentive Plan (Details) false false R77.htm 000780 - Disclosure - Note 12: Stock-based Compensation: Schedule of Stock Based Compensation (Details) Sheet http://bsdmc.com/20141231/role/idr_DisclosureNote12StockBasedCompensationScheduleOfStockBasedCompensationDetails Note 12: Stock-based Compensation: Schedule of Stock Based Compensation (Details) false false R78.htm 000790 - Disclosure - Note 12: Stock-based Compensation (Details) Sheet http://bsdmc.com/20141231/role/idr_DisclosureNote12StockBasedCompensationDetails Note 12: Stock-based Compensation (Details) false false R79.htm 000800 - Disclosure - Note 12: Stock-based Compensation: Schedule of Assumptions Used (Details) Sheet http://bsdmc.com/20141231/role/idr_DisclosureNote12StockBasedCompensationScheduleOfAssumptionsUsedDetails Note 12: Stock-based Compensation: Schedule of Assumptions Used (Details) false false R80.htm 000810 - Disclosure - Note 12: Stock-based Compensation: Stock Option Rollforward (Details) Sheet http://bsdmc.com/20141231/role/idr_DisclosureNote12StockBasedCompensationStockOptionRollforwardDetails Note 12: Stock-based Compensation: Stock Option Rollforward (Details) false false R81.htm 000820 - Disclosure - Note 13: Supplemental Cash Flow Information (Details) Sheet http://bsdmc.com/20141231/role/idr_DisclosureNote13SupplementalCashFlowInformationDetails Note 13: Supplemental Cash Flow Information (Details) false false R82.htm 000830 - Disclosure - Note 14: Commitments and Contingencies (Details) Sheet http://bsdmc.com/20141231/role/idr_DisclosureNote14CommitmentsAndContingenciesDetails Note 14: Commitments and Contingencies (Details) false false All Reports Book All Reports Process Flow-Through: 000020 - Statement - Balance Sheets Process Flow-Through: Removing column 'Dec. 31, 2013' Process Flow-Through: Removing column 'Aug. 31, 2012' Process Flow-Through: 000030 - Statement - Balance Sheets Parenthetical Process Flow-Through: 000040 - Statement - Statements of Comprehensive Loss Process Flow-Through: Removing column '12 Months Ended Dec. 31, 2014' Process Flow-Through: 000060 - Statement - Statements of Cash Flows Process Flow-Through: Removing column '12 Months Ended Dec. 31, 2014' bsdm-20141231.xml bsdm-20141231.xsd bsdm-20141231_cal.xml bsdm-20141231_def.xml bsdm-20141231_lab.xml bsdm-20141231_pre.xml true true XML 104 R74.htm IDEA: XBRL DOCUMENT v2.4.1.9
Note 11: Income Taxes: Schedule of Income Tax (Provision) Benefit Computed at Federal Rates (Details) (USD $)
 4 Months Ended 12 Months Ended
Dec. 31, 2014
Dec. 31, 2013
Aug. 31, 2014
Aug. 31, 2013
Details        
Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount $ 1,281,000us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate   $ 2,428,000us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate $ 2,805,000us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Compensation Cost, Amount (66,000)us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost   (287,000)us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost (335,000)us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount 124,000us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes   236,000us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes 272,000us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes
Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount 33,000us-gaap_IncomeTaxReconciliationTaxCreditsResearch   99,000us-gaap_IncomeTaxReconciliationTaxCreditsResearch 106,000us-gaap_IncomeTaxReconciliationTaxCreditsResearch
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount (1,360,000)us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance   (2,480,000)us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance (2,905,000)us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
Effective Income Tax Rate Reconciliation, Deduction, Other, Amount (12,000)us-gaap_IncomeTaxReconciliationDeductionsOther   2,000us-gaap_IncomeTaxReconciliationDeductionsOther 55,062us-gaap_IncomeTaxReconciliationDeductionsOther
Income tax provision       $ (2,000)us-gaap_IncomeTaxExpenseBenefit $ (1,938)us-gaap_IncomeTaxExpenseBenefit
XML 105 R38.htm IDEA: XBRL DOCUMENT v2.4.1.9
Note 1: Organization and Significant Accounting Policies: Use of Estimates in The Preparation of Financial Statements (Policies)
 12 Months Ended
Dec. 31, 2014
Policies  
Use of Estimates in The Preparation of Financial Statements

Use of Estimates in the Preparation of Financial Statements – The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ from those estimates.
XML 106 R20.htm IDEA: XBRL DOCUMENT v2.4.1.9
Note 14: Commitments and Contingencies
 12 Months Ended
Dec. 31, 2014
Notes  
Note 14: Commitments and Contingencies

Note 14:  Commitments and Contingencies

 

Employment Agreement - CEO

 

On January 9, 2015, we entered into an Employment Agreement (“CEO Agreement”) with Clinton E. Carnell Jr., our President and Chief Executive Officer (“CEO”).  The CEO Agreement confirms the appointment as President and CEO, and service as a member of  the Company’s Board of Directors, and sets the CEO’s annual base salary at $350,000, with a review at least annually by the Compensation Committee of the Board of Directors.  The CEO Agreement provides for an annual bonus of $150,000 for the first year of employment, and a bonus of $150,000, or a pro rata portion thereof, for the second year of employment.  If the Company completes and closes in fiscal year 2015 an equity offering that generates to the Company at least $5.0 million in net proceeds, then the Company will engage a compensation consulting firm to conduct a study of compensation of CEO’s in companies comparable to the Company, which study shall then be used to negotiate Mr. Carnell’s overall compensation after December 31, 2015.  If the Company does not complete and close such an equity offering in 2015, then the Company shall engage a compensation consulting firm in 2016 to negotiate Mr. Carnell’s salary after December 31, 2016.  The CEO Agreement also provides an award of a nonqualified stock option to purchase 1,400,000 shares of common stock at a price per share of $0.46, the closing price of the Company’s common stock on November 10, 2014, the date the option was granted.  The options will vest at one-third each year on the anniversaries of the grant.  Under the CEO Agreement the CEO is entitled to participate in all employee benefit plans, practices and programs maintained by the Company for its employees.  Additional provisions of the CEO Agreement include indemnification for expenses associated with defending certain claims made against the CEO as a result of his position with the Company, and directors’ and officers’ liability insurance providing coverage during the term of the CEO Agreement and for a period of six years following the termination of the CEO Agreement.  The CEO Agreement also provides that if he is terminated by the Company other than for cause, or if he resigns for good reason and complies with certain requirements, the Company is obligated to pay him an amount equal to his base salary (the “CEO Severance Payment”) and provide employee benefits for two years following termination.  If the CEO Agreement is terminated for cause, he shall receive only the portion of his base salary that is due to him through the effective date of his termination.  If the CEO Agreement is terminated by reason of his death, his estate shall receive his salary through the end of the month in which he died plus all employee benefits due to him through the end of such month.   If a Change in Control (as defined in the CEO Agreement) occurs with respect to the Company, and during the six months immediately following the Change of Control, (i) the Company terminates him without cause; or (ii) he terminates his employment with good reason, then in addition to the CEO Severance Payment, all options or incentive awards granted to him will immediately vest and become exercisable for a period of 180 days following the termination.  The CEO Agreement also contains a confidentiality agreement, and a one-year non-competition and non-solicitation agreement.  The CEO Agreement contains a claw back provision that enables the Company to claw back any incentive-based compensation or other compensation from him if required by any law, government regulation, stock exchange listing requirement, or Company policy adopted as required by such law, government regulation, or stock exchange listing requirement.

 

The Company’s former President and CEO, Mr. Harold R. Wolcott, relinquished his positions as President and CEO upon the Company’s hiring of its new President and CEO.  Mr. Wolcott will continue to serve on the Company’s board of directors.  On April 28, 2014, the Company entered into a letter agreement with Mr. Wolcott, pursuant to which Mr. Wolcott will receive severance benefits that supersede the severance benefits Mr. Wolcott was previously entitled to receive under his employment agreement.  Pursuant to the letter agreement, upon Mr. Wolcott ceasing to serve as President and CEO of the Company for any reason (other than for cause), the Company will pay to Mr. Wolcott an amount equal to his current base salary, and the vesting of his equity awards will immediately vest and become exercisable.  On November 10, 2014, the Company entered into a consulting agreement with Mr. Wolcott, who resigned as President and CEO effective November 10, 2014.

 

Employment Agreement – CFO

 

On September 16, 2014, the Company entered into an employment agreement (the “CFO Agreement”) with its Chief Financial Officer (“CFO”).  The CFO Agreement provides that his base salary shall be $200,000, to be reviewed at least annually by the Compensation Committee of the Board of Directors. The CFO Agreement provides that the CFO is entitled to participate in any annual incentive bonus programs, employee benefit plans adopted or maintained by the Company, and the Company’s Stock Incentive Plan.  Additional provisions of the CFO Agreement include indemnification for expenses associated with defending certain claims made against the CFO as a result of his position with the Company, and directors’ and officers’ liability insurance providing coverage during the term of the CFO Agreement and for a period of six years following the termination of the CFO Agreement.  If the CFO is terminated by the Company other than for cause, or resigns for good reason, and complies with certain requirements, the Company is obligated to pay him an amount equal to his base salary (the “CFO Severance Payment”) and provide employee benefits for one year following termination.  If the CFO Agreement is terminated for cause, he shall receive only the portion of his base salary that is due to him through the effective date of his termination.  If the CFO Agreement is terminated by reason of his death, his estate shall receive his salary through the end of the month in which he died plus all employee benefits due to him through the end of such month.  If a Change in Control (as defined in the CFO Agreement) occurs with respect to the Company, and during the six months immediately following the Change of Control, (i) the Company terminates him without cause; (ii) he terminates his employment with good reason; or (iii) he terminates the CFO Agreement but also agrees to continue serving as CFO for the longer of (a) six months and (b) until a new CFO is appointed, then in addition to the CFO Severance Payment, all options or incentive awards granted to him will immediately vest and become exercisable for a period of 180 days following the termination.  The CFO Agreement also contains a confidentiality agreement, and a one-year non-competition and non-solicitation agreement.  The CFO Agreement contains a claw back provision that enables the Company to claw back any incentive-based compensation or other compensation from him if required by any law, government regulation, stock exchange listing requirement, or Company policy adopted as required by such law, government regulation, or stock exchange listing requirement.

 

Employment Agreement – CTO

 

On December 19, 2014, the Company terminated, without cause, the employment of its Chief Technical Officer (“CTO”).  Under the terms of an employment agreement dated November 2, 1988, the Company is obligated to provide severance pay for a one-year period, which pay includes an extension of all rights, privileges and benefits as an employee (including medical insurance).  The one-year severance pay shall be equal to the CTO’s average annual salary for the 12-month period immediately prior to the termination.  The terms of the employment agreement also require us to pay the CTO for accrued, unused vacation at the time of termination, and include a non-competition covenant prohibiting him from competing with us for one year following his termination.  We may continue the non-competition period for up to four additional years by notifying the CTO in writing and by continuing the severance payments for the additional years during which the non-competition period is extended.